Number	0
of	0
glucocorticoid	9
receptors	10
in	0
lymphocytes	7
and	0
their	0
sensitivity	0
to	0
hormone	0
action	0
.	0

The	0
study	0
demonstrated	0
a	0
decreased	0
level	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
peripheral	7
blood	8
lymphocytes	8
from	0
hypercholesterolemic	0
subjects	0
,	0
and	0
an	0
elevated	0
level	0
in	0
patients	0
with	0
acute	0
myocardial	0
infarction	0
.	0

In	0
the	0
lymphocytes	7
with	0
a	0
high	0
GR	9
number	0
,	0
dexamethasone	0
inhibited	0
[	0
3H	0
]	0
-thymidine	0
and	0
[	0
3H	0
]	0
-acetate	0
incorporation	0
into	0
DNA	0
and	0
cholesterol	0
,	0
respectively	0
,	0
in	0
the	0
same	0
manner	0
as	0
in	0
the	0
control	7
cells	8
.	0

On	0
the	0
other	0
hand	0
,	0
a	0
decreased	0
GR	9
number	0
resulted	0
in	0
a	0
less	0
efficient	0
dexamethasone	0
inhibition	0
of	0
the	0
incorporation	0
of	0
labeled	0
compounds	0
.	0

These	0
data	0
showed	0
that	0
the	0
sensitivity	0
of	0
lymphocytes	7
to	0
glucocorticoids	0
changed	0
only	0
with	0
a	0
decrease	0
of	0
GR	9
level	0
.	0

[	0
1	9
,	10
25-Dihydroxyvitamin	10
D3	10
receptors	10
in	0
lymphocytes	7
and	0
T-	7
and	8
B-lymphocyte	8
count	0
in	0
patients	0
with	0
glomerulonephritis	0
]	0

Content	0
of	0
receptors	0
to	0
hormonal	0
form	0
of	0
vitamin	0
D3	0
,	0
1.25	0
(	0
OH	0
)	0
2D3	0
,	0
constituted	0
27.3	0
fmole/mg	0
of	0
protein	0
in	0
lymphocytes	7
of	0
peripheric	0
blood	0
of	0
children	0
with	0
glomerulonephritis	0
.	0

In	0
the	0
patients	0
concentration	0
of	0
total	0
and	0
ionized	0
form	0
of	0
Ca2+	0
was	0
decreased	0
down	0
to	0
2.04	0
mmole/L	0
and	0
1.09	0
mmole/L	0
,	0
respectively	0
,	0
while	0
an	0
increase	0
in	0
parathormone	0
(	0
PTH	0
)	0
by	0
36	0
%	0
and	0
a	0
distinct	0
decrease	0
in	0
25	0
(	0
OH	0
)	0
D	0
concentration	0
(	0
lower	0
than	0
1.25	0
ng/ml	0
)	0
was	0
found	0
in	0
blood	0
;	0
content	0
of	0
cAMP	0
was	0
also	0
decreased	0
in	0
lymphocytes	0
by	0
33	0
%	0
.	0

At	0
the	0
same	0
time	0
,	0
total	0
content	0
of	0
T	7
lymphocytes	8
was	0
decreased	0
1.5-fold	0
in	0
peripheric	0
blood	0
.	0

Treatment	0
with	0
I-hydroxyvitamin	0
D3	0
(	0
1-1.5	0
mg	0
daily	0
,	0
within	0
4	0
weeks	0
)	0
led	0
to	0
normalization	0
of	0
total	0
and	0
ionized	0
form	0
of	0
Ca2+	0
and	0
of	0
25	0
(	0
OH	0
)	0
D	0
,	0
but	0
did	0
not	0
affect	0
the	0
PTH	0
content	0
in	0
blood	0
.	0

Concentration	0
of	0
the	0
receptors	9
to	0
1.25	0
(	0
OH	0
)	0
2D3	0
was	0
elevated	0
up	0
to	0
39.7	0
fmole/mg	0
after	0
I	0
week	0
of	0
the	0
treatment	0
,	0
whereas	0
it	0
was	0
decreased	0
to	0
the	0
initial	0
level	0
24.8	0
fmole/mg	0
within	0
4	0
weeks	0
;	0
simultaneous	0
alteration	0
in	0
the	0
cAMP	0
content	0
was	0
observed	0
in	0
lymphocytes	7
.	0

Treatment	0
with	0
1-	0
(	0
OH	0
)	0
D3	0
normalized	0
also	0
the	0
T	7
lymphocytes	8
content	0
in	0
peripheric	0
blood	0
.	0

The	0
data	0
obtained	0
suggest	0
that	0
under	0
conditions	0
of	0
glomerulonephritis	0
only	0
high	0
content	0
of	0
receptors	9
to	0
1.25	0
(	0
OH	0
)	0
2D3	0
in	0
lymphocytes	7
enabled	0
to	0
perform	0
the	0
cell	0
response	0
to	0
the	0
hormone	0
effect	0
.	0

Tumor	0
and	0
serum	0
beta-2-microglobulin	0
expression	0
in	0
women	0
with	0
breast	0
cancer	0
.	0

To	0
investigate	0
whether	0
the	0
tumor	7
expression	0
of	0
beta-2-microglobulin	9
(	0
beta	9
2-M	10
)	0
could	0
serve	0
as	0
a	0
marker	0
of	0
tumor	0
biologic	0
behavior	0
,	0
the	0
authors	0
studied	0
specimens	0
of	0
breast	7
carcinomas	8
from	0
60	0
consecutive	0
female	0
patients	0
.	0

Presence	0
of	0
beta	9
2-M	10
was	0
analyzed	0
by	0
immunohistochemistry	0
.	0

No	0
significant	0
correlations	0
were	0
found	0
between	0
tumor	9
beta	10
2-M	10
expression	0
and	0
several	0
histologic	0
attributes	0
such	0
as	0
type	0
,	0
histologic	0
and	0
nuclear	0
grades	0
,	0
mitotic	0
index	0
,	0
necrosis	0
,	0
vascular	0
invasion	0
,	0
and	0
lymphocytic	0
infiltration	0
.	0

Likewise	0
,	0
beta	9
2-M	10
was	0
not	0
associated	0
with	0
markers	0
of	0
disease	0
extension	0
such	0
as	0
TNM	0
,	0
(	0
UICC	0
,	0
classification	0
of	0
malignant	7
tumors	8
)	0
staging	0
and	0
axillary	0
lymph	0
node	0
involvement	0
or	0
with	0
estrogen	0
,	0
progesterone	0
,	0
and	0
glucocorticoid	0
receptor	0
levels	0
.	0

However	0
,	0
there	0
was	0
a	0
significantly	0
positive	0
association	0
between	0
tumor	9
beta	10
2-M	10
expression	0
and	0
the	0
degree	0
of	0
lymphocytic	0
infiltration	0
in	0
the	0
tumor	0
tissue	0
.	0

Beta	9
2-M	10
serum	0
levels	0
were	0
determined	0
by	0
an	0
enzyme-linked	0
immunosorbent	0
assay	0
in	0
samples	0
from	0
22	0
of	0
the	0
above	0
women	0
.	0

Although	0
some	0
of	0
the	0
highest	0
values	0
had	0
been	0
obtained	0
in	0
women	0
with	0
larger	0
(	0
T4	0
)	0
primary	0
tumors	0
,	0
the	0
authors	0
failed	0
to	0
detect	0
any	0
statistical	0
relationship	0
between	0
beta	9
2-M	10
expression	0
in	0
the	0
tumor	0
with	0
serum	0
levels	0
or	0
between	0
serum	9
beta	10
2-M	10
and	0
the	0
above	0
histologic	0
,	0
laboratory	0
,	0
and	0
clinical	0
factors	0
.	0

[	0
Preliminary	0
observation	0
of	0
level	0
free-form	9
E	10
receptor	10
levels	0
in	0
serum	0
of	0
normal	0
childbearing-aged	0
and	0
pregnant	0
women	0
]	0

In	0
137	0
cases	0
of	0
childbearing-aged	0
and	0
pregnant	0
women	0
,	0
free	9
form	10
E	10
receptor	10
levels	0
(	0
sE	9
)	0
in	0
serum	0
were	0
measured	0
by	0
ELISA	0
.	0

The	0
level	0
of	0
sE	9
was	0
significantly	0
decreased	0
during	0
the	0
first	0
trimester	0
,	0
slightly	0
higher	0
in	0
the	0
second	0
trimester	0
,	0
and	0
recovered	0
to	0
normal	0
in	0
the	0
third	0
trimester	0
.	0

The	0
level	0
remained	0
lower	0
in	0
29	0
PIH	0
women	0
but	0
appeared	0
higher	0
in	0
overdue	0
pregnancies	0
as	0
compared	0
with	0
the	0
normal	0
3rd	0
trimester	0
range	0
.	0

The	0
results	0
indicate	0
that	0
there	0
is	0
a	0
relationship	0
between	0
a	0
change	0
in	0
T	7
cell	8
function	0
and	0
pregnancy	0
.	0

Kappa	9
B-specific	10
DNA	10
binding	10
proteins	10
:	0
role	0
in	0
the	0
regulation	0
of	0
human	1
interleukin-2	2
gene	2
expression	0
.	0

Transcriptional	0
activation	0
of	0
the	0
human	1
interleukin-2	2
(	2
IL-2	2
)	2
gene	2
,	0
like	0
induction	0
of	0
the	0
IL-2	1
receptor	2
alpha	2
(	2
IL-2R	2
alpha	2
)	2
gene	2
and	0
the	0
type	0
1	0
human	0
immunodeficiency	0
virus	0
(	0
HIV-1	0
)	0
,	0
is	0
shown	0
to	0
be	0
modulated	0
by	0
a	0
kappa	9
B-like	10
enhancer	10
element	10
.	0

Mutation	0
of	0
a	0
kappa	1
B	2
core	2
sequence	2
identified	0
in	0
the	0
IL-2	1
promoter	2
(	0
-206	0
to	0
-195	0
)	0
partially	0
inhibits	0
both	0
mitogen-	0
and	0
HTLV-I	0
Tax-mediated	0
activation	0
of	0
this	0
transcription	9
unit	10
and	0
blocks	0
the	0
specific	0
binding	0
of	0
two	0
inducible	9
cellular	10
factors	10
.	0

These	0
kappa	9
B-specific	10
proteins	10
(	0
80	0
to	0
90	0
and	0
50	0
to	0
55	0
kilodaltons	0
)	0
similarly	0
interact	0
with	0
the	0
functional	0
kappa	9
B	10
enhancer	10
present	0
in	0
the	0
IL-2R	1
alpha	2
promoter	2
.	0

These	0
data	0
suggest	0
that	0
these	0
kappa	9
B-specific	10
proteins	10
have	0
a	0
role	0
in	0
the	0
coordinate	0
regulation	0
of	0
this	0
growth	0
factor-growth	0
factor	0
receptor	0
gene	0
system	0
that	0
controls	0
T	7
cell	8
proliferation	0
.	0

Novel	0
region	0
within	0
the	0
V	1
kappa	2
gene	2
promoter	2
is	0
responsible	0
for	0
tissue	0
and	0
stage-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
in	0
human	7
lymphoid	8
neoplasms	8
.	0

Immunoglobulin	9
gene-specific	10
transacting	10
factors	10
have	0
been	0
shown	0
to	0
play	0
a	0
role	0
in	0
lymphoid	0
tissue-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
.	0

The	0
role	0
of	0
these	0
factors	0
in	0
B-cell	7
differentiation	0
and	0
stage-specific	0
expression	0
of	0
these	0
genes	0
is	0
,	0
however	0
,	0
not	0
fully	0
understood	0
.	0

We	0
have	0
used	0
a	0
model	0
of	0
human	0
lymphoid	0
neoplasia	0
to	0
address	0
this	0
question	0
.	0

Different	0
fragments	0
of	0
unrearranged	1
human	2
variable	2
region	2
of	0
immunoglobulin	1
kappa	2
gene	2
(	0
V	1
kappa	2
)	0
were	0
used	0
for	0
cell-free	0
in	0
vitro	0
transcription	0
and	0
DNA	0
mobility	0
shift	0
assays	0
.	0

Previously	0
described	0
enhancement	0
of	0
in	0
vitro	0
transcription	0
that	0
was	0
only	0
seen	0
with	0
nuclear	0
extracts	0
derived	0
from	0
B-cell	7
neoplasms	8
corresponding	0
to	0
the	0
late	0
stages	0
of	0
B-cell	7
differentiation	0
was	0
shown	0
to	0
be	0
dependent	0
on	0
the	0
actions	0
of	0
these	0
factor	0
(	0
s	0
)	0
on	0
the	0
DNA	0
region	0
within	0
the	0
V	1
kappa	2
gene	2
promoter	2
.	0

This	0
region	0
is	0
located	0
within	0
the	0
920	0
bp	0
fragment	0
located	0
210	0
bp	0
upstream	0
from	0
the	0
coding	0
region	0
and	0
this	0
fragment	0
represents	0
a	0
possible	0
novel	0
DNA	0
region	0
,	0
which	0
plays	0
a	0
role	0
in	0
the	0
stage-	0
and	0
tissue-specific	0
expression	0
of	0
immunoglobulin	1
genes	2
.	0

[	0
Determination	0
of	0
the	0
sensitivity	0
to	0
glucocorticoids	9
in	0
vitro	0
]	0

A	0
modified	0
method	0
for	0
the	0
determination	0
of	0
glucocorticoid	9
receptors	10
in	0
human	7
lymphocytes	8
is	0
suggested	0
.	0

The	0
principal	0
distinction	0
of	0
the	0
method	0
is	0
standardization	0
by	0
the	0
lymphocyte	7
count	0
in	0
a	0
sample	0
(	0
1	0
mln	0
)	0
and	0
the	0
labeled	0
hormone	9
concentration	0
.	0

The	0
modification	0
saves	0
time	0
and	0
money	0
,	0
limits	0
the	0
range	0
of	0
the	0
data	0
variations	0
,	0
and	0
makes	0
use	0
of	0
a	0
lesser	0
volume	0
of	0
blood	0
.	0

Examinations	0
of	0
70	0
children	0
aged	0
4	0
to	0
15	0
suffering	0
from	0
the	0
nephrotic	0
form	0
of	0
glomerulonephritis	0
have	0
made	0
it	0
possible	0
to	0
distinguish	0
two	0
groups	0
of	0
patients	0
:	0
with	0
relatively	0
high	0
values	0
of	0
specific	0
binding	0
X	0
=	0
6820.1	0
+/-	0
530.0	0
(	0
n	0
=	0
30	0
,	0
p	0
=	0
0.95	0
,	0
t	0
=	0
2.04	0
)	0
,	0
this	0
corresponding	0
to	0
a	0
clinical	0
form	0
of	0
hormone	9
-sensitive	0
glomerulonephritis	0
,	0
and	0
with	0
relatively	0
low	0
values	0
of	0
specific	0
binding	0
X	0
=	0
1815.2	0
+/-	0
302.8	0
(	0
n	0
=	0
40	0
,	0
p	0
=	0
0.95	0
,	0
t	0
=	0
1.96	0
)	0
,	0
that	0
corresponds	0
to	0
hormone	9
-resistant	0
glomerulonephritis	0
.	0

Dynamic	0
studies	0
have	0
not	0
shown	0
any	0
statistically	0
significant	0
changes	0
in	0
the	0
specific	0
binding	0
values	0
.	0

These	0
results	0
permit	0
regarding	0
the	0
specific	0
binding	0
value	0
as	0
a	0
prognostic	0
criterion	0
in	0
the	0
assessment	0
of	0
corticosteroid	9
therapy	0
;	0
this	0
allows	0
a	0
wide	0
employment	0
of	0
the	0
described	0
method	0
in	0
practical	0
nephrology	0
.	0

Octamer-binding	9
proteins	10
from	0
B	5
or	6
HeLa	6
cells	6
stimulate	0
transcription	0
of	0
the	0
immunoglobulin	1
heavy-chain	2
promoter	2
in	0
vitro	0
.	0

The	0
B-cell	7
-type	0
specificity	0
of	0
the	0
immunoglobulin	9
(	0
Ig	9
)	0
heavy-chain	0
and	0
light-chain	0
promoters	0
is	0
mediated	0
by	0
an	0
octanucleotide	1
(	2
OCTA	2
)	2
element	2
,	0
ATGCAAAT	0
,	0
that	0
is	0
also	0
a	0
functional	0
component	0
of	0
other	0
RNA	1
polymerase	2
II	2
promoters	2
,	0
such	0
as	0
snRNA	0
and	0
histone	0
H2B	0
promoters	0
.	0

Two	0
nuclear	9
proteins	10
that	0
bind	0
specifically	0
and	0
with	0
high	0
affinity	0
to	0
the	0
OCTA	1
element	2
have	0
been	0
identified	0
.	0

NF-A1	9
is	0
present	0
in	0
a	0
variety	0
of	0
cell	0
types	0
,	0
whereas	0
the	0
presence	0
of	0
NF-A2	9
is	0
essentially	0
confined	0
to	0
B	7
cells	8
,	0
leading	0
to	0
the	0
hypothesis	0
that	0
NF-A2	9
activates	0
cell-type-specific	0
transcription	0
of	0
the	0
Ig	1
promoter	2
and	0
NF-A1	9
mediates	0
the	0
other	0
responses	0
of	0
the	0
OCTA	1
element	2
.	0

Extracts	0
of	0
the	0
B-cell	5
line	6
,	0
BJA-B	5
,	0
contain	0
high	0
levels	0
of	0
NF-A2	9
and	0
specifically	0
transcribe	0
Ig	1
promoters	2
.	0

In	0
contrast	0
,	0
extracts	0
from	0
HeLa	5
cells	6
transcribed	0
the	0
Ig	1
promoter	2
poorly	0
.	0

Surprisingly	0
,	0
addition	0
of	0
either	0
affinity-enriched	0
NF-A2	0
or	0
NF-A1	0
to	0
either	0
a	0
HeLa	0
extract	0
or	0
a	0
partially	0
purified	0
reaction	0
system	0
specifically	0
stimulates	0
the	0
Ig	1
promoter	2
.	0

This	0
suggests	0
that	0
the	0
constitutive	0
OCTA-binding	9
factor	10
NF-A1	10
can	0
activate	0
transcription	0
of	0
the	0
Ig	1
promoter	2
and	0
that	0
B-cell	7
-specific	0
transcription	0
of	0
this	0
promoter	0
,	0
at	0
least	0
in	0
vitro	0
,	0
is	0
partially	0
due	0
to	0
a	0
quantitative	0
difference	0
in	0
the	0
amount	0
of	0
OCTA-binding	9
protein	10
.	0

Because	0
NF-A1	9
can	0
stimulate	0
Ig	9
transcription	0
,	0
the	0
inability	0
of	0
this	0
factor	0
to	0
activate	0
in	0
vivo	0
the	0
Ig	1
promoter	2
to	0
the	0
same	0
degree	0
as	0
the	0
snRNA	1
promoters	2
probably	0
reflects	0
a	0
difference	0
in	0
the	0
context	0
of	0
the	0
OCTA	1
element	2
in	0
these	0
two	0
types	0
of	0
promoters	1
.	0

Identification	0
of	0
a	0
putative	0
regulator	0
of	0
early	1
T	2
cell	2
activation	2
genes	2
.	0

Molecules	0
involved	0
in	0
the	0
antigen	0
receptor-dependent	0
regulation	0
of	0
early	1
T	2
cell	2
activation	2
genes	2
were	0
investigated	0
with	0
the	0
use	0
of	0
functional	0
sequences	0
of	0
the	0
T	9
cell	10
activation-specific	10
enhancer	10
of	0
interleukin-2	9
(	0
IL-2	9
)	0
.	0

One	0
of	0
these	0
sequences	0
forms	0
a	0
protein	0
complex	0
,	0
NFAT-1	9
,	0
specifically	0
with	0
nuclear	0
extracts	0
of	0
activated	0
T	7
cells	8
.	0

This	0
complex	0
appeared	0
10	0
to	0
25	0
minutes	0
before	0
the	0
activation	0
of	0
the	0
IL-2	1
gene	2
.	0

Studies	0
with	0
inhibitors	0
of	0
protein	0
synthesis	0
indicated	0
that	0
the	0
time	0
of	0
synthesis	0
of	0
the	0
activator	0
of	0
the	0
IL-2	1
gene	2
in	0
Jurkat	5
T	6
cells	6
corresponds	0
to	0
the	0
time	0
of	0
appearance	0
of	0
NFAT-1	9
.	0

NFAT-1	9
,	0
or	0
a	0
very	0
similar	0
protein	0
,	0
bound	0
functional	0
sequences	0
of	0
the	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
;	0
the	0
LTR	1
of	0
this	0
virus	0
is	0
known	0
to	0
be	0
stimulated	0
during	0
early	0
T	7
cell	8
activation	0
.	0

The	0
binding	1
site	2
for	0
this	0
complex	0
activated	0
a	0
linked	0
promoter	0
after	0
transfection	0
into	0
antigen	7
receptor-activated	8
T	8
cells	8
but	0
not	0
other	0
cell	0
types	0
.	0

These	0
characteristics	0
suggest	0
that	0
NFAT-1	9
transmits	0
signals	0
initiated	0
at	0
the	0
T	9
cell	10
antigen	10
receptor	10
.	0

Characterization	0
of	0
thyroid	9
hormone	10
receptors	10
in	0
human	5
IM-9	6
lymphocytes	6
.	0

Although	0
putatively	0
identified	0
more	0
than	0
10	0
years	0
ago	0
,	0
thyroid	9
hormone	10
receptors	10
in	0
human	0
tissues	0
remain	0
poorly	0
characterized	0
.	0

As	0
a	0
first	0
step	0
towards	0
understanding	0
the	0
mechanism	0
of	0
thyroid	0
hormone	0
action	0
in	0
man	0
we	0
have	0
characterized	0
T3	9
binding	10
sites	10
in	0
nuclei	0
of	0
the	0
human	5
lymphoblastoid	6
line	6
,	0
IM-9	5
cells	6
.	0

In	0
whole	0
cell	0
experiments	0
at	0
37	0
degrees	0
C	0
,	0
nuclear	0
binding	0
of	0
[	9
125I	10
]	10
T3	10
was	0
saturable	0
(	0
Kd	0
34	0
+/-	0
6	0
pmol/l	0
)	0
and	0
of	0
finite	0
capacity	0
(	0
approximately	0
equal	0
to	0
350	0
sites/cell	0
)	0
.	0

The	0
binding	9
sites	10
were	0
extracted	0
from	0
a	0
nuclear	0
pellet	0
by	0
treatment	0
with	0
0.4	0
mol/l	0
KCl	0
and	0
sonication	0
.	0

Separation	0
of	0
bound	0
from	0
free	0
[	9
125I	10
]	10
T3	10
in	0
the	0
extracts	0
was	0
achieved	0
using	0
the	0
calcium	0
phosphate	0
matrix	0
,	0
hydroxyapatite	0
at	0
a	0
concentration	0
of	0
0.3	0
ml	0
of	0
a	0
150	0
g/l	0
slurry	0
.	0

Rectilinear	0
Scatchard	0
plots	0
were	0
obtained	0
only	0
when	0
the	0
hydroxyapatite	0
was	0
washed	0
with	0
a	0
buffer	0
containing	0
0.5	0
%	0
Triton	0
X-100	0
.	0

Under	0
these	0
conditions	0
T3	9
binding	10
sites	10
in	0
the	0
nuclear	0
extracts	0
were	0
present	0
at	0
a	0
concentration	0
of	0
22.4	0
+/-	0
8.6	0
fmol/mg	0
protein	0
and	0
showed	0
an	0
affinity	0
of	0
(	0
Kd	0
,	0
room	0
temperature	0
)	0
140	0
+/-	0
10	0
pmol/l	0
.	0

The	0
same	0
assay	0
system	0
was	0
used	0
to	0
determine	0
the	0
hierarchy	0
of	0
affinities	0
for	0
a	0
range	0
of	0
natural	0
and	0
synthetic	0
analogues	0
.	0

Calling	0
T3	0
100	0
,	0
the	0
order	0
of	0
potencies	0
observed	0
was	0
:	0
Triac	0
,	0
500	0
;	0
3	0
,	0
5-diiodo-3'-isopropylthyronine	0
,	0
89	0
;	0
T4	0
,	0
32	0
;	0
3	0
,	0
5-dimethyl-3'isopropylthyronine	0
2	0
;	0
3	0
,	0
5-T2	0
,	0
0.7	0
,	0
rT3	0
,	0
0.4	0
;	0
3'5'-T2	0
,	0
less	0
than	0
0.01	0
.	0

These	0
results	0
suggest	0
that	0
the	0
T3	9
binding	10
sites	10
present	0
in	0
human	5
IM-9	6
lymphocyte	6
nuclei	0
and	0
extracts	0
thereof	0
are	0
thyroid	9
hormone	10
receptors	10
.	0

These	0
cells	0
may	0
be	0
a	0
useful	0
tool	0
to	0
increase	0
our	0
understanding	0
of	0
human	9
T3	10
receptors	10

Definition	0
of	0
T-cell	9
specific	10
DNA-binding	10
factors	10
that	0
interact	0
with	0
a	0
3'-silencer	1
in	0
the	0
CD4+	1
T-cell	2
gene	2
Rpt-1	2
.	0

Analysis	0
of	0
the	0
region	0
3	0
'	0
to	0
the	0
CD4+	1
T-cell	2
gene	2
Rpt-1	2
(	0
encoding	0
regulatory	0
protein	0
T-lymphocyte	9
1	10
)	0
led	0
to	0
the	0
definition	0
of	0
a	0
silencer	1
element	2
that	0
inhibits	0
heterologous	1
gene	2
expression	0
in	0
certain	0
CD4+	7
T-cell	8
lines	8
but	0
not	0
in	0
B-cell	7
or	0
non-lymphoid	7
cell	8
lines	8
.	0

Functional	0
silencer	1
activity	0
in	0
vivo	0
was	0
associated	0
with	0
the	0
presence	0
of	0
a	0
specific	0
silencer-DNA-protein	9
complex	10
in	0
electrophoretic	0
mobility	0
shift	0
assays	0
with	0
T-cell	7
extracts	0
.	0

Formation	0
of	0
this	0
complex	0
was	0
selectively	0
inhibited	0
by	0
the	0
region	0
in	0
HIV-1	1
containing	0
a	0
silencer	1
element	2
.	0

We	0
discuss	0
the	0
possibility	0
that	0
DNA-binding	9
factors	10
may	0
coregulate	0
HIV-1	0
and	0
Rpt-1	0
gene	0
expression	0
through	0
a	0
common	0
transcriptional	1
silencer	2
element	2
.	0

Congenital	0
immunodeficiencies	0
associated	0
with	0
absence	0
of	0
HLA	9
class	10
II	10
antigens	10
on	0
lymphocytes	7
result	0
from	0
distinct	0
mutations	0
in	0
trans-acting	9
factors	10
.	0

Coordinate	0
regulation	0
of	0
HLA	1
class	2
II	2
gene	2
expression	0
during	0
development	0
and	0
coinduction	0
of	0
class	1
II	2
genes	2
by	0
soluble	9
factors	10
suggests	0
that	0
common	0
trans-acting	9
factor	10
(	0
s	0
)	0
control	0
expression	0
of	0
these	0
genes	0
.	0

In	0
B-lymphoblastoid	7
cell	8
lines	8
derived	0
from	0
two	0
independent	0
class	0
II-deficient	0
bare	0
lymphocyte	0
syndrome	0
patients	0
,	0
we	0
observed	0
a	0
drastic	0
decrease	0
in	0
transcription	0
rates	0
of	0
the	0
class	1
II	2
genes	2
.	0

When	0
these	0
cell	0
lines	0
are	0
fused	0
,	0
class	1
II	2
genes	2
are	0
reexpressed	0
,	0
indicating	0
that	0
immunodeficiencies	0
in	0
bare	0
lymphocyte	0
syndrome	0
patients	0
are	0
the	0
result	0
of	0
two	0
distinct	0
mutations	0
.	0

Further	0
studies	0
show	0
that	0
genes	0
governing	0
the	0
expression	0
of	0
class	9
II	10
antigens	10
fall	0
into	0
at	0
least	0
three	0
complementation	0
groups	0
;	0
two	0
of	0
these	0
were	0
previously	0
unidentified	0
in	0
mutant	5
cell	6
lines	6
generated	0
in	0
vitro	0
.	0

In	0
addition	0
,	0
we	0
report	0
the	0
identification	0
of	0
two	0
discrete	0
complexes	0
,	0
NFX1.1	9
and	0
NFX1.2	9
,	0
that	0
bind	0
to	0
the	0
DRA	1
X	2
consensus	2
element	2
.	0

Though	0
the	0
mutation	0
in	0
at	0
least	0
one	0
mutant	5
line	6
generated	0
in	0
vitro	0
(	0
RJ2.2.5	5
)	0
affects	0
products	0
functioning	0
via	0
interaction	0
with	0
the	0
X	1
box	2
,	0
clear	0
alterations	0
in	0
either	0
NFX1.1	9
or	0
NFX1.2	9
are	0
not	0
found	0
in	0
any	0
of	0
the	0
mutant	5
cell	6
lines	6
.	0

In	0
vivo	0
responsiveness	0
to	0
glucocorticoid	0
correlated	0
with	0
glucocorticoid	9
receptor	10
content	0
in	0
peripheral	7
blood	8
leukocytes	8
in	0
normal	0
humans	0
.	0

Dexamethasone	0
loading	0
tests	0
(	0
0.1	0
mg	0
dexamethasone/kg	0
,	0
iv	0
)	0
were	0
performed	0
in	0
18	0
normal	0
males	0
to	0
evaluate	0
the	0
individual	0
responsiveness	0
to	0
glucocorticoid	0
.	0

There	0
were	0
inter-individual	0
differences	0
in	0
increase	0
in	0
peripheral	7
blood	8
polymorphonuclear	8
leukocyte	8
count	0
,	0
decrease	0
in	0
peripheral	7
blood	8
lymphocyte	8
count	0
,	0
and	0
increase	0
in	0
plasma	0
free	0
fatty	0
acids	0
levels	0
after	0
dexamethasone	0
injection	0
.	0

In	0
addition	0
,	0
there	0
was	0
a	0
significant	0
correlation	0
between	0
the	0
maximum	0
increase	0
in	0
polymorphonuclear	7
leukocytes	8
and	0
the	0
maximum	0
decrease	0
in	0
lymphocytes	7
(	0
r	0
=	0
0.7514	0
,	0
p	0
less	0
than	0
0.0003	0
)	0
.	0

Simultaneous	0
measurements	0
of	0
glucocorticoid	9
receptor	10
content	0
by	0
whole-cell	0
assay	0
revealed	0
that	0
glucocorticoid	9
receptor	10
content	0
in	0
polymorphonuclear	7
leukocytes	8
linearly	0
correlated	0
with	0
that	0
in	0
the	0
corresponding	0
lymphocytes	7
(	0
r	0
=	0
0.9482	0
,	0
p	0
less	0
than	0
0.0001	0
)	0
.	0

There	0
were	0
also	0
significant	0
correlations	0
between	0
the	0
maximum	0
increase	0
in	0
polymorphonuclear	7
leukocytes	8
and	0
glucocorticoid	9
receptor	10
content	0
in	0
polymorphonuclear	7
leukocytes	8
(	0
r	0
=	0
0.7239	0
,	0
p	0
less	0
than	0
0.0007	0
)	0
,	0
and	0
between	0
the	0
maximum	0
decrease	0
in	0
lymphocytes	7
and	0
glucocorticoid	9
receptor	10
content	0
in	0
lymphocytes	7
(	0
r	0
=	0
0.7703	0
,	0
p	0
less	0
than	0
0.0002	0
)	0
.	0

These	0
results	0
suggest	0
that	0
individual	0
differences	0
are	0
preserved	0
both	0
in	0
glucocorticoid	0
responsiveness	0
and	0
in	0
glucocorticoid	9
receptor	10
content	0
in	0
peripheral	7
blood	8
leukocytes	8
in	0
normal	0
humans	0
.	0

Estradiol	0
receptors	0
in	0
the	0
cytosol	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
in	0
hepatitis	0
B	0
virus	0
carriers	0
treated	0
with	0
interferon-alpha	9
.	0

Estradiol	9
receptors	10
in	0
the	0
cytosol	0
of	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
the	0
effects	0
of	0
interferon-alpha	9
(	0
IFN-alpha	9
)	0
on	0
estradiol	9
receptors	10
were	0
studied	0
in	0
asymptomatic	0
hepatitis	0
B	0
virus	0
(	0
HBV	0
)	0
carriers	0
,	0
patients	0
with	0
chronic	0
hepatitis	0
B	0
and	0
normal	0
controls	0
.	0

The	0
level	0
of	0
estradiol	9
receptors	10
in	0
the	0
cytosol	0
of	0
mononuclear	7
cells	8
was	0
significantly	0
lower	0
in	0
asymptomatic	0
HBV	0
carriers	0
and	0
patients	0
with	0
chronic	0
hepatitis	0
B	0
,	0
compared	0
to	0
normal	0
controls	0
.	0

This	0
low	0
level	0
of	0
cytosol	0
estradiol	9
receptors	10
in	0
patients	0
with	0
chronic	0
hepatitis	0
B	0
was	0
increased	0
by	0
the	0
administration	0
of	0
IFN-alpha	9
.	0

In	0
addition	0
,	0
when	0
peripheral	7
blood	8
mononuclear	8
cells	8
from	0
patients	0
with	0
chronic	0
hepatitis	0
B	0
were	0
incubated	0
with	0
IFN-alpha	9
in	0
vitro	0
,	0
the	0
level	0
of	0
cytosol	0
estradiol	9
receptors	10
also	0
increased	0
by	0
increasing	0
the	0
concentration	0
of	0
IFN-alpha	9
.	0

We	0
previously	0
reported	0
that	0
the	0
response	0
of	0
mononuclear	7
cells	8
to	0
estrogen	0
is	0
impaired	0
in	0
HBV	0
carriers	0
,	0
and	0
our	0
present	0
results	0
suggested	0
that	0
this	0
may	0
be	0
due	0
to	0
the	0
low	0
level	0
of	0
estradiol	9
receptors	10
in	0
the	0
cytosol	0
of	0
mononuclear	7
cells	8
.	0

Association	0
of	0
increased	0
lytic	0
effector	0
cell	0
function	0
with	0
high	0
estrogen	9
receptor	10
levels	0
in	0
tumor-bearing	0
patients	0
with	0
breast	0
cancer	0
.	0

Tumor-bearing	0
patients	0
with	0
breast	0
cancer	0
were	0
assayed	0
for	0
their	0
natural	7
killer	8
(	8
NK	8
)	8
cell	8
activity	0
and	0
for	0
the	0
function	0
of	0
activated	0
cytotoxic	7
T-cells	8
,	0
as	0
assessed	0
by	0
lectin-dependent	0
cellular	0
cytotoxicity	0
(	0
LDCC	0
)	0
.	0

Tumor-bearing	0
patients	0
with	0
breast	0
cancer	0
had	0
a	0
significant	0
increase	0
in	0
NK	7
activity	0
and	0
in	0
LDCC	0
,	0
as	0
compared	0
with	0
healthy	0
control	0
individuals	0
.	0

Although	0
the	0
enhanced	0
NK	7
cell	8
activity	0
and	0
LDCC	0
were	0
closely	0
associated	0
with	0
high	0
levels	0
(	0
greater	0
than	0
31	0
fmol/mg	0
)	0
of	0
estrogen	9
receptor	10
(	0
ER	9
)	0
content	0
in	0
the	0
primary	0
tumor	0
,	0
no	0
other	0
clinical	0
or	0
histologic	0
correlation	0
between	0
the	0
increase	0
in	0
either	0
parameter	0
of	0
cytotoxic	7
effector	8
cell	8
function	0
could	0
be	0
found	0
.	0

Thus	0
,	0
ER	9
levels	0
greater	0
than	0
31	0
fmol/mg	0
might	0
be	0
associated	0
with	0
increased	0
cytotoxic	7
effector	8
cell	8
function	0
in	0
tumor-bearing	0
patients	0
with	0
breast	0
cancer	0
.	0

Properties	0
of	0
glucocorticoid	9
receptors	10
in	0
Epstein-Barr	5
virus-transformed	6
lymphocytes	6
from	0
patients	0
with	0
familial	0
cortisol	0
resistance	0
.	0

In	0
a	0
previous	0
report	0
of	0
two	0
patients	0
with	0
familial	0
glucocorticoid	0
resistance	0
due	0
to	0
reduced	0
numbers	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
,	0
we	0
have	0
shown	0
decreased	0
numbers	0
of	0
GR	9
in	0
peripheral	7
mononuclear	8
cells	8
and	0
cultured	5
fibroblasts	6
but	0
normal	0
affinity	0
of	0
GR	9
in	0
both	0
patients	0
.	0

In	0
this	0
study	0
,	0
peripheral	7
lymphocytes	8
from	0
these	0
patients	0
,	0
one	0
patient	0
's	0
son	0
and	0
daughter	0
,	0
and	0
normal	0
subjects	0
were	0
transformed	0
with	0
Epstein-Barr	0
virus	0
.	0

Reduced	0
numbers	0
and	0
normal	0
affinity	0
of	0
GR	9
were	0
found	0
in	0
the	0
Epstein-Barr	5
virus-transformed	6
lymphocytes	6
from	0
both	0
patients	0
while	0
the	0
son	0
and	0
daughter	0
had	0
normal	0
numbers	0
and	0
affinity	0
of	0
GR	9
.	0

The	0
thermal	0
stability	0
of	0
GR	9
and	0
thermal	0
activation	0
of	0
cytosolic	9
receptors	10
in	0
both	0
patients	0
were	0
found	0
to	0
be	0
normal	0
.	0

Although	0
the	0
percentages	0
of	0
nuclear	0
bound	0
GR	9
were	0
similar	0
in	0
both	0
patients	0
and	0
normal	0
controls	0
,	0
the	0
absolute	0
amounts	0
of	0
nuclear	0
bound	0
GR	9
of	0
the	0
patients	0
were	0
about	0
one-half	0
that	0
of	0
normal	0
controls	0
.	0

These	0
abnormal	0
properties	0
of	0
GR	9
(	0
reduced	0
numbers	0
of	0
GR	9
)	0
were	0
preserved	0
in	0
the	0
transformed	5
cells	6
from	0
the	0
patients	0
.	0

Octamer	0
transcription	0
factors	0
1	0
and	0
2	0
each	0
bind	0
to	0
two	0
different	0
functional	1
elements	2
in	0
the	0
immunoglobulin	1
heavy-chain	2
promoter	2
.	0

Immunoglobulin	1
heavy-chain	2
genes	2
contain	0
two	0
conserved	1
sequence	2
elements	2
5	0
'	0
to	0
the	0
site	0
of	0
transcription	0
initiation	0
:	0
the	0
octamer	0
ATGCAAAT	0
and	0
the	0
heptamer	0
CTCATGA	0
.	0

Both	0
of	0
these	0
elements	0
are	0
required	0
for	0
normal	1
cell-specific	2
promoter	2
function	0
.	0

The	0
present	0
study	0
demonstrates	0
that	0
both	0
the	0
ubiquitous	9
and	10
lymphoid-cell-specific	10
octamer	10
transcription	10
factors	10
(	0
OTF-1	9
and	0
OTF-2	9
,	0
respectively	0
)	0
interact	0
specifically	0
with	0
each	0
of	0
the	0
two	0
conserved	1
sequence	2
elements	2
,	0
forming	0
either	0
homo-	9
or	10
heterodimeric	10
complexes	10
.	0

This	0
was	0
surprising	0
,	0
since	0
the	0
heptamer	0
and	0
octamer	0
sequence	0
motifs	0
bear	0
no	0
obvious	0
similarity	0
to	0
each	0
other	0
.	0

Binding	0
of	0
either	0
factor	0
to	0
the	0
octamer	1
element	2
occurred	0
independently	0
.	0

However	0
,	0
OTF	9
interaction	0
with	0
the	0
heptamer	1
sequence	2
appeared	0
to	0
require	0
the	0
presence	0
of	0
an	0
intact	0
octamer	0
motif	0
and	0
occurred	0
with	0
a	0
spacing	0
of	0
either	0
2	1
or	2
14	2
base	2
pairs	2
between	0
the	0
two	0
elements	0
,	0
suggesting	0
coordinate	0
binding	0
resulting	0
from	0
protein-protein	0
interactions	0
.	0

The	0
degeneracy	0
in	0
sequences	0
recognized	0
by	0
the	0
OTFs	9
may	0
be	0
important	0
in	0
widening	0
the	0
range	0
over	0
which	0
gene	0
expression	0
can	0
be	0
modulated	0
and	0
in	0
establishing	0
cell	0
type	0
specificity	0
.	0

Identification	0
of	0
a	0
novel	0
lymphoid	9
specific	10
octamer	10
binding	10
protein	10
(	0
OTF-2B	9
)	0
by	0
proteolytic	0
clipping	0
bandshift	0
assay	0
(	0
PCBA	0
)	0
.	0

The	0
octamer	0
sequence	0
ATGCAAAT	0
is	0
found	0
in	0
the	0
promoters	0
of	0
immunoglobulin	1
(	2
Ig	2
)	2
heavy	2
and	2
light	2
chain	2
genes	2
and	0
in	0
the	0
heavy	1
chain	2
enhancer	2
and	0
is	0
a	0
major	0
determinant	0
of	0
the	0
cell	0
type	0
specific	0
expression	0
of	0
Ig	1
genes	2
in	0
B	7
cells	8
.	0

An	0
apparent	0
paradox	0
is	0
that	0
the	0
same	0
sequence	0
serves	0
as	0
an	0
upstream	1
promoter	2
or	2
enhancer	2
element	2
in	0
a	0
variety	0
of	0
housekeeping	1
genes	2
such	0
as	0
the	0
histone	1
H2B	2
and	2
U	2
snRNA	2
genes	2
.	0

The	0
differential	0
usage	0
of	0
this	0
regulatory	0
sequence	0
motif	0
is	0
thought	0
to	0
be	0
mediated	0
by	0
different	0
species	0
of	0
octamer	9
binding	10
proteins	10
.	0

One	0
species	0
of	0
100	0
kd	0
,	0
designated	0
OTF-1	9
,	0
is	0
present	0
in	0
all	0
cell	0
types	0
and	0
may	0
exert	0
its	0
activating	0
function	0
only	0
when	0
it	0
can	0
interact	0
with	0
additional	0
adjacent	0
transcription	9
factors	10
.	0

The	0
lymphoid	9
cell	10
specific	10
octamer	10
binding	10
protein	10
of	0
60	0
kd	0
(	0
OTF-2A	9
)	0
specifically	0
stimulates	0
Ig	1
promoters	2
which	0
consist	0
essentially	0
of	0
a	0
TATA-box	1
and	0
an	0
octamer	1
sequence	2
upstream	0
of	0
it	0
.	0

Here	0
we	0
present	0
evidence	0
for	0
yet	0
another	0
B	9
cell	10
specific	10
octamer	10
binding	10
protein	10
of	0
75	0
kd	0
(	0
OTF-2B	9
)	0
.	0

From	0
several	0
findings	0
,	0
including	0
the	0
absence	0
of	0
OTF-2B	9
(	0
but	0
not	0
OTF-2A	9
)	0
from	0
a	0
lymphocyte	5
line	6
that	0
can	0
not	0
respond	0
to	0
the	0
IgH	1
enhancer	2
,	0
we	0
propose	0
a	0
role	0
of	0
the	0
novel	9
octamer	10
factor	10
in	0
the	0
long	0
range	0
activation	0
by	0
the	0
IgH	1
enhancer	2
.	0

We	0
have	0
used	0
the	0
proteolytic	0
clipping	0
bandshift	0
assay	0
(	0
PCBA	0
)	0
technique	0
to	0
distinguish	0
the	0
three	0
different	0
forms	0
found	0
in	0
B	7
cells	8
.	0

This	0
analysis	0
indicates	0
that	0
the	0
75	0
kd-species	0
OTF-2B	9
is	0
closely	0
related	0
to	0
the	0
60	9
kd	10
species	10
OTF-2A	10
.	0

Inhibition	0
of	0
interleukin	9
2	10
-induced	0
proliferation	0
of	0
cloned	5
murine	6
T	6
cells	6
by	0
glucocorticoids	0
.	0

Possible	0
involvement	0
of	0
an	0
inhibitory	9
protein	10
.	0

The	0
ability	0
of	0
glucocorticoids	0
to	0
inhibit	0
interleukin	9
2	10
(	0
IL	9
2	10
)	0
-induced	0
T	7
cell	8
proliferation	0
in	0
two	0
cytotoxic	5
T	6
cell	6
(	6
CTL	6
)	6
clones	6
has	0
been	0
studied	0
.	0

A	0
complete	0
inhibition	0
of	0
DNA	0
synthesis	0
by	0
dexamethasone	0
(	0
Dx	0
)	0
could	0
be	0
observed	0
when	0
IL	5
2-depleted	6
cultures	6
of	0
CTL	5
were	0
either	0
incubated	0
for	0
6	0
h	0
with	0
the	0
hormone	9
prior	0
to	0
the	0
addition	0
of	0
IL	9
2	10
or	0
treated	0
simultaneously	0
with	0
Dx	0
and	0
a	0
low	0
concentration	0
of	0
IL	9
2	10
.	0

No	0
significant	0
reduction	0
in	0
the	0
number	0
and	0
affinity	0
of	0
IL	9
2	10
receptors	10
was	0
seen	0
after	0
6	0
h	0
incubation	0
with	0
Dx	0
.	0

The	0
order	0
of	0
potency	0
observed	0
with	0
the	0
different	0
steroids	0
indicated	0
that	0
this	0
inhibitory	0
effect	0
was	0
mediated	0
through	0
binding	0
to	0
a	0
specific	0
glucocorticoid	9
receptor	10
.	0

The	0
action	0
of	0
these	0
hormones	9
possibly	0
involves	0
the	0
synthesis	0
of	0
an	0
inhibitory	9
protein	10
(	0
s	0
)	0
,	0
since	0
the	0
presence	0
of	0
cycloheximide	0
during	0
the	0
incubation	0
with	0
Dx	0
prevented	0
the	0
inhibition	0
of	0
DNA	0
synthesis	0
.	0

Furthermore	0
,	0
supernatant	0
from	0
Dx-treated	0
CTL	5
contained	0
a	0
nondialyzable	0
factor	0
which	0
inhibited	0
DNA	0
synthesis	0
and	0
cell	0
growth	0
of	0
CTL	5
clones	6
induced	0
by	0
IL	9
2	10
.	0

Blocking	0
of	0
IL	9
2	10
synthesis	0
and	0
IL	9
2	10
receptor	10
formation	0
have	0
been	0
proposed	0
as	0
one	0
of	0
the	0
major	0
mechanisms	0
of	0
glucocorticoid-induced	0
immunosuppression	0
.	0

Our	0
results	0
indicate	0
that	0
these	0
hormones	9
may	0
also	0
affect	0
T	7
cell	8
proliferation	0
by	0
inhibiting	0
IL	9
2	10
activity	0
.	0

Identification	0
and	0
purification	0
of	0
a	0
human	9
immunoglobulin-enhancer-binding	10
protein	10
(	0
NF-kappa	9
B	10
)	0
that	0
activates	0
transcription	0
from	0
a	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
promoter	2
in	0
vitro	0
.	0

The	0
enhancer-binding	9
factor	10
NF-kappa	10
B	10
,	0
which	0
is	0
found	0
only	0
in	0
cells	0
that	0
transcribe	0
immunoglobulin	1
light	2
chain	2
genes	2
,	0
has	0
been	0
purified	0
from	0
nuclear	0
extracts	0
of	0
Namalwa	5
cells	6
(	0
human	5
Burkitt	6
lymphoma	6
cells	6
)	0
by	0
sequence-specific	0
DNA	0
affinity	0
chromatography	0
.	0

The	0
purified	0
NF-kappa	9
B	10
has	0
been	0
identified	0
as	0
a	0
51-kDa	9
polypeptide	10
by	0
UV-crosslinking	0
analysis	0
.	0

``	0
Footprint	0
''	0
and	0
methylation-interference	0
analyses	0
have	0
shown	0
that	0
purified	0
NF-kappa	9
B	10
has	0
a	0
binding	0
activity	0
specific	0
for	0
the	0
kappa	1
light	2
chain	2
enhancer	2
sequence	2
.	0

The	0
purified	0
factor	0
activated	0
in	0
vitro	0
transcription	0
of	0
the	0
human	1
immunodeficiency	2
virus	2
type	2
I	2
promoter	2
by	0
binding	0
to	0
an	0
upstream	1
NF-kappa	2
B-binding	2
site	2

Lymphocyte	7
glucocorticoid	9
receptor	10
binding	0
in	0
depression	0
:	0
normal	0
values	0
following	0
recovery	0
.	0

The	0
number	0
of	0
glucocorticoid	9
receptor	10
sites	0
in	0
lymphocytes	7
and	0
plasma	0
cortisol	0
concentrations	0
were	0
measured	0
in	0
20	0
patients	0
who	0
had	0
recovered	0
from	0
major	0
depressive	0
disorder	0
and	0
20	0
healthy	0
control	0
subjects	0
.	0

The	0
number	0
of	0
glucocorticoid	9
receptor	10
sites	0
in	0
lymphocytes	7
from	0
the	0
recovered	0
depressed	0
group	0
was	0
not	0
significantly	0
different	0
from	0
that	0
of	0
the	0
control	0
group	0
.	0

Although	0
the	0
mean	0
plasma	0
cortisol	0
concentration	0
in	0
recovered	0
depressives	0
was	0
higher	0
than	0
in	0
control	0
subjects	0
,	0
the	0
difference	0
only	0
just	0
reached	0
significance	0
.	0

This	0
study	0
shows	0
that	0
the	0
reduction	0
in	0
glucocorticoid	9
receptor	10
numbers	0
which	0
occurs	0
during	0
acute	0
depressive	0
illness	0
does	0
not	0
persist	0
on	0
recovery	0
and	0
is	0
,	0
therefore	0
,	0
state-dependent	0
.	0

Identification	0
and	0
purification	0
of	0
a	0
human	9
lymphoid-specific	10
octamer-binding	10
protein	10
(	0
OTF-2	9
)	0
that	0
activates	0
transcription	0
of	0
an	0
immunoglobulin	1
promoter	2
in	0
vitro	0
.	0

The	0
octamer	0
sequence	0
5'-ATGCAAAT	0
,	0
in	0
either	0
orientation	0
,	0
serves	0
as	0
an	0
upstream	1
element	2
in	0
a	0
variety	0
of	0
promoters	1
and	0
also	0
occurs	0
as	0
a	0
modular	1
enhancer	2
element	2
.	0

It	0
is	0
of	0
particular	0
interest	0
in	0
immunoglobulin	1
genes	2
since	0
it	0
is	0
found	0
in	0
the	0
upstream	1
regions	2
of	0
all	0
heavy	1
and	2
light	2
chain	2
promoters	2
and	0
in	0
the	0
heavy	1
chain	2
enhancer	2
,	0
both	0
of	0
which	0
are	0
known	0
to	0
be	0
necessary	0
for	0
cell-specific	0
expression	0
.	0

We	0
report	0
here	0
the	0
chromatographic	0
separation	0
of	0
ubiquitous	9
and	10
B	10
cell-specific	10
octamer-binding	10
proteins	10
.	0

The	0
B	9
cell	10
factor	10
was	0
purified	0
to	0
homogeneity	0
using	0
affinity	0
chromatography	0
and	0
consists	0
of	0
three	0
peptides	0
of	0
62	0
,	0
61	0
,	0
and	0
58.5	0
+/-	0
1.5	0
kd	0
.	0

Each	0
of	0
the	0
polypeptides	0
was	0
renatured	0
after	0
SDS-PAGE	0
and	0
shown	0
to	0
bind	0
to	0
the	0
octamer	0
sequence	0
.	0

The	0
specific	0
DNA	0
binding	0
activity	0
of	0
the	0
pure	0
B	9
cell-specific	10
factor	10
was	0
indistinguishable	0
from	0
that	0
of	0
the	0
affinity-purified	9
ubiquitous	10
factor	10
.	0

This	0
B	9
cell-specific	10
octamer-binding	10
factor	10
,	0
in	0
pure	0
form	0
,	0
activated	0
transcription	0
from	0
a	0
kappa	1
light	2
chain	2
promoter	2
in	0
vitro	0
,	0
thus	0
demonstrating	0
that	0
it	0
is	0
indeed	0
a	0
B	9
cell-specific	10
transcription	10
factor	10
for	0
this	0
gene	0
.	0

In	0
addition	0
to	0
the	0
ubiquitous	9
and	10
B	10
cell-specific	10
octamer-binding	10
factors	10
,	0
we	0
identified	0
several	0
additional	0
proteins	0
,	0
one	0
of	0
which	0
is	0
B	7
cell	8
-specific	0
,	0
that	0
interact	0
with	0
the	0
kappa	1
promoter	2
.	0

Decreased	0
deoxyribonucleic	0
acid	0
binding	0
of	0
glucocorticoid-receptor	9
complex	10
in	0
cultured	0
skin	5
fibroblasts	6
from	0
a	0
patient	0
with	0
the	0
glucocorticoid	0
resistance	0
syndrome	0
.	0

A	0
patient	0
with	0
the	0
syndrome	0
of	0
glucocorticoid	0
resistance	0
was	0
studied	0
.	0

A	0
27-yr-old	0
woman	0
initially	0
was	0
diagnosed	0
as	0
having	0
Cushing	0
's	0
disease	0
,	0
based	0
on	0
the	0
findings	0
of	0
high	0
plasma	0
ACTH	0
and	0
serum	0
cortisol	0
levels	0
,	0
increased	0
urinary	0
cortisol	0
secretion	0
,	0
resistance	0
to	0
adrenal	0
suppression	0
with	0
dexamethasone	0
,	0
and	0
bilateral	0
adrenal	0
hyperplasia	0
by	0
computed	0
tomography	0
and	0
scintigraphy	0
of	0
the	0
adrenal	0
glands	0
.	0

However	0
,	0
she	0
had	0
no	0
signs	0
or	0
symptoms	0
of	0
Cushing	0
's	0
syndrome	0
.	0

During	0
a	0
5-yr	0
follow-up	0
,	0
no	0
clinical	0
abnormalities	0
developed	0
,	0
although	0
hypercortisolism	0
persisted	0
.	0

End-organ	0
resistance	0
to	0
cortisol	0
was	0
suspected	0
.	0

To	0
explain	0
the	0
end-organ	0
resistance	0
to	0
cortisol	0
,	0
the	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
peripheral	7
mononuclear	8
leukocytes	8
and	0
cultured	5
skin	6
fibroblasts	6
from	0
a	0
forearm	0
skin	0
biopsy	0
were	0
characterized	0
and	0
compared	0
with	0
the	0
results	0
of	0
similar	0
studies	0
in	0
normal	0
subjects	0
.	0

The	0
patient	0
's	0
GR	9
in	0
whole	0
cell	0
assays	0
had	0
an	0
increased	0
dissociation	0
constant	0
(	0
Kd	0
)	0
.	0

In	0
the	0
cytosol	0
of	0
cultured	5
skin	6
fibroblasts	6
from	0
the	0
patient	0
,	0
there	0
was	0
also	0
decreased	0
binding	0
capacity	0
.	0

The	0
thermal	0
stability	0
and	0
the	0
sedimentation	0
coefficient	0
in	0
a	0
sucrose	0
density	0
gradient	0
of	0
the	0
receptors	0
in	0
the	0
cytosol	0
of	0
cultured	5
skin	6
fibroblasts	6
from	0
the	0
patient	0
and	0
normal	0
subjects	0
were	0
similar	0
.	0

GR	5
complex	6
activation	6
,	0
analyzed	0
by	0
DEAE-cellulose	5
chromatography	6
,	0
was	0
decreased	0
in	0
the	0
patient	0
.	0

DNA	1
binding	0
of	0
the	0
GR	9
complex	10
after	0
temperature-induced	0
activation	0
was	0
lower	0
in	0
the	0
patient	0
than	0
in	0
normal	0
subjects	0
.	0

Nuclear	0
translocation	0
of	0
GR	9
complexes	10
from	0
the	0
patient	0
was	0
also	0
slightly	0
decreased	0
.	0

These	0
results	0
suggest	0
that	0
the	0
patient	0
's	0
glucocorticoid	0
resistance	0
was	0
due	0
to	0
a	0
decrease	0
in	0
the	0
affinity	0
of	0
the	0
receptor	0
for	0
glucocorticoids	0
and	0
a	0
decrease	0
in	0
the	0
binding	0
of	0
the	0
GR	9
complex	10
to	0
DNA	1
.	0

Granulocyte-macrophage	9
colony-stimulating	10
factor	10
.	0

Sensitive	0
and	0
receptor-mediated	0
regulation	0
by	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
in	0
normal	0
human	7
peripheral	8
blood	8
lymphocytes	8
.	0

We	0
show	0
that	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25	0
[	0
OH	0
]	0
2D3	0
)	0
,	0
the	0
most	0
hormonally	0
active	0
metabolite	0
of	0
vitamin	0
D3	0
,	0
modulates	0
sensitively	0
and	0
specifically	0
both	0
the	0
protein	0
and	0
messenger	3
RNA	4
accumulation	0
of	0
the	0
multilineage	9
growth	10
factor	10
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
.	0

The	0
regulation	0
of	0
GM-CSF	9
expression	0
is	0
seen	0
in	0
both	0
normal	7
human	8
mitogen-activated	8
T	8
lymphocytes	8
and	0
T	5
lymphocytes	6
from	6
a	6
line	6
(	6
S-LB1	6
)	6
transformed	6
with	6
human	6
T	6
cell	6
lymphotropic	6
virus	6
1	6
(	0
HTLV-1	0
)	0
.	0

In	0
contrast	0
,	0
cells	0
from	0
a	0
HTLV-1	5
transformed	6
T	6
lymphocyte	6
line	6
(	0
Ab-VDR	5
)	0
established	0
from	0
a	0
patient	0
with	0
vitamin	0
D-resistant	0
rickets	0
type	0
II	0
with	0
undetectable	0
1	9
,	10
25	10
(	10
OH	10
)	10
2D3	10
cellular	10
receptors	10
are	0
resistant	0
to	0
the	0
action	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

Inhibition	0
of	0
GM-CSF	9
expression	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
can	0
occur	0
independently	0
of	0
interleukin	9
2	10
regulation	0
and	0
is	0
probably	0
mediated	0
through	0
cellular	9
1	10
,	10
25	10
(	10
OH	10
)	10
2D3	10
receptors	10
.	0

We	0
conclude	0
that	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
may	0
be	0
important	0
in	0
the	0
physiology	0
of	0
hematopoiesis	0
.	0

Altered	0
interaction	0
between	0
triiodothyronine	0
and	0
its	0
nuclear	9
receptors	10
in	0
absence	0
of	0
cortisol	0
:	0
a	0
proposed	0
mechanism	0
for	0
increased	0
thyrotropin	0
secretion	0
in	0
corticosteroid	0
deficiency	0
states	0
.	0

Thyroid	0
hormones	0
occasionally	0
appear	0
less	0
effective	0
when	0
administered	0
alone	0
to	0
patients	0
with	0
panhypopituitarism	0
,	0
and	0
manifestations	0
suggestive	0
of	0
hypothyroidism	0
have	0
been	0
reported	0
in	0
patients	0
suffering	0
from	0
untreated	0
Addison	0
's	0
disease	0
.	0

In	0
the	0
latter	0
condition	0
,	0
thyrotropin	0
secretion	0
is	0
increased	0
:	0
this	0
occurs	0
already	0
after	0
as	0
little	0
as	0
2	0
days	0
of	0
temporary	0
withdrawal	0
of	0
therapy	0
with	0
substitution	0
doses	0
of	0
corticosteroids	0
while	0
circulating	0
levels	0
of	0
thyroid	0
hormones	0
remain	0
within	0
normal	0
limits	0
.	0

Therefore	0
,	0
a	0
possible	0
role	0
of	0
cortisol	0
in	0
interaction	0
between	0
triiodothyronine	0
and	0
its	0
nuclear	9
receptors	10
was	0
examined	0
at	0
the	0
level	0
of	0
circulating	0
lymphocytes	0
obtained	0
from	0
patients	0
with	0
primary	0
or	0
secondary	0
adrenocortical	0
failure	0
.	0

The	0
affinity	0
of	0
these	0
receptors	0
was	0
found	0
to	0
be	0
decreased	0
,	0
by	0
more	0
than	0
50	0
%	0
on	0
average	0
,	0
in	0
the	0
absence	0
of	0
cortisol	0
treatments	0
.	0

This	0
change	0
was	0
promptly	0
corrected	0
upon	0
resumption	0
of	0
therapy	0
.	0

The	0
number	0
of	0
binding	0
sites	0
was	0
not	0
significantly	0
modified	0
.	0

The	0
influence	0
of	0
cortisol	0
on	0
thyroid	9
hormone	10
receptors	10
discussed	0
here	0
might	0
account	0
for	0
the	0
clinical	0
observations	0
mentioned	0
above	0
.	0

Inhibition	0
by	0
cortisol	0
of	0
human	7
natural	8
killer	8
(	8
NK	8
)	8
cell	8
activity	0
.	0

The	0
effects	0
of	0
cortisol	0
on	0
the	0
natural	7
killer	8
(	0
NK	0
)	0
activity	0
of	0
human	7
peripheral	8
blood	8
mononuclear	8
(	8
PBM	8
)	8
cells	8
were	0
studied	0
in	0
vitro	0
using	0
a	0
direct	0
4-h	0
51Cr-release	0
assay	0
and	0
K	5
562	6
cell	6
line	6
as	0
a	0
target	0
.	0

Preincubation	0
for	0
20	0
h	0
of	0
PBM	7
cells	8
drawn	0
from	0
healthy	0
donors	0
with	0
1	0
X	0
10	0
(	0
-8	0
)	0
to	0
1	0
X	0
10	0
(	0
-5	0
)	0
M	0
cortisol	0
resulted	0
in	0
a	0
significant	0
decrease	0
of	0
NK	7
cell	8
activity	0
.	0

The	0
magnitude	0
of	0
the	0
suppression	0
was	0
directly	0
related	0
to	0
the	0
steroid	0
concentration	0
and	0
inversely	0
related	0
to	0
the	0
number	0
of	0
effector	7
cells	8
.	0

Cortisol	0
was	0
able	0
to	0
minimize	0
the	0
enhancement	0
of	0
NK	0
cytotoxicity	0
obtainable	0
in	0
the	0
presence	0
of	0
immune	0
interferon	0
(	0
IFN-gamma	0
)	0
.	0

A	0
significantly	0
higher	0
suppression	0
was	0
achieved	0
after	0
sequential	0
exposure	0
of	0
PBM	7
cells	8
to	0
cortisol	0
and	0
equimolar	0
levels	0
of	0
prostaglandin	0
E2	0
(	0
PgE2	0
)	0
.	0

The	0
concomitant	0
incubation	0
with	0
theophylline	0
and	0
isobutyl-methylxanthine	0
failed	0
to	0
enhance	0
the	0
cortisol-induced	0
suppression	0
,	0
whereas	0
PgE2-dependent	0
inhibition	0
significantly	0
increased	0
after	0
exposure	0
of	0
PBM	7
cells	8
to	0
methyl-xanthines	0
.	0

The	0
inhibitory	0
effect	0
of	0
cortisol	0
was	0
partially	0
or	0
totally	0
prevented	0
by	0
the	0
concomitant	0
incubation	0
with	0
equimolar	0
amounts	0
of	0
11-deoxycortisol	0
and	0
RU	0
486	0
but	0
not	0
of	0
progesterone	0
.	0

Treatment	0
of	0
NK	7
effectors	8
with	0
a	0
monoclonal	9
anti-human	10
corticosteroid-binding	10
globulin	10
(	10
CBG	10
)	10
antibody	10
produced	0
an	0
enhancement	0
of	0
the	0
spontaneous	0
NK	7
activity	0
and	0
a	0
partial	0
suppression	0
of	0
cortisol-mediated	0
effects	0
.	0

Our	0
results	0
suggest	0
that	0
endogenous	0
glucocorticoids	0
play	0
a	0
role	0
in	0
the	0
regulation	0
of	0
NK	0
cell-mediated	0
cytotoxicity	0
.	0

Since	0
the	0
effect	0
of	0
cortisol	0
was	0
additive	0
to	0
that	0
of	0
PgE2	0
and	0
was	0
not	0
changed	0
by	0
phosphodiesterase	9
inhibitors	0
,	0
it	0
is	0
conceivable	0
that	0
the	0
hormone	0
acts	0
at	0
a	0
level	0
different	0
from	0
the	0
adenylate	9
cyclase	10
-	0
phosphodiesterase	9
system	0
.	0

Data	0
obtained	0
with	0
the	0
use	0
of	0
antiglucocorticoids	0
and	0
the	0
anti-CBG	9
antibody	10
are	0
compatible	0
with	0
a	0
role	0
both	0
of	0
high-affinity	0
glucocorticoid	9
receptors	10
and	0
of	0
CBG	9
in	0
mediating	0
cortisol	0
action	0
on	0
the	0
human	7
NK	8
cell	8
activity	0
.	0

Interaction	0
of	0
cell-type-specific	9
nuclear	10
proteins	10
with	0
immunoglobulin	1
VH	2
promoter	2
region	2
sequences	2
.	0

All	0
human	1
and	2
murine	2
immunoglobulin	2
heavy	2
chain	2
variable	2
region	2
(	2
VH	2
)	2
genes	2
contain	0
the	0
sequence	0
ATGCAAAT	0
approximately	0
70	0
nucleotides	0
5	0
'	0
from	0
the	0
site	0
of	0
transcription	0
initiation	0
.	0

This	0
octanucleotide	0
,	0
in	0
reverse	0
orientation	0
,	0
is	0
also	0
found	0
in	0
all	0
light	1
chain	2
variable	2
region	2
(	2
VL	2
)	2
genes	2
,	0
and	0
in	0
the	0
immunoglobulin	1
heavy	2
chain	2
transcriptional	2
enhancer	2
.	0

Transfection	0
studies	0
have	0
established	0
that	0
this	0
octamer	0
is	0
involved	0
in	0
the	0
lymphoid-specific	0
transcription	0
of	0
immunoglobulin	1
genes	2
.	0

Octamer-containing	1
fragments	2
have	0
been	0
reported	0
to	0
bind	0
a	0
factor	0
present	0
in	0
nuclear	0
extracts	0
of	0
human	5
cell	6
lines	6
;	0
however	0
,	0
identical	0
binding	0
activity	0
was	0
detected	0
in	0
both	0
B	5
lymphoid	6
and	6
non-lymphoid	6
cells	6
.	0

Here	0
we	0
establish	0
that	0
nuclear	0
extracts	0
from	0
distinct	0
cell	0
types	0
differ	0
in	0
their	0
ability	0
to	0
interact	0
with	0
octamer-containing	1
fragments	2
.	0

We	0
have	0
also	0
detected	0
a	0
DNA-protein	0
interaction	0
that	0
may	0
be	0
involved	0
in	0
the	0
cell-type	0
specificity	0
of	0
immunoglobulin	9
expression	0
,	0
and	0
we	0
have	0
determined	0
that	0
a	0
sequence	0
upstream	0
of	0
the	0
octamer	0
participates	0
in	0
an	0
interaction	0
with	0
a	0
nuclear	9
protein	10
(	0
s	0
)	0
.	0

Preferential	0
transcription	0
of	0
HTLV-I	1
LTR	2
in	0
cell-free	0
extracts	0
of	0
human	7
T	8
cells	8
producing	0
HTLV-I	9
viral	10
proteins	10
.	0

The	0
promoters	1
of	0
the	0
adenovirus	1
2	2
major	2
late	2
gene	2
,	0
the	0
mouse	1
beta-globin	2
gene	2
,	0
the	0
mouse	1
immunoglobulin	2
VH	2
gene	2
and	0
the	0
LTR	1
of	0
the	0
human	0
T-lymphotropic	0
retrovirus	0
type	0
I	0
were	0
tested	0
for	0
their	0
transcription	0
activities	0
in	0
cell-free	0
extracts	0
of	0
four	0
cell	0
lines	0
;	0
HeLa	5
,	0
CESS	5
(	0
Epstein-Barr	5
virus-transformed	6
human	6
B	6
cell	6
line	6
)	0
,	0
MT-1	5
(	0
HTLV-I-infected	5
human	6
T	6
cell	6
line	6
without	0
viral	0
protein	0
synthesis	0
)	0
,	0
and	0
MT-2	5
(	0
HTLV-I-infected	5
human	6
T	6
cell	6
line	6
producing	0
viral	9
proteins	10
)	0
.	0

LTR	1
was	0
preferentially	0
transcribed	0
in	0
the	0
extracts	0
of	0
MT-2	5
although	0
the	0
other	0
three	0
genes	0
were	0
transcribed	0
with	0
relatively	0
constant	0
efficiencies	0
in	0
different	0
extracts	0
.	0

The	0
results	0
agree	0
well	0
with	0
the	0
previous	0
in	0
vivo	0
studies	0
on	0
the	0
promoter	0
activity	0
of	0
HTLV-I	1
LTR	2
.	0

Mixing	0
of	0
HeLa	0
and	0
MT-2	0
extracts	0
revealed	0
the	0
presence	0
of	0
a	0
LTR-specific	0
stimulating	0
activity	0
in	0
MT-2	0
extracts	0
.	0

A	0
nuclear	9
factor	10
that	0
binds	0
to	0
a	0
conserved	0
sequence	0
motif	0
in	0
transcriptional	1
control	2
elements	2
of	0
immunoglobulin	1
genes	2
.	0

Trans-acting	9
factors	10
that	0
mediate	0
B-cell	0
specific	0
transcription	0
of	0
immunoglobulin	1
genes	2
have	0
been	0
postulated	0
based	0
on	0
an	0
analysis	0
of	0
the	0
expression	0
of	0
exogenously	0
introduced	0
immunoglobulin	1
gene	2
recombinants	2
in	0
lymphoid	7
and	8
non-lymphoid	8
cells	8
.	0

Two	0
B-cell-specific	0
,	0
cis-acting	1
transcriptional	2
regulatory	2
elements	2
have	0
been	0
identified	0
.	0

One	0
element	0
is	0
located	0
in	0
the	0
intron	0
between	0
the	0
variable	0
(	0
V	0
)	0
and	0
constant	0
(	0
C	0
)	0
regions	0
of	0
both	0
heavy	1
and	2
kappa	2
light-chain	2
genes	2
and	0
acts	0
as	0
a	0
transcriptional	0
enhancer	0
.	0

The	0
second	0
element	1
is	0
found	0
upstream	0
of	0
both	0
heavy	1
and	2
kappa	2
light-chain	2
gene	2
promoters	2
.	0

This	0
element	0
directs	0
lymphoid-specific	0
transcription	0
even	0
in	0
the	0
presence	0
of	0
viral	1
enhancers	2
.	0

We	0
have	0
sought	0
nuclear	0
factors	0
that	0
might	0
bind	0
specifically	0
to	0
these	0
two	0
regulatory	1
elements	2
by	0
application	0
of	0
a	0
modified	0
gel	0
electrophoresis	0
DNA	0
binding	0
assay	0
.	0

We	0
report	0
here	0
the	0
identification	0
of	0
a	0
human	9
B-cell	10
nuclear	10
factor	10
(	0
IgNF-A	9
)	0
that	0
binds	0
to	0
DNA	1
sequences	2
in	0
the	0
upstream	1
regions	2
of	0
both	0
the	0
mouse	1
heavy	2
and	2
kappa	2
light-chain	2
gene	2
promoters	2
and	0
also	0
to	0
the	0
mouse	1
heavy-chain	2
gene	2
enhancer	2
.	0

This	0
sequence-specific	0
binding	0
is	0
probably	0
mediated	0
by	0
a	0
highly	0
conserved	0
sequence	0
motif	0
,	0
ATTTGCAT	0
,	0
present	0
in	0
all	0
three	0
transcriptional	1
elements	2
.	0

Interestingly	0
,	0
a	0
factor	0
showing	0
similar	0
binding	0
specificity	0
to	0
IgNF-A	1
is	0
also	0
present	0
in	0
human	5
HeLa	6
cells	6
.	0

The	0
new	0
world	0
primates	0
as	0
animal	0
models	0
of	0
glucocorticoid	0
resistance	0
.	0

Many	0
New	0
World	0
primate	0
species	0
have	0
greatly	0
increased	0
plasma	0
cortisol	0
concentrations	0
,	0
decreased	0
plasma	0
cortisol	0
binding	0
globulin	0
capacity	0
and	0
affinity	0
,	0
marked	0
resistance	0
of	0
the	0
hypothalamic-pituitary-adrenal	0
axis	0
to	0
suppression	0
by	0
dexamethasone	0
,	0
and	0
no	0
biological	0
evidence	0
of	0
glucocorticoid	0
excess	0
.	0

These	0
primates	0
also	0
have	0
high	0
levels	0
of	0
circulating	0
progesterone	0
,	0
estrogen	0
,	0
mineralocorticoid	0
,	0
androgen	0
and	0
vitamin	0
D	0
.	0

The	0
glucocorticoid	0
target	0
tissues	0
that	0
have	0
been	0
examined	0
(	0
circulating	7
mononuclear	8
lymphocytes	8
and	0
cultured	5
skin	6
fibroblasts	6
)	0
have	0
normal	0
concentrations	0
of	0
glucocorticoid	9
receptors	10
with	0
decreased	0
affinity	0
for	0
dexamethasone	0
.	0

Transformation	0
of	0
B-lymphocytes	7
with	0
the	0
Epstein-Barr	0
virus	0
leads	0
to	0
glucocorticoid	9
receptor	10
induction	0
that	0
is	0
less	0
than	0
that	0
observed	0
with	0
cells	0
from	0
Old	0
World	0
primates	0
.	0

The	0
receptor	0
in	0
these	0
cells	0
has	0
a	0
low	0
affinity	0
for	0
dexamethasone	0
.	0

The	0
low	0
affinity	0
leads	0
to	0
an	0
increased	0
loss	0
of	0
specific	0
bound	0
ligand	0
during	0
thermal	0
activation	0
.	0

Meroreceptor	0
generation	0
is	0
normal	0
.	0

The	0
molecular	0
weight	0
of	0
the	0
receptor	0
,	0
determined	0
by	0
SDS-PAGE	0
,	0
is	0
similar	0
to	0
that	0
of	0
Old	0
World	0
primates	0
(	0
approximately	0
92	0
,	0
000	0
)	0
and	0
the	0
activation	0
pattern	0
per	0
se	0
,	0
examined	0
in	0
vitro	0
by	0
heating	0
cytosol	0
and	0
performing	0
phosphocellulose	0
chromatography	0
,	0
appears	0
similar	0
to	0
that	0
of	0
human	0
controls	0
.	0

The	0
ratios	0
of	0
nuclear	0
to	0
cytosolic	9
hormone-receptor-complexes	10
and	0
of	0
cytosolic	0
activated	0
to	0
unactivated	9
receptor	10
complexes	10
in	0
intact	0
cells	0
are	0
similar	0
to	0
Old	0
World	0
primates	0
.	0

Results	0
from	0
mixing	0
studies	0
do	0
not	0
support	0
the	0
hypothesis	0
that	0
a	0
binding	0
inhibitor	0
(	0
s	0
)	0
or	0
a	0
deficient	0
cytosolic	0
positive	0
modifier	0
(	0
s	0
)	0
of	0
binding	0
underlies	0
the	0
findings	0
in	0
these	0
primates	0
.	0

The	0
New	0
World	0
primates	0
,	0
unlike	0
men	0
with	0
the	0
syndrome	0
of	0
primary	0
cortisol	0
resistance	0
,	0
have	0
compensated	0
for	0
their	0
condition	0
with	0
intra-adrenal	0
and	0
mineralocorticoid	0
receptor	0
adaptations	0
.	0

Thus	0
,	0
unlike	0
Old	0
World	0
primates	0
,	0
cortisol	0
in	0
New	0
World	0
primates	0
has	0
only	0
weak	0
sodium-retaining	0
potency	0
because	0
the	0
aldosterone	9
receptor	10
has	0
a	0
low	0
affinity	0
for	0
cortisol	0
.	0

The	0
common	0
element	0
that	0
would	0
explain	0
the	0
apparent	0
resistance	0
to	0
six	0
steroid	0
hormones	0
in	0
New	0
World	0
primates	0

Acetylation	0
and	0
modulation	0
of	0
erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
activity	0
by	0
interaction	0
with	0
histone	9
acetyltransferases	10
.	0

Erythroid	9
Kruppel-like	10
factor	10
(	0
EKLF	9
)	0
is	0
a	0
red	9
cell-specific	10
transcriptional	10
activator	10
that	0
is	0
crucial	0
for	0
consolidating	0
the	0
switch	0
to	0
high	0
levels	0
of	0
adult	0
beta-globin	0
expression	0
during	0
erythroid	0
ontogeny	0
.	0

EKLF	9
is	0
required	0
for	0
integrity	0
of	0
the	0
chromatin	0
structure	0
at	0
the	0
beta-like	1
globin	2
locus	2
,	0
and	0
it	0
interacts	0
with	0
a	0
positive-acting	9
factor	10
in	0
vivo	0
.	0

We	0
find	0
that	0
EKLF	9
is	0
an	0
acetylated	9
transcription	10
factor	10
,	0
and	0
that	0
it	0
interacts	0
in	0
vivo	0
with	0
CBP	9
,	0
p300	9
,	0
and	0
P/CAF	9
.	0

However	0
,	0
its	0
interactions	0
with	0
these	0
histone	9
acetyltransferases	10
are	0
not	0
equivalent	0
,	0
as	0
CBP	9
and	0
p300	9
,	0
but	0
not	0
P/CAF	9
,	0
utilize	0
EKLF	9
as	0
a	0
substrate	0
for	0
in	0
vitro	0
acetylation	0
within	0
its	0
trans-activation	0
region	0
.	0

The	0
functional	0
effects	0
of	0
these	0
interactions	0
are	0
that	0
CBP	9
and	0
p300	9
,	0
but	0
not	0
P/CAF	9
,	0
enhance	0
EKLF	9
's	0
transcriptional	0
activation	0
of	0
the	0
beta-globin	1
promoter	2
in	0
erythroid	7
cells	8
.	0

These	0
results	0
establish	0
EKLF	9
as	0
a	0
tissue-specific	9
transcription	10
factor	10
that	0
undergoes	0
post-translational	0
acetylation	0
and	0
suggest	0
a	0
mechanism	0
by	0
which	0
EKLF	9
is	0
able	0
to	0
alter	0
chromatin	0
structure	0
and	0
induce	0
beta-globin	0
expression	0
within	0
the	0
beta-like	1
globin	2
cluster	2
.	0

Recognition	0
of	0
herpes	9
simplex	10
virus	10
type	10
2	10
tegument	10
proteins	10
by	0
CD4	7
T	8
cells	8
infiltrating	0
human	0
genital	0
herpes	0
lesions	0
.	0

The	0
local	0
cellular	0
immune	0
response	0
to	0
herpes	0
simplex	0
virus	0
(	0
HSV	0
)	0
is	0
important	0
in	0
the	0
control	0
of	0
recurrent	0
HSV	0
infection	0
.	0

The	0
antiviral	0
functions	0
of	0
infiltrating	7
CD4-bearing	8
T	8
cells	8
may	0
include	0
cytotoxicity	0
,	0
inhibition	0
of	0
viral	0
growth	0
,	0
lymphokine	0
secretion	0
,	0
and	0
support	0
of	0
humoral	0
and	0
CD8	0
responses	0
.	0

The	0
antigens	0
recognized	0
by	0
many	0
HSV-specific	7
CD4	8
T	8
cells	8
localizing	0
to	0
genital	0
HSV-2	0
lesions	0
are	0
unknown	0
.	0

T	7
cells	8
recognizing	0
antigens	0
encoded	0
within	0
map	0
units	0
0.67	0
to	0
0.73	0
of	0
HSV	1
DNA	2
are	0
frequently	0
recovered	0
from	0
herpetic	0
lesions	0
.	0

Expression	0
cloning	0
with	0
this	0
region	0
of	0
DNA	0
now	0
shows	0
that	0
tegument	9
protein	10
VP22	9
and	0
the	0
viral	9
dUTPase	10
,	0
encoded	0
by	0
genes	1
UL49	2
and	2
UL50	2
,	0
respectively	0
,	0
are	0
T-cell	9
antigens	10
.	0

Separate	0
epitopes	9
in	0
VP22	9
were	0
defined	0
for	0
T-cell	5
clones	6
from	0
each	0
of	0
three	0
patients	0
.	0

Reactivity	0
with	0
the	0
tegument	9
protein	10
encoded	0
by	0
UL21	1
was	0
identified	0
for	0
an	0
additional	0
patient	0
.	0

Three	0
new	0
epitopes	0
were	0
identified	0
in	0
VP16	9
,	0
a	0
tegument	9
protein	10
associated	0
with	0
VP22	9
.	0

Some	0
tegument-specific	5
CD4	6
T-cell	6
clones	6
exhibited	0
cytotoxic	0
activity	0
against	0
HSV-infected	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
herpes	9
simplex	10
tegument	10
proteins	10
are	0
processed	0
for	0
antigen	0
presentation	0
in	0
vivo	0
and	0
are	0
possible	0
candidate	0
compounds	0
for	0
herpes	0
simplex	0
vaccines	0
.	0

Fibrinogen	9
activates	0
NF-kappa	9
B	10
transcription	10
factors	10
in	0
mononuclear	7
phagocytes	8
.	0

Adhesion	0
to	0
extracellular	0
matrices	0
is	0
known	0
to	0
modulate	0
leukocyte	0
activation	0
,	0
although	0
the	0
mechanisms	0
are	0
not	0
fully	0
understood	0
.	0

Mononuclear	7
phagocytes	8
are	0
exposed	0
to	0
fibrinous	0
provisional	0
matrix	0
throughout	0
migration	0
into	0
inflammatory	0
foci	0
,	0
so	0
this	0
study	0
was	0
undertaken	0
to	0
determine	0
whether	0
fibrinogen	0
triggers	0
activation	0
of	0
NF-kappa	9
B	10
transcription	10
factors	10
.	0

U937	5
cells	6
differentiated	0
with	0
PMA	0
in	0
nonadherent	5
culture	6
were	0
shown	0
to	0
express	0
two	0
fibrinogen-binding	9
integrins	10
,	0
predominately	0
CD11b/CD18	9
,	0
and	0
to	0
a	0
lesser	0
extent	0
,	0
CD11c/CD18	9
.	0

Cells	0
stimulated	0
with	0
fibrinogen	9
(	0
10-100	0
microg/ml	0
)	0
/Mn2+	0
(	0
50	0
microM	0
)	0
for	0
2	0
h	0
were	0
examined	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

NF-kappa	9
B	10
activation	0
,	0
minimal	0
in	0
unstimulated	7
cells	8
,	0
was	0
substantially	0
up-regulated	0
by	0
fibrinogen	9
.	0

Fibrinogen	9
also	0
caused	0
activation	0
of	0
AP-1	9
,	0
but	0
not	0
SP1	9
or	0
cAMP	9
response	10
element-binding	10
protein	10
(	10
CREB	10
)	10
factors	10
.	0

Blocking	0
mAbs	9
against	0
CD18	9
and	0
CD11b	9
abrogated	0
fibrinogen	9
-induced	0
NF-kappa	9
B	10
activation	0
.	0

To	0
determine	0
the	0
effects	0
on	0
transcriptional	0
regulation	0
,	0
U937	5
cells	6
were	0
transfected	0
with	0
a	0
plasmid	0
containing	0
the	0
HIV-1	1
enhancer	2
(	0
bearing	0
two	0
NF-kappa	1
B	2
sites	2
)	0
coupled	0
to	0
a	0
chloramphenicol	1
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
.	0

Cells	0
were	0
subsequently	0
stimulated	0
with	0
1	0
)	0
PMA	0
for	0
24	0
h	0
,	0
inducing	0
CAT	0
activity	0
by	0
2.6-fold	0
,	0
2	0
)	0
fibrinogen	9
/Mn2+	0
for	0
2	0
h	0
,	0
inducing	0
CAT	0
activity	0
by	0
3.2-fold	0
,	0
or	0
3	0
)	0
costimulation	0
with	0
fibrinogen	9
and	0
PMA	0
,	0
inducing	0
5.7-fold	0
the	0
CAT	0
activity	0
induced	0
by	0
PMA	0
alone	0
.	0

We	0
conclude	0
that	0
contact	0
with	0
fibrinogen-derived	9
proteins	10
may	0
contribute	0
to	0
mononuclear	0
phagocyte	0
activation	0
by	0
signaling	0
through	0
CD11b/CD18	9
,	0
resulting	0
in	0
selective	0
activation	0
of	0
transcriptional	9
regulatory	10
factors	10
,	0
including	0
NF-kappa	9
B	10
.	0

Peripheral	7
blood	8
T	8
cells	8
and	8
monocytes	8
and	0
B	5
cell	6
lines	6
derived	0
from	0
patients	0
with	0
lupus	0
express	0
estrogen	0
receptor	0
transcripts	0
similar	0
to	0
those	0
of	0
normal	7
cells	8
.	0

OBJECTIVE	0
:	0
To	0
identify	0
and	0
characterize	0
estrogen	3
receptor	4
(	4
ER	4
)	4
transcripts	4
expressed	0
in	0
immune	7
cells	8
of	0
patients	0
with	0
systemic	0
lupus	0
erythematosus	0
(	0
SLE	0
)	0
and	0
healthy	0
donors	0
.	0

METHODS	0
:	0
Peripheral	7
blood	8
monocytes	8
and	8
T	8
cells	8
were	0
prepared	0
from	0
patients	0
with	0
SLE	0
(	0
n	0
=	0
6	0
)	0
and	0
healthy	0
donors	0
(	0
n	0
=	0
8	0
)	0
.	0

T	7
cells	8
were	0
separated	0
into	0
CD4	7
and	0
CD8	7
.	0

Some	0
monocytes	7
and	0
T	7
cells	8
were	0
stimulated	0
with	0
estradiol	0
,	0
PMA	0
,	0
and	0
ionomycin	0
.	0

Epstein-Barr	0
virus-transformed	0
B	5
cell	6
lines	6
(	0
n	0
=	0
7	0
)	0
and	0
B	5
cell	6
hybridomas	6
(	0
n	0
=	0
2	0
)	0
established	0
from	0
patients	0
with	0
SLE	0
and	0
a	0
healthy	0
individual	0
were	0
used	0
as	0
a	0
B	0
cell	0
source	0
.	0

These	0
cells	0
were	0
examined	0
for	0
ER	3
mRNA	4
by	0
reverse	0
transcription	0
nested	0
polymerase	0
chain	0
reaction	0
.	0

Amplified	0
cDNA	1
were	0
sequenced	0
by	0
standard	0
methods	0
.	0

RESULTS	0
:	0
In	0
all	0
cells	0
tested	0
,	0
ER	3
mRNA	4
was	0
expressed	0
without	0
prior	0
in	0
vitro	0
stimulation	0
.	0

Partial	0
sequences	0
from	0
exons	1
1-8	2
were	0
nearly	0
identical	0
to	0
the	0
published	0
sequence	0
of	0
the	0
human	3
ER	4
mRNA	4
.	0

There	0
were	0
no	0
notable	0
differences	0
in	0
the	0
ER	3
transcripts	4
between	0
patients	0
and	0
healthy	0
controls	0
.	0

Variant	0
receptor	0
transcripts	0
lacking	0
exon	1
5	2
or	0
exon	1
7	2
,	0
which	0
encodes	0
the	0
hormone	9
binding	10
domain	10
,	0
were	0
identified	0
in	0
the	0
majority	0
of	0
the	0
cells	0
.	0

Precise	0
deletion	0
of	0
the	0
exons	0
suggests	0
that	0
they	0
are	0
alternatively	0
spliced	0
transcripts	0
.	0

Whether	0
the	0
detected	0
transcripts	0
are	0
translated	0
into	0
functional	9
receptor	10
proteins	10
remains	0
to	0
be	0
determined	0
.	0

In	0
vitro	0
stimulation	0
did	0
not	0
affect	0
ER	3
mRNA	4
expression	0
.	0

The	0
presence	0
of	0
variants	0
did	0
not	0
correlate	0
with	0
disease	0
activity	0
or	0
medication	0
.	0

CONCLUSION	0
:	0
Monocytes	7
,	0
T	7
cells	8
,	0
and	0
B	7
cells	8
in	0
patients	0
express	0
transcripts	0
of	0
the	0
normal	0
wild	9
type	10
ER	10
and	0
the	0
hormone	9
binding	10
domain	10
variants	10
in	0
vivo	0
.	0

DNA	0
damaging	0
agents	0
induce	0
expression	0
of	0
Fas	9
ligand	10
and	0
subsequent	0
apoptosis	0
in	0
T	7
lymphocytes	8
via	0
the	0
activation	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
.	0

Apoptosis	0
induced	0
by	0
DNA	0
damage	0
and	0
other	0
stresses	0
can	0
proceed	0
via	0
expression	0
of	0
Fas	9
ligand	10
(	0
FasL	9
)	0
and	0
ligation	0
of	0
its	0
receptor	0
,	0
Fas	0
(	0
CD95	0
)	0
.	0

We	0
report	0
that	0
activation	0
of	0
the	0
two	0
transcription	9
factors	10
NF-kappa	10
B	10
and	10
AP-1	10
is	0
crucially	0
involved	0
in	0
FasL	9
expression	0
induced	0
by	0
etoposide	0
,	0
teniposide	0
,	0
and	0
UV	0
irradiation	0
.	0

A	0
nondegradable	9
mutant	10
of	0
I	9
kappa	10
B	10
blocked	0
both	0
FasL	9
expression	0
and	0
apoptosis	0
induced	0
by	0
DNA	0
damage	0
but	0
not	0
Fas	0
ligation	0
.	0

These	0
stimuli	0
also	0
induced	0
the	0
stress-activated	0
kinase	0
pathway	0
(	0
SAPK/JNK	0
)	0
,	0
which	0
was	0
required	0
for	0
the	0
maximal	0
induction	0
of	0
apoptosis	0
.	0

A	0
1.2	0
kb	0
FasL	1
promoter	2
responded	0
to	0
DNA	0
damage	0
,	0
as	0
well	0
as	0
coexpression	0
with	0
p65	9
Rel	10
or	0
Fos/Jun	9
.	0

Mutations	0
in	0
the	0
relevant	0
NF-kappa	1
B	2
and	2
AP-1	2
binding	2
sites	2
eliminated	0
these	0
responses	0
.	0

Thus	0
,	0
activation	0
of	0
NF-kappa	9
B	10
and	0
AP-1	9
contributes	0
to	0
stress-induced	0
apoptosis	0
via	0
the	0
expression	0
of	0
FasL	9
.	0

A	0
small	0
,	0
nonpeptidyl	0
mimic	0
of	0
granulocyte-colony-stimulating	9
factor	10
[	0
see	0
commetns	0
]	0

A	0
nonpeptidyl	0
small	0
molecule	0
SB	0
247464	0
,	0
capable	0
of	0
activating	0
granulocyte-colony-stimulating	9
factor	10
(	0
G-CSF	9
)	0
signal	0
transduction	0
pathways	0
,	0
was	0
identified	0
in	0
a	0
high-throughput	0
assay	0
in	0
cultured	7
cells	8
.	0

Like	0
G-CSF	9
,	0
SB	0
247464	0
induced	0
tyrosine	0
phosphorylation	0
of	0
multiple	9
signaling	10
proteins	10
and	0
stimulated	0
primary	7
murine	8
bone	8
marrow	8
cells	8
to	0
form	0
granulocytic	7
colonies	8
in	0
vitro	0
.	0

It	0
also	0
elevated	0
peripheral	7
blood	8
neutrophil	8
counts	0
in	0
mice	0
.	0

The	0
extracellular	0
domain	0
of	0
the	0
murine	9
G-CSF	10
receptor	10
was	0
required	0
for	0
the	0
activity	0
of	0
SB	0
247464	0
,	0
suggesting	0
that	0
the	0
compound	0
acts	0
by	0
oligomerizing	9
receptor	10
chains	10
.	0

The	0
results	0
indicate	0
that	0
a	0
small	0
molecule	0
can	0
activate	0
a	0
receptor	0
that	0
normally	0
binds	0
a	0
relatively	0
large	0
protein	0
ligand	0
.	0

Minimal	0
residual	0
disease	0
in	0
acute	0
myelogenous	0
leukemia	0
with	0
PML/RAR	9
alpha	10
or	0
AML1/ETO	3
mRNA	4
and	0
phenotypic	0
analysis	0
of	0
possible	0
T	7
and	8
natural	8
killer	8
cells	8
in	0
bone	0
marrow	0
.	0

Here	0
we	0
studied	0
minimal	0
residual	0
disease	0
(	0
MRD	0
)	0
of	0
patients	0
with	0
acute	0
myeloid	0
leukemia	0
(	0
AML	0
)	0
who	0
have	0
PML/RAR	9
alpha	10
or	0
AML1/ETO	9
as	0
well	0
as	0
the	0
phenotypic	0
analysis	0
of	0
lymphocyte	7
subsets	8
involved	0
in	0
antitumor	0
immunity	0
.	0

Eight	0
patients	0
in	0
long-term	0
(	0
LT	0
;	0
3	0
to	0
15	0
years	0
)	0
and	0
15	0
patients	0
in	0
short-term	0
(	0
ST	0
;	0
up	0
to	0
3	0
years	0
)	0
remission	0
were	0
studied	0
.	0

Using	0
the	0
reverse	0
transcription-polymerase	0
chain	0
reaction	0
(	0
RT	0
)	0
assay	0
,	0
the	0
limit	0
of	0
detection	0
was	0
10	0
(	0
-5	0
)	0
to	0
10	0
(	0
-6	0
)	0
for	0
PML/RAR	3
alpha	4
transcript	4
and	0
10	0
(	0
-4	0
)	0
to	0
10	0
(	0
-5	0
)	0
for	0
the	0
AML1/ETO	3
transcript	4
.	0

Simultaneously	0
,	0
T	7
lymphocyte	8
subsets	8
and	0
NK	7
cells	8
from	0
the	0
peripheral	0
blood	0
(	0
PB	0
)	0
and	0
bone	0
marrow	0
(	0
BM	0
)	0
were	0
investigated	0
by	0
flow	0
cytometric	0
analysis	0
.	0

Four	0
of	0
the	0
eight	0
patients	0
in	0
LT	0
and	0
7	0
of	0
the	0
15	0
patients	0
in	0
ST	0
remission	0
were	0
MRD-positive	0
.	0

Although	0
all	0
MRD-positive	0
patients	0
in	0
LT	0
remission	0
are	0
still	0
until	0
now	0
event-free	0
,	0
3	0
of	0
the	0
7	0
MRD-positive	0
(	0
MRD+	0
)	0
patients	0
in	0
ST	0
remission	0
soon	0
relapsed	0
.	0

The	0
total	0
populations	0
of	0
CD4	9
+	0
,	0
CD8	9
+	0
and	0
CD56	9
+	0
[	0
possible	0
T-cell	7
and	8
natural	8
killer	8
(	8
T/NK	8
)	8
populations	8
]	0
in	0
the	0
BM	0
of	0
ST	0
patients	0
and	0
MRD+/LT	0
patients	0
were	0
significantly	0
(	0
p	0
<	0
.01	0
)	0
low	0
.	0

The	0
CD8+	7
CD28+	8
population	8
showed	0
the	0
same	0
tendency	0
(	0
p	0
<	0
.01-.02	0
)	0
.	0

The	0
T/NK	7
subsets	8
in	0
the	0
BM	0
of	0
MRD-negative	0
(	0
MRD-	0
)	0
LT	0
(	0
MRD-/LT	0
)	0
patients	0
showed	0
similar	0
numbers	0
of	0
cells	0
as	0
normal	0
volunteers	0
.	0

Basically	0
,	0
the	0
total	0
percentage	0
of	0
the	0
CD4+	7
,	8
CD8+	8
and	8
CD56+	8
cell	8
populations	8
in	0
the	0
BM	0
was	0
increased	0
and	0
in	0
the	0
following	0
order	0
:	0
MRD-/LT	0
patients	0
,	0
normal	0
volunteers	0
,	0
MRD+/LT	0
patients	0
and	0
MRD+	0
or	0
-/ST	0
patients	0
.	0

The	0
percentages	0
of	0
the	0
T/NK-cell	7
subsets	8
in	0
the	0
PB	0
were	0
not	0
significantly	0
different	0
among	0
these	0
groups	0
.	0

Thus	0
,	0
the	0
difference	0
of	0
the	0
possible	0
T/NK-cell	7
phenotype	0
in	0
the	0
BM	0
may	0
strongly	0
influence	0
clinical	0
and	0
molecular	0
remission	0
.	0

These	0
results	0
still	0
remain	0
to	0
be	0
confirmed	0
by	0
further	0
studies	0
of	0
the	0
functional	0
anti-tumor	0
immunity	0
of	0
T/NK	7
cells	8
of	0
AML	7
in	0
remission	0
.	0

Mycobacterium	0
tuberculosis	0
mannose-capped	0
lipoarabinomannan	0
can	0
induce	0
NF-kappaB	9
-dependent	0
activation	0
of	0
human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
in	0
T	7
cells	8
.	0

Tuberculosis	0
has	0
emerged	0
as	0
an	0
epidemic	0
,	0
extended	0
by	0
the	0
large	0
number	0
of	0
individuals	0
infected	0
with	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
.	0

The	0
major	0
goal	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
the	0
mycobacterial	0
cell	0
wall	0
component	0
mannose-capped	0
lipoarabinomannan	0
(	0
ManLAM	0
)	0
of	0
Mycobacterium	0
tuberculosis	0
(	0
M.	0
tuberculosis	0
)	0
could	0
activate	0
transcription	0
of	0
HIV-1	0
in	0
T	7
cells	8
with	0
the	0
use	0
of	0
an	0
in	0
vitro	0
cell	0
culture	0
system	0
.	0

These	0
experiments	0
are	0
of	0
prime	0
importance	0
considering	0
that	0
CD4	9
-expressing	0
T	7
lymphocytes	8
represent	0
the	0
major	0
virus	0
reservoir	0
in	0
the	0
peripheral	0
blood	0
of	0
infected	0
individuals	0
.	0

Using	0
the	0
1G5	5
cell	6
line	6
harbouring	0
the	0
luciferase	0
reporter	0
gene	0
under	0
the	0
control	0
of	0
the	0
HIV-1	1
LTR	2
,	0
it	0
was	0
first	0
found	0
that	0
culture	0
protein	0
filtrates	0
(	0
CFP	0
)	0
from	0
M.	0
tuberculosis	0
or	0
purified	0
ManLAM	0
could	0
activate	0
HIV-1	1
LTR-dependent	2
gene	2
expression	0
unlike	0
similarly	0
prepared	0
CFP	0
extracts	0
devoid	0
of	0
ManLAM	0
.	0

The	0
implication	0
of	0
protein	9
tyrosine	10
kinase	10
(	10
s	10
)	10
,	0
protein	9
kinase	10
A	10
and/or	0
protein	9
kinase	10
C	10
was	0
highlighted	0
by	0
the	0
abrogation	0
of	0
the	0
ManLAM-mediated	0
activation	0
of	0
HIV-1	0
LTR-driven	0
gene	0
expression	0
using	0
herbimycin	0
A	0
and	0
H7	0
.	0

It	0
was	0
also	0
determined	0
,	0
using	0
electrophoresis	0
mobility	0
shift	0
assays	0
,	0
that	0
M.	0
tuberculosis	0
ManLAM	0
led	0
to	0
the	0
nuclear	0
translocation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	10
.	0

M.	0
tuberculosis	0
ManLAM	0
resulted	0
in	0
clear	0
induction	0
of	0
the	0
luciferase	1
gene	2
placed	0
under	0
the	0
control	0
of	0
the	0
wild-type	1
,	2
but	2
not	2
the	2
kappaB-mutated	2
,	2
HIV-1	2
LTR	2
region	2
.	0

Finally	0
,	0
the	0
ManLAM-mediated	0
activation	0
of	0
HIV-1	0
LTR	0
transcription	0
was	0
found	0
to	0
be	0
independent	0
of	0
the	0
autocrine	0
or	0
paracrine	0
action	0
of	0
endogenous	9
TNF-alpha	10
.	0

The	0
results	0
suggest	0
that	0
M.	0
tuberculosis	0
can	0
upregulate	0
HIV-1	0
expression	0
in	0
T	7
cells	8
and	0
could	0
thus	0
have	0
the	0
potential	0
to	0
influence	0
the	0
pathogenesis	0
of	0
HIV-1	0
infection	0
.	0

Human	1
immunodeficiency	2
virus	2
type	2
1	2
long	2
terminal	2
repeat	2
quasispecies	0
differ	0
in	0
basal	0
transcription	0
and	0
nuclear	0
factor	0
recruitment	0
in	0
human	7
glial	8
cells	8
and	8
lymphocytes	8
.	0

The	0
generation	0
of	0
genomic	0
diversity	0
during	0
the	0
course	0
of	0
infection	0
has	0
the	0
potential	0
to	0
affect	0
all	0
aspects	0
of	0
HIV-1	0
replication	0
,	0
including	0
expression	0
of	0
the	0
proviral	0
genome	0
.	0

To	0
gain	0
a	0
better	0
understanding	0
of	0
the	0
impact	0
of	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
sequence	0
diversity	0
on	0
LTR-directed	1
gene	2
expression	0
in	0
cells	0
of	0
the	0
central	0
nervous	0
system	0
(	0
CNS	0
)	0
and	0
immune	0
system	0
,	0
we	0
amplified	0
and	0
cloned	0
LTRs	1
from	0
proviral	0
DNA	0
in	0
HIV-1-infected	0
peripheral	0
blood	0
.	0

Sequence	0
analysis	0
of	0
nineteen	0
LTRs	1
cloned	0
from	0
2	0
adult	0
and	0
3	0
pediatric	0
patients	0
revealed	0
an	0
average	0
of	0
33	0
nucleotide	0
changes	0
(	0
with	0
respect	0
to	0
the	0
sequence	0
of	0
the	0
LAI	1
LTR	2
)	0
within	0
the	0
455-bp	1
U3	2
region	2
.	0

Transient	0
expression	0
analyses	0
in	0
cells	0
of	0
neuroglial	0
and	0
lymphocytic	0
origin	0
demonstrated	0
that	0
some	0
of	0
these	0
LTRs	1
had	0
activities	0
which	0
varied	0
significantly	0
from	0
the	0
LAI	1
LTR	2
in	0
U-373	5
MG	6
cells	6
(	0
an	0
astrocytoma	5
cell	6
line	6
)	0
as	0
well	0
as	0
in	0
Jurkat	5
cells	6
(	0
a	0
CD4-positive	5
lymphocyte	6
cell	6
line	6
)	0
.	0

While	0
LTRs	1
which	0
demonstrated	0
the	0
highest	0
activities	0
in	0
U-373	5
MG	6
cells	6
also	0
yielded	0
high	0
activities	0
in	0
Jurkat	5
cells	6
,	0
the	0
LTRs	1
were	0
generally	0
more	0
active	0
in	0
Jurkat	5
cells	6
when	0
compared	0
to	0
the	0
LAI	1
LTR	2
.	0

Differences	0
in	0
LTR	1
sequence	2
also	0
resulted	0
in	0
differences	0
in	0
transcription	0
factor	0
recruitment	0
to	0
cis-acting	1
sites	2
within	0
the	0
U3	1
region	2
of	0
the	0
LTR	1
,	0
as	0
demonstrated	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

In	0
particular	0
,	0
naturally	0
occurring	0
sequence	0
variation	0
impacted	0
transcription	9
factor	10
binding	0
to	0
an	0
activating	9
transcription	10
factor	10
/	0
cAMP	9
response	10
element	10
binding	10
(	0
ATF	9
/	0
CREB	9
)	0
binding	0
site	0
(	0
located	0
between	0
the	0
LEF-1	1
and	2
distal	2
NF-kappaB	2
transcription	2
factor	2
binding	2
sites	2
)	0
that	0
we	0
identified	0
in	0
previous	0
studies	0
of	0
the	0
HIV-1	1
LTR	2
.	0

These	0
findings	0
suggest	0
that	0
LTR	1
sequence	2
changes	0
can	0
significantly	0
affect	0
basal	0
LTR	0
function	0
and	0
transcription	0
factor	0
recruitment	0
,	0
which	0
may	0
,	0
in	0
turn	0
,	0
alter	0
the	0
course	0
of	0
viral	0
replication	0
in	0
cells	0
of	0
CNS	0
and	0
immune	0
system	0
origin	0
.	0

HMG	9
box	10
containing	10
transcription	10
factors	10
in	0
lymphocyte	7
differentiation	0
.	0

The	0
identification	0
of	0
the	0
mammalian	1
sex-determining	2
gene	2
Sry	2
has	0
led	0
to	0
the	0
discovery	0
of	0
a	0
large	0
family	0
of	0
related	0
(	0
'	0
HMG	9
box	10
'	0
)	0
transcription	9
factors	10
that	0
control	0
developmental	0
events	0
in	0
yeast	0
,	0
C.	0
elegans	0
,	0
Drosophila	0
and	0
vertebrates	0
.	0

In	0
lymphocyte	7
differentiation	0
,	0
several	0
HMG	9
box	10
proteins	10
play	0
a	0
decisive	0
role	0
.	0

Sox-4	9
is	0
important	0
for	0
very	0
early	0
B-cell	0
differentiation	0
,	0
while	0
TCF-1	9
/	0
LEF-1	9
play	0
a	0
crucial	0
role	0
in	0
early	0
thymocyte	0
development	0
.	0

TCF/LEF	9
proteins	10
have	0
recently	0
been	0
found	0
to	0
constitute	0
a	0
downstream	0
component	0
of	0
the	0
Wingless/Wnt	0
signal	0
transduction	0
pathway	0
.	0

In	0
flies	0
,	0
this	0
pathway	0
controls	0
segment	0
polarity	0
;	0
in	0
Xenopus	0
it	0
controls	0
the	0
definition	0
of	0
the	0
body	0
axis	0
.	0

Deregulation	0
of	0
the	0
pathway	0
occurs	0
in	0
several	0
human	7
tumors	8
.	0

These	0
insights	0
in	0
the	0
molecular	0
events	0
that	0
are	0
involved	0
in	0
TCF/LEF	9
function	0
in	0
these	0
organisms	0
may	0
eventually	0
lead	0
to	0
the	0
understanding	0
of	0
the	0
function	0
of	0
these	0
HMG	9
box	10
proteins	10
in	0
lymphoid	0
development	0

Transcriptional	0
regulation	0
by	0
C/EBP	9
alpha	10
and	10
-beta	10
in	0
the	0
expression	0
of	0
the	0
gene	0
for	0
the	0
MRP14	9
myeloid	10
calcium	10
binding	10
protein	10
.	0

Transcriptional	0
regulation	0
of	0
the	0
gene	0
for	0
the	0
myeloid	9
calcium	10
binding	10
protein	10
,	0
MRP14	9
,	0
was	0
investigated	0
in	0
human	5
monocytic	6
leukemia	6
cell	6
lines	6
.	0

The	0
MRP14	1
gene	2
was	0
not	0
expressed	0
in	0
monoblastic	5
ML-1	6
cells	6
,	0
promonocytic	5
U-937	6
cells	6
,	0
or	0
promyelocytic	5
HL-60	6
cells	6
.	0

On	0
the	0
other	0
hand	0
,	0
the	0
gene	0
was	0
expressed	0
in	0
monocytic	5
THP-1	6
cells	6
and	0
in	0
the	0
HL-60	5
cells	6
treated	0
with	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
VD3	0
)	0
.	0

The	0
level	0
of	0
MRP14	9
in	0
VD3-treated	0
HL-60	5
cells	6
was	0
two-fold	0
higher	0
than	0
that	0
in	0
THP-1	5
cells	6
.	0

Among	0
several	0
known	0
transcription	1
factor	2
binding	2
motifs	2
,	0
nuclear	9
protein	10
(	10
s	10
)	10
of	0
VD3-treated	5
HL-60	6
cells	6
and	6
THP-1	6
cells	6
bound	0
to	0
the	0
CCAAT/enhancer	1
binding	2
protein	2
(	2
C/EBP	2
)	2
-binding	2
motif	2
that	0
was	0
located	0
in	0
the	0
upstream	1
region	2
of	0
the	0
MRP14	1
gene	2
(	0
-81	0
)	0
,	0
as	0
evidenced	0
by	0
the	0
competitive	0
gel	0
mobility-shift	0
assay	0
.	0

An	0
antibody	0
for	0
C/EBP	9
alpha	10
super-shifted	0
the	0
nucleoprotein	9
complex	10
in	0
THP-1	5
cells	6
but	0
not	0
in	0
the	0
VD3-treated	5
HL-60	6
cells	6
,	0
whereas	0
an	0
antibody	0
for	0
C/EBP	9
beta	10
blocked	0
the	0
formation	0
of	0
the	0
complex	0
with	0
the	0
nuclear	9
factor	10
of	0
the	0
HL-60	5
cells	6
but	0
not	0
with	0
that	0
of	0
THP-1	5
cells	6
.	0

An	0
anti-C/EBP	9
delta	10
antibody	10
had	0
no	0
effect	0
on	0
the	0
complex	0
in	0
either	0
cell	0
.	0

Thus	0
,	0
it	0
was	0
concluded	0
that	0
C/EBP	9
alpha	10
and	10
-beta	10
were	0
able	0
to	0
bind	0
to	0
the	0
C/EBP	9
motif	10
,	0
and	0
that	0
C/EBP	9
alpha	10
bound	0
to	0
the	0
motif	0
in	0
THP-1	5
cells	6
and	0
C/EBP	9
beta	10
bound	0
to	0
that	0
in	0
the	0
VD3-treated	5
HL-60	6
cells	6
.	0

Furthermore	0
,	0
to	0
examine	0
the	0
transcriptional	0
activity	0
of	0
the	0
C/EBP	9
motif	10
,	0
we	0
transfected	0
several	0
constructed	0
luciferase	1
reporter	2
DNAs	2
into	0
HL-60	5
cells	6
and	0
THP-1	5
cells	6
.	0

The	0
luciferase	0
activity	0
of	0
the	0
C/EBP	9
motif	10
in	0
HL-60	5
cells	6
was	0
increased	0
by	0
VD3	0
treatment	0
.	0

The	0
C/EBP	9
motif	10
in	0
the	0
MRP14	1
gene	2
was	0
confirmed	0
to	0
function	0
as	0
a	0
regulatory	0
region	0
in	0
VD3-treated	5
HL-60	6
cells	6
and	6
THP-1	6
cells	6
by	0
the	0
assay	0
.	0

Since	0
C/EBP	9
beta	10
was	0
also	0
detected	0
in	0
VD3-untreated	5
HL-60	6
cells	6
by	0
immunoblotting	0
,	0
VD3	0
activated	0
C/EBP	9
beta	10
to	0
bind	0
to	0
the	0
motif	0
,	0
probably	0
through	0
post-translational	0
modification	0
.	0

Patients	0
with	0
high-risk	0
myelodysplastic	0
syndrome	0
can	0
have	0
polyclonal	0
or	0
clonal	0
haemopoiesis	0
in	0
complete	0
haematological	0
remission	0
.	0

The	0
clonality	0
of	0
mature	7
peripheral	8
blood-derived	8
myeloid	8
and	8
lymphoid	8
cells	8
and	0
bone	7
marrow	8
haemopoietic	8
progenitors	8
from	0
18	0
females	0
with	0
myelodysplasia	0
(	0
MDS	0
)	0
(	0
five	0
refractory	0
anaemia	0
,	0
RA	0
;	0
one	0
RA	0
with	0
ringed	7
sideroblasts	8
,	0
RARS	0
;	0
three	0
chronic	0
myelomonocytic	0
leukaemia	0
,	0
CMML	0
;	0
four	0
RA	0
with	0
excess	0
of	0
blasts	0
,	0
RAEB	0
;	0
five	0
RAEB	0
in	0
transformation	0
,	0
RAEB-t	0
)	0
was	0
studied	0
by	0
X-chromosome	1
inactivation	0
analysis	0
.	0

Using	0
the	0
human	0
androgen-receptor	0
(	0
HUMARA	0
)	0
assay	0
,	0
we	0
analysed	0
the	0
clonal	0
patterns	0
of	0
highly	7
purified	8
immature	8
CD34+	8
38-	8
and	8
committed	8
CD34+	8
38+	8
marrow-derived	8
progenitors	8
,	0
and	0
CD16+	7
14-	8
granulocytes	8
,	0
CD14+	7
monocytes	8
,	0
CD3+	7
T	8
and	8
CD19+	8
B	8
lymphocytes	8
from	0
peripheral	0
blood	0
.	0

In	0
high-risk	0
patients	0
(	0
RAEB	0
,	0
RAEB-t	0
)	0
,	0
clonality	0
analysis	0
was	0
performed	0
before	0
and	0
after	0
intensive	0
remission-induction	0
treatment	0
.	0

All	0
patients	0
,	0
except	0
one	0
with	0
RA	0
,	0
had	0
predominance	0
of	0
a	0
single	0
clone	0
in	0
their	0
granulocytes	7
and	0
monocytes	7
.	0

The	0
same	0
clonal	0
pattern	0
was	0
found	0
in	0
CD34+	7
progenitor	8
cells	8
.	0

In	0
contrast	0
,	0
CD3+	7
T	8
lymphocytes	8
were	0
polyclonal	0
or	0
oligoclonal	0
in	0
14/18	0
patients	0
.	0

X-chromosome	1
inactivation	0
patterns	0
of	0
CD19+	7
B	8
cells	8
were	0
highly	0
concordant	0
with	0
CD3+	7
T	8
cells	8
except	0
for	0
two	0
patients	0
(	0
one	0
RA	0
,	0
one	0
CMML	0
)	0
with	0
monoclonal	7
B	8
and	8
polyclonal	8
T	8
lymphocytes	8
,	0
therefore	0
suggesting	0
a	0
clonal	0
mutation	0
in	0
a	0
progenitor	7
common	0
to	0
the	0
myeloid	7
and	8
B-lymphoid	8
lineages	8
or	0
the	0
coexistence	0
of	0
MDS	0
and	0
a	0
B-cell	0
disorder	0
in	0
these	0
particular	0
patients	0
.	0

After	0
high-dose	0
non-myeloablative	0
chemotherapy	0
,	0
polyclonal	0
haemopoiesis	0
was	0
reinstalled	0
in	0
the	0
mature	7
myeloid	8
cells	8
and	0
immature	0
and	0
committed	7
marrow	8
progenitors	8
in	0
three	0
of	0
four	0
patients	0
achieving	0
complete	0
haematological	0
remission	0
.	0

Therefore	0
we	0
conclude	0
that	0
most	0
haematological	0
remissions	0
in	0
MDS	0
are	0
associated	0
with	0
restoration	0
of	0
polyclonal	0
haemopoiesis	0
.	0

Prominent	0
sex	0
steroid	0
metabolism	0
in	0
human	7
lymphocytes	8
.	0

Steroid	0
metabolism	0
was	0
investigated	0
in	0
cultured	5
human	6
B-lymphoblastoid	6
cells	6
(	0
B-LCL	5
)	0
,	0
and	0
peripheral	7
blood	8
T	8
and	8
B	8
cells	8
.	0

Gene	0
expression	0
was	0
examined	0
by	0
reverse-transcription	0
polymerase	0
chain	0
reaction	0
amplification	0
(	0
RT-PCR	0
)	0
.	0

Appropriate	0
sized	0
transcripts	3
were	0
detected	0
in	0
both	0
cultured	0
and	0
fresh	0
peripheral	7
lymphocytes	8
for	0
CYP11A	9
,	0
CYP17	9
,	0
HSD11L	9
(	0
11beta-hydroxysteroid	9
dehydrogenase	10
I	10
)	0
,	0
HSD17B1	9
(	0
17beta-hydroxysteroid	9
dehydrogenase	10
type	10
I	10
)	0
and	0
SRD5A1	9
(	0
5alpha-reductase	9
I	10
)	0
.	0

B-LCL	0
,	0
but	0
not	0
T	7
and	8
B	8
cells	8
,	0
expressed	0
CYP11B	9
.	0

There	0
was	0
minimal	0
expression	0
of	0
HSD3B1	9
and	0
HSD3B2	9
(	0
3beta-hydroxysteroid	9
dehydrogenase	10
I	10
and	10
II	10
)	0
in	0
B-LCL	5
and	0
T	7
cells	8
.	0

Transcripts	0
for	0
CYP19	9
and	0
HSD11K	9
were	0
not	0
detected	0
.	0

Corresponding	0
enzymatic	0
activity	0
was	0
detectable	0
only	0
for	0
17-hydroxysteroid	9
dehydrogenase	10
and	0
5alpha-reductase	9
,	0
respectively	0
producing	0
testosterone	0
and	0
5alpha-dihydrotestosterone	0
.	0

Steroid	0
identities	0
were	0
confirmed	0
by	0
gas	0
chromatography/mass	0
spectrometry	0
(	0
GC/MS	0
)	0
.	0

One	0
metabolite	0
thought	0
to	0
be	0
deoxycorticosterone	0
was	0
identified	0
by	0
GC/MS	0
as	0
6alpha-hydroxypregnanolone	0
.	0

It	0
was	0
concluded	0
that	0
sex	0
hormone	0
metabolism	0
,	0
including	0
androgen	0
synthesis	0
,	0
occurs	0
in	0
lymphocytes	0
,	0
and	0
may	0
modulate	0
immune	0
response	0
.	0

Human	7
white	8
blood	8
cells	8
and	0
hair	0
follicles	0
are	0
good	0
sources	0
of	0
mRNA	3
for	0
the	0
pterin	9
carbinolamine	10
dehydratase/dimerization	10
cofactor	10
of	0
HNF1	9
for	0
mutation	0
detection	0
.	0

Pterin	9
carbinolamine	10
dehydratase/dimerization	10
cofactor	10
of	0
HNF1	9
(	0
PCD/DCoH	9
)	0
is	0
a	0
protein	0
that	0
has	0
a	0
dual	0
function	0
.	0

It	0
is	0
a	0
pterin	9
4alpha-carbinolamine	10
dehydratase	10
that	0
is	0
involved	0
in	0
the	0
regeneration	0
of	0
the	0
cofactor	9
tetrahydrobiopterin	10
during	0
the	0
phenylalanine	0
hydroxylase-	0
catalyzed	0
hydroxylation	0
of	0
phenylalanine	0
.	0

In	0
addition	0
,	0
it	0
is	0
the	0
dimerization	0
cofactor	0
of	0
HNF1	9
that	0
is	0
able	0
to	0
activate	0
the	0
transcriptional	0
activity	0
of	0
HNF1	9
.	0

Deficiencies	0
in	0
the	0
gene	0
for	0
this	0
dual	9
functional	10
protein	10
result	0
in	0
hyperphenylalaninemia	0
.	0

Here	0
we	0
report	0
for	0
the	0
first	0
time	0
that	0
the	0
PCD/DCoH	3
mRNA	4
is	0
present	0
in	0
human	7
white	8
blood	8
cells	8
and	0
hair	0
follicles	0
.	0

Taking	0
advantage	0
of	0
this	0
finding	0
,	0
a	0
sensitive	0
,	0
rapid	0
and	0
convenient	0
method	0
for	0
screening	0
mutations	0
occurring	0
in	0
the	0
coding	0
region	0
of	0
this	0
gene	0
has	0
been	0
described	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Biochemical	0
characterization	0
of	0
the	0
NF-Y	9
transcription	10
factor	10
complex	10
during	0
B	0
lymphocyte	0
development	0
.	0

The	0
transcription	9
factor	10
,	0
NF-Y	9
,	0
plays	0
a	0
critical	0
role	0
in	0
tissue-specific	0
major	1
histocompatibility	2
complex	2
class	2
II	2
gene	2
transcription	0
.	0

In	0
this	0
report	0
the	0
biochemical	0
properties	0
of	0
the	0
heterotrimeric	9
NF-Y	10
complex	10
have	0
been	0
characterized	0
during	0
stage-specific	0
B-cell	0
development	0
,	0
and	0
in	0
several	0
class	5
II-	6
mutant	6
B-cell	6
lines	6
,	0
which	0
represent	0
distinct	0
bare	0
lymphocyte	0
syndrome	0
class	0
II	0
genetic	0
complementation	0
groups	0
.	0

The	0
NF-Y	9
complex	10
derived	0
from	0
class	7
II+	8
mature	8
B-cells	8
bound	0
with	0
high	0
affinity	0
to	0
anion	9
exchangers	10
,	0
and	0
eluted	0
as	0
an	0
intact	0
trimeric	9
complex	10
,	0
whereas	0
,	0
NF-Y	9
derived	0
from	0
class	7
II-	8
plasma	8
B-cells	8
,	0
and	0
from	0
bare	5
lymphocyte	6
syndrome	6
group	6
II	6
cell	6
lines	6
,	0
RJ2.2.5	5
and	0
RM3	5
,	0
dissociated	0
into	0
discrete	0
NF-YA	9
and	0
NF-YB	9
:	10
C	10
subunit	9
fractions	10
.	0

Recombination	0
of	0
the	0
MPC11	9
plasma	10
B-cell	10
derived	10
NF-Y	10
A	10
:	10
B	10
:	10
C	10
complex	10
with	0
the	0
low	0
molecular	0
mass	0
protein	0
fraction	0
,	0
NF-Y-associated	9
factors	10
(	0
YAFs	9
)	0
,	0
derived	0
from	0
mature	0
A20	0
B-cell	0
nuclei	0
,	0
conferred	0
high	0
affinity	0
anion	0
exchange	0
binding	0
to	0
NF-Y	9
as	0
an	0
intact	9
trimeric	10
complex	10
.	0

Recombination	0
of	0
the	0
native	9
NF-YA	10
:	10
B	10
:	10
C	10
complex	10
with	0
the	0
transcriptional	9
cofactor	10
,	0
PC4	9
,	0
likewise	0
conferred	0
high	9
affinity	10
NF-Y	10
binding	0
to	0
anion	9
exchangers	10
,	0
and	0
stabilized	0
NF-Y	9
interaction	0
with	0
CCAAT-box	1
DNA	2
motifs	2
in	0
vitro	0
.	0

Interaction	0
between	0
PC4	9
and	0
NF-Y	9
was	0
mapped	0
to	0
the	0
C-terminal	9
region	10
of	0
PC4	9
,	0
and	0
the	0
subunit	9
interaction	10
subdomain	10
of	0
the	0
highly	9
conserved	10
DNA	10
binding-subunit	10
interaction	10
domain	10
(	0
DBD	9
)	0
of	0
NF-YA	9
.	0

These	0
results	0
suggest	0
that	0
in	0
class	7
II+	8
mature	8
B-cells	8
NF-Y	9
is	0
associated	0
with	0
the	0
protein	0
cofactor	0
,	0
PC4	9
,	0
which	0
may	0
play	0
an	0
important	0
role	0
in	0
NF-Y-mediated	0
transcriptional	0
control	0
of	0
class	1
II	2
genes	2
.	0

Arrest	0
of	0
B	0
lymphocyte	0
terminal	0
differentiation	0
by	0
CD40	0
signaling	0
:	0
mechanism	0
for	0
lack	0
of	0
antibody-secreting	7
cells	8
in	0
germinal	0
centers	0
.	0

Despite	0
extensive	0
research	0
,	0
the	0
role	0
of	0
CD40	9
signaling	0
in	0
B	0
cell	0
terminal	0
differentiation	0
remains	0
controversial	0
.	0

Here	0
we	0
show	0
that	0
CD40	9
engagement	0
arrests	0
B	0
cell	0
differentiation	0
prior	0
to	0
plasma	0
cell	0
formation	0
.	0

This	0
arrest	0
is	0
manifested	0
at	0
a	0
molecular	0
level	0
as	0
a	0
reduction	0
in	0
mRNA	0
levels	0
of	0
secretory	0
immunoglobulin	0
gene	0
products	0
such	0
as	0
mu	0
(	0
s	0
)	0
and	0
J	0
chain	0
as	0
well	0
as	0
the	0
loss	0
of	0
the	0
transcriptional	9
regulator	10
BLIMP-1	9
.	0

Furthermore	0
,	0
the	0
inhibition	0
of	0
B	0
cell	0
differentiation	0
by	0
CD40	9
engagement	0
could	0
not	0
be	0
overcome	0
by	0
either	0
mitogens	9
or	0
cytokines	9
,	0
but	0
could	0
be	0
reversed	0
by	0
antibodies	0
that	0
interfere	0
with	0
the	0
CD40	9
/	0
gp39	9
interaction	0
.	0

These	0
data	0
suggest	0
that	0
secretory	0
immunoglobulin	0
is	0
not	0
produced	0
by	0
B	7
cells	8
that	0
are	0
actively	0
engaged	0
by	0
gp39-expressing	7
T	8
cells	8
.	0

A	0
positively	0
charged	0
alpha-lipoic	0
acid	0
analogue	0
with	0
increased	0
cellular	0
uptake	0
and	0
more	0
potent	0
immunomodulatory	0
activity	0
.	0

alpha-Lipoic	0
acid	0
(	0
LA	0
)	0
is	0
taken	0
up	0
by	0
cells	0
and	0
reduced	0
to	0
its	0
potent	0
dithiol	0
form	0
,	0
dihydrolipoate	0
(	0
DHLA	0
)	0
,	0
much	0
of	0
which	0
is	0
rapidly	0
effluxed	0
out	0
from	0
cells	0
.	0

To	0
improve	0
retention	0
in	0
cells	0
,	0
the	0
LA	0
molecule	0
was	0
modified	0
to	0
confer	0
a	0
positive	0
charge	0
at	0
physiological	0
pH	0
.	0

N	0
,	0
N-dimethyl	0
,	0
N'-2-amidoethyl-lipoate	0
was	0
synthesized	0
.	0

The	0
protonated	0
form	0
of	0
the	0
new	0
molecule	0
is	0
referred	0
to	0
as	0
LA-Plus	0
.	0

The	0
uptake	0
of	0
LA-Plus	0
by	0
human	7
Wurzburg	8
T	8
cells	8
was	0
higher	0
compared	0
to	0
that	0
of	0
LA	0
.	0

Several-fold	0
higher	0
amounts	0
of	0
DHLA-Plus	0
,	0
the	0
corresponding	0
reduced	0
form	0
of	0
LA-Plus	0
,	0
were	0
detected	0
in	0
LA-Plus	0
treated	0
cells	0
compared	0
to	0
the	0
amount	0
of	0
DHLA	0
found	0
in	0
cells	0
treated	0
with	0
LA	0
.	0

At	0
100	0
microM	0
,	0
LA	0
did	0
not	0
but	0
LA-Plus	0
inhibited	0
H2O2	0
induced	0
NF-kappaB	9
activation	0
and	0
NF-kappaB	9
directed	0
IL-2	9
receptor	10
expression	0
.	0

Both	0
LA	0
and	0
LA-Plus	0
synergised	0
with	0
selenium	0
in	0
inhibiting	0
H2O2	0
induced	0
NF-kappaB	9
activation	0
.	0

At	0
150	0
microM	0
LA-Plus	0
,	0
but	0
not	0
LA	0
,	0
inhibited	0
TNFalpha	9
induced	0
NF-kappaB	9
activation	0
.	0

At	0
5	0
microM	0
LA-Plus	0
,	0
but	0
not	0
LA	0
,	0
protected	0
against	0
both	0
spontaneous	0
and	0
etoposide	0
induced	0
apoptosis	0
in	0
rat	7
thymocytes	8
.	0

LA-Plus	0
is	0
thus	0
an	0
improved	0
form	0
of	0
LA	0
with	0
increased	0
therapeutic	0
potential	0
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Carrier	0
identification	0
in	0
X-linked	0
immunodeficiency	0
diseases	0
.	0

OBJECTIVE	0
:	0
Carrier	0
identification	0
in	0
X-linked	0
immunodeficiency	0
disorders	0
can	0
be	0
based	0
on	0
the	0
demonstration	0
of	0
non-random	0
X	0
inactivation	0
(	0
NRXI	0
)	0
in	0
affected	7
blood	8
cell	8
lineages	8
when	0
growth	0
is	0
impaired	0
in	0
cells	0
expressing	0
the	0
abnormal	1
gene	2
.	0

We	0
examined	0
the	0
utility	0
of	0
seeking	0
evidence	0
of	0
NRXI	0
to	0
test	0
the	0
carrier	0
status	0
of	0
women	0
in	0
families	0
affected	0
by	0
X-linked	0
severe	0
combined	0
immunodeficiency	0
(	0
XSCID	0
)	0
and	0
X-linked	0
hypogammaglobulinaemia	0
(	0
XLH	0
)	0
,	0
to	0
identify	0
as	0
carriers	0
the	0
mothers	0
of	0
boys	0
with	0
SCID	0
or	0
hypogammaglobulinaemia	0
whose	0
phenotype	0
suggested	0
X-linkage	0
and	0
to	0
infer	0
X-linkage	0
in	0
boys	0
with	0
SCID	0
or	0
hypogammaglobulinaemia	0
whose	0
disease	0
was	0
not	0
clearly	0
X-linked	0
on	0
the	0
basis	0
either	0
of	0
family	0
history	0
or	0
clinical	0
and	0
immunological	0
characteristics	0
.	0

METHODOLOGY	0
:	0
A	0
polymerase	0
chain	0
reaction-based	0
method	0
was	0
used	0
to	0
amplify	0
a	0
polymorphic	0
CAG	1
repeat	2
in	0
the	0
first	1
exon	2
of	0
the	0
androgen	1
receptor	2
gene	2
after	0
selective	0
digestion	0
of	0
the	0
active	1
X	2
chromosome	2
with	0
a	0
methylation-sensitive	9
enzyme	10
,	0
HpaII	9
to	0
distinguish	0
between	0
the	0
paternal	1
and	2
maternal	2
alleles	2
and	0
to	0
identify	0
their	0
methylation	0
status	0
.	0

RESULTS	0
:	0
Heterozygosity	0
was	0
found	0
in	0
24	0
of	0
31	0
female	0
subjects	0
(	0
77	0
%	0
)	0
.	0

As	0
anticipated	0
,	0
NRXI	0
could	0
be	0
demonstrated	0
in	0
all	0
lymphoid	7
cells	8
studied	0
from	0
obligate	0
carriers	0
of	0
XSCID	0
and	0
an	0
obligate	0
carrier	0
of	0
XLH	0
but	0
not	0
on	0
a	0
carrier	0
of	0
X-linked	0
immunodeficiency	0
with	0
hyper-IgM	9
.	0

The	0
finding	0
of	0
NRXI	0
in	0
the	0
mother	0
of	0
a	0
boy	0
with	0
a	0
SCID	0
variant	0
showed	0
her	0
to	0
be	0
a	0
carrier	0
of	0
XSCID	0
and	0
establishes	0
that	0
her	0
son	0
has	0
XSCID	0
,	0
not	0
otherwise	0
evident	0
from	0
available	0
data	0
.	0

CONCLUSIONS	0
:	0
This	0
PCR	0
assay	0
provides	0
a	0
rapid	0
method	0
for	0
carrier	0
detection	0
of	0
X-linked	0
immunodeficiencies	0
,	0
and	0
has	0
allowed	0
us	0
to	0
expand	0
the	0
phenotype	0
of	0
XSCID	0

Leukocyte-endothelial	0
interaction	0
is	0
augmented	0
by	0
high	0
glucose	0
concentrations	0
and	0
hyperglycemia	0
in	0
a	0
NF-kB-dependent	0
fashion	0
.	0

We	0
addressed	0
the	0
role	0
of	0
hyperglycemia	0
in	0
leukocyte-endothelium	0
interaction	0
under	0
flow	0
conditions	0
by	0
exposing	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
for	0
24	0
h	0
to	0
normal	0
(	0
5	0
mM	0
)	0
,	0
high	0
concentration	0
of	0
glucose	0
(	0
30	0
mM	0
)	0
,	0
advanced	0
glycosylation	0
end	0
product-albumin	9
(	0
100	0
microg/ml	0
)	0
,	0
or	0
hyperglycemic	0
(	0
174-316	0
mg/dl	0
)	0
sera	0
from	0
patients	0
with	0
diabetes	0
and	0
abnormal	0
hemoglobin	0
A1c	0
(	0
8.1+/-1.4	0
%	0
)	0
.	0

At	0
the	0
end	0
of	0
incubation	0
endothelial	7
cells	8
were	0
perfused	0
with	0
total	0
leukocyte	0
suspension	0
in	0
a	0
parallel	0
plate	0
flow	0
chamber	0
under	0
laminar	0
flow	0
(	0
1.5	0
dyn/cm2	0
)	0
.	0

Rolling	0
and	0
adherent	7
cells	8
were	0
evaluated	0
by	0
digital	0
image	0
processing	0
.	0

Results	0
showed	0
that	0
30	0
mM	0
glucose	0
significantly	0
(	0
P	0
<	0
0.01	0
)	0
increased	0
the	0
number	0
of	0
adherent	7
leukocytes	8
to	0
endothelial	7
cells	8
in	0
respect	0
to	0
control	0
(	0
5	0
mM	0
glucose	0
;	0
151+/-19	0
versus	0
33+/-8	0
cells/mm2	0
)	0
.	0

A	0
similar	0
response	0
was	0
induced	0
by	0
endothelial	0
stimulation	0
with	0
IL-1beta	9
,	0
here	0
used	0
as	0
positive	0
control	0
(	0
195+/-20	0
cells/mm2	0
)	0
.	0

The	0
number	0
of	0
rolling	7
cells	8
on	0
endothelial	0
surface	0
was	0
not	0
affected	0
by	0
high	0
glucose	0
level	0
.	0

Stable	0
adhesion	0
of	0
leukocytes	7
to	0
glucose-treated	0
as	0
well	0
as	0
to	0
IL-1beta-stimulated	7
endothelial	8
cells	8
was	0
preceded	0
by	0
short	0
interaction	0
of	0
leukocytes	7
with	0
the	0
endothelial	0
surface	0
.	0

The	0
distance	0
travelled	0
by	0
leukocytes	7
before	0
arrest	0
on	0
30	0
mM	0
glucose	0
,	0
or	0
on	0
IL-1beta-treated	7
endothelial	8
cells	8
,	0
was	0
significantly	0
(	0
P	0
<	0
0.01	0
)	0
higher	0
than	0
that	0
observed	0
for	0
leukocytes	7
adhering	0
on	0
control	0
endothelium	0
(	0
30	0
mM	0
glucose	0
:	0
76.7+/-3.5	0
;	0
IL1beta	0
:	0
69.7+/-4	0
versus	0
5	0
mM	0
glucose	0
:	0
21.5+/-5	0
microm	0
)	0
.	0

Functional	0
blocking	0
of	0
E-selectin	9
,	0
intercellular	9
cell	10
adhesion	10
molecule-1	10
,	0
and	0
vascular	9
cell	10
adhesion	10
molecule-1	10
on	0
endothelial	7
cells	8
with	0
the	0
corresponding	0
mouse	9
mAb	10
significantly	0
inhibited	0
glucose-induced	0
increase	0
in	0
leukocyte	0
adhesion	0
(	0
67+/-16	0
,	0
83+/-12	0
,	0
62+/-8	0
versus	0
144+/-21	0
cells/	0
mm2	0
)	0
.	0

Confocal	0
fluorescence	0
microscopy	0
studies	0
showed	0
that	0
30	0
mM	0
glucose	0
induced	0
an	0
increase	0
in	0
endothelial	0
surface	0
expression	0
of	0
E-selectin	9
,	0
intercellular	9
cell	10
adhesion	10
molecule-1	10
,	0
and	0
vascular	9
cell	10
adhesion	10
molecule-1	10
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
of	0
nuclear	0
extracts	0
of	0
human	7
umbilical	8
vein	8
endothelial	8
cells	8
(	0
HUVEC	0
)	0
exposed	0
for	0
1	0
h	0
to	0
30	0
mM	0
glucose	0
revealed	0
an	0
intense	0
NF-kB	9
activation	0
.	0

Treatment	0
of	0
HUVEC	0
exposed	0
to	0
high	0
glucose	0
with	0
the	0
NF-kB	9
inhibitors	10
pyrrolidinedithiocarbamate	0
(	0
100	0
microM	0
)	0
and	0
tosyl-phe-chloromethylketone	0
(	0
25	0
microM	0
)	0
significantly	0
reduced	0
(	0
P	0
<	0
0.05	0
)	0
leukocyte	0
adhesion	0
in	0
respect	0
to	0
HUVEC	0
treated	0
with	0
glucose	0
alone	0
.	0

A	0
significant	0
(	0
P	0
<	0
0.01	0
)	0
inhibitory	0
effect	0
on	0
glucose-induced	0
leukocyte	0
adhesion	0
was	0
observed	0
after	0
blocking	0
protein	9
kinase	10
C	10
activity	0
with	0
staurosporine	0
(	0
5	0
nM	0
)	0
.	0

When	0
HUVEC	0
were	0
treated	0
with	0
specific	0
antisense	0
oligodesoxynucleotides	0
against	0
PKCalpha	9
and	10
PKCepsilon	10
isoforms	10
before	0
the	0
addition	0
of	0
30	0
mM	0
glucose	0
,	0
a	0
significant	0
(	0
P	0
<	0
0.05	0
)	0
reduction	0
in	0
the	0
adhesion	0
was	0
also	0
seen	0
.	0

Advanced	0
glycosylation	0
end	0
product-albumin	9
significantly	0
increased	0
the	0
number	0
of	0
adhering	7
leukocytes	8
in	0
respect	0
to	0
native	9
albumin	10
used	0
as	0
control	0
(	0
110+/-16	0
versus	0
66+/-7	0
,	0
P	0
<	0
0.01	0
)	0
.	0

Sera	0
from	0
diabetic	0
patients	0
significantly	0
(	0
P	0
<	0
0.01	0
)	0
enhanced	0
leukocyte	0
adhesion	0
as	0
compared	0
with	0
controls	0
,	0
despite	0
normal	0
levels	0
of	0
IL-1beta	9
and	0
TNFalpha	9
in	0
these	0
sera	0
.	0

These	0
data	0
indicate	0
that	0
high	0
glucose	0
concentration	0
and	0
hyperglycemia	0
promote	0
leukocyte	0
adhesion	0
to	0
the	0
endothelium	0
through	0
upregulation	0
of	0
cell	0
surface	0
expression	0
of	0
adhesive	0
proteins	0
,	0
possibly	0
depending	0
on	0
NF-kB	9
activation	0
.	0

Ikaros	9
in	0
hemopoietic	0
lineage	0
determination	0
and	0
homeostasis	0
.	0

Studies	0
on	0
the	0
molecular	0
mechanisms	0
that	0
control	0
hemopoietic	0
differentiation	0
have	0
focused	0
on	0
signaling	0
cascades	0
and	0
nuclear	0
effectors	0
that	0
drive	0
this	0
complex	0
developmental	0
system	0
in	0
a	0
regulated	0
fashion	0
.	0

Here	0
we	0
review	0
the	0
role	0
of	0
Ikaros	9
,	0
the	0
founding	0
member	0
of	0
a	0
unique	0
family	0
of	0
zinc	9
finger	10
transcription	10
factors	10
in	0
this	0
developmental	0
process	0
.	0

Studies	0
on	0
an	0
Ikaros	9
null	0
mutation	0
have	0
revealed	0
an	0
essential	0
role	0
for	0
this	0
factor	0
in	0
lymphoid	0
cell	0
fate	0
determination	0
and	0
at	0
subsequent	0
branch	0
points	0
of	0
the	0
T	0
cell	0
differentiation	0
pathway	0
.	0

Differences	0
in	0
the	0
phenotypes	0
of	0
a	0
null	0
and	0
a	0
dominant	1
negative	2
(	2
DN	2
)	2
Ikaros	2
mutation	2
provide	0
insight	0
into	0
a	0
regulatory	0
network	0
through	0
which	0
Ikaros	9
proteins	10
exert	0
their	0
effects	0
in	0
development	0
.	0

In	0
addition	0
a	0
comparative	0
analysis	0
of	0
the	0
hemopoietic	7
stem	8
cell	8
and	0
precursor	0
compartment	0
resulting	0
from	0
the	0
two	0
Ikaros	1
mutations	2
reveals	0
a	0
profound	0
yet	0
not	0
absolute	0
requirement	0
for	0
Ikaros	9

Induction	0
of	0
early	9
B	10
cell	10
factor	10
(	0
EBF	9
)	0
and	0
multiple	1
B	2
lineage	2
genes	2
by	0
the	0
basic	9
helix-loop-helix	10
transcription	10
factor	10
E12	9
.	0

The	0
transcription	9
factors	10
encoded	0
by	0
the	0
E2A	9
and	0
early	9
B	10
cell	10
factor	10
(	0
EBF	9
)	0
genes	0
are	0
required	0
for	0
the	0
proper	0
development	0
of	0
B	7
lymphocytes	8
.	0

However	0
,	0
the	0
absence	0
of	0
B	7
lineage	8
cells	8
in	0
E2A-	0
and	0
EBF-deficient	0
mice	0
has	0
made	0
it	0
difficult	0
to	0
determine	0
the	0
function	0
or	0
relationship	0
between	0
these	0
proteins	0
.	0

We	0
report	0
the	0
identification	0
of	0
a	0
novel	0
model	0
system	0
in	0
which	0
the	0
role	0
of	0
E2A	9
and	0
EBF	9
in	0
the	0
regulation	0
of	0
multiple	0
B	0
lineage	0
traits	0
can	0
be	0
studied	0
.	0

We	0
found	0
that	0
the	0
conversion	0
of	0
70Z/3	5
pre-B	6
lymphocytes	6
to	0
cells	0
with	0
a	0
macrophage-like	0
phenotype	0
is	0
associated	0
with	0
the	0
loss	0
of	0
E2A	9
and	0
EBF	9
.	0

Moreover	0
,	0
we	0
show	0
that	0
ectopic	0
expression	0
of	0
the	0
E2A	9
protein	0
E12	9
in	0
this	0
macrophage	5
line	6
results	0
in	0
the	0
induction	0
of	0
many	1
B	2
lineage	2
genes	2
,	0
including	0
EBF	9
,	0
IL7Ralpha	9
,	0
lambda5	9
,	0
and	0
Rag-1	0
,	0
and	0
the	0
ability	0
to	0
induce	0
kappa	9
light	10
chain	10
in	0
response	0
to	0
mitogen	0
.	0

Activation	0
of	0
EBF	9
may	0
be	0
one	0
of	0
the	0
critical	0
functions	0
of	0
E12	9
in	0
regulating	0
the	0
B	0
lineage	0
phenotype	0
since	0
expression	0
of	0
EBF	9
alone	0
leads	0
to	0
the	0
activation	0
of	0
a	0
subset	0
of	0
E12	9
-inducible	0
traits	0
.	0

Our	0
data	0
demonstrate	0
that	0
,	0
in	0
the	0
context	0
of	0
this	0
macrophage	5
line	6
,	0
E12	9
induces	0
expression	0
of	0
EBF	9
and	0
together	0
these	0
transcription	9
factors	10
coordinately	0
regulate	0
numerous	0
B	1
lineage-associated	2
genes	2
.	0

Activation-induced	0
down-regulation	0
of	0
retinoid	9
receptor	10
RXRalpha	10
expression	0
in	0
human	7
T	8
lymphocytes	8
.	0

Role	0
of	0
cell	0
cycle	0
regulation	0
.	0

A	0
5.4-kilobase	3
mRNA	4
,	0
the	0
expression	0
of	0
which	0
is	0
down-regulated	0
after	0
treatment	0
of	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
with	0
various	0
T	0
cell-activating	0
agents	0
,	0
was	0
isolated	0
using	0
an	0
mRNA	0
differential	0
display	0
method	0
.	0

Nucleotide	0
sequence	0
analysis	0
identified	0
the	0
5	3
'	4
end	4
of	0
this	0
RNA	3
as	0
human	3
retinoid	4
receptor	4
RXRalpha	4
mRNA	4
.	0

Here	0
,	0
we	0
report	0
the	0
nucleotide	0
sequence	0
of	0
3.6	1
kilobases	2
of	0
this	0
RNA	0
,	0
which	0
represents	0
the	0
3	3
'	4
end	4
of	0
RXRalpha	3
mRNA	4
,	0
the	0
sequence	0
of	0
which	0
has	0
not	0
been	0
previously	0
described	0
.	0

Activated	0
PBMCs	7
also	0
expressed	0
lower	0
levels	0
of	0
RXRalpha	9
protein	0
,	0
and	0
a	0
DNA	0
binding	0
assay	0
showed	0
that	0
the	0
activation-induced	0
loss	0
of	0
RXRalpha	3
mRNA	4
and	0
protein	0
expression	0
correlated	0
with	0
the	0
loss	0
of	0
DNA	0
binding	0
activity	0
of	0
this	0
protein	0
.	0

We	0
present	0
evidence	0
that	0
the	0
transition	0
from	0
G0/G1	0
to	0
S	0
phase	0
of	0
the	0
cell	0
cycle	0
results	0
in	0
the	0
down-regulation	0
of	0
RXRalpha	9
expression	0
and	0
that	0
cell	0
cycle	0
inhibitors	0
,	0
which	0
block	0
the	0
cells	0
in	0
G1	0
phase	0
,	0
prevent	0
this	0
down-regulation	0
.	0

The	0
decrease	0
in	0
the	0
levels	0
of	0
RXRalpha	3
mRNA	4
was	0
found	0
to	0
be	0
regulated	0
at	0
the	0
post-transcriptional	0
level	0
and	0
involved	0
new	0
protein	0
synthesis	0
.	0

These	0
observations	0
indicate	0
that	0
the	0
levels	0
of	0
RXRalpha	9
expression	0
in	0
T	0
lymphocytes	0
are	0
coupled	0
to	0
cell	0
cycle	0
progression	0
,	0
and	0
there	0
is	0
tight	0
regulatory	0
control	0
of	0
RXRalpha	9
expression	0
during	0
the	0
transition	0
from	0
G0/G1	0
to	0
S	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

Epidemiology	0
and	0
pathogenesis	0
of	0
AIDS-related	0
lymphomas	0
.	0

Among	0
patients	0
with	0
congenital	0
and	0
acquired	0
immunodeficiencies	0
,	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
NHLs	0
)	0
are	0
the	0
most	0
common	0
tumors	0
of	0
the	0
immune	0
system	0
.	0

In	0
the	0
setting	0
of	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
infection	0
,	0
as	0
many	0
as	0
10	0
%	0
to	0
20	0
%	0
of	0
people	0
ultimately	0
developed	0
NHLs	0
.	0

These	0
tumors	0
are	0
clinically	0
aggressive	0
,	0
frequently	0
involve	0
extranodal	0
sites	0
,	0
and	0
often	0
exhibit	0
unique	0
features	0
that	0
distinguish	0
them	0
from	0
NHL	0
arising	0
in	0
individuals	0
with	0
other	0
forms	0
of	0
immunosuppression	0
.	0

Important	0
in	0
the	0
development	0
of	0
HIV-associated	0
NHL	0
are	0
cytokines	9
and	0
other	0
factors	0
that	0
induce	0
B-cell	0
proliferation	0
and	0
increase	0
the	0
likelihood	0
of	0
mutations	0
of	0
c-myc	1
,	0
bcl-6	1
,	0
and	0
other	0
tumor-suppressor	1
genes	2
with	0
carcinogenic	0
potential	0
.	0

Specific	0
forms	0
of	0
HIV-associated	0
NHL	0
are	0
linked	0
to	0
expression	0
of	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
-latent	10
proteins	10
;	0
the	0
newly	0
described	0
DNA	0
virus	0
,	0
Karposi	0
's	0
sarcoma-associated	0
herpesvirus/human	0
herpesvirus-8	0
(	0
KSHV/HHV-8	0
)	0
;	0
and	0
perhaps	0
HIV	0
.	0

Elucidation	0
of	0
the	0
factors	0
that	0
contribute	0
to	0
the	0
high	0
incidence	0
of	0
NHL	0
among	0
patients	0
infected	0
with	0
HIV	0
provides	0
insights	0
into	0
important	0
elements	0
of	0
lymphomagenesis	0
.	0

Matrix	9
metalloproteinase	10
expression	0
in	0
human	0
breast	0
cancer	0
:	0
an	0
immunohistochemical	0
study	0
including	0
correlation	0
with	0
cathepsin	9
D	10
,	0
type	9
IV	10
collagen	10
,	0
laminin	9
,	0
fibronectin	9
,	0
EGFR	9
,	0
c-erbB-2	9
oncoprotein	10
,	0
p53	9
,	0
steroid	0
receptors	0
status	0
and	0
proliferative	0
indices	0
.	0

Matrix	9
metalloproteinase	10
s	0
(	0
MMPs	9
)	0
are	0
a	0
group	0
of	0
enzymes	0
thought	0
to	0
be	0
responsible	0
for	0
both	0
normal	0
connective	0
tissue	0
matrix	0
remodelling	0
and	0
accelerated	0
breakdown	0
associated	0
with	0
tumour	0
development	0
.	0

The	0
current	0
study	0
aimed	0
to	0
investigate	0
the	0
immunohistochemical	0
expression	0
of	0
matrix	9
metalloproteinase	10
3	10
(	0
MMP-3	9
,	0
stromelysin-1	9
)	0
in	0
correlation	0
with	0
the	0
expression	0
of	0
Basement	9
Membrane	10
(	10
BM	10
)	10
antigen	10
(	0
type	9
IV	10
collagen	10
,	0
laminin	9
)	0
,	0
fibronectin	9
,	0
cathepsin	9
D	10
,	0
p53	9
,	0
c-erbB-2	9
,	0
proliferative	0
activity	0
(	0
Ki-67	9
,	0
PCNA	9
)	0
,	0
steroid	0
receptor	0
content	0
as	0
well	0
as	0
to	0
the	0
other	0
conventional	0
clinicopathological	0
parameters	0
in	0
breast	0
cancer	0
.	0

This	0
study	0
was	0
performed	0
on	0
a	0
series	0
of	0
frozen	0
and	0
paraffin	0
sections	0
from	0
84	0
breast	0
cancer	0
specimens	0
by	0
immunohistochemistry	0
using	0
the	0
monoclonal	9
antibody	10
MMP-3	10
(	0
Ab-1	9
)	0
.	0

Stromelysin-1	9
(	0
ST1	9
)	0
was	0
observed	0
in	0
about	0
10	0
%	0
of	0
epithelial	7
cells	8
in	0
the	0
control	0
groups	0
(	0
cases	0
of	0
fibrocystic	0
and	0
benign	0
proliferative	0
breast	0
disease	0
)	0
,	0
while	0
expression	0
(	0
>	0
10	0
%	0
of	0
expression	0
)	0
was	0
detected	0
in	0
89.7	0
%	0
of	0
tumours	0
.	0

The	0
expression	0
of	0
ST1	9
in	0
carcinoma	0
cells	0
was	0
strongly	0
associated	0
with	0
its	0
presence	0
in	0
the	0
stroma	0
(	0
p	0
<	0
0.001	0
)	0
.	0

A	0
significantly	0
positive	0
correlation	0
was	0
found	0
between	0
ST1	9
expression	0
,	0
and	0
p53	9
tumour	0
suppressor	0
gene	0
product	0
(	0
p	0
=	0
0.004	0
)	0
,	0
and	0
a	0
relationship	0
with	0
c-erbB-2	9
protein	0
and	0
progesterone	0
receptor	0
status	0
was	0
also	0
indicated	0
.	0

These	0
findings	0
suggest	0
that	0
ST1	9
expression	0
in	0
breast	0
cancer	0
tissue	0
is	0
irrespective	0
of	0
the	0
expression	0
of	0
the	0
extracellular	0
matrix	0
component	0
,	0
the	0
proteolytic	9
enzyme	10
cathepsin	9
D	10
and	0
the	0
growth	0
fraction	0
of	0
the	0
tumour	0
,	0
and	0
that	0
it	0
could	0
be	0
a	0
potential	0
new	0
prognostic	0
marker	0
in	0
breast	0
cancer	0
.	0

Use	0
of	0
transfected	5
liver	6
cells	6
to	0
evaluate	0
potential	0
mechanisms	0
of	0
alcohol-induced	0
liver	0
injury	0
[	0
see	0
comments	0
]	0

There	0
is	0
increased	0
activity	0
of	0
the	0
proinflammatory	9
cytokine	10
,	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
in	0
alcoholic	0
liver	0
disease	0
(	0
ALD	0
)	0
.	0

Hepatic	0
neutrophil	0
infiltration	0
is	0
a	0
principal	0
injurious	0
manifestation	0
of	0
ALD	0
.	0

TNF	9
can	0
induce	0
cellular	0
oxidative	0
injury	0
directly	0
,	0
and	0
indirectly	0
by	0
inducing	0
neutrophil	0
chemotactic	0
factor	0
(	0
IL-8	9
)	0
production	0
by	0
hepatocytes	0
.	0

IL-8	9
activates	0
and	0
chemotactically	0
attracts	0
neutrophils	0
to	0
the	0
liver	0
where	0
they	0
release	0
oxidizing	0
substances	0
.	0

Patients	0
with	0
ALD	0
also	0
have	0
decreased	0
protective	9
factors	10
for	0
cellular	0
oxidative	0
injury	0
.	0

Manganous	9
superoxide	10
dismutase	10
(	0
MnSOD	9
)	0
is	0
an	0
antioxidant	9
protective	10
factor	10
.	0

The	0
objectives	0
of	0
these	0
studies	0
were	0
to	0
investigate	0
mechanisms	0
for	0
induction	0
of	0
an	0
injurious	9
factor	10
(	0
IL-8	9
)	0
and	0
a	0
protective	9
factor	10
(	0
MnSOD	9
)	0
in	0
the	0
HepG2	5
human	6
hepatoma	6
cell	6
line	6
.	0

In	0
the	0
first	0
set	0
of	0
experiments	0
,	0
IL-8	1
gene	2
reporter	2
constructs	2
were	0
used	0
to	0
transiently	0
transfect	0
a	0
derivative	0
(	0
MVh2E1-9	5
)	0
of	0
the	0
HepG2	5
cell	6
line	6
which	0
expresses	0
P-4502E1	9
and	0
metabolizes	0
ethanol	0
.	0

Inactivation	0
of	0
the	0
NF-kappaB	1
and	2
3'NF-IL-6	2
DNA	2
binding	2
sites	2
decreased	0
IL-8	1
gene	2
transcriptional	0
activation	0
in	0
response	0
to	0
TNF	9
while	0
inactivation	0
of	0
the	0
5'NF-IL-6	1
binding	2
site	2
increased	0
IL-8	1
gene	2
transcriptional	0
activity	0
in	0
response	0
to	0
TNF	9
.	0

This	0
system	0
may	0
be	0
useful	0
to	0
assess	0
the	0
effects	0
of	0
ethanol	0
on	0
TNF	9
-induced	0
hepatocyte	0
IL-8	9
production	0
.	0

In	0
the	0
second	0
set	0
of	0
experiments	0
,	0
HepG2	5
cells	6
were	0
cultured	0
in	0
25	0
to	0
100	0
mmol	0
concentrations	0
of	0
ethanol	0
.	0

Both	0
TNF	9
and	0
ethanol	0
increased	0
HepG2	5
cell	6
MnSOD	9
activity	0
in	0
short-term	0
(	0
72	0
hr	0
)	0
cultures	0
with	0
ethanol	0
.	0

However	0
,	0
after	0
long-term	0
(	0
10	0
weeks	0
)	0
culture	0
with	0
ethanol	0
,	0
there	0
was	0
no	0
induction	0
of	0
MnSOD	9
by	0
ethanol	0
and	0
there	0
was	0
a	0
diminished	0
induction	0
of	0
MnSOD	9
in	0
response	0
to	0
TNF	9
.	0

Further	0
studies	0
are	0
needed	0
to	0
assess	0
the	0
effect	0
of	0
this	0
diminished	0
induction	0
of	0
MnSOD	9
with	0
chronic	0
ethanol	0
culture	0
on	0
HepG2	5
cell	6
susceptibility	0
to	0
TNF	5
cytotoxicity	6
.	0

We	0
conclude	0
that	0
transfected	0
liver	5
cell	6
lines	6
can	0
be	0
used	0
to	0
evaluate	0
mechanisms	0
for	0
increased	0
injurious	9
factors	10
and	0
decreased	0
protective	9
factors	10
in	0
alcoholic	0
liver	0
injury	0
.	0

Tissue	0
factor	0
transcription	0
driven	0
by	0
Egr-1	9
is	0
a	0
critical	0
mechanism	0
of	0
murine	9
pulmonary	10
fibrin	10
deposition	0
in	0
hypoxia	0
.	0

Local	0
hypoxemia	0
and	0
stasis	0
trigger	0
thrombosis	0
.	0

We	0
have	0
demonstrated	0
previously	0
that	0
in	0
a	0
murine	0
model	0
of	0
normobaric	0
hypoxia	0
pulmonary	0
fibrin	9
deposition	0
is	0
a	0
result	0
of	0
expression	0
of	0
tissue	9
factor	10
,	0
especially	0
in	0
oxygen-deprived	9
mononuclear	10
phagocytes	10
(	0
MPs	9
)	0
.	0

We	0
now	0
show	0
that	0
transcription	9
factor	10
early-growth-response	10
gene	10
product	10
(	0
Egr-1	9
)	0
is	0
rapidly	0
activated	0
in	0
hypoxia	0
,	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
,	0
and	0
is	0
responsible	0
for	0
transcription	0
and	0
expression	0
of	0
tissue	9
factor	10
in	0
hypoxic	0
lung	0
.	0

MPs	9
and	0
HeLa	5
cells	6
subjected	0
to	0
hypoxia	0
(	0
pO2	0
approximately	0
13	0
torr	0
)	0
had	0
increased	0
levels	0
of	0
tissue	3
factor	4
transcripts	4
(	0
approximately	0
18-fold	0
)	0
and	0
an	0
increased	0
rate	0
of	0
transcription	0
(	0
approximately	0
15-fold	0
)	0
,	0
based	0
on	0
nuclear	0
run-on	0
analysis	0
.	0

Gel-shift	0
analysis	0
of	0
nuclear	0
extracts	0
from	0
hypoxic	9
MPs	10
and	0
HeLa	5
cells	6
demonstrated	0
increased	0
DNA-binding	0
activity	0
at	0
the	0
serum	1
response	2
region	2
(	0
SRR	0
;	0
-111/+14	0
bp	0
)	0
of	0
the	0
tissue	1
factor	2
promoter	2
at	0
Egr-1	1
motifs	2
.	0

Using	0
32P-labeled	0
Egr	0
consensus	0
oligonucleotide	0
,	0
we	0
observed	0
induction	0
of	0
DNA-binding	0
activity	0
in	0
nuclear	0
extracts	0
from	0
hypoxic	0
lung	0
and	0
HeLa	5
cells	6
because	0
of	0
activation	0
of	0
Egr-1	9
,	0
by	0
means	0
of	0
supershift	0
analysis	0
.	0

Transient	0
transfection	0
of	0
HeLa	5
cells	6
with	0
chimeric	1
plasmids	2
containing	0
wild-type	9
or	10
mutant	10
SRR	10
from	0
the	0
tissue	1
factor	2
promoter	2
showed	0
that	0
intact	1
Sp1	2
sites	2
are	0
necessary	0
for	0
basal	0
promoter	0
activity	0
,	0
whereas	0
the	0
integrity	0
of	0
Egr-1	1
sites	2
was	0
required	0
for	0
hypoxia-enhanced	0
expression	0
.	0

A	0
central	0
role	0
for	0
Egr-1	9
in	0
hypoxia-mediated	0
tissue	0
factor	0
expression	0
was	0
confirmed	0
by	0
experiments	0
with	0
homozygous	0
Egr-1	9
null	0
mice	0
;	0
wild-type	0
mice	0
subjected	0
to	0
oxygen	9
deprivation	10
expressed	10
tissue	10
factor	10
and	0
showed	0
fibrin	9
deposition	0
,	0
but	0
hypoxic	0
homozygous	0
Egr-1	9
null	0
mice	0
displayed	0
neither	0
tissue	9
factor	10
nor	0
fibrin	9
.	0

These	0
data	0
delineate	0
a	0
novel	0
biology	0
for	0
hypoxia-induced	0
fibrin	9
deposition	0
,	0
in	0
which	0
oxygen	0
deprivation-induced	0
activation	0
of	0
Egr-1	9
,	0
resulting	0
in	0
expression	0
of	0
tissue	9
factor	10
,	0
has	0
an	0
unexpected	0
and	0
central	0
role	0
.	0

Kinetics	0
of	0
cytokine	0
and	0
NFAT	0
gene	0
expression	0
in	0
human	5
interleukin-2-dependent	6
T	6
lymphoblasts	6
stimulated	0
via	0
T-cell	9
receptor	10
.	0

T	7
cells	8
respond	0
to	0
mitogenic	0
or	0
antigenic	0
stimulation	0
by	0
proliferation	0
and	0
by	0
turning	0
on	0
cytokine	0
gene	0
expression	0
.	0

Here	0
we	0
have	0
analysed	0
the	0
kinetics	0
and	0
nature	0
of	0
cytokine	0
production	0
in	0
human	7
peripheral	8
blood-derived	8
T	8
lymphoblasts	8
stimulated	0
with	0
anti-CD3	9
antibodies	10
or	0
Lens	9
culinaris	10
lectin	10
(	0
LCL	9
)	0
.	0

T	7
cells	8
were	0
purified	0
from	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
and	0
primarily	0
activated	0
with	0
anti-CD3	9
antibodies	10
and	0
cultured	0
in	0
the	0
presence	0
of	0
interleukin-2	9
(	0
IL-2	9
)	0
.	0

Anti-CD3-restimulated	0
T	7
cells	8
(	0
mainly	0
CD8+	0
)	0
produced	0
IL-2	9
,	0
interferon-gamma	9
(	0
IFN-gamma	9
)	0
and	0
tumour	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
and	0
low	0
levels	0
of	0
IL-4	3
and	4
IL-10	4
transcripts	4
and	0
proteins	0
.	0

No	0
IL-6	1
gene	2
expression	0
was	0
observed	0
.	0

In	0
LCL-stimulated	7
cells	8
the	0
cytokine	0
production	0
pattern	0
was	0
very	0
similar	0
.	0

Steady-state	0
mRNA	0
levels	0
of	0
IL-2	9
,	0
IL-10	9
and	0
IFN-gamma	9
peaked	0
at	0
3	0
hr	0
after	0
anti-CD3	0
stimulation	0
and	0
declined	0
rapidly	0
thereafter	0
.	0

The	0
kinetics	0
of	0
TNF-alpha	3
mRNA	4
expression	0
was	0
faster	0
,	0
being	0
at	0
its	0
peak	0
level	0
1	0
hr	0
after	0
stimulation	0
.	0

Anti-CD3-stimulated	0
IL-2	1
gene	2
expression	0
was	0
down-regulated	0
by	0
protein	0
synthesis	0
inhibitor	0
,	0
whereas	0
IL-10	1
,	2
IFN-gamma	2
and	2
TNF-alpha	2
genes	2
were	0
readily	0
induced	0
independent	0
of	0
ongoing	0
protein	0
synthesis	0
.	0

T-cell	9
receptor	10
stimulation	0
also	0
induced	0
a	0
very	0
rapid	0
expression	0
of	0
c-jun	1
,	2
c-fos	2
and	2
NFATc1	2
(	2
NFATc	2
)	2
genes	2
,	0
the	0
gene	0
products	0
of	0
which	0
are	0
involved	0
in	0
cytokine	0
gene	0
expression	0
.	0

In	0
conclusion	0
,	0
the	0
cytokines	9
synthesized	0
by	0
IL-2-dependent	7
T	8
cells	8
were	0
predominantly	0
IL-2	9
,	0
IFN-gamma	9
and	0
TNF-alpha	9
.	0

An	0
animal	0
model	0
to	0
study	0
local	0
oxidation	0
of	0
LDL	0
and	0
its	0
biological	0
effects	0
in	0
the	0
arterial	0
wall	0
.	0

Oxidized	0
LDL	0
(	0
oxLDL	0
)	0
is	0
present	0
in	0
atherosclerotic	0
lesions	0
and	0
is	0
believed	0
to	0
play	0
a	0
key	0
role	0
in	0
atherogenesis	0
.	0

Mainly	0
on	0
the	0
basis	0
of	0
cell	0
culture	0
studies	0
,	0
oxLDL	0
has	0
been	0
shown	0
to	0
produce	0
many	0
biological	0
effects	0
that	0
influence	0
the	0
atherosclerotic	0
process	0
.	0

To	0
study	0
LDL	0
oxidation	0
in	0
vivo	0
,	0
we	0
have	0
established	0
a	0
model	0
in	0
which	0
Sprague-Dawley	0
rats	0
are	0
given	0
a	0
single	0
injection	0
of	0
unmodified	0
human	0
LDL	0
(	0
>	0
or	0
=	0
4	0
mg/kg	0
body	0
weight	0
)	0
.	0

Within	0
6	0
hours	0
,	0
an	0
accumulation	0
of	0
apolipoprotein	0
B	0
and	0
epitopes	9
present	0
on	0
oxLDL	0
are	0
detected	0
in	0
the	0
arterial	0
endothelium	0
and	0
media	0
.	0

The	0
presence	0
of	0
oxLDL	0
is	0
associated	0
with	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor-kappaB	10
in	0
the	0
endothelium	0
as	0
well	0
as	0
endothelial	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
.	0

Injection	0
of	0
LDL	0
enriched	0
with	0
the	0
antioxidant	0
probucol	0
resulted	0
in	0
arterial	0
accumulation	0
of	0
apolipoprotein	0
B	0
,	0
but	0
the	0
expression	0
of	0
oxLDL-specific	0
epitopes	0
was	0
reduced	0
at	0
24	0
hours	0
.	0

Thus	0
,	0
this	0
simple	0
model	0
has	0
the	0
potential	0
to	0
analyze	0
the	0
mechanisms	0
behind	0
and	0
biological	0
effects	0
of	0
LDL	0
oxidation	0
in	0
vivo	0
.	0

Molecular	0
mechanisms	0
of	0
promoter	0
regulation	0
of	0
the	0
gp34	1
gene	2
that	0
is	0
trans-activated	0
by	0
an	0
oncoprotein	9
Tax	10
of	0
human	0
T	0
cell	0
leukemia	0
virus	0
type	0
I	0
.	0

We	0
investigated	0
the	0
molecular	0
mechanism	0
of	0
transcriptional	0
activation	0
of	0
the	0
gp34	1
gene	2
by	0
the	0
Tax	9
oncoprotein	10
of	0
human	0
T	0
cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
.	0

gp34	9
is	0
a	0
type	9
II	10
transmembrane	10
molecule	10
belonging	0
to	0
the	0
tumor	0
necrosis	0
factor	0
family	0
and	0
is	0
constitutively	0
expressed	0
on	0
HTLV-I-producing	7
cells	8
but	0
not	0
normal	7
resting	8
T	8
cells	8
.	0

The	0
transcriptional	0
regulatory	0
region	0
of	0
the	0
gp34	1
gene	2
was	0
activated	0
by	0
HTLV-I	0
Tax	9
in	0
the	0
human	5
T	6
cell	6
line	6
Jurkat	6
,	0
in	0
which	0
endogenous	0
gp34	9
is	0
induced	0
by	0
Tax	9
.	0

Sequence	0
analysis	0
demonstrated	0
that	0
two	0
NF-kappaB-like	1
elements	2
(	0
1	0
and	0
2	0
)	0
were	0
present	0
in	0
the	0
regulatory	1
region	2
.	0

Both	0
NF-kappaB-like	1
elements	2
were	0
able	0
to	0
bind	0
to	0
NF-kappaB	9
or	0
its	0
related	0
factor	0
(	0
s	0
)	0
in	0
a	0
Tax	9
-dependent	0
manner	0
.	0

Chloramphenicol	9
acetyltransferase	10
assays	0
indicated	0
that	0
NF-kappaB-like	1
element	2
1	2
was	0
Tax	9
-responsive	0
,	0
although	0
the	0
activity	0
was	0
lower	0
than	0
that	0
the	0
native	1
promoter	2
.	0

NF-kappaB	9
-like	0
element	0
2	0
elevated	0
promoter	0
activity	0
when	0
combined	0
with	0
NF-kappaB-like	1
element	2
1	2
,	0
indicating	0
cooperative	0
function	0
of	0
the	0
elements	0
for	0
maximum	0
promoter	0
function	0
.	0

Unlike	0
typical	0
NF-kappaB	1
elements	2
,	0
the	0
NF-kappaB-like	1
elements	2
in	0
gp34	9
were	0
not	0
activated	0
by	0
treatment	0
of	0
Jurkat	5
cells	6
with	0
phorbol	0
ester	0
despite	0
induction	0
of	0
the	0
NF-kappaB	9
-like	0
binding	0
activity	0
.	0

Chloramphenicol	9
acetyltransferase	10
reporter	0
assays	0
using	0
the	0
region	0
upstream	0
of	0
the	0
NF-kappaB-like	1
elements	2
identified	0
an	0
upstream	0
region	0
that	0
reduced	0
transcription	0
from	0
cognate	1
and	2
noncognate	2
core	2
promoters	2
in	0
a	0
Tax-independent	0
manner	0
.	0

Our	0
results	0
imply	0
complex	0
regulation	0
of	0
expression	0
of	0
the	0
gp34	1
gene	2
and	0
suggest	0
implication	0
of	0
gp34	9
in	0
proliferation	0
of	0
HTLV-I	0
infected	0
T	0
cells	0
.	0

beta-Amyloid	9
fibrils	10
activate	0
parallel	0
mitogen-activated	9
protein	10
kinase	10
pathways	0
in	0
microglia	7
and	0
THP1	5
monocytes	6
.	0

The	0
senile	0
plaques	0
of	0
Alzheimer	0
's	0
disease	0
are	0
foci	0
of	0
local	0
inflammatory	0
responses	0
,	0
as	0
evidenced	0
by	0
the	0
presence	0
of	0
acute	9
phase	10
proteins	10
and	0
oxidative	0
damage	0
.	0

Fibrillar	9
forms	10
of	0
beta-amyloid	9
(	0
Abeta	9
)	0
,	0
which	0
are	0
the	0
primary	0
constituents	0
of	0
senile	0
plaques	0
,	0
have	0
been	0
shown	0
to	0
activate	0
tyrosine	0
kinase-dependent	0
signal	0
transduction	0
cascades	0
,	0
resulting	0
in	0
inflammatory	0
responses	0
in	0
microglia	7
.	0

However	0
,	0
the	0
downstream	0
signaling	0
pathways	0
mediating	0
Abeta	9
-induced	0
inflammatory	0
events	0
are	0
not	0
well	0
characterized	0
.	0

We	0
report	0
that	0
exposure	0
of	0
primary	7
rat	8
microglia	8
and	0
human	5
THP1	6
monocytes	6
to	0
fibrillar	9
Abeta	10
results	0
in	0
the	0
tyrosine	9
kinase	10
-dependent	0
activation	0
of	0
two	0
parallel	0
signal	0
transduction	0
cascades	0
involving	0
members	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	10
MAPK	10
)	10
superfamily	10
.	0

Abeta	9
stimulated	0
the	0
rapid	0
,	0
transient	0
activation	0
of	0
extracellular	9
signal-regulated	10
kinase	10
1	10
(	0
ERK1	9
)	0
and	0
ERK2	9
in	0
microglia	7
and	0
ERK2	9
in	0
THP1	5
monocytes	6
.	0

A	0
second	0
superfamily	9
member	10
,	0
p38	9
MAPK	10
,	0
was	0
also	0
activated	0
with	0
similar	0
kinetics	0
.	0

Scavenger	9
receptor	10
and	0
receptor	9
for	10
advanced	10
glycated	10
end	10
products	10
(	0
RAGE	9
)	0
ligands	0
failed	0
to	0
activate	0
ERK	9
and	0
p38	9
MAPK	10
in	0
the	0
absence	0
of	0
significant	0
increases	0
in	0
protein	0
tyrosine	0
phosphorylation	0
,	0
demonstrating	0
that	0
scavenger	9
receptors	10
and	0
RAGE	9
are	0
not	0
linked	0
to	0
these	0
pathways	0
.	0

Importantly	0
,	0
the	0
stress-activated	9
protein	10
kinases	10
(	0
SAPKs	9
)	0
were	0
not	0
significantly	0
activated	0
in	0
response	0
to	0
Abeta	9
.	0

Downstream	0
effectors	0
of	0
the	0
MAPK	0
signal	0
transduction	0
cascades	0
include	0
MAPKAP	9
kinases	10
,	0
such	0
as	0
RSK1	9
and	0
RSK2	9
,	0
as	0
well	0
as	0
transcription	9
factors	10
.	0

Exposure	0
of	0
microglia	7
and	0
THP1	5
monocytes	6
to	0
Abeta	9
resulted	0
in	0
the	0
activation	0
of	0
RSK1	9
and	0
RSK2	9
and	0
phosphorylation	0
of	0
cAMP	9
response	10
element-binding	10
protein	10
at	0
Ser133	0
,	0
providing	0
a	0
mechanism	0
for	0
Abeta	9
-induced	0
changes	0
in	0
gene	0
expression	0

Regulation	0
of	0
cellular	9
retinoic	10
acid	10
binding	10
protein	10
(	0
CRABP	9
II	10
)	0
during	0
human	7
monocyte	8
differentiation	0
in	0
vitro	0
.	0

Cellular	9
retinoic	10
acid	10
binding	10
proteins	10
(	0
CRABP	9
)	0
are	0
low	9
molecular	10
weight	10
proteins	10
whose	0
precise	0
function	0
remains	0
unknown	0
.	0

They	0
bind	0
retinoids	0
and	0
may	0
thereby	0
modulate	0
the	0
intracellular	0
steady-state	0
concentration	0
of	0
retinoids	0
.	0

Whereas	0
CRABP	9
I	10
is	0
ubiquitously	0
expressed	0
,	0
CRABP	9
II	10
is	0
mainly	0
detected	0
in	0
various	0
cell	0
types	0
of	0
the	0
skin	0
.	0

By	0
representative	0
difference	0
analysis	0
we	0
found	0
that	0
CRABP	9
II	10
is	0
also	0
strongly	0
expressed	0
in	0
human	7
monocyte-derived	8
macrophages	8
(	0
MAC	7
)	0
but	0
not	0
in	0
freshly	7
isolated	8
monocytes	8
(	0
MO	7
)	0
.	0

The	0
CRABP	3
II	4
mRNA	4
was	0
gradually	0
upregulated	0
during	0
differentiation	0
from	0
MO	7
to	0
MAC	7
in	0
the	0
presence	0
of	0
2	0
%	0
serum	0
.	0

Adherence	0
,	0
which	0
is	0
important	0
for	0
MO	7
differentiation	0
,	0
induced	0
CRABP	9
II	10
expression	0
,	0
but	0
the	0
addition	0
of	0
10	0
(	0
-7	0
)	0
M	0
retinoic	0
acid	0
inhibited	0
the	0
upregulation	0
of	0
CRABP	9
II	10
expression	0
during	0
MO/MAC	0
differentiation	0
.	0

As	0
MO	7
can	0
differentiate	0
along	0
the	0
classical	0
pathway	0
not	0
only	0
to	0
MAC	7
but	0
also	0
to	0
dendritic	0
cells	0
we	0
analyzed	0
the	0
expression	0
of	0
CRABP	9
II	10
in	0
MO-derived	7
dendritic	8
cells	8
cultured	0
with	0
10	0
%	0
FCS	9
,	0
IL-4	9
,	0
and	0
GM-CSF	9
.	0

In	0
contrast	0
to	0
MAC	7
,	0
MO-derived	7
dendritic	8
cells	8
showed	0
an	0
extremely	0
low	0
expression	0
of	0
CRABP	9
II	10
.	0

From	0
these	0
results	0
we	0
conclude	0
(	0
1	0
)	0
that	0
the	0
availability	0
and	0
the	0
metabolism	0
of	0
retinoids	0
may	0
be	0
different	0
in	0
MAC	7
compared	0
to	0
MO	7
and	0
dendritic	7
cells	8
and	0
(	0
2	0
)	0
that	0
this	0
may	0
influence	0
differentiation	0
and	0
activation	0
of	0
those	0
cells	0
.	0

Transcription	9
factor	10
B-cell-specific	10
activator	10
protein	10
(	0
BSAP	9
)	0
is	0
differentially	0
expressed	0
in	0
B	7
cells	8
and	0
in	0
subsets	0
of	0
B-cell	0
lymphomas	0
.	0

The	0
paired	1
box	2
containing	2
gene	2
PAX-5	1
encodes	0
the	0
transcription	9
factor	10
BSAP	9
(	0
B-cell-specific	9
activator	10
protein	10
)	0
,	0
which	0
plays	0
a	0
key	0
role	0
in	0
B-lymphocyte	0
development	0
.	0

Despite	0
its	0
known	0
involvement	0
in	0
a	0
rare	0
subtype	0
of	0
non-Hodgkin	0
's	0
lymphoma	0
(	0
NHL	0
)	0
,	0
a	0
detailed	0
examination	0
of	0
BSAP	9
expression	0
in	0
NHL	0
has	0
not	0
been	0
previously	0
reported	0
.	0

In	0
this	0
study	0
,	0
we	0
analyzed	0
normal	0
and	0
malignant	0
lymphoid	0
tissues	0
and	0
cell	5
lines	6
,	0
including	0
102	0
cases	0
of	0
B-cell	0
NHL	0
,	0
23	0
cases	0
of	0
T-	0
and	0
null-cell	0
NHL	0
,	0
and	0
18	0
cases	0
of	0
Hodgkin	0
's	0
disease	0
.	0

Normal	0
lymphoid	0
tissues	0
showed	0
strong	0
nuclear	0
BSAP	9
expression	0
in	0
mantle	7
zone	8
B	8
cells	8
,	0
less	0
intense	0
reactivity	0
in	0
follicular	7
center	8
B	8
cells	8
,	0
and	0
no	0
expression	0
in	0
cells	0
of	0
the	0
T-cell-rich	0
zones	0
.	0

Monocytoid	7
B	8
cells	8
showed	0
weak	0
expression	0
,	0
whereas	0
plasma	7
cells	8
and	0
extrafollicular	7
large	8
transformed	8
B	8
cells	8
were	0
negative	0
.	0

Of	0
the	0
102	0
B-cell	0
NHLs	0
,	0
83	0
(	0
81	0
%	0
)	0
demonstrated	0
BSAP	9
expression	0
.	0

All	0
of	0
the	0
13	0
(	0
100	0
%	0
)	0
B-cell	0
chronic	0
lymphocytic	0
leukemias	0
(	0
B-CLLs	0
)	0
,	0
21	0
of	0
(	0
100	0
%	0
)	0
mantle	7
cells	8
(	0
MCLs	7
)	0
,	0
and	0
20	0
of	0
21	0
(	0
95	0
%	0
)	0
follicular	0
lymphomas	0
(	0
FLs	0
)	0
were	0
positive	0
.	0

Moderate	0
staining	0
intensities	0
were	0
found	0
in	0
most	0
B-CLL	0
and	0
FL	0
cases	0
,	0
whereas	0
most	0
MCLs	7
showed	0
strong	0
reactions	0
,	0
paralleling	0
the	0
strong	0
reactivity	0
of	0
nonmalignant	7
mantle	8
cells	8
.	0

Eight	0
of	0
12	0
(	0
67	0
%	0
)	0
marginal	0
zone	0
lymphoma	0
cases	0
showed	0
negative	0
or	0
low	0
BSAP	9
levels	0
,	0
and	0
17	0
of	0
24	0
(	0
71	0
%	0
)	0
large	0
B-cell	0
lymphomas	0
displayed	0
moderate	0
to	0
strong	0
expression	0
.	0

None	0
of	0
the	0
23	0
T-	0
and	0
null-cell	0
lymphomas	0
reacted	0
with	0
the	0
BSAP	9
antisera	0
,	0
whereas	0
in	0
Hodgkin	0
's	0
disease	0
,	0
2	0
of	0
4	0
(	0
50	0
%	0
)	0
nodular	0
lymphocytic	0
predominance	0
and	0
5	0
of	0
14	0
(	0
36	0
%	0
)	0
classical	0
cases	0
showed	0
weak	0
nuclear	0
or	0
nucleolar	0
BSAP	9
reactions	0
in	0
a	0
fraction	0
of	0
the	0
tumor	7
cells	8
.	0

Western	0
blot	0
analysis	0
showed	0
a	0
52-kD	0
BSAP	9
band	0
in	0
B-cell	5
lines	6
,	0
but	0
not	0
in	0
non-B-cell	5
or	6
plasma	6
cell	6
lines	6
.	0

We	0
conclude	0
that	0
BSAP	9
expression	0
is	0
largely	0
restricted	0
to	0
lymphomas	0
of	0
B-cell	7
lineage	8
and	0
that	0
BSAP	9
expression	0
varies	0
in	0
B-cell	7
subsets	8
and	0
subtypes	0
of	0
B-cell	0
NHL	0
.	0

The	0
high	0
levels	0
of	0
BSAP	9
,	0
especially	0
those	0
found	0
in	0
large-cell	7
lymphomas	8
and	0
in	0
some	0
follicular	7
lymphomas	8
,	0
may	0
be	0
a	0
consequence	0
of	0
deregulated	0
gene	0
expression	0
and	0
suggest	0
a	0
possible	0
involvement	0
of	0
PAX-5	1
in	0
certain	0
B-cell	0
malignancies	0
.	0

This	0
is	0
a	0
US	0
government	0
work	0
.	0

There	0
are	0
no	0
restrictions	0
on	0
its	0
use	0
.	0

Mitogen	0
and	0
growth	0
factor-induced	0
activation	0
of	0
a	0
STAT-like	9
molecule	10
in	0
channel	7
catfish	8
lymphoid	8
cells	8
.	0

This	0
article	0
describes	0
the	0
identification	0
of	0
a	0
putative	9
STAT	10
molecule	10
in	0
the	0
channel	0
catfish	0
(	0
Ictalurus	0
punctatus	0
)	0
,	0
the	0
first	0
report	0
of	0
such	0
a	0
molecule	0
in	0
a	0
'lower	0
'	0
vertebrate	0
.	0

A	0
monoclonal	9
antibody	10
against	0
human	9
STAT6	10
recognizes	0
an	0
approximately	0
100	9
kDa	10
molecule	10
that	0
becomes	0
activated	0
and	0
translocates	0
to	0
the	0
nucleus	0
upon	0
both	0
growth	0
factor	0
and	0
mitogen	0
stimulation	0
of	0
catfish	0
leukocytes	0
.	0

This	0
presumed	0
catfish	9
STAT	10
binds	0
the	0
mammalian	1
interferon-gamma	2
activation	2
site	2
,	0
a	0
known	0
motif	0
of	0
mammalian	0
STAT	0
binding	0
,	0
as	0
shown	0
by	0
electromobility	0
shift	0
assays	0
.	0

Purification	0
of	0
the	0
proteins	0
present	0
in	0
these	0
DNA	9
complexes	10
confirms	0
that	0
the	0
catfish	0
reactive	0
molecule	0
binds	0
to	0
the	0
interferon-gamma	1
activation	2
site	2
sequence	2
.	0

These	0
results	0
suggest	0
that	0
STAT	9
molecules	10
have	0
been	0
highly	0
conserved	0
in	0
vertebrate	0
evolution	0
.	0

Isolation	0
and	0
analysis	0
of	0
a	0
T	5
cell	6
clone	6
variant	6
exhibiting	0
constitutively	0
phosphorylated	9
Ser133	10
cAMP	10
response	10
element-binding	10
protein	10
.	0

In	0
driving	0
T	0
cell	0
proliferation	0
,	0
IL-2	9
stimulates	0
a	0
new	0
program	0
of	0
gene	0
expression	0
that	0
includes	0
proliferating	9
cell	10
nuclear	10
antigen	10
(	0
PCNA	9
)	0
,	0
a	0
requisite	0
processivity	0
factor	0
for	0
DNA	9
polymerase	10
delta	10
.	0

PCNA	9
transcription	0
is	0
regulated	0
in	0
part	0
through	0
tandem	0
CRE	1
sequences	2
in	0
the	0
promoter	9
and	10
CRE	10
binding	10
proteins	10
;	0
IL-2	9
stimulates	0
CREB	0
phosphorylation	0
in	0
the	0
resting	5
cloned	6
T	6
lymphocyte	6
,	0
L2	5
.	0

After	0
culturing	0
L2	5
cells	6
for	0
greater	0
than	0
91	0
days	0
,	0
we	0
consistently	0
isolate	0
a	0
stable	0
variant	0
that	0
exhibits	0
constitutive	0
CREB	0
phosphorylation	0
.	0

L2	5
and	6
L2	6
variant	6
cells	6
were	0
tested	0
for	0
IL-2	9
responsiveness	0
and	0
rapamycin	0
sensitivity	0
with	0
respect	0
to	0
specific	0
kinase	0
activity	0
,	0
PCNA	0
expression	0
and	0
proliferation	0
.	0

In	0
L2	5
cells	6
,	0
IL-2	9
stimulated	0
and	0
rapamycin	0
inhibited	0
the	0
following	0
:	0
cAMP-independent	0
CREB	9
kinase	10
activity	0
,	0
PCNA	0
expression	0
and	0
proliferation	0
.	0

In	0
L2	5
variant	6
cells	6
,	0
CREB	9
kinase	10
activity	0
was	0
constitutively	0
high	0
;	0
IL-2	9
stimulated	0
and	0
rapamycin	0
blocked	0
PCNA	0
expression	0
and	0
proliferation	0
.	0

These	0
results	0
indicate	0
that	0
IL-2	9
induces	0
a	0
rapamycin-sensitive	0
,	0
cAMP-independent	0
CREB	9
kinase	10
activity	0
in	0
L2	5
cells	6
.	0

However	0
,	0
phosphorylation	0
of	0
CREB	9
alone	0
is	0
not	0
sufficient	0
to	0
drive	0
PCNA	9
expression	0
and	0
L2	0
cell	0
proliferation	0
in	0
the	0
absence	0
of	0
IL-2	9
.	0

Serotonin	0
derivative	0
,	0
N-	0
(	0
p-coumaroyl	0
)	0
serotonin	0
,	0
inhibits	0
the	0
production	0
of	0
TNF-alpha	9
,	0
IL-1alpha	9
,	0
IL-1beta	9
,	0
and	0
IL-6	9
by	0
endotoxin-stimulated	7
human	8
blood	8
monocytes	8
.	0

We	0
have	0
reported	0
that	0
N-	0
(	0
p-coumaroyl	0
)	0
serotonin	0
(	0
CS	0
)	0
and	0
its	0
derivatives	0
with	0
antioxidative	0
activity	0
are	0
present	0
in	0
safflower	0
seeds	0
.	0

As	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
are	0
implicated	0
in	0
the	0
signaling	0
of	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
we	0
examined	0
whether	0
CS	0
has	0
a	0
suppressive	0
effect	0
on	0
inflammatory	9
cytokine	10
generation	0
from	0
human	7
monocyte	8
s	0
in	0
vitro	0
.	0

CS	0
at	0
50-200	0
microM	0
reduced	0
tumor	9
necrosis	10
factor	10
(	0
TNF	9
)	0
,	0
interleukin-1	9
(	0
IL-1	9
)	0
,	0
and	0
IL-6	9
activities	0
in	0
the	0
culture	0
supernatants	0
from	0
LPS-stimulated	5
human	6
blood	6
monocytes	6
without	0
cytotoxicity	0
.	0

ELISA	0
assay	0
revealed	0
that	0
the	0
production	0
of	0
TNF-alpha	9
,	0
IL-1alpha	9
,	0
IL-1beta	9
,	0
and	0
IL-6	9
was	0
inhibited	0
by	0
CS	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
LPS-induced	0
expression	0
of	0
these	0
cytokine	3
mRNA	4
in	0
monocytes	7
was	0
suppressed	0
by	0
CS	0
.	0

NF-kappaB	0
activation	0
was	0
also	0
inhibited	0
by	0
CS	0
.	0

These	0
findings	0
indicate	0
that	0
CS	0
has	0
a	0
suppressive	0
effect	0
on	0
proinflammatory	0
cytokine	0
production	0
from	0
monocytes	7
,	0
and	0
this	0
effect	0
is	0
based	0
in	0
part	0
on	0
the	0
suppression	0
of	0
cytokine	3
mRNA	4
expression	0
through	0
inhibition	0
of	0
NF-kappaB	9
activation	0
.	0

Elevated	0
expression	0
of	0
differentiation	3
inhibitory	4
factor	4
nm23	4
mRNA	4
in	0
monoblastic	0
crisis	0
of	0
a	0
patient	0
with	0
chronic	0
myelogenous	0
leukemia	0
.	0

Differentiation	9
inhibitory	10
factor	10
nm23	1
gene	2
has	0
been	0
found	0
to	0
be	0
expressed	0
in	0
high	0
quantities	0
in	0
acute	0
myelogenous	0
leukemia	0
(	0
AML	0
)	0
,	0
especially	0
in	0
acute	0
monocytic	0
leukemia	0
(	0
AML-M5	0
)	0
and	0
is	0
suggested	0
as	0
a	0
new	0
prognostic	0
factor	0
in	0
AML-M5	0
.	0

We	0
report	0
an	0
example	0
of	0
elevated	0
expression	0
of	0
nm23	3
mRNA	4
in	0
a	0
patient	0
with	0
chronic	0
myelogenous	0
leukemia	0
(	0
CML	0
)	0
who	0
developed	0
monoblastic	0
crisis	0
.	0

Relative	0
levels	0
of	0
nm23-H1	3
and	4
-H2	4
mRNA	4
extracted	0
from	0
the	0
patient	0
's	0
peripheral	7
blood	8
mononuclear	8
cells	8
and	0
bone	7
marrow	8
mononuclear	8
cells	8
were	0
measured	0
by	0
quantitative	0
reverse	0
transcriptase	0
polymerase	0
chain	0
reaction	0
.	0

The	0
level	0
of	0
nm23-H1	3
mRNA	4
in	0
CML	5
cells	6
at	0
the	0
chronic	0
phase	0
was	0
as	0
high	0
as	0
that	0
in	0
bone	7
marrow	8
cells	8
from	0
healthy	0
volunteers	0
.	0

The	0
mRNA	0
level	0
of	0
nm23-H2	9
was	0
slightly	0
below	0
the	0
normal	0
level	0
.	0

At	0
blastic	0
crisis	0
,	0
however	0
,	0
expression	0
of	0
both	0
nm23-H1	3
and	4
-H2	4
mRNA	4
was	0
elevated	0
to	0
about	0
three	0
to	0
nine	0
times	0
of	0
that	0
at	0
the	0
chronic	0
phase	0
.	0

Proliferated	7
blastic	8
cells	8
were	0
positive	0
for	0
non-specific	9
esterase	10
,	0
and	0
the	0
serum	0
lysozyme	0
level	0
was	0
elevated	0
and	0
diagnosed	0
as	0
monoblastic	0
crisis	0
.	0

The	0
patient	0
received	0
combined	0
chemotherapy	0
but	0
response	0
was	0
partial	0
.	0

These	0
findings	0
are	0
compatible	0
with	0
our	0
previous	0
report	0
that	0
nm23	1
gene	2
is	0
overexpressed	0
in	0
monocytic	0
leukemia	0
.	0

Increased	0
transcription	0
decreases	0
the	0
spontaneous	0
mutation	0
rate	0
at	0
the	0
thymidine	1
kinase	2
locus	2
in	0
human	7
cells	8
.	0

Transcription	0
increases	0
DNA	0
repair	0
efficiency	0
and	0
modulates	0
the	0
distribution	0
of	0
certain	0
types	0
of	0
DNA	0
damage	0
.	0

Furthermore	0
,	0
increased	0
transcription	0
level	0
stimulates	0
spontaneous	0
mutation	0
rate	0
in	0
yeast	0
.	0

We	0
explored	0
whether	0
transcription	0
level	0
affects	0
spontaneous	0
mutation	0
rate	0
in	0
human	7
cells	8
.	0

We	0
first	0
developed	0
two	0
thymidine	5
kinase	6
(	6
tk	6
)	6
inducible	6
human	6
cell	6
lines	6
using	0
the	0
Gal4-Estrogen	0
receptor	0
system	0
.	0

In	0
our	0
TK6i-G3	5
and	6
G9	6
tk	6
heterozygous	6
cell	6
lines	6
,	0
the	0
active	0
tk	1
allele	2
is	0
linked	0
to	0
an	0
inducible	0
promoter	1
element	2
.	0

Tk	3
mRNA	4
is	0
induced	0
following	0
treatment	0
with	0
estrogen	0
.	0

Spontaneous	0
mutation	0
rate	0
was	0
significantly	0
decreased	0
in	0
human	5
cell	6
lines	6
after	0
induction	0
in	0
contrast	0
to	0
the	0
report	0
in	0
yeast	0
.	0

Thus	0
,	0
humans	0
may	0
have	0
evolved	0
different	0
or	0
additional	0
mechanisms	0
to	0
deal	0
with	0
transcription	0
related	0
spontaneous	0
mutagenesis	0
.	0

Copyright	0
1998	0
Elsevier	0
Science	0
B.V	0
.	0

All	0
rights	0
reserved	0
.	0

Mutation	0
of	0
BCL-6	1
gene	2
in	0
normal	0
B	7
cells	8
by	0
the	0
process	0
of	0
somatic	0
hypermutation	0
of	0
Ig	1
genes	2
.	0

Immunoglobulin	1
(	2
Ig	2
)	2
genes	2
are	0
hypermutated	0
in	0
B	7
lymphocytes	8
that	0
are	0
the	0
precursors	0
to	0
memory	7
B	8
cells	8
.	0

The	0
mutations	0
are	0
linked	0
to	0
transcription	0
initiation	0
,	0
but	0
non-Ig	1
promoters	2
are	0
permissible	0
for	0
the	0
mutation	0
process	0
;	0
thus	0
,	0
other	0
genes	0
expressed	0
in	0
mutating	0
B	7
cells	8
may	0
also	0
be	0
subject	0
to	0
somatic	0
hypermutation	0
.	0

Significant	0
mutations	0
were	0
not	0
observed	0
in	0
c-MYC	1
,	2
S14	2
,	2
or	2
alpha-fetoprotein	2
(	2
AFP	2
)	2
genes	2
,	0
but	0
BCL-6	9
was	0
highly	0
mutated	0
in	0
a	0
large	0
proportion	0
of	0
memory	7
B	8
cells	8
of	0
normal	0
individuals	0
.	0

The	0
mutation	0
pattern	0
was	0
similar	0
to	0
that	0
of	0
Ig	1
genes	2
.	0

CD28-mediated	0
activation	0
in	0
CD45RA+	7
and	8
CD45RO+	8
T	8
cells	8
:	0
enhanced	0
levels	0
of	0
reactive	0
oxygen	0
intermediates	0
and	0
c-Rel	0
nuclear	0
translocation	0
in	0
CD45RA+	7
cells	8
.	0

We	0
have	0
analyzed	0
the	0
effect	0
of	0
complete	0
T	0
cell	0
activation	0
(	0
anti-CD3	0
plus	0
anti-CD28	0
)	0
on	0
the	0
activation	0
of	0
NF-kappaB	9
in	0
CD45RA+	7
(	8
naive	8
)	8
and	8
CD45RO+	8
(	8
memory/effector	8
)	8
T	8
cells	8
.	0

Long	0
exposure	0
(	0
24	0
h	0
)	0
induced	0
stronger	0
NF-kappaB	9
DNA	0
binding	0
in	0
CD45RA+	7
cells	8
than	0
in	0
CD45RO+	7
cells	8
.	0

Analysis	0
of	0
the	0
nuclear	9
c-Rel	10
protein	10
indicated	0
that	0
after	0
anti-CD3+anti-CD28	0
stimulation	0
the	0
level	0
of	0
c-Rel	9
was	0
higher	0
in	0
CD45RA+	7
cells	8
.	0

Analysis	0
of	0
the	0
cytoplasmic	9
inhibitor	10
IkappaBalpha	9
indicated	0
that	0
anti-CD3+anti-CD28	0
stimulation	0
induced	0
a	0
long-lasting	0
degradation	0
in	0
CD45RA+	7
cells	8
but	0
in	0
CD45RO+	7
cells	8
the	0
degradation	0
process	0
was	0
more	0
rapid	0
.	0

Because	0
the	0
CD28	9
costimulus	0
is	0
known	0
to	0
induce	0
the	0
production	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROIs	0
)	0
,	0
the	0
intracellular	0
ROI	0
levels	0
in	0
CD45RA+	7
and	8
CD45RO+	8
cells	8
were	0
compared	0
by	0
flow	0
cytometry	0
.	0

ROIs	0
were	0
produced	0
in	0
both	0
cell	0
types	0
,	0
but	0
more	0
strongly	0
in	0
CD45RA+	7
cells	8
.	0

The	0
data	0
presented	0
in	0
this	0
study	0
further	0
emphasize	0
the	0
differences	0
between	0
CD45RA+	7
and	8
CD45RO+	8
T	8
lymphocytes	8
in	0
ROI-dependent	0
signaling	0
pathways	0
.	0

Non-Hodgkin	0
's	0
lymphoma	0
involving	0
bilateral	0
breasts	0
[	0
see	0
comments	0
]	0

We	0
describe	0
here	0
two	0
cases	0
of	0
diffuse	0
large	0
cell	0
type	0
non-Hodgkin	0
's	0
lymphoma	0
affecting	0
the	0
bilateral	0
breasts	0
.	0

The	0
contralateral	0
tumor	0
in	0
one	0
case	0
appeared	0
17	0
months	0
after	0
the	0
first	0
mastectomy	0
,	0
whereas	0
the	0
bilateral	0
tumors	0
occurred	0
concurrently	0
in	0
the	0
other	0
patient	0
who	0
was	0
pregnant	0
and	0
showed	0
widespread	0
dissemination	0
at	0
initial	0
presentation	0
.	0

Lymphoma	7
cells	8
from	0
both	0
cases	0
showed	0
the	0
mature	0
B-cell	0
immunophenotype	0
and	0
had	0
rearrangements	0
of	0
the	0
BCL6	1
gene	2
.	0

Both	0
patients	0
developed	0
progressive	0
disease	0
despite	0
chemo-radiotherapy	0
and	0
died	0
of	0
leukemic	0
manifestations	0
.	0

There	0
were	0
no	0
apparent	0
pathological	0
features	0
of	0
lymphomas	0
of	0
mucosa-associated	0
lymphoid	0
tissue	0
origin	0

Biochemical	0
characterization	0
of	0
MIP-1	9
alpha	10
nuclear	10
protein	10
.	0

A	0
family	0
of	0
hematopoietic	9
specific	10
transcription	10
factors	10
,	0
MIP-1	9
alpha	10
nuclear	10
protein	10
(	10
MNP	10
)	10
family	10
,	0
has	0
recently	0
been	0
identified	0
.	0

They	0
are	0
intimately	0
involved	0
in	0
regulating	0
the	0
transcription	0
of	0
the	0
huMIP-1	1
alpha	2
gene	2
in	0
monocytes	7
,	0
T-cells	7
,	0
and	0
transformed	7
B-cells	8
.	0

One	0
member	0
of	0
the	0
family	0
(	0
MNP-1	9
)	0
is	0
essential	0
for	0
promoter	0
activity	0
in	0
monocytes	7
and	0
B-cells	7
,	0
while	0
another	0
(	0
MNP-2	9
)	0
is	0
required	0
for	0
full	0
promotor	0
activity	0
in	0
T-cells	7
.	0

A	0
third	0
member	0
of	0
the	0
family	0
(	0
MNP-3	9
)	0
is	0
expressed	0
in	0
PMA	5
induced	6
HL60	6
cells	6
and	0
probably	0
has	0
a	0
role	0
in	0
monocyte	0
differentiation	0
.	0

In	0
this	0
communication	0
we	0
demonstrate	0
by	0
two	0
techniques	0
that	0
MNP-1	9
and	0
MNP-2	9
are	0
distinct	0
but	0
related	0
factors	0
,	0
and	0
we	0
present	0
further	0
evidence	0
to	0
show	0
that	0
MNP-1	9
acts	0
as	0
a	0
heterodimer	9
.	0

Bcl-3	9
expression	0
and	0
nuclear	0
translocation	0
are	0
induced	0
by	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
and	0
erythropoietin	9
in	0
proliferating	7
human	8
erythroid	8
precursors	8
.	0

Bcl-3	9
is	0
a	0
proto-oncogene	1
involved	0
in	0
the	0
chromosomal	0
translocation	0
t	1
(	2
14	2
;	2
19	2
)	2
found	0
in	0
some	0
patients	0
with	0
chronic	0
lymphocytic	0
leukemia	0
.	0

It	0
shares	0
structural	0
similarities	0
with	0
and	0
is	0
a	0
member	0
of	0
the	0
IkappaB	9
family	10
of	0
proteins	0
.	0

In	0
this	0
report	0
,	0
involvement	0
of	0
Bcl-3	9
in	0
hematopoietic	0
growth	0
factor-stimulated	0
erythroid	0
proliferation	0
and	0
differentiation	0
was	0
examined	0
.	0

In	0
TF-1	5
cells	6
,	0
an	0
erythroleukemia	5
cell	6
line	6
,	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
and	0
erythropoietin	9
(	0
Epo	9
)	0
greatly	0
enhanced	0
Bcl-3	9
expression	0
at	0
both	0
the	0
protein	0
and	0
mRNA	0
levels	0
in	0
association	0
with	0
stimulation	0
of	0
proliferation	0
.	0

Bcl-3	9
protein	0
was	0
also	0
highly	0
expressed	0
in	0
early	7
burst-forming	8
unit-erythroid	8
(	8
BFU-E	8
)	8
-derived	8
erythroid	8
precursors	8
(	0
day	0
7	0
)	0
and	0
decreased	0
during	0
maturation	0
(	0
days	0
10	0
and	0
14	0
)	0
,	0
suggesting	0
that	0
Bcl-3	9
is	0
involved	0
in	0
normal	0
erythroid	0
proliferation	0
.	0

In	0
these	0
hematopoietic	7
cells	8
,	0
Bcl-3	9
was	0
hyperphosphorylated	0
.	0

GM-CSF	9
and	0
Epo	9
modulated	0
the	0
subcellular	0
localization	0
of	0
Bcl-3	9
.	0

Upon	0
stimulation	0
of	0
TF-1	5
cells	6
with	0
GM-CSF	9
or	0
Epo	9
,	0
the	0
nuclear	0
translocation	0
of	0
Bcl-3	9
was	0
dramatically	0
enhanced	0
.	0

Overexpression	0
of	0
Bcl-3	9
in	0
TF-1	5
cells	6
by	0
transient	0
transfection	0
along	0
with	0
the	0
NF-kappaB	9
factors	10
p50	10
or	10
p52	10
resulted	0
in	0
significant	0
induction	0
of	0
an	0
human	1
immunodeficiency	2
virus-type	2
1	2
(	2
HIV-1	2
)	2
kappaB-TATA-luceriferase	2
reporter	2
plasmid	2
,	0
demonstrating	0
that	0
Bcl-3	9
has	0
a	0
positive	0
role	0
in	0
transactivation	0
of	0
kappaB-containing	1
genes	2
in	0
erythroid	7
cells	8
.	0

Stimulation	0
with	0
GM-CSF	9
enhanced	0
c-myb	3
mRNA	4
expression	0
in	0
these	0
cells	0
.	0

Bcl-3	9
in	0
nuclear	0
extracts	0
of	0
TF-1	5
cells	6
bound	0
to	0
a	0
kappaB	1
enhancer	2
in	0
the	0
c-myb	1
promoter	2
together	0
with	0
NF-kappaB2/p52	9
and	0
this	0
binding	0
activity	0
was	0
enhanced	0
by	0
GM-CSF	9
stimulation	0
.	0

Furthermore	0
,	0
cotransfection	0
of	0
Bcl-3	9
with	0
p52	9
or	0
p50	9
in	0
TF-1	5
cells	6
resulted	0
in	0
significant	0
activation	0
of	0
a	0
c-myb	1
kappaB-TATA-luceriferase	2
reporter	2
plasmid	2
.	0

These	0
findings	0
suggest	0
that	0
Bcl-3	9
may	0
participate	0
in	0
the	0
transcriptional	0
regulation	0
of	0
certain	0
kappaB-containing	1
genes	2
involved	0
in	0
hematopoiesis	0
,	0
including	0
c-myb	1
.	0

Copyright	0
1998	0
by	0
The	0
American	0
Society	0
of	0
Hematology	0
.	0

5-Lipoxygenase	9
compartmentalization	0
in	0
granulocytic	0
cells	0
is	0
modulated	0
by	0
an	0
internal	9
bipartite	10
nuclear	10
localizing	10
sequence	10
and	0
nuclear	9
factor	10
kappa	10
B	10
complex	10
formation	0
.	0

A	0
region	0
of	0
basic	0
amino	0
acids	0
spanning	0
residues	9
639-656	10
in	0
the	0
human	9
5-lipoxygenase	10
sequence	10
resembles	0
a	0
consensus	9
bipartite	10
nuclear	10
localizing	10
sequence	10
.	0

A	0
synthetic	0
peptide	0
consisting	0
of	0
the	0
Kaposi	9
fibroblast	10
growth	10
factor	10
signal	10
sequence	10
fused	0
to	0
the	0
5-lipoxygenase639-656	9
bipartite	10
nuclear	10
localizing	10
sequence	10
has	0
a	0
prominent	0
inhibitory	0
effect	0
on	0
5-lipoxygenase	9
catalysis	0
in	0
granulocytic	0
HL-60	5
cells	6
activated	0
by	0
calcium	0
ionophor	0
A23187	0
.	0

Recombinant	0
5-lipoxygenase	9
was	0
not	0
affected	0
by	0
the	0
peptide	0
.	0

The	0
peptide	0
also	0
inhibited	0
redistribution	0
of	0
5-lipoxygenase	9
from	0
the	0
cytosol	0
to	0
the	0
nuclear	0
membrane	0
of	0
HL-60	5
cells	6
stimulated	0
by	0
A23187	0
.	0

5-Lipoxygenase	9
protein	10
was	0
detected	0
in	0
nuclear	9
factor	10
kappaB	10
(	10
NF-kappaB	10
)	10
p65	10
subunit	10
immunoprecipitate	0
fractions	0
prepared	0
from	0
HL-60	5
cell	6
lysates	0
.	0

The	0
amount	0
of	0
5-lipoxygenase	9
protein	10
coimmunoprecipitated	0
by	0
NF-kappaB	0
antiserum	0
was	0
increased	0
following	0
A23187	0
stimulation	0
.	0

In	0
cells	0
treated	0
with	0
agents	0
that	0
block	0
5-lipoxygenase	9
translocation	0
to	0
the	0
nucleus	0
,	0
5-lipoxygenase	9
protein	0
appearing	0
in	0
the	0
NF-kappaB	9
immunoprecipitate	0
was	0
diminished	0
.	0

Our	0
results	0
implicate	0
an	0
internal	9
bipartite	10
nuclear	10
localizing	10
sequence	10
as	0
a	0
regulatory	0
domain	0
that	0
modulates	0
5-lipoxygenase	9
redistribution	0
and	0
catalysis	0
in	0
granulocytic	7
cells	8
.	0

Additionally	0
,	0
our	0
results	0
suggest	0
that	0
molecular	0
determinants	0
which	0
govern	0
5-lipoxygenase	0
and	0
NF-kappaB	0
redistribution	0
to	0
the	0
nucleus	0
may	0
be	0
coordinately	0
controlled	0
in	0
granulocytic	7
cells	8
.	0

Copyright	0
1998	0
Academic	0
Press	0
.	0

Inhibition	0
of	0
CD28/CD3-mediated	0
costimulation	0
of	0
naive	7
and	8
memory	8
human	8
T	8
lymphocytes	8
by	0
intracellular	0
incorporation	0
of	0
polyclonal	9
antibodies	10
specific	0
for	0
the	0
activator	9
protein-1	10
transcriptional	10
complex	10
.	0

A	0
number	0
of	0
indirect	0
methods	0
have	0
been	0
utilized	0
in	0
demonstrating	0
activator	9
protein-1	10
transcription	0
factor	0
function	0
in	0
IL-2	0
promoter	0
activity	0
.	0

However	0
,	0
there	0
has	0
been	0
no	0
direct	0
demonstration	0
that	0
activator	9
protein-1	10
is	0
involved	0
in	0
CD28-dependent	0
costimulation	0
of	0
IL-2	1
gene	2
transcription	0
in	0
freshly	0
isolated	0
naive	7
and	8
memory	8
human	8
T	8
lymphocytes	8
.	0

To	0
address	0
this	0
issue	0
,	0
the	0
method	0
of	0
scrape	0
loading	0
was	0
applied	0
to	0
purified	7
peripheral	8
blood	8
T	8
lymphocytes	8
.	0

Since	0
scrape	0
loading	0
relies	0
on	0
adherent	7
cells	8
,	0
peripheral	7
blood	8
human	8
T	8
(	8
PB-T	8
)	8
cells	8
were	0
immobilized	0
on	0
the	0
nonspecific	0
cell	0
attachment	0
factor	0
poly-L-lysine	0
.	0

Cells	0
scraped	0
off	0
poly-L-lysine	0
in	0
the	0
presence	0
of	0
Ig	9
FITC	10
efficiently	0
incorporated	0
Ig	0
,	0
with	0
relatively	0
uniform	0
fluorescence	0
.	0

T	0
cells	0
retained	0
their	0
physical	0
parameters	0
as	0
measured	0
by	0
forward	0
and	0
side	0
light	0
scatter	0
,	0
and	0
functional	0
activity	0
as	0
measured	0
by	0
costimulation	0
of	0
proliferation	0
and	0
IL-2	9
production	0
after	0
being	0
scraped	0
off	0
this	0
substrate	0
.	0

CD28/CD3-costimulated	7
T	8
cells	8
produced	0
intracellular	0
IL-2	9
from	0
all	0
subsets	0
measured	0
(	0
CD4+	7
,	0
CD4-	7
,	0
CD45RO+	7
,	0
and	0
CD45RO-	7
)	0
.	0

IL-2	9
production	0
and	0
intracellular	0
accumulation	0
in	0
nonscraped	0
PB-T	7
cells	8
activated	0
with	0
CD28/CD3	0
coligation	0
were	0
skewed	0
favoring	0
CD45RO+	7
and	8
CD4+	8
subsets	8
,	0
as	0
was	0
IL-2	9
production	0
in	0
scraped	0
PB-T	7
cells	8
.	0

The	0
intracellular	0
incorporation	0
of	0
Abs	0
specific	0
for	0
c-Fos	9
and	10
c-Jun	10
family	10
members	10
by	0
scrape	0
loading	0
inhibited	0
the	0
production	0
and	0
intracellular	0
accumulation	0
of	0
IL-2	9
within	0
6	0
h	0
of	0
costimulation	0
with	0
PMA/ionomycin	0
,	0
or	0
costimulation	0
by	0
CD28	0
and	0
CD3	0
ligation	0
.	0

Scrape	0
loading	0
thus	0
provides	0
an	0
efficient	0
mechanism	0
for	0
intracellular	0
incorporation	0
of	0
macromolecules	0
,	0
and	0
the	0
first	0
direct	0
evidence	0
that	0
c-Fos	9
and	0
c-Jun	9
are	0
involved	0
in	0
transcription	0
of	0
the	0
IL-2	1
gene	2
within	0
its	0
correct	0
chromosomal	0
context	0
,	0
in	0
resting	0
human	0
T	0
lymphocyte	0
subpopulations	0
.	0

Differential	0
expression	0
of	0
Nur77	9
family	10
members	10
in	0
human	7
T-lymphotropic	8
virus	8
type	8
1-infected	8
cells	8
:	0
transactivation	0
of	0
the	0
TR3/nur77	1
gene	2
by	0
Tax	9
protein	10
.	0

We	0
analyzed	0
the	0
differential	0
expression	0
and	0
regulation	0
of	0
three	0
members	0
of	0
the	0
Nur77	9
transcription	10
factor	10
family	10
by	0
the	0
human	0
T-lymphotropic	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
Tax	9
protein	10
.	0

We	0
have	0
demonstrated	0
that	0
in	0
both	0
HTLV-1-infected	7
cells	8
and	0
Tax-expressing	5
JPX-9	6
cells	6
,	0
TR3/nur77	9
is	0
highly	0
expressed	0
,	0
whereas	0
neither	0
NOR-1	0
nor	0
NOT	0
expression	0
is	0
detectable	0
.	0

Transient	0
transfection	0
analysis	0
further	0
confirmed	0
the	0
Tax	9
transactivation	0
of	0
the	0
TR3/nur77	9
promoter	0
but	0
not	0
the	0
NOR-1	1
promoter	2
in	0
different	0
cell	0
types	0
.	0

Furthermore	0
,	0
expression	0
of	0
a	0
luciferase	1
reporter	2
gene	2
driven	0
by	0
the	0
NGFI-B	1
(	2
rat	2
homolog	2
of	2
TR3/Nur77	2
)	2
response	2
element	2
(	0
NBRE	1
)	0
provided	0
evidence	0
that	0
Tax	9
-mediated	0
transactivation	0
resulted	0
in	0
the	0
induction	0
of	0
a	0
functional	0
protein	0
.	0

Cotransfection	0
assays	0
with	0
the	0
TR3/nur77	1
promoter	2
sequence	2
or	0
the	0
NBRE	1
binding	0
motif	0
together	0
with	0
a	0
series	0
of	0
Tax	9
mutants	0
have	0
shown	0
that	0
Tax	9
-induced	0
TR3/nur77	9
expression	0
is	0
mediated	0
by	0
CREB/ATF-related	9
transcription	10
factors	10
.	0

Negative	0
regulation	0
of	0
the	0
heat	0
shock	0
transcriptional	0
response	0
by	0
HSBP1	9
.	0

In	0
response	0
to	0
stress	0
,	0
heat	9
shock	10
factor	10
1	10
(	0
HSF1	9
)	0
acquires	0
rapid	0
DNA	0
binding	0
and	0
transient	0
transcriptional	0
activity	0
while	0
undergoing	0
conformational	0
transition	0
from	0
an	0
inert	0
non-DNA-binding	9
monomer	10
to	0
active	0
functional	0
trimers	0
.	0

Attenuation	0
of	0
the	0
inducible	0
transcriptional	0
response	0
occurs	0
during	0
heat	0
shock	0
or	0
upon	0
recovery	0
at	0
non-stress	0
conditions	0
and	0
involves	0
dissociation	0
of	0
the	0
HSF1	9
trimer	10
and	0
loss	0
of	0
activity	0
.	0

We	0
have	0
used	0
the	0
hydrophobic	9
repeats	10
of	0
the	0
HSF1	9
trimerization	0
domain	0
in	0
the	0
yeast	0
two-hybrid	0
protein	0
interaction	0
assay	0
to	0
identify	0
heat	9
shock	10
factor	10
binding	10
protein	10
1	10
(	0
HSBP1	9
)	0
,	0
a	0
novel	0
,	0
conserved	0
,	0
76-amino-acid	9
protein	10
that	0
contains	0
two	0
extended	0
arrays	0
of	0
hydrophobic	9
repeats	10
that	0
interact	0
with	0
the	0
HSF1	9
heptad	10
repeats	10
.	0

HSBP1	9
is	0
nuclear-localized	0
and	0
interacts	0
in	0
vivo	0
with	0
the	0
active	0
trimeric	0
state	0
of	0
HSF1	9
that	0
appears	0
during	0
heat	0
shock	0
.	0

During	0
attenuation	0
of	0
HSF1	9
to	0
the	0
inert	0
monomer	0
,	0
HSBP1	9
associates	0
with	0
Hsp70	0
.	0

HSBP1	9
negatively	0
affects	0
HSF1	9
DNA-binding	0
activity	0
,	0
and	0
overexpression	0
of	0
HSBP1	9
in	0
mammalian	7
cells	8
represses	0
the	0
transactivation	0
activity	0
of	0
HSF1	9
.	0

To	0
establish	0
a	0
biological	0
role	0
for	0
HSBP1	9
,	0
the	0
homologous	0
Caenorhabditis	9
elegans	10
protein	10
was	0
overexpressed	0
in	0
body	7
wall	8
muscle	8
cells	8
and	0
was	0
shown	0
to	0
block	0
activation	0
of	0
the	0
heat	0
shock	0
response	0
from	0
a	0
heat	1
shock	2
promoter-reporter	2
construct	2
.	0

Alteration	0
in	0
the	0
level	0
of	0
HSBP1	9
expression	0
in	0
C.	0
elegans	0
has	0
severe	0
effects	0
on	0
survival	0
of	0
the	0
animals	0
after	0
thermal	0
and	0
chemical	0
stress	0
,	0
consistent	0
with	0
a	0
role	0
for	0
HSBP1	9
as	0
a	0
negative	0
regulator	0
of	0
the	0
heat	0
shock	0
response	0
.	0

Long-range	0
transcriptional	0
regulation	0
of	0
cytokine	0
gene	0
expression	0
.	0

Most	0
studies	0
on	0
the	0
control	0
of	0
cytokine	0
gene	0
expression	0
have	0
involved	0
the	0
functional	0
analysis	0
of	0
proximal	1
promoters	2
.	0

Recent	0
work	0
has	0
identified	0
distal	1
elements	2
that	0
mediate	0
long-range	0
cytokine	0
gene	0
regulation	0
and	0
has	0
implicated	0
chromatin	0
reorganization	0
in	0
regulation	0
of	0
cytokine	1
gene	2
loci	2
.	0

These	0
studies	0
have	0
begun	0
to	0
elucidate	0
the	0
basis	0
for	0
cell-specificity	0
and	0
high-level	0
expression	0
of	0
cytokine	1
genes	2
.	0

A	0
signaling	0
complex	0
of	0
Ca2+-calmodulin-dependent	9
protein	10
kinase	10
IV	10
and	0
protein	9
phosphatase	10
2A	10
[	0
see	0
comments	0
]	0

Stimulation	0
of	0
T	7
lymphocytes	8
results	0
in	0
a	0
rapid	0
increase	0
in	0
intracellular	0
calcium	0
concentration	0
(	0
[	0
Ca2+	0
]	0
i	0
)	0
that	0
parallels	0
the	0
activation	0
of	0
Ca2+-calmodulin-dependent	9
protein	10
kinase	10
IV	10
(	0
CaMKIV	9
)	0
,	0
a	0
nuclear	9
enzyme	10
that	0
can	0
phosphorylate	0
and	0
activate	0
the	0
cyclic	9
adenosine	10
monophosphate	10
(	10
cAMP	10
)	10
response	10
element-binding	10
protein	10
(	0
CREB	9
)	0
.	0

However	0
,	0
inactivation	0
of	0
CaMKIV	9
occurs	0
despite	0
the	0
sustained	0
increase	0
in	0
[	0
Ca2+	0
]	0
i	0
that	0
is	0
required	0
for	0
T	0
cell	0
activation	0
.	0

A	0
stable	0
and	0
stoichiometric	0
complex	0
of	0
CaMKIV	9
with	0
protein	9
serine-threonine	10
phosphatase	10
2A	10
(	0
PP2A	9
)	0
was	0
identified	0
in	0
which	0
PP2A	9
dephosphorylates	0
CaMKIV	9
and	0
functions	0
as	0
a	0
negative	0
regulator	0
of	0
CaMKIV	9
signaling	0
.	0

In	0
Jurkat	5
T	6
cells	6
,	0
inhibition	0
of	0
PP2A	9
activity	0
by	0
small	0
t	0
antigen	0
enhanced	0
activation	0
of	0
CREB	9
-mediated	0
transcription	0
by	0
CaMKIV	9
.	0

These	0
findings	0
reveal	0
an	0
intracellular	0
signaling	0
mechanism	0
whereby	0
a	0
protein	9
serine-threonine	10
kinase	10
(	0
CaMKIV	9
)	0
is	0
regulated	0
by	0
a	0
tightly	0
associated	0
protein	9
serine-threonine	10
phosphatase	10
(	0
PP2A	9
)	0
.	0

Hypoxia	0
down-regulates	0
MCP-1	9
expression	0
:	0
implications	0
for	0
macrophage	0
distribution	0
in	0
tumors	0
.	0

Monocyte	9
chemoattractant	10
protein	10
1	10
(	0
MCP-1	9
)	0
is	0
likely	0
to	0
contribute	0
to	0
the	0
macrophage	7
infiltrate	8
in	0
human	0
ovarian	0
carcinomas	0
.	0

Although	0
MCP-1	9
is	0
predominantly	0
expressed	0
by	0
the	0
tumor	0
parenchyma	0
,	0
macrophages	0
accumulate	0
at	0
highest	0
density	0
in	0
necrotic	0
regions	0
,	0
which	0
are	0
associated	0
with	0
low	0
oxygen	0
tensions	0
.	0

Tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
can	0
stimulate	0
MCP-1	9
production	0
and	0
is	0
also	0
present	0
within	0
ovarian	0
carcinomas	0
.	0

We	0
have	0
investigated	0
the	0
effect	0
of	0
hypoxia	0
both	0
on	0
MCP-1	9
expression	0
in	0
ovarian	5
cancer	6
cell	6
lines	6
and	0
monocyte	0
migration	0
.	0

Hypoxia	0
down-regulated	0
TNF-alpha-induced	3
MCP-1	4
mRNA	4
and	0
protein	0
production	0
by	0
ovarian	7
cancer	8
cells	8
.	0

The	0
effect	0
was	0
mimicked	0
by	0
cobalt	0
chloride	0
and	0
desferrioxamine	0
,	0
consistent	0
with	0
a	0
specific	0
oxygen-sensing	0
mechanism	0
.	0

Unlike	0
antioxidants	0
,	0
hypoxia	0
did	0
not	0
inhibit	0
nuclear	0
factor	0
KB	0
mobilization	0
.	0

Monocyte	0
migration	0
in	0
response	0
to	0
MCP-1	9
was	0
also	0
diminished	0
under	0
hypoxic	0
conditions	0
.	0

Down-regulation	0
of	0
MCP-1	9
expression	0
and	0
the	0
inhibition	0
of	0
monocyte	0
migration	0
are	0
independent	0
effects	0
of	0
hypoxia	0
that	0
may	0
contribute	0
to	0
the	0
distribution	0
of	0
macrophages	7
within	0
ovarian	0
tumors	0
.	0

Activation	0
of	0
nuclear	9
factor	10
kappa	10
B	10
inflammatory	0
bowel	0
disease	0
[	0
see	0
comments	0
]	0

BACKGROUND	0
:	0
Expression	0
of	0
pro-inflammatory	9
cytokines	10
is	0
increased	0
in	0
the	0
intestinal	0
lamina	0
propria	0
of	0
patients	0
with	0
inflammatory	0
bowel	0
disease	0
(	0
IBD	0
)	0
.	0

Nuclear	9
factor	10
kappa	10
B	10
(	0
NF	9
kappa	10
B	10
)	0
controls	0
transcription	0
of	0
inflammation	1
genes	2
.	0

On	0
activation	0
,	0
NF	9
kappa	10
B	10
is	0
rapidly	0
released	0
from	0
its	0
cytoplasmic	9
inhibitor	10
(	0
I	9
kappa	10
B	10
)	0
,	0
transmigrates	0
into	0
the	0
nucleus	0
,	0
and	0
binds	0
to	0
DNA	1
response	2
elements	2
in	0
gene	0
promoter	0
regions	0
.	0

AIMS	0
:	0
To	0
investigate	0
whether	0
increased	0
activation	0
of	0
NF	9
kappa	10
B	10
is	0
important	0
in	0
IBD	0
and	0
may	0
be	0
down-regulated	0
by	0
anti-inflammatory	0
treatment	0
.	0

METHODS	0
:	0
Activation	0
of	0
NF	9
kappa	10
B	10
was	0
determined	0
by	0
western	0
blot	0
assessment	0
and	0
electrophoretic	0
mobility	0
shift	0
assay	0
in	0
nuclear	0
extracts	0
of	0
colonic	0
biopsy	0
samples	0
as	0
well	0
as	0
lamina	7
propria	8
mononuclear	8
cells	8
.	0

RESULTS	0
:	0
Nuclear	0
levels	0
of	0
NF	9
kappa	10
B	10
p65	9
are	0
increased	0
in	0
lamina	0
propria	0
biopsy	0
specimens	0
from	0
patients	0
with	0
Crohn	0
's	0
disease	0
in	0
comparison	0
with	0
patients	0
with	0
ulcerative	0
colitis	0
and	0
controls	0
.	0

Increased	0
activation	0
of	0
NF	9
kappa	10
B	10
was	0
detected	0
in	0
lamina	7
propria	8
mononuclear	8
cells	8
from	0
patients	0
with	0
active	0
IBD	0
.	0

Corticosteroids	0
strongly	0
inhibit	0
intestinal	0
NF	9
kappa	10
B	10
activation	0
in	0
IBD	0
in	0
vivo	0
and	0
in	0
vitro	0
by	0
stabilising	0
the	0
cytosolic	9
inhibitor	10
I	9
kappa	10
B	10
alpha	0
against	0
activation	0
induced	0
degradation	0
.	0

CONCLUSIONS	0
:	0
In	0
both	0
IBDs	0
,	0
but	0
particularly	0
Crohn	0
's	0
disease	0
,	0
increased	0
activation	0
of	0
NF	9
kappa	10
B	10
may	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
the	0
inflammatory	0
response	0
.	0

Inhibition	0
of	0
NF	9
kappa	10
B	10
activation	0
may	0
represent	0
a	0
mechanism	0
by	0
which	0
steroids	0
exert	0
an	0
anti-inflammatory	0
effect	0
in	0
IBD	0

Insufficient	0
glycemic	0
control	0
increases	0
nuclear	9
factor-kappa	10
B	10
binding	0
activity	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
isolated	0
from	0
patients	0
with	0
type	0
1	0
diabetes	0
.	0

OBJECTIVE	0
:	0
The	0
redox-sensitive	9
transcription	10
factor	10
nuclear	10
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
is	0
believed	0
to	0
contribute	0
to	0
late	0
diabetic	0
complications	0
.	0

It	0
is	0
unknown	0
whether	0
NF-kappa	9
B	10
is	0
influenced	0
by	0
glycemic	0
control	0
.	0

RESEARCH	0
DESIGN	0
AND	0
METHODS	0
:	0
To	0
determine	0
whether	0
NF-kappa	9
B	10
is	0
activated	0
in	0
patients	0
with	0
insufficient	0
glycemic	0
control	0
(	0
HbA1c	0
>	0
10	0
%	0
)	0
,	0
we	0
developed	0
a	0
tissue	0
culture-independent	0
electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
-based	0
semiquantitative	0
detection	0
system	0
that	0
allowed	0
us	0
to	0
determine	0
NF-kappa	9
B	10
activation	0
in	0
ex	0
vivo-isolated	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
.	0

We	0
included	0
43	0
patients	0
with	0
type	0
1	0
diabetes	0
in	0
this	0
cross-sectional	0
study	0
.	0

10	0
of	0
those	0
received	0
the	0
antioxidant	0
thioctic	0
acid	0
(	0
600	0
mg/day	0
p.o.	0
)	0
for	0
2	0
weeks	0
.	0

RESULTS	0
:	0
Monocytes	0
of	0
patients	0
with	0
HbA1c	0
levels	0
>	0
10	0
%	0
demonstrated	0
significantly	0
higher	0
NF-kappa	9
B	10
binding	0
activity	0
in	0
an	0
EMSA	0
and	0
a	0
stronger	0
NF-kappa	9
B	10
staining	0
in	0
immunohistochemistry	0
than	0
monocytes	7
of	0
patients	0
with	0
HbA1c	0
levels	0
of	0
6-8	0
%	0
.	0

The	0
increase	0
in	0
NF-kappa	9
B	10
activation	0
correlated	0
with	0
an	0
increase	0
in	0
plasmatic	0
markers	0
of	0
lipid	0
peroxidation	0
.	0

Treatment	0
with	0
the	0
antioxidant	0
thioctic	0
acid	0
decreased	0
NF-kappa	9
B	10
binding	0
activity	0
.	0

CONCLUSIONS	0
:	0
Hyperglycemia	0
induces	0
activation	0
of	0
the	0
transcription	0
factor	0
NF-kappa	9
B	10
in	0
ex	0
vivo-isolated	0
PBMCs	7
of	0
patients	0
with	0
type	0
1	0
diabetes	0
.	0

NF-kappa	9
B	10
activation	0
is	0
at	0
least	0
partially	0
dependent	0
on	0
oxidative	0
stress	0
,	0
since	0
the	0
antioxidant	0
thioctic	0
acid	0
significantly	0
lowered	0
the	0
extent	0
of	0
NF-kappa	9
B	10
binding	0
activity	0
.	0

Synergistic	0
activation	0
of	0
MAP	9
kinase	10
(	0
ERK1/2	9
)	0
by	0
erythropoietin	9
and	0
stem	9
cell	10
factor	10
is	0
essential	0
for	0
expanded	0
erythropoiesis	0
.	0

Stem	9
cell	10
factor	10
(	0
SCF	9
)	0
and	0
erythropoietin	9
(	0
EPO	9
)	0
work	0
synergistically	0
to	0
support	0
erythropoiesis	0
,	0
but	0
the	0
mechanism	0
for	0
this	0
synergism	0
is	0
unknown	0
.	0

By	0
using	0
purified	5
human	6
erythroid	6
colony-forming	6
cells	6
(	0
ECFC	5
)	0
,	0
we	0
have	0
found	0
that	0
SCF	9
and	0
EPO	9
synergistically	0
activate	0
MAP	9
kinase	10
(	0
MAPK	9
,	0
ERK1/2	9
)	0
,	0
which	0
correlates	0
with	0
the	0
cell	0
growth	0
and	0
thus	0
may	0
be	0
responsible	0
for	0
the	0
synergistic	0
effects	0
.	0

Treatment	0
of	0
the	0
cells	0
with	0
PD98059	0
and	0
wortmannin	0
,	0
inhibitors	0
of	0
MEK	9
and	0
PI-3	9
kinase	10
,	0
respectively	0
,	0
inhibited	0
the	0
synergistic	0
activation	0
of	0
MAPK	9
and	0
also	0
the	0
cell	0
growth	0
,	0
further	0
supporting	0
this	0
conclusion	0
.	0

Wortmannin	0
only	0
inhibits	0
MAPK	9
activation	0
induced	0
by	0
EPO	9
but	0
not	0
that	0
by	0
SCF	9
,	0
suggesting	0
that	0
SCF	9
and	0
EPO	9
may	0
activate	0
MAPK	9
through	0
different	0
pathways	0
,	0
which	0
would	0
facilitate	0
synergy	0
.	0

Furthermore	0
,	0
EPO	9
,	0
but	0
not	0
SCF	9
,	0
led	0
to	0
activation	0
of	0
STAT5	9
,	0
whereas	0
SCF	9
and	0
wortmannin	0
had	0
no	0
effect	0
on	0
the	0
EPO	9
-induced	0
STAT5	9
activation	0
,	0
suggesting	0
that	0
STAT5	9
is	0
not	0
involved	0
in	0
the	0
synergistic	0
action	0
of	0
SCF	9
and	0
EPO	9
.	0

Together	0
,	0
the	0
data	0
suggest	0
that	0
synergistic	0
activation	0
of	0
MAPK	9
by	0
SCF	9
and	0
EPO	9
is	0
essential	0
for	0
expanded	0
erythropoiesis	0
.	0

Copyright	0
1998	0
by	0
The	0
American	0
Society	0
of	0
Hematology	0
.	0

The	0
molecular	0
and	0
phenotypic	0
profile	0
of	0
primary	0
central	0
nervous	0
system	0
lymphoma	0
identifies	0
distinct	0
categories	0
of	0
the	0
disease	0
and	0
is	0
consistent	0
with	0
histogenetic	0
derivation	0
from	0
germinal	7
center-related	8
B	8
cells	8
.	0

Primary	0
central	0
nervous	0
system	0
lymphoma	0
(	0
PCNSL	0
)	0
is	0
a	0
major	0
cause	0
of	0
morbidity	0
and	0
mortality	0
among	0
human	0
immunodeficiency	0
virus	0
(	0
HIV	0
)	0
-infected	0
individuals	0
.	0

The	0
precise	0
histogenetic	0
derivation	0
and	0
the	0
molecular	0
pathogenesis	0
of	0
PCNSL	0
is	0
poorly	0
understood	0
.	0

In	0
an	0
attempt	0
to	0
clarify	0
the	0
histogenesis	0
and	0
pathogenesis	0
of	0
these	0
lymphomas	0
,	0
49	0
PCNSL	0
(	0
26	0
acquired	0
immunodeficiency	0
syndrome	0
[	0
AIDS	0
]	0
-related	0
and	0
23	0
AIDS-unrelated	0
)	0
were	0
analyzed	0
for	0
multiple	0
biologic	0
markers	0
,	0
which	0
are	0
known	0
to	0
bear	0
histogenetic	0
and	0
pathogenetic	0
significance	0
for	0
mature	0
B-cell	0
neoplasms	0
.	0

PCNSL	0
associated	0
frequently	0
(	0
50.0	0
%	0
)	0
with	0
mutations	0
of	0
BCL-6	1
5	2
'	2
noncoding	2
regions	2
,	0
which	0
are	0
regarded	0
as	0
a	0
marker	0
of	0
B-cell	0
transition	0
through	0
the	0
germinal	0
center	0
(	0
GC	0
)	0
.	0

Expression	0
of	0
BCL-6	9
protein	10
,	0
which	0
is	0
restricted	0
to	0
GC	7
B	8
cells	8
throughout	0
physiologic	0
B-cell	0
maturation	0
,	0
was	0
detected	0
in	0
100	0
%	0
AIDS-unrelated	0
PCNSL	0
and	0
in	0
56.2	0
%	0
AIDS-related	0
cases	0
.	0

Notably	0
,	0
among	0
AIDS-related	0
PCNSL	0
,	0
expression	0
of	0
BCL-6	9
was	0
mutually	0
exclusive	0
with	0
expression	0
of	0
Epstein-Barr	9
virus	10
(	10
EBV	10
)	10
-encoded	10
latent	10
membrane	10
protein	10
(	10
LMP	10
)	10
-1	10
and	0
,	0
with	0
few	0
exceptions	0
,	0
also	0
of	0
BCL-2	9
.	0

All	0
but	0
one	0
PCNSL	0
expressed	0
hMSH2	0
,	0
which	0
among	0
mature	7
B	8
cells	8
selectively	0
stains	0
GC	7
B	8
cells	8
.	0

These	0
data	0
suggest	0
that	0
PCNSL	0
may	0
be	0
frequently	0
related	0
to	0
GC	7
B	8
cells	8
and	0
may	0
be	0
segregated	0
into	0
two	0
major	0
biologic	0
categories	0
based	0
on	0
the	0
expression	0
pattern	0
of	0
BCL-6	9
,	0
LMP-1	9
,	0
and	0
BCL-2	9
.	0

BCL-6	9
(	0
+	0
)	0
/	0
LMP-1	9
(	0
-	0
)	0
/	0
BCL-2	9
(	0
-	0
)	0
PCNSL	0
occur	0
both	0
in	0
the	0
presence	0
and	0
in	0
the	0
absence	0
of	0
HIV	0
infection	0
and	0
consistently	0
display	0
a	0
large	0
noncleaved	0
cell	0
morphology	0
.	0

Conversely	0
,	0
BCL-6	9
(	0
-	0
)	0
/	0
LMP-1	9
(	0
+	0
)	0
/	0
BCL-2	9
(	0
+	0
)	0
PCNSL	0
are	0
restricted	0
to	0
HIV-infected	0
hosts	0
and	0
are	0
represented	0
by	0
lymphomas	0
with	0
immunoblastic	0
features	0
.	0

These	0
data	0
are	0
relevant	0
for	0
the	0
pathogenesis	0
and	0
histogenesis	0
of	0
PCNSL	0
and	0
may	0
be	0
helpful	0
to	0
segregate	0
distinct	0
biologic	0
and	0
prognostic	0
categories	0
of	0
these	0
lymphomas	0
.	0

Copyright	0
1998	0
by	0
The	0
American	0
Society	0
of	0
Hematology	0
.	0

Antioxidant	0
regulation	0
of	0
phorbol	0
ester-induced	0
adhesion	0
of	0
human	5
Jurkat	6
T-cells	6
to	0
endothelial	7
cells	8
.	0

Regulation	0
of	0
adhesion	0
molecule	0
expression	0
and	0
function	0
by	0
reactive	0
oxygen	0
species	0
via	0
specific	0
redox	0
sensitive	0
mechanisms	0
have	0
been	0
reported	0
.	0

The	0
effects	0
of	0
clinically	0
safe	0
antioxidants	0
in	0
the	0
regulation	0
of	0
adhesion	0
molecule	0
expression	0
in	0
human	7
endothelial	8
cells	8
(	0
ECV	0
)	0
,	0
and	0
adherence	0
of	0
human	5
Jurkat	6
T	6
cells	6
to	0
ECV	7
cells	8
were	0
investigated	0
.	0

The	0
thiol	0
antioxidant	0
,	0
alpha-lipoate	0
,	0
at	0
clinically	0
relevant	0
doses	0
down-regulated	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
-induced	0
adhesion	0
molecule	0
expression	0
and	0
cell-cell	0
adhesion	0
.	0

Inhibition	0
of	0
PMA-induced	0
ICAM-1	0
and	0
VCAM-1	0
expression	0
as	0
well	0
as	0
PMA-induced	0
adhesion	0
of	0
Jurkat	5
T-cells	6
to	0
ECV	7
cells	8
by	0
alpha-lipoate	0
was	0
dose	0
dependent	0
(	0
50-250	0
microM	0
)	0
.	0

The	0
effect	0
was	0
significant	0
for	0
ICAM-1	9
(	0
p	0
<	0
.01	0
)	0
and	0
VCAM-1	9
(	0
p	0
<	0
.01	0
)	0
expression	0
in	0
cells	0
pretreated	0
with	0
100	0
microM	0
alpha-lipoate	0
compared	0
to	0
PMA-activated	7
untreated	8
cells	8
.	0

Inhibition	0
of	0
PMA-induced	0
adhesion	0
molecule	0
expression	0
and	0
cell-cell	0
adhesion	0
was	0
more	0
pronounced	0
when	0
a	0
combination	0
of	0
antioxidants	0
,	0
alpha-lipoate	0
and	0
alpha-tocopherol	0
,	0
were	0
used	0
compared	0
to	0
the	0
use	0
of	0
either	0
of	0
these	0
antioxidant	0
alone	0
.	0

The	0
regulation	0
of	0
adhesion	0
molecule	0
expression	0
and	0
function	0
by	0
low	0
concentration	0
of	0
antioxidants	0
investigated	0
does	0
not	0
appear	0
to	0
be	0
NF-kappaB	9
regulated	0
or	0
transcription	0
dependent	0
because	0
no	0
change	0
in	0
the	0
mRNA	0
response	0
was	0
observed	0
.	0

Protein	9
kinase	10
C	10
(	0
PKC	9
)	0
has	0
been	0
suggested	0
to	0
regulate	0
PMA-induced	0
adhesion	0
molecule	0
expression	0
by	0
post-transcriptional	0
stabilization	0
of	0
adhesion	3
molecule	4
mRNA	4
.	0

Alpha-lipoate	0
pretreatment	0
did	0
not	0
influence	0
the	0
response	0
of	0
PKC	9
activity	0
to	0
PMA	0
.	0

Oxidants	0
are	0
known	0
to	0
be	0
involved	0
in	0
the	0
regulation	0
of	0
cell	0
adhesion	0
processes	0
.	0

Treatment	0
of	0
ECV	7
cells	8
with	0
PMA	0
induced	0
generation	0
of	0
intracellular	0
oxidants	0
.	0

Alpha-lipoate	0
(	0
100	0
or	0
250	0
microM	0
)	0
treatment	0
decreased	0
PMA-induced	0
generation	0
of	0
intracellular	0
oxidants	0
.	0

The	0
inhibitory	0
effect	0
of	0
low	0
concentration	0
of	0
alpha-lipaote	0
alone	0
or	0
in	0
combination	0
with	0
alpha-tocopherol	0
on	0
agonist-induced	0
adhesion	0
processes	0
observed	0
in	0
this	0
study	0
may	0
be	0
of	0
potential	0
therapeutic	0
value	0
.	0

Binding	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
to	0
CD4	9
and	10
CXCR4	10
receptors	10
differentially	0
regulates	0
expression	0
of	0
inflammatory	1
genes	2
and	0
activates	0
the	0
MEK	9
/ERK	0
signaling	0
pathway	0
.	0

We	0
have	0
previously	0
shown	0
that	0
binding	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
virions	0
to	0
CD4	9
receptors	10
stimulates	0
association	0
of	0
Lck	9
with	0
Raf-1	9
and	0
results	0
in	0
the	0
activation	0
of	0
Raf-1	9
kinase	0
in	0
a	0
Ras-independent	0
manner	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
demonstrate	0
that	0
HIV-1	9
envelope	10
glycoproteins	10
of	0
both	0
T-cell-tropic	0
and	0
macrophagetropic	0
strains	0
rapidly	0
activate	0
the	0
ERK/mitogen-activated	0
protein	0
(	0
MAP	0
)	0
kinase	0
pathway	0
and	0
the	0
binding	0
of	0
nuclear	9
transcription	10
factors	10
(	0
AP-1	9
,	0
NF-kappaB	9
,	0
and	0
C/EBP	9
)	0
and	0
stimulate	0
expression	0
of	0
cytokine	1
and	2
chemokine	2
genes	2
.	0

The	0
activation	0
of	0
this	0
signaling	0
pathway	0
requires	0
functional	0
CD4	9
receptors	10
and	0
is	0
independent	0
of	0
binding	0
to	0
CXCR4	9
.	0

Binding	0
of	0
the	0
natural	0
ligand	0
stromal	9
cell-derived	10
factor	10
1	10
(	0
SDF-1	9
)	0
to	0
CXCR4	9
,	0
which	0
inhibits	0
entry	0
of	0
T-cell-tropic	0
HIV-1	0
,	0
activates	0
also	0
the	0
ERK/	0
MAP	9
kinase	10
pathway	0
.	0

However	0
,	0
SDF-1	9
did	0
not	0
affect	0
the	0
CD4-mediated	0
expression	0
of	0
cytokine	1
and	2
chemokine	2
genes	2
.	0

These	0
results	0
provide	0
firm	0
molecular	0
evidence	0
that	0
binding	0
of	0
HIV-1	9
envelope	10
glycoproteins	10
to	0
CD4	9
receptor	10
initiates	0
a	0
signaling	0
pathway	0
(	0
s	0
)	0
independent	0
of	0
the	0
binding	0
to	0
the	0
chemokine	9
receptor	10
that	0
leads	0
to	0
the	0
aberrant	0
expression	0
of	0
inflammatory	1
genes	2
and	0
may	0
contribute	0
significantly	0
to	0
HIV-1	0
replication	0
as	0
well	0
as	0
to	0
deregulation	0
of	0
the	0
immune	0
system	0
.	0

Antigen	0
receptor	0
signaling	0
induces	0
MAP	0
kinase-mediated	0
phosphorylation	0
and	0
degradation	0
of	0
the	0
BCL-6	9
transcription	9
factor	10
.	0

The	0
bcl-6	1
proto-oncogene	2
encodes	0
a	0
POZ/zinc	9
finger	10
transcriptional	10
repressor	10
expressed	0
in	0
germinal	7
center	8
(	8
GC	8
)	8
B	8
and	8
T	8
cells	8
and	0
required	0
for	0
GC	0
formation	0
and	0
antibody	0
affinity	0
maturation	0
.	0

Deregulation	0
of	0
bcl-6	1
expression	0
by	0
chromosomal	0
rearrangements	0
and	0
point	0
mutations	0
of	0
the	0
bcl-6	1
promoter	2
region	2
are	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
B-cell	0
lymphoma	0
.	0

The	0
signals	0
regulating	0
bcl-6	1
expression	0
are	0
not	0
known	0
.	0

Here	0
we	0
show	0
that	0
antigen	0
receptor	0
activation	0
leads	0
to	0
BCL-6	9
phosphorylation	0
by	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
.	0

Phosphorylation	0
,	0
in	0
turn	0
,	0
targets	0
BCL-6	9
for	0
rapid	0
degradation	0
by	0
the	0
ubiquitin	9
/	0
proteasome	9
pathway	0
.	0

These	0
findings	0
indicate	0
that	0
BCL-6	9
expression	0
is	0
directly	0
controlled	0
by	0
the	0
antigen	0
receptor	0
via	0
MAPK	9
activation	0
.	0

This	0
signaling	0
pathway	0
may	0
be	0
crucial	0
for	0
the	0
control	0
of	0
B-cell	0
differentiation	0
and	0
antibody	0
response	0
and	0
has	0
implications	0
for	0
the	0
regulation	0
of	0
other	0
POZ/zinc	9
finger	10
transcription	10
factors	10
in	0
other	0
tissues	0
.	0

Glucocorticoid	9
receptors	10
are	0
differentially	0
expressed	0
in	0
the	0
cells	0
and	0
tissues	0
of	0
the	0
immune	0
system	0
.	0

Cytosolic	9
glucocorticoid	10
receptor	10
(	0
GR	9
)	0
binding	0
studies	0
on	0
immune	0
tissues	0
demonstrate	0
that	0
the	0
thymus	0
exhibits	0
three	0
to	0
four	0
times	0
higher	0
levels	0
of	0
GR	9
protein	10
than	0
the	0
spleen	0
.	0

High	0
levels	0
of	0
GR	9
are	0
consistent	0
with	0
the	0
exquisite	0
sensitivity	0
of	0
the	0
thymus	0
to	0
glucocorticoid	0
exposure	0
.	0

Nevertheless	0
,	0
whole	0
cell	0
binding	0
studies	0
reveal	0
similar	0
levels	0
of	0
GR	9
in	0
immature	7
thymic	8
T	8
lymphocytes	8
and	0
more	0
mature	0
,	0
splenic	7
T	8
lymphocytes	8
.	0

Moreover	0
,	0
whole	0
cell	0
binding	0
techniques	0
indicate	0
that	0
neutrophils	7
(	0
which	0
represent	0
roughly	0
30	0
%	0
of	0
splenic	7
leukocytes	8
)	0
exhibit	0
higher	0
GR	9
than	0
both	0
T	7
and	8
B	8
lymphocytes	8
,	0
further	0
contradicting	0
results	0
from	0
cytosolic	0
binding	0
studies	0
.	0

To	0
address	0
these	0
inconsistencies	0
,	0
GR	9
protein	10
was	0
assessed	0
in	0
immune	7
cells	8
and	8
tissues	8
using	0
cytosolic	0
radioligand	0
binding	0
.	0

Western	0
blot	0
analysis	0
,	0
and	0
immunocytochemistry	0
.	0

Consistent	0
with	0
previous	0
cytosolic	0
receptor	0
binding	0
studies	0
on	0
immune	0
tissue	0
homogenates	0
,	0
thymic	0
T	7
cells	8
were	0
found	0
to	0
have	0
higher	0
levels	0
of	0
GR	9
than	0
T	7
cells	8
isolated	0
from	0
the	0
spleen	0
.	0

In	0
addition	0
,	0
neutrophils	0
were	0
found	0
to	0
have	0
fewer	0
GR	9
than	0
lymphocytes	7
and	0
monocytes	7
.	0

These	0
results	0
indicate	0
a	0
meaningful	0
relationship	0
between	0
receptor	0
expression	0
and	0
known	0
sensitivity	0
to	0
glucocorticoids	0
.	0

Functional	0
replacement	0
of	0
the	0
mouse	1
E2A	2
gene	2
with	0
a	0
human	1
HEB	2
cDNA	2
.	0

The	0
mammalian	1
E2A	2
,	2
HEB	2
,	2
and	2
E2-2	2
genes	2
encode	0
a	0
unique	0
class	0
of	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
transcription	10
factors	10
that	0
are	0
evolutionarily	0
conserved	0
and	0
essential	0
for	0
embryonic	0
and	0
postnatal	0
development	0
.	0

While	0
the	0
structural	0
and	0
functional	0
similarities	0
among	0
the	0
gene	9
products	10
are	0
well	0
demonstrated	0
,	0
it	0
is	0
not	0
clear	0
why	0
deletion	0
of	0
E2A	1
,	0
but	0
not	0
HEB	1
or	0
E2-2	1
,	0
leads	0
to	0
a	0
complete	0
arrest	0
in	0
B-lymphocyte	0
development	0
.	0

To	0
understand	0
the	0
molecular	0
basis	0
of	0
the	0
functional	0
specificity	0
between	0
E2A	1
and	0
HEB	1
/	0
E2-2	1
in	0
mammalian	0
development	0
,	0
we	0
generated	0
and	0
tested	0
a	0
panel	0
of	0
E2A	1
knockin	0
mutations	0
including	0
subtle	0
mutations	0
in	0
the	0
E12	1
and	2
E47	2
exons	2
and	0
substitution	0
of	0
both	0
E12	1
and	2
E47	2
exons	2
with	0
a	0
human	1
HEB	2
cDNA	2
.	0

We	0
find	0
that	0
the	0
alternatively	0
spliced	0
E12	9
and	10
E47	10
bHLH	10
proteins	10
of	0
the	0
E2A	1
gene	2
play	0
similar	0
and	0
additive	0
roles	0
in	0
supporting	0
B	7
lymphopoiesis	8
.	0

Further	0
,	0
we	0
find	0
that	0
HEB	1
driven	0
by	0
the	0
endogenous	1
E2A	2
promoter	2
can	0
functionally	0
replace	0
E2A	1
in	0
supporting	0
B-cell	0
commitment	0
and	0
differentiation	0
toward	0
completion	0
.	0

Finally	0
,	0
the	0
postnatal	0
lethality	0
associated	0
with	0
E2A	1
disruption	0
is	0
fully	0
rescued	0
by	0
the	0
addition	0
of	0
HEB	1
.	0

This	0
study	0
suggests	0
that	0
the	0
functional	0
divergence	0
among	0
E12	1
,	0
E47	1
,	0
and	0
HEB	1
in	0
different	0
cell	0
types	0
is	0
partially	0
defined	0
by	0
the	0
context	0
of	0
gene	0
expression	0
.	0

Biased	0
dependency	0
of	0
CD80	9
versus	0
CD86	9
in	0
the	0
induction	0
of	0
transcription	9
factors	10
regulating	0
the	0
human	1
IL-2	2
promoter	2
.	0

In	0
addition	0
to	0
the	0
signals	0
obtained	0
by	0
ligation	0
of	0
the	0
TCR	0
,	0
T	7
cells	8
need	0
additional	0
,	0
co-stimulatory	0
signals	0
to	0
be	0
activated	0
.	0

One	0
such	0
co-stimulatory	0
signal	0
is	0
delivered	0
when	0
CD28	9
on	0
T	7
cells	8
binds	0
to	0
CD80	9
or	0
CD86	9
on	0
antigen-presenting	7
cells	8
(	0
APC	7
)	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
analyzed	0
the	0
ability	0
of	0
CD80	9
and	0
CD86	9
to	0
co-stimulate	7
human	8
T	8
cells	8
activated	0
by	0
superantigen	0
.	0

Using	0
the	0
Raji	5
B	6
cell	6
lymphoma	6
,	0
which	0
express	0
similar	0
levels	0
of	0
CD80	9
and	0
CD86	9
,	0
it	0
was	0
found	0
that	0
T	0
cell	0
proliferation	0
was	0
mainly	0
co-stimulated	0
by	0
CD80	9
.	0

To	0
further	0
characterize	0
the	0
consequences	0
of	0
this	0
biased	0
co-stimulatory	0
dependency	0
,	0
we	0
employed	0
a	0
well-defined	0
system	0
of	0
transfected	0
CHO	5
cells	6
expressing	0
human	9
MHC	10
class	10
II	10
together	0
with	0
CD80	9
,	0
CD86	9
or	0
CD80	9
and	0
CD86	9
.	0

Proliferation	0
of	0
freshly	0
prepared	0
CD4+	7
T	8
cells	8
required	0
the	0
presence	0
of	0
either	0
CD80	9
or	0
CD86	9
.	0

However	0
,	0
IL-2	9
production	0
reached	0
only	0
suboptimal	0
levels	0
in	0
the	0
presence	0
of	0
CD86	9
but	0
optimal	0
levels	0
with	0
CD80	9
.	0

To	0
analyze	0
IL-2	9
transcriptional	0
activity	0
in	0
CD80	9
and	0
CD86	9
co-stimulated	0
T	7
cells	8
we	0
used	0
Jurkat	5
T	6
cells	6
transfected	0
with	0
luciferase	1
reporter	2
gene	2
constructs	2
.	0

CD80	9
induced	0
higher	0
levels	0
of	0
IL-2	1
promoter	2
-enhancer	0
activity	0
compared	0
to	0
CD86	9
.	0

Furthermore	0
,	0
the	0
activity	0
of	0
transcription	9
factors	10
regulating	0
the	0
IL-2	1
promoter-enhancer	2
region	2
including	0
activation	9
protein-1	10
,	0
CD28	1
response	2
element	2
and	0
nuclear	9
factor	10
kappaB	10
were	0
4-8	0
times	0
higher	0
after	0
CD80	9
compared	0
to	0
CD86	9
ligation	0
.	0

Our	0
results	0
suggest	0
that	0
the	0
eventual	0
appearance	0
of	0
CD80	9
on	0
recently	0
activated	0
CD86+	7
APC	8
is	0
important	0
for	0
the	0
superinduction	0
of	0
IL-2	9
production	0
and	0
to	0
support	0
vigorous	0
T	0
cell	0
proliferation	0
.	0

Duplication	0
of	0
the	0
DR3	1
gene	2
on	0
human	1
chromosome	2
1p36	2
and	0
its	0
deletion	0
in	0
human	7
neuroblastoma	8
.	0

The	0
human	1
DR3	2
gene	2
,	0
whose	0
product	0
is	0
also	0
known	0
as	0
Wsl-1/APO-3/TRAMP/LARD	9
,	0
encodes	0
a	0
tumor	9
necrosis	10
factor-related	10
receptor	10
that	0
is	0
expressed	0
primarily	0
on	0
the	0
surface	0
of	0
thymocytes	7
and	0
lymphocytes	7
.	0

DR3	9
is	0
capable	0
of	0
inducing	0
both	0
NF-kappa	9
B	10
activation	0
and	0
apoptosis	0
when	0
overexpressed	0
in	0
mammalian	7
cells	8
,	0
although	0
its	0
ligand	0
has	0
not	0
yet	0
been	0
identified	0
.	0

We	0
report	0
here	0
that	0
the	0
DR3	1
gene	2
locus	2
is	0
tandemly	0
duplicated	0
on	0
human	1
chromosome	2
band	2
1p36.2-p36.3	2
and	0
that	0
these	0
genes	0
are	0
hemizygously	0
deleted	0
and/or	0
translocated	0
to	0
another	0
chromosome	0
in	0
neuroblastoma	5
(	6
NB	6
)	6
cell	6
lines	6
with	0
amplified	0
MYCN	0
.	0

Duplication	0
of	0
at	0
least	0
a	0
portion	0
of	0
the	0
DR3	1
gene	2
,	0
including	0
the	0
extracellular	9
and	10
transmembrane	10
regions	10
but	0
not	0
the	0
cytoplasmic	9
domain	10
,	0
was	0
demonstrated	0
by	0
both	0
fluorescence	0
in	0
situ	0
hybridization	0
and	0
genomic	0
Southern	0
blotting	0
.	0

In	0
most	0
NB	5
cell	6
lines	6
,	0
both	0
the	0
DR3	1
and	2
the	2
DR3L	2
sequences	2
are	0
simultaneously	0
deleted	0
and/or	0
translocated	0
to	0
another	0
chromosome	1
.	0

Finally	0
,	0
DR3/	9
Wsl-1	10
protein	10
expression	0
is	0
quite	0
variable	0
among	0
these	0
NB	5
cell	6
lines	6
,	0
with	0
very	0
low	0
or	0
undetectable	0
levels	0
in	0
7	0
of	0
17	0
NB	5
cell	6
lines	6

Differential	0
protection	0
of	0
normal	7
and	8
malignant	8
human	8
myeloid	8
progenitors	8
(	0
CFU-GM	7
)	0
from	0
Ara-C	0
toxicity	0
using	0
cycloheximide	0
.	0

Cycloheximide	0
,	0
a	0
reversible	0
protein	0
synthesis	0
inhibitor	0
,	0
is	0
thought	0
to	0
block	0
DNA	0
replication	0
in	0
normal	7
cells	8
by	0
preventing	0
synthesis	0
of	0
a	0
labile	9
protein	10
.	0

In	0
animal	0
systems	0
,	0
cycloheximide	0
protects	0
normal	7
cells	8
from	0
cytotoxic	0
S-phase	0
specific	0
agents	0
,	0
such	0
as	0
cytosine	0
arabinoside	0
(	0
Ara-C	0
)	0
.	0

Malignant	7
cells	8
appear	0
not	0
to	0
be	0
susceptible	0
to	0
cycloheximide-induced	0
cycle	0
arrest	0
and	0
,	0
subsequently	0
,	0
may	0
not	0
be	0
protected	0
from	0
Ara-C	0
cytotoxicity	0
.	0

The	0
effect	0
of	0
cycloheximide	0
on	0
granulocyte/macrophage	7
progenitors	8
(	0
CFU-GM	7
)	0
after	0
in	0
vitro	0
Ara-C	0
exposure	0
was	0
examined	0
using	0
normal	0
human	0
bone	0
marrow	0
,	0
malignant	7
progenitors	8
from	0
patients	0
with	0
chronic	0
myelogenous	0
leukemia	0
(	0
CML	0
)	0
,	0
and	0
clonogenic	5
cells	6
from	0
the	0
human	5
acute	6
nonlymphocytic	6
leukemia	6
cell	6
lines	6
HL-60	6
and	6
KG-1	6
.	0

Mononuclear	5
or	6
clonogenic	6
cells	6
were	0
incubated	0
for	0
one	0
hour	0
with	0
cycloheximide	0
,	0
followed	0
by	0
the	0
addition	0
,	0
for	0
three	0
or	0
17	0
hours	0
,	0
of	0
Ara-C	0
before	0
being	0
plated	0
in	0
a	0
methylcellulose	0
culture	0
system	0
.	0

CFU-GM	0
survival	0
was	0
significantly	0
increase	0
if	0
normal	0
cells	0
were	0
treated	0
with	0
cycloheximide	0
before	0
Ara-C	0
exposure	0
.	0

Similar	0
cycloheximide	0
pretreatment	0
of	0
CML	7
progenitors	8
and	0
clonogenic	5
HL-60	6
and	6
KG-1	6
cells	6
failed	0
to	0
protect	0
CFU-GM	7
from	0
Ara-C-induced	0
cytotoxicity	0
.	0

Primary	0
cortisol	0
resistance	0
accompanied	0
by	0
a	0
reduction	0
in	0
glucocorticoid	9
receptors	10
in	0
two	0
members	0
of	0
the	0
same	0
family	0
.	0

This	0
report	0
describes	0
studies	0
of	0
a	0
man	0
suspected	0
of	0
having	0
primary	0
cortisol	0
resistance	0
.	0

This	0
conclusion	0
is	0
based	0
on	0
his	0
high	0
plasma	0
cortisol	0
levels	0
and	0
high	0
24-h	0
urinary	0
17-hydroxycorticosteroid	0
and	0
cortisol	0
excretion	0
,	0
plus	0
the	0
fact	0
that	0
he	0
had	0
no	0
manifestations	0
of	0
Cushing	0
's	0
syndrome	0
.	0

Among	0
family	0
members	0
tested	0
,	0
his	0
mother	0
also	0
had	0
hypercortisolemia	0
.	0

Both	0
mother	0
and	0
son	0
had	0
high	0
levels	0
of	0
unbound	0
plasma	0
cortisol	0
,	0
but	0
their	0
plasma	0
ACTH	0
concentrations	0
were	0
within	0
the	0
normal	0
range	0
.	0

Both	0
were	0
partially	0
resistant	0
to	0
dexamethasone	0
adrenal	0
suppression	0
,	0
and	0
both	0
had	0
mild	0
hypertension	0
without	0
hypokalemia	0
.	0

To	0
study	0
this	0
apparent	0
end-organ	0
resistance	0
to	0
cortisol	0
,	0
we	0
examined	0
the	0
glucocorticoid	9
receptors	10
in	0
peripheral	7
mononuclear	8
cells	8
.	0

Using	0
whole	0
cell	0
assays	0
,	0
glucocorticoid	9
receptors	10
in	0
both	0
patients	0
were	0
found	0
to	0
have	0
reduced	0
total	0
binding	0
capacity	0
.	0

We	0
conclude	0
that	0
these	0
two	0
patients	0
,	0
members	0
of	0
the	0
same	0
family	0
,	0
have	0
primary	0
cortisol	0
resistance	0
accompanied	0
by	0
a	0
reduced	0
number	0
of	0
glucocorticoid	9
receptors	10
.	0

[	0
Glucocorticoid	9
receptors	10
and	0
response	0
to	0
polychemotherapy	0
in	0
acute	0
lymphatic	0
leukemia	0
]	0

Glucocorticoid	9
receptor	10
(	0
GR	9
)	0
levels	0
were	0
quantified	0
in	0
leukemic	7
blasts	8
from	0
peripheral	0
blood	0
of	0
86	0
patients	0
with	0
acute	0
lymphoblastic	0
leukemia	0
.	0

The	0
subsequent	0
achievement	0
of	0
complete	0
remission	0
after	0
combination	0
chemotherapy	0
was	0
correlated	0
with	0
high	0
receptor	0
levels	0
.	0

Forty-seven	0
of	0
50	0
patients	0
with	0
leukemic	7
cells	8
containing	0
more	0
than	0
6	0
,	0
000	0
receptor	0
sites	0
and	0
22	0
of	0
36	0
patients	0
with	0
cells	0
containing	0
less	0
than	0
6	0
,	0
000	0
receptor	0
sites	0
achieved	0
remission	0
.	0

The	0
study	0
of	0
glucocorticoid	9
receptors	10
in	0
leukemic	7
cells	8
may	0
predict	0
response	0
to	0
combination	0
chemotherapy	0
in	0
patients	0
with	0
acute	0
lymphoblastic	0
leukemia	0
.	0

Specific	0
uptake	0
of	0
1	0
,	0
25-dihydroxycholecalciferol	0
by	0
human	7
chronic	8
myeloid	8
leukemia	8
cells	8
.	0

We	0
have	0
examined	0
mononuclear	5
cell	6
preparations	6
from	0
patients	0
with	0
chronic	0
myeloid	0
leukemia	0
[	0
CML	0
]	0
for	0
binding	0
of	0
and	0
response	0
to	0
1	0
,	0
25-dihydroxycholecalciferol	0
[	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
]	0
.	0

Whole	0
cells	0
specifically	0
took	0
up	0
[	0
3H	0
]	0
-1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
with	0
high	0
affinity	0
(	0
Kd	0
3.6	0
X	0
10	0
(	0
-11	0
)	0
M	0
)	0
and	0
low	0
capacity	0
.	0

Subcellular	0
fractionation	0
of	0
labeled	5
cells	6
showed	0
that	0
binding	0
was	0
restricted	0
to	0
cytosols	0
and	0
nuclei	0
.	0

Sucrose	0
gradient	0
centrifugation	0
of	0
cells	0
preincubated	0
with	0
[	0
3H	0
]	0
-1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
revealed	0
a	0
single	0
3.6S	0
peak	0
which	0
was	0
totally	0
displaced	0
with	0
100-fold	0
excess	0
nonradioactive	0
hormone	0
.	0

However	0
,	0
we	0
were	0
unable	0
to	0
demonstrate	0
specific	0
binding	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
by	0
postlabeling	0
standard	0
cytosol	0
preparations	0
.	0

In	0
addition	0
,	0
cytosols	0
prepared	0
from	0
a	0
mixture	0
of	0
CML	5
cells	6
and	0
1	5
,	6
25-	6
(	6
OH	6
)	6
2D3	6
receptor-positive	6
T47D	6
(	0
human	0
breast	0
cancer	0
)	0
cells	0
had	0
less	0
than	0
10	0
%	0
of	0
the	0
binding	0
measured	0
in	0
T47D	5
cytosol	0
alone	0
.	0

However	0
,	0
the	0
levels	0
of	0
binding	0
in	0
T47D	5
cytosols	0
were	0
not	0
reduced	0
if	0
the	0
receptors	0
were	0
occupied	0
with	0
[	0
3H	0
]	0
-1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
prior	0
to	0
the	0
addition	0
of	0
the	0
CML	5
cytosols	0
.	0

Thus	0
,	0
CML	5
cells	6
appear	0
to	0
contain	0
both	0
the	0
receptor	0
for	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
and	0
an	0
unknown	0
substance	0
which	0
prevents	0
its	0
detection	0
following	0
the	0
preparation	0
of	0
cytosol	0
.	0

Cells	0
from	0
patients	0
with	0
CML	0
in	0
the	0
chronic	0
phase	0
specifically	0
bound	0
more	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
[	0
18.0	0
+/-	0
3.2	0
(	0
S.E.	0
)	0
fmol/10	0
(	0
7	0
)	0
cells	0
]	0
than	0
did	0
those	0
in	0
acute	0
myeloid	0
transformation	0
[	0
7.2	0
+/-	0
1.5	0
]	0
or	0
than	0
did	0
cells	0
from	0
patients	0
with	0
acute	0
myeloid	0
leukemia	0
[	0
2.6	0
+/-	0
0.8	0
]	0
.	0

Only	0
cells	0
from	0
the	0
first	0
group	0
of	0
patients	0
responded	0
to	0
the	0
addition	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
by	0
differentiating	0
along	0
the	0
monocyte-macrophage	0
pathway	0
.	0

We	0
conclude	0
that	0
the	0
differentiation-induction	0
effect	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
is	0
likely	0
to	0
depend	0
on	0
adequate	0
levels	0
of	0
receptor	0
and	0
that	0
intact	7
cells	8
rather	0
than	0
cytosol	0
preparations	0
should	0
be	0
studied	0
before	0
cells	0
of	0
a	0
particular	0
tissue	0
are	0
designated	0
as	0
receptor	0
negative	0
.	0

Effect	0
of	0
cell	0
cycle	0
position	0
on	0
dexamethasone	0
binding	0
by	0
mouse	5
and	6
human	6
lymphoid	6
cell	6
lines	6
:	0
correlation	0
between	0
an	0
increase	0
in	0
dexamethasone	0
binding	0
during	0
S	0
phase	0
and	0
dexamethasone	0
sensitivity	0
.	0

We	0
determined	0
the	0
effect	0
of	0
cell	0
cycle	0
position	0
on	0
the	0
amount	0
of	0
dexamethasone	0
that	0
was	0
specifically	0
bound	0
by	0
mouse	5
and	6
human	6
lymphoid	6
cell	6
lines	6
.	0

Cell	5
lines	6
that	0
were	0
either	0
sensitive	0
or	0
resistant	0
to	0
growth	0
inhibition	0
by	0
dexamethasone	0
were	0
compared	0
.	0

Exponentially	7
growing	8
cells	8
were	0
separated	0
by	0
centrifugal	0
elutriation	0
into	0
fractions	0
that	0
corresponded	0
to	0
different	0
positions	0
in	0
the	0
cell	0
cycle	0
.	0

The	0
cell	0
cycle	0
phase	0
distribution	0
of	0
each	0
fraction	0
was	0
estimated	0
by	0
flow	0
cytometry	0
and	0
autoradiography	0
.	0

The	0
amount	0
of	0
dexamethasone	0
bound	0
per	0
cell	0
in	0
each	0
fraction	0
was	0
measured	0
by	0
a	0
whole	0
cell	0
binding	0
assay	0
.	0

In	0
three	0
dexamethasone-sensitive	5
cell	6
lines	6
(	0
two	0
mouse	0
and	0
one	0
human	0
)	0
,	0
we	0
found	0
that	0
the	0
amount	0
of	0
dexamethasone	0
bound	0
per	0
cell	0
increased	0
2-4-fold	0
between	0
G1	0
phase	0
and	0
S	0
phase	0
,	0
and	0
then	0
decreased	0
during	0
G2/M	0
phase	0
.	0

Results	0
were	0
the	0
same	0
when	0
the	0
amount	0
of	0
dexamethasone	0
bound	0
per	0
milligram	0
of	0
cell	9
protein	10
was	0
measured	0
.	0

Binding	0
affinity	0
was	0
the	0
same	0
during	0
G1	0
phase	0
and	0
S	0
phase	0
,	0
but	0
the	0
proportion	0
of	0
bound	0
dexamethasone	0
that	0
translocated	0
to	0
the	0
nucleus	0
was	0
greater	0
during	0
S	0
phase	0
.	0

In	0
contrast	0
,	0
we	0
found	0
that	0
the	0
amount	0
of	0
dexamethasone	0
bound	0
per	0
cell	0
by	0
three	0
dexamethasone-resistant	5
cell	6
lines	6
(	0
two	0
mouse	0
and	0
one	0
human	0
)	0
did	0
not	0
increase	0
during	0
S	0
phase	0
.	0

Our	0
results	0
indicate	0
that	0
cell	0
cycle	0
changes	0
in	0
dexamethasone	0
binding	0
are	0
not	0
simply	0
related	0
to	0
changes	0
in	0
cell	9
protein	10
or	0
cell	0
volume	0
during	0
the	0
cell	0
cycle	0
.	0

An	0
increase	0
in	0
dexamethasone	0
binding	0
during	0
S	0
phase	0
may	0
be	0
required	0
for	0
dexamethasone	0
to	0
inhibit	0
cell	0
growth	0
,	0
and	0
a	0
failure	0
of	0
dexamethasone	0
binding	0
to	0
increase	0
during	0
S	0
phase	0
might	0
represent	0
a	0
new	0
mechanism	0
of	0
dexamethasone	0
resistance	0
in	0
lymphoid	7
cells	8
.	0

Presence	0
and	0
steroid	0
inducibility	0
of	0
glutamine	9
synthetase	10
in	0
human	7
leukemic	8
cells	8
.	0

Glutamine	9
synthetase	10
(	0
EC	0
6.3.1.2	0
;	0
GS	0
)	0
is	0
present	0
in	0
lymphoblasts	7
from	0
patients	0
with	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
as	0
well	0
as	0
in	0
normal	7
peripheral	8
blood	8
lymphocytes	8
.	0

In	0
16	0
out	0
of	0
20	0
ALL	0
patients	0
studied	0
exposure	0
of	0
the	0
cells	0
to	0
physiological	0
concentrations	0
of	0
dexamethasone	0
in	0
vitro	0
increased	0
enzyme	9
activity	0
above	0
the	0
control	0
levels	0
.	0

The	0
increase	0
was	0
specific	0
for	0
glucocorticoid	9
receptor	10
ligands	0
.	0

A	0
direct	0
correlation	0
was	0
found	0
between	0
the	0
magnitude	0
of	0
glucocorticoid-mediated	0
increase	0
of	0
GS	0
activity	0
and	0
the	0
cellular	0
levels	0
of	0
specific	0
glucocorticoid	9
receptors	10
assayed	0
in	0
the	0
same	0
cell	7
specimen	8
.	0

Moreover	0
,	0
the	0
basal	0
levels	0
of	0
the	0
enzyme	9
measured	0
in	0
cells	0
prior	0
to	0
exposure	0
to	0
dexamethasone	0
correlated	0
negatively	0
with	0
receptor	0
density	0
.	0

It	0
is	0
suggested	0
that	0
the	0
presence	0
of	0
steroid-inducible	9
GS	10
in	0
ALL	7
cells	8
may	0
prove	0
to	0
be	0
a	0
marker	0
for	0
functional	9
receptor	10
sites	10
.	0

Binding	0
of	0
progestins	0
to	0
the	0
glucocorticoid	9
receptor	10
.	0

Correlation	0
to	0
their	0
glucocorticoid-like	0
effects	0
on	0
in	0
vitro	0
functions	0
of	0
human	7
mononuclear	8
leukocytes	8
.	0

A	0
number	0
of	0
physiological	0
and	0
synthetic	0
progestins	0
were	0
tested	0
for	0
their	0
ability	0
to	0
compete	0
with	0
[	0
3H	0
]	0
dexamethasone	0
for	0
the	0
binding	0
to	0
the	0
glucocorticoid	9
receptor	10
of	0
human	7
mononuclear	8
leukocytes	8
and	0
their	0
ability	0
to	0
elicit	0
glucocorticoid-like	0
effects	0
on	0
the	0
same	0
cells	0
.	0

As	0
compared	0
to	0
the	0
reference	0
compound	0
dexamethasone	0
(	0
relative	0
receptor	0
binding	0
affinity	0
defined	0
as	0
100	0
%	0
)	0
,	0
two	0
potent	0
synthetic	0
progestins	0
with	0
a	0
pregnane-type	0
structure	0
,	0
megestrol	0
acetate	0
and	0
medroxyprogesterone	0
acetate	0
,	0
were	0
found	0
to	0
display	0
a	0
considerable	0
binding	0
affinity	0
towards	0
the	0
receptor	0
(	0
46	0
and	0
42	0
%	0
,	0
respectively	0
)	0
.	0

The	0
relative	0
binding	0
affinity	0
of	0
the	0
naturally	0
occurring	0
ligand	0
,	0
cortisol	0
,	0
to	0
the	0
receptor	0
was	0
clearly	0
lower	0
(	0
25	0
%	0
)	0
.	0

The	0
effective	0
binding	0
of	0
medroxyprogesterone	0
acetate	0
to	0
the	0
glucocorticoid	9
receptor	10
was	0
confirmed	0
by	0
direct	0
binding	0
studies	0
utilizing	0
a	0
tritiated	0
derivative	0
of	0
this	0
steroid	0
.	0

No	0
evidence	0
for	0
the	0
existence	0
of	0
a	0
specific	0
progesterone	9
receptor	10
in	0
human	7
mononuclear	8
leukocytes	8
was	0
obtained	0
as	0
judged	0
by	0
the	0
results	0
of	0
competition	0
experiments	0
where	0
a	0
progesterone	0
receptor-specific	0
ligand	0
[	0
3H	0
]	0
Org	0
2058	0
was	0
used	0
.	0

Medroxyprogesterone	0
acetate	0
and	0
megestrol	0
acetate	0
also	0
induced	0
glucocorticoid-like	0
effects	0
on	0
the	0
lymphocyte	7
functions	0
.	0

These	0
included	0
inhibition	0
of	0
the	0
proliferative	0
responses	0
to	0
the	0
T-cell	9
mitogens	10
concanavalin	9
A	10
and	0
phytohaemagglutinin	9
and	0
an	0
enhanced	0
accumulation	0
of	0
immunoglobulin	7
secreting	8
cells	8
in	0
pokeweed	5
mitogen-stimulated	6
cultures	6
.	0

The	0
progestin	0
effect	0
appears	0
to	0
be	0
mediated	0
through	0
a	0
radiosensitive	0
(	0
suppressor	0
)	0
subpopulation	0
of	0
T	7
lymphocytes	8
.	0

In	0
contrast	0
,	0
the	0
synthetic	0
progestins	0
related	0
structurally	0
to	0
19-nortestosterone	0
,	0
norethisterone	0
and	0
d-norgestrel	0
,	0
were	0
virtually	0
devoid	0
of	0
binding	0
affinity	0
towards	0
the	0
glucocorticoid	9
receptor	10
nor	0
did	0
they	0
measurably	0
influence	0
the	0
in	0
vitro	0
lymphocyte	7
functions	0
.	0

These	0
studies	0
demonstrate	0
that	0
certain	0
progestins	0
in	0
common	0
clinical	0
use	0
probably	0
possess	0
inherent	0
glucocorticoid	0
activity	0
and	0
suggest	0
that	0
side	0
effects	0
attributable	0
to	0
this	0
character	0
(	0
e.g.	0
suppression	0
of	0
the	0
pituitary-adrenal	0
axis	0
)	0
might	0
be	0
expected	0
when	0
these	0
compounds	0
are	0
used	0
in	0
pharmacological	0
doses	0
.	0

Metabolic	0
and	0
ultrastructural	0
aspects	0
of	0
the	0
in	0
vitro	0
lysis	0
of	0
chronic	7
lymphocytic	8
leukemia	8
cells	8
by	0
glucocorticoids	0
.	0

Human	7
chronic	8
lymphocytic	8
leukemia	8
(	8
CLL	8
)	8
cells	8
like	0
prothymocytes	7
and	0
immunoactivated	7
T-lymphocytes	8
are	0
readily	0
lysed	0
in	0
vitro	0
by	0
pharmacological	0
concentrations	0
of	0
glucocorticoids	0
such	0
as	0
cortisol	0
,	0
whereas	0
peripheral	7
blood	8
lymphocytes	8
and	0
thymocytes	7
are	0
unaffected	0
by	0
the	0
hormone	9
.	0

In	0
this	0
study	0
,	0
metabolic	0
and	0
ultrastructural	0
aspects	0
of	0
the	0
cortisol-induced	0
killing	0
process	0
of	0
CLL	7
cells	8
are	0
recorded	0
.	0

In	0
vitro	0
lysis	0
was	0
found	0
to	0
be	0
temperature	0
dependent	0
and	0
was	0
detected	0
only	0
after	0
6	0
to	0
8	0
hr	0
incubation	0
with	0
cortisol	0
by	0
means	0
of	0
the	0
trypan	0
blue	0
exclusion	0
test	0
.	0

However	0
,	0
30	0
min	0
of	0
incubation	0
with	0
cortisol	0
at	0
either	0
37	0
degrees	0
or	0
4	0
degrees	0
followed	0
by	0
the	0
removal	0
of	0
the	0
hormone	9
was	0
still	0
sufficient	0
to	0
induce	0
the	0
lytic	0
process	0
.	0

Ultrastructural	0
studies	0
demonstrated	0
sequential	0
changes	0
in	0
the	0
cytoplasm	0
,	0
including	0
swelling	0
of	0
mitochondria	0
and	0
cytoplasmic	0
decompartmentalization	0
,	0
followed	0
by	0
loss	0
of	0
surface	0
microvilli	0
with	0
the	0
appearance	0
of	0
``	0
holes	0
''	0
in	0
the	0
cell	0
membrane	0
,	0
and	0
subsequent	0
condensation	0
of	0
nuclear	1
chromatin	2
.	0

The	0
large	0
holes	0
in	0
the	0
membrane	0
appearing	0
after	0
6	0
hr	0
of	0
incubation	0
with	0
the	0
hormone	9
may	0
be	0
the	0
cause	0
for	0
the	0
penetration	0
of	0
the	0
viable	0
stain	0
into	0
the	0
dead	7
cells	8
,	0
as	0
seen	0
by	0
light	0
microscopy	0
.	0

Addition	0
of	0
metabolic	0
inhibitors	0
including	0
actinomycin	0
D	0
,	0
puromycin	0
,	0
and	0
cycloheximide	0
following	0
administration	0
of	0
cortisol	0
resulted	0
in	0
inhibition	0
of	0
the	0
cell	0
lysis	0
.	0

An	0
excess	0
of	0
an	0
antagonist	0
such	0
as	0
cortexolone	0
was	0
found	0
to	0
inhibit	0
the	0
cortisol-induced	0
cytolysis	0
of	0
the	0
CLL	5
cells	6
.	0

It	0
is	0
suggested	0
that	0
the	0
glucocorticoid-induced	0
lysis	0
of	0
human	5
CLL	6
cells	6
is	0
similar	0
to	0
the	0
phenomenon	0
observed	0
in	0
rat	7
or	8
murine	8
lymphocytes	8
and	0
is	0
mediated	0
by	0
interaction	0
of	0
the	0
steroid	0
molecule	0
with	0
the	0
cytoplasmic	9
receptor	10
.	0

The	0
resulting	0
complex	0
appears	0
to	0
activate	0
specific	0
gene	1
(	0
s	0
)	0
the	0
products	0
of	0
which	0
eventually	0
cause	0
cytolysis	0
.	0

Glucocorticoid	9
receptors	10
in	0
lymphoid	0
tumors	0
.	0

There	0
is	0
a	0
range	0
of	0
levels	0
of	0
glucocorticoid	9
receptor	10
numbers	0
seen	0
in	0
the	0
various	0
subclasses	0
of	0
acute	0
lymphatic	0
leukemia	0
(	0
ALL	0
)	0
.	0

This	0
variability	0
can	0
not	0
be	0
explained	0
by	0
the	0
known	0
correlation	0
between	0
active	0
cell	0
proliferation	0
and	0
an	0
increase	0
in	0
the	0
number	0
of	0
receptors	0
,	0
since	0
the	0
tumors	0
with	0
the	0
highest	0
growth	0
fraction	0
(	0
i.e.	0
,	0
Burkitt	0
's	0
lymphoma	0
and	0
T-cell	0
leukemia	0
)	0
tend	0
to	0
have	0
lower	0
average	0
receptor	0
numbers	0
than	0
do	0
tumors	0
with	0
lower	0
growth	0
fractions	0
such	0
as	0
common	0
ALL	0
.	0

All	0
clinical	0
specimens	0
from	0
patients	0
with	0
lymphatic	0
leukemia	0
have	0
some	0
measurable	0
level	0
of	0
glucocorticoid	9
receptors	10
;	0
therefore	0
,	0
the	0
resistance	0
seen	0
in	0
vivo	0
can	0
not	0
be	0
explained	0
by	0
the	0
lack	0
of	0
receptors	0
.	0

However	0
,	0
there	0
has	0
been	0
a	0
positive	0
correlation	0
,	0
in	0
our	0
hands	0
,	0
with	0
receptor	0
level	0
and	0
prognosis	0
.	0

On	0
the	0
basis	0
of	0
in	0
vitro	0
models	0
,	0
it	0
is	0
proposed	0
that	0
perhaps	0
the	0
high	5
receptor	6
cell	6
lines	6
(	0
i.e.	0
,	0
common	0
ALL	0
of	0
childhood	0
)	0
have	0
relative	0
stability	0
of	0
their	0
genetic	0
material	0
making	0
glucocorticoid-resistant	0
mutations	0
less	0
likely	0
to	0
occur	0
in	0
patients	0
with	0
these	0
cells	0
than	0
in	0
low-receptor	5
cell	6
lines	6
(	0
i.e.	0
,	0
T-cell	0
leukemia	0
)	0
.	0

This	0
greater	0
genetic	0
variability	0
in	0
the	0
low-receptor	5
lines	6
could	0
account	0
for	0
the	0
earlier	0
emergence	0
of	0
clinical	0
glucocorticoid	0
resistance	0
in	0
these	0
patients	0
.	0

[	0
Tumor	0
histology	0
and	0
steroid	9
receptors	10
in	0
breast	0
carcinoma	0
]	0

In	0
Specimens	0
of	0
115	0
patients	0
with	0
breast	0
cancer	0
4	0
tumorparameters	0
(	0
tumorsize	0
,	0
tumorboder	0
,	0
nucleargrade	0
,	0
lymphocytic	0
stromal	0
reaction	0
)	0
3	0
features	0
of	0
regional	0
lymphnodes	0
(	0
sinushistiocytosis	0
,	0
T-cellreaction	0
,	0
lymphnode	0
metastases	0
)	0
and	0
estrogen	9
and	10
progesteron	10
receptors	10
were	0
determined	0
.	0

A	0
strong	0
sinushistiocytosis	0
and	0
T-cellreaction	0
could	0
be	0
verified	0
mainly	0
in	0
metastases	0
in	0
free	0
lymphnodes	0
.	0

The	0
steroid	9
receptor	10
content	0
does	0
not	0
correlate	0
with	0
histological	0
parameters	0

Aldosterone-receptor	9
deficiency	0
in	0
pseudohypoaldosteronism	0
.	0

Pseudohypoaldosteronism	0
,	0
a	0
syndrome	0
characterized	0
by	0
salt	0
wasting	0
and	0
failure	0
to	0
thrive	0
,	0
usually	0
presents	0
in	0
infancy	0
as	0
high	0
urinary	0
levels	0
of	0
sodium	0
despite	0
hyponatremia	0
,	0
hyperkalemia	0
,	0
hyperreninemia	0
,	0
and	0
elevated	0
aldosterone	0
levels	0
.	0

We	0
have	0
investigated	0
this	0
syndrome	0
for	0
the	0
possibility	0
of	0
abnormal	9
Type	10
I	10
or	0
``	9
mineralocorticoid-like	10
''	10
receptors	10
,	0
which	0
have	0
intrinsic	0
steroid	0
specificity	0
indistinguishable	0
from	0
that	0
of	0
renal	9
mineralocorticoid	10
receptors	10
and	0
are	0
found	0
in	0
many	0
tissues	0
and	0
cells	7
,	0
including	0
mononuclear	7
leukocytes	8
.	0

We	0
have	0
studied	0
three	0
patients	0
with	0
pseudohypoaldosteronism	0
:	0
the	0
28-year-old	0
index	0
case	0
in	0
Melbourne	0
(	0
Patient	0
1	0
)	0
and	0
two	0
siblings	0
in	0
Munich	0
,	0
eight	0
and	0
two	0
years	0
of	0
age	0
(	0
Patients	0
2	0
and	0
3	0
)	0
;	0
clinically	0
,	0
Patient	0
3	0
had	0
a	0
less	0
severe	0
case	0
than	0
his	0
sister	0
.	0

Percoll-separated	7
control	8
monocytes	8
bound	0
[	0
3H	0
]	0
aldosterone	0
with	0
high	0
affinity	0
(	0
Kd	0
approximately	0
3	0
nM	0
)	0
and	0
limited	0
capacity	0
(	0
150	0
to	0
600	0
sites	0
per	0
cell	0
)	0
.	0

On	0
repeated	0
examination	0
,	0
no	0
[	0
3H	0
]	0
aldosterone	0
binding	0
was	0
found	0
in	0
monocytes	7
from	0
Patients	0
1	0
and	0
2	0
;	0
in	0
Patient	0
3	0
,	0
the	0
levels	0
were	0
62	0
sites	0
per	0
cell	0
,	0
more	0
than	0
2	0
S.D.	0
below	0
those	0
of	0
the	0
control	0
.	0

Levels	0
in	0
the	0
parents	0
of	0
the	0
Munich	0
patients	0
(	0
first	0
cousins	0
)	0
were	0
normal	0
.	0

It	0
appears	0
that	0
pseudohypoaldosteronism	0
is	0
caused	0
by	0
a	0
Type	0
I	0
receptor	0
defect	0
,	0
that	0
the	0
defect	0
may	0
be	0
complete	0
or	0
partial	0
,	0
that	0
transmission	0
may	0
be	0
autosomal	0
recessive	0
,	0
and	0
that	0
the	0
study	0
of	0
patients	0
with	0
pseudohypoaldosteronism	0
may	0
indicate	0
physiologic	0
roles	0
for	0
Type	9
I	10
receptors	10
in	0
nonepithelial	0
tissues	0
.	0

Glucocorticoid	0
inhibition	0
of	0
urokinase-like	9
plasminogen	10
activators	10
in	0
cultured	5
human	6
lymphoblasts	6
.	0

Two	0
human	5
lymphoblast	6
cell	6
lines	6
,	0
LICR-LON-HMy2	5
(	0
HMy2	5
cells	6
)	0
and	0
GM4672A	5
cells	6
,	0
are	0
moderately	0
growth	0
inhibited	0
by	0
dexamethasone	0
(	0
1	0
,	0
4-pregnadien-9-fluoro-16	0
alpha-methyl-11	0
beta	0
,	0
17	0
alpha	0
,	0
21-triol-3	0
,	0
20-dione	0
)	0
(	0
Dex	0
)	0
.	0

Both	0
cell	0
types	0
secrete	0
a	0
urokinase	9
(	10
UK	10
)	10
-like	10
plasminogen	10
activator	10
(	0
PA	9
)	0
.	0

Treatment	0
of	0
both	0
HMy2	5
and	6
GM4672A	6
cells	6
with	0
Dex	0
for	0
1-4	0
days	0
inhibits	0
extracellular	0
PA	9
activity	0
in	0
a	0
concentration-dependent	0
manner	0
,	0
being	0
half-maximal	0
at	0
approximately	0
1	0
X	0
10	0
(	0
-9	0
)	0
M	0
.	0

Inhibition	0
of	0
PA	9
in	0
both	0
cell	0
types	0
is	0
specific	0
for	0
active	0
glucocorticoids	0
,	0
and	0
this	0
specificity	0
parallels	0
the	0
ability	0
of	0
various	0
steroids	0
to	0
bind	0
to	0
glucocorticoid	9
receptors	10
.	0

HMy2	5
cell	6
PA	9
is	0
fully	0
suppressible	0
by	0
Dex	0
,	0
whereas	0
up	0
to	0
one	0
third	0
of	0
the	0
activator	0
expressed	0
by	0
GM4672A	5
cells	6
is	0
resistant	0
to	0
glucocorticoid	0
inhibition	0
.	0

Mixing	0
experiments	0
using	0
a	0
UK	0
standard	0
and	0
conditioned	0
media	0
from	0
Dex-treated	5
cells	6
suggest	0
an	0
absence	0
of	0
glucocorticoid-inducible	9
inhibitors	10
to	0
UK	9
or	0
plasmin	9
in	0
both	0
cell	0
types	0
.	0

However	0
,	0
conditioned	0
media	0
from	0
Dex-treated	5
GM4672A	6
cells	6
inhibits	0
a	0
portion	0
of	0
the	0
homologous	0
cellular	0
activator	0
in	0
conditioned	0
media	0
from	0
control	0
GM4672A	5
cells	6
.	0

Thus	0
,	0
low	0
levels	0
of	0
glucocorticoid-inducible	9
inhibitors	10
may	0
contribute	0
to	0
,	0
but	0
can	0
not	0
fully	0
account	0
for	0
,	0
Dex	0
inhibition	0
of	0
GM4672A	9
PA	10
activity	0
.	0

Glucocorticoid-inducible	9
inhibitors	10
in	0
HMy2	5
cells	6
are	0
either	0
totally	0
absent	0
or	0
are	0
present	0
at	0
undetectable	0
levels	0
.	0

Thus	0
,	0
regulation	0
of	0
UK-like	9
PAs	10
in	0
HMy2	5
and	6
GM4672A	6
cells	6
differs	0
with	0
respect	0
to	0
the	0
extent	0
to	0
which	0
glucocorticoids	0
inhibit	0
constitutively	9
expressed	10
activator	10
levels	0
,	0
as	0
well	0
as	0
the	0
possible	0
contribution	0
of	0
glucocorticoid-inducible	9
inhibitors	10
to	0
the	0
regulatory	0
process	0
in	0
GM4672A	5
cells	6
.	0

Characterization	0
of	0
aldosterone	0
binding	0
sites	0
in	0
circulating	7
human	8
mononuclear	8
leukocytes	8
.	0

Aldosterone	0
binding	0
sites	0
in	0
human	5
mononuclear	6
leukocytes	6
were	0
characterized	0
after	0
separation	0
of	0
cells	0
from	0
blood	0
by	0
a	0
Percoll	0
gradient	0
.	0

After	0
washing	0
and	0
resuspension	0
in	0
RPMI-1640	0
medium	0
,	0
cells	0
were	0
incubated	0
at	0
37	0
degrees	0
C	0
for	0
1	0
h	0
with	0
different	0
concentrations	0
of	0
[	0
3H	0
]	0
aldosterone	0
plus	0
a	0
100-fold	0
concentration	0
of	0
RU-26988	0
(	0
11	0
alpha	0
,	0
17	0
alpha-dihydroxy-17	0
beta-propynylandrost-1	0
,	0
4	0
,	0
6-trien-3-one	0
)	0
,	0
with	0
or	0
without	0
an	0
excess	0
of	0
unlabeled	0
aldosterone	0
.	0

Aldosterone	0
binds	0
to	0
a	0
single	0
class	0
of	0
receptors	0
with	0
an	0
affinity	0
of	0
2.7	0
+/-	0
0.5	0
nM	0
(	0
means	0
+/-	0
SD	0
,	0
n	0
=	0
14	0
)	0
and	0
a	0
capacity	0
of	0
290	0
+/-	0
108	0
sites/cell	0
(	0
n	0
=	0
14	0
)	0
.	0

The	0
specificity	0
data	0
show	0
a	0
hierarchy	0
of	0
affinity	0
of	0
desoxycorticosterone	0
=	0
corticosterone	0
=	0
aldosterone	0
greater	0
than	0
hydrocortisone	0
greater	0
than	0
dexamethasone	0
.	0

The	0
results	0
indicate	0
that	0
mononuclear	7
leukocytes	8
could	0
be	0
useful	0
for	0
studying	0
the	0
physiological	0
significance	0
of	0
these	0
mineralocorticoid	9
receptors	10
and	0
their	0
regulation	0
in	0
humans	0
.	0

Mineralocorticoid	9
and	10
glucocorticoid	10
receptors	10
in	0
circulating	7
mononuclear	8
leukocytes	8
of	0
patients	0
with	0
primary	0
hyperaldosteronism	0
.	0

Mineralocorticoid	9
and	10
glucocorticoid	10
receptors	10
were	0
measured	0
in	0
circulating	7
mononuclear	8
leukocytes	8
in	0
5	0
patients	0
affected	0
by	0
Conn	0
's	0
syndrome	0
(	0
3	0
cases	0
of	0
bilateral	0
adrenal	0
hyperplasia	0
and	0
2	0
cases	0
of	0
adenoma	0
plus	0
unilateral	0
hyperplasia	0
)	0
.	0

The	0
number	0
of	0
the	0
binding	0
sites	0
per	0
cell	0
resulted	0
significantly	0
lower	0
(	0
189	0
+/-	0
114	0
,	0
mean	0
+/-	0
SD	0
)	0
,	0
as	0
compared	0
with	0
the	0
normal	0
controls	0
(	0
298	0
+/-	0
105	0
)	0
.	0

The	0
affinity	0
of	0
aldosterone	0
for	0
the	0
receptor	0
was	0
found	0
to	0
be	0
not	0
different	0
than	0
that	0
of	0
healthy	0
control	0
subjects	0
.	0

The	0
capacity	0
and	0
the	0
affinity	0
of	0
dexamethasone	0
for	0
glucocorticoid	9
receptors	10
ranged	0
in	0
the	0
normal	0
values	0
.	0

These	0
data	0
suggest	0
a	0
possible	0
down-regulation	0
of	0
mineralocorticoid	9
receptors	10
in	0
humans	0
.	0

Short-term	0
and	0
long-term	0
effects	0
of	0
estrogen	0
on	0
lymphoid	0
tissues	0
and	0
lymphoid	7
cells	8
with	0
some	0
remarks	0
on	0
the	0
significance	0
for	0
carcinogenesis	0
.	0

Estrogens	0
have	0
long	0
been	0
thought	0
to	0
play	0
a	0
role	0
in	0
regulating	0
the	0
immune	0
system	0
.	0

The	0
difference	0
in	0
some	0
types	0
of	0
immune	0
responses	0
between	0
males	0
and	0
females	0
is	0
well-known	0
,	0
as	0
is	0
the	0
pronounced	0
thymic	0
involution	0
induced	0
by	0
exogenous	0
estrogens	0
.	0

Estrogens	0
stimulate	0
some	0
aspects	0
of	0
macrophage	7
activity	0
and	0
,	0
depending	0
on	0
dose	0
and	0
mitogen	9
,	0
inhibit	0
or	0
stimulate	0
lymphocyte	0
proliferative	0
response	0
in	0
vitro	0
.	0

Another	0
example	0
is	0
the	0
estrogen	0
effect	0
on	0
the	0
delayed	0
type	0
hypersensitivity	0
response	0
.	0

A	0
broad	0
review	0
is	0
given	0
of	0
such	0
estrogen	0
effects	0
on	0
lymphoid	7
tissue	8
and	0
immune	0
response	0
.	0

Most	0
of	0
the	0
studies	0
published	0
so	0
far	0
are	0
phenomenological	0
.	0

However	0
,	0
the	0
recent	0
description	0
of	0
estrogen	9
receptors	10
in	0
the	0
thymus	0
and	0
in	0
some	0
lymphocyte	5
subpopulations	6
,	0
as	0
well	0
as	0
a	0
deeper	0
understanding	0
of	0
regulating	0
factors	0
in	0
the	0
immune	0
system	0
,	0
open	0
the	0
possibility	0
of	0
a	0
more	0
detailed	0
understanding	0
of	0
the	0
estrogen	0
mechanism	0
of	0
interference	0
.	0

Estrogen	0
effects	0
in	0
adults	0
are	0
reversible	0
.	0

After	0
treating	0
neonatal	0
mice	0
with	0
the	0
synthetic	0
estrogen	0
diethylstilbestrol	0
(	0
DES	0
)	0
,	0
disturbances	0
are	0
induced	0
in	0
lymphocyte	5
populations	6
and	0
lymphocyte	7
functions	0
which	0
are	0
permanent	0
and	0
irreversible	0
.	0

Lymphocytes	7
from	0
adult	0
,	0
neonatally	0
DES-treated	0
female	0
mice	0
have	0
a	0
reduced	0
mitogen	0
response	0
to	0
ConA	9
and	0
LPS	9
(	0
T	9
and	10
B	10
cell	10
mitogen	10
)	0
and	0
the	0
delayed	0
type	0
hypersensitivity	0
response	0
is	0
depressed	0
.	0

A	0
detailed	0
analysis	0
demonstrated	0
a	0
decreased	0
T	7
helper	8
cell	8
population	0
.	0

The	0
activity	0
of	0
Natural	7
Killer	8
cells	8
is	0
permanently	0
reduced	0
and	0
this	0
functional	0
impairment	0
is	0
related	0
to	0
a	0
decreased	0
number	0
of	0
these	0
cells	0
,	0
in	0
turn	0
determined	0
at	0
the	0
bone	0
marrow	0
level	0
.	0

The	0
same	0
animals	0
have	0
an	0
increased	0
sensitivity	0
to	0
chemical	0
carcinogens	0
(	0
methylcholanthrene	0
)	0
and	0
they	0
spontaneously	0
develop	0
epithelial	0
changes	0
in	0
the	0
uterine	0
cervix	0
which	0
morphologically	0
are	0
similar	0
to	0
adenocarcinoma	0
.	0

The	0
association	0
between	0
estrogen-associated	0
malignancy	0
and	0
estrogen	0
effects	0
in	0
lymphocyte	7
functions	0
deserves	0
further	0
study	0
.	0

Drugs	0
affecting	0
the	0
hormonal	0
receptors	0
of	0
normal	7
and	8
leukaemic	8
peripheral	8
leucocytes	8
.	0

The	0
authors	0
investigated	0
the	0
behaviour	0
of	0
steroid	0
hormone	0
uptake	0
in	0
leukaemic	7
cells	8
(	0
CML	5
,	0
CLL	5
,	0
AML	5
,	0
ALL	5
)	0
,	0
in	0
basal	0
conditions	0
and	0
after	0
incubation	0
with	0
drugs	0
which	0
modify	0
the	0
cellular	0
concentration	0
of	0
cAMP	0
,	0
PGE	0
and	0
PGF	0
.	0

The	0
results	0
demonstrated	0
the	0
presence	0
in	0
leukaemic	7
cells	8
of	0
an	0
alteration	0
in	0
the	0
incorporation	0
of	0
steroid	0
hormones	0
.	0

This	0
alteration	0
was	0
scarcely	0
modified	0
by	0
incubation	0
with	0
theophylline	9
,	0
which	0
increases	0
cellular	0
concentration	0
of	0
cAMP	0
.	0

On	0
the	0
other	0
hand	0
,	0
it	0
was	0
moderately	0
counteracted	0
by	0
thioproline	0
and	0
was	0
evidently	0
inhibited	0
by	0
flurbiprofen	0
,	0
which	0
also	0
reduced	0
cellular	0
concentrations	0
of	0
prostaglandins	0
,	0
particularly	0
PGE2	0
,	0
with	0
the	0
exception	0
of	0
PGF2	0
which	0
showed	0
a	0
poor	0
response	0
.	0

Differences	0
were	0
observed	0
in	0
the	0
behavior	0
of	0
hormonal	0
uptake	0
of	0
CML	5
,	0
in	0
contrast	0
to	0
that	0
of	0
AML	5
,	6
CLL	6
and	6
ALL	6
peripheral	6
leucocytes	6
.	0

Human	0
breast	0
cancer	0
and	0
impaired	0
NK	7
cell	8
function	0
.	0

Recent	0
advances	0
in	0
tumor	0
immunology	0
have	0
led	0
to	0
the	0
discovery	0
of	0
a	0
new	0
lymphoid	7
cell	8
with	0
unique	0
antitumor	0
activity	0
.	0

Natural	7
killer	8
(	8
NK	8
)	8
cells	8
form	0
an	0
antitumor	0
surveillance	0
system	0
and	0
appear	0
to	0
be	0
vital	0
in	0
preventing	0
tumor	0
growth	0
and	0
metastasis	0
in	0
animal	0
models	0
.	0

We	0
studied	0
NK	7
activity	0
in	0
patients	0
with	0
benign	0
and	0
malignant	0
breast	0
disease	0
,	0
using	0
a	0
chromium-51	0
release	0
microtiter	0
cytotoxicity	0
assay	0
with	0
K562	5
cells	6
as	0
targets	0
.	0

Compared	0
with	0
benign	0
controls	0
,	0
patients	0
with	0
malignancies	0
had	0
significantly	0
depressed	0
NK	7
-mediated	0
lysis	0
(	0
P	0
less	0
than	0
0.01	0
)	0
.	0

Furthermore	0
,	0
lysis	0
in	0
those	0
with	0
advanced	0
disease	0
(	0
stages	0
II	0
,	0
III	0
,	0
and	0
IV	0
)	0
was	0
significantly	0
less	0
than	0
in	0
those	0
with	0
limited	0
disease	0
(	0
stage	0
I	0
)	0
(	0
P	0
less	0
than	0
0.01	0
)	0
.	0

NK	7
activity	0
was	0
not	0
correlated	0
to	0
estrogen	0
or	0
progesterone	0
receptor	0
states	0
.	0

Positive	0
correlation	0
of	0
a	0
depressed	0
natural	0
killer	0
activity	0
with	0
the	0
extent	0
of	0
tumor	0
spread	0
supports	0
the	0
concept	0
of	0
an	0
NK	7
cell	8
immune	0
surveillance	0
system	0
in	0
breast	0
cancer	0
and	0
emphasizes	0
its	0
importance	0
in	0
this	0
malignancy	0
.	0

Immunosuppressive	0
effect	0
of	0
serum	0
progesterone	0
during	0
pregnancy	0
depends	0
on	0
the	0
progesterone	0
binding	0
capacity	0
of	0
the	0
lymphocytes	7
.	0

Cytotoxic	0
activity	0
and	0
progesterone	0
binding	0
capacity	0
of	0
the	0
lymphocytes	7
,	0
together	0
with	0
serum	0
progesterone	0
concentrations	0
,	0
were	0
determined	0
in	0
women	0
with	0
normal	0
pregnancy	0
or	0
with	0
a	0
clinical	0
diagnosis	0
of	0
threatened	0
abortion	0
or	0
threatened	0
premature	0
labour	0
.	0

The	0
lymphocytes	0
of	0
women	0
with	0
threatened	0
abortion	0
or	0
threatened	0
premature	0
labour	0
showed	0
significantly	0
higher	0
cytotoxic	0
activity	0
(	0
P	0
less	0
than	0
0.001	0
)	0
and	0
significantly	0
lower	0
progesterone	0
binding	0
capacity	0
(	0
P	0
less	0
than	0
0.001	0
)	0
than	0
did	0
lymphocytes	7
obtained	0
from	0
the	0
healthy	0
pregnant	0
women	0
.	0

Significant	0
inverse	0
correlation	0
was	0
found	0
between	0
progesterone	0
binding	0
capacity	0
and	0
cytotoxic	0
activity	0
of	0
the	0
lymphocytes	7
(	0
P	0
less	0
than	0
0.001	0
)	0
,	0
but	0
the	0
progesterone	0
concentration	0
of	0
the	0
pregnancy	0
serum	0
appeared	0
to	0
have	0
no	0
influence	0
on	0
the	0
other	0
two	0
parameters	0
.	0

The	0
findings	0
indicate	0
that	0
intact	0
progesterone	0
binding	0
capacity	0
of	0
the	0
lymphocytes	7
is	0
an	0
essential	0
factor	0
for	0
the	0
manifestation	0
of	0
the	0
blocking	0
effect	0
exerted	0
by	0
pregnancy	0
serum	0
on	0
lymphocyte	7
cytotoxicity	0
in	0
vitro	0
.	0

Serum	0
sex	0
steroid	0
and	0
peptide	0
hormone	0
concentrations	0
,	0
and	0
endometrial	0
estrogen	0
and	0
progestin	0
receptor	0
levels	0
during	0
administration	0
of	0
human	9
leukocyte	10
interferon	10
.	0

Five	0
normally	0
cycling	0
healthy	0
women	0
were	0
given	0
daily	0
subcutaneous	0
injections	0
of	0
human	9
leukocyte	10
interferon	10
(	0
3	0
X	0
10	0
(	0
6	0
)	0
units/day	0
)	0
from	0
the	0
3rd	0
through	0
23rd	0
day	0
of	0
the	0
menstrual	0
cycle	0
,	0
and	0
serum	0
steroid	0
and	0
peptide	0
hormone	0
concentrations	0
monitored	0
at	0
3-day	0
intervals	0
during	0
the	0
treatment	0
and	0
the	0
preceding	0
control	0
cycle	0
.	0

Concentrations	0
of	0
cytosol	9
and	10
nuclear	10
estrogen	10
receptors	10
(	0
ERC	9
and	0
ERN	9
,	0
respectively	0
)	0
and	0
progestin	9
receptors	10
(	0
PRC	9
and	0
PRN	9
)	0
were	0
also	0
measured	0
from	0
endometrial	0
biopsies	0
taken	0
on	0
the	0
24th	0
day	0
of	0
the	0
control	0
and	0
treatment	0
cycle	0
.	0

In	0
addition	0
,	0
an	0
extensive	0
monitoring	0
of	0
clinical	0
chemical	0
and	0
hematological	0
tests	0
from	0
the	0
blood	0
samples	0
were	0
performed	0
.	0

Serum	0
estradiol	0
and	0
progesterone	0
concentrations	0
were	0
significantly	0
decreased	0
during	0
the	0
treatment	0
cycle	0
,	0
suggesting	0
that	0
interferon	9
interacts	0
in	0
vivo	0
with	0
the	0
function	0
of	0
both	0
FSH	0
and	0
LH	0
.	0

No	0
significant	0
changes	0
were	0
observed	0
in	0
the	0
serum	0
peptide	0
hormone	0
concentrations	0
measured	0
(	0
FSH	0
,	0
LH	0
,	0
prolactin	0
,	0
insulin	0
,	0
growth	0
hormone	0
and	0
TSH	0
)	0
;	0
neither	0
were	0
the	0
levels	0
of	0
endometrial	9
ERC	10
,	10
ERN	10
,	10
PRC	10
and	10
PRN	10
affected	0
by	0
interferon	9
administration	0
.	0

As	0
expected	0
,	0
interferon	9
administration	0
resulted	0
in	0
decreased	0
leukocyte	7
counts	0
.	0

Moreover	0
,	0
an	0
increasing	0
tendency	0
in	0
the	0
activities	0
of	0
serum	9
alkaline	10
phosphatase	10
and	0
gamma-glutamyltransferase	9
during	0
the	0
interferon	9
therapy	0
shows	0
that	0
interferon	9
may	0
slightly	0
interfere	0
with	0
the	0
liver	0
function	0
.	0

These	0
results	0
suggest	0
that	0
one	0
of	0
the	0
mechanisms	0
by	0
which	0
interferon	9
treatment	0
may	0
affect	0
the	0
growth	0
of	0
hormone-dependent	0
neoplasms	0
could	0
be	0
the	0
interaction	0
with	0
production	0
and/or	0
function	0
of	0
circulating	0
hormonal	0
compounds	0
.	0

[	0
Glucocorticoid	9
receptor	10
level	0
in	0
the	0
blood	7
leukocytes	8
in	0
different	0
acute	0
diseases	0
]	0

Content	0
of	0
glucocorticoid	9
receptors	10
in	0
cytosol	0
of	0
blood	7
leukocytes	8
,	0
concentration	0
of	0
cortisol	0
and	0
amount	0
of	0
leukocytes	7
in	0
blood	0
were	0
studied	0
in	0
20	0
patients	0
with	0
acute	0
impairments	0
within	0
the	0
second	0
day	0
of	0
the	0
disease	0
.	0

Content	0
of	0
receptors	0
in	0
cytosol	0
of	0
blood	0
leukocytes	0
was	0
studied	0
using	0
3H-triamcinolone	0
acetonide	0
.	0

Distinct	0
increase	0
in	0
amount	0
of	0
the	0
leukocyte	9
glucocorticoid	10
receptors	10
was	0
found	0
in	0
patients	0
with	0
poisoning	0
by	0
dichlorethane	0
and	0
hypnotic	0
drugs	0
under	0
conditions	0
of	0
acute	0
myocardial	0
infarction	0
.	0

In	0
acute	0
pancreatitis	0
content	0
of	0
the	0
leukocyte	9
receptors	10
was	0
not	0
altered	0
as	0
compared	0
with	0
controls	0
.	0

Concentration	0
of	0
endogenous	0
cortisol	0
was	0
increased	0
in	0
blood	0
of	0
all	0
the	0
patients	0
,	0
except	0
of	0
the	0
cases	0
of	0
acetate	0
intoxication	0
.	0

Reverse	0
correlation	0
was	0
observed	0
between	0
concentration	0
of	0
cortisol	0
in	0
blood	0
and	0
content	0
of	0
glucocorticoid	0
receptors	0
in	0
leukocytes	7
.	0

But	0
in	0
the	0
patients	0
with	0
acute	0
pancreatitis	0
the	0
decrease	0
in	0
content	0
of	0
leukocyte	9
glucocorticoid	10
receptors	10
was	0
not	0
observed	0
although	0
there	0
was	0
an	0
increase	0
in	0
cortisol	0
concentration	0
in	0
blood	0
.	0

The	0
role	0
of	0
glucocorticoid	9
receptors	10
in	0
immunological	0
processes	0
under	0
conditions	0
of	0
purulent	0
complications	0
and	0
possibility	0
to	0
regulate	0
the	0
metabolism	0
in	0
leukocytes	7

Therapeutic	0
concentrations	0
of	0
glucocorticoids	0
suppress	0
the	0
antimicrobial	0
activity	0
of	0
human	7
macrophages	8
without	0
impairing	0
their	0
responsiveness	0
to	0
gamma	9
interferon	10
.	0

By	0
exposing	0
human	7
blood-derived	8
macrophages	8
and	8
alveolar	8
macrophages	8
in	0
vitro	0
to	0
dexamethasone	0
,	0
we	0
showed	0
in	0
these	0
studies	0
that	0
glucocorticoids	0
markedly	0
suppress	0
the	0
antimicrobial	0
activity	0
of	0
macrophages	7
but	0
not	0
macrophage	7
activation	0
by	0
lymphokines	7
.	0

As	0
little	0
as	0
2.5	0
X	0
10	0
(	0
-8	0
)	0
mol/liter	0
of	0
dexamethasone	0
prevented	0
macrophages	7
from	0
inhibiting	0
germination	0
of	0
Aspergillus	0
spores	0
or	0
from	0
eliminating	0
ingested	0
bacteria	0
such	0
as	0
Listeria	0
,	0
Nocardia	0
,	0
or	0
Salmonella	0
.	0

Damage	0
to	0
macrophage	7
function	0
was	0
inhibited	0
by	0
progesterone	0
and	0
appeared	0
to	0
be	0
receptor-mediated	0
.	0

In	0
accordance	0
with	0
in	0
vivo	0
observations	0
,	0
dexamethasone	0
required	0
24-36	0
h	0
to	0
suppress	0
antimicrobial	0
activity	0
.	0

While	0
glucocorticoids	0
interfered	0
with	0
base-line	0
activity	0
of	0
macrophages	7
,	0
dexamethasone	0
concentrations	0
comparable	0
to	0
drug	0
levels	0
in	0
patients	0
had	0
no	0
effect	0
on	0
macrophage	7
activation	0
.	0

Proliferating	0
lymphocytes	7
and	0
gamma-interferon	9
thus	0
increased	0
the	0
antimicrobial	0
activity	0
of	0
phagocytes	7
exposed	0
to	0
glucocorticoids	0
over	0
that	0
of	0
control	0
cells	0
.	0

Macrophage	0
activation	0
and	0
correction	0
of	0
the	0
dexamethasone	0
effect	0
by	0
gamma-interferon	9
,	0
however	0
,	0
was	0
dependent	0
on	0
the	0
pathogen	0
.	0

The	0
lymphokine	9
enhanced	0
the	0
antimicrobial	0
activity	0
of	0
dexamethasone-treated	5
macrophages	6
against	0
Listeria	0
and	0
Salmonella	0
but	0
not	0
against	0
Aspergillus	0
or	0
Nocardia	0
.	0

Dexamethasone-induced	0
damage	0
to	0
the	0
antimicrobial	0
activity	0
of	0
human	7
macrophages	8
in	0
vitro	0
parallels	0
observations	0
that	0
glucocorticoids	0
render	0
laboratory	0
animals	0
susceptible	0
to	0
listeriosis	0
and	0
aspergillosis	0
by	0
damaging	0
resident	0
macrophages	5
.	0

Suppression	0
of	0
macrophage	7
antimicrobial	0
activity	0
should	0
thus	0
be	0
considered	0
when	0
treating	0
patients	0
with	0
glucocorticoids	0
;	0
its	0
prevention	0
by	0
gamma-interferon	9
might	0
be	0
beneficial	0
for	0
some	0
but	0
not	0
all	0
pathogens	0
.	0

Interleukin	9
2	10
receptor	10
(	0
Tac	9
antigen	10
)	0
expression	0
in	0
HTLV-I-associated	0
adult	0
T-cell	7
leukemia	0
.	0

Interleukin-2	9
(	0
IL-2	9
)	0
is	0
a	0
lymphokine	9
synthesized	0
by	0
some	0
T-cells	7
following	0
activation	0
.	0

Resting	0
T-cells	7
do	0
not	0
express	0
IL-2	9
receptors	10
,	0
but	0
receptors	0
are	0
rapidly	0
expressed	0
on	0
T-cells	7
following	0
interaction	0
of	0
antigens	0
,	0
mitogens	0
,	0
or	0
monoclonal	9
antibodies	10
with	0
the	0
antigen-specific	9
T-cell	10
receptor	10
complex	10
.	0

Using	0
anti-Tac	9
,	0
a	0
monoclonal	9
antibody	10
that	0
recognizes	0
the	0
IL-2	9
receptor	10
,	0
the	0
receptor	0
has	0
been	0
purified	0
and	0
shown	0
to	0
be	0
a	0
Mr	0
33	0
,	0
000	0
peptide	0
that	0
is	0
posttranslationally	0
glycosylated	0
to	0
a	0
Mr	0
55	0
,	0
000	0
mature	0
form	0
.	0

Normal	0
resting	0
T-cells	7
and	0
most	0
leukemic	5
T-cell	6
populations	6
do	0
not	0
express	0
IL-2	9
receptors	10
;	0
however	0
,	0
the	0
leukemic	7
cells	8
of	0
the	0
11	0
patients	0
examined	0
who	0
had	0
human	0
T-cell	0
lymphotropic	0
virus-associated	0
adult	0
T-cell	0
leukemia	0
expressed	0
the	0
Tac	9
antigen	10
.	0

In	0
human	7
T-cell	8
lymphotropic	8
virus-I	8
infected	8
cells	8
,	0
the	0
Mr	0
42	0
,	0
000	0
long	0
open	9
reading	10
frame	10
protein	10
encoded	0
in	0
part	0
by	0
the	0
pX	1
region	2
of	0
this	0
virus	0
may	0
act	0
as	0
a	0
transacting	9
transcriptional	10
activator	10
that	0
induces	0
IL-2	1
receptor	2
gene	2
transcription	0
,	0
thus	0
providing	0
an	0
explanation	0
for	0
the	0
constant	0
association	0
of	0
IL-2	9
receptor	10
expression	0
with	0
adult	0
T-cell	0
lymphotropic	0
virus-I	0
infection	0
of	0
lymphoid	7
cells	8
.	0

The	0
constant	0
expression	0
of	0
large	0
numbers	0
of	0
IL-2	9
receptors	10
which	0
may	0
be	0
aberrant	0
may	0
play	0
a	0
role	0
in	0
the	0
uncontrolled	0
growth	0
of	0
adult	7
T-cell	8
leukemia	8
cells	8
.	0

Two	0
patients	0
with	0
Tac-positive	0
adult	0
T-cell	0
leukemia	0
have	0
been	0
treated	0
with	0
the	0
anti-Tac	9
.	0

One	0
of	0
the	0
patients	0
had	0
6-	0
and	0
3-mo	0
remissions	0
of	0
his	0
leukemia	0
following	0
two	0
courses	0
of	0
therapy	0
with	0
this	0
monoclonal	9
antibody	10
directed	0
toward	0
this	0
growth	9
factor	10
receptor	10
.	0

Lymphocyte	7
glucocorticoid	9
receptor	10
binding	0
in	0
depressed	0
patients	0
with	0
hypercortisolemia	0
.	0

Despite	0
elevated	0
levels	0
of	0
serum	0
and	0
urinary	0
cortisol	0
,	0
patients	0
with	0
depressive	0
illness	0
manifest	0
none	0
of	0
the	0
clinical	0
stigmata	0
of	0
glucocorticoid	0
excess	0
.	0

This	0
hypercortisolemia	0
in	0
the	0
absence	0
of	0
clinical	0
effects	0
suggests	0
a	0
state	0
of	0
hormone	0
resistance	0
and	0
could	0
be	0
mediated	0
by	0
alterations	0
in	0
the	0
glucocorticoid	9
receptor	10
.	0

Earlier	0
studies	0
have	0
shown	0
that	0
small	0
doses	0
of	0
glucocorticoids	0
cause	0
a	0
decrease	0
in	0
glucocorticoid	9
receptor	10
binding	0
in	0
normal	0
human	7
lymphocytes	8
.	0

White	0
cells	0
from	0
depressed	0
patients	0
with	0
significant	0
hypercortisolemia	0
would	0
be	0
expected	0
to	0
show	0
a	0
similar	0
change	0
in	0
receptor	0
concentration	0
if	0
peripheral	0
tissues	0
are	0
adequately	0
exposed	0
to	0
and	0
sensitive	0
to	0
the	0
hormone	0
.	0

In	0
this	0
study	0
we	0
compared	0
the	0
binding	0
of	0
[	0
3H	0
]	0
dexamethasone	0
to	0
lymphocytes	7
from	0
normal	0
subjects	0
and	0
depressed	0
patients	0
with	0
hypercortisolemia	0
.	0

Lymphocytes	7
from	0
normal	0
subjects	0
had	0
a	0
mean	0
receptor	0
concentration	0
of	0
10.2	0
+/-	0
0.66	0
fm/10	0
(	0
6	0
)	0
cells	0
(	0
S.E.M.	0
)	0
and	0
a	0
dissociation	0
constant	0
of	0
4.8	0
+/-	0
0.47	0
nM	0
.	0

Lymphocytes	7
from	0
depressed	0
patients	0
with	0
abnormal	0
0800	0
h	0
serum	0
cortisol	0
after	0
dexamethasone	0
had	0
a	0
mean	0
receptor	0
concentration	0
of	0
8.8	0
+/-	0
0.75	0
fm/10	0
(	0
6	0
)	0
cells	0
,	0
which	0
was	0
not	0
significantly	0
different	0
from	0
that	0
in	0
lymphocytes	7
from	0
normal	0
subjects	0
or	0
from	0
depressed	0
subjects	0
with	0
normal	0
post-dexamethasone	0
cortisol	0
levels	0
(	0
9.4	0
+/-	0
0.95	0
fm/10	0
(	0
6	0
)	0
cells	0
)	0
.	0

Lymphocytes	7
from	0
depressed	0
patients	0
with	0
elevated	0
urinary	0
free	0
cortisol	0
excretion	0
(	0
UFC	0
)	0
also	0
had	0
normal	0
receptor	0
concentration	0
and	0
binding	0
affinity	0
for	0
dexamethasone	0
.	0

The	0
lack	0
of	0
a	0
change	0
in	0
lymphocyte	7
glucocorticoid	9
receptor	10
concentration	0
in	0
the	0
presence	0
of	0
cortisol	0
excess	0
suggests	0
the	0
possibility	0
that	0
hypercortisolemia	0
in	0
depressive	0
illness	0
represents	0
a	0
state	0
of	0
peripheral	0
glucocorticoid	0
resistance	0
.	0

Structure	0
and	0
regulation	0
of	0
the	0
glucocorticoid	9
hormone	10
receptor	10
.	0

The	0
glucocorticoid	9
receptor	10
is	0
an	0
intracellular	9
protein	10
which	0
possesses	0
three	0
distinct	0
domains	0
,	0
one	0
that	0
binds	0
agonist	0
and	0
antagonist	0
steroids	0
,	0
one	0
that	0
binds	0
DNA	0
,	0
and	0
one	0
that	0
binds	0
anti-receptor	9
antibodies	10
and	0
is	0
required	0
for	0
glucocorticoid	0
modulation	0
of	0
gene	0
expression	0
.	0

In	0
intact	0
cells	0
,	0
receptor	0
number	0
,	0
affinity	0
and	0
activity	0
can	0
change	0
in	0
response	0
to	0
factors	0
that	0
bind	0
to	0
the	0
receptor	0
,	0
or	0
that	0
act	0
indirectly	0
through	0
ill-defined	0
mechanisms	0
which	0
may	0
include	0
resumption	0
or	0
arrest	0
of	0
cell	0
cycling	0
and	0
variations	0
in	0
intracellular	0
calcium	0
ion	0
concentrations	0
.	0

Some	0
of	0
these	0
factors	0
appear	0
to	0
exert	0
their	0
effect	0
by	0
controlling	0
critical	0
receptor	0
properties	0
such	0
as	0
ATP-dependent	0
phosphorylation	0
,	0
integrity	0
of	0
thiol	9
groups	10
,	0
and	0
exposure	0
of	0
key	9
amino	10
acid	10
residues	10
.	0

Glucocorticoid	0
agonists	0
promote	0
the	0
'transformation	0
'	0
of	0
the	0
receptor	0
into	0
the	0
DNA-binding	0
state	0
,	0
which	0
is	0
competent	0
for	0
modulating	0
gene	0
expression	0
.	0

Glucocorticoid	0
antagonists	0
are	0
steroids	0
that	0
interact	0
with	0
the	0
receptor	0
but	0
either	0
fail	0
to	0
produce	0
a	0
stable	9
complex	10
or	0
produce	0
a	0
stable	9
but	10
inefficient	10
complex	10
.	0

Although	0
substituent	0
groups	0
that	0
confer	0
agonist	0
or	0
antagonist	0
activity	0
to	0
the	0
steroid	0
have	0
been	0
identified	0
,	0
the	0
molecular	0
determinants	0
of	0
this	0
difference	0
at	0
the	0
receptor	0
level	0
remain	0
unknown	0
.	0

Most	0
in	0
vitro	0
and	0
in	0
vivo	0
data	0
on	0
receptor	0
regulation	0
can	0
be	0
accommodated	0
by	0
postulating	0
the	0
existence	0
of	0
an	0
intracellular	0
cycle	0
that	0
involves	0
five	0
states	0
of	0
the	0
receptor	0
.	0

The	0
active	0
free	0
receptor	0
is	0
phosphorylated	0
,	0
reduced	0
,	0
and	0
presumably	0
oligomeric	0
(	0
state	0
A	0
)	0
.	0

Following	0
binding	0
of	0
an	0
agonist	0
(	0
state	0
B	0
)	0
,	0
it	0
can	0
become	0
transformed	0
by	0
dissociation	0
into	0
its	0
subunits	0
and	0
dephosphorylation	0
(	0
state	0
C	0
)	0
.	0

The	0
transformed	9
receptor	10
then	0
interacts	0
with	0
chromatin	1
(	0
state	0
D	0
)	0
.	0

Dissociation	0
of	0
the	0
steroid	0
and	0
oxidation	0
of	0
receptor	9
thiol	10
group	10
(	0
s	0
)	0
lead	0
to	0
the	0
inactive	0
receptor	0
form	0
(	0
state	0
E	0
)	0
.	0

Reduction	0
and	0
rephosphorylation	0
of	0
the	0
receptor	0
enable	0
it	0
to	0
bind	0
steroids	0
again	0
so	0
that	0
the	0
cycle	0
is	0
closed	0
.	0

Thermodynamics	0
of	0
steroid	0
binding	0
to	0
the	0
human	9
glucocorticoid	10
receptor	10
.	0

The	0
thermodynamics	0
of	0
the	0
interaction	0
of	0
glucocorticoids	0
with	0
their	0
receptor	0
were	0
studied	0
in	0
cytosol	0
from	0
human	7
lymphoblastoid	8
cells	8
.	0

The	0
rate	0
and	0
affinity	0
constants	0
of	0
dexamethasone	0
and	0
cortisol	0
between	0
0	0
degree	0
and	0
25	0
degrees	0
C	0
were	0
calculated	0
by	0
curve-fitting	0
from	0
time-course	0
and	0
equilibrium	0
kinetics	0
.	0

The	0
data	0
were	0
consistent	0
with	0
a	0
simple	0
reversible	0
bimolecular	0
interaction	0
.	0

Arrhenius	0
and	0
Va	0
n't	0
Hoff	0
plots	0
were	0
curvilinear	0
for	0
both	0
steroids	0
.	0

At	0
equilibrium	0
,	0
the	0
solution	0
for	0
the	0
equation	0
delta	0
G	0
=	0
delta	0
H	0
-	0
T	0
X	0
delta	0
S	0
(	0
eqn.	0
1	0
)	0
was	0
(	0
in	0
kJ	0
X	0
mol-1	0
)	0
-47	0
=	0
36	0
-	0
83	0
(	0
dexamethasone	0
)	0
and	0
-42	0
=	0
-9	0
-	0
33	0
(	0
cortisol	0
)	0
at	0
0	0
degree	0
C	0
.	0

Enthalpy	0
and	0
entropy	0
changes	0
decreased	0
quasi-linearly	0
with	0
temperature	0
such	0
that	0
,	0
at	0
25	0
degrees	0
C	0
,	0
the	0
respective	0
values	0
were	0
-50	0
=	0
-75	0
+	0
25	0
and	0
-43	0
=	0
-48	0
+	0
5	0
.	0

Thus	0
,	0
for	0
both	0
steroids	0
,	0
the	0
interaction	0
was	0
entropy-driven	0
at	0
low	0
temperature	0
and	0
became	0
entirely	0
enthalpy-driven	0
at	0
20	0
degrees	0
C	0
.	0

Thermodynamic	0
values	0
for	0
the	0
transition	0
state	0
were	0
calculated	0
from	0
the	0
rate	0
constants	0
.	0

For	0
the	0
forward	0
reaction	0
,	0
eqn.	0
(	0
1	0
)	0
gave	0
45	0
=	0
84	0
-	0
39	0
(	0
dexamethasone	0
)	0
and	0
46	0
=	0
60	0
-	0
14	0
(	0
cortisol	0
)	0
at	0
0	0
degree	0
C	0
,	0
and	0
44	0
=	0
24	0
+	0
20	0
(	0
dexamethasone	0
)	0
and	0
46	0
=	0
28	0
+	0
18	0
(	0
cortisol	0
)	0
at	0
25	0
degrees	0
C	0
.	0

These	0
data	0
fit	0
quite	0
well	0
with	0
a	0
two-step	0
model	0
[	0
Ross	0
&	0
Subramanian	0
(	0
1981	0
)	0
Biochemistry	0
20	0
,	0
3096-3102	0
]	0
proposed	0
for	0
ligand-protein	0
interactions	0
,	0
which	0
involves	0
a	0
partial	0
immobilization	0
of	0
the	0
reacting	0
species	0
governed	0
by	0
hydrophobic	0
forces	0
,	0
followed	0
by	0
stabilization	0
of	0
the	0
complex	0
by	0
short-range	0
interactions	0
.	0

On	0
the	0
basis	0
of	0
this	0
model	0
,	0
an	0
analysis	0
of	0
the	0
transition-state	0
thermodynamics	0
led	0
to	0
the	0
conclusion	0
that	0
no	0
more	0
than	0
half	0
of	0
the	0
steroid	0
molecular	0
area	0
is	0
engaged	0
in	0
the	0
binding	0
process	0
.	0

Cell	0
cycle-related	0
changes	0
in	0
number	0
of	0
T-lymphocyte	9
receptors	10
for	0
glucocorticoids	0
and	0
insulin	0
.	0

Enriched	0
human	7
peripheral	8
T-lymphocytes	8
were	0
stimulated	0
with	0
PHA	0
and	0
examined	0
for	0
variations	0
in	0
insulin	0
and	0
glucocorticoid	0
(	0
dexamethasone	0
)	0
receptor	0
numbers	0
during	0
the	0
early	0
phases	0
of	0
the	0
cell	0
cycle	0
.	0

Cells	0
in	0
G0	0
,	0
G1a	0
and	0
G1b	0
phases	0
,	0
where	0
the	0
G1a	0
-	0
G1b	0
transition	0
is	0
an	0
Interleukin	9
2	10
dependent	0
event	0
,	0
were	0
quantitated	0
by	0
flow	0
cytometry	0
.	0

Few	0
but	0
significant	0
numbers	0
of	0
glucocorticoid	9
receptors	10
(	0
2700/cell	0
)	0
and	0
no	0
insulin	9
receptors	10
(	0
-1/cell	0
)	0
were	0
found	0
in	0
the	0
resting	0
(	0
G0	0
)	0
phase	0
.	0

As	0
cells	0
entered	0
the	0
G1a	0
phase	0
the	0
specific	0
binding	0
of	0
dexamethasone	0
increased	0
and	0
of	0
insulin	0
took	0
place	0
.	0

Although	0
the	0
specific	0
binding	0
further	0
increased	0
as	0
T-cells	7
entered	0
the	0
G1b	0
phase	0
(	0
as	0
measured	0
at	0
44	0
h	0
of	0
incubation	0
and	0
using	0
hydroxyurea-treated	5
cells	6
)	0
,	0
the	0
major	0
changes	0
in	0
the	0
specific	0
binding	0
of	0
dexamethasone	0
took	0
place	0
during	0
the	0
period	0
16	0
-	0
20	0
h	0
after	0
stimulation	0
.	0

Based	0
on	0
these	0
findings	0
,	0
it	0
is	0
concluded	0
that	0
both	0
receptor	0
types	0
(	0
cell	9
membrane	10
and	10
cytoplasmic	10
receptors	10
)	0
are	0
being	0
formed	0
and	0
increased	0
at	0
G1	0
phase	0
prior	0
to	0
cell	0
proliferation	0
,	0
indicating	0
the	0
importance	0
of	0
G1	0
phase	0
in	0
immunoregulation	0
.	0

Glucocorticoid	9
receptors	10
and	0
cortico-sensitivity	0
in	0
a	0
human	5
clonal	6
monocytic	6
cell	6
line	6
,	0
CM-SM	5
.	0

CM-SM	5
is	0
a	0
clonal	5
line	6
of	0
human	7
precursor	8
mononuclear	8
phagocytes	8
inducible	0
to	0
macrophage	7
differentiation	0
in	0
response	0
to	0
the	0
tumor	0
promoter	0
phorbol	0
ester	0
12-O-tetradecanoyl-phorbol-13-acetate	0
(	0
TPA	0
)	0
.	0

Untreated	0
CM-SM	0
cells	0
contain	0
single	0
class	0
,	0
high-affinity	0
(	0
KD	0
=	0
4.0	0
X	0
10	0
(	0
-9	0
)	0
M	0
)	0
glucocorticoid-specific	0
receptor	0
sites	0
(	0
approximately	0
60	0
,	0
000	0
per	0
cell	0
)	0
,	0
as	0
measured	0
by	0
a	0
whole	0
cell	0
assay	0
,	0
at	0
37	0
degrees	0
C	0
,	0
using	0
[	0
3H	0
]	0
triamcinolone	0
acetonide	0
(	0
TA	0
)	0
.	0

Exposure	0
of	0
CM-SM	5
to	0
dexamethasone	0
(	0
DEX	0
)	0
produced	0
a	0
progressive	0
,	0
dose-	0
and	0
time-related	0
series	0
of	0
changes	0
in	0
CM-SM	5
cell	0
growth	0
,	0
saturation	0
density	0
,	0
morphology	0
,	0
and	0
functional	0
properties	0
,	0
with	0
half-maximal	0
effects	0
at	0
about	0
10	0
(	0
-9	0
)	0
M	0
for	0
DEX	0
.	0

TA-receptor	0
sites	0
rapidly	0
decreased	0
(	0
about	0
70	0
%	0
)	0
after	0
DEX	0
treatment	0
,	0
without	0
any	0
apparent	0
change	0
in	0
steroid	0
specificity	0
and	0
affinity	0
.	0

After	0
5	0
days	0
in	0
culture	0
with	0
a	0
saturating	0
concentration	0
(	0
3.6	0
X	0
10	0
(	0
-8	0
)	0
M	0
)	0
of	0
hormone	0
,	0
the	0
cells	0
reached	0
a	0
saturation	0
density	0
of	0
about	0
9.0	0
X	0
10	0
(	0
6	0
)	0
viable	0
cells/ml	0
(	0
about	0
4.0	0
X	0
10	0
(	0
6	0
)	0
viable	0
cells/ml	0
in	0
the	0
controls	0
)	0
,	0
while	0
the	0
modal	0
volume	0
of	0
the	0
resulting	0
cell	5
population	6
was	0
approximately	0
60	0
%	0
,	0
as	0
compared	0
to	0
the	0
volume	0
of	0
untreated	5
cells	6
.	0

DEX-treated	5
cells	6
appeared	0
less	0
differentiated	0
than	0
controls	0
,	0
as	0
assessed	0
by	0
combined	0
morphologic	0
,	0
antigenic	0
,	0
and	0
cytoenzymatic	0
analyses	0
.	0

DEX	0
almost	0
completely	0
inhibited	0
TPA	0
activation	0
of	0
the	0
following	0
macrophage	7
functions	0
:	0
adherency	0
to	0
the	0
culture	0
plate	0
,	0
expression	0
of	0
lysosomal	9
enzymes	10
,	0
Fc	9
and	10
C3	10
receptors	10
,	0
and	0
stimulation	0
of	0
phagocytosis	0
.	0

After	0
removal	0
of	0
DEX	0
,	0
the	0
cells	0
,	0
within	0
a	0
few	0
passages	0
,	0
returned	0
to	0
a	0
state	0
apparently	0
identical	0
to	0
the	0
untreated	0
controls	0
and	0
could	0
be	0
induced	0
to	0
macrophage	7
differentiation	0
in	0
response	0
to	0
TPA	0
.	0

Acute	0
lymphoblastic	0
leukemia	0
in	0
children	0
:	0
current	0
status	0
,	0
controversies	0
,	0
and	0
future	0
perspective	0
.	0

Disease-free	0
survival	0
(	0
DFS	0
)	0
in	0
childhood	0
ALL	0
is	0
60	0
%	0
,	0
and	0
survival	0
in	0
good	0
,	0
average	0
,	0
and	0
poor	0
prognostic	0
groups	0
defined	0
by	0
initial	0
WBC	0
and	0
age	0
is	0
90	0
,	0
60	0
,	0
and	0
45	0
%	0
,	0
respectively	0
.	0

Additional	0
immunological	0
,	0
morphological	0
,	0
biochemical	0
,	0
cytokinetic	0
,	0
and	0
cytogenetic	0
factors	0
have	0
been	0
identified	0
,	0
illustrating	0
the	0
heterogeneity	0
of	0
ALL	0
and	0
its	0
derivation	0
from	0
malignant	5
clones	6
at	0
various	0
stages	0
of	0
differentiation	0
and	0
with	0
varying	0
rates	0
of	0
proliferation	0
.	0

Of	0
biologic	0
importance	0
,	0
these	0
factors	0
may	0
refine	0
further	0
the	0
characteristic	0
features	0
of	0
clinically-determined	0
prognostic	0
groups	0
.	0

Multivariate	0
analysis	0
of	0
large	0
prospective	0
trials	0
with	0
homogeneous	0
therapy	0
will	0
be	0
required	0
to	0
determine	0
the	0
independent	0
prognostic	0
importance	0
of	0
these	0
factors	0
.	0

Current	0
treatment	0
strategies	0
in	0
ALL	0
include	0
(	0
1	0
)	0
tailoring	0
therapy	0
and	0
its	0
intensity	0
to	0
prognostic	0
groups	0
;	0
(	0
2	0
)	0
multiple-drug	0
combinations	0
in	0
induction	0
;	0
(	0
3	0
)	0
early	0
use	0
of	0
intrathecal	0
(	0
IT	0
)	0
methotrexate	0
(	0
MTX	0
)	0
;	0
(	0
4	0
)	0
CNS	0
prophylaxis	0
with	0
IT	0
MTX	0
alone	0
in	0
good	0
prognosis	0
patients	0
and	0
combined	0
cranial	0
radiation	0
(	0
CXRT	0
)	0
,	0
1800	0
rads	0
plus	0
IT	0
MTX	0
,	0
in	0
average	0
and	0
poor	0
prognosis	0
patients	0
.	0

Current	0
studies	0
show	0
a	0
CNS	0
relapse	0
rate	0
of	0
5	0
%	0
in	0
all	0
prognostic	0
groups	0
.	0

Late	0
neuropsychological	0
defects	0
caused	0
by	0
cranial	0
XRT	0
and	0
IT	0
MTX	0
have	0
prompted	0
programs	0
designed	0
to	0
reduce	0
the	0
potential	0
late	0
toxicity	0
of	0
CNS	0
prophylaxis	0
.	0

More	0
pronounced	0
in	0
younger	0
children	0
,	0
these	0
abnormalities	0
include	0
decreased	0
IQ	0
,	0
visual-motor	0
incoordination	0
,	0
poor	0
performance	0
in	0
mathematics	0
,	0
and	0
memory	0
dysfunction	0
.	0

Until	0
1980	0
,	0
more	0
intensive	0
induction	0
,	0
consolidation	0
,	0
and	0
maintenance	0
therapy	0
had	0
failed	0
to	0
prolong	0
DFS	0
in	0
children	0
with	0
a	0
poor	0
prognosis	0
.	0

In	0
West	0
Germany	0
(	0
Berlin-Frankfurt-Muenster	0
protocol	0
)	0
a	0
70	0
to	0
75	0
%	0
DFS	0
is	0
seen	0
in	0
all	0
patients	0
regardless	0
of	0
initial	0
WBC	0
,	0
suggesting	0
that	0
effective	0
therapy	0
will	0
override	0
prognostic	0
factors	0
.	0

Ultra-high-dose	0
MTX	0
,	0
without	0
cranial	0
radiation	0
,	0
is	0
also	0
showing	0
promise	0
in	0
poor	0
prognosis	0
patients	0
.	0

Other	0
issues	0
include	0
the	0
optimal	0
duration	0
of	0
therapy	0
,	0
the	0
role	0
of	0
testicular	0
biopsies	0
,	0
and	0
prophylactic	0
testicular	0
radiation	0
.	0

Recent	0
studies	0
suggest	0
that	0
prognostic	0
factors	0
lose	0
their	0
significance	0
after	0
2	0
years	0
of	0
continuous	0
complete	0
remission	0
and	0
that	0
2	0
years	0
of	0
maintenance	0
therapy	0
is	0
adequate	0
.	0

Bilateral	0
open-wedge	0
testicular	0
biopsies	0
have	0
identified	0
occult	0
testicular	0
disease	0
in	0
8	0
to	0
10	0
%	0
of	0
males	0
.	0

A	0
unified	0
approach	0
to	0
children	0
with	0
leukemia/lymphoma	0
,	0
a	0
group	0
with	0
a	0
particularly	0
poor	0
prognosis	0
,	0
utilizing	0
NHL-type	0
therapy	0
may	0
be	0
more	0
effective	0
than	0
conventional	0
ALL	0
therapy	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
400	0
WORDS	0
)	0

Glucocorticoid	9
receptor	10
and	0
in	0
vitro	0
sensitivity	0
to	0
steroid	0
hormones	0
in	0
human	0
lymphoproliferative	0
diseases	0
and	0
myeloid	0
leukemia	0
.	0

The	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
quantitation	0
by	0
a	0
whole-cell	0
assay	0
and/or	0
cytosol	0
technique	0
and	0
the	0
in	0
vitro	0
sensitivity	0
to	0
steroids	0
have	0
been	0
assessed	0
in	0
peripheral	7
blood	8
cells	8
from	0
normal	0
donors	0
and	0
patients	0
with	0
chronic	0
lymphatic	0
leukemia	0
(	0
CLL	0
)	0
,	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
,	0
lymphosarcoma	0
cell	0
leukemia	0
(	0
LSCL	0
)	0
,	0
acute	0
nonlymphatic	0
leukemia	0
(	0
ANLL	0
)	0
,	0
and	0
chronic	0
myeloid	0
leukemia	0
(	0
CML	0
)	0
.	0

Within	0
the	0
lymphoproliferative	0
diseases	0
,	0
ALL	5
cells	6
exhibited	0
the	0
highest	0
GR	9
concentration	0
(	0
regardless	0
of	0
the	0
method	0
used	0
)	0
and	0
the	0
highest	0
in	0
vitro	0
inhibition	0
of	0
spontaneous	0
[	0
3H	0
]	0
thymidine	0
(	0
[	0
3H	0
]	0
TdR	0
)	0
uptake	0
by	0
glucocorticoids	0
.	0

A	0
significant	0
relationship	0
between	0
GR	9
concentration	0
(	0
whole-cell	0
assay	0
)	0
and	0
in	0
vitro	0
sensitivity	0
to	0
dexamethasone	0
was	0
also	0
found	0
.	0

On	0
the	0
contrary	0
,	0
CLL	5
cells	6
presented	0
the	0
highest	0
sensitivity	0
to	0
glucocorticoids	0
in	0
PHA-stimulated	5
cell	6
cultures	6
.	0

Cells	0
from	0
the	0
only	0
two	0
ALL	0
patients	0
who	0
did	0
not	0
undergo	0
a	0
remission	0
after	0
glucocorticoid-inclusive	0
chemotherapy	0
had	0
both	0
the	0
lowest	0
in	0
vitro	0
sensitivity	0
to	0
dexamethasone	0
and	0
the	0
lowest	0
GR	0
concentration	0
with	0
whole-cell	0
assay	0
.	0

Concerning	0
myeloid	0
leukemia	0
,	0
ANLL	0
patients	0
had	0
GR	9
concentrations	0
slightly	0
higher	0
than	0
those	0
found	0
in	0
the	0
ALL	0
group	0
but	0
exhibited	0
the	0
lowest	0
degree	0
of	0
inhibition	0
of	0
spontaneous	0
[	0
3H	0
]	0
TdR	0
uptake	0
by	0
dexamethasone	0
(	0
stimulatory	0
effects	0
occurred	0
in	0
some	0
cases	0
)	0
.	0

CML	5
cells	6
exhibited	0
an	0
inhibition	0
degree	0
by	0
in	0
vitro	0
glucocorticoids	0
significantly	0
higher	0
than	0
that	0
of	0
ANLL	5
cells	6
but	0
not	0
different	0
from	0
that	0
of	0
lymphoproliferative	0
diseases	0
.	0

No	0
clear	0
relationship	0
among	0
GR	0
pattern	0
,	0
in	0
vitro	0
cell	0
sensitivity	0
to	0
glucocorticoids	0
,	0
and	0
clinicohematologic	0
parameters	0
was	0
observed	0
in	0
myeloid	0
leukemia-bearing	0
patients	0
.	0

Glucocorticoid	9
receptors	10
and	0
in	0
vitro	0
corticosensitivity	0
of	0
peanut-positive	5
and	6
peanut-negative	6
human	6
thymocyte	6
subpopulations	6
.	0

In	0
6	0
human	0
thymus	0
glands	0
,	0
the	0
immature	0
subset	0
of	0
thymocytes	7
was	0
separated	0
from	0
the	0
more	0
mature	0
one	0
,	0
by	0
differential	0
peanut	0
lectin	0
agglutination	0
.	0

These	0
2	0
cell	0
subpopulations	0
were	0
analyzed	0
for	0
glucocorticoid	9
receptor	10
content	0
by	0
using	0
a	0
whole	0
cell	0
assay	0
,	0
with	0
(	0
3H	0
)	0
-triamcinolone	0
acetonide	0
as	0
tracer	0
.	0

The	0
unagglutinated	7
thymocytes	8
(	0
peanut	0
negative	0
)	0
contained	0
about	0
2	0
times	0
more	0
receptor	0
sites	0
per	0
cell	0
than	0
agglutinated	0
(	0
peanut	0
positive	0
)	0
ones	0
(	0
7650	0
+/-	0
1550	0
S.D.	0
verus	0
3195	0
+/-	0
896	0
S.D.	0
)	0
.	0

The	0
affinity	0
for	0
steroid	0
was	0
similar	0
in	0
both	0
cell	0
subsets	0
,	0
as	0
was	0
the	0
stereospecificity	0
for	0
glucocorticoids	0
,	0
the	0
time-course	0
of	0
steroid-receptor	0
association	0
,	0
and	0
cytoplasmic	0
to	0
nuclear	0
translocation	0
.	0

Despite	0
the	0
greater	0
number	0
of	0
glucocorticoid	9
receptor	10
sites	0
,	0
the	0
peanut-negative	5
thymocyte	6
subpopulation	6
did	0
not	0
differ	0
from	0
the	0
peanut-positive	5
one	0
in	0
its	0
sensitivity	0
to	0
the	0
inhibitory	0
effects	0
of	0
triamcinolone	0
acetonide	0
,	0
as	0
determined	0
by	0
measurements	0
of	0
the	0
incorporation	0
of	0
radiolabeled	0
precursors	0
of	0
protein	0
and	0
DNA	0
.	0

Moreover	0
,	0
the	0
peanut-negative	5
subset	6
appeared	0
more	0
resistant	0
in	0
vitro	0
to	0
the	0
steroid-induced	0
cell	0
lysis	0
as	0
compared	0
to	0
the	0
peanut-positive	5
one	0
.	0

Thus	0
,	0
our	0
data	0
suggest	0
that	0
glucocorticoid	0
receptor	0
density	0
and	0
corticosensitivity	0
are	0
not	0
directly	0
correlated	0
and	0
that	0
the	0
number	0
of	0
glucocorticoid	9
receptor	10
sites	0
may	0
be	0
dependent	0
on	0
the	0
degree	0
of	0
immunologic	0
maturation	0

Defective	0
binding	0
and	0
function	0
of	0
1	9
,	10
25-dihydroxyvitamin	10
D3	10
receptors	10
in	0
peripheral	7
mononuclear	8
cells	8
of	0
patients	0
with	0
end-organ	0
resistance	0
to	0
1	0
,	0
25-dihydroxyvitamin	0
D	0
.	0

Lectin-induced	0
DNA	0
synthesis	0
by	0
peripheral	7
mononuclear	8
cells	8
from	0
17	0
normal	0
donors	0
was	0
inhibited	0
(	0
40-60	0
%	0
)	0
by	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
(	0
1	0
,	0
25	0
[	0
OH	0
]	0
2D3	0
)	0
at	0
physiological	0
concentrations	0
(	0
10	0
(	0
-10	0
)	0
-10	0
(	0
-9	0
)	0
M	0
)	0
.	0

The	0
lymphocytes	7
acquire	0
specific	0
receptors	0
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
upon	0
activation	0
by	0
the	0
lectins	9
.	0

This	0
process	0
precedes	0
the	0
inhibitory	0
effect	0
of	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

We	0
studied	0
lymphocytes	7
from	0
six	0
patients	0
from	0
four	0
different	0
kindreds	0
with	0
the	0
syndrome	0
of	0
hereditary	0
end-organ	0
resistance	0
to	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D	0
(	0
the	0
so-called	0
vitamin	0
D-dependent	0
rickets	0
type	0
II	0
)	0
.	0

In	0
five	0
patients	0
(	0
three	0
kindreds	0
)	0
peripheral	7
blood	8
mononuclear	8
cells	8
did	0
not	0
acquire	0
receptors	0
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
upon	0
phytohemagglutinin-induced	0
activation	0
.	0

Moreover	0
,	0
in	0
contrast	0
to	0
normal	7
lymphocytes	8
,	0
the	0
mitogenic	0
stimulation	0
of	0
these	0
patients	0
'	0
lymphocytes	7
by	0
phytohemagglutinin	9
and	0
concanavalin	0
A	0
was	0
not	0
inhibited	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
.	0

Activated	0
lymphocytes	7
of	0
the	0
sixth	0
patient	0
from	0
a	0
fourth	0
kindred	0
exhibited	0
normal	0
binding	0
of	0
[	0
3H	0
]	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
but	0
the	0
hormone	0
failed	0
to	0
inhibit	0
the	0
mitogenic	0
stimulation	0
.	0

A	0
similar	0
pattern	0
of	0
the	0
vitamin	0
D	0
effector	0
system	0
was	0
previously	0
observed	0
in	0
fibroblasts	0
cultured	0
from	0
skin	0
biopsies	0
of	0
the	0
same	0
group	0
of	0
patients	0
.	0

The	0
conclusions	0
from	0
these	0
findings	0
are	0
:	0
(	0
a	0
)	0
the	0
inhibition	0
of	0
mitogenic	0
stimulation	0
by	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
is	0
mediated	0
by	0
specific	9
functional	10
receptors	10
to	0
the	0
hormone	0
;	0
and	0
(	0
b	0
)	0
the	0
receptors	0
for	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
in	0
mononuclear	7
cells	8
are	0
probably	0
controlled	0
genetically	0
by	0
the	0
same	0
mechanisms	0
as	0
the	0
effector	0
system	0
in	0
well-characterized	0
target	0
organs	0
of	0
the	0
hormone	0
,	0
such	0
as	0
intestine	0
and	0
kidney	0
.	0

Glucocorticoid	9
receptors	10
of	0
mononuclear	7
leukocytes	8
from	0
myasthenia	0
gravis	0
patients	0
.	0

The	0
present	0
study	0
was	0
performed	0
to	0
analyse	0
glucocorticoid	9
receptor	10
(	0
GR	9
)	0
binding	0
in	0
peripheral	7
blood	8
mononuclear	8
leukocytes	8
(	0
MNL	7
)	0
from	0
39	0
myasthenia	0
gravis	0
(	0
MG	0
)	0
patients	0
(	0
unoperated	0
patients	0
(	0
n	0
=	0
13	0
)	0
,	0
thymectomized	0
patients	0
(	0
n	0
=	0
14	0
)	0
and	0
patients	0
receiving	0
glucocorticoids	0
:	0
thymectomized	0
(	0
n	0
=	0
11	0
)	0
and	0
unoperated	0
(	0
n	0
=	0
6	0
]	0
.	0

A	0
whole	0
cell	0
binding	0
assay	0
with	0
3	0
(	0
H	0
)	0
dexamethasone	0
was	0
used	0
.	0

GR	9
mean	0
values	0
were	0
significantly	0
higher	0
in	0
the	0
MNL	7
of	0
MG	0
patients	0
(	0
thymectomized	0
or	0
not	0
)	0
not	0
receiving	0
glucocorticoid	0
than	0
in	0
the	0
MNL	7
of	0
healthy	0
donors	0
.	0

Affinity	0
was	0
within	0
the	0
normal	0
range	0
.	0

Sex	0
,	0
age	0
or	0
clinical	0
forms	0
of	0
illness	0
did	0
not	0
influence	0
the	0
results	0
.	0

In	0
patients	0
receiving	0
prednisone	0
(	0
Pd	0
)	0
the	0
GR	9
values	0
were	0
significantly	0
lower	0
than	0
in	0
MG	0
patients	0
without	0
Pd	0
therapy	0
,	0
independent	0
of	0
Pd	0
dose	0
or	0
time	0
of	0
administration	0
.	0

No	0
differences	0
in	0
receptor	0
binding	0
between	0
normal	0
subjects	0
and	0
MG	0
patients	0
receiving	0
Pd	0
have	0
been	0
found	0
.	0

Immunological	0
interference	0
of	0
high	0
dose	0
corticosteroids	0
.	0

High-dose	0
corticosteroids	0
(	0
HDC	0
)	0
will	0
influence	0
cellular	0
as	0
well	0
as	0
humoral	0
participants	0
of	0
the	0
immune	0
response	0
.	0

The	0
lymphoid	0
tissue	0
will	0
decrease	0
in	0
size	0
and	0
weight	0
after	0
prolonged	0
treatment	0
with	0
HDC	0
.	0

Lymphocyte	0
functions	0
will	0
be	0
impaired	0
.	0

Reduced	0
synthesis	0
of	0
B-	7
as	8
well	8
as	8
T-lymphocytes	8
will	0
be	0
seen	0
.	0

The	0
inhibitory	0
effect	0
on	0
B-cell	7
function	0
can	0
be	0
observed	0
both	0
as	0
decreased	0
serum	0
levels	0
of	0
immunoglobulins	9
and	0
as	0
impaired	0
binding	0
of	0
antibodies	9
and	0
complement	0
to	0
the	0
cellular	0
surface	0
.	0

Reduced	0
T-cell	7
function	0
indicated	0
by	0
impaired	0
stimulation	0
by	0
PHA	9
and	0
porkweed	9
as	0
well	0
as	0
by	0
impaired	0
lymphokinin	0
effects	0
on	0
leukocyte	7
migration	0
inhibition	0
has	0
been	0
reported	0
.	0

Reduced	0
lymphocyte	0
adherence	0
to	0
antigen	0
and	0
suppressed	0
lymphocyte	0
reaction	0
have	0
also	0
been	0
observed	0
.	0

Humoral	0
factors	0
involved	0
in	0
chemotaxis	0
,	0
opsonisation	0
,	0
phagocytosis	0
,	0
vascular	0
permeability	0
leading	0
to	0
leakage	0
of	0
fluid	0
and	0
cells	0
and	0
factors	0
involved	0
in	0
lysis	0
of	0
antigens	0
are	0
impaired	0
.	0

This	0
can	0
be	0
explained	0
partly	0
by	0
the	0
observed	0
reduced	0
complement	0
activation	0
via	0
the	0
alternative	0
as	0
well	0
as	0
the	0
classical	0
pathway	0
in	0
association	0
with	0
HDC	0
therapy	0
.	0

Acute	0
processes	0
with	0
increased	0
vascular	0
permeability	0
and	0
accumulation	0
of	0
leukocytes	7
as	0
impairing	0
factors	0
could	0
be	0
influenced	0
beneficially	0
by	0
HDC	0
therapy	0
.	0

This	0
positive	0
effect	0
can	0
be	0
seen	0
in	0
treatment	0
of	0
septic	0
shock	0
or	0
rejection	0
of	0
a	0
transplant	0
.	0

However	0
,	0
if	0
sepsis	0
or	0
rejection	0
is	0
not	0
rapidly	0
reversed	0
,	0
complications	0
such	0
as	0
multisystem	0
organ	0
failure	0
and	0
bacteremia	0
are	0
prone	0
to	0
appear	0
.	0

Identification	0
of	0
human	9
leukemic	10
glucocorticoid	10
receptors	10
using	0
affinity	0
labeling	0
and	0
anti-human	9
glucocorticoid	10
receptor	10
antibodies	10
.	0

Antisera	0
raised	0
against	0
human	9
lymphoid	10
glucocorticoid	10
receptors	10
were	0
used	0
in	0
combination	0
with	0
the	0
glucocorticoid	0
receptor	0
affinity	0
label	0
[	0
3H	0
]	0
dexamethasone	0
21-mesylate	0
[	0
(	0
3H	0
]	0
DM	0
)	0
to	0
identify	0
the	0
glucocorticoid	9
receptors	10
of	0
the	0
human	5
B-lymphoblastoid	6
cell	6
line	6
IM-9	5
and	0
the	0
human	5
T-cell	6
leukemic	6
cell	6
line	6
CEM-C7	5
.	0

Antisera	0
were	0
obtained	0
following	0
immunization	0
of	0
New	0
Zealand	0
White	0
rabbits	0
with	0
[	9
3H	10
]	10
triamcinolone	10
acetonide	10
[	10
(	10
3H	10
]	10
TA	10
)	10
-glucocorticoid	10
receptor	10
complexes	10
partially	0
purified	0
by	0
two-stage	0
DNA-cellulose	0
chromatography	0
.	0

The	0
presence	0
of	0
anti-human	9
glucocorticoid	10
receptor	10
antibodies	10
was	0
verified	0
by	0
:	0
(	0
a	0
)	0
adsorption	0
of	0
[	9
3H	10
]	10
TA-receptor-antibody	10
complexes	10
to	0
Protein	9
A	10
;	0
(	0
b	0
)	0
a	0
shift	0
to	0
higher	0
apparent	0
molecular	0
weight	0
in	0
the	0
elution	0
position	0
from	0
Sephacryl	0
S300	0
of	0
[	9
3H	10
]	10
TA-receptor	10
complexes	10
incubated	0
with	0
immune	0
serum	0
;	0
and	0
(	0
c	0
)	0
the	0
ability	0
of	0
immune	0
serum	0
to	0
displace	0
[	9
3H	10
]	10
TA-receptor	10
complexes	10
on	0
sucrose	0
gradients	0
.	0

These	0
antibodies	9
also	0
recognized	0
rat	0
liver	0
and	0
murine	9
S49	10
cell	10
glucocorticoid	10
receptors	10
.	0

Sodium	0
dodecyl	0
sulfate-polyacrylamide	0
gel	0
electrophoresis	0
of	0
[	0
3H	0
]	0
DM-labeled	0
IM-9	0
cytosol	0
identified	0
a	0
major	0
competable	0
band	0
with	0
a	0
molecular	0
weight	0
of	0
approximately	0
90	0
,	0
000	0
,	0
three	0
minor	0
competable	0
components	0
with	0
molecular	0
weights	0
of	0
approximately	0
78	0
,	0
000	0
,	0
approximately	0
51	0
,	0
000	0
,	0
and	0
approximately	0
38	0
,	0
500	0
,	0
and	0
at	0
least	0
21	0
other	0
noncompetable	0
components	0
.	0

Following	0
immunoprecipitation	0
of	0
[	0
3H	0
]	0
DM-labeled	0
cytosol	0
with	0
immune	0
serum	0
,	0
only	0
the	0
Mr	0
90	0
,	0
000	0
and	0
78	0
,	0
000	0
components	0
were	0
seen	0
.	0

Sodium	0
dodecyl	0
sulfate-polyacrylamide	0
gel	0
electrophoresis	0
of	0
[	0
3H	0
]	0
DM-labeled	0
CEM-C7	0
cytosol	0
revealed	0
a	0
larger	0
number	0
of	0
[	0
3H	0
]	0
DM-labeled	0
components	0
.	0

However	0
,	0
after	0
immunoprecipitation	0
of	0
[	0
3H	0
]	0
DM-labeled	0
CEM-C7	0
cytosol	0
,	0
a	0
predominant	0
competable	0
component	0
with	0
a	0
molecular	0
weight	0
of	0
90	0
,	0
000	0
was	0
easily	0
identified	0
.	0

This	0
component	0
was	0
markedly	0
diminished	0
when	0
cytosols	0
from	0
the	0
glucocorticoid	5
receptor-deficient	6
cell	6
line	6
ICR-27	5
were	0
used	0
.	0

Thus	0
,	0
the	0
combination	0
of	0
affinity	0
labeling	0
and	0
anti-human	9
glucocorticoid	10
receptor	10
antibodies	10
is	0
capable	0
of	0
providing	0
direct	0
physical	0
identification	0
of	0
human	9
lymphoid	10
glucocorticoid	10
receptors	10
.	0

Effect	0
of	0
thymosin	0
on	0
glucocorticoid	9
receptor	10
activity	0
and	0
glucocorticoid	0
sensitivity	0
of	0
human	7
thymocytes	8
.	0

Incubation	0
with	0
thymosin	0
fraction	0
5	0
,	0
(	0
TMS	0
F5	0
at	0
300	0
micrograms/ml	0
)	0
a	0
partially	0
purified	0
thymic	0
factor	0
,	0
reduced	0
the	0
steroid	0
binding	0
activity	0
of	0
human	7
infant	8
thymocytes	8
from	0
9.6	0
+/-	0
2.1	0
fmole/ml	0
to	0
5.0	0
+/-	0
2.0	0
fmole/ml	0
.	0

The	0
glucocorticoid	9
receptor	10
activity	0
in	0
normal	0
infant	0
thymocytes	0
was	0
found	0
to	0
be	0
2	0
,	0
146	0
+/-	0
726	0
(	0
s.d.	0
)	0
sites	0
per	0
cell	0
with	0
dissociation	0
constant	0
of	0
1.4	0
+/-	0
0.6	0
X	0
10	0
(	0
-8	0
)	0
M	0
.	0

TMS	0
F5	0
also	0
increased	0
the	0
resistance	0
of	0
human	0
thymocytes	0
to	0
the	0
cytolytic	0
effect	0
of	0
dexamethasone	0
(	0
2.5	0
X	0
10	0
(	0
-8	0
)	0
M	0
)	0
to	0
168.6	0
+/-	0
30.2	0
%	0
of	0
control	0
(	0
P	0
less	0
than	0
0.01	0
)	0
.	0

In	0
animals	0
,	0
medullary	7
and	8
peripheral	8
blood	8
T	8
cells	8
are	0
more	0
resistant	0
to	0
glucocorticoids	0
than	0
immature	7
thymic	8
T	8
cells	8
.	0

The	0
results	0
show	0
that	0
thymosin	0
can	0
induce	0
changes	0
consistent	0
with	0
differentiation	0
in	0
human	7
thymocytes	8
.	0

These	0
in	0
vitro	0
results	0
are	0
consistent	0
with	0
a	0
physiological	0
role	0
of	0
thymosin	0
in	0
intrathymic	0
T	0
cell	0
maturation	0
in	0
man	0
.	0

Incubation	0
of	0
a	0
human	5
malignant	6
thymus	6
derived	6
T	6
cell	6
line	6
(	0
MOLT	5
3	6
)	0
with	0
TMS	0
F5	0
also	0
resulted	0
in	0
a	0
significant	0
reduction	0
of	0
the	0
number	0
of	0
steroid	0
binding	0
sites	0
to	0
44.2	0
+/-	0
15.3	0
%	0
of	0
control	0
(	0
P	0
less	0
than	0
0.05	0
)	0
,	0
but	0
TMS	0
F5	0
did	0
not	0
significantly	0
reduce	0
the	0
glucocorticoid	0
sensitivity	0
of	0
MOLT	5
3	6
cells	6
.	0

Specific	9
high-affinity	10
receptors	10
for	0
1	0
,	0
25-dihydroxyvitamin	0
D3	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
:	0
presence	0
in	0
monocytes	7
and	0
induction	0
in	0
T	7
lymphocytes	8
following	0
activation	0
.	0

Human	7
peripheral	8
blood	8
monocytes	8
have	0
high	0
affinity	0
binding	0
sites	0
for	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
(	0
Kd	0
0.14	0
nM	0
,	0
sedimentation	0
coefficient	0
3.7S	0
)	0
.	0

Resting	7
human	8
peripheral	8
blood	8
T	8
lymphocytes	8
,	0
however	0
,	0
do	0
not	0
have	0
a	0
demonstrable	0
1	9
,	10
25-	10
(	10
OH	10
)	10
2D3	10
receptor	10
.	0

After	0
activation	0
with	0
phytohemagglutinin	9
the	0
T	7
cells	8
exhibit	0
the	0
receptor	0
within	0
24	0
h	0
,	0
and	0
this	0
expression	0
is	0
blocked	0
by	0
cycloheximide	0
.	0

The	0
receptor	0
in	0
activated	7
T	8
lymphocytes	8
has	0
a	0
sedimentation	0
coefficient	0
of	0
3.7S	0
and	0
a	0
high	0
affinity	0
(	0
Kd	0
0.10	0
nM	0
)	0
for	0
the	0
ligand	0
.	0

Effects	0
of	0
chronic	0
glucocorticoid	0
excess	0
in	0
man	0
on	0
insulin	0
binding	0
to	0
circulating	7
cells	8
:	0
differences	0
between	0
endogenous	0
and	0
exogenous	0
hypercorticism	0
.	0

We	0
measured	0
[	0
125I	0
]	0
insulin	0
binding	0
to	0
circulating	7
monocytes	8
or	8
erythrocytes	8
from	0
16	0
patients	0
with	0
chronic	0
glucocorticoid	0
excess	0
,	0
9	0
chronically	0
treated	0
with	0
prednisone	0
and	0
7	0
with	0
adrenocortical	0
hyperfunction	0
.	0

With	0
monocytes	7
,	0
[	0
125I	0
]	0
insulin	0
binding	0
was	0
iincreased	0
in	0
all	0
patients	0
.	0

Analysis	0
of	0
binding	0
data	0
indicated	0
that	0
increased	0
binding	0
in	0
patients	0
treated	0
with	0
prednisone	0
was	0
due	0
to	0
an	0
ncrease	0
in	0
receptor	0
concentration	0
,	0
whereas	0
in	0
patients	0
with	0
adrenocortical	0
hyperfunction	0
,	0
it	0
was	0
due	0
to	0
an	0
increase	0
in	0
receptor	0
affinity	0
.	0

With	0
erythrocytes	0
from	0
patients	0
with	0
adrenocortical	0
hyperfunction	0
there	0
was	0
an	0
increase	0
in	0
receptor	0
affinity	0
and	0
a	0
decrease	0
in	0
receptor	0
concentration	0
,	0
so	0
that	0
the	0
binding	0
of	0
[	0
125I	0
]	0
insulin	0
was	0
normal	0
.	0

The	0
disparity	0
of	0
results	0
between	0
endogenous	0
and	0
exogenous	0
hypercorticism	0
,	0
between	0
the	0
two	0
cell	0
types	0
,	0
and	0
between	0
the	0
present	0
studies	0
and	0
previous	0
studies	0
suggest	0
that	0
the	0
effects	0
of	0
glucocorticoid	0
excess	0
on	0
the	0
insulin	9
receptor	10
are	0
extremely	0
complex	0
and	0
wide-ranging	0
and	0
that	0
in	0
this	0
condition	0
,	0
extrapolations	0
in	0
humans	0
from	0
data	0
with	0
circulating	7
cells	8
to	0
liver	0
and	0
muscle	0
may	0
not	0
be	0
appropriate	0
.	0

Reduced	0
level	0
of	0
cellular	9
glucocorticoid	10
receptors	10
in	0
patients	0
with	0
anorexia	0
nervosa	0
.	0

Specific	0
glucocorticoid	9
receptors	10
were	0
measured	0
in	0
circulating	0
mononuclear	7
leukocytes	8
from	0
12	0
patients	0
with	0
anorexia	0
nervosa	0
and	0
21	0
healthy	0
control	0
subjects	0
.	0

Cells	0
from	0
patients	0
were	0
found	0
to	0
contain	0
a	0
significantly	0
(	0
p	0
less	0
than	0
0.01	0
)	0
lower	0
level	0
of	0
glucocorticoid	9
receptor	10
(	0
3830	0
+/-	0
210	0
sites/cell	0
,	0
mean	0
+/-	0
SE	0
)	0
than	0
those	0
from	0
controls	0
(	0
4930	0
+/-	0
250	0
sites/cell	0
)	0
.	0

A	0
partial	0
glucocorticoid	9
receptor	10
defect	0
may	0
well	0
explain	0
the	0
abnormal	0
cortisol	0
metabolism	0
and	0
glucocorticoid	0
resistance	0
commonly	0
found	0
in	0
patients	0
with	0
anorexia	0
nervosa	0
.	0

Regulation	0
of	0
the	0
glucocorticoid	9
receptor	10
in	0
human	7
lymphocytes	8
.	0

The	0
presence	0
of	0
a	0
glucocorticoid	9
receptor	10
in	0
human	7
lymphocytes	8
is	0
well	0
established	0
,	0
but	0
factors	0
affecting	0
its	0
regulation	0
have	0
not	0
been	0
described	0
.	0

Using	0
a	0
competitive	0
binding	0
whole	0
cell	0
assay	0
,	0
we	0
have	0
examined	0
the	0
binding	0
of	0
[	0
3H	0
]	0
-dexamethasone	0
at	0
24	0
and	0
37	0
degrees	0
C	0
in	0
untreated	0
normal	0
subjects	0
and	0
in	0
healthy	0
subjects	0
taking	0
various	0
glucocorticoid	0
preparations	0
.	0

At	0
24	0
degrees	0
C	0
normal	7
human	8
lymphocytes	8
had	0
6000	0
binding	0
sites/cell	0
and	0
a	0
dissociation	0
constant	0
of	0
4	0
x	0
10	0
(	0
-9	0
)	0
M	0
.	0

The	0
administration	0
of	0
1	0
mg	0
of	0
dexamethasone	0
,	0
5	0
mg	0
of	0
prednisone	0
,	0
and	0
37.5	0
mg	0
of	0
cortisone	0
acetate	0
resulted	0
in	0
a	0
30	0
%	0
decrease	0
in	0
binding	0
sites	0
after	0
1	0
week	0
with	0
no	0
change	0
in	0
binding	0
affinity	0
.	0

No	0
changes	0
in	0
the	0
number	0
of	0
binding	0
sites	0
was	0
noted	0
before	0
1	0
week	0
and	0
the	0
diminished	0
number	0
persisted	0
for	0
1	0
week	0
after	0
discontinuation	0
of	0
glucocorticoid	0
treatment	0
.	0

Lymphocytes	7
from	0
hospitalized	0
patients	0
taking	0
40-60	0
mg	0
of	0
dexamethasone	0
daily	0
demonstrated	0
the	0
same	0
change	0
in	0
number	0
of	0
binding	0
sites	0
that	0
was	0
seen	0
in	0
normal	0
subjects	0
taking	0
1	0
mg	0
of	0
dexamethasone	0
.	0

When	0
binding	0
assays	0
were	0
carried	0
out	0
at	0
physiologic	0
temperature	0
there	0
was	0
the	0
same	0
decrease	0
in	0
number	0
of	0
binding	0
sites	0
after	0
dexamethasone	0
administration	0
,	0
and	0
in	0
addition	0
,	0
there	0
was	0
a	0
two-fold	0
increase	0
in	0
binding	0
affinity	0
.	0

Glucocorticoid	0
administration	0
results	0
in	0
a	0
time-dependent	0
decrease	0
in	0
the	0
number	0
of	0
lymphocyte	0
glucocorticoid	0
binding	0
sites	0
that	0
is	0
independent	0
of	0
the	0
type	0
of	0
glucocorticoid	0
administered	0
.	0

This	0
is	0
the	0
first	0
in	0
vivo	0
demonstration	0
that	0
glucocorticoids	0
modulate	0
their	0
own	0
receptors	0
in	0
man	0
.	0

Immunoglobulin	0
localization	0
in	0
benign	0
and	0
malignant	0
lesions	0
of	0
the	0
human	0
mammary	0
gland	0
.	0

Using	0
direct	0
imunofluorescence	0
,	0
lesions	0
from	0
266	0
human	0
breast	0
specimens	0
were	0
studied	0
for	0
the	0
presence	0
of	0
IgA	0
,	0
IgM	0
,	0
or	0
IgG	0
localization	0
.	0

The	0
lesions	0
included	0
benign	0
elements	0
from	0
66	0
subcutaneous	0
mastectomy	0
specimens	0
in	0
which	0
the	0
absence	0
of	0
simultaneous	0
breast	0
malignancy	0
was	0
documented	0
,	0
primary	0
breast	0
carcinomas	0
from	0
153	0
mastectomy	0
specimens	0
,	0
and	0
47	0
biopsies	0
containing	0
metastatic	0
breast	0
cancer	0
.	0

A	0
statistically	0
significant	0
association	0
of	0
IgA	9
and	0
IgM	9
with	0
benign	0
lesions	0
was	0
contrasted	0
to	0
the	0
association	0
of	0
IgG	9
with	0
malignant	0
lesions	0
.	0

In	0
both	0
primary	0
and	0
metastatic	0
lesions	0
,	0
IgG	9
localization	0
was	0
associated	0
with	0
estrogen-receptor-poor	0
primary	0
cancers	0
as	0
compared	0
with	0
estrogen-receptor-rich	0
primary	0
cancers	0
.	0

Among	0
primary	0
breast	0
cancer	0
patients	0
,	0
IgG	9
localization	0
in	0
the	0
tumor	0
correlated	0
with	0
relative	0
lymphopenia	0
.	0

A	0
shorter	0
disease-free	0
interval	0
was	0
noted	0
in	0
association	0
with	0
IgG	9
localization	0
among	0
the	0
metastatic	0
breast	0
lesions	0
.	0

No	0
statistically	0
significant	0
association	0
between	0
stage	0
of	0
disease	0
and	0
immunoglobulin	0
presence	0
was	0
demonstrable	0
.	0

Moderate-to-severe	0
intraductal	0
epithelial	0
hyperplasias	0
were	0
more	0
often	0
associated	0
with	0
immunoglobulin	9
G	10
localization	0
that	0
were	0
other	0
benign	0
lesions	0

Correlation	0
of	0
steroid	9
receptors	10
with	0
histologic	0
differentiation	0
in	0
mammary	0
carcinoma	0
.	0

A	0
Singapore	0
experience	0
.	0

Cancer	0
of	0
the	0
breast	0
is	0
the	0
most	0
common	0
tumor	0
in	0
females	0
in	0
Singapore	0
,	0
with	0
the	0
rate	0
of	0
20.7	0
per	0
100	0
,	0
000	0
per	0
year	0
(	0
1977	0
estimate	0
)	0
,	0
which	0
is	0
predicted	0
to	0
increase	0
to	0
29.8	0
per	0
100	0
,	0
000	0
women	0
per	0
year	0
by	0
1995	0
.	0

A	0
detailed	0
histopathologic	0
review	0
of	0
50	0
primary	0
breast	0
cancer	0
tumors	0
analyzed	0
for	0
estrogen	9
receptor	10
(	0
ER	9
)	0
level	0
was	0
carried	0
out	0
and	0
a	0
variety	0
of	0
morphologic	0
features	0
correlated	0
with	0
ER	9
results	0
to	0
identify	0
any	0
factors	0
that	0
will	0
improve	0
the	0
management	0
and	0
prognosis	0
for	0
breast	0
cancer	0
.	0

Cytosol	0
was	0
incubated	0
with	0
3H-estradiol	0
in	0
the	0
presence	0
and	0
absence	0
of	0
cold	0
diethylstilbestrol	0
,	0
and	0
bound	0
and	0
free	0
hormone	0
were	0
separated	0
by	0
Dextran-coated	0
charcoal	0
method	0
.	0

Tumors	0
binding	0
more	0
than	0
5	0
fmol/mg	0
cytosol	9
protein	10
were	0
classified	0
as	0
ER	9
-positive	0
.	0

Progesterone	9
receptor	10
(	0
PR	9
)	0
level	0
was	0
analyzed	0
in	0
some	0
specimens	0
with	0
the	0
use	0
of	0
a	0
similar	0
method	0
.	0

Most	0
of	0
the	0
patients	0
were	0
Chinese	0
(	0
90	0
%	0
)	0
.	0

Three	0
patients	0
were	0
Malays	0
,	0
one	0
was	0
Indian	0
,	0
and	0
one	0
was	0
European	0
in	0
this	0
series	0
.	0

Results	0
indicated	0
that	0
there	0
was	0
strong	0
correlation	0
between	0
ER	9
level	0
,	0
age	0
,	0
and	0
histologic	0
grade	0
of	0
the	0
tumors	0
.	0

No	0
correlation	0
existed	0
between	0
absence	0
or	0
presence	0
of	0
lymph	0
node	0
metastases	0
and	0
ER	9
.	0

Although	0
there	0
was	0
a	0
trend	0
for	0
ER	9
-positive	0
tumors	0
to	0
have	0
a	0
low-grade	0
lymphocytic	0
infiltration	0
,	0
the	0
difference	0
was	0
not	0
statistically	0
significant	0
.	0

Mononuclear	7
cells	8
infiltrating	0
human	0
mammary	0
carcinomas	0
:	0
immunohistochemical	0
analysis	0
with	0
monoclonal	9
antibodies	10
.	0

Breast	0
carcinomas	0
were	0
examined	0
by	0
the	0
immunoperoxidase	0
technique	0
using	0
antisera	0
specific	0
for	0
lymphocyte	7
subsets	8
,	0
monocytes	7
,	0
NK	7
cells	8
and	0
major	9
histocompatibility	10
antigens	10
(	0
HLA-A	9
,	0
-B	9
,	0
-C	0
;	0
Ia-like	9
)	0
.	0

Sixty-four	0
per	0
cent	0
of	0
the	0
patients	0
had	0
a	0
moderate	0
or	0
strong	0
mononuclear	0
cell	0
infiltration	0
,	0
77	0
%	0
of	0
the	0
patients	0
without	0
mononuclear	7
cell	8
infiltration	0
had	0
receptors	0
for	0
estrogens	0
as	0
compared	0
to	0
51	0
%	0
of	0
the	0
patients	0
with	0
infiltration	0
.	0

The	0
majority	0
of	0
the	0
infiltrating	7
mononuclear	8
cells	8
were	0
T	7
cells	8
;	0
generally	0
the	0
OKT8	5
cells	6
were	0
predominant	0
.	0

The	0
Leu	0
3A/OKT8	0
cell	0
ratio	0
was	0
not	0
related	0
to	0
histological	0
type	0
,	0
tumor	0
size	0
,	0
age	0
of	0
the	0
patient	0
or	0
presence	0
of	0
metastases	0
.	0

Some	0
of	0
the	0
T	0
cells	0
had	0
the	0
Ia	9
antigen	10
and	0
were	0
thus	0
probably	0
activated	0
.	0

The	0
B	7
cells	8
were	0
either	0
absent	0
or	0
less	0
numerous	0
than	0
the	0
T	0
cells	0
.	0

There	0
was	0
no	0
relation	0
between	0
their	0
distribution	0
and	0
the	0
various	0
parameters	0
studied	0
.	0

A	0
few	0
monocytes	7
were	0
heterogeneous	0
according	0
to	0
their	0
markers	0
(	0
OKM	9
I	10
and	0
acid	0
phosphatase	0
)	0
.	0

In	0
6	0
cases	0
only	0
there	0
was	0
a	0
strong	0
infiltration	0
of	0
mononuclear	7
cells	8
positive	0
for	0
acid	9
phosphatase	10
.	0

The	0
number	0
of	0
the	0
natural	7
killer	8
cells	8
was	0
also	0
low	0
.	0

Only	0
a	0
few	0
mononuclear	0
infiltrating	0
cells	0
had	0
receptors	0
for	0
transferrin	0
.	0

There	0
was	0
a	0
positive	0
correlation	0
between	0
the	0
inflammatory	0
infiltration	0
and	0
the	0
presence	0
of	0
HLA	9
class-I	10
antigens	10
on	0
tumor	7
cell	8
s	0
.	0

Some	0
of	0
the	0
antisera	0
specific	0
for	0
lymphocyte	7
subsets	8
also	0
stained	0
the	0
breast	7
carcinoma	8
cells	8
.	0

The	0
great	0
variations	0
in	0
the	0
subsets	0
of	0
mononuclear	7
cells	8
in	0
breast	0
carcinomas	0
may	0
correspond	0
to	0
various	0
systems	0
of	0
defense	0
against	0
neoplasm	0
.	0

A	0
case	0
of	0
male	0
pseudohermaphroditism	0
with	0
normal	0
androgen	9
receptor	10
binding	0
and	0
47	0
,	0
XYY	0
karyotype	0
.	0

A	0
case	0
of	0
male	0
pseudohermaphroditism	0
with	0
47	0
,	0
XYY	0
karyotype	0
in	0
blood	0
and	0
cutaneous	7
fibroblasts	8
is	0
described	0
.	0

The	0
plasma	0
testosterone	0
response	0
to	0
HCG	0
stimulation	0
was	0
slightly	0
below	0
the	0
normal	0
range	0
on	0
two	0
occasions	0
suggesting	0
a	0
deficit	0
of	0
gonadal	0
function	0
.	0

A	0
study	0
of	0
the	0
receptors	0
for	0
dihydrotestosterone	0
in	0
fibroblasts	7
of	0
genital	0
and	0
nongenital	0
skin	0
showed	0
a	0
normal	0
concentration	0
of	0
receptors	0
in	0
genital	0
skin	0
;	0
5-alpha-reductase	9
activity	0
in	0
fibroblasts	7
of	0
the	0
genital	0
skin	0
was	0
low	0
,	0
but	0
the	0
plasma	0
relationship	0
testosterone/dihydrotestosterone	0
under	0
HCG	0
stimulation	0
was	0
normal	0
.	0

The	0
diagnostic	0
possibility	0
of	0
a	0
complete	0
testicular	0
feminization	0
syndrome	0
with	0
normal	0
receptors	0
for	0
dihydrotestosterone	0
is	0
commented	0
on	0
.	0

1	0
,	0
25-Dihydroxyvitamin	0
D3	0
inhibits	0
antigen-induced	0
T	7
cell	8
activation	0
.	0

The	0
proliferative	0
response	0
of	0
murine	7
spleen	8
and	8
thymus	8
cells	8
to	0
antigen	9
but	0
not	0
to	0
lectin	9
was	0
inhibited	0
by	0
the	0
active	0
metabolite	0
of	0
vitamin	0
D3	0
,	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
.	0

To	0
directly	0
examine	0
the	0
effect	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
on	0
T	7
cell	8
activation	0
in	0
the	0
absence	0
of	0
other	0
complicating	0
interactions	0
,	0
we	0
utilized	0
a	0
panel	0
of	0
cloned	0
Ia-restricted	5
T	6
cell	6
hybridomas	6
that	0
secrete	0
IL	9
2	10
on	0
activation	0
by	0
cloned	0
Ia-bearing	7
stimulator	8
cells	8
(	0
TA3	7
)	0
or	0
when	0
stimulated	0
by	0
mitogen	0
.	0

Physiologic	0
concentrations	0
of	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
(	0
0.01	0
to	0
0.1	0
nm	0
)	0
inhibited	0
the	0
antigen-induced	0
secretion	0
of	0
IL	0
2	0
by	0
several	0
of	0
these	0
T	5
cell	6
hybridomas	6
.	0

This	0
inhibition	0
was	0
dependent	0
on	0
the	0
concentration	0
of	0
the	0
free	0
hormone	0
and	0
could	0
be	0
overcome	0
by	0
increasing	0
the	0
number	0
of	0
Ia-bearing	5
stimulator	6
cells	6
used	0
.	0

Pretreatment	0
of	0
the	0
T	5
hybridoma	6
but	0
not	0
the	0
TA3	5
stimulator	6
cell	6
with	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
resulted	0
in	0
inhibition	0
of	0
activation	0
.	0

These	0
results	0
are	0
consistent	0
with	0
the	0
finding	0
that	0
specific	0
1	9
,	10
25-	10
(	10
OH	10
)	10
2D3	10
receptors	10
are	0
present	0
on	0
the	0
T	0
cell	0
hybridomas	0
but	0
are	0
lacking	0
in	0
TA3	5
cells	6
.	0

1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
failed	0
,	0
however	0
,	0
to	0
inhibit	0
the	0
activation	0
of	0
the	0
T	5
cell	6
hybridomas	6
by	0
lectin	9
or	0
by	0
an	0
anti-Thy-1	9
antibody	10
.	0

These	0
findings	0
suggest	0
that	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
may	0
be	0
interfering	0
with	0
early	0
events	0
of	0
antigen-induced	0
T	7
cell	8
activation	0
,	0
perhaps	0
by	0
hindering	0
T	7
cell	8
recognition	0
of	0
the	0
relevant	0
antigen	0
on	0
stimulator	0
cell	0
surfaces	0
.	0

This	0
system	0
should	0
prove	0
useful	0
in	0
studying	0
the	0
molecular	0
mechanisms	0
by	0
which	0
1	0
,	0
25-	0
(	0
OH	0
)	0
2D3	0
acts	0
to	0
inhibit	0
T	0
cell	0
activation	0
and	0
subsequent	0
IL	9
2	10
production	0
.	0

Glucocorticoid	9
receptors	10
and	0
steroid	0
sensitivity	0
in	0
normal	0
and	0
neoplastic	0
human	0
lymphoid	0
tissues	0
:	0
a	0
review	0
.	0

The	0
determination	0
of	0
estrogen	9
and	10
progesterone	10
receptors	10
in	0
breast	0
cancer	0
has	0
been	0
shown	0
to	0
be	0
useful	0
in	0
predicting	0
the	0
response	0
to	0
endocrine	0
therapy	0
.	0

Given	0
their	0
well-known	0
inhibitory	0
effects	0
on	0
lymphoid	0
tissue	0
,	0
glucocorticoids	0
have	0
been	0
used	0
widely	0
in	0
the	0
treatment	0
of	0
leukemia	0
.	0

Given	0
these	0
facts	0
,	0
over	0
the	0
last	0
10	0
years	0
,	0
several	0
investigators	0
have	0
measured	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
normal	0
and	0
neoplastic	0
lymphoid	0
tissue	0
to	0
see	0
whether	0
their	0
number	0
correlated	0
with	0
glucocorticoid	0
responsiveness	0
in	0
vitro	0
or	0
in	0
vivo	0
.	0

No	0
clear	0
correlation	0
could	0
be	0
established	0
between	0
the	0
level	0
of	0
glucocorticoid	9
receptor	10
and	0
the	0
in	0
vitro	0
action	0
of	0
steroids	0
in	0
normal	0
and	0
neoplastic	0
lymphoid	0
tissue	0
.	0

In	0
contrast	0
,	0
attempts	0
to	0
correlate	0
glucocorticoid	9
receptor	10
levels	0
in	0
acute	0
lymphocytic	0
leukemia	0
to	0
in	0
vivo	0
steroid	0
responsiveness	0
and	0
immunological	0
type	0
using	0
the	0
whole-cell-binding	0
assay	0
for	0
receptor	0
determination	0
and	0
selecting	0
the	0
patients	0
according	0
to	0
age	0
and	0
immunological	0
criteria	0
have	0
been	0
more	0
successful	0
.	0

[	0
Glucocorticoid	9
receptors	10
in	0
normal	7
human	8
lymphocytes	8
]	0

Glucocorticoid	7
(	8
GC	8
)	8
receptors	8
were	0
studied	0
in	0
intact	0
lymphocytes	7
from	0
11	0
donors	0
.	0

GC	0
binding	0
parameters	0
were	0
found	0
to	0
be	0
highly	0
reproducible	0
in	0
repeated	0
experiments	0
with	0
lymphocytes	7
.	0

It	0
was	0
shown	0
that	0
GC	9
receptors	10
in	0
donors	0
'	0
lymphocytes	7
could	0
be	0
distributed	0
into	0
two	0
different	0
classes	0
similarly	0
to	0
the	0
pattern	0
seen	0
in	0
skin	7
fibroblasts	8
.	0

Human	7
lymphocytes	8
are	0
an	0
adequate	0
object	0
for	0
studying	0
genetically	0
determined	0
variability	0
of	0
GC	9
receptors	10
and	0
its	0
clinical	0
importance	0
.	0

Specific	0
estrogen	9
binding	10
sites	10
in	0
human	7
lymphoid	8
cells	8
and	0
thymic	7
cells	8
.	0

The	0
binding	0
of	0
estrogen	0
in	0
preparations	0
of	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
,	8
as	0
well	0
as	0
by	0
splenic	7
and	8
thymic	8
cells	8
is	0
demonstrated	0
by	0
three	0
different	0
approaches	0
(	0
Dextran-coated	0
charcoal	0
method	0
,	0
whole	0
cell	0
assay	0
,	0
and	0
gel	0
filtration	0
on	0
a	0
sepharose	0
4B	0
column	0
)	0
.	0

Scatchard	0
's	0
analysis	0
of	0
[	0
3H	0
]	0
-moxestrol	0
(	0
R2858	0
)	0
and	0
[	0
3H	0
]	0
-estradiol	0
binding	0
proves	0
the	0
existence	0
of	0
a	0
single	0
class	0
of	0
receptor	9
sites	10
having	0
a	0
dissociation	0
constant	0
of	0
0.18-2.4	0
X	0
10	0
(	0
-9	0
)	0
M	0
.	0

Physicochemical	0
properties	0
of	0
the	0
binder	0
,	0
including	0
binding	0
capacity	0
and	0
steroid	0
specificity	0
,	0
are	0
quite	0
similar	0
to	0
those	0
reported	0
for	0
the	0
thymus	0
of	0
small	0
mammalian	0
species	0
or	0
human	0
thymoma	0
.	0

Administration	0
of	0
fibroblast	9
interferon	10
to	0
patients	0
with	0
advanced	0
breast	0
cancer	0
:	0
possible	0
effects	0
on	0
skin	0
metastasis	0
and	0
on	0
hormone	9
receptors	10
.	0

Eleven	0
patients	0
with	0
metastasized	0
breast	0
cancer	0
received	0
8	0
intramuscular	0
injections	0
of	0
6	0
x	0
10	0
(	0
6	0
)	0
units	0
of	0
human	9
fibroblast	10
interferon	10
over	0
a	0
period	0
of	0
40	0
days	0
.	0

The	0
injections	0
did	0
not	0
cause	0
local	0
irritation	0
or	0
inflammation	0
.	0

Fever	0
occurred	0
in	0
only	0
1	0
of	0
the	0
11	0
patients	0
.	0

Although	0
several	0
types	0
of	0
metastases	0
were	0
monitored	0
,	0
only	0
skin	0
nodules	0
consistently	0
(	0
10	0
out	0
of	0
11	0
patients	0
)	0
exhibited	0
changes	0
that	0
were	0
suggestive	0
of	0
a	0
therapeutic	0
effect	0
of	0
the	0
treatment	0
regimen	0
:	0
either	0
a	0
simple	0
decrease	0
in	0
size	0
of	0
some	0
nodules	0
or	0
central	0
necrosis	0
accompanied	0
by	0
an	0
inflammatory	0
reaction	0
.	0

NK-activity	0
of	0
peripheral	7
blood	8
leukocytes	8
was	0
significantly	0
increased	0
after	0
administration	0
of	0
the	0
first	0
dose	0
;	0
the	0
effect	0
of	0
subsequent	0
injections	0
was	0
less	0
clear	0
.	0

Receptors	0
for	0
estrogens	0
and	0
progestogens	0
were	0
increased	0
in	0
the	0
tumor	0
biopsies	0
of	0
2	0
out	0
of	0
2	0
and	0
5	0
out	0
of	0
6	0
patients	0
tested	0
respectively	0
.	0

Decreased	0
glucocorticoid	9
receptor	10
binding	0
in	0
adrenal	0
insufficiency	0
.	0

To	0
examine	0
the	0
effect	0
of	0
glucocorticoid	0
deficiency	0
on	0
the	0
glucocorticoid	9
receptor	10
,	0
we	0
examine	0
the	0
binding	0
of	0
[	0
3H	0
]	0
dexamethasone	0
to	0
lymphocytes	7
in	0
normal	0
subjects	0
and	0
patients	0
with	0
adrenal	0
insufficiency	0
before	0
and	0
after	0
glucocorticoid	0
replacement	0
therapy	0
.	0

Using	0
a	0
whole	0
cell	0
competitive	0
binding	0
assay	0
,	0
normal	7
human	8
lymphocytes	8
had	0
5977	0
+/-	0
1487	0
(	0
mean	0
+/-	0
SD	0
)	0
binding	0
sites/cell	0
and	0
a	0
dissociation	0
constant	0
of	0
10	0
+/-	0
2	0
nM	0
.	0

Lymphocytes	7
from	0
patients	0
with	0
untreated	0
adrenal	0
insufficiency	0
had	0
fewer	0
binding	9
sites	10
(	0
3364	0
+/-322	0
)	0
and	0
a	0
2-fold	0
increase	0
in	0
binding	0
affinity	0
(	0
5.4	0
+/-	0
0.9	0
mM	0
)	0
.	0

The	0
administration	0
of	0
conventional	0
replacement	0
doses	0
of	0
cortisone	0
acetate	0
for	0
6	0
months	0
caused	0
no	0
change	0
in	0
receptor	0
number	0
,	0
but	0
was	0
associated	0
with	0
a	0
decrease	0
in	0
binding	0
affinity	0
toward	0
normal	0
.	0

After	0
long	0
term	0
glucocorticoid	0
replacement	0
therapy	0
,	0
binding	0
parameters	0
were	0
similar	0
to	0
those	0
in	0
patients	0
before	0
treatment	0
.	0

The	0
physiological	0
implications	0
of	0
the	0
decreased	0
receptor	0
number	0
and	0
increased	0
binding	0
affinity	0
in	0
adrenal	0
insufficiency	0
remain	0
to	0
be	0
elucidated	0
.	0

Glucocorticoid	9
receptor	10
concentrations	0
and	0
terminal	0
transferase	9
activity	0
as	0
indicators	0
of	0
prognosis	0
in	0
acute	0
non-lymphocytic	0
leukaemia	0
.	0

Activity	0
of	0
terminal	9
deoxynucleotidyl	10
transferase	10
(	0
TdT	9
)	0
,	0
adenosine	9
deaminase	10
,	0
and	0
5'nucleotidase	9
and	0
the	0
cellular	0
concentration	0
of	0
glucocorticoid	9
(	10
dexamethasone	10
)	10
receptor	10
were	0
determined	0
in	0
25	0
patients	0
with	0
acute	0
non-lymphocytic	0
leukaemia	0
.	0

All	0
patients	0
were	0
treated	0
according	0
to	0
a	0
common	0
protocol	0
.	0

Increased	0
activity	0
of	0
TdT	9
(	0
greater	0
than	0
0.1	0
unit/microgram	0
DNA	0
)	0
was	0
found	0
in	0
11	0
patients	0
.	0

This	0
group	0
of	0
patients	0
was	0
shown	0
to	0
have	0
higher	0
remission	0
and	0
survival	0
rates	0
(	0
p	0
=	0
0.06	0
)	0
compared	0
with	0
patients	0
with	0
low	0
activity	0
of	0
TdT	0
.	0

The	0
glucocorticoid	9
receptor	10
concentration	0
of	0
the	0
leukaemic	7
blast	8
cells	8
ranged	0
from	0
0	0
to	0
0.94	0
fmol/microgram	0
DNA	0
.	0

Thirteen	0
patients	0
had	0
blast	7
cells	8
with	0
a	0
glucocorticoid	9
receptor	10
concentration	0
over	0
0.22	0
fmol/microgram	0
DNA	0
.	0

These	0
patients	0
had	0
significantly	0
increased	0
remission	0
and	0
survival	0
rates	0
(	0
p	0
=	0
0.006	0
)	0
compared	0
with	0
those	0
with	0
a	0
low	0
receptor	0
concentration	0
.	0

This	0
finding	0
can	0
not	0
be	0
explained	0
by	0
a	0
difference	0
in	0
sensitivity	0
to	0
glucocorticoids	0
since	0
these	0
were	0
not	0
used	0
as	0
therapeutic	0
agents	0
.	0

Adenosine	9
deaminase	10
and	0
5'nucleotidase	9
activities	0
both	0
varied	0
within	0
two	0
orders	0
of	0
magnitude	0
.	0

No	0
correlation	0
could	0
be	0
found	0
between	0
activities	0
of	0
these	0
enzymes	0
and	0
remission	0
or	0
survival	0
rate	0
.	0

These	0
results	0
show	0
that	0
measurements	0
of	0
TdT	9
activity	0
and	0
the	0
glucocorticoid	9
receptor	10
concentration	0
yield	0
valuable	0
prognostic	0
information	0
in	0
acute	0
non-lymphocytic	0
leukaemia	0

[	0
3H	0
]	0
cortivazol	0
:	0
a	0
unique	0
high	0
affinity	0
ligand	0
for	0
the	0
glucocorticoid	9
receptor	10
.	0

Cortivazol	0
(	0
CVZ	0
)	0
and	0
deacylcortivazol	0
(	0
DAC	0
)	0
are	0
pyrazolosteroids	0
with	0
potent	0
glucocorticoid	0
activity	0
.	0

In	0
previous	0
work	0
we	0
showed	0
that	0
DAC	0
is	0
40-fold	0
more	0
potent	0
than	0
dexamethasone	0
(	0
DEX	0
)	0
in	0
lysing	0
leukemic	7
lymphoblasts	8
.	0

To	0
assess	0
the	0
interaction	0
between	0
these	0
atypical	0
steroids	0
and	0
the	0
glucocorticoid	9
receptor	10
,	0
we	0
examined	0
the	0
binding	0
of	0
[	0
3H	0
]	0
CVZ	0
to	0
cytosol	0
from	0
glucocorticoid-sensitive	5
and	6
-resistant	6
variants	6
of	0
the	0
human	5
leukemic	6
cell	6
line	6
CEM	5
C7	6
.	0

In	0
glucocorticoid-sensitive	5
cells	6
[	0
3H	0
]	0
CVZ	0
causes	0
a	0
2-fold	0
induction	0
of	0
glutamine	9
synthetase	10
and	0
binds	0
to	0
a	0
protein	0
in	0
the	0
4.6	0
S	0
region	0
of	0
high	0
salt	0
sucrose	0
gradients	0
.	0

On	0
DEAE-cellulose	0
chromatography	0
,	0
[	9
3H	10
]	10
CVZ-receptor	10
complexes	10
show	0
a	0
shift	0
from	0
high	0
(	0
0.25	0
M	0
KP	0
)	0
to	0
low	0
salt	0
(	0
0.09	0
M	0
KP	0
)	0
eluting	0
forms	0
upon	0
activation	0
.	0

CVZ	0
competes	0
for	0
a	0
97	0
,	0
000-dalton	0
protein	0
labeled	0
by	0
[	0
3H	0
]	0
dexamethasone	0
mesylate	0
.	0

Scatchard	0
analysis	0
of	0
the	0
binding	0
of	0
[	0
3H	0
]	0
CVZ	0
in	0
glucocorticoid-sensitive	5
cells	6
revealed	0
a	0
curvilinear	0
plot	0
which	0
resolved	0
into	0
high	0
(	0
0.4	0
nM	0
)	0
and	0
low	0
(	0
11	0
nM	0
)	0
affinity	0
components	0
.	0

The	0
receptor	0
concentration	0
of	0
the	0
low	0
affinity	0
site	0
(	0
0.30	0
pmol/mg	0
protein	0
)	0
was	0
approximately	0
twice	0
that	0
of	0
the	0
high	9
affinity	10
site	10
(	0
0.14	0
pmol/mg	0
protein	0
)	0
.	0

Dissociation	0
experiments	0
with	0
dilution	0
and/or	0
excess	0
unlabeled	0
CVZ	0
supported	0
the	0
presence	0
of	0
independent	0
sites	0
.	0

In	0
contrast	0
,	0
the	0
binding	0
of	0
[	0
3H	0
]	0
DEX	0
to	0
C7	0
cytosol	0
revealed	0
a	0
single	0
class	0
of	0
binding	0
sites	0
(	0
Kd	0
=	0
1.9	0
nM	0
;	0
receptor	0
concentration	0
,	0
0.46	0
pmol/mg	0
protein	0
)	0
.	0

Examination	0
of	0
the	0
binding	0
of	0
[	0
3H	0
]	0
CVZ	0
using	0
10	0
(	0
-5	0
)	0
M	0
DEX	0
as	0
the	0
competing	0
ligand	0
showed	0
that	0
DEX	0
binds	0
only	0
to	0
the	0
low	0
affinity	0
site	0
detected	0
by	0
[	0
3H	0
]	0
CVZ	0
.	0

In	0
cytosol	0
from	0
a	0
glucocorticoid-resistant	5
cell	6
line	6
with	0
virtually	0
no	0
[	0
3H	0
]	0
DEX	0
binding	0
,	0
[	0
3H	0
]	0
CVZ	0
detected	0
a	0
single	0
high	9
affinity	10
binding	10
site	10
that	0
was	0
similar	0
in	0
dissociation	0
constant	0
(	0
0.8	0
nM	0
)	0
and	0
receptor	0
concentration	0
(	0
0.13	0
pmol/mg	0
protein	0
)	0
to	0
the	0
high	9
affinity	10
site	10
detected	0
in	0
the	0
glucocorticoid-sensitive	5
cell	6
line	6
C7	5
.	0

A	0
controlled	0
pore	0
glass	0
bead	0
assay	0
for	0
the	0
measurement	0
of	0
cytoplasmic	9
and	10
nuclear	10
glucocorticoid	10
receptors	10
.	0

An	0
assay	0
for	0
the	0
quantitation	0
of	0
cytoplasmic	9
and	10
nuclear	10
glucocorticoid	10
receptors	10
in	0
lymphoid	0
tissue	0
has	0
been	0
developed	0
using	0
controlled	0
pore	0
glass	0
(	0
CPG	0
)	0
beads	0
.	0

Soluble	0
receptor	9
--	10
3H-steroid	10
complex	10
(	0
cytosol	0
or	0
nuclear	0
extract	0
)	0
is	0
adsorbed	0
quantitatively	0
within	0
the	0
crevasses	0
of	0
porous	0
glass	0
beads	0
.	0

Excess	0
labeled	0
steroid	0
as	0
well	0
as	0
most	0
non-specifically	0
bound	0
steroid	0
is	0
easily	0
washed	0
away	0
,	0
leaving	0
the	0
hormone-receptor	9
complex	10
retained	0
by	0
the	0
beads	0
.	0

Bound	0
3H-steroid	0
is	0
eluted	0
with	0
ethanol	0
and	0
measured	0
for	0
radioactivity	0
.	0

This	0
procedure	0
which	0
is	0
simple	0
,	0
rapid	0
,	0
and	0
highly	0
reproducible	0
is	0
carried	0
out	0
using	0
frozen	0
samples	0
(	0
stable	0
for	0
many	0
months	0
)	0
containing	0
as	0
few	0
as	0
1	0
X	0
10	0
(	0
7	0
)	0
cells	0
.	0

A	0
comparison	0
of	0
the	0
CPG	0
assay	0
to	0
dextran	0
coated	0
charcoal	0
and	0
a	0
whole	0
cell	0
assay	0
demonstrates	0
that	0
CPG	0
and	0
dextran	0
coated	0
charcoal	0
give	0
equivalent	0
measurements	0
of	0
cytosolic	9
receptor	10
concentration	0
,	0
while	0
the	0
CPG	0
and	0
whole	0
cell	0
assays	0
provide	0
equivalent	0
values	0
for	0
total	0
receptor	0
content	0
.	0

Plasmacytoid	0
blast	0
crisis	0
in	0
B-cell	7
chronic	0
lymphocytic	0
leukemia	0
:	0
effect	0
of	0
estradiol	0
on	0
growth	0
and	0
differentiation	0
in	0
vitro	0
.	0

Evolution	0
of	0
a	0
case	0
of	0
chronic	0
lymphocytic	0
leukemia	0
(	0
CLL	0
)	0
into	0
blast	0
crisis	0
was	0
found	0
to	0
be	0
characterized	0
by	0
three	0
unusual	0
features	0
(	0
1	0
)	0
the	0
phenotype	0
of	0
the	0
emerging	7
blast	8
cells	8
was	0
that	0
of	0
pre-plasmacytoid	7
cells	8
as	0
shown	0
by	0
plasma	0
cell	0
morphology	0
and	0
an	0
immunological	0
phenotype	0
corresponding	0
partially	0
with	0
CLL-	7
or	8
intermediate	8
B-cells	8
,	0
partially	0
with	0
plasma	7
cells	8
(	0
terminal	9
transferase	10
-	0
,	0
common	0
acute	9
lymphocytic	10
leukemia	10
antigen	10
-	0
,	0
Ia+	9
,	0
surface	9
immunoglobulin	10
heavy	10
chains	10
-	0
,	0
surface	9
kappa	10
light	10
chains	10
+	0
,	0
intracytoplasmic	9
immunoglobulin	10
A+	10
and	10
G+	10
,	0
BA-1+	9
,	0
polyclonal	0
gammaglobulin	0
production	0
)	0
;	0
(	0
2	0
)	0
cytogenetic	0
analysis	0
of	0
spontaneous	0
metaphases	0
revealed	0
that	0
in	0
addition	0
to	0
the	0
typical	0
CLL	0
abnormality	0
,	0
trisomy	0
12	0
,	0
in	0
all	0
of	0
the	0
cells	0
,	0
an	0
additional	0
translocation	0
between	0
chromosomes	1
14	2
and	2
17	2
was	0
present	0
in	0
40	0
%	0
with	0
a	0
presumptive	0
breakpoint	0
on	0
chromosome	1
14	2
(	0
q12-3	0
)	0
never	0
described	0
before	0
(	0
commonly	0
q32	0
)	0
and	0
(	0
3	0
)	0
the	0
progression	0
of	0
the	0
disease	0
was	0
associated	0
with	0
a	0
striking	0
increase	0
in	0
the	0
expression	0
by	0
the	0
transformed	7
cells	8
of	0
specific	0
binding	0
sites	0
for	0
estradiol	0
(	0
E2	0
)	0
due	0
to	0
an	0
actual	0
increase	0
in	0
total	0
cellular	9
receptor	10
proteins	10
and	0
not	0
to	0
a	0
change	0
in	0
receptor	0
affinity	0
for	0
E2	0
.	0

The	0
functional	0
status	0
of	0
the	0
steroid	9
receptors	10
was	0
confirmed	0
by	0
nuclear	0
transfer	0
of	0
the	0
cytoplasmic	9
hormone-receptor	10
complex	10
upon	0
temperature	0
activation	0
.	0

Since	0
the	0
rise	0
in	0
E2-receptor	9
display	0
paralleled	0
a	0
large	0
increase	0
in	0
the	0
proliferative	0
activity	0
of	0
the	0
cells	0
as	0
well	0
as	0
a	0
change	0
in	0
their	0
maturation	0
status	0
the	0
question	0
was	0
raised	0
as	0
to	0
whether	0
the	0
E2-receptor	9
should	0
be	0
considered	0
as	0
a	0
physiological	0
marker	0
of	0
growth	0
rate	0
or	0
of	0
cellular	0
differentiation	0
.	0

Exposure	0
of	0
the	0
patient	0
's	0
blast	7
cells	8
to	0
E2	0
in	0
vitro	0
resulted	0
in	0
cessation	0
of	0
cell	0
growth	0
following	0
at	0
least	0
one	0
mitosis	0
after	0
addition	0
of	0
the	0
inducer	0
as	0
seen	0
from	0
the	0
replacement	0
of	0
the	0
large	7
blasts	8
by	0
small	0
CLL-like	7
cells	8
without	0
definite	0
signs	0
of	0
alteration	0
of	0
the	0
differentiation	0
status	0
.	0

This	0
suggests	0
the	0
association	0
of	0
E2-receptor	9
expression	0
with	0
control	0
of	0
growth	0
rather	0
than	0
cell	0
maturation	0
.	0

Multiple	0
forms	0
and	0
fragments	0
of	0
cytosolic	9
glucocorticoid	10
receptors	10
from	0
human	7
leukemic	8
cells	8
and	0
normal	7
lymphocytes	8
.	0

Therapy	0
with	0
glucocorticoids	0
is	0
generally	0
more	0
effective	0
in	0
acute	0
lymphoblastic	0
leukemia	0
than	0
in	0
other	0
types	0
of	0
human	0
leukemia	0
.	0

Previous	0
studies	0
,	0
however	0
,	0
have	0
not	0
revealed	0
any	0
consistent	0
relationship	0
between	0
clinical	0
responsiveness	0
and	0
the	0
cellular	0
or	0
cytosolic	0
concentration	0
of	0
glucocorticoid-binding	9
sites	10
.	0

The	0
objectives	0
of	0
this	0
study	0
were	0
to	0
determine	0
whether	0
there	0
are	0
intrinsic	0
structural	0
differences	0
among	0
the	0
glucocorticoid	9
receptors	10
in	0
various	0
types	0
of	0
leukemic	7
cells	8
and	0
normal	7
lymphocytes	8
and	0
to	0
investigate	0
the	0
role	0
of	0
endogenous	9
peptidases	10
in	0
receptor	0
degradation	0
.	0

Cytosols	0
were	0
prepared	0
from	0
fresh	7
or	8
rapidly	8
frozen	8
leukocytes	8
from	0
6	0
healthy	0
adults	0
and	0
35	0
high-risk	0
leukemia	0
patients	0
(	0
median	0
white	0
blood	0
cell	0
count	0
,	0
150	0
,	0
000	0
cells/microliter	0
;	0
median	0
age	0
,	0
13	0
years	0
)	0
.	0

Receptors	0
were	0
labeled	0
with	0
[	0
3H	0
]	0
triamcinolone	0
acetonide	0
and	0
quantitated	0
by	0
charcoal-dextran	0
treatment	0
or	0
Sephadex	0
LH-20	0
chromatography	0
.	0

Mean	0
and	0
median	0
cytosolic	0
receptor	0
concentrations	0
in	0
12	0
acute	0
lymphoblastic	0
leukemia	0
specimens	0
lacking	0
the	0
standard	0
B-cell	0
or	0
T-cell	0
markers	0
(	0
``	0
null	0
cells	0
''	0
)	0
were	0
approximately	0
4-fold	0
higher	0
than	0
in	0
23	0
other	0
leukemic	7
cell	8
specimens	8
.	0

No	0
other	0
consistent	0
differences	0
in	0
receptor	0
content	0
were	0
observed	0
.	0

Agarose	0
filtration	0
and	0
ultracentrifugation	0
in	0
hypotonic	0
buffers	0
containing	0
20	0
mM	0
Na2MoO4	0
revealed	0
complexes	0
of	0
similar	0
size	0
and	0
shape	0
in	0
all	0
clinical	0
specimens	0
tested	0
and	0
two	0
established	0
leukemic	5
cell	6
lines	6
.	0

They	0
had	0
Stokes	0
radii	0
(	0
Rs	0
)	0
of	0
8.1	0
+/-	0
0.5	0
(	0
S.D.	0
)	0
nm	0
(	0
n	0
=	0
50	0
)	0
,	0
sedimentation	0
coefficients	0
of	0
9.5	0
+/-	0
0.3S	0
(	0
n	0
=	0
40	0
)	0
,	0
molecular	0
weights	0
of	0
approximately	0
330	0
,	0
000	0
,	0
and	0
axial	0
ratios	0
(	0
a/b	0
)	0
of	0
approximately	0
12	0
.	0

In	0
hypertonic	0
,	0
molybdate-free	0
buffer	0
,	0
these	0
oligomeric	9
complexes	10
were	0
dissociated	0
into	0
subunits	0
with	0
Rs	0
of	0
5.9	0
+/-	0
0.3	0
nm	0
(	0
n	0
=	0
12	0
)	0
and	0
a/b	0
of	0
11	0
to	0
12	0
,	0
as	0
observed	0
previously	0
for	0
other	0
receptors	0
.	0

Fragmentation	0
of	0
the	0
oligomer	9
and	0
the	0
subunit	9
was	0
evident	0
in	0
some	0
cytosols	0
.	0

High	0
activities	0
of	0
peptidases	9
of	0
various	0
specificities	0
were	0
detected	0
in	0
leukemic	0
cell	0
cytosols	0
,	0
as	0
in	0
other	0
cytosols	0
,	0
by	0
fluorometric	0
assays	0
with	0
derivatives	0
of	0
7-amino-4-methylcoumarin	0
.	0

Receptor	0
cleavage	0
by	0
these	0
and	0
other	0
endogenous	9
enzymes	10
may	0
account	0
for	0
previous	0
observations	0
of	0
``	0
abnormal	0
''	0
receptors	0
in	0
cytosols	0
from	0
some	0
leukemic	7
specimens	8
.	0

We	0
conclude	0
that	0
intrinsic	0
structural	0
defects	0
in	0
the	0
receptors	0
are	0
unlikely	0
explanations	0
for	0
the	0
unresponsiveness	0
of	0
some	0
types	0
of	0
leukemia	0
to	0
steroid	0
therapy	0
.	0

Glucocorticoid	9
receptor	10
number	0
and	0
intracellular	0
water	0
space	0
.	0

In	0
order	0
to	0
elucidate	0
the	0
relationship	0
between	0
cell	0
water	0
content	0
and	0
number	0
of	0
glucocorticoid	9
receptors	10
,	0
eleven	0
normal	0
and	0
malignant	7
lymphoid	8
or	8
myelomonocytic	8
cell	8
types	8
originating	0
from	0
mouse	0
,	0
rat	0
and	0
man	0
were	0
investigated	0
.	0

The	0
cellular	0
water	0
space	0
was	0
measured	0
with	0
3H2O	0
,	0
and	0
glucocorticoid	9
receptor	10
number	0
was	0
measured	0
in	0
a	0
whole-cell	0
binding	0
assay	0
with	0
[	0
3H	0
]	0
dexamethasone	0
at	0
30	0
and	0
37	0
degrees	0
C	0
.	0

The	0
intracellular	0
water	0
phase	0
concentration	0
of	0
glucocorticoid	9
receptors	10
(	0
around	0
40	0
nmol/l	0
cell	0
water	0
)	0
,	0
and	0
the	0
dependence	0
of	0
receptor	0
affinity	0
on	0
temperature	0
were	0
similar	0
in	0
normal	7
and	8
malignant	8
rodent	8
and	8
human	8
cells	8
.	0

It	0
is	0
concluded	0
that	0
comparisons	0
of	0
glucocorticoid	9
receptor	10
levels	0
are	0
best	0
made	0
on	0
the	0
basis	0
of	0
intracellular	9
receptor	10
concentrations	0
.	0

Covalent	0
labeling	0
of	0
rat	7
thymocyte	8
and	0
human	9
lymphoid	10
glucocorticoid	10
receptor	10
.	0

Lymphoid	7
cells	8
contain	0
specific	0
receptors	9
for	0
glucocorticoids	0
.	0

We	0
have	0
used	0
[	0
3H	0
]	0
dexamethasone-21-mesylate	0
to	0
label	0
covalently	0
glucocorticoid	9
receptors	10
in	0
rat	7
thymic	8
lymphocytes	8
and	0
in	0
neoplastic	7
cells	8
obtained	0
from	0
patients	0
with	0
acute	0
lymphoblastic	0
leukemia	0
and	0
malignant	0
lymphoma	0
.	0

The	0
covalently	0
labeled	0
glucocorticoid	9
receptors	10
were	0
identified	0
by	0
polyacrylamide	0
gel	0
electrophoresis	0
(	0
in	0
the	0
presence	0
of	0
0.1	0
%	0
sodium	0
dodecyl	0
sulfate	0
)	0
.	0

In	0
cytosolic	0
fractions	0
prepared	0
from	0
rat	7
thymic	8
lymphocytes	8
,	0
[	0
3H	0
]	0
-dexamethasone-21-mesylate	0
labels	0
a	0
protein	0
(	0
Mr	0
approximately	0
equal	0
to	0
95	0
,	0
000	0
)	0
which	0
was	0
identified	0
as	0
the	0
glucocorticoid	9
receptor	10
by	0
the	0
following	0
criteria	0
:	0
(	0
a	0
)	0
labeling	0
of	0
this	0
moiety	0
is	0
inhibited	0
by	0
treatment	0
with	0
a	0
100-fold	0
molar	0
excess	0
of	0
glucocorticoids	0
,	0
such	0
as	0
dexamethasone	0
and	0
triamcinolone	0
acetonide	0
;	0
and	0
(	0
b	0
)	0
the	0
covalently	0
labeled	0
Mr	0
approximately	0
equal	0
to	0
95	0
,	0
000	0
protein	0
is	0
activated	0
(	0
by	0
heating	0
at	0
20	0
degrees	0
for	0
30	0
min	0
)	0
to	0
a	0
form	0
that	0
binds	0
to	0
DNA-cellulose	0
.	0

When	0
intact	7
thymocytes	8
are	0
treated	0
with	0
[	0
3H	0
]	0
dexamethasone-21-mesylate	0
,	0
an	0
Mr	0
approximately	0
equal	0
to	0
95	0
,	0
000	0
moiety	0
is	0
also	0
labeled	0
covalently	0
.	0

Approximately	0
35	0
%	0
of	0
the	0
glucocorticoid	9
receptors	10
can	0
be	0
labeled	0
covalently	0
when	0
intact	0
thymocytes	7
are	0
treated	0
with	0
100	0
nM	0
[	0
3H	0
]	0
dexamethasone-21-mesylate	0
for	0
30	0
min	0
at	0
4	0
degrees	0
.	0

Neoplastic	7
cells	8
from	0
acute	0
lymphoblastic	0
leukemia	0
and	0
malignant	0
lymphoma	0
were	0
treated	0
with	0
[	0
3H	0
]	0
dexamethasone-21-mesylate	0
.	0

In	0
all	0
samples	0
,	0
an	0
Mr	0
approximately	0
equal	0
to	0
95	0
,	0
000	0
moiety	0
was	0
labeled	0
covalently	0
;	0
labeling	0
was	0
inhibited	0
by	0
excess	0
glucocorticoid	0
.	0

Smaller	9
moieties	10
were	0
also	0
identified	0
by	0
competition	0
experiments	0
;	0
these	0
may	0
represent	0
proteolytic	9
fragments	10
of	0
the	0
Mr	0
approximately	0
equal	0
to	0
95	0
,	0
000	0
receptor	0
.	0

Thus	0
,	0
in	0
rat	7
and	8
human	8
lymphoid	8
cells	8
,	0
[	0
3H	0
]	0
dexamethasone-21-mesylate	0
can	0
be	0
used	0
to	0
label	0
covalently	0
the	0
glucocorticoid	9
receptor	10
.	0

The	0
association	0
of	0
cytosol	0
oestrogen	9
and	10
progesterone	10
receptors	10
with	0
histological	0
features	0
of	0
breast	0
cancer	0
and	0
early	0
recurrence	0
of	0
disease	0
.	0

Two	0
hundred	0
and	0
eighty-eight	0
primary	0
breast	0
tumours	0
were	0
examined	0
for	0
the	0
presence	0
or	0
absence	0
of	0
oestrogen	9
(	10
REc	10
)	10
and	10
progesterone	10
(	10
RPc	10
)	10
receptors	10
.	0

Analysis	0
has	0
shown	0
a	0
relative	0
interdependence	0
between	0
the	0
steroid	9
receptor	10
status	0
of	0
primary	0
breast	0
cancer	0
and	0
other	0
prognostic	0
variables	0
such	0
as	0
histological	0
grade	0
,	0
lymphocytic	0
infiltration	0
and	0
tumour	0
elastosis	0
.	0

There	0
were	0
significant	0
associations	0
between	0
epithelial	0
cellularity	0
,	0
stromal	0
fibrosis	0
and	0
the	0
value	0
of	0
REc	9
in	0
those	0
tumours	0
in	0
which	0
the	0
receptor	0
was	0
present	0
.	0

Cellularity	0
and	0
fibrosis	0
were	0
unrelated	0
to	0
the	0
presence	0
or	0
absence	0
of	0
oestrogen	9
receptor	10
.	0

By	0
contrast	0
,	0
neither	0
the	0
presence	0
or	0
absence	0
nor	0
the	0
value	0
of	0
RPc	9
could	0
be	0
related	0
to	0
cellularity	0
or	0
fibrosis	0
.	0

The	0
value	0
of	0
REc	9
and	0
RPc	9
analysis	0
as	0
an	0
indicator	0
of	0
prognosis	0
was	0
examined	0
in	0
a	0
sub-group	0
of	0
175	0
patients	0
receiving	0
no	0
additional	0
treatment	0
following	0
mastectomy	0
.	0

Overall	0
relapse-free	0
survival	0
(	0
RFS	0
)	0
was	0
no	0
different	0
for	0
those	0
patients	0
with	0
receptors	0
compared	0
to	0
those	0
without	0
them	0
(	0
REc	9
P	0
=	0
0.11	0
,	0
RPc	0
P	0
=	0
0.7	0
)	0
.	0

There	0
was	0
no	0
difference	0
in	0
RFS	0
of	0
receptor	0
positive	0
and	0
negative	0
tumours	0
when	0
the	0
axillary	0
node	0
status	0
was	0
taken	0
into	0
account	0
.	0

Clinical	0
implications	0
of	0
glucocorticoid	9
receptors	10
in	0
human	0
leukemia	0
.	0

Normal	7
lymphoid	8
cells	8
contain	0
glucocorticoid	9
receptor	10
.	0

A	0
variety	0
of	0
stimuli	0
that	0
activate	0
these	0
cells	0
also	0
induce	0
increases	0
in	0
receptor	0
concentration	0
.	0

Similar	0
glucocorticoid	9
receptors	10
can	0
be	0
detected	0
in	0
lymphoid	7
cells	8
from	0
patients	0
with	0
acute	0
lymphoblastic	0
leukemia	0
(	0
ALL	0
)	0
.	0

Absence	0
of	0
the	0
glucocorticoid	9
receptor	10
(	0
usually	0
found	0
in	0
treated	0
patients	0
)	0
predicts	0
lack	0
of	0
glucocorticoid	0
responsiveness	0
.	0

Furthermore	0
,	0
in	0
our	0
hands	0
,	0
glucocorticoid	9
receptor	10
levels	0
correlate	0
with	0
the	0
duration	0
of	0
complete	0
remission	0
in	0
ALL	0
(	0
though	0
not	0
in	0
other	0
forms	0
of	0
leukemia	0
)	0
.	0

This	0
association	0
is	0
independent	0
of	0
cell	0
type	0
,	0
age	0
,	0
sex	0
,	0
or	0
initial	0
leukocyte	7
count	0
.	0

The	0
level	0
of	0
receptor	0
shows	0
a	0
negative	0
correlation	0
with	0
increasing	0
aggressiveness	0
of	0
the	0
tumor	0
(	0
null-cell	0
leukemia	0
greater	0
than	0
T-cell	0
leukemia	0
greater	0
than	0
Burkitt	0
's	0
lymphoma	0
)	0
.	0

Corticosteroid-mediated	0
immunoregulation	0
in	0
man	0
.	0

Glucocorticoids	0
have	0
profound	0
and	0
complex	0
effects	0
on	0
the	0
human	0
immune	0
response	0
.	0

However	0
,	0
the	0
precise	0
mechanisms	0
of	0
the	0
corticosteroid-induced	0
immunoregulation	0
in	0
man	0
have	0
not	0
been	0
precisely	0
defined	0
.	0

Intracytoplasmic	9
corticosteroid-specific	10
receptors	10
appear	0
to	0
be	0
an	0
important	0
common	0
pathway	0
for	0
steroid-induced	0
changes	0
,	0
but	0
variations	0
of	0
receptor	0
parameters	0
do	0
not	0
account	0
for	0
the	0
multifaceted	0
effects	0
on	0
the	0
immune	0
system	0
.	0

Human	7
circulating	8
mononuclear	8
cells	8
redistribute	0
out	0
of	0
the	0
intravascular	0
compartment	0
following	0
treatment	0
with	0
corticosteroids	0
.	0

Although	0
certain	0
components	0
at	0
this	0
redistribution	0
phenomenon	0
have	0
been	0
well-characterized	0
,	0
the	0
importance	0
of	0
this	0
compartmental	0
cellular	0
shift	0
with	0
respect	0
to	0
the	0
mechanisms	0
of	0
corticosteroid-induced	0
immunoregulation	0
are	0
less	0
well-defined	0
.	0

Recent	0
observations	0
that	0
activated	7
lymphocytes	8
may	0
be	0
sensitive	0
to	0
the	0
lytic	0
effects	0
of	0
glucocorticoids	0
suggest	0
that	0
under	0
certain	0
situations	0
the	0
elimination	0
of	0
selected	0
subsets	0
of	0
cells	0
may	0
be	0
a	0
relevant	0
mechanism	0
of	0
corticosteroid-mediated	0
immunoregulation	0
in	0
man	0
.	0

Corticosteroid-mediated	0
effects	0
on	0
monocyte	7
function	0
may	0
be	0
an	0
important	0
mechanism	0
of	0
drug-induced	7
immunoregulation	8
in	0
monocyte-dependent	7
responses	8
.	0

In	0
some	0
experimental	0
conditions	0
,	0
corticosteroids	0
inhibit	0
Interleukin	9
1	10
production	0
by	0
monocytes	7
.	0

The	0
immunoregulatory	0
effects	0
of	0
corticosteroids	0
on	0
lymphocyte	7
immune	0
responses	0
are	0
complex	0
.	0

In	0
vitro	0
corticosteroids	0
appear	0
to	0
selectively	0
affect	0
early	0
immunoregulatory	0
events	0
as	0
opposed	0
to	0
altering	0
an	0
established	0
response	0
.	0

Multiple	0
sites	0
of	0
steroid-induced	0
modulations	0
of	0
human	7
B	8
cell	8
responses	0
have	0
been	0
defined	0
.	0

Human	5
lymphoid	6
cell	6
lines	6
and	0
glucocorticoids	0
:	0
II	0
.	0

Whole	0
cell	0
and	0
cytoplasmic	0
binding	0
properties	0
of	0
lymphoblastoid	5
,	6
leukaemia	6
and	6
lymphoma	6
lines	6
.	0

The	0
glucocorticoid	0
binding	0
properties	0
of	0
18	0
human	5
lymphoid	6
cell	6
lines	6
(	0
HLCL	5
)	0
have	0
been	0
investigated	0
.	0

The	0
specificity	0
of	0
steroid	0
binding	0
was	0
confirmed	0
with	0
various	0
glucocorticoid	0
agonists	0
and	0
antagonists	0
.	0

A	0
gradation	0
in	0
whole	0
cell	0
and	0
cytoplasmic	0
glucocorticoid	0
binding	0
capacity	0
was	0
observed	0
in	0
the	0
different	0
cell	0
line	0
types	0
:	0
lymphoblastoid	5
greater	0
than	0
lymphoma	5
greater	0
than	0
leukaemia	5
.	0

The	0
cytoplasmic	9
receptors	10
of	0
leukaemia	5
and	6
lymphoblastoid	6
lines	6
appeared	0
to	0
contain	0
both	0
proteinaceous	0
and	0
phospholipid	0
components	0
.	0

Cytoplasmic	9
steroid-receptor	10
complexes	10
exhibited	0
a	0
wide	0
range	0
of	0
sedimentation	0
coefficients	0
(	0
8.5-11.3S	0
)	0
in	0
low	0
ionic	0
strength	0
buffer	0
but	0
there	0
was	0
no	0
correlation	0
with	0
cell	0
line	0
type	0
or	0
glucocorticoid	0
sensitivity	0
.	0

Activation	0
of	0
these	0
complexes	0
by	0
heat	0
(	0
37	0
degrees	0
C	0
)	0
or	0
exposure	0
to	0
high	0
ionic	0
strength	0
buffer	0
(	0
0.3	0
M	0
NaCl	0
)	0
induced	0
nuclear	0
binding	0
of	0
steroid	0
but	0
only	0
complexes	0
in	0
high	0
ionic	0
strength	0
buffer	0
manifested	0
changes	0
in	0
sedimentation	0
coefficient	0
.	0

No	0
correlation	0
was	0
observed	0
between	0
the	0
level	0
or	0
nature	0
of	0
glucocorticoid	0
binding	0
and	0
the	0
cytolethal	0
or	0
cytostatic	0
responsiveness	0
of	0
HLCL	5
to	0
glucocorticoid	0
treatment	0
in	0
vitro	0
.	0

The	0
resistance	0
to	0
cytolethal	0
effects	0
can	0
not	0
be	0
ascribed	0
to	0
a	0
failure	0
of	0
cells	0
to	0
take	0
up	0
and	0
bind	0
steroid	0
or	0
to	0
significant	0
differences	0
in	0
the	0
molecular	0
species	0
of	0
cytoplasmic	9
receptors	10
present	0
.	0

The	0
molecular	0
mechanisms	0
by	0
which	0
glucocorticoids	0
achieve	0
cytolethal	0
responses	0
in	0
human	7
lymphoid	8
cells	8

CD28	9
-mediated	0
activation	0
in	0
CD45RA+	7
and	8
CD45RO+	8
T	8
cells	8
:	0
enhanced	0
levels	0
of	0
reactive	0
oxygen	0
intermediates	0
and	0
c-Rel	9
nuclear	0
translocation	0
in	0
CD45RA+	7
cells	8
.	0

We	0
have	0
analyzed	0
the	0
effect	0
of	0
complete	0
T	0
cell	0
activation	0
(	0
anti-CD3	9
plus	0
anti-CD28	9
)	0
on	0
the	0
activation	0
of	0
NF-kappaB	9
in	0
CD45RA+	7
(	8
naive	8
)	8
and	8
CD45RO+	8
(	8
memory/effector	8
)	8
T	8
cells	8
.	0

Long	0
exposure	0
(	0
24	0
h	0
)	0
induced	0
stronger	0
NF-kappaB	9
DNA	0
binding	0
in	0
CD45RA+	7
cells	8
than	0
in	0
CD45RO+	7
cells	8
.	0

Analysis	0
of	0
the	0
nuclear	9
c-Rel	10
protein	10
indicated	0
that	0
after	0
anti-CD3+anti-CD28	0
stimulation	0
the	0
level	0
of	0
c-Rel	9
was	0
higher	0
in	0
CD45RA+	7
cells	8
.	0

Analysis	0
of	0
the	0
cytoplasmic	0
inhibitor	0
IkappaBalpha	9
indicated	0
that	0
anti-CD3+anti-CD28	0
stimulation	0
induced	0
a	0
long-lasting	0
degradation	0
in	0
CD45RA+	7
cells	8
but	0
in	0
CD45RO+	7
cells	8
the	0
degradation	0
process	0
was	0
more	0
rapid	0
.	0

Because	0
the	0
CD28	0
costimulus	0
is	0
known	0
to	0
induce	0
the	0
production	0
of	0
reactive	0
oxygen	0
intermediates	0
(	0
ROIs	0
)	0
,	0
the	0
intracellular	0
ROI	0
levels	0
in	0
CD45RA+	7
and	8
CD45RO+	8
cells	8
were	0
compared	0
by	0
flow	0
cytometry	0
.	0

ROIs	0
were	0
produced	0
in	0
both	0
cell	0
types	0
,	0
but	0
more	0
strongly	0
in	0
CD45RA+	7
cells	8
.	0

The	0
data	0
presented	0
in	0
this	0
study	0
further	0
emphasize	0
the	0
differences	0
between	0
CD45RA+	7
and	8
CD45RO+	8
T	8
lymphocytes	8
in	0
ROI-dependent	0
signaling	0
pathways	0
.	0

Ikaros	9
in	0
hemopoietic	5
lineage	6
determination	0
and	0
homeostasis	0
.	0

Studies	0
on	0
the	0
molecular	0
mechanisms	0
that	0
control	0
hemopoietic	0
differentiation	0
have	0
focused	0
on	0
signaling	0
cascades	0
and	0
nuclear	0
effectors	0
that	0
drive	0
this	0
complex	0
developmental	0
system	0
in	0
a	0
regulated	0
fashion	0
.	0

Here	0
we	0
review	0
the	0
role	0
of	0
Ikaros	9
,	0
the	0
founding	0
member	0
of	0
a	0
unique	0
family	0
of	0
zinc	9
finger	10
transcription	10
factors	10
in	0
this	0
developmental	0
process	0
.	0

Studies	0
on	0
an	0
Ikaros	9
null	0
mutation	0
have	0
revealed	0
an	0
essential	0
role	0
for	0
this	0
factor	0
in	0
lymphoid	7
cell	8
fate	0
determination	0
and	0
at	0
subsequent	0
branch	0
points	0
of	0
the	0
T	7
cell	8
differentiation	0
pathway	0
.	0

Differences	0
in	0
the	0
phenotypes	0
of	0
a	0
null	0
and	0
a	0
dominant	0
negative	0
(	0
DN	0
)	0
Ikaros	0
mutation	0
provide	0
insight	0
into	0
a	0
regulatory	0
network	0
through	0
which	0
Ikaros	9
proteins	10
exert	0
their	0
effects	0
in	0
development	0
.	0

In	0
addition	0
a	0
comparative	0
analysis	0
of	0
the	0
hemopoietic	7
stem	8
cell	8
and	0
precursor	0
compartment	0
resulting	0
from	0
the	0
two	0
Ikaros	9
mutations	0
reveals	0
a	0
profound	0
yet	0
not	0
absolute	0
requirement	0
for	0
Ikaros	9
in	0
the	0
production	0
and	0
differentiation	0
of	0
these	0
populations	0
.	0

Overexpression	0
of	0
p65	0
and	0
c-Jun	0
substitutes	0
for	0
B7-1	0
costimulation	0
by	0
targeting	0
the	0
CD28RE	1
within	0
the	0
IL-2	1
promoter	2
.	0

The	0
role	0
of	0
Rel	9
and	0
activation	9
protein-1	10
(	0
AP-1	9
)	0
in	0
IL-2	1
promoter	2
activity	0
in	0
B7-1-	7
and	8
leukocyte	8
function-associated	8
Ag-3	8
(	8
LFA.	8
3	8
)	8
-costimulated	8
T	8
cells	8
has	0
been	0
evaluated	0
.	0

We	0
demonstrate	0
that	0
overexpression	0
of	0
c-Jun	9
but	0
not	0
c-Fos	9
increases	0
IL-2	1
promoter	2
activity	0
in	0
both	0
B7-1-	7
and	8
LFA-3-costimulated	8
Jurkat	8
T	8
cells	8
.	0

Cotransfection	0
of	0
both	0
c-Jun	0
and	0
c-Fos	0
substitutes	0
for	0
B7-1	0
costimulation	0
in	0
driving	0
an	0
activation	1
protein-1	2
response	2
element	2
but	0
not	0
for	0
the	0
IL-2	1
promoter	2
.	0

Overexpression	0
of	0
Rel	9
proteins	10
demonstrated	0
that	0
p65-expressing	5
Jurkat	6
cells	6
transcribed	0
equally	0
well	0
a	0
nuclear	1
factor	2
kappabeta	2
reporter	2
construct	2
when	0
costimulated	0
with	0
B7-1	9
or	0
LFA-3	9
,	0
but	0
transcription	0
of	0
IL-2	1
promoter	2
or	0
CD28	1
response	2
element	2
(	2
CD28RE	2
)	2
-driven	2
reporters	2
was	0
superior	0
in	0
B7-1-costimulated	5
cells	6
.	0

Combined	0
expression	0
of	0
c-Jun	9
and	0
p65	9
induced	0
vigorous	0
transcription	0
of	0
IL-2	1
promoter-	2
and	2
CD28RE-driven	2
reporter	2
constructs	2
in	0
both	0
LFA-3-	7
and	8
B7-1-costimulated	8
Jurkat	8
cells	8
.	0

Mutating	0
the	0
CD28RE	1
but	0
not	0
the	0
upstream	1
nuclear	2
factor	2
kappabeta-binding	2
site	2
in	0
the	0
IL-2	1
promoter	2
reduced	0
B7-1	9
-driven	0
transcription	0
>	0
90	0
%	0
.	0

The	0
results	0
implicates	0
a	0
major	0
role	0
of	0
the	0
CD28RE	1
in	0
the	0
integration	0
of	0
p65	9
/	0
c-Jun	9
-mediated	0
transcription	0
within	0
the	0
IL-2	1
promoter	2
.	0

We	0
suggest	0
that	0
the	0
transition	0
from	0
an	0
autocrine	0
LFA-3	9
-driven	0
immune	0
response	0
to	0
a	0
B7	0
--	0
induced	0
paracrine	0
immune	0
response	0
involves	0
the	0
activation	0
of	0
c-Jun	9
and	0
p65	9
,	0
which	0
target	0
the	0
CD28RE	1
region	0
of	0
the	0
IL-2	1
promoter	2
.	0

Defects	0
in	0
actin-cap	0
formation	0
in	0
Vav-deficient	0
mice	0
implicate	0
an	0
actin	0
requirement	0
for	0
lymphocyte	0
signal	0
transduction	0
.	0

BACKGROUND	0
:	0
Antigen-receptor	0
interactions	0
on	0
lymphocytes	7
result	0
in	0
local	0
clustering	0
of	0
actin	9
,	0
receptors	0
and	0
signaling	0
molecules	0
into	0
an	0
asymmetric	0
membrane	0
structure	0
termed	0
a	0
cap	0
.	0

Although	0
actin	0
polymerization	0
is	0
known	0
to	0
be	0
required	0
,	0
the	0
mechanisms	0
underlying	0
cap	0
formation	0
are	0
unclear	0
.	0

We	0
have	0
studied	0
the	0
events	0
underlying	0
cap	0
formation	0
using	0
mice	0
bearing	0
a	0
null	0
mutation	0
in	0
vav	1
(	0
vav	1
-/-	0
)	0
,	0
a	0
gene	0
that	0
encodes	0
a	0
guanine-nucleotide	9
exchange	10
factor	10
for	0
the	0
GTPase	9
Rac	10
.	0

RESULTS	0
:	0
Lymphocytes	7
from	0
vav	1
-/-	0
mice	0
failed	0
to	0
form	0
T-cell	0
receptor	0
caps	0
following	0
activation	0
and	0
had	0
a	0
defective	0
actin	0
cytoskeleton	0
.	0

The	0
vav-/-	7
T	8
cells	8
were	0
deficient	0
in	0
interleukin-2	0
(	0
IL-2	0
)	0
production	0
and	0
proliferation	0
,	0
and	0
the	0
peak	0
of	0
Ca2+	0
mobilization	0
was	0
reduced	0
although	0
of	0
normal	0
duration	0
.	0

Activation	0
of	0
Jun	9
N-terminal	10
kinase	10
or	0
stress-activated	9
kinase	10
(	0
JNK	9
or	0
SAPK	9
)	0
and	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
and	0
the	0
induction	0
of	0
the	0
transcription	9
factor	10
NF-ATc1	1
and	2
egr-1	2
genes	2
was	0
normal	0
.	0

Despite	0
the	0
reduced	0
Ca2+	0
mobilization	0
,	0
translocation	0
of	0
cytoplasmic	9
NF-ATc	10
to	0
the	0
nucleus	0
was	0
normal	0
,	0
reflecting	0
that	0
the	0
lower	0
levels	0
of	0
Ca2+	0
in	0
vav-/-	7
cells	8
were	0
still	0
sufficient	0
to	0
activate	0
calcineurin	9
.	0

Treatment	0
of	0
lymphocytes	7
with	0
cytochalasin	0
D	0
,	0
which	0
blocks	0
actin	0
polymerization	0
,	0
inhibited	0
cap	0
formation	0
and	0
produced	0
defects	0
in	0
signaling	0
and	0
IL-2	0
transcriptional	0
induction	0
in	0
response	0
to	0
antigen-receptor	0
signaling	0
that	0
were	0
nearly	0
identical	0
to	0
those	0
seen	0
in	0
vav-/-	7
cells	8
.	0

In	0
transfection	0
studies	0
,	0
either	0
constitutively	0
active	0
Vav	9
or	0
Rac	9
could	0
complement	0
constitutively	0
active	0
calcineurin	9
to	0
activate	0
NF-AT-dependent	0
transcription	0
.	0

CONCLUSIONS	0
:	0
These	0
results	0
indicate	0
that	0
Vav	9
is	0
required	0
for	0
cap	0
formation	0
in	0
lymphocytes	7
.	0

Furthermore	0
,	0
the	0
correlation	0
between	0
cap	0
formation	0
,	0
IL-2	0
production	0
and	0
proliferation	0
supports	0
the	0
hypothesis	0
that	0
an	0
actin-dependent	0
pathway	0
is	0
a	0
source	0
of	0
specialized	0
growth	0
regulatory	0
signals	0
.	0

CD14	9
-dependent	0
activation	0
of	0
human	7
endothelial	8
cells	8
by	0
Bacteroides	0
fragilis	0
outer	0
membrane	0
.	0

We	0
studied	0
the	0
capacity	0
of	0
isolated	0
Bacteriodes	0
fragilis	0
outer	0
membrane	0
,	0
B.	0
fragilis	0
NCTC9343	0
lipopolysaccharide	0
(	0
LPS	0
;	0
endotoxin	0
)	0
,	0
and	0
B.	0
fragilis	0
NCTC9343	0
capsular	0
polysaccharides	0
to	0
activate	0
human	0
umbilical	0
vein	0
endothelial	0
cell	0
(	0
HUVEC	0
)	0
monolayers	0
.	0

To	0
assess	0
HUVEC	0
activation	0
,	0
E-selectin	9
expression	0
was	0
measured	0
by	0
enzyme-linked	0
immunosorbent	0
assay	0
(	0
ELISA	0
)	0
,	0
Northern	0
blot	0
analysis	0
for	0
E-selectin-specific	3
mRNA	4
,	0
and	0
electrophoretic	0
gel	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
for	0
NF-kappa	9
B	10
,	0
a	0
transcription	9
factor	10
necessary	0
for	0
E-selectin	1
gene	2
activation	0
.	0

Exposure	0
of	0
HUVECs	7
to	0
B.	0
fragilis	0
outer	0
membrane	0
fractions	0
,	0
separated	0
from	0
other	0
components	0
of	0
the	0
B.	0
fragilis	0
cell	0
wall	0
by	0
isopycnic	0
,	0
sucrose	0
gradient	0
centrifugation	0
,	0
significantly	0
increased	0
surface	0
expression	0
of	0
E-selectin	9
and	0
induced	0
functional	0
endothelial	7
cell	8
-dependent	0
leukocyte	0
adhesion	0
.	0

B.	0
fragilis	0
outer	0
membranes	0
induced	0
translocation	0
of	0
NF-kappa	9
B	10
to	0
HUVEC	0
nuclei	0
and	0
accumulation	0
of	0
E-selectin	3
mRNA	4
in	0
HUVEC	0
cytoplasm	0
.	0

E-selectin	0
expression	0
induced	0
by	0
B.	0
fragilis	0
outer	0
membranes	0
was	0
not	0
blocked	0
by	0
polymixin	0
B	0
.	0

In	0
contrast	0
,	0
E-selectin	0
expression	0
induced	0
by	0
outer	0
membrane	0
fractions	0
purified	0
from	0
E.	0
coli	0
was	0
competitively	0
inhibited	0
by	0
polymixin	0
B	0
.	0

Neither	0
purified	0
B.	0
fragilis	0
LPS	0
,	0
a	0
prominent	0
constituent	0
of	0
the	0
outer	0
membrane	0
,	0
nor	0
purified	0
B.	0
fragilis	0
capsular	0
polysaccharides	0
induced	0
HUVEC	0
activation	0
.	0

Two	0
different	0
monoclonal	9
antibodies	10
directed	0
against	0
human	9
CD14	10
completely	0
inhibited	0
B.	0
fragilis	0
outer	0
membrane-induced	0
NF-kappa	9
B	10
activation	0
,	0
E-selectin	0
transcription	0
,	0
and	0
E-selectin	0
surface	0
expression	0
.	0

We	0
conclude	0
that	0
the	0
outer	0
membrane	0
component	0
of	0
the	0
B.	0
fragilis	0
cell	0
wall	0
contains	0
a	0
proinflammatory	0
factor	0
(	0
s	0
)	0
,	0
that	0
is	0
not	0
LPS	0
,	0
which	0
induces	0
human	7
endothelial	8
cell	8
activation	0
by	0
a	0
soluble	0
CD14	9
-dependent	0
mechanism	0
.	0

NF-kappaB	9
protects	0
HIV-1-infected	0
myeloid	7
cells	8
from	0
apoptosis	0
.	0

HIV-1	0
infection	0
of	0
primary	7
monocytic	8
cells	8
and	0
myeloid	5
cell	6
lines	6
results	0
in	0
sustained	0
NF-kappaB	0
activation	0
.	0

Recently	0
,	0
NF-kappaB	0
induction	0
has	0
been	0
shown	0
to	0
play	0
a	0
role	0
in	0
protecting	0
cells	0
from	0
programmed	0
cell	0
death	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
sought	0
to	0
investigate	0
whether	0
constitutive	0
NF-kappaB	9
activity	0
in	0
chronically	0
HIV-1-infected	0
promonocytic	5
U937	6
(	6
U9-IIIB	6
)	6
and	6
myeloblastic	6
PLB-985	6
(	6
PLB-IIIB	6
)	6
cells	6
affects	0
apoptotic	0
signaling	0
.	0

TNFalpha	9
and	0
cycloheximide	0
caused	0
infected	0
cells	0
to	0
undergo	0
apoptosis	0
more	0
rapidly	0
than	0
parental	5
U937	6
and	0
PLB-985	5
cells	6
.	0

Inhibition	0
of	0
TNFalpha	9
-induced	0
NF-kappaB	0
activation	0
using	0
the	0
antioxidant	0
N-acetylcysteine	0
(	0
NAC	0
)	0
resulted	0
in	0
increased	0
apoptosis	0
in	0
both	0
U937	5
and	6
U9-IIIB	6
cells	6
,	0
while	0
preactivation	0
of	0
NF-kappaB	9
with	0
the	0
non-apoptotic	9
inducer	10
IL-1beta	10
caused	0
a	0
relative	0
decrease	0
in	0
apoptosis	0
.	0

Inhibition	0
of	0
constitutive	0
NF-kappaB	9
activity	0
in	0
U9-IIIB	5
and	6
PLB-IIIB	6
cells	6
also	0
induced	0
apoptosis	0
,	0
suggesting	0
that	0
NF-kappaB	7
protects	8
cells	8
from	0
a	0
persistent	0
apoptotic	0
signal	0
.	0

TNFalpha	9
plus	0
NAC	0
treatment	0
resulted	0
in	0
a	0
marked	0
decrease	0
in	0
Bcl-2	9
protein	10
levels	0
in	0
HIV-1-infected	7
cells	8
,	0
coupled	0
with	0
an	0
increase	0
in	0
Bax	9
protein	10
compared	0
to	0
uninfected	0
cells	0
,	0
suggesting	0
that	0
the	0
difference	0
in	0
susceptibility	0
to	0
TNFalpha	9
-induced	0
apoptosis	0
may	0
relate	0
to	0
the	0
differences	0
in	0
relative	0
levels	0
of	0
Bcl-2	9
and	0
Bax	9
.	0

The	0
protective	0
role	0
of	0
NF-kappaB	9
in	0
blocking	0
TNFalpha-	0
and	0
HIV-1-induced	0
apoptosis	0
was	0
supported	0
by	0
studies	0
in	0
Jurkat	5
T	6
cells	6
engineered	0
to	0
express	0
IkappaB	9
alpha	10
repressor	10
mutants	10
(	0
TD-IkappaB	9
)	0
under	0
the	0
control	0
of	0
a	0
tetracycline-responsive	1
promoter	2
.	0

Cells	0
underwent	0
apoptosis	0
in	0
response	0
to	0
TNFalpha	9
only	0
when	0
NF-kappaB	0
activation	0
was	0
inhibited	0
by	0
TD-IkappaB	9
expression	0
.	0

As	0
was	0
observed	0
for	0
the	0
U9-IIIB	5
cells	6
,	0
TNFalpha	9
treatment	0
also	0
induced	0
a	0
marked	0
decrease	0
in	0
Bcl-2	9
protein	10
levels	0
in	0
TD-IkappaB	7
expressing	8
cells	8
.	0

These	0
experiments	0
demonstrate	0
that	0
apoptotic	0
signaling	0
is	0
perturbed	0
in	0
HIV-1-infected	0
U9-IIIB	5
cells	6
and	0
indicate	0
that	0
NF-kappaB	0
activation	0
may	0
play	0
an	0
additional	0
protective	0
role	0
against	0
HIV-1-induced	0
apoptosis	0
in	0
myeloid	7
cells	8
.	0

Human	7
normal	8
peripheral	8
blood	8
B-lymphocytes	8
are	0
deficient	0
in	0
DNA-dependent	0
protein	0
kinase	0
activity	0
due	0
to	0
the	0
expression	0
of	0
a	0
variant	0
form	0
of	0
the	0
Ku86	9
protein	10
.	0

The	0
heterodimeric	0
Ku	9
protein	10
,	0
which	0
comprises	0
a	0
86	9
kDa	10
(	10
Ku86	10
)	10
amd	0
a	0
70	9
kDa	10
(	10
Ku70	10
)	10
subunits	10
,	0
is	0
an	0
abundant	0
nuclear	9
DNA-binding	10
protein	10
which	0
binds	0
in	0
vitro	0
to	0
DNA	1
termini	2
without	0
sequence	0
specificity	0
.	0

Ku	9
is	0
the	0
DNA-targeting	9
component	10
of	0
the	0
large	0
catalytic	9
sub-unit	10
of	0
the	0
DNA-dependent	9
protein	10
kinase	10
complex	10
(	0
DNA-PK	9
[	10
CS	10
]	10
)	0
,	0
that	0
plays	0
a	0
critical	0
role	0
in	0
mammalian	0
double-strand	0
break	0
repair	0
and	0
lymphoid	0
V	0
(	0
D	0
)	0
J	0
recombination	0
.	0

By	0
using	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
we	0
demonstrated	0
that	0
in	0
addition	0
to	0
the	0
major	9
Ku	10
x	10
DNA	10
complex	10
usually	0
detected	0
in	0
cell	0
line	0
extracts	0
,	0
a	0
second	0
complex	0
with	0
faster	0
electrophoretic	0
mobility	0
was	0
observed	0
in	0
normal	0
peripheral	7
blood	8
lymphocytes	8
(	0
PBL	7
)	0
extracts	0
.	0

The	0
presence	0
of	0
this	0
faster	9
migrating	10
complex	10
was	0
restricted	0
to	0
B	7
cells	8
among	0
the	0
circulating	7
lymphocyte	8
population	8
.	0

Western	0
blot	0
analysis	0
revealed	0
that	0
B	7
cells	8
express	0
a	0
variant	0
form	0
of	0
the	0
Ku86	9
protein	10
with	0
an	0
apparent	0
molecular	0
weight	0
of	0
69	0
kDa	0
,	0
and	0
not	0
the	0
86	9
kDa-	10
full-length	10
protein	10
.	0

Although	0
the	0
heterodimer	9
Ku70/variant-Ku86	10
binds	0
to	0
DNA-ends	1
,	0
this	0
altered	0
form	0
of	0
the	0
Ku	9
heterodimer	10
has	0
a	0
decreased	0
ability	0
to	0
recruit	0
the	0
catalytic	9
component	10
of	0
the	0
complex	0
,	0
DNA-PK	9
(	10
CS	10
)	10
,	0
which	0
contributes	0
to	0
an	0
absence	0
of	0
detectable	0
DNA-PK	0
activity	0
in	0
B	7
cells	8
.	0

These	0
data	0
provide	0
a	0
molecular	0
basis	0
for	0
the	0
increased	0
sensitivity	0
of	0
B	7
cells	8
to	0
ionizing	0
radiation	0
and	0
identify	0
a	0
new	0
mechanism	0
of	0
regulation	0
of	0
DNA-PK	0
activity	0
that	0
operates	0
in	0
vivo	0
.	0

Co-stimulation	0
of	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
with	0
IL-2	9
and	0
anti-CD3	9
monoclonal	10
antibodies	10
induces	0
phosphorylation	0
of	0
CREB	9
.	0

Phosphorylation	0
of	0
the	0
cAMP-response	9
element	10
binding	10
protein	10
CREB	10
within	0
1	0
h	0
of	0
CD2	9
but	0
not	0
CD3	9
cross-linking	0
of	0
human	7
PBMC	8
was	0
recently	0
demonstrated	0
.	0

The	0
absence	0
of	0
P-CREB	9
following	0
CD3	0
cross-linking	0
was	0
unexpected	0
,	0
as	0
other	0
laboratories	0
reported	0
increased	0
phosphorylation	0
of	0
CREB	9
following	0
CD3	0
cross-linking	0
of	0
the	0
Jurkat	5
lymphocyte	6
cell	6
line	6
.	0

Due	0
to	0
Jurkat	5
T-cells	6
being	0
IL-2-independent	0
,	0
it	0
was	0
postulated	0
that	0
IL-2	9
might	0
provide	0
a	0
necessary	0
co-stimulus	0
for	0
phosphorylation	0
of	0
CREB	9
in	0
primary	7
lymphocytes	8
.	0

Therefore	0
,	0
P-CREB	9
was	0
evaluated	0
following	0
co-stimulation	0
of	0
human	7
PBMC	8
through	0
the	0
IL-2	9
and	10
CD2	10
or	10
CD3	10
receptors	10
.	0

IL-2	9
did	0
not	0
further	0
augment	0
phosphorylation	0
of	0
CREB	9
following	0
CD2	0
cross-linking	0
.	0

However	0
,	0
while	0
neither	0
IL-2	9
nor	0
CD3	0
cross-linking	0
alone	0
induced	0
P-CREB	9
,	0
a	0
4.5-fold	0
increase	0
in	0
phosphorylation	0
of	0
CREB	9
within	0
1	0
h	0
of	0
IL-2/CD3	0
co-stimulation	0
was	0
observed	0
.	0

Phosphorylation	0
was	0
not	0
associated	0
with	0
the	0
induction	0
of	0
cAMP	0
,	0
and	0
inhibition	0
of	0
PKA	0
signaling	0
had	0
no	0
effect	0
on	0
P-CREB	9
.	0

Consistent	0
with	0
signal	0
transduction	0
through	0
p56lck	9
or	0
p59fyn	9
,	0
inhibition	0
of	0
PTK	0
signaling	0
reduced	0
phosphorylation	0
50	0
%	0
.	0

Interestingly	0
,	0
inhibiting	0
PKC	0
signaling	0
with	0
calphostin	0
C	0
further	0
increased	0
P-CREB	0
levels	0
3-fold	0
over	0
that	0
observed	0
in	0
IL-2/CD3	7
co-stimulated	8
cells	8
not	0
pretreated	0
with	0
a	0
PKC	0
inhibitor	0
.	0

In	0
contrast	0
to	0
previous	0
studies	0
performed	0
in	0
the	0
absence	0
of	0
exogenous	9
IL-2	10
,	0
no	0
increase	0
in	0
binding	0
of	0
CREB	9
to	0
a	0
32P-labeled	0
oligonucleotide	0
probe	0
was	0
observed	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

These	0
data	0
suggest	0
that	0
the	0
IL-2	9
and	0
CD3	9
signaling	0
pathways	0
provide	0
a	0
necessary	0
and	0
co-operative	0
stimulus	0
promoting	0
phosphorylation	0
of	0
CREB	9
following	0
receptor	0
cross-linking	0
.	0

HIV-1	0
infection	0
induces	0
a	0
selective	0
reduction	0
in	0
STAT5	0
protein	0
expression	0
.	0

HIV-1	0
infection	0
is	0
accompanied	0
by	0
qualitative	0
and	0
quantitative	0
defects	0
in	0
CD4+	7
T	8
lymphocytes	8
.	0

Loss	0
of	0
immune	0
function	0
in	0
HIV	0
patients	0
is	0
usually	0
associated	0
with	0
a	0
profound	0
dysregulation	0
of	0
cytokine	9
production	0
.	0

To	0
investigate	0
whether	0
cytokine	9
signaling	0
defects	0
occur	0
during	0
HIV	0
infection	0
,	0
PHA	7
blasts	8
from	0
healthy	0
human	0
donors	0
were	0
infected	0
with	0
two	0
strains	0
of	0
HIV-1	0
and	0
screened	0
for	0
the	0
expression	0
of	0
STAT	9
proteins	10
used	0
in	0
cytokine	9
signaling	0
.	0

A	0
selective	0
decrease	0
in	0
STAT5B	9
was	0
seen	0
8	0
days	0
after	0
infection	0
with	0
the	0
BZ167	0
dual-tropic	0
HIV	0
isolate	0
,	0
but	0
not	0
with	0
the	0
Ba-L	0
,	0
M-tropic	0
strain	0
.	0

Based	0
on	0
these	0
findings	0
,	0
purified	7
T	8
cells	8
from	0
HIV-infected	0
patients	0
in	0
different	0
stages	0
of	0
disease	0
were	0
also	0
tested	0
for	0
STAT	0
expression	0
;	0
decreases	0
in	0
STAT5A	9
,	0
STAT5B	9
,	0
and	0
STAT1alpha	9
were	0
observed	0
in	0
all	0
patients	0
.	0

The	0
reduction	0
in	0
STATs	9
seen	0
in	0
vivo	0
and	0
in	0
vitro	0
after	0
HIV	0
infection	0
may	0
contribute	0
to	0
the	0
loss	0
of	0
T	7
cell	8
function	0
in	0
HIV	0
disease	0
.	0

Transcription	9
factors	10
that	0
regulate	0
monocyte	7
/	0
macrophage	7
differentiation	0
.	0

Although	0
all	0
the	0
cells	0
in	0
an	0
organism	0
contain	0
the	0
same	0
genetic	0
information	0
,	0
differences	0
in	0
the	0
cell	0
phenotype	0
arise	0
from	0
the	0
expression	0
of	0
lineage-specific	1
genes	2
.	0

During	0
myelopoiesis	0
,	0
external	0
differentiating	0
signals	0
regulate	0
the	0
expression	0
of	0
a	0
set	0
of	0
transcription	9
factors	10
.	0

The	0
combined	0
action	0
of	0
these	0
transcription	9
factors	10
subsequently	0
determines	0
the	0
expression	0
of	0
myeloid-specific	1
genes	2
and	0
the	0
generation	0
of	0
monocytes	7
and	0
macrophages	7
.	0

In	0
particular	0
,	0
the	0
transcription	9
factor	10
PU.1	10
has	0
a	0
critical	0
role	0
in	0
this	0
process	0
.	0

We	0
review	0
the	0
contribution	0
of	0
several	0
transcription	9
factors	10
to	0
the	0
control	0
of	0
macrophage	7
development	0

Transcription	9
factor	10
LKLF	10
is	0
sufficient	0
to	0
program	0
T	0
cell	0
quiescence	0
via	0
a	0
c-Myc	0
--	0
dependent	0
pathway	0
.	0

T	7
lymphocytes	8
circulate	0
in	0
a	0
quiescent	0
state	0
until	0
they	0
encounter	0
cognate	9
antigen	10
bound	0
to	0
the	0
surface	0
of	0
an	0
antigen-presenting	7
cell	8
.	0

The	0
molecular	0
pathways	0
that	0
regulate	0
T	0
cell	0
quiescence	0
remain	0
largely	0
unknown	0
.	0

Here	0
we	0
show	0
that	0
forced	0
expression	0
of	0
the	0
lung	9
Kruppel-like	10
transcription	10
factor	10
(	0
LKLF	9
)	0
in	0
Jurkat	5
T	6
cells	6
is	0
sufficient	0
to	0
program	0
a	0
quiescent	0
phenotype	0
characterized	0
by	0
decreased	0
proliferation	0
,	0
reduced	0
cell	0
size	0
and	0
protein	0
synthesis	0
and	0
decreased	0
surface	0
expression	0
of	0
activation	0
markers	0
.	0

Conversely	0
,	0
LKLF-deficient	7
peripheral	8
T	8
cells	8
produced	0
by	0
gene	0
targeting	0
showed	0
increased	0
proliferation	0
,	0
increased	0
cell	0
size	0
and	0
enhanced	0
expression	0
of	0
surface	0
activation	0
markers	0
in	0
vivo	0
.	0

LKLF	9
appeared	0
to	0
function	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
decreasing	0
expression	0
of	0
the	0
proto-oncogene	1
encoding	0
c-Myc	9
.	0

Forced	0
expression	0
of	0
LKLF	9
was	0
associated	0
with	0
markedly	0
decreased	0
c-Myc	9
expression	0
.	0

In	0
addition	0
,	0
many	0
effects	0
of	0
LKLF	9
expression	0
were	0
mimicked	0
by	0
expression	0
of	0
the	0
dominant-negative	9
MadMyc	10
protein	10
and	0
rescued	0
by	0
overexpression	0
of	0
c-Myc	9
.	0

Thus	0
,	0
LKLF	9
is	0
both	0
necessary	0
and	0
sufficient	0
to	0
program	0
quiescence	0
in	0
T	7
cells	8
and	0
functions	0
,	0
in	0
part	0
,	0
by	0
negatively	0
regulating	0
a	0
c-Myc	0
--	0
dependent	0
pathway	0
.	0

HTLV-1	9
p12	10
(	10
I	10
)	10
protein	10
enhances	0
STAT5	0
activation	0
and	0
decreases	0
the	0
interleukin-2	9
requirement	0
for	0
proliferation	0
of	0
primary	7
human	8
peripheral	8
blood	8
mononuclear	8
cells	8
.	0

The	0
p12	9
(	10
I	10
)	10
protein	10
,	0
encoded	0
by	0
the	0
pX	1
open	2
reading	2
frame	2
I	2
of	0
the	0
human	0
T-lymphotropic	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
,	0
is	0
a	0
hydrophobic	9
protein	10
that	0
localizes	0
to	0
the	0
endoplasmic	0
reticulum	0
and	0
the	0
Golgi	0
.	0

Although	0
p12	9
(	10
I	10
)	10
contains	0
4	0
minimal	0
proline-rich	0
,	0
src	9
homology	10
3-binding	10
motifs	10
(	0
PXXP	9
)	0
,	0
a	0
characteristic	0
commonly	0
found	0
in	0
proteins	0
involved	0
in	0
signaling	0
pathways	0
,	0
it	0
has	0
not	0
been	0
known	0
whether	0
p12	9
(	10
I	10
)	10
has	0
a	0
role	0
in	0
modulating	0
intracellular	0
signaling	0
pathways	0
.	0

This	0
study	0
demonstrated	0
that	0
p12	9
(	10
I	10
)	10
binds	0
to	0
the	0
cytoplasmic	9
domain	10
of	0
the	0
interleukin-2	9
receptor	10
(	10
IL-2R	10
)	10
beta	10
chain	10
that	0
is	0
involved	0
in	0
the	0
recruitment	0
of	0
the	0
Jak1	9
and	10
Jak3	10
kinases	10
.	0

As	0
a	0
result	0
of	0
this	0
interaction	0
,	0
p12	9
(	10
I	10
)	10
increases	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
5	10
(	0
STAT5	9
)	0
DNA	0
binding	0
and	0
transcriptional	0
activity	0
and	0
this	0
effect	0
depends	0
on	0
the	0
presence	0
of	0
both	0
IL-2R	9
beta	10
and	10
gamma	10
(	10
c	10
)	10
chains	10
and	0
Jak3	9
.	0

Transduction	0
of	0
primary	5
human	6
peripheral	6
blood	6
mononuclear	6
cells	6
(	0
PBMCs	7
)	0
with	0
a	0
human	1
immunodeficiency	2
virus	2
type	2
1-based	2
retroviral	2
vector	2
expressing	0
p12	9
(	10
I	10
)	10
also	0
resulted	0
in	0
increased	0
STAT5	9
phosphorylation	0
and	0
DNA	0
binding	0
.	0

However	0
,	0
p12	9
(	10
I	10
)	10
could	0
increase	0
proliferation	0
of	0
human	7
PBMCs	8
only	0
after	0
stimulation	0
of	0
T-cell	9
receptors	10
by	0
treatment	0
of	0
cells	0
with	0
low	0
concentrations	0
of	0
alphaCD3	9
and	10
alphaCD28	10
antibodies	10
.	0

In	0
addition	0
,	0
the	0
proliferative	0
advantage	0
of	0
p12	7
(	8
I	8
)	8
-transduced	8
PBMCs	8
was	0
evident	0
mainly	0
at	0
low	0
concentrations	0
of	0
IL-2	9
.	0

Together	0
,	0
these	0
data	0
indicate	0
that	0
p12	9
(	10
I	10
)	10
may	0
confer	0
a	0
proliferative	0
advantage	0
on	0
HTLV-1-infected	7
cells	8
in	0
the	0
presence	0
of	0
suboptimal	0
antigen	0
stimulation	0
and	0
that	0
this	0
event	0
may	0
account	0
for	0
the	0
clonal	0
proliferation	0
of	0
infected	7
T	8
cells	8
in	0
vivo	0
.	0

(	0
Blood.	0
2001	0
;	0
98	0
:	0
823-829	0
)	0

Single	0
dose	0
intranasal	0
administration	0
of	0
retinal	9
autoantigen	10
generates	0
a	0
rapid	0
accumulation	0
and	0
cell	0
activation	0
in	0
draining	0
lymph	0
node	0
and	0
spleen	0
:	0
implications	0
for	0
tolerance	0
therapy	0
.	0

BACKGROUND/AIMS	0
:	0
A	0
single	0
intranasal	0
delivery	0
of	0
retinal	9
autoantigen	10
suppresses	0
effectively	0
experimental	0
autoimmune	0
uveoretinitis	0
(	0
EAU	0
)	0
.	0

To	0
further	0
unravel	0
underlying	0
mechanisms	0
the	0
authors	0
wished	0
to	0
determine	0
,	0
firstly	0
,	0
the	0
kinetics	0
of	0
antigen	0
delivery	0
and	0
,	0
secondly	0
,	0
the	0
early	0
cellular	0
responses	0
involved	0
in	0
the	0
initial	0
stages	0
of	0
nasal	0
mucosal	0
tolerance	0
induction	0
.	0

METHODS	0
:	0
Flow	0
cytometry	0
,	0
cell	0
proliferation	0
assays	0
,	0
and	0
microscopy	0
were	0
used	0
to	0
track	0
antigen	9
following	0
a	0
single	0
,	0
intranasal	0
dose	0
of	0
Alexa-488	9
labelled	10
retinal	10
antigen	10
.	0

RESULTS	0
:	0
A	0
rapid	0
accumulation	0
of	0
antigen	9
within	0
both	0
superficial	0
cervical	0
lymph	0
nodes	0
(	0
SCLN	0
)	0
and	0
spleen	0
was	0
observed	0
after	0
30	0
minutes	0
.	0

Significant	0
proliferative	0
responses	0
to	0
IRBP	0
were	0
elicited	0
by	0
48	0
hours	0
indicating	0
that	0
systemic	0
priming	0
of	0
naive	7
T	8
cells	8
to	0
retinal	9
antigen	10
had	0
occurred	0
.	0

Cell	0
activation	0
was	0
further	0
confirmed	0
by	0
immunoprecipitation	0
studies	0
,	0
which	0
demonstrated	0
phosphorylation	0
of	0
STAT4	9
but	0
not	0
STAT6	9
in	0
both	0
lymph	0
nodes	0
and	0
spleen	0
.	0

However	0
,	0
at	0
24	0
hours	0
,	0
STAT4	0
heterodimerisation	0
with	0
STAT	9
3	10
was	0
only	0
observed	0
in	0
spleen	0
.	0

CONCLUSIONS	0
:	0
The	0
results	0
provide	0
novel	0
evidence	0
that	0
following	0
a	0
single	0
intranasal	0
application	0
rapid	0
transfer	0
of	0
antigen	9
occurs	0
.	0

Resulting	0
T	0
cell	0
proliferation	0
develops	0
consequent	0
to	0
differential	0
cell	0
signalling	0
in	0
SCLN	0
and	0
spleen	0
.	0

Further	0
understanding	0
of	0
these	0
underlying	0
cellular	0
mechanisms	0
,	0
in	0
particular	0
as	0
is	0
inferred	0
by	0
the	0
results	0
the	0
contribution	0
of	0
local	0
versus	0
systemic	0
tolerance	0
induction	0
,	0
may	0
assist	0
in	0
strategies	0
to	0
clinically	0
apply	0
mucosal	0
tolerance	0
therapy	0
successfully	0
.	0

Regulation	0
of	0
interleukin	9
(	10
IL	10
)	10
-18	10
receptor	10
alpha	10
chain	10
expression	0
on	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
during	0
T	0
helper	0
(	0
Th	0
)	0
1/Th2	0
differentiation	0
.	0

Critical	0
downregulatory	0
role	0
of	0
IL-4	9
.	0

Interleukin	9
(	10
IL	10
)	10
-18	10
has	0
been	0
well	0
characterized	0
as	0
a	0
costimulatory	9
factor	10
for	0
the	0
induction	0
of	0
IL-12-mediated	9
interferon	10
(	10
IFN	10
)	10
-gamma	10
production	0
by	0
T	7
helper	8
(	8
Th	8
)	8
1	8
cells	8
,	0
but	0
also	0
can	0
induce	0
IL-4	0
production	0
and	0
thus	0
facilitate	0
the	0
differentiation	0
of	0
Th2	7
cells	8
.	0

To	0
determine	0
the	0
mechanisms	0
by	0
which	0
IL-18	9
might	0
regulate	0
these	0
diametrically	0
distinct	0
immune	0
responses	0
,	0
we	0
have	0
analyzed	0
the	0
role	0
of	0
cytokines	9
in	0
the	0
regulation	0
of	0
IL-18	9
receptor	10
alpha	10
chain	10
(	0
IL-18Ralpha	9
)	0
expression	0
.	0

The	0
majority	0
of	0
peripheral	7
CD4	8
(	8
+	8
)	8
T	8
cells	8
constitutively	0
expressed	0
the	0
IL-18Ralpha	9
.	0

Upon	0
antigen	0
stimulation	0
in	0
the	0
presence	0
of	0
IL-12	9
,	0
marked	0
enhancement	0
of	0
IL-18Ralpha	9
expression	0
was	0
observed	0
.	0

IL-12	9
-mediated	0
upregulation	0
of	0
IL-18Ralpha	9
required	0
IFN-gamma	9
.	0

Activated	7
CD4	8
(	8
+	8
)	8
T	8
cells	8
that	0
expressed	0
low	0
levels	0
of	0
IL-18Ralpha	9
could	0
produce	0
IFN-gamma	9
when	0
stimulated	0
with	0
the	0
combination	0
of	0
IL-12	9
and	0
IL-18	9
,	0
while	0
CD4	7
(	8
+	8
)	8
cells	8
which	0
expressed	0
high	0
levels	0
of	0
IL-18Ralpha	9
could	0
respond	0
to	0
IL-18	9
alone	0
.	0

In	0
contrast	0
,	0
T	0
cell	0
stimulation	0
in	0
the	0
presence	0
of	0
IL-4	9
resulted	0
in	0
a	0
downregulation	0
of	0
IL-18Ralpha	9
expression	0
.	0

Both	0
IL-4	7
(	8
-/	8
)	8
-	8
and	8
signal	8
transducer	8
and	8
activator	8
of	8
transcription	8
(	8
Stat	8
)	8
6	8
(	8
-/	8
)	8
-	8
T	8
cells	8
expressed	0
higher	0
levels	0
of	0
IL-18Ralpha	9
after	0
TCR	0
stimulation	0
.	0

Furthermore	0
,	0
activated	7
T	8
cells	8
from	0
Stat6	0
(	0
-/	0
)	0
-	0
mice	0
produced	0
more	0
IFN-gamma	9
in	0
response	0
to	0
IL-18	9
than	0
wild-type	0
controls	0
.	0

Thus	0
,	0
positive/negative	0
regulation	0
of	0
the	0
IL-18Ralpha	9
by	0
the	0
major	0
inductive	0
cytokines	9
(	0
IL-12	9
and	0
IL-4	9
)	0
determines	0
the	0
capacity	0
of	0
IL-18	9
to	0
polarize	0
an	0
immune	0
response	0
.	0

Glucocorticoid-regulated	9
transcription	10
factors	10
.	0

Glucocorticoids	0
are	0
the	0
most	0
effective	0
antiinflammatory	0
drugs	0
used	0
in	0
the	0
treatment	0
of	0
asthma	0
.	0

They	0
act	0
by	0
binding	0
to	0
a	0
specific	0
receptor	0
(	0
GR	9
)	0
that	0
,	0
upon	0
activation	0
,	0
translocates	0
to	0
the	0
nucleus	0
and	0
either	0
increases	0
(	0
transactivates	0
)	0
or	0
decreases	0
(	0
transrepresses	0
)	0
gene	0
expression	0
.	0

Inhibition	0
of	0
pro-inflammatory	9
transcription	10
factors	10
such	0
as	0
activator	9
protein	10
(	10
AP	10
)	10
-1	10
,	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STATs	9
)	0
,	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
and	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
is	0
thought	0
to	0
be	0
a	0
major	0
action	0
of	0
glucocorticoids	0
.	0

Acetylation	0
of	0
histones	9
allows	0
unwinding	0
of	0
the	0
local	1
DNA	2
structure	2
and	0
enables	0
RNA	9
polymerase	10
II	10
to	0
enhance	0
gene	0
transcription	0
.	0

Histone	0
acetylation	0
is	0
regulated	0
by	0
a	0
balance	0
between	0
the	0
activity	0
of	0
histone	9
acetyltransferases	10
(	0
HATs	9
)	0
and	0
histone	9
deacetylases	10
(	0
HDACs	9
)	0
.	0

GR	9
acts	0
as	0
a	0
direct	0
inhibitor	0
of	0
NF-kappa	0
B-induced	0
HAT	0
activity	0
and	0
also	0
by	0
recruiting	0
HDAC2	9
to	0
the	0
NF-kappa	9
B/HAT	10
complex	10
.	0

A	0
sub-group	0
of	0
patients	0
with	0
glucocorticoid-insensitive	0
asthma	0
have	0
an	0
inability	0
to	0
induce	0
histone	0
acetylation	0
in	0
response	0
to	0
dexamethasone	0
suggesting	0
reduced	0
expression	0
of	0
a	0
GR-specific	9
HAT	10
.	0

This	0
suggests	0
that	0
pharmacological	0
manipulation	0
of	0
specific	0
histone	0
acetylation	0
status	0
is	0
a	0
potentially	0
useful	0
approach	0
for	0
the	0
treatment	0
of	0
inflammatory	0
diseases	0
.	0

Identification	0
of	0
the	0
precise	0
mechanism	0
by	0
which	0
activated	9
GR	10
recruits	0
HDAC2	9
may	0
reveal	0
new	0
targets	0
for	0
the	0
development	0
of	0
drugs	0
that	0
may	0
dissociate	0
the	0
antiinflammatory	0
actions	0
of	0
glucocorticoids	0
from	0
their	0
side	0
effects	0
that	0
are	0
largely	0
due	0
to	0
gene	0
induction	0
.	0

Copyright	0
Academic	0
Press	0
.	0

Differential	0
ultraviolet-B-induced	0
immunomodulation	0
in	0
XPA	0
,	0
XPC	0
,	0
and	0
CSB	0
DNA	0
repair-deficient	0
mice	0
.	0

Ultraviolet	0
B	0
irradiation	0
has	0
serious	0
consequences	0
for	0
cellular	0
immunity	0
and	0
can	0
suppress	0
the	0
rejection	0
of	0
skin	0
tumors	0
and	0
the	0
resistance	0
to	0
infectious	0
diseases	0
.	0

DNA	0
damage	0
plays	0
a	0
crucial	0
role	0
in	0
these	0
immunomodulatory	0
effects	0
of	0
ultraviolet	0
B	0
,	0
as	0
impaired	0
repair	0
of	0
ultraviolet-B-induced	0
DNA	0
damage	0
has	0
been	0
shown	0
to	0
cause	0
suppression	0
of	0
cellular	0
immunity	0
.	0

Ultraviolet-B-induced	0
DNA	0
damage	0
is	0
repaired	0
by	0
the	0
nucleotide	0
excision	0
repair	0
mechanism	0
very	0
efficiently	0
.	0

Nucleotide	0
excision	0
repair	0
comprises	0
two	0
subpathways	0
:	0
transcription-coupled	0
and	0
global	0
genome	0
repair	0
.	0

In	0
this	0
study	0
the	0
immunologic	0
consequences	0
of	0
specific	0
nucleotide	0
excision	0
repair	0
defects	0
in	0
three	0
mouse	0
models	0
,	0
XPA	0
,	0
XPC	0
,	0
and	0
CSB	0
mutant	0
mice	0
,	0
were	0
investigated	0
.	0

XPA	0
mice	0
carry	0
a	0
total	0
nucleotide	0
excision	0
repair	0
defect	0
,	0
whereas	0
XPC	0
and	0
CSB	0
mice	0
only	0
lack	0
global	0
genome	0
and	0
transcription-coupled	0
nucleotide	0
excision	0
repair	0
,	0
respectively	0
.	0

Our	0
data	0
demonstrate	0
that	0
cellular	0
immune	0
parameters	0
in	0
XPA	0
,	0
XPC	0
,	0
and	0
CSB	0
mice	0
are	0
normal	0
compared	0
with	0
their	0
wild-type	0
(	0
control	0
)	0
littermates	0
.	0

This	0
may	0
indicate	0
that	0
the	0
reported	0
altered	0
cellular	0
responses	0
in	0
xeroderma	0
pigmentosum	0
patients	0
are	0
not	0
constitutive	0
but	0
could	0
be	0
due	0
to	0
external	0
factors	0
,	0
such	0
as	0
ultraviolet	0
B	0
.	0

Upon	0
exposure	0
to	0
ultraviolet	0
B	0
,	0
only	0
XPA	0
mice	0
are	0
very	0
sensitive	0
to	0
ultraviolet-B-induced	0
inhibition	0
of	0
Th1-mediated	0
contact	0
hypersensitivity	0
responses	0
and	0
interferon-gamma	9
production	0
in	0
skin	0
draining	0
lymph	0
nodes	0
.	0

Lipopolysaccharide-stimulated	0
tumor	9
necrosis	10
factor	10
alpha	10
and	0
interleukin-10	9
production	0
are	0
significantly	0
augmented	0
in	0
both	0
XPA	0
and	0
CSB	0
mice	0
after	0
ultraviolet	0
B	0
exposure	0
.	0

Lymph	0
node	0
cell	0
numbers	0
were	0
increased	0
very	0
significantly	0
in	0
XPA	0
,	0
mildly	0
increased	0
in	0
CSB	0
,	0
and	0
not	0
in	0
XPC	0
mice	0
.	0

In	0
general	0
XPC	0
mice	0
do	0
not	0
exhibit	0
any	0
indication	0
of	0
enhanced	0
ultraviolet	0
B	0
susceptibility	0
with	0
regard	0
to	0
the	0
immune	0
parameters	0
analyzed	0
.	0

These	0
data	0
suggest	0
that	0
both	0
global	0
genome	0
repair	0
and	0
transcription-coupled	0
repair	0
are	0
needed	0
to	0
prevent	0
immunomodulation	0
by	0
ultraviolet	0
B	0
,	0
whereas	0
transcription-coupled	0
repair	0
is	0
the	0
major	0
DNA	0
repair	0
subpathway	0
of	0
nucleotide	0
excision	0
repair	0
that	0
prevents	0
the	0
acute	0
ultraviolet-B-induced	0
effects	0
such	0
as	0
erythema	0
.	0

Biomechanical	0
strain	0
induces	0
class	0
a	0
scavenger	9
receptor	10
expression	0
in	0
human	7
monocyte/macrophages	8
and	0
THP-1	7
cells	8
:	0
a	0
potential	0
mechanism	0
of	0
increased	0
atherosclerosis	0
in	0
hypertension	0
.	0

BACKGROUND	0
:	0
Although	0
hypertension	0
is	0
an	0
important	0
risk	0
factor	0
for	0
the	0
development	0
of	0
atherosclerosis	0
,	0
the	0
mechanisms	0
for	0
this	0
interaction	0
are	0
incompletely	0
described	0
.	0

Previous	0
studies	0
have	0
suggested	0
that	0
biomechanical	0
strain	0
regulates	0
macrophage	0
phenotype	0
.	0

We	0
tested	0
the	0
hypothesis	0
that	0
biomechanical	0
strain	0
can	0
induce	0
expression	0
of	0
the	0
class	9
A	10
scavenger	10
receptor	10
(	0
SRA	9
)	0
,	0
an	0
important	0
lipoprotein	9
receptor	10
in	0
atherogenesis	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
Human	7
monocyte/macrophages	8
or	0
THP-1	7
cells	8
were	0
cultured	0
in	0
a	0
device	0
that	0
imposes	0
uniform	0
biaxial	0
cyclic	0
1-Hz	0
strains	0
of	0
0	0
%	0
,	0
1	0
%	0
,	0
2	0
%	0
,	0
or	0
3	0
%	0
,	0
and	0
SRA	9
expression	0
was	0
analyzed	0
.	0

Mechanical	0
strains	0
induced	0
SRA	3
mRNA	4
(	0
3.5+/-0.6-fold	0
at	0
3	0
%	0
strain	0
for	0
48	0
hours	0
,	0
P	0
<	0
0.01	0
)	0
and	0
SRA	9
protein	10
in	0
THP-1	7
cells	8
in	0
an	0
amplitude-dependent	0
manner	0
.	0

This	0
induction	0
was	0
accompanied	0
by	0
augmented	0
expression	0
of	0
the	0
class	9
B	10
scavenger	10
receptor	10
CD36	10
(	0
2.8+/-0.3-fold	0
,	0
P	0
<	0
0.001	0
)	0
but	0
not	0
by	0
increased	0
peroxisome	9
proliferator-activated	10
receptor-gamma	10
expression	0
.	0

To	0
evaluate	0
this	0
effect	0
in	0
vivo	0
,	0
apolipoprotein	0
E	0
(	0
-/-	0
)	0
mice	0
were	0
randomly	0
assigned	0
to	0
receive	0
standard	0
chow	0
,	0
a	0
high-cholesterol	0
diet	0
,	0
or	0
a	0
high-cholesterol	0
diet	0
with	0
hypertension	0
induced	0
by	0
angiotensin	0
II	0
infusion	0
for	0
8	0
weeks	0
.	0

Immunohistochemistry	0
revealed	0
that	0
among	0
macrophages	7
in	0
atherosclerotic	0
lesions	0
of	0
the	0
aorta	0
,	0
the	0
proportion	0
of	0
macrophages	7
with	0
SRA	9
expression	0
was	0
highest	0
in	0
hypertensive	0
animals	0
on	0
a	0
high-cholesterol	0
diet	0
(	0
43.9+/-0.7	0
%	0
,	0
versus	0
12.0+/-2.0	0
%	0
for	0
normotensive	0
animals	0
on	0
a	0
high-cholesterol	0
diet	0
and	0
4.7+/-4.7	0
%	0
for	0
animals	0
on	0
standard	0
chow	0
;	0
P	0
<	0
0.001	0
)	0
.	0

CONCLUSIONS	0
:	0
Biomechanical	0
strain	0
induces	0
SRA	9
expression	0
by	0
monocyte/macrophages	7
,	0
suggesting	0
a	0
novel	0
mechanism	0
for	0
promotion	0
of	0
atherosclerosis	0
in	0
hypertensive	0
patients	0
.	0

High	0
glucose	0
induces	0
MCP-1	0
expression	0
partly	0
via	0
tyrosine	0
kinase-AP-1	0
pathway	0
in	0
peritoneal	7
mesothelial	8
cells	8
.	0

BACKGROUND	0
:	0
High	0
glucose	0
in	0
peritoneal	0
dialysis	0
solutions	0
has	0
been	0
implicated	0
in	0
the	0
pathogenesis	0
of	0
peritoneal	0
fibrosis	0
in	0
chronic	0
ambulatory	0
peritoneal	0
dialysis	0
(	0
CAPD	0
)	0
patients	0
.	0

However	0
,	0
the	0
mechanisms	0
are	0
not	0
very	0
clear	0
.	0

Peritoneal	7
macrophages	8
seem	0
to	0
participate	0
in	0
the	0
process	0
of	0
peritoneal	0
fibrosis	0
and	0
monocyte	9
chemoattractant	10
protein-1	10
(	0
MCP-1	9
)	0
plays	0
a	0
key	0
role	0
in	0
the	0
recruitment	0
of	0
monocytes	7
toward	0
the	0
peritoneal	0
cavity	0
.	0

However	0
,	0
little	0
is	0
known	0
about	0
the	0
effect	0
of	0
high	0
glucose	0
on	0
MCP-1	9
expression	0
and	0
its	0
signal	0
transduction	0
pathway	0
in	0
human	7
peritoneal	8
mesothelial	8
cells	8
.	0

METHODS	0
:	0
Mesothelial	7
cells	8
were	0
cultured	0
with	0
glucose	0
(	0
5	0
to	0
100	0
mmol/L	0
)	0
or	0
mannitol	0
chronically	0
for	0
up	0
to	0
seven	0
days	0
.	0

MCP-1	9
expression	0
of	0
mRNA	0
and	0
protein	0
was	0
measured	0
by	0
Northern	0
blot	0
analysis	0
and	0
enzyme-linked	0
immunosorbent	0
assay	0
(	0
ELISA	0
)	0
.	0

Chemotactic	0
activity	0
of	0
high-glucose-conditioned	0
culture	0
supernatant	0
was	0
measured	0
by	0
chemotactic	0
assay	0
.	0

To	0
examine	0
the	0
roles	0
of	0
the	0
transcription	9
factors	10
activator	9
protein-1	10
(	0
AP-1	9
)	0
and	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
,	0
electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
was	0
performed	0
.	0

RESULTS	0
:	0
Glucose	0
induced	0
MCP-1	3
mRNA	4
expression	0
in	0
a	0
time-	0
and	0
dose-dependent	0
manner	0
.	0

MCP-1	9
protein	10
in	0
cell	0
culture	0
supernant	0
was	0
also	0
increased	0
.	0

Equivalent	0
concentrations	0
of	0
mannitol	0
had	0
no	0
significant	0
effect	0
.	0

High-glucose-conditioned	0
supernatant	0
possessed	0
an	0
increased	0
chemotactic	0
activity	0
for	0
monocytes	7
,	0
which	0
was	0
neutralized	0
by	0
anti-MCP-1	9
antibody	10
.	0

EMSA	0
revealed	0
that	0
glucose	0
increased	0
the	0
AP-1	9
binding	0
activity	0
in	0
a	0
time-	0
and	0
dose-dependent	0
manner	0
,	0
but	0
not	0
NF-kappaB	9
.	0

Curcumin	0
,	0
an	0
inhibitor	0
of	0
AP-1	9
,	0
dose-dependently	0
suppressed	0
the	0
induction	0
of	0
MCP-1	3
mRNA	4
by	0
high	0
glucose	0
.	0

Tyrosine	0
kinase	0
inhibitors	0
such	0
as	0
genistein	0
(	0
12.5	0
to	0
50	0
micromol/L	0
)	0
and	0
herbimycin	0
A	0
(	0
0.1	0
to	0
1	0
micromol/L	0
)	0
inhibited	0
the	0
high-glucose-induced	0
MCP-1	3
mRNA	4
expression	0
in	0
a	0
dose-dependent	0
manner	0
,	0
and	0
also	0
suppressed	0
the	0
high-glucose-induced	0
AP-1	9
binding	0
activity	0
.	0

CONCLUSIONS	0
:	0
:	0
High	0
glucose	0
induced	0
mesothelial	0
MCP-1	9
expression	0
partly	0
via	0
the	0
tyrosine	0
kinase-	0
AP-1	9
pathway	0
.	0

Signal	0
thresholds	0
and	0
modular	0
synergy	0
during	0
expression	0
of	0
costimulatory	0
molecules	0
in	0
B	7
lymphocytes	8
.	0

We	0
analyzed	0
intracellular	0
pathways	0
modulating	0
surface	0
densities	0
of	0
CD80	9
and	0
CD86	9
in	0
B	7
cells	8
activated	0
through	0
ligation	0
of	0
the	0
Ag	9
receptor	10
,	0
and	0
the	0
adhesion	9
molecule	10
CD54	9
.	0

Whereas	0
B	9
cell	10
Ag	10
receptor	10
(	0
BCR	9
)	0
cross-linking	0
alone	0
stimulated	0
increased	0
expression	0
of	0
CD86	9
,	0
up-regulation	0
of	0
CD80	9
required	0
dual	0
stimulation	0
with	0
anti-IgM	9
and	0
anti-CD54	9
.	0

The	0
principal	0
downstream	0
component	0
contributed	0
by	0
BCR	9
signaling	0
,	0
toward	0
both	0
CD80	9
and	0
CD86	9
induction	0
,	0
was	0
the	0
elevated	0
concentration	0
of	0
free	0
cytoplasmic	0
Ca	0
(	0
2+	0
)	0
,	0
recruited	0
by	0
way	0
of	0
capacitative	0
influx	0
.	0

This	0
alone	0
was	0
sufficient	0
to	0
generate	0
an	0
increase	0
in	0
CD86	9
levels	0
.	0

However	0
,	0
CD80	9
enhancement	0
required	0
the	0
concerted	0
action	0
of	0
both	0
intracellular	0
Ca	0
(	0
2+	0
)	0
concentration	0
and	0
CD54-initiated	0
pathways	0
.	0

The	0
nexus	0
between	0
anti-IgM	0
and	0
anti-CD54	0
stimulation	0
,	0
in	0
the	0
context	0
of	0
CD80	9
regulation	0
,	0
was	0
identified	0
to	0
involve	0
a	0
self-propagating	0
process	0
of	0
sequential	0
synergy	0
.	0

The	0
first	0
step	0
involved	0
amplified	0
accumulation	0
of	0
intracellular	0
cAMP	0
,	0
as	0
a	0
result	0
of	0
cross-talk	0
between	0
BCR	9
-mobilized	0
Ca	0
(	0
2+	0
)	0
and	0
CD54-derived	0
signals	0
.	0

This	0
then	0
facilitated	0
a	0
second	0
synergistic	0
interaction	0
between	0
Ca	0
(	0
2+	0
)	0
and	0
cAMP	0
,	0
culminating	0
in	0
CD80	9
expression	0
.	0

Our	0
findings	0
of	0
distinct	0
signal	0
transducer	0
requirements	0
,	0
with	0
the	0
added	0
consequences	0
of	0
cross-talk	0
,	0
offers	0
an	0
explanation	0
for	0
variable	0
modulation	0
of	0
costimulatory	0
molecule	0
expression	0
in	0
response	0
to	0
diverse	0
physiological	0
stimuli	0
.	0

Importantly	0
,	0
these	0
results	0
also	0
reveal	0
how	0
concentration	0
threshold	0
barriers	0
for	0
recruitment	0
of	0
individual	0
second	0
messengers	0
can	0
be	0
overcome	0
by	0
constructive	0
convergence	0
of	0
signaling	0
modules	0
.	0

The	0
role	0
of	0
Epstein-Barr	0
virus	0
in	0
neoplastic	0
transformation	0
.	0

In	0
this	0
review	0
,	0
we	0
focus	0
on	0
new	0
data	0
from	0
basic	0
,	0
translational	0
and	0
clinical	0
research	0
relating	0
to	0
the	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
.	0

Beside	0
its	0
well-known	0
tropism	0
for	0
B	7
lymphocytes	8
and	0
epithelial	7
cells	8
,	0
EBV	0
also	0
infects	0
T	7
lymphocytes	8
,	0
monocytes	7
and	0
granulocytes	7
.	0

After	0
primary	0
infection	0
,	0
EBV	0
persists	0
throughout	0
the	0
life	0
span	0
in	0
resting	7
memory	8
B	8
cells	8
,	0
from	0
where	0
it	0
is	0
reactivated	0
upon	0
breakdown	0
of	0
cellular	0
immunity	0
.	0

In	0
the	0
process	0
of	0
neoplastic	0
transformation	0
,	0
the	0
EBV-encoded	1
latent	2
membrane	2
protein	2
1	2
(	2
LMP1	2
)	2
oncogene	2
represents	0
the	0
major	0
driving	0
force	0
.	0

LMP1	9
acts	0
like	0
a	0
constitutively	9
activated	10
receptor	10
of	0
the	0
tumor	9
necrosis	10
factor	10
receptor	10
family	10
and	0
allows	0
the	0
amplification	0
or	0
bypassing	0
of	0
physiological	0
regulatory	0
signals	0
through	0
direct	0
and	0
indirect	0
interactions	0
with	0
proteins	0
of	0
the	0
tumor	9
necrosis	10
factor	10
receptor-associated	10
factor	10
(	10
TRAF	10
)	10
family	10
.	0

TRAF2	9
-mediated	0
NF-kappaB	9
activation	0
,	0
AP-1	9
induction	0
and	0
JAK3	9
/	0
STAT	9
activation	0
may	0
result	0
in	0
sustained	0
proliferation	0
leading	0
to	0
lymphoma	5
.	0

The	0
ability	0
of	0
LMP1	9
to	0
suppress	0
germinal	0
center	0
formation	0
and	0
its	0
capacity	0
to	0
mediate	0
its	0
own	0
transcriptional	0
activation	0
shed	0
new	0
light	0
on	0
the	0
pathogenesis	0
of	0
EBV-associated	0
latency	0
type	0
II	0
lymphoproliferations	0
like	0
Hodgkin	0
's	0
disease	0
and	0
angioimmunoblastic	0
lymphadenopathy	0
.	0

The	0
carboxy	9
terminus	10
of	0
LMP1	9
is	0
also	0
a	0
reliable	0
marker	0
for	0
individual	0
EBV	0
strain	0
identification	0
and	0
thus	0
offers	0
new	0
possibilities	0
in	0
tracing	0
the	0
molecular	0
events	0
leading	0
to	0
posttransplant	0
lymphoproliferative	0
disorders	0
(	0
PTLDs	0
)	0
.	0

Cytotoxic	7
T	8
lymphocytes	8
directed	0
against	0
well-characterized	0
epitopes	0
of	0
EBV	1
latency	2
genes	2
represent	0
an	0
already	0
successful	0
and	0
promising	0
therapeutic	0
approach	0
to	0
EBV-associated	5
lymphomas	6
,	0
in	0
particular	0
PTLDs	0

Interferon-alpha	9
drives	0
T	0
cell-mediated	0
immunopathology	0
in	0
the	0
intestine	0
.	0

The	0
ability	0
of	0
interferon	9
(	10
IFN	10
)	10
-alpha	10
to	0
induce	0
autoimmunity	0
and	0
exacerbate	0
Th1	0
diseases	0
is	0
well	0
known	0
.	0

We	0
have	0
recently	0
described	0
enhanced	0
expression	0
of	0
IFN-alpha	9
in	0
the	0
mucosa	0
of	0
patients	0
with	0
celiac	0
disease	0
(	0
CD	0
)	0
,	0
a	0
gluten-sensitive	0
Th1-mediated	0
enteropathy	0
,	0
characterized	0
by	0
villous	0
atrophy	0
and	0
crypt	0
cell	0
hyperplasia	0
.	0

Previous	0
studies	0
from	0
this	0
laboratory	0
have	0
shown	0
that	0
T	7
cell	8
activation	0
in	0
explant	0
cultures	0
of	0
human	0
fetal	0
gut	0
can	0
also	0
result	0
in	0
villous	0
atrophy	0
and	0
crypt	0
cell	0
hyperplasia	0
.	0

We	0
have	0
,	0
therefore	0
,	0
examined	0
changes	0
that	0
take	0
place	0
in	0
explant	0
cultures	0
of	0
human	0
fetal	0
gut	0
after	0
activation	0
of	0
T	7
cells	8
with	0
anti-CD3	9
and/or	0
IFN-alpha	9
.	0

We	0
show	0
that	0
activation	0
of	0
T	7
cells	8
with	0
anti-CD3	9
alone	0
elicits	0
a	0
small	0
IFN-gamma	9
and	0
TNF-alpha	9
response	0
with	0
no	0
tissue	0
injury	0
.	0

Similarly	0
,	0
no	0
changes	0
are	0
seen	0
in	0
explants	0
cultured	0
with	0
IFN-alpha	9
alone	0
.	0

However	0
,	0
addition	0
of	0
IFN-alpha	9
with	0
anti-CD3	9
results	0
in	0
enhanced	0
Th1	0
response	0
and	0
crypt	0
cell	0
hyperplasia	0
.	0

This	0
is	0
associated	0
with	0
enhanced	0
phosphorylation	0
of	0
STAT1	9
,	0
STAT3	9
,	0
and	0
Fyn	9
,	10
a	10
Src	10
homology	10
tyrosine	10
kinase	10
,	0
which	0
interacts	0
with	0
both	0
TCR	0
and	0
IFN-alpha	0
signal	0
components	0
.	0

Together	0
these	0
data	0
indicate	0
that	0
IFN-alpha	9
can	0
facilitate	0
activation	0
of	0
Th1-reactive	7
cells	8
in	0
the	0
gut	0
and	0
drive	0
immunopathology	0
.	0

Suppression	0
of	0
tumor	9
necrosis	10
factor	10
alpha	10
production	0
by	0
cAMP	0
in	0
human	7
monocytes	8
:	0
dissociation	0
with	0
mRNA	0
level	0
and	0
independent	0
of	0
interleukin-10	9
.	0

BACKGROUND	0
:	0
Elevation	0
of	0
cellular	0
cAMP	0
inhibits	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-stimulated	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
production	0
and	0
increases	0
the	0
expression	0
of	0
interleukin	9
(	10
IL	10
)	10
-10	10
in	0
mononuclear	7
cells	8
.	0

TNF-alpha	1
gene	2
expression	0
obligates	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	9
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
.	0

Exogenous	0
IL-10	9
inhibits	0
NF-kappaB	9
in	0
monocytes	7
and	0
thus	0
attenuates	0
TNF-alpha	9
production	0
.	0

We	0
examined	0
the	0
role	0
of	0
endogenous	0
IL-10	9
in	0
the	0
regulation	0
of	0
NF-kappaB	9
activation	0
and	0
TNF-alpha	9
production	0
in	0
human	7
monocytes	8
by	0
cAMP	0
.	0

METHODS	0
:	0
Human	7
monocytes	8
were	0
stimulated	0
with	0
Escherichia	0
coli	0
LPS	0
(	0
100	0
ng/ml	0
)	0
with	0
and	0
without	0
forskolin	0
(	0
FSK	0
,	0
50	0
microM	0
)	0
or	0
dibutyryl	0
cyclic	0
AMP	0
(	0
dbcAMP	0
,	0
100	0
microM	0
)	0
.	0

Cytokine	9
(	0
TNF-alpha	9
and	0
IL-10	9
)	0
release	0
was	0
measured	0
by	0
immunoassay	0
.	0

TNF-alpha	3
mRNA	4
was	0
measured	0
by	0
reverse	0
transcription	0
polymerase	0
chain	0
reaction	0
,	0
and	0
NF-kappaB	9
DNA	0
binding	0
activity	0
was	0
assessed	0
by	0
gel	0
mobility	0
shift	0
assay	0
.	0

RESULTS	0
:	0
cAMP-elevating	0
agents	0
inhibited	0
LPS-stimulated	0
TNF-alpha	9
release	0
(	0
0.77	0
+/-	0
0.13	0
ng/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
+	0
dbcAMP	0
and	0
0.68	0
+/-	0
0.19	0
ng/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
+	0
FSK	0
,	0
both	0
P	0
<	0
0.05	0
vs	0
1.61	0
+/-	0
0.34	0
ng/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
alone	0
)	0
.	0

Conversely	0
,	0
cAMP	0
enhanced	0
LPS-stimulated	0
IL-10	9
release	0
(	0
100	0
+/-	0
21.5	0
pg/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
+	0
dbcAMP	0
and	0
110	0
+/-	0
25.2	0
pg/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
+	0
FSK	0
,	0
both	0
P	0
<	0
0.05	0
vs	0
53.3	0
+/-	0
12.8	0
pg/10	0
(	0
6	0
)	0
cells	0
in	0
LPS	0
alone	0
)	0
.	0

Neither	0
TNF-alpha	3
mRNA	4
expression	0
nor	0
NF-kappaB	9
activation	0
stimulated	0
by	0
LPS	0
was	0
inhibited	0
by	0
the	0
cAMP-elevating	0
agents	0
.	0

Neutralization	0
of	0
IL-10	9
with	0
a	0
specific	0
antibody	9
did	0
not	0
attenuate	0
the	0
effect	0
of	0
cAMP-elevating	0
agents	0
on	0
TNF-alpha	9
production	0
.	0

CONCLUSION	0
:	0
The	0
results	0
indicate	0
that	0
cAMP	0
inhibits	0
LPS-stimulated	0
TNF-alpha	9
production	0
through	0
a	0
posttranscriptional	0
mechanism	0
that	0
is	0
independent	0
of	0
endogenous	0
IL-10	9
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Activation	0
of	0
the	0
p21	1
(	2
CIP1/WAF1	2
)	2
promoter	2
by	0
bone	9
morphogenetic	10
protein-2	10
in	0
mouse	0
B	5
lineage	6
cells	6
.	0

BMPs	9
exert	0
a	0
negative	0
growth	0
effect	0
on	0
various	0
types	0
of	0
cells	0
.	0

We	0
have	0
previously	0
reported	0
that	0
BMP-2	9
inhibited	0
the	0
growth	0
of	0
HS-72	5
mouse	6
hybridoma	6
cells	6
by	0
inducing	0
p21	0
(	0
CIP1/WAF1	0
)	0
expression	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
demonstrated	0
that	0
BMP-2	9
activated	0
the	0
mouse	0
p21	1
(	2
CIP1/WAF1	2
)	2
promoter	2
in	0
HS-72	5
cells	6
,	0
and	0
that	0
a	0
29-base	1
pair	2
(	2
b	2
)	2
region	2
of	0
the	0
promoter	0
(	0
-1928/-1900	0
relative	0
to	0
the	0
TATA	1
box	2
)	0
,	0
conserved	0
between	0
mice	0
and	0
humans	0
,	0
was	0
responsive	0
to	0
BMP-2	9
as	0
well	0
as	0
expression	0
of	0
Smad1	9
,	0
Smad4	9
,	0
and	0
constitutively	0
active	0
mutants	0
of	0
BMP	9
type	10
I	10
receptors	10
.	0

Furthermore	0
,	0
an	0
oligonucleotide	0
containing	0
the	0
29-b	1
region	2
was	0
found	0
to	0
be	0
associated	0
with	0
Smad4	9
and	0
phosphorylated	9
Smad1	10
in	0
the	0
nuclear	0
extract	0
of	0
BMP-2	9
-stimulated	0
HS-72	5
cells	6
.	0

These	0
results	0
suggested	0
that	0
BMP-2	9
might	0
activate	0
p21	0
(	0
CIP1/WAF1	0
)	0
transcription	0
by	0
inducing	0
a	0
binding	0
of	0
Smad4	9
and	0
Smad1	9
to	0
the	0
29-b	1
region	2
in	0
HS-72	5
cells	6
.	0

Dendritic	7
cell	8
development	0
from	0
common	0
myeloid	7
progenitors	8
.	0

Dendritic	7
cells	8
(	0
DCs	7
)	0
are	0
professional	0
antigen-presenting	7
cells	8
which	0
both	0
initiate	0
adaptive	0
immune	0
responses	0
and	0
control	0
tolerance	0
to	0
self-antigens	9
.	0

It	0
has	0
been	0
suggested	0
that	0
these	0
different	0
effects	0
on	0
responder	0
cells	0
depend	0
on	0
subsets	0
of	0
DCs	7
arising	0
from	0
either	0
myeloid	0
or	0
lymphoid	0
hematopoietic	0
origins	0
.	0

In	0
this	0
model	0
,	0
CD8	7
alpha+	8
Mac-1-	8
DCs	8
are	0
supposed	0
to	0
be	0
of	0
lymphoid	0
while	0
CD8	7
alpha-	8
Mac-1+	8
DCs	8
are	0
supposed	0
to	0
be	0
of	0
myeloid	0
origin	0
.	0

Here	0
we	0
summarize	0
our	0
findings	0
that	0
both	0
CD8	7
alpha+	8
and	8
CD8	8
alpha-	8
DCs	8
can	0
arise	0
from	0
clonogenic	7
common	8
myeloid	8
progenitors	8
(	0
CMPs	7
)	0
in	0
both	0
thymus	0
and	0
spleen	0
.	0

Therefore	0
CD8	9
alpha	10
expression	0
DCs	7
does	0
not	0
indicate	0
a	0
lymphoid	0
origin	0
and	0
differences	0
among	0
CD8	7
alpha+	8
and	8
CD8	8
alpha-	8
DCs	8
might	0
rather	0
reflect	0
maturation	0
status	0
than	0
ontogeny	0
.	0

On	0
the	0
basis	0
of	0
transplantation	0
studies	0
,	0
it	0
seems	0
likely	0
that	0
most	0
of	0
the	0
DCs	7
in	0
secondary	0
lymphoid	0
organs	0
and	0
a	0
substantial	0
fraction	0
of	0
thymic	7
DCs	8
are	0
myeloid-derived	0
.	0

Macrophage	0
stimulation	0
with	0
Murabutide	0
,	0
an	0
HIV-suppressive	0
muramyl	0
peptide	0
derivative	0
,	0
selectively	0
activates	0
extracellular	9
signal-regulated	10
kinases	10
1	10
and	10
2	10
,	0
C/EBPbeta	9
and	0
STAT1	9
:	0
role	0
of	0
CD14	9
and	0
Toll-like	9
receptors	10
2	10
and	10
4	10
.	0

The	0
smallest	0
unit	0
of	0
bacterial	0
peptidoglycans	0
known	0
to	0
be	0
endowed	0
with	0
biological	0
activities	0
is	0
muramyl	0
dipeptide	0
(	0
MDP	0
)	0
.	0

A	0
clinically	0
acceptable	0
synthetic	0
derivative	0
of	0
MDP	0
,	0
namely	0
murabutide	0
(	0
MB	0
)	0
,	0
has	0
been	0
found	0
to	0
present	0
interesting	0
pharmacological	0
properties	0
and	0
to	0
suppress	0
HIV-1	0
replication	0
in	0
monocyte-derived	7
macrophages	8
(	0
MDM	7
)	0
.	0

We	0
have	0
addressed	0
the	0
signaling	0
events	0
activated	0
in	0
MDM	7
following	0
stimulation	0
with	0
either	0
MB	0
or	0
the	0
potent	0
immunostimulant	0
LPS	0
.	0

We	0
also	0
examined	0
whether	0
signaling	0
by	0
muramyl	0
peptides	0
involves	0
the	0
use	0
of	0
cell	9
surface	10
receptors	10
,	0
including	0
CD14	9
and	0
Toll-like	9
receptor	10
2	10
(	0
TLR2	9
)	0
or	0
TLR4	9
that	0
are	0
known	0
to	0
be	0
signal-transducing	9
receptors	10
for	0
other	0
bacterial	0
cell	0
wall	0
components	0
.	0

We	0
demonstrate	0
that	0
,	0
unlike	0
LPS	0
,	0
the	0
safe	0
immunomodulator	0
MB	0
selectively	0
activates	0
extracellular	9
signal-regulated	10
kinases	10
(	10
Erk	10
)	10
1/2	10
,	0
in	0
the	0
absence	0
of	0
detectable	0
Jun	9
N-terminal	10
kinase	10
(	0
JNK	9
)	0
or	0
p38	9
mitogen-activated	10
kinase	10
activation	0
.	0

Furthermore	0
,	0
STAT1	9
activation	0
but	0
weak	0
or	0
no	0
activation	0
of	0
STAT3	9
or	0
STAT5	9
respectively	0
,	0
could	0
be	0
detected	0
in	0
MB-stimulated	7
MDM	8
.	0

Using	0
MonoMac6	5
cells	6
,	0
we	0
observed	0
high	0
C/EBPbeta	9
and	0
AP-1	9
but	0
weaker	0
and	0
transient	0
NF-kappaB	9
activation	0
by	0
MB	0
.	0

Moreover	0
,	0
the	0
truncated	0
form	0
of	0
C/EBPbeta	9
,	0
known	0
to	0
repress	0
HIV-1	0
transcription	0
,	0
was	0
detected	0
in	0
extracts	0
from	0
MB-treated	5
THP-1	6
cells	6
.	0

Surprisingly	0
,	0
neither	0
MB	0
nor	0
MDP	0
were	0
able	0
to	0
transduce	0
signals	0
via	0
CD14	9
and	0
TLR2	9
or	10
4	10
.	0

These	0
findings	0
present	0
major	0
differences	0
in	0
the	0
early	0
cell	0
activation	0
process	0
between	0
LPS	0
and	0
muramyl	0
peptides	0
,	0
and	0
strongly	0
argue	0
for	0
the	0
implication	0
of	0
co-receptors	9
other	0
than	0
TLR2	9
and	0
TLR4	9
in	0
mediating	0
the	0
signaling	0
events	0
induced	0
by	0
defined	0
subunits	0
of	0
bacterial	0
peptidoglycans	0
.	0

Nuclear	9
peroxisome	10
proliferator-activated	10
receptors	10
alpha	10
and	10
gamma	10
have	0
opposing	0
effects	0
on	0
monocyte	0
chemotaxis	0
in	0
endometriosis	0
.	0

The	0
peroxisome	9
proliferator-activated	10
receptors	10
(	10
PPARs	10
)	10
alpha	10
and	10
gamma	10
are	0
nuclear	9
receptors	10
that	0
play	0
important	0
roles	0
in	0
inflammatory	0
diseases	0
like	0
ulcerative	0
colitis	0
and	0
arthritis	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
the	0
possible	0
role	0
of	0
PPARs	9
in	0
macrophage	0
attraction	0
into	0
the	0
peritoneal	0
cavity	0
of	0
patients	0
with	0
endometriosis	0
.	0

We	0
identified	0
PPAR-alpha	3
and	4
-gamma	4
messenger	0
RNA	0
by	0
RT-PCR	0
and	0
protein	0
by	0
immunoblotting	0
of	0
lysates	0
of	0
peritoneal	7
macrophages	8
and	0
monocytic	5
U937	6
cells	6
.	0

Using	0
immunocytochemistry	0
,	0
we	0
localized	0
PPAR-alpha	9
and	10
-gamma	10
within	0
the	0
nuclei	0
of	0
both	0
cell	0
types	0
.	0

Monocyte	0
chemotactic	0
activity	0
of	0
peritoneal	0
fluid	0
from	0
patients	0
with	0
endometriosis	0
was	0
quantified	0
in	0
Boyden	0
chambers	0
.	0

Migration	0
of	0
U937	5
cells	6
was	0
increased	0
by	0
WY	0
14643	0
and	0
reduced	0
by	0
rosiglitazone	0
.	0

Peritoneal	0
fluid	0
from	0
patients	0
with	0
endometriosis	0
activated	0
U937	5
cells	6
transiently	0
transfected	0
with	0
a	0
PPAR-alpha/GAL4	1
luciferase	2
reporter	2
.	0

By	0
contrast	0
,	0
peritoneal	0
fluid	0
did	0
not	0
cause	0
significant	0
activation	0
of	0
PPAR-gamma/GAL4	1
constructs	2
.	0

The	0
U937	5
cells	6
transiently	0
transfected	0
with	0
a	0
PPAR	1
response	2
element	2
luciferase	2
reporter	2
showed	0
disease	0
stage-dependent	0
up-regulation	0
when	0
treated	0
with	0
peritoneal	0
fluid	0
from	0
patients	0
with	0
endometriosis	0
.	0

Treatment	0
with	0
peritoneal	0
fluid	0
from	0
healthy	0
controls	0
down-regulated	0
PPAR	0
response	0
element	0
transactivation	0
.	0

We	0
conclude	0
that	0
peritoneal	0
fluid	0
of	0
endometriosis	0
patients	0
contains	0
activators	0
of	0
PPAR-alpha	9
that	0
stimulate	0
macrophage	0
chemotaxis	0
.	0

Inhibitors	0
of	0
PPAR-alpha	9
or	0
activators	0
of	0
PPAR-gamma	9
could	0
be	0
developed	0
for	0
the	0
treatment	0
of	0
inflammation	0
associated	0
with	0
endometriosis	0
.	0

Long-term-impaired	0
expression	0
of	0
nuclear	9
factor-kappa	10
B	10
and	0
I	9
kappa	10
B	10
alpha	10
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
of	0
trauma	0
patients	0
.	0

Nuclear	9
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
expression	0
and	0
dimer	0
characteristics	0
were	0
studied	0
in	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
of	0
major-trauma	0
patients	0
and	0
healthy	0
controls	0
.	0

Analysis	0
of	0
PBMCs	7
on	0
days	0
1	0
,	0
3	0
,	0
5	0
,	0
and	0
10	0
after	0
trauma	0
revealed	0
that	0
expression	0
of	0
both	0
p65p50	9
heterodimers	10
and	0
p50p50	9
homodimers	10
was	0
significantly	0
reduced	0
compared	0
with	0
that	0
in	0
controls	0
.	0

In	0
vitro	0
lipopolysaccharide	0
(	0
LPS	0
)	0
stimulation	0
of	0
PBMCs	7
induced	0
NF-kappa	0
B	0
translocation	0
.	0

However	0
,	0
throughout	0
the	0
survey	0
,	0
p65p50	0
activation	0
remained	0
significantly	0
lower	0
in	0
trauma	0
patients	0
than	0
in	0
controls	0
.	0

After	0
LPS	0
stimulation	0
in	0
vitro	0
,	0
the	0
p65p50/p50p50	0
ratio	0
was	0
significantly	0
lower	0
in	0
PBMCs	7
from	0
trauma	0
patients	0
than	0
from	0
healthy	0
controls	0
.	0

The	0
ex	0
vivo	0
expression	0
of	0
I	9
kappa	10
B	10
alpha	10
was	0
higher	0
in	0
PBMCs	7
of	0
controls	0
than	0
of	0
trauma	0
patients	0
.	0

LPS	0
did	0
not	0
induce	0
I	0
kappa	0
B	0
expression	0
in	0
PBMCs	7
from	0
trauma	0
patients	0
,	0
but	0
strong	0
induction	0
was	0
obtained	0
with	0
staphylococci	0
,	0
suggesting	0
that	0
this	0
defect	0
is	0
not	0
universal	0
and	0
depends	0
on	0
the	0
nature	0
of	0
the	0
activating	0
signal	0
.	0

Although	0
no	0
direct	0
correlation	0
was	0
found	0
between	0
levels	0
of	0
interleukin-10	9
or	0
transforming	9
growth	10
factor-beta	10
and	0
NF-kappa	9
B	10
,	0
these	0
immunosuppressive	9
cytokines	10
were	0
significantly	0
elevated	0
in	0
trauma	0
patients	0
by	0
10	0
days	0
after	0
admission	0
.	0

The	0
long-term	0
low-basal	0
and	0
LPS-induced	0
nuclear	0
translocation	0
of	0
NF-kappa	9
B	10
recalled	0
long-term	0
immunoparalysis	0
observed	0
in	0
patients	0
with	0
severe	0
inflammatory	0
stress	0
such	0
as	0
trauma	0
.	0

Hepatic	0
ischemia-reperfusion	0
injury	0
.	0

BACKGROUND	0
:	0
The	0
morbidity	0
associated	0
with	0
liver	0
transplantation	0
and	0
major	0
hepatic	0
resections	0
is	0
partly	0
a	0
result	0
of	0
ischemia-reperfusion	0
injury	0
.	0

DATA	0
SOURCES	0
:	0
The	0
entire	0
world	0
literature	0
on	0
the	0
subject	0
was	0
searched	0
via	0
Medline	0
.	0

Keywords	0
included	0
reperfusion	0
injury	0
,	0
transplantation	0
,	0
liver	0
resection	0
,	0
nitric	0
oxide	0
,	0
endothelin	0
,	0
cytokines	9
,	0
Kupffer	7
cells	8
,	0
ischemic/ischaemic	0
preconditioning	0
,	0
and	0
nuclear	9
factor-kappa	10
B	10
.	0

CONCLUSIONS	0
:	0
An	0
imbalance	0
between	0
endothelin	0
and	0
nitric	0
oxide	0
levels	0
results	0
in	0
failure	0
of	0
the	0
hepatic	0
microcirculation	0
at	0
the	0
onset	0
of	0
reperfusion	0
.	0

Activation	0
of	0
nuclear	9
factor-kappa	10
B	10
in	0
the	0
liver	0
promotes	0
proinflammatory	9
cytokine	10
and	0
adhesion	9
molecule	10
synthesis	0
.	0

These	0
result	0
in	0
oxygen-derived	0
free	0
radical	0
production	0
and	0
neutrophil	0
recruitment	0
,	0
further	0
contributing	0
to	0
cellular	0
injury	0
.	0

Various	0
therapeutic	0
modalities	0
acting	0
on	0
the	0
above	0
mediators	0
have	0
been	0
successfully	0
used	0
to	0
attenuate	0
reperfusion	0
injury	0
in	0
animal	0
models	0
of	0
hepatic	0
transplantation	0
and	0
resection	0
.	0

Application	0
of	0
the	0
knowledge	0
gained	0
from	0
animal	0
models	0
of	0
hepatic	0
ischemia-reperfusion	0
to	0
the	0
clinical	0
setting	0
will	0
improve	0
the	0
outcome	0
of	0
hepatic	0
surgery	0
.	0

Down-regulation	0
of	0
IL-12	1
p40	2
gene	2
in	0
Plasmodium	0
berghei-infected	0
mice	0
.	0

We	0
analyzed	0
the	0
mechanism	0
that	0
causes	0
suppression	0
of	0
IL-12	1
p40	2
gene	2
induction	0
during	0
Plasmodium	0
berghei	0
infection	0
.	0

Although	0
IL-12	9
together	0
with	0
IFN-gamma	9
plays	0
an	0
important	0
role	0
in	0
protection	0
against	0
pathogenic	0
infection	0
,	0
the	0
IL-12	9
p70	10
protein	10
production	0
of	0
infected	7
macrophages	8
is	0
lower	0
than	0
that	0
by	0
the	0
uninfected	7
macrophages	8
.	0

We	0
showed	0
in	0
the	0
present	0
study	0
that	0
the	0
induction	0
of	0
IL-12	1
p40	2
gene	2
but	0
not	0
IL-12	1
p35	2
gene	2
in	0
macrophages	7
of	0
P.	0
berghei-infected	0
mice	0
was	0
profoundly	0
inhibited	0
.	0

The	0
inhibition	0
was	0
induced	0
by	0
interaction	0
with	0
macrophages	7
that	0
had	0
contacted	0
with	0
P.	7
berghei-infected	8
erythrocytes	8
and	0
was	0
mediated	0
by	0
a	0
soluble	0
factor	0
,	0
IL-10	9
.	0

There	0
was	0
comparable	0
activation	0
of	0
NF-kappaB	9
in	0
uninfected	7
and	8
infected	8
cells	8
.	0

The	0
induction	0
of	0
IFN-regulatory	1
factor-1	2
gene	2
was	0
comparable	0
in	0
transcription	0
level	0
in	0
uninfected	7
and	8
infected	8
cells	8
,	0
while	0
the	0
unidentified	0
complex	0
formation	0
of	0
IFN-regulatory	9
factor-1	10
was	0
observed	0
in	0
infected	7
cells	8
.	0

Therefore	0
,	0
the	0
inhibition	0
of	0
the	0
IL-12	1
p40	2
gene	2
induction	0
appeared	0
to	0
be	0
regulated	0
at	0
transcriptional	0
regulation	0
level	0
of	0
the	0
gene	0
.	0

The	0
Friend	9
of	10
GATA	10
proteins	10
U-shaped	0
,	0
FOG-1	9
,	0
and	0
FOG-2	9
function	0
as	0
negative	0
regulators	0
of	0
blood	0
,	0
heart	0
,	0
and	0
eye	0
development	0
in	0
Drosophila	0
.	0

Friend	9
of	10
GATA	10
(	10
FOG	10
)	10
proteins	10
regulate	0
GATA	0
factor-activated	0
gene	0
transcription	0
.	0

During	0
vertebrate	0
hematopoiesis	0
,	0
FOG	9
and	10
GATA	10
proteins	10
cooperate	0
to	0
promote	0
erythrocyte	0
and	0
megakaryocyte	0
differentiation	0
.	0

The	0
Drosophila	9
FOG	10
homologue	10
U-shaped	10
(	0
Ush	9
)	0
is	0
expressed	0
similarly	0
in	0
the	0
blood	0
cell	0
anlage	0
during	0
embryogenesis	0
.	0

During	0
hematopoiesis	0
,	0
the	0
acute	0
myeloid	0
leukemia	0
1	0
homologue	0
Lozenge	7
and	8
Glial	8
cells	8
missing	0
are	0
required	0
for	0
the	0
production	0
of	0
crystal	7
cells	8
and	0
plasmatocytes	7
,	0
respectively	0
.	0

However	0
,	0
additional	0
factors	0
have	0
been	0
predicted	0
to	0
control	0
crystal	0
cell	0
proliferation	0
.	0

In	0
this	0
report	0
,	0
we	0
show	0
that	0
Ush	9
is	0
expressed	0
in	0
hemocyte	7
precursors	8
and	0
plasmatocytes	7
throughout	0
embryogenesis	0
and	0
larval	0
development	0
,	0
and	0
the	0
GATA	9
factor	10
Serpent	10
is	0
essential	0
for	0
Ush	9
embryonic	0
expression	0
.	0

Furthermore	0
,	0
loss	0
of	0
ush	0
function	0
results	0
in	0
an	0
overproduction	0
of	0
crystal	7
cells	8
,	0
whereas	0
forced	0
expression	0
of	0
Ush	9
reduces	0
this	0
cell	0
population	0
.	0

Murine	9
FOG-1	10
and	10
FOG-2	10
also	0
can	0
repress	0
crystal	0
cell	0
production	0
,	0
but	0
a	0
mutant	0
version	0
of	0
FOG-2	9
lacking	0
a	0
conserved	0
motif	0
that	0
binds	0
the	0
corepressor	9
C-terminal	10
binding	10
protein	10
fails	0
to	0
affect	0
the	0
cell	0
lineage	0
.	0

The	0
GATA	9
factor	10
Pannier	10
(	0
Pnr	9
)	0
is	0
required	0
for	0
eye	0
and	0
heart	0
development	0
in	0
Drosophila	0
.	0

When	0
Ush	9
,	0
FOG-1	9
,	0
FOG-2	9
,	0
or	0
mutant	9
FOG-2	10
is	0
coexpressed	0
with	0
Pnr	9
during	0
these	0
developmental	0
processes	0
,	0
severe	0
eye	0
and	0
heart	0
phenotypes	0
result	0
,	0
consistent	0
with	0
a	0
conserved	0
negative	0
regulation	0
of	0
Pnr	9
function	0
.	0

These	0
results	0
indicate	0
that	0
the	0
fly	0
and	0
mouse	0
FOG	9
proteins	10
function	0
similarly	0
in	0
three	0
distinct	0
cellular	0
contexts	0
in	0
Drosophila	0
,	0
but	0
may	0
use	0
different	0
mechanisms	0
to	0
regulate	0
genetic	0
events	0
in	0
blood	0
vs	0
.	0
cardial	5
or	6
eye	6
cell	6
lineages	6

The	0
RING	9
finger	10
protein	10
Siah-1	9
regulates	0
the	0
level	0
of	0
the	0
transcriptional	9
coactivator	10
OBF-1	9
.	0

The	0
transcriptional	9
coactivator	10
OBF-1	9
,	0
which	0
interacts	0
with	0
Oct-1	9
and	0
Oct-2	9
and	0
the	0
octamer	1
site	2
DNA	2
,	0
has	0
been	0
shown	0
to	0
be	0
critical	0
for	0
development	0
of	0
a	0
normal	0
immune	0
response	0
and	0
the	0
formation	0
of	0
germinal	0
centers	0
in	0
secondary	0
lymphoid	0
organs	0
.	0

Here	0
we	0
have	0
identified	0
the	0
RING	9
finger	10
protein	10
Siah-1	9
as	0
a	0
protein	0
interacting	0
specifically	0
with	0
OBF-1	9
.	0

This	0
interaction	0
is	0
mediated	0
by	0
the	0
C-terminal	9
part	0
of	0
Siah-1	9
and	0
by	0
residues	0
in	0
the	0
N-terminus	9
of	0
OBF-1	9
,	0
partly	0
distinct	0
from	0
the	0
residues	0
required	0
for	0
formation	0
of	0
a	0
complex	0
with	0
the	0
Oct	9
POU	10
domains	10
and	0
the	0
DNA	0
.	0

Interaction	0
between	0
Siah-1	9
and	0
OBF-1	9
leads	0
to	0
downregulation	0
of	0
OBF-1	0
protein	0
level	0
but	0
not	0
mRNA	0
,	0
and	0
to	0
a	0
corresponding	0
reduction	0
in	0
octamer	0
site-dependent	0
transcription	0
activation	0
.	0

Inhibition	0
of	0
the	0
ubiquitin-proteasome	0
pathway	0
in	0
B	7
cells	8
leads	0
to	0
elevated	0
levels	0
of	0
OBF-1	9
protein	10
.	0

Furthermore	0
,	0
in	0
immunized	0
mice	0
,	0
OBF-1	9
protein	10
amounts	0
are	0
dramatically	0
increased	0
in	0
primary	7
activated	8
B	8
cells	8
,	0
without	0
concomitant	0
increase	0
in	0
OBF-1	3
mRNA	4
.	0

These	0
data	0
suggest	0
that	0
Siah-1	9
is	0
part	0
of	0
a	0
novel	0
regulatory	0
loop	0
controlling	0
the	0
level	0
of	0
OBF-1	9
protein	10
in	0
B	7
cells	8
.	0

The	0
beta-catenin	0
--	0
TCF-1	0
pathway	0
ensures	0
CD4	7
(	8
+	8
)	8
CD8	8
(	8
+	8
)	8
thymocyte	8
survival	0
.	0

The	0
association	0
of	0
trans-acting	9
T	10
cell	10
factors	10
(	0
TCFs	9
)	0
or	0
lymphoid	9
enhancer	10
factor	10
1	10
(	0
LEF-1	9
)	0
with	0
their	0
coactivator	0
beta-catenin	0
mediates	0
transient	0
transcriptional	0
responses	0
to	0
extracellular	0
Wnt	0
signals	0
.	0

We	0
show	0
here	0
that	0
T	0
cell	0
maturation	0
depends	0
on	0
the	0
presence	0
of	0
the	0
beta-catenin	9
--	10
binding	10
domain	10
in	0
TCF-1	9
.	0

This	0
domain	0
is	0
necessary	0
to	0
mediate	0
the	0
survival	0
of	0
immature	0
CD4	7
(	8
+	8
)	8
CD8	8
(	8
+	8
)	8
double-positive	8
(	8
DP	8
)	8
thymocytes	8
.	0

Accelerated	0
spontaneous	0
thymocyte	0
death	0
in	0
the	0
absence	0
of	0
TCF-1	9
correlates	0
with	0
aberrantly	0
low	0
expression	0
of	0
the	0
anti-apoptotic	9
protein	10
Bcl-x	9
(	10
L	10
)	10
.	0

Increasing	0
anti-apoptotic	0
effectors	0
in	0
thymocytes	7
by	0
the	0
use	0
of	0
a	0
Bcl-2	1
transgene	2
rescued	0
TCF-1-deficient	7
DP	8
thymocytes	8
from	0
apoptosis	0
.	0

Thus	0
,	0
TCF-1	9
,	0
upon	0
association	0
with	0
beta-catenin	0
,	0
transiently	0
ensures	0
the	0
survival	0
of	0
immature	7
T	8
cells	8
,	0
which	0
enables	0
them	0
to	0
generate	0
and	0
edit	0
T	9
cell	10
receptor	10
(	10
TCR	10
)	10
alpha	10
chains	10
and	0
attempt	0
TCR	9
-mediated	0
positive	0
selection	0
.	0

TRAIL/Apo2L	9
ligand	10
selectively	0
induces	0
apoptosis	0
and	0
overcomes	0
drug	0
resistance	0
in	0
multiple	0
myeloma	0
:	0
therapeutic	0
applications	0
.	0

Multiple	0
myeloma	0
(	0
MM	0
)	0
remains	0
incurable	0
and	0
novel	0
treatments	0
are	0
urgently	0
needed	0
.	0

Preclinical	0
in	0
vitro	0
and	0
in	0
vivo	0
evaluations	0
were	0
performed	0
to	0
assess	0
the	0
potential	0
therapeutic	0
applications	0
of	0
human	0
recombinant	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-related	10
apoptosis-inducing	10
ligand/Apo2	10
ligand	10
(	0
TRAIL/Apo2L	9
)	0
in	0
MM	0
.	0

TRAIL/Apo2L	9
potently	0
induced	0
apoptosis	0
of	0
MM	7
cells	8
from	0
patients	0
and	0
the	0
majority	0
of	0
MM	5
cell	6
lines	6
,	0
including	0
cells	0
sensitive	0
or	0
resistant	0
to	0
dexamethasone	0
(	0
Dex	0
)	0
,	0
doxorubicin	0
(	0
Dox	0
)	0
,	0
melphalan	0
,	0
and	0
mitoxantrone	0
.	0

TRAIL/Apo2L	9
also	0
overcame	0
the	0
survival	0
effect	0
of	0
interleukin	9
6	10
on	0
MM	7
cells	8
and	0
did	0
not	0
affect	0
the	0
survival	0
of	0
peripheral	7
blood	8
and	8
bone	8
marrow	8
mononuclear	8
cells	8
and	0
purified	7
B	8
cells	8
from	0
healthy	0
donors	0
.	0

The	0
status	0
of	0
the	0
TRAIL	9
receptors	10
(	0
assessed	0
by	0
immunoblotting	0
and	0
flow	0
cytometry	0
)	0
could	0
not	0
predict	0
TRAIL	0
sensitivity	0
of	0
MM	7
cells	8
.	0

The	0
anti-MM	0
activity	0
of	0
TRAIL/Apo2L	9
was	0
confirmed	0
in	0
nu/xid/bg	0
mice	0
xenografted	0
with	0
human	7
MM	8
cells	8
;	0
TRAIL	9
(	0
500	0
microg	0
intraperitoneally	0
daily	0
for	0
14	0
days	0
)	0
was	0
well	0
tolerated	0
and	0
significantly	0
suppressed	0
the	0
growth	0
of	0
plasmacytomas	7
.	0

Dox	0
up-regulated	0
the	0
expression	0
of	0
the	0
TRAIL	9
receptor	10
death	9
receptor	10
5	10
(	0
DR5	9
)	0
and	0
synergistically	0
enhanced	0
the	0
effect	0
of	0
TRAIL	9
not	0
only	0
against	0
MM	7
cells	8
sensitive	0
to	0
,	0
but	0
also	0
against	0
those	0
resistant	0
to	0
,	0
Dex-	0
or	0
Dox-induced	0
apoptosis	0
.	0

Nuclear	0
factor	0
(	0
NF	0
)	0
-kappaB	0
inhibitors	0
,	0
such	0
as	0
SN50	0
(	0
a	0
cell-permeable	0
inhibitor	0
of	0
the	0
nuclear	0
translocation	0
and	0
transcriptional	0
activity	0
of	0
NF-kappaB	9
)	0
or	0
the	0
proteasome	0
inhibitor	0
PS-341	0
,	0
enhanced	0
the	0
proapoptotic	0
activity	0
of	0
TRAIL/Apo2L	9
against	0
TRAIL-sensitive	7
MM	8
cells	8
,	0
whereas	0
SN50	0
reversed	0
the	0
TRAIL	0
resistance	0
of	0
ARH-77	7
and	8
IM-9	8
MM	8
cells	8
.	0

Importantly	0
,	0
normal	7
B	8
lymphocytes	8
were	0
not	0
sensitized	0
to	0
TRAIL	9
by	0
either	0
Dox	0
,	0
SN50	0
,	0
or	0
PS-341	0
.	0

These	0
preclinical	0
studies	0
suggest	0
that	0
TRAIL/Apo2L	9
can	0
overcome	0
conventional	0
drug	0
resistance	0
and	0
provide	0
the	0
basis	0
for	0
clinical	0
trials	0
of	0
TRAIL	9
-based	0
treatment	0
regimens	0
to	0
improve	0
outcome	0
in	0
patients	0
with	0
MM	0
.	0

(	0
Blood.	0
2001	0
;	0
98	0
:	0
795-804	0
)	0

CD28	9
costimulation	0
is	0
required	0
not	0
only	0
to	0
induce	0
IL-12	9
receptor	10
but	0
also	0
to	0
render	0
janus	9
kinases/STAT4	10
responsive	0
to	0
IL-12	9
stimulation	0
in	0
TCR-triggered	7
T	8
cells	8
.	0

The	0
activation	0
of	0
resting	7
T	8
cells	8
for	0
the	0
acquisition	0
of	0
various	0
functions	0
depends	0
on	0
whether	0
CD28	0
costimulatory	0
signals	0
are	0
provided	0
upon	0
T	0
cell	0
receptor	0
stimulation	0
.	0

Here	0
,	0
we	0
investigated	0
how	0
CD28	0
costimulation	0
functions	0
to	0
allow	0
TCR	9
-triggered	0
resting	7
T	8
cells	8
to	0
acquire	0
IL-12	9
responsiveness	0
.	0

When	0
T	7
cells	8
are	0
stimulated	0
with	0
low	0
doses	0
of	0
anti-CD3	9
mAb	10
,	0
CD28	0
costimulation	0
was	0
required	0
for	0
the	0
optimal	0
levels	0
of	0
IL-12	9
receptor	10
(	0
IL-12R	9
)	0
expression	0
.	0

However	0
,	0
stimulation	0
of	0
T	7
cells	8
with	0
high	0
doses	0
of	0
anti-CD3	9
alone	0
induced	0
comparable	0
levels	0
of	0
IL-12R	9
expression	0
to	0
those	0
induced	0
upon	0
CD28	0
costimulation	0
.	0

Nevertheless	0
,	0
there	0
was	0
a	0
substantial	0
difference	0
in	0
IL-12	9
responsiveness	0
between	0
these	0
two	0
groups	0
of	0
T	7
cells	8
:	0
compared	0
to	0
anti-CD28-costimulated	7
T	8
cells	8
,	0
T	7
cells	8
that	0
were	0
not	0
costimulated	0
with	0
anti-CD28	9
exhibited	0
decreased	0
levels	0
of	0
Janus	9
kinases	10
(	0
JAK	9
)	0
JAK2/TYK2	9
and	0
STAT4	9
phosphorylation	0
and	0
IFN-y	0
production	0
following	0
IL-12	9
stimulation	0
.	0

Importantly	0
,	0
STAT6	0
phosphorylation	0
following	0
IL-4	0
stimulation	0
was	0
not	0
decreased	0
in	0
anti-CD28-uncostimulated	7
T	8
cells	8
.	0

These	0
resutls	0
indicate	0
that	0
CD28	0
costimulation	0
not	0
only	0
contributes	0
to	0
up-regulating	0
IL-12R	9
expression	0
but	0
is	0
also	0
required	0
to	0
render	0
JAKs/STAT4	9
responsive	0
to	0
IL-12	9
stimulation	0
.	0

Constitutively	0
activated	0
Akt-1	9
is	0
vital	0
for	0
the	0
survival	0
of	0
human	7
monocyte-differentiated	8
macrophages	8
.	0

Role	0
of	0
Mcl-1	9
,	0
independent	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
,	0
Bad	9
,	0
or	0
caspase	0
activation	0
.	0

Recent	0
data	0
from	0
mice	0
deficient	0
for	0
phosphatase	9
and	0
tensin	1
homologue	2
deleted	0
from	0
chromosome	1
10	2
or	0
src	9
homology	10
2	10
domain-containing	10
5	10
'	10
inositol	10
phosphatase	10
,	0
phosphatases	9
that	0
negatively	0
regulate	0
the	0
phosphatidylinositol	9
3-kinase	10
(	0
PI3K	9
)	0
pathway	0
,	0
revealed	0
an	0
increased	0
number	0
of	0
macrophages	7
in	0
these	0
animals	0
,	0
suggesting	0
an	0
essential	0
role	0
for	0
the	0
PI3K	9
pathway	0
for	0
macro-phage	7
survival	0
.	0

Here	0
,	0
we	0
focused	0
on	0
the	0
role	0
of	0
the	0
PI3K-regulated	9
serine/threonine	10
kinase	10
Akt-1	9
in	0
modulating	0
macrophage	7
survival	0
.	0

Akt-1	9
was	0
constitutively	0
activated	0
in	0
human	7
macrophages	8
and	0
addition	0
of	0
the	0
PI3K	9
inhibitor	0
,	0
LY294002	0
,	0
suppressed	0
the	0
activation	0
of	0
Akt-1	9
and	0
induced	0
cell	0
death	0
.	0

Furthermore	0
,	0
suppression	0
of	0
Akt-1	9
by	0
inhibition	0
of	0
PI3K	9
or	0
a	0
dominant	9
negative	10
(	10
DN	10
)	10
Akt-1	10
resulted	0
in	0
loss	0
of	0
mitochondrial	0
transmembrane	0
potential	0
,	0
activation	0
of	0
caspases-9	9
and	10
-3	10
,	0
and	0
DNA	0
fragmentation	0
.	0

The	0
effects	0
of	0
PI3K	9
inhibition	0
were	0
reversed	0
by	0
the	0
ectopic	0
expression	0
of	0
constitutively	0
activated	0
Akt-1	9
or	0
Bcl-x	9
(	10
L	10
)	10
.	0

Inhibition	0
of	0
PI3K	9
/Akt-1	0
pathway	0
either	0
by	0
LY294002	0
or	0
DN	9
Akt-1	10
had	0
no	0
effect	0
on	0
the	0
constitutive	0
or	0
inducible	0
activation	0
of	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
in	0
human	7
macrophages	8
.	0

However	0
,	0
after	0
inhibition	0
of	0
the	0
PI3K	9
/	0
Akt-1	9
pathway	0
,	0
a	0
marked	0
decrease	0
in	0
the	0
expression	0
of	0
the	0
antiapoptotic	9
molecule	10
Mcl-1	9
,	0
but	0
not	0
other	0
Bcl-2	9
family	10
members	10
was	0
observed	0
,	0
and	0
Mcl-1	9
rescued	0
macrophages	7
from	0
LY294002-induced	0
cell	0
death	0
.	0

Further	0
,	0
inhibition	0
of	0
Mcl-1	9
by	0
antisense	0
oligonucleotides	0
,	0
also	0
resulted	0
in	0
macrophage	7
apoptosis	0
.	0

Thus	0
,	0
our	0
findings	0
demonstrate	0
that	0
the	0
constitutive	0
activation	0
of	0
Akt-1	9
regulates	0
macrophage	7
survival	0
through	0
Mcl-1	9
,	0
which	0
is	0
independent	0
of	0
caspases	9
,	0
NF-kappaB	9
,	0
or	0
Bad	9
.	0

GRbeta	0
expression	0
in	0
nasal	7
polyp	8
inflammatory	8
cells	8
and	0
its	0
relationship	0
to	0
the	0
anti-inflammatory	0
effects	0
of	0
intranasal	0
fluticasone	0
.	0

BACKGROUND	0
:	0
Nasal	0
polyposis	0
disease	0
is	0
an	0
inflammatory	0
disorder	0
with	0
intense	0
eosinophilic	0
infiltration	0
of	0
respiratory	0
mucosa	0
that	0
is	0
often	0
difficult	0
to	0
control	0
with	0
topical	0
steroids	0
.	0

Recent	0
evidence	0
suggests	0
that	0
overexpression	0
of	0
the	0
glucocorticoid	9
receptor	10
splice	10
variant	10
GRbeta	9
in	0
inflammatory	7
cells	8
might	0
contribute	0
to	0
steroid	0
insensitivity	0
in	0
diseases	0
such	0
as	0
asthma	0
.	0

OBJECTIVE	0
:	0
The	0
purposes	0
of	0
this	0
investigation	0
were	0
to	0
determine	0
whether	0
nasal	7
polyp	8
(	8
NP	8
)	8
inflammatory	8
cells	8
overexpress	0
GRbeta	9
and	0
to	0
examine	0
whether	0
GRbeta	9
overexpression	0
is	0
associated	0
with	0
insensitivity	0
to	0
the	0
potent	0
topical	0
steroid	0
fluticasone	0
propionate	0
(	0
FP	0
)	0
.	0

METHODS	0
:	0
Biopsies	0
were	0
obtained	0
from	0
10	0
subjects	0
with	0
NPs	0
before	0
and	0
4	0
weeks	0
after	0
treatment	0
with	0
intranasal	0
FP	0
.	0

Middle	0
turbinates	0
biopsies	0
from	0
6	0
healthy	0
,	0
nonallergic	0
subjects	0
served	0
as	0
normal	0
controls	0
.	0

Biopsies	0
were	0
immunostained	0
for	0
inflammatory	0
cell	0
markers	0
as	0
well	0
as	0
GRbeta	9
and	0
probed	0
for	0
various	0
cytokine	3
mRNA	4
.	0

The	0
anti-inflammatory	0
response	0
to	0
FP	0
was	0
examined	0
in	0
relation	0
to	0
pretreatment	0
levels	0
of	0
GRbeta	0
expression	0
.	0

RESULTS	0
:	0
The	0
total	0
numbers	0
of	0
inflammatory	7
cells	8
were	0
increased	0
in	0
NPs	7
.	0

The	0
percentage	0
of	0
inflammatory	7
cells	8
expressing	0
GRbeta	9
was	0
also	0
increased	0
(	0
40.5	0
%	0
+/-	0
19.2	0
%	0
vs	0
16.1	0
%	0
+/-	0
4.0	0
%	0
,	0
P	0
=.009	0
)	0
.	0

GRbeta	9
expression	0
in	0
NPs	7
was	0
almost	0
exclusive	0
to	0
T	7
lymphocytes	8
,	0
eosinophils	7
,	0
and	0
macrophages	7
.	0

An	0
inverse	0
correlation	0
was	0
observed	0
between	0
the	0
baseline	0
inflammatory	0
cell	0
GRbeta	9
expression	0
and	0
the	0
reduction	0
after	0
FP	0
treatment	0
in	0
EG2-positive	7
eosinophils	8
,	0
CD4-positive	7
T	8
lymphocytes	8
,	0
endothelial	0
VCAM-1	9
expression	0
,	0
and	0
IL-4	7
mRNA-positive	8
cells	8
.	0

NPs	7
that	0
were	0
``	0
FP-insensitive	0
''	0
in	0
terms	0
of	0
suppression	0
of	0
eosinophil	7
numbers	0
(	0
major	9
basic	10
protein	10
-positive	0
)	0
had	0
a	0
significantly	0
greater	0
percentage	0
of	0
GRbeta-positive	7
inflammatory	8
cells	8
,	0
a	0
higher	0
ratio	0
of	0
GRbeta-positive/GRalpha-positive	7
cells	8
,	0
and	0
increased	0
numbers	0
of	0
GRbeta-positive	7
eosinophils	8
and	0
macrophages	7
in	0
comparison	0
with	0
those	0
that	0
were	0
``	0
FP-sensitive.	0
''	0

``	7
FP-insensitive	8
''	8
NPs	8
also	0
demonstrated	0
a	0
higher	0
percentage	0
of	0
IL-5-positive	7
inflammatory	8
cells	8
expressing	0
GRbeta	9
before	0
and	0
after	0
FP	0
treatment	0
.	0

CONCLUSION	0
:	0
GRbeta	9
expression	0
appears	0
to	0
be	0
a	0
marker	0
of	0
steroid	0
insensitivity	0
in	0
NPs	7
.	0

Expression	0
of	0
GRbeta	9
by	0
NP	7
inflammatory	8
cells	8
,	0
particularly	0
T	7
cells	8
and	0
eosinophils	7
,	0
might	0
render	0
them	0
resistant	0
to	0
suppression	0
by	0
topical	0
steroids	0
and	0
thereby	0
contribute	0
to	0
persistent	0
NP	7
inflammation	0
.	0

Transcriptional	0
regulation	0
of	0
galectin-10	9
(	0
eosinophil	9
Charcot-Leyden	10
crystal	10
protein	10
)	0
:	0
a	0
GC	1
box	2
(	0
-44	0
to	0
-50	0
)	0
controls	0
butyric	0
acid	0
induction	0
of	0
gene	0
expression	0
.	0

Galectin-10	9
(	0
gal-10	9
,	0
also	0
known	0
as	0
Charcot-Leyden	9
crystal	10
protein	10
)	0
is	0
a	0
member	0
of	0
the	0
galectin	9
family	10
of	0
beta-galactoside	9
binding	10
proteins	10
that	0
is	0
expressed	0
uniquely	0
in	0
eosinophilic	7
and	8
basophilic	8
leukocytes	8
.	0

To	0
gain	0
a	0
better	0
understanding	0
of	0
galectin	0
gene	0
expression	0
,	0
we	0
present	0
an	0
analysis	0
of	0
the	0
transcriptional	0
regulation	0
of	0
the	0
gene	0
encoding	0
gal-10	9
.	0

Analysis	0
of	0
the	0
minimal	1
promoter	2
revealed	0
nine	0
consensus-binding	1
sites	2
for	0
transcription	9
factors	10
,	0
including	0
several	0
that	0
are	0
also	0
found	0
in	0
the	0
minimal	1
promoters	2
of	0
galectins	1
-1	2
,	2
-2	2
,	2
and	2
-3	2
.	0

The	0
decrease	0
in	0
gal-10	0
promoter	0
activity	0
after	0
disruption	0
of	0
either	0
the	0
GC	1
box	2
(	0
-44	0
to	0
-50	0
)	0
or	0
the	0
Oct	1
site	2
(	0
-255	0
to	0
-261	0
)	0
suggests	0
that	0
these	0
sites	0
,	0
along	0
with	0
the	0
previously	0
characterized	0
GATA	1
and	2
EoTF	2
sites	2
,	0
are	0
necessary	0
for	0
full	0
promoter	0
activity	0
.	0

By	0
supershift	0
analysis	0
,	0
we	0
demonstrate	0
binding	0
of	0
the	0
transcription	9
factors	10
Sp1	9
and	0
Oct1	9
to	0
the	0
consensus	1
GC	2
box	2
and	0
the	0
Oct	1
site	2
,	0
respectively	0
.	0

Similar	0
to	0
gal-1	1
,	0
gal-10	0
expression	0
is	0
induced	0
by	0
butyric	0
acid	0
,	0
an	0
effect	0
that	0
is	0
lost	0
upon	0
ablation	0
of	0
the	0
GC	1
box	2
.	0

Additionally	0
,	0
we	0
demonstrate	0
AML3	0
binding	0
to	0
the	0
consensus	1
AML	2
site	2
and	0
YY1	9
binding	10
to	0
the	0
Inr	1
sequence	2
,	0
both	0
elements	0
functioning	0
as	0
silencers	0
in	0
the	0
gal-10	1
promoter	2
.	0

Tumour-stromal	0
interactions	0
.	0

Role	0
of	0
the	0
stroma	0
in	0
mammary	0
development	0
.	0

Mammary	0
development	0
depends	0
on	0
branching	0
morphogenesis	0
,	0
namely	0
the	0
bifurcation	0
and	0
extension	0
of	0
ductal	0
growth	0
points	0
(	0
end	0
buds	0
)	0
and	0
secretory	0
lobules	0
into	0
a	0
more	0
or	0
less	0
fatty	0
stroma	0
.	0

Because	0
breast	0
carcinomas	0
are	0
overwhelmingly	0
ductal	0
in	0
origin	0
,	0
this	0
review	0
focuses	0
on	0
stromal	0
influences	0
guiding	0
postnatal	0
ductal	0
development	0
and	0
there	0
is	0
only	0
the	0
briefest	0
account	0
of	0
the	0
role	0
of	0
embryonic	0
stroma	0
(	0
mesenchyme	0
)	0
.	0

The	0
stroma	0
as	0
the	0
necessary	0
target	0
for	0
endocrine	0
mammogens	0
and	0
the	0
source	0
of	0
stimulatory	0
growth	0
factors	0
is	0
described	0
and	0
the	0
importance	0
of	0
mammary	0
epithelium-induced	0
modifications	0
of	0
the	0
periductal	0
stroma	0
is	0
emphasized	0
.	0

Evidence	0
is	0
presented	0
that	0
if	0
they	0
are	0
to	0
grow	0
,	0
end	0
buds	0
must	0
condition	0
proximal	0
fatty	0
stroma	0
by	0
recruiting	0
white	7
blood	8
cells	8
as	0
well	0
as	0
inducing	0
stromal	0
cell	0
division	0
and	0
,	0
possibly	0
,	0
estrogen	9
receptors	10
.	0

The	0
induction	0
of	0
a	0
fibrous	0
stromal	0
tunic	0
around	0
the	0
end	0
bud	0
is	0
described	0
and	0
its	0
likely	0
role	0
as	0
a	0
complex	0
ductal	0
morphogen	0
is	0
discussed	0
;	0
a	0
possible	0
role	0
in	0
growth	0
inhibition	0
is	0
also	0
considered	0
.	0

Although	0
the	0
signals	0
governing	0
fibrotic	0
induction	0
,	0
ductal	0
morphogenesis	0
,	0
and	0
growth	0
inhibition	0
are	0
unknown	0
,	0
a	0
role	0
for	0
transforming	0
growth	9
factor-beta	10
is	0
highly	0
likely	0
and	0
is	0
discussed	0
.	0

Finally	0
,	0
a	0
need	0
for	0
new	0
conceptual	0
and	0
experimental	0
approaches	0
to	0
understanding	0
stromal-epithelial	0
signaling	0
is	0
discussed	0
.	0

Adipophilin	9
is	0
a	0
sensitive	0
marker	0
for	0
lipid	0
loading	0
in	0
human	7
blood	8
monocytes	8
.	0

Adipophilin	9
,	0
a	0
marker	0
of	0
lipid	0
accumulation	0
initially	0
described	0
in	0
adipocytes	7
,	0
was	0
recently	0
shown	0
to	0
be	0
induced	0
in	0
macrophage	7
foam	8
cells	8
.	0

We	0
found	0
that	0
even	0
freshly	7
isolated	8
blood	8
monocytes	8
express	0
adipophilin	9
and	0
that	0
the	0
amount	0
of	0
adipophilin	9
protein	10
is	0
variable	0
in	0
monocytes	7
from	0
different	0
healthy	0
individuals	0
.	0

However	0
,	0
the	0
physiological	0
expression	0
of	0
adipophilin	9
does	0
not	0
correlate	0
with	0
the	0
levels	0
of	0
free	0
fatty	0
acids	0
,	0
cholesterylesters	0
or	0
free	0
cholesterol	0
.	0

Enzymatically	9
modified	10
low-density	10
lipoprotein	10
(	0
E-LDL	9
)	0
induces	0
rapid	0
foam	0
cell	0
formation	0
in	0
monocytes	7
and	0
upregulates	0
adipophilin	9
mRNA	0
and	0
protein	0
within	0
2	0
h	0
of	0
incubation	0
.	0

This	0
rapid	0
induction	0
of	0
adipophilin	9
is	0
accompanied	0
by	0
a	0
significant	0
increase	0
of	0
free	0
fatty	0
acids	0
in	0
monocytes	7
incubated	0
with	0
E-LDL	9
.	0

Adipophilin	9
facilitates	0
the	0
uptake	0
of	0
free	0
fatty	0
acids	0
,	0
and	0
here	0
we	0
demonstrate	0
that	0
free	0
fatty	0
acids	0
increase	0
is	0
related	0
to	0
the	0
early	0
upregulation	0
of	0
adipophilin	0
expression	0
in	0
blood	7
monocytes	8
.	0

Fatty	0
acids	0
are	0
ligands	0
for	0
peroxisome	9
proliferator-activated	10
receptor-gamma	10
(	0
PPARgamma	9
)	0
,	0
and	0
the	0
upregulation	0
of	0
adipophilin	3
mRNA	4
by	0
PPARgamma	9
agonists	0
like	0
15d-PGJ	0
(	0
2	0
)	0
and	0
ciglitazone	0
indicates	0
that	0
PPARgamma	9
may	0
mediate	0
the	0
induction	0
of	0
adipophilin	0
expression	0
in	0
human	7
blood	8
monocytes	8
.	0

Constitutive	0
expression	0
of	0
MHC	1
class	2
II	2
genes	2
in	0
melanoma	5
cell	6
lines	6
results	0
from	0
the	0
transcription	0
of	0
class	1
II	2
transactivator	2
abnormally	0
initiated	0
from	0
its	0
B	1
cell-specific	2
promoter	2
.	0

In	0
melanoma	5
cell	6
lines	6
,	0
two	0
different	0
patterns	0
of	0
MHC	0
class	0
II	0
expression	0
have	0
been	0
described	0
,	0
either	0
an	0
IFN	0
gamma-inducible	0
expression	0
of	0
HLA-DR	1
and	0
HLA-DP	1
,	0
with	0
a	0
faint	0
or	0
null	0
expression	0
of	0
HLA-DQ	1
,	0
resembling	0
that	0
described	0
for	0
melanocytes	7
,	0
or	0
a	0
constitutive	0
expression	0
,	0
i.e.	0
,	0
IFN-gamma	0
independent	0
,	0
of	0
all	0
three	0
HLA-D	1
isotypes	2
.	0

As	0
this	0
latter	0
phenotype	0
has	0
been	0
associated	0
with	0
a	0
more	0
rapid	0
progression	0
of	0
melanoma	0
tumors	0
,	0
we	0
have	0
analyzed	0
in	0
different	0
melanoma	5
cell	6
lines	6
the	0
molecular	0
mechanisms	0
leading	0
to	0
this	0
abnormal	0
pattern	0
of	0
MHC	0
class	0
II	0
expression	0
.	0

In	0
agreement	0
with	0
the	0
evidence	0
of	0
a	0
coordinate	0
transcription	0
of	0
the	0
HLA-D	1
genes	2
in	0
these	0
cell	0
lines	0
,	0
we	0
have	0
shown	0
the	0
constitutive	0
expression	0
of	0
CIITA	3
(	4
class	4
II	4
transactivator	4
)	4
transcripts	4
,	0
CIITA	9
being	0
known	0
as	0
the	0
master	0
switch	0
of	0
MHC	0
class	0
II	0
expression	0
.	0

Unexpectedly	0
,	0
these	0
transcripts	0
initiate	0
from	0
promoter	1
III	2
of	0
the	0
CIITA	1
gene	2
,	0
a	0
promoter	0
that	0
is	0
mainly	0
used	0
constitutively	0
in	0
B	7
lymphocytes	8
.	0

This	0
expression	0
was	0
further	0
shown	0
to	0
occur	0
through	0
factor	0
(	0
s	0
)	0
acting	0
on	0
the	0
enhancer	0
located	0
upstream	0
of	0
CIITA	1
promoter	2
III	2
,	0
which	0
was	0
previously	0
described	0
in	0
epithelioid	7
cells	8
as	0
an	0
IFN-gamma-response	0
sequence	0
.	0

The	0
hypothesis	0
of	0
a	0
general	0
abnormality	0
of	0
the	0
IFN-gamma	0
transduction	0
pathway	0
was	0
dismissed	0
.	0

Constitutive	0
transcription	0
of	0
CIITA	1
from	0
promoter	1
III	2
having	0
been	0
observed	0
in	0
unrelated	0
melanoma	5
cell	6
lines	6
,	0
we	0
propose	0
the	0
hypothesis	0
that	0
this	0
phenomenon	0
might	0
not	0
be	0
a	0
random	0
event	0
,	0
but	0
could	0
be	0
linked	0
to	0
the	0
neoplasic	0
state	0
of	0
the	0
melanoma	7
cells	8

Caspase	9
-mediated	0
calcineurin	0
activation	0
contributes	0
to	0
IL-2	9
release	0
during	0
T	0
cell	0
activation	0
.	0

Calcineurin	9
,	0
a	0
Ca	9
(	10
2+	10
)	10
/calmodulin-dependent	10
Ser/Thr	10
phosphatase	10
(	10
protein	10
phosphatase	10
2B	10
)	10
,	0
plays	0
a	0
critical	0
role	0
in	0
IL-2	0
production	0
during	0
T	0
cell	0
activation	0
.	0

It	0
has	0
been	0
previously	0
reported	0
that	0
IL-2	9
release	0
in	0
activated	0
Jurkat	5
T	6
requires	0
caspase-like	0
activity	0
(	0
Posmantur	0
et	0
al.	0
(	0
1998	0
)	0
Exp.	0
Cell.	0
Res.	0
244	0
,	0
302-309	0
)	0
.	0

We	0
report	0
here	0
that	0
the	0
60-kDa	9
catalytic	10
subunit	10
of	0
calcineurin	9
A	10
(	0
Cn	9
A	10
)	0
was	0
partially	0
cleaved	0
to	0
a	0
45-kDa	9
form	0
in	0
phytohemagglutinin	0
A	0
(	0
PHA	0
)	0
or	0
phorbol	0
ester	0
+	0
ionomycin	0
(	0
P	0
+	0
I	0
)	0
-activated	0
Jurkat	5
cells	6
.	0

In	0
parallel	0
,	0
proteolytic	0
activation	0
of	0
upstream	0
caspases	9
(	0
caspase-8	0
and	0
-9	0
)	0
as	0
well	0
as	0
effector	9
caspase-3	10
was	0
also	0
observed	0
.	0

Cn	9
A	10
cleavage	0
was	0
caspase	0
mediated	0
,	0
since	0
it	0
was	0
inhibitable	0
by	0
pan-caspase	0
inhibitor	0
Cbz-Asp-CH	0
(	0
2	0
)	0
OC	0
(	0
O	0
)	0
-2	0
,	0
6-dichlorobenzene	0
(	0
Z-D-DCB	0
)	0
.	0

Cn	9
A	10
cleavage	0
was	0
also	0
observed	0
when	0
purified	0
calcineurin	9
was	0
digested	0
in	0
vitro	0
with	0
caspase-3	9
.	0

Truncated	9
Cn	10
A	10
was	0
associated	0
with	0
enhanced	0
phosphatase	0
activity	0
and	0
reduced	0
calmodulin	0
sensitivity	0
.	0

Furthermore	0
,	0
in	0
PHA	0
or	0
P	0
+	0
I-activated	0
Jurkat	5
cells	6
,	0
dephosphorylation	0
of	0
calcineurin	9
substrate	0
NFATc	9
(	0
a	0
transcription	9
factor	10
known	0
to	0
be	0
involved	0
in	0
transactivation	0
of	0
the	0
IL-2	1
gene	2
)	0
,	0
was	0
also	0
suppressed	0
by	0
Z-D-DCB	0
.	0

Taken	0
together	0
,	0
our	0
results	0
suggest	0
that	0
caspase-mediated	0
cleavage	0
of	0
Cn	9
A	10
contributes	0
to	0
IL-2	0
production	0
during	0
T	0
cell	0
activation	0
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Maturation	0
of	0
human	7
dendritic	8
cells	8
as	0
sulfasalazine	0
target	0
.	0

AIM	0
:	0
Sulfasalazine	0
,	0
a	0
nonsteroidal	0
anti-inflammatory	0
drug	0
,	0
is	0
effective	0
in	0
treating	0
some	0
autoimmune	0
diseases	0
,	0
but	0
its	0
mechanism	0
of	0
action	0
is	0
unclear	0
.	0

To	0
determine	0
whether	0
dendritic	7
cells	8
could	0
be	0
a	0
possible	0
target	0
of	0
the	0
drug	0
,	0
we	0
studied	0
the	0
effects	0
of	0
sulfasalazine	0
and	0
its	0
metabolites	0
,	0
aminosalicylate	0
and	0
sulfapyridine	0
,	0
on	0
in	0
vitro	0
maturation	0
(	0
terminal	0
differentiation	0
)	0
of	0
human	7
myeloid	8
dendritic	8
cells	8
.	0

METHODS	0
:	0
We	0
prepared	0
immature	7
dendritic	8
cells	8
by	0
incubating	0
CD14-positive	7
cells	8
in	0
the	0
presence	0
of	0
granulocyte-	9
macrophage	10
colony-stimulating	10
factor	10
and	0
interleukin	9
(	10
IL	10
)	10
-4	10
.	0

The	0
cells	0
were	0
matured	0
by	0
addition	0
of	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
-a	10
,	0
IL-1	9
beta	10
,	0
and	0
prostaglandin	9
E2	10
in	0
the	0
presence	0
of	0
sulfasalazine	0
or	0
its	0
metabolites	0
--	0
aminosalicylate	0
and	0
sulfapyridine	0
,	0
or	0
their	0
combinations	0
.	0

We	0
quantified	0
the	0
effect	0
of	0
drugs	0
on	0
the	0
dendritic	0
cell	0
characteristics	0
,	0
such	0
as	0
stimulation	0
of	0
autologous	0
and	0
allogeneic	0
pan-T	0
cell	0
proliferation	0
,	0
surface	0
marker	0
phenotype	0
,	0
IL-12	0
p40	0
subunit	0
secretion	0
,	0
and	0
activation	0
of	0
nuclear	9
transcription	10
factor	10
(	10
NF	10
)	10
-kappa	10
B	10
.	0

RESULTS	0
:	0
Dendritic	7
cells	8
treated	0
with	0
sulfasalazine	0
(	0
1.25	0
micromol/L	0
or	0
2.5	0
micromol/L	0
)	0
could	0
not	0
stimulate	0
T	7
cells	8
(	0
p	0
<	0
0.028	0
,	0
two-sided	0
paired	0
t-test	0
)	0
.	0

In	0
distinction	0
to	0
drug-free	0
maturing	0
dendritic	7
cells	8
,	0
2.5	0
micromol/L	0
sulfasalazine	0
upregulated	0
the	0
levels	0
of	0
CD14	9
and	0
CD68	9
and	0
downregulated	0
the	0
levels	0
of	0
CD40	9
,	0
CD80	9
,	0
and	0
CD83	9
(	0
for	0
all	0
CD	0
markers	0
,	0
p	0
<	0
0.03	0
for	0
difference	0
between	0
measurements	0
in	0
the	0
absence	0
and	0
the	0
presence	0
of	0
sulfasalazine	0
)	0
.	0

From	0
concentration-dependent	0
changes	0
in	0
CD83	0
expression	0
,	0
we	0
found	0
an	0
apparent	0
ID50	0
>	0
>	0
1.5	0
micromol/L	0
sulfasalazine	0
.	0

The	0
apparent	0
ID50	0
value	0
for	0
aminosalicylate-inhibited	0
maturation	0
was	0
4	0
micromol/L	0
.	0

Sulfapyridine	0
had	0
no	0
effect	0
.	0

At	0
1.25	0
micromol/L	0
,	0
sulfasalazine	0
largely	0
inhibited	0
NF-kB	0
activation	0
in	0
dendritic	7
cells	8
.	0

CONCLUSION	0
:	0
Maturing	7
human	8
dendritic	8
cells	8
are	0
hundred-fold	0
more	0
sensitive	0
to	0
sulfasalazine	0
than	0
T	7
cells	8
and	0
NK	7
cells	8
and	0
the	0
most	0
sensitive	0
human	0
cells	0
described	0
so	0
far	0
.	0

Thus	0
,	0
dendritic	0
cell	0
maturation	0
is	0
an	0
important	0
target	0
of	0
sulfasalazine	0
.	0

Because	0
of	0
the	0
role	0
of	0
dendritic	7
cells	8
in	0
(	0
auto	0
)	0
immunity	0
,	0
inhibition	0
of	0
their	0
maturation	0
might	0
provide	0
a	0
target	0
for	0
further	0
optimization	0
of	0
sulfasalazine	0
therapy	0
.	0

Defective	0
function	0
of	0
the	0
proteasome	9
in	0
autoimmunity	0
:	0
involvement	0
of	0
impaired	0
NF-kappaB	0
activation	0
.	0

Type	0
1	0
diabetes	0
(	0
also	0
known	0
as	0
insulin-dependent	0
diabetes	0
mellitus	0
or	0
juvenile-onset	0
diabetes	0
)	0
is	0
usually	0
caused	0
by	0
T	0
cell-mediated	0
autoimmunity	0
,	0
with	0
a	0
prediabetic	0
state	0
characterized	0
by	0
the	0
production	0
of	0
autoantibodies	9
specific	0
for	0
proteins	0
expressed	0
by	0
pancreatic	7
beta	8
cells	8
.	0

The	0
nonobese	0
patient	0
with	0
diabetes	0
(	0
NOD	0
)	0
mouse	0
is	0
a	0
spontaneous	0
model	0
of	0
type	0
1	0
diabetes	0
with	0
a	0
strong	0
genetic	0
component	0
that	0
maps	0
to	0
the	0
major	1
histocompatibility	2
complex	2
(	2
MHC	2
)	2
region	2
of	0
the	0
genome	1
.	0

A	0
specific	0
proteasome	9
defect	0
has	0
been	0
identified	0
in	0
NOD	0
mouse	0
in	0
select	0
lymphocytic	5
and	6
monocytic	6
lineages	6
that	0
results	0
from	0
down-regulation	0
of	0
expression	0
of	0
the	0
proteasome	9
subunit	10
LMP2	10
,	0
which	0
is	0
encoded	0
by	0
a	0
gene	0
in	0
the	0
MHC	1
genomic	2
region	2
.	0

This	0
defect	0
prevents	0
the	0
proteolytic	0
processing	0
required	0
for	0
the	0
production	0
and	0
activation	0
of	0
the	0
transcription	9
factor	10
nuclear	10
factor-kappaB	10
(	0
NF-kappaB	9
)	0
,	0
which	0
plays	0
important	0
roles	0
in	0
immune	0
and	0
inflammatory	0
responses	0
,	0
as	0
well	0
as	0
increases	0
the	0
susceptibility	0
of	0
the	0
affected	0
cells	0
to	0
apoptosis	0
induced	0
by	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
.	0

The	0
novel	0
role	0
of	0
the	0
proteasome	9
in	0
dysfunction	0
in	0
autoimmunity	0
is	0
presented	0
and	0
documented	0
to	0
be	0
both	0
tissue	0
and	0
developmental	0
stage	0
specific	0
.	0

We	0
propose	0
a	0
role	0
of	0
the	0
proteasome	9
as	0
a	0
step	0
in	0
disease	0
pathogenesis	0
and	0
tissue	0
targeting	0
.	0

Down-regulation	0
of	0
TDT	0
transcription	0
in	0
CD4	7
(	8
+	8
)	8
CD8	8
(	8
+	8
)	8
thymocytes	8
by	0
Ikaros	9
proteins	10
in	0
direct	0
competition	0
with	0
an	0
Ets	9
activator	10
.	0

Ikaros	9
is	0
a	0
unique	0
regulator	0
of	0
lymphopoiesis	0
that	0
associates	0
with	0
pericentromeric	1
heterochromatin	2
and	0
has	0
been	0
implicated	0
in	0
heritable	0
gene	0
inactivation	0
.	0

Binding	0
and	0
competition	0
experiments	0
demonstrate	0
that	0
Ikaros	9
dimers	10
compete	0
with	0
an	0
Ets	9
activator	10
for	0
occupancy	0
of	0
the	0
lymphocyte-specific	1
TdT	2
promoter	2
.	0

Mutations	0
that	0
selectively	0
disrupt	0
Ikaros	0
binding	0
to	0
an	0
integrated	1
TdT	2
promoter	2
had	0
no	0
effect	0
on	0
promoter	0
function	0
in	0
a	0
CD4	5
(	6
+	6
)	6
CD8	6
(	6
+	6
)	6
thymocyte	6
line	6
.	0

However	0
,	0
these	0
mutations	0
abolished	0
down-regulation	0
on	0
differentiation	0
,	0
providing	0
evidence	0
that	0
Ikaros	9
plays	0
a	0
direct	0
role	0
in	0
repression	0
.	0

Reduced	0
access	0
to	0
restriction	0
enzyme	0
cleavage	0
suggested	0
that	0
chromatin	0
alterations	0
accompany	0
down-regulation	0
.	0

The	0
Ikaros-dependent	0
down-regulation	0
event	0
and	0
the	0
observed	0
chromatin	0
alterations	0
appear	0
to	0
precede	0
pericentromeric	0
repositioning	0
.	0

Current	0
models	0
propose	0
that	0
the	0
functions	0
of	0
Ikaros	9
should	0
be	0
disrupted	0
by	0
a	0
small	0
isoform	9
that	0
retains	0
the	0
dimerization	9
domain	10
and	0
lacks	0
the	0
DNA-binding	9
domain	10
.	0

Surprisingly	0
,	0
in	0
the	0
CD4	5
(	6
+	6
)	6
CD8	6
(	6
+	6
)	6
thymocyte	6
line	6
,	0
overexpression	0
of	0
a	0
small	9
Ikaros	10
isoform	10
had	0
no	0
effect	0
on	0
differentiation	0
or	0
on	0
the	0
pericentromeric	0
targeting	0
and	0
DNA-binding	0
properties	0
of	0
Ikaros	9
.	0

Rather	0
,	0
the	0
small	0
isoform	9
assembled	0
into	0
multimeric	9
complexes	10
with	0
DNA-bound	9
Ikaros	10
at	0
the	0
pericentromeric	0
foci	0
.	0

The	0
capacity	0
for	0
in	0
vivo	0
multimer	0
formation	0
suggests	0
that	0
interactions	0
between	0
Ikaros	9
dimers	10
bound	0
to	0
the	0
TdT	1
promoter	2
and	0
those	0
bound	0
to	0
pericentromeric	1
repeat	2
sequences	2
may	0
contribute	0
to	0
the	0
pericentromeric	0
repositioning	0
of	0
the	0
inactive	1
gene	2
.	0

Type	9
I	10
interferons	10
and	0
IL-12	9
:	0
convergence	0
and	0
cross-regulation	0
among	0
mediators	0
of	0
cellular	0
immunity	0
.	0

Therapeutic	0
use	0
of	0
type	9
I	10
IFN	10
(	0
IFN-alpha/beta	9
)	0
has	0
become	0
common	0
.	0

Many	0
of	0
the	0
diverse	0
diseases	0
targeted	0
are	0
marked	0
by	0
pathogenetic	0
abnormalities	0
in	0
cell-mediated	0
immunity	0
(	0
CMI	0
)	0
,	0
these	0
cellular	0
immune	0
responses	0
either	0
causing	0
injury	0
to	0
the	0
host	0
,	0
lacking	0
sufficient	0
vigor	0
for	0
virus	0
or	0
tumor	0
clearance	0
,	0
or	0
both	0
.	0

In	0
general	0
,	0
therapeutic	0
efficacy	0
is	0
limited	0
.	0

It	0
is	0
thus	0
notable	0
that	0
the	0
pleiotropic	0
effects	0
of	0
type	9
I	10
IFN	10
on	0
CMI	0
remain	0
poorly	0
understood	0
.	0

We	0
characterized	0
the	0
effects	0
of	0
type	9
I	10
IFN	10
on	0
the	0
production	0
of	0
IL-12	9
,	0
the	0
central	9
immunoregulatory	10
cytokine	10
of	0
the	0
CD4	9
(	10
+	10
)	10
T	10
cell	10
arm	10
of	0
CMI	0
.	0

We	0
show	0
that	0
type	9
I	10
IFN	10
are	0
potent	0
inhibitors	0
of	0
IL-12	0
production	0
by	0
human	7
monocytes/macrophages	8
.	0

The	0
underlying	0
mechanism	0
involves	0
transcriptional	0
inhibition	0
of	0
the	0
IL-12p40	1
gene	2
,	0
marked	0
by	0
down-regulation	0
of	0
PU.1	0
binding	0
activity	0
at	0
the	0
upstream	1
Ets	2
site	2
of	0
the	0
IL-12p40	1
promoter	2
.	0

Type	9
I	10
IFN	10
have	0
previously	0
been	0
shown	0
to	0
be	0
able	0
to	0
substitute	0
for	0
IL-12	9
in	0
driving	0
IFN-gamma	0
production	0
from	0
T	7
and	8
NK	8
cells	8
.	0

The	0
ability	0
of	0
IFN-alpha/beta	9
to	0
suppress	0
IL-12	0
production	0
while	0
up-regulating	0
IFN-gamma	0
production	0
suggests	0
a	0
possible	0
mechanistic	0
basis	0
for	0
the	0
difficulties	0
of	0
employing	0
these	0
cytokines	9
in	0
diseases	0
involving	0
abnormalities	0
of	0
CMI	0
.	0

Nuclear	9
factor-kappaB	10
suppressive	0
and	0
inhibitor-kappaB	9
stimulatory	0
effects	0
of	0
troglitazone	0
in	0
obese	0
patients	0
with	0
type	0
2	0
diabetes	0
:	0
evidence	0
of	0
an	0
antiinflammatory	0
action	0
?	0

It	0
has	0
been	0
shown	0
recently	0
that	0
troglitazone	0
exerts	0
an	0
anti-inflammatory	0
effect	0
,	0
in	0
vitro	0
,	0
and	0
in	0
experimental	0
animals	0
.	0

To	0
test	0
these	0
properties	0
in	0
humans	0
,	0
we	0
investigated	0
the	0
effect	0
of	0
troglitazone	0
on	0
the	0
proinflammatory	9
transcription	10
factor	10
nuclear	10
factor-kappaB	10
and	0
its	0
inhibitory	9
protein	10
IkappaB	10
in	0
mononuclear	7
cells	8
(	0
MNC	7
)	0
and	0
plasma	9
soluble	10
intracellular	10
adhesion	10
molecule-1	10
,	0
monocyte	9
chemoattractant	10
protein-1	10
,	0
plasminogen	9
activator	10
inhibitor-1	10
,	0
and	0
C-reactive	9
protein	10
.	0

We	0
also	0
examined	0
the	0
effect	0
of	0
troglitazone	0
on	0
reactive	0
oxygen	0
species	0
generation	0
,	0
p47	0
(	0
phox	0
)	0
subunit	0
expression	0
,	0
9-hydroxyoctadecadienoic	0
acid	0
(	0
9-HODE	0
)	0
,	0
13-HODE	0
,	0
o-tyrosine	0
,	0
and	0
m-tyrosine	0
in	0
obese	0
patients	0
with	0
type	0
2	0
diabetes	0
.	0

Seven	0
obese	0
patients	0
with	0
type	0
2	0
diabetes	0
were	0
treated	0
with	0
troglitazone	0
(	0
400	0
mg/day	0
)	0
for	0
4	0
weeks	0
.	0

Blood	0
samples	0
were	0
obtained	0
at	0
weekly	0
intervals	0
.	0

Nuclear	9
factor-kappaB	10
binding	0
activity	0
in	0
MNC	7
nuclear	0
extracts	0
was	0
significantly	0
inhibited	0
after	0
troglitazone	0
treatment	0
at	0
week	0
1	0
and	0
continued	0
to	0
be	0
inhibited	0
up	0
to	0
week	0
4	0
.	0

On	0
the	0
other	0
hand	0
,	0
IkappaB	0
protein	0
levels	0
increased	0
significantly	0
after	0
troglitazone	0
treatment	0
at	0
week	0
1	0
,	0
and	0
this	0
increase	0
persisted	0
throughout	0
the	0
study	0
.	0

Plasma	9
monocyte	10
chemoattractant	10
protein-1	10
and	0
soluble	9
intracellular	10
adhesion	10
molecule-1	10
concentrations	0
did	0
not	0
decrease	0
significantly	0
after	0
troglitazone	0
treatment	0
,	0
although	0
there	0
was	0
a	0
trend	0
toward	0
inhibition	0
.	0

Reactive	0
oxygen	0
species	0
generation	0
by	0
polymorphonuclear	7
cells	8
and	0
MNC	7
,	0
p47	9
(	10
phox	10
)	10
subunit	10
protein	10
quantities	0
,	0
plasminogen	9
activator	10
inhibitor-1	10
,	0
and	0
C-reactive	9
protein	10
levels	0
decreased	0
significantly	0
after	0
troglitazone	0
intake	0
.	0

13-HODE/linoleic	0
acid	0
and	0
9-HODE/linoleic	0
acid	0
ratios	0
also	0
decreased	0
after	0
troglitazone	0
intake	0
.	0

However	0
,	0
o-tyrosine/phenylalanine	0
and	0
m-tyrosine/phenylalanine	0
ratios	0
did	0
not	0
change	0
significantly	0
.	0

These	0
data	0
show	0
that	0
troglitazone	0
has	0
profound	0
antiinflammatory	0
effects	0
in	0
addition	0
to	0
antioxidant	0
effects	0
in	0
obese	0
type	0
2	0
diabetics	0
;	0
these	0
effects	0
may	0
be	0
relevant	0
to	0
the	0
recently	0
described	0
beneficial	0
antiatherosclerotic	0
effects	0
of	0
troglitazone	0
at	0
the	0
vascular	0
level	0
.	0

OX40	0
stimulation	0
by	0
gp34/OX40	9
ligand	10
enhances	0
productive	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
infection	0
.	0

OX40	9
is	0
a	0
member	0
of	0
the	0
tumor	9
necrosis	10
factor	10
(	10
TNF	10
)	10
receptor	10
superfamily	10
and	0
known	0
to	0
be	0
an	0
important	0
costimulatory	9
molecule	10
expressed	0
on	0
activated	7
T	8
cells	8
.	0

To	0
investigate	0
the	0
role	0
of	0
costimulation	0
of	0
OX40	9
in	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
by	0
its	0
natural	0
ligand	0
,	0
gp34	9
,	0
the	0
OX40-transfected	5
ACH-2	6
cell	6
line	6
,	6
ACH-2/OX40	6
,	0
chronically	0
infected	0
with	0
HIV-1	0
,	0
was	0
cocultured	0
with	0
paraformaldehyde	0
(	0
PFA	0
)	0
-fixed	0
gp34-transfected	5
mouse	6
cell	6
line	6
,	6
SV-T2/gp34	6
.	0

The	0
results	0
showed	0
that	0
HIV-1	0
production	0
was	0
strongly	0
induced	0
.	0

This	0
was	0
followed	0
by	0
apparent	0
apoptosis	0
,	0
and	0
both	0
processes	0
were	0
specifically	0
inhibited	0
by	0
the	0
gp34	9
-specific	0
neutralizing	9
monoclonal	10
antibody	10
5A8	10
.	0

Endogenous	0
TNF	9
alpha	10
(	0
TNF-alpha	9
)	0
and	0
TNF-beta	9
production	0
were	0
not	0
involved	0
in	0
the	0
enhanced	0
HIV-1	0
production	0
.	0

Furthermore	0
,	0
enhanced	0
HIV-1	0
transcription	0
in	0
gp34	9
-stimulated	0
ACH-2/OX40	5
cells	6
was	0
dependent	0
on	0
the	0
kappa	1
B	2
site	2
of	0
the	0
HIV-1	1
long	2
terminal	2
repeat	2
,	0
and	0
the	0
OX40-gp34	0
interaction	0
activated	0
NF-kappa	9
B	10
consisting	0
of	0
p50	9
and	10
p65	10
subunits	10
.	0

When	0
primary	0
activated	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
acutely	0
infected	0
with	0
HIV-1	0
(	0
NL4-3	0
)	0
(	0
CXCR4-using	5
T-cell-line-tropic	6
)	0
were	0
cocultured	0
with	0
PFA-fixed	0
gp34	7
(	8
+	8
)	8
human	8
T-cell	8
leukemia	0
virus	0
type	0
1-bearing	0
MT-2	5
cells	6
or	0
SV-T2/gp34	5
cells	6
,	0
HIV-1	0
production	0
was	0
also	0
markedly	0
enhanced	0
.	0

The	0
enhancement	0
was	0
again	0
significantly	0
inhibited	0
by	0
5A8	9
.	0

The	0
present	0
study	0
first	0
shows	0
that	0
OX40-gp34	0
interaction	0
stimulates	0
HIV-1	0
expression	0
and	0
suggests	0
that	0
OX40	0
triggering	0
by	0
gp34	9
may	0
play	0
an	0
important	0
role	0
in	0
enhancing	0
HIV-1	0
production	0
in	0
both	0
acutely	0
and	0
latently	0
infected	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
in	0
vivo	0
.	0

Troglitazone	0
,	0
a	0
PPARgamma	0
ligand	0
,	0
inhibits	0
osteopontin	0
gene	0
expression	0
in	0
human	7
monocytes/macrophage	8
THP-1	8
cells	8
.	0

Peroxizome	9
proliferator-activated	10
receptor-gamma	10
(	0
PPARgamma	9
)	0
is	0
a	0
member	0
of	0
the	0
nuclear	9
receptor	10
family	10
of	0
transcription	9
factors	10
that	0
regulate	0
adipocyte	0
differentiation	0
.	0

Recent	0
studies	0
indicate	0
that	0
liganded	9
PPARgamma	10
not	0
only	0
promotes	0
differentiation	0
but	0
also	0
inhibits	0
the	0
activation	0
of	0
macrophages	7
.	0

Osteopontin	9
,	0
a	0
component	0
of	0
extracellular	0
matrix	0
,	0
is	0
synthesized	0
by	0
macrophages	7
in	0
atherosclerotic	0
plaques	0
.	0

In	0
this	0
study	0
,	0
we	0
examined	0
whether	0
PPARgamma	9
ligand	0
regulates	0
osteopontin	0
gene	0
expression	0
in	0
THP-1	5
cells	6
,	0
a	0
cell	0
line	0
derived	0
from	0
human	7
monocytic	8
leukemia	8
cells	8
which	0
can	0
differentiate	0
to	0
macrophage	7
upon	0
stimulation	0
with	0
phorbol	0
ester	0
PMA	0
.	0

Northern	0
blot	0
analysis	0
showed	0
that	0
osteopontin	0
expression	0
is	0
markedly	0
induced	0
in	0
response	0
to	0
PMA	0
.	0

Troglitazone	0
,	0
a	0
PPARgamma	9
ligand	0
,	0
dramatically	0
attenuated	0
the	0
PMA-induced	0
osteopontin	0
expression	0
.	0

Transient	0
transfection	0
assays	0
of	0
the	0
human	1
osteopontin	2
promoter/luciferase	2
construct	2
which	0
contains	0
a	0
5'-flanking	1
region	2
between	0
-1500	0
and	0
+87	0
relative	0
to	0
the	0
transcription	1
start	2
site	2
demonstrate	0
that	0
either	0
treatment	0
with	0
troglitazone	0
or	0
cotransfection	0
of	0
PPARgamma	1
expression	2
vector	2
inhibits	0
osteopontin	0
promoter	0
activity	0
.	0

These	0
data	0
indicate	0
that	0
troglitazone	0
reduces	0
osteopontin	0
gene	0
expression	0
at	0
transcriptional	0
level	0
through	0
PPARgamma	9
activation	0
,	0
and	0
suggest	0
the	0
role	0
of	0
troglitazone	0
in	0
inhibiting	0
the	0
ability	0
of	0
macrophages	7
to	0
produce	0
extracellular	0
matrix	0
,	0
which	0
is	0
particularly	0
relevant	0
to	0
atherosclerotic	0
plaque	0
formation	0
.	0

Transcription	9
factor	10
NF-kappa	10
B	10
regulates	0
Ig	9
lambda	10
light	0
chain	0
gene	0
rearrangement	0
.	0

The	0
tissue-	0
and	0
stage-specific	0
assembly	0
of	0
Ig	1
and	2
TCR	2
genes	2
is	0
mediated	0
by	0
a	0
common	0
V	9
(	10
D	10
)	10
J	10
recombinase	10
complex	10
in	0
precursor	7
lymphocytes	8
.	0

Directed	0
alterations	0
in	0
the	0
accessibility	0
of	0
V	1
,	2
D	2
,	2
and	2
J	2
gene	2
segments	2
target	0
the	0
recombinase	9
to	0
specific	0
Ag	1
receptor	2
loci	2
.	0

Accessibility	0
within	0
a	0
given	0
locus	1
is	0
regulated	0
by	0
the	0
functional	0
interaction	0
of	0
transcription	9
factors	10
with	0
cognate	1
enhancer	2
elements	2
and	0
correlates	0
with	0
the	0
transcriptional	0
activity	0
of	0
unrearranged	0
gene	1
segments	2
.	0

As	0
demonstrated	0
in	0
our	0
prior	0
studies	0
,	0
rearrangement	0
of	0
the	0
Igkappa	1
locus	2
is	0
regulated	0
by	0
the	0
inducible	9
transcription	10
factor	10
NF-kappaB	9
.	0

In	0
contrast	0
to	0
the	0
Igkappa	1
locus	2
,	0
known	0
transcriptional	1
control	2
elements	2
in	0
the	0
Iglambda	1
locus	2
lack	0
functional	0
NF-kappaB	1
binding	2
sites	2
.	0

Consistent	0
with	0
this	0
observation	0
,	0
the	0
expression	0
of	0
assembled	0
Iglambda	1
genes	2
in	0
mature	7
B	8
cells	8
has	0
been	0
shown	0
to	0
be	0
NF-kappaB	9
independent	0
.	0

Nonetheless	0
,	0
we	0
now	0
show	0
that	0
specific	0
repression	0
of	0
NF-kappaB	9
inhibits	0
germline	0
transcription	0
and	0
recombination	0
of	0
Iglambda	1
gene	2
segments	2
in	0
precursor	7
B	8
cells	8
.	0

Molecular	0
analyses	0
indicate	0
that	0
the	0
block	0
in	0
NF-kappaB	9
impairs	0
Iglambda	0
rearrangement	0
at	0
the	0
level	0
of	0
recombinase	9
accessibility	0
.	0

In	0
contrast	0
,	0
the	0
activities	0
of	0
known	0
Iglambda	1
promoter	2
and	0
enhancer	1
elements	2
are	0
unaffected	0
in	0
the	0
same	0
cellular	0
background	0
.	0

These	0
findings	0
expand	0
the	0
range	0
of	0
NF-kappaB	9
action	0
in	0
precursor	7
B	8
cells	8
beyond	0
Igkappa	9
to	0
include	0
the	0
control	0
of	0
recombinational	0
accessibility	0
at	0
both	0
L	1
chain	2
loci	2
.	0

Moreover	0
,	0
our	0
results	0
strongly	0
suggest	0
the	0
existence	0
of	0
a	0
novel	0
Iglambda	1
regulatory	2
element	2
that	0
is	0
either	0
directly	0
or	0
indirectly	0
activated	0
by	0
NF-kappaB	9
during	0
the	0
early	0
stages	0
of	0
B	0
cell	0
development	0
.	0

Transcription	9
factor	10
STAT5A	9
is	0
a	0
substrate	0
of	0
Bruton	9
's	10
tyrosine	10
kinase	10
in	0
B	7
cells	8
.	0

STAT5A	9
is	0
a	0
molecular	0
regulator	0
of	0
proliferation	0
,	0
differentiation	0
,	0
and	0
apoptosis	0
in	0
lymphohematopoietic	7
cells	8
.	0

Here	0
we	0
show	0
that	0
STAT5A	9
can	0
serve	0
as	0
a	0
functional	0
substrate	0
of	0
Bruton	9
's	10
tyrosine	10
kinase	10
(	0
BTK	9
)	0
.	0

Purified	9
recombinant	10
BTK	10
was	0
capable	0
of	0
directly	0
binding	0
purified	9
recombinant	10
STAT5A	10
with	0
high	0
affinity	0
(	0
K	0
(	0
d	0
)	0
=	0
44	0
nm	0
)	0
,	0
as	0
determined	0
by	0
surface	0
plasmon	0
resonance	0
using	0
a	0
BIAcore	0
biosensor	0
system	0
.	0

BTK	9
was	0
also	0
capable	0
of	0
tyrosine-phosphorylating	0
ectopically	0
expressed	0
recombinant	9
STAT5A	10
on	0
Tyr	0
(	0
694	0
)	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
in	0
a	0
Janus	9
kinase	10
3	10
-independent	0
fashion	0
.	0

BTK	9
phosphorylated	0
the	0
Y665F	9
,	10
Y668F	10
,	10
and	10
Y682F	10
,	10
Y683F	10
mutants	10
but	0
not	0
the	0
Y694F	9
mutant	10
of	0
STAT5A	9
.	0

STAT5A	0
mutations	0
in	0
the	0
Src	9
homology	10
2	10
(	10
SH2	10
)	10
and	10
SH3	10
domains	10
did	0
not	0
alter	0
the	0
BTK	9
-mediated	0
tyrosine	0
phosphorylation	0
.	0

Recombinant	9
BTK	10
proteins	10
with	0
mutant	0
pleckstrin	0
homology	0
,	0
SH2	9
,	10
or	10
SH3	10
domains	10
were	0
capable	0
of	0
phosphorylating	0
STAT5A	9
,	0
whereas	0
recombinant	9
BTK	10
proteins	10
with	0
SH1/kinase	0
domain	0
mutations	0
were	0
not	0
.	0

In	0
pull-down	0
experiments	0
,	0
only	0
full-length	9
BTK	10
and	0
its	0
SH1/kinase	9
domain	10
(	0
but	0
not	0
the	0
pleckstrin	0
homology	0
,	0
SH2	9
,	10
or	10
SH3	10
domains	10
)	0
were	0
capable	0
of	0
binding	0
STAT5A	9
.	0

Ectopically	0
expressed	0
BTK	9
kinase	10
domain	10
was	0
capable	0
of	0
tyrosine-phosphorylating	0
STAT5A	9
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

BTK	9
-mediated	0
tyrosine	0
phosphorylation	0
of	0
ectopically	0
expressed	0
wild	0
type	0
(	0
but	0
not	0
Tyr	9
(	10
694	10
)	10
mutant	10
)	0
STAT5A	9
enhanced	0
its	0
DNA	0
binding	0
activity	0
.	0

In	0
BTK	9
-competent	0
chicken	0
B	7
cells	8
,	0
anti-IgM-stimulated	0
tyrosine	0
phosphorylation	0
of	0
STAT5	9
protein	10
was	0
prevented	0
by	0
pretreatment	0
with	0
the	0
BTK	9
inhibitor	0
LFM-A13	0
but	0
not	0
by	0
pretreatment	0
with	0
the	0
JAK3	0
inhibitor	0
HI-P131	0
.	0

B	0
cell	0
antigen	0
receptor	0
ligation	0
resulted	0
in	0
enhanced	0
tyrosine	0
phosphorylation	0
of	0
STAT5	9
in	0
BTK	9
-deficient	0
chicken	0
B	7
cells	8
reconstituted	0
with	0
wild	9
type	10
human	10
BTK	10
but	0
not	0
in	0
BTK	9
-deficient	0
chicken	0
B	7
cells	8
reconstituted	0
with	0
kinase-inactive	9
mutant	10
BTK	10
.	0

Similarly	0
,	0
anti-IgM	0
stimulation	0
resulted	0
in	0
enhanced	0
tyrosine	0
phosphorylation	0
of	0
STAT5A	9
in	0
BTK	9
-competent	0
B	7
cells	8
from	0
wild	0
type	0
mice	0
but	0
not	0
in	0
BTK	9
-deficient	0
B	7
cells	8
from	0
XID	0
mice	0
.	0

In	0
contrast	0
to	0
B	7
cells	8
from	0
XID	0
mice	0
,	0
B	7
cells	8
from	0
JAK3	0
knockout	0
mice	0
showed	0
a	0
normal	0
STAT5A	0
phosphorylation	0
response	0
to	0
anti-IgM	0
stimulation	0
.	0

These	0
findings	0
provide	0
unprecedented	0
experimental	0
evidence	0
that	0
BTK	9
plays	0
a	0
nonredundant	0
and	0
pivotal	0
role	0
in	0
B	0
cell	0
antigen	0
receptor-mediated	0
STAT5A	0
activation	0
in	0
B	7
cells	8

Role	0
of	0
T-bet	9
in	0
commitment	0
of	0
TH1	7
cells	8
before	0
IL-12	9
-dependent	0
selection	0
.	0

How	0
cytokines	9
control	0
differentiation	0
of	0
helper	7
T	8
(	8
TH	8
)	8
cells	8
is	0
controversial	0
.	0

We	0
show	0
that	0
T-bet	9
,	0
without	0
apparent	0
assistance	0
from	0
interleukin	9
12	10
(	10
IL-12	10
)	10
/	0
STAT4	9
,	0
specifies	0
TH1	7
effector	0
fate	0
by	0
targeting	0
chromatin	0
remodeling	0
to	0
individual	0
interferon-gamma	1
(	2
IFN-gamma	2
)	2
alleles	2
and	0
by	0
inducing	0
IL-12	1
receptor	2
beta2	2
expression	0
.	0

Subsequently	0
,	0
it	0
appears	0
that	0
IL-12	9
/	0
STAT4	9
serves	0
two	0
essential	0
functions	0
in	0
the	0
development	0
of	0
TH1	7
cells	8
:	0
as	0
growth	9
signal	10
,	0
inducing	0
survival	0
and	0
cell	0
division	0
;	0
and	0
as	0
trans-activator	9
,	0
prolonging	0
IFN-gamma	9
synthesis	0
through	0
a	0
genetic	0
interaction	0
with	0
the	0
coactivator	9
,	0
CREB-binding	9
protein	10
.	0

These	0
results	0
suggest	0
that	0
a	0
cytokine	9
does	0
not	0
simply	0
induce	0
TH	0
fate	0
choice	0
but	0
instead	0
may	0
act	0
as	0
an	0
essential	0
secondary	0
stimulus	0
that	0
mediates	0
selective	0
survival	0
of	0
a	0
lineage	0
.	0

Stat6	9
is	0
necessary	0
and	0
sufficient	0
for	0
IL-4	0
's	0
role	0
in	0
Th2	0
differentiation	0
and	0
cell	0
expansion	0
.	0

IL-4	9
plays	0
a	0
critical	0
role	0
in	0
the	0
differentiation	0
of	0
T	0
CR-stimulated	7
naive	8
CD4	8
T	8
cells	8
to	0
the	0
Th2	0
phenotype	0
.	0

In	0
response	0
to	0
IL-4	9
,	0
the	0
IL-4R	9
activates	0
a	0
set	0
of	0
phosphotyrosine	9
binding	10
domain-containing	10
proteins	10
,	0
including	0
insulin	9
receptor	10
substrate	10
1/2	10
,	0
Shc	9
,	0
and	0
IL-4R	9
interacting	10
protein	10
,	0
as	0
well	0
as	0
Stat6	9
.	0

Stat6	9
has	0
been	0
shown	0
to	0
be	0
required	0
for	0
Th2	0
differentiation	0
.	0

To	0
determine	0
the	0
roles	0
of	0
the	0
phosphotyrosine	9
binding	10
adaptors	10
in	0
Th2	0
differentiation	0
,	0
we	0
prepared	0
a	0
retrovirus	0
containing	0
a	0
mutant	0
of	0
the	0
human	9
(	10
h	10
)	10
IL-4R	10
alpha-chain	10
,	0
Y497F	9
,	0
which	0
is	0
unable	0
to	0
recruit	0
these	0
adaptors	0
.	0

The	0
mutant	9
hIL-4Ralpha	10
,	0
as	0
well	0
as	0
the	0
wild-type	9
(	10
WT	10
)	10
hIL-4Ralpha	10
,	0
was	0
introduced	0
into	0
naive	7
CD4	8
T	8
cells	8
.	0

Upon	0
hIL-4	0
stimulation	0
,	0
Y497F	9
worked	0
as	0
well	0
as	0
the	0
WT	9
hIL-4Ralpha	10
in	0
driving	0
Th2	0
differentiation	0
,	0
as	0
measured	0
by	0
Gata3	0
up-regulation	0
and	0
IL-4	0
production	0
.	0

Furthermore	0
,	0
IL-4-driven	0
cell	0
expansion	0
was	0
also	0
normal	0
in	0
the	0
cells	0
infected	0
with	0
Y497F	9
,	0
although	0
cells	0
infected	0
with	0
Y497F	9
were	0
not	0
capable	0
of	0
phosphorylating	0
insulin	9
receptor	10
substrate	10
2	10
.	0

These	0
results	0
suggest	0
that	0
the	0
signal	0
pathway	0
mediated	0
by	0
Y497	9
is	0
dispensable	0
for	0
both	0
IL-4	9
-driven	0
Th2	0
differentiation	0
and	0
cell	0
expansion	0
.	0

Both	0
WT	9
and	10
Y497F	10
hIL-4Ralpha	10
lose	0
the	0
ability	0
to	0
drive	0
Th2	0
differentiation	0
and	0
cell	0
expansion	0
in	0
Stat6-knockout	7
CD4	8
T	8
cells	8
.	0

A	0
constitutively	0
activated	0
form	0
of	0
Stat6	9
introduced	0
into	0
CD4	7
T	8
cells	8
resulted	0
in	0
both	0
Th2	0
differentiation	0
and	0
enhanced	0
cell	0
expansion	0
.	0

Thus	0
,	0
activated	9
Stat6	10
is	0
necessary	0
and	0
sufficient	0
to	0
mediate	0
both	0
IL-4	9
-driven	0
Th2	0
differentiation	0
and	0
cell	0
expansion	0
in	0
CD4	7
T	8
cells	8
.	0

The	0
effect	0
of	0
HIV-1	9
regulatory	10
proteins	10
on	0
cellular	0
genes	0
:	0
derepression	0
of	0
the	0
IL-2	1
promoter	2
by	0
Tat	9
.	0

In	0
HIV-infected	0
individuals	0
dysregulation	0
of	0
the	0
immune	0
system	0
is	0
characterized	0
by	0
severe	0
disorders	0
of	0
the	0
cytokine	0
network	0
.	0

Increase	0
secretion	0
of	0
IL-2	9
,	0
the	0
major	0
T	7
cell	8
growth	0
and	0
differentiation	0
cytokine	9
,	0
may	0
play	0
a	0
decisive	0
role	0
in	0
sensitization	0
of	0
T	7
cells	8
for	0
activation	0
induced	0
apoptosis	0
and	0
indirect	0
death	0
of	0
activated	7
T	8
cells	8
through	0
augmented	0
virus	0
replication	0
.	0

We	0
investigated	0
the	0
cause	0
of	0
enhanced	0
IL-2	0
secretion	0
and	0
found	0
that	0
the	0
HIV	9
Tat	10
induces	0
this	0
effect	0
.	0

We	0
demonstrate	0
that	0
increased	0
IL-2	0
secretion	0
is	0
due	0
to	0
Tat	9
-enhanced	0
IL-2	1
promoter	2
activation	0
.	0

Tat	9
derepresses	0
and	0
activates	0
the	0
distal	1
AP-1	2
site	2
(	0
position	1
-185	2
to	2
-177	2
)	0
in	0
the	0
IL-2	1
promoter	2
.	0

In	0
nonstimulated	7
T	8
cells	8
a	0
repressor	0
complex	0
containing	0
NF-IL6	9
,	0
JunB	9
,	0
c-Fos	9
and	0
Fra-1	9
is	0
formed	0
on	0
the	0
AP-1	1
(	2
IL-2/d	2
)	2
site	2
and	0
represses	0
IL-2	1
promoter	2
activity	0
.	0

After	0
T	0
cell	0
activation	0
,	0
a	0
heterodimeric	9
activator	10
containing	0
p65	9
and	0
c-Jun	9
binds	0
to	0
the	0
AP-1	1
(	2
IL-2/d	2
)	2
site	2
.	0

HIV	9
Tat	10
enhances	0
activation	0
of	0
NF-kappaB	9
and	0
consequently	0
,	0
activates	0
the	0
AP-1	1
(	2
IL-2/d	2
)	2
site	2
.	0

Our	0
data	0
provide	0
evidence	0
for	0
a	0
novel	0
mechanism	0
by	0
which	0
HIV	9
Tat	10
dysregulates	0
IL-2	0
production	0
and	0
therefore	0
may	0
contribute	0
to	0
the	0
HIV-1	0
infection	0
in	0
a	0
way	0
yet	0
to	0
be	0
clarified	0
.	0

Transforming	9
growth	10
factor-beta1	10
interferes	0
with	0
thrombopoietin-induced	0
signal	0
transduction	0
in	0
megakaryoblastic	7
and	8
erythroleukemic	8
cells	8
.	0

OBJECTIVE	0
:	0
Thrombopoietin	9
(	0
TPO	9
)	0
and	0
transforming	9
growth	10
factor-beta	10
(	10
1	10
)	10
(	0
TGF-beta	9
(	10
1	10
)	10
)	0
have	0
been	0
shown	0
to	0
exert	0
opposite	0
effects	0
on	0
proliferation	0
and	0
megakaryocytic	0
differentiation	0
of	0
hematopoietic	7
cells	8
.	0

To	0
determine	0
whether	0
TGF-beta	9
(	10
1	10
)	10
interferes	0
directly	0
with	0
TPO	9
-induced	0
signal	0
transduction	0
in	0
hematopoietic	7
cells	8
,	0
we	0
compared	0
the	0
regulatory	0
effects	0
in	0
the	0
TPO	9
-responsive	0
cell	0
lines	0
Mo-7e	0
and	0
HEL	0
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
The	0
cells	0
were	0
stimulated	0
by	0
100	0
ng/mL	0
TPO	9
and/or	0
100	0
ng/mL	0
TGF-beta1	9
and	0
analyzed	0
for	0
proliferation	0
(	0
3H	0
thymidine	0
incorporation	0
)	0
,	0
viability	0
(	0
trypan	0
blue	0
exclusion	0
)	0
,	0
and	0
protein	0
expression	0
and	0
phosphorylation	0
(	0
Western	0
blot	0
)	0
.	0

RESULTS	0
:	0
TPO	9
enhanced	0
the	0
proliferation	0
of	0
Mo-7e	5
cells	6
as	0
determined	0
by	0
3H-thymidine	0
incorporation	0
,	0
whereas	0
TGF-beta1	9
suppressed	0
baseline	0
cell	0
growth	0
and	0
antagonized	0
the	0
proliferative	0
effect	0
of	0
TPO	9
.	0

TPO	9
-induced	0
proliferation	0
also	0
was	0
reduced	0
by	0
a	0
specific	0
inhibitor	0
of	0
the	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
pathway	0
(	0
PD098059	0
)	0
,	0
which	0
inhibits	0
activation	0
of	0
the	0
MAPK	9
extracellular	10
signal-regulated	10
kinases	10
(	0
ERK	9
)	0
ERK1	9
and	0
ERK2	9
,	0
and	0
AG490	0
,	0
an	0
inhibitor	0
of	0
Janus	9
kinase-2	10
,	0
which	0
completely	0
blocked	0
TPO	9
-induced	0
proliferation	0
.	0

As	0
demonstrated	0
by	0
Western	0
blotting	0
,	0
TGF-beta1	9
reduced	0
the	0
TPO	9
-stimulated	0
ERK1	9
/	0
ERK2	9
and	0
STAT5	0
phosphorylation	0
in	0
Mo-7e	5
and	6
HEL	6
cells	6
.	0

This	0
effect	0
was	0
completely	0
reversed	0
by	0
preincubation	0
with	0
a	0
tyrosine	0
phosphatase	0
inhibitor	0
(	0
Na3VO4	0
)	0
,	0
which	0
suggests	0
that	0
TGF-beta1	9
activated	0
a	0
phosphatase	9
.	0

Although	0
STAT3	9
also	0
was	0
activated	0
by	0
TPO	9
,	0
STAT3	9
activation	0
remained	0
unaltered	0
by	0
TGF-beta1	9
.	0

CONCLUSION	0
:	0
Taken	0
together	0
,	0
these	0
data	0
suggest	0
that	0
TGF-beta1	9
modulates	0
TPO	9
-mediated	0
effects	0
on	0
megakaryocytic	0
proliferation	0
by	0
interfering	0
with	0
TPO	9
-induced	0
signal	0
transduction	0
,	0
particularly	0
by	0
reducing	0
the	0
activities	0
of	0
MAPK	9
ERK1/ERK2	10
and	10
STAT5	10
.	0

Invariant	9
chain	10
induces	0
B	0
cell	0
maturation	0
by	0
activating	0
a	0
TAF	9
(	10
II	10
)	10
105-NF-kappaB	10
-dependent	0
transcription	0
program	0
.	0

Early	0
stages	0
of	0
B	0
cell	0
development	0
occur	0
in	0
the	0
bone	0
marrow	0
,	0
resulting	0
in	0
formation	0
of	0
immature	7
B	8
cells	8
.	0

From	0
there	0
these	0
immature	7
cells	8
migrate	0
to	0
the	0
spleen	0
where	0
they	0
differentiate	0
to	0
mature	7
cells	8
.	0

This	0
final	0
maturation	0
step	0
is	0
crucial	0
for	0
the	0
B	7
cells	8
to	0
become	0
responsive	0
to	0
antigens	9
and	0
to	0
participate	0
in	0
the	0
immune	0
response	0
.	0

Recently	0
,	0
invariant	9
chain	10
(	0
Ii	9
)	0
,	0
a	0
major	9
histocompatibility	10
complex	10
class	10
II	10
chaperone	10
,	0
as	0
well	0
as	0
the	0
transcription	9
factors	10
c-Rel	9
and	0
p65/RelA	9
,	0
were	0
found	0
to	0
play	0
a	0
role	0
in	0
the	0
final	0
antigen-independent	0
differentiation	0
stage	0
of	0
B	7
cells	8
in	0
the	0
spleen	0
.	0

In	0
this	0
study	0
,	0
we	0
investigated	0
a	0
possible	0
link	0
between	0
Ii	9
-dependent	0
B	0
cell	0
maturation	0
and	0
the	0
NF-kappaB	0
pathway	0
.	0

Our	0
studies	0
indicate	0
that	0
Ii	9
-induced	0
B	0
cell	0
maturation	0
involves	0
activation	0
of	0
transcription	0
mediated	0
by	0
the	0
NF-kappaB	9
p65/RelA	10
homodimer	10
and	0
requires	0
the	0
B	9
cell-enriched	10
coactivator	10
TBP-associated	9
factor	10
(	10
II	10
)	10
105	10
.	0

Androgens	0
indirectly	0
accelerate	0
thymocyte	7
apoptosis	0
.	0

Apoptotic	0
processes	0
,	0
or	0
the	0
disturbance	0
of	0
the	0
natural	0
regulation	0
of	0
these	0
processes	0
,	0
may	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
autoimmune	0
diseases	0
(	0
AID	0
)	0
.	0

Women	0
are	0
,	0
in	0
general	0
,	0
more	0
susceptible	0
than	0
men	0
to	0
develop	0
AID	0
like	0
rheumatoid	0
arthritis	0
.	0

Androgens	0
and	0
glucocorticoids	0
,	0
in	0
contrast	0
to	0
oestrogens	0
,	0
have	0
favourable	0
effects	0
in	0
AID	0
models	0
as	0
well	0
as	0
in	0
human	0
AID	0
.	0

It	0
is	0
known	0
that	0
glucocorticoids	0
(	0
GC	0
)	0
,	0
used	0
for	0
treatment	0
of	0
AID	0
,	0
increase	0
apoptosis	0
in	0
the	0
thymus	0
resulting	0
in	0
decreased	0
numbers	0
of	0
CD4+	7
CD8+	8
thymocytes	8
.	0

It	0
was	0
asked	0
whether	0
androgens	0
,	0
in	0
contrast	0
to	0
oestrogens	0
,	0
exert	0
their	0
favourable	0
effects	0
in	0
the	0
treatment	0
of	0
AID	0
by	0
a	0
mechanism	0
comparable	0
to	0
that	0
described	0
for	0
GC	0
by	0
eliminating	0
the	0
apoptosis	0
prone	0
CD4+	7
CD8+	8
population	8
in	0
the	0
thymus	0
.	0

Although	0
both	0
androgens	0
and	0
oestrogens	0
proved	0
thymolytic	0
,	0
a	0
significantly	0
decreased	0
percentage	0
of	0
CD4+	7
CD8+	8
thymocytes	8
was	0
observed	0
by	0
flow	0
cytometry	0
after	0
treatment	0
of	0
mice	0
with	0
the	0
androgen	0
methyltestosterone	0
,	0
but	0
not	0
with	0
the	0
oestrogen	0
ethinylestradiol	0
.	0

To	0
investigate	0
whether	0
the	0
observed	0
thymolytic	0
effects	0
were	0
due	0
to	0
the	0
presence	0
of	0
hormone	9
receptors	10
on	0
thymocytes	7
,	0
cells	0
were	0
isolated	0
from	0
the	0
thymus	0
and	0
incubated	0
with	0
androgens	0
or	0
oestrogens	0
to	0
measure	0
apoptosis	0
.	0

Several	0
techniques	0
were	0
used	0
to	0
determine	0
thymocyte	7
apoptosis	0
in	0
vitro	0
,	0
but	0
no	0
enhanced	0
apoptotic	0
signal	0
was	0
observed	0
.	0

Using	0
the	0
very	0
sensitive	0
TUNEL	0
assay	0
,	0
no	0
direct	0
effect	0
of	0
androgens	0
on	0
thymocytes	7
in	0
vitro	0
could	0
be	0
observed	0
.	0

This	0
is	0
in	0
sharp	0
contrast	0
to	0
the	0
high	0
signal	0
observed	0
with	0
GC	0
.	0

Therefore	0
,	0
upon	0
in	0
vivo	0
androgen	0
treatment	0
,	0
other	0
cells	0
containing	0
androgen	9
receptors	10
than	0
thymocytes	7
are	0
probably	0
involved	0
in	0
inducing	0
the	0
increase	0
in	0
thymic	0
apoptosis	0
.	0

To	0
study	0
the	0
role	0
of	0
the	0
androgen	9
receptor	10
on	0
thymocyte	7
apoptosis	0
,	0
androgen	9
receptor	10
mutant	0
(	0
Tfm/Y	0
)	0
mice	0
were	0
treated	0
with	0
androgens	0
.	0

No	0
alterations	0
of	0
thymocyte	7
subpopulations	8
were	0
seen	0
,	0
suggesting	0
that	0
changes	0
in	0
the	0
percentage	0
of	0
CD4+	7
CD8+	8
thymocytes	8
after	0
administration	0
of	0
androgens	0
depend	0
on	0
the	0
presence	0
of	0
functional	0
androgen	9
receptors	10
.	0

Thus	0
,	0
it	0
is	0
concluded	0
that	0
androgens	0
indirectly	0
accelerate	0
thymocyte	7
apoptosis	0
in	0
vivo	0
.	0

Inhibition	0
of	0
the	0
transcription	9
factors	10
AP-1	9
and	0
NF-kappaB	9
in	0
CD4	7
T	8
cells	8
by	0
peroxisome	9
proliferator-activated	10
receptor	10
gamma	10
ligands	10
.	0

The	0
peroxisome	9
proliferator-activated	10
receptor	10
gamma	10
(	0
PPARgamma	9
)	0
,	0
a	0
member	0
of	0
the	0
nuclear	9
hormone	10
receptor	10
superfamily	10
,	0
is	0
essential	0
for	0
adipocyte	0
differentiation	0
and	0
glucose	0
homeostasis	0
.	0

PPARgamma	9
has	0
been	0
found	0
recently	0
to	0
regulate	0
macrophage	0
activation	0
in	0
response	0
to	0
mitogens	9
and	0
inflammation	0
.	0

Our	0
study	0
shows	0
PPARgamma	9
to	0
be	0
preferentially	0
expressed	0
in	0
the	0
nuclei	0
of	0
resting	7
T	8
cells	8
and	0
to	0
increase	0
upon	0
activation	0
of	0
T	7
cells	8
by	0
either	0
anti-CD3	9
and	0
anti-CD28	9
or	0
phorbol	0
myristyl	0
acetate	0
(	0
PMA	0
)	0
.	0

We	0
also	0
found	0
the	0
PPARgamma	9
ligand	10
ciglitizone	0
to	0
attenuate	0
the	0
activation	0
of	0
T	7
cells	8
by	0
inhibiting	0
cytokine	0
gene	0
expression	0
and	0
anti-CD3	9
and	0
anti-CD28	9
or	0
PMA-induced	0
proliferative	0
responses	0
.	0

Inhibition	0
of	0
both	0
the	0
proliferative	0
response	0
and	0
inflammatory	0
cytokine	0
expression	0
in	0
CD4	7
T	8
cells	8
was	0
correlated	0
with	0
suppression	0
of	0
the	0
activated	0
transcription	9
factors	10
AP1	9
and	0
NF-kappaB	9
.	0

PPARgamma	9
ligands	10
also	0
strongly	0
inhibited	0
SEA-induced	0
Vbeta3	0
T	0
cell	0
activation	0
in	0
vivo	0
.	0

These	0
results	0
,	0
together	0
with	0
previous	0
findings	0
of	0
the	0
inhibitory	0
effect	0
of	0
PPARgamma	9
ligands	10
on	0
activated	7
macrophages	8
,	0
provide	0
clear	0
evidence	0
for	0
PPARgamma	9
as	0
a	0
negative	9
regulator	10
of	0
the	0
inflammatory	0
activation	0
of	0
both	0
macrophage	7
and	0
T	7
cells	8
.	0

PPARgamma	9
may	0
thus	0
be	0
a	0
potential	0
therapeutic	0
target	0
for	0
the	0
treatment	0
of	0
autoimmunity	0
.	0

A	0
prominent	0
role	0
for	0
activator	9
protein-1	10
in	0
the	0
transcription	0
of	0
the	0
human	1
2B4	2
(	2
CD244	2
)	2
gene	2
in	0
NK	7
cells	8
.	0

The	0
cell	9
surface	10
glycoprotein	10
2B4	10
(	0
CD244	9
)	0
of	0
the	0
Ig	9
superfamily	10
is	0
involved	0
in	0
the	0
regulation	0
of	0
NK	7
and	0
T	7
lymphocyte	8
functions	0
.	0

We	0
have	0
recently	0
identified	0
CD48	9
as	0
the	0
high	9
affinity	10
counterreceptor	10
for	0
2B4	9
in	0
both	0
mice	0
and	0
humans	0
.	0

The	0
cytoplasmic	9
domain	10
of	0
2B4	9
associates	0
with	0
src	9
homology	10
2	10
domain-containing	10
protein	10
or	0
signaling	9
lymphocyte	10
activation	10
molecule-associated	10
protein	10
,	0
whose	0
mutation	0
is	0
the	0
underlying	0
genetic	0
defect	0
in	0
the	0
X-linked	0
lymphoproliferative	0
syndrome	0
.	0

In	0
this	0
study	0
,	0
we	0
report	0
the	0
molecular	0
cloning	0
and	0
characterization	0
of	0
the	0
human	1
2B4	2
(	2
h2B4	2
)	2
promoter	2
.	0

Through	0
primer	0
extension	0
analysis	0
,	0
we	0
found	0
that	0
the	0
transcription	0
of	0
the	0
h2B4	1
gene	2
initiates	0
at	0
multiple	0
start	0
sites	0
.	0

We	0
isolated	0
h2B4	1
genomic	2
clones	2
and	0
PCR	0
amplified	0
the	0
5	1
'	2
untranslated	2
region	2
containing	0
the	0
promoter	1
elements	2
.	0

We	0
have	0
identified	0
a	0
functional	0
AP-1	1
site	2
that	0
lies	0
between	0
(	0
-106	0
to	0
-100	0
)	0
through	0
transient	0
transfection	0
analysis	0
in	0
YT	5
cells	6
,	0
a	0
human	5
NK	6
cell	6
line	6
.	0

EMSAs	0
with	0
Abs	9
specific	0
for	0
various	0
protein	9
factors	10
of	0
the	0
AP-1	9
family	10
revealed	0
that	0
multiple	0
members	0
of	0
the	0
Jun	9
family	10
are	0
involved	0
in	0
the	0
regulation	0
of	0
the	0
h2B4	1
gene	2
.	0

Mutation	0
of	0
the	0
AP-1	1
site	2
not	0
only	0
abolishes	0
protein/DNA	0
interactions	0
but	0
also	0
promoter	0
activity	0
.	0

These	0
results	0
demonstrate	0
a	0
significant	0
role	0
for	0
AP-1	9
in	0
the	0
transcriptional	0
regulation	0
of	0
the	0
h2B4	1
gene	2
.	0

Functional	0
correction	0
of	0
FA-C	7
cells	8
with	0
FANCC	9
suppresses	0
the	0
expression	0
of	0
interferon	1
gamma-inducible	2
genes	2
.	0

Because	0
hematopoietic	7
cells	8
derived	0
from	0
Fanconi	0
anemia	0
(	0
FA	0
)	0
patients	0
of	0
the	0
C-complementation	0
group	0
(	0
FA-C	0
)	0
are	0
hypersensitive	0
to	0
the	0
inhibitory	0
effects	0
of	0
interferon	9
gamma	10
(	0
IFNgamma	9
)	0
,	0
the	0
products	0
of	0
certain	0
IFNgamma-inducible	1
genes	2
known	0
to	0
influence	0
hematopoietic	0
cell	0
survival	0
were	0
quantified	0
.	0

High	0
constitutive	0
expression	0
of	0
the	0
IFNgamma-inducible	1
genes	2
,	0
IFN-stimulated	9
gene	10
factor	10
3	10
gamma	10
subunit	10
(	0
ISGF3gamma	9
)	0
,	0
IFN	9
regulatory	10
factor-1	10
(	0
IRF-1	9
)	0
,	0
and	0
the	0
cyclin-dependent	9
kinase	10
inhibitor	10
p21	10
(	0
WAF1	9
)	0
was	0
found	0
in	0
FANCC	9
mutant	0
B	7
lymphoblasts	8
,	0
low-density	7
bone	8
marrow	8
cells	8
,	0
and	0
murine	7
embryonic	8
fibroblasts	8
.	0

Paradoxically	0
,	0
these	0
cells	0
do	0
not	0
activate	9
signal	10
transducer	10
and	10
activator	10
of	10
transcription	10
(	10
STAT	10
)	10
1	10
properly	0
.	0

In	0
an	0
attempt	0
to	0
clarify	0
mechanisms	0
by	0
which	0
FA-C	7
cells	8
overexpress	0
IFNgamma-inducible	1
genes	2
in	0
the	0
face	0
of	0
defective	0
STAT1	0
phosphorylation	0
,	0
it	0
was	0
reasoned	0
that	0
decreased	0
levels	0
of	0
activated	9
STAT1	10
might	0
result	0
in	0
reduced	0
expression	0
of	0
a	0
hematopoietic	9
IFNgamma-responsive	10
protein	10
that	0
normally	0
modulates	0
expression	0
of	0
other	0
IFNgamma-responsive	1
genes	2
.	0

Levels	0
of	0
the	0
IFNgamma	9
-inducible	0
factor	0
IFN	9
consensus	10
sequence	10
binding	10
protein	10
(	0
ICSBP	9
)	0
,	0
a	0
negative	9
trans-acting	10
regulator	10
of	0
some	0
IFNgamma-inducible	1
genes	2
,	0
were	0
quantified	0
.	0

ICSBP	9
levels	0
were	0
reduced	0
in	0
FA-C	7
B	8
lymphoblasts	8
and	0
MEFs	7
.	0

However	0
,	0
enforced	0
expression	0
of	0
ICSBP	9
failed	0
to	0
down-regulate	0
IRF-1	9
,	0
ISGF3gamma	9
,	0
and	0
p21	9
(	10
WAF1	10
)	10
.	0

Thus	0
,	0
the	0
FANCC	9
protein	10
functions	0
to	0
modulate	0
expression	0
of	0
a	0
family	0
of	0
genes	0
that	0
in	0
normal	0
cells	0
are	0
inducible	0
only	0
by	0
specific	0
environmental	0
cues	0
for	0
apoptosis	0
or	0
mitogenic	0
inhibition	0
,	0
but	0
it	0
does	0
so	0
independently	0
of	0
the	0
classic	0
IFN-STAT1	0
pathway	0
and	0
is	0
not	0
the	0
direct	0
result	0
of	0
reduced	0
ICSBP	9
expression	0
.	0

A	0
genetic	0
investigation	0
of	0
E2A	0
function	0
in	0
lymphocyte	0
development	0
.	0

Lymphocytes	7
are	0
derived	0
from	0
hematopoietic	7
stem	8
cells	8
(	0
HSC	7
)	0
following	0
a	0
series	0
of	0
regulated	0
differentiation	0
events	0
.	0

Multipotent	7
HSCs	8
become	0
committed	0
to	0
the	0
B	5
cell	6
lineage	6
in	0
bone	0
marrow	0
and	0
the	0
T	5
cell	6
lineage	6
in	0
the	0
thymus	0
after	0
receiving	0
appropriate	0
signals	0
from	0
the	0
corresponding	0
microenvironment	0
.	0

These	0
committed	0
lymphoid	7
cells	8
must	0
then	0
undergo	0
V	0
(	0
D	0
)	0
J	0
recombination	0
at	0
the	0
immunoglobulin	1
gene	2
or	0
T	1
cell	2
receptor	2
gene	2
locus	2
resulting	0
in	0
clonal	0
production	0
of	0
functional	0
B	7
or	8
T	8
lymphocytes	8
,	0
respectively	0
.	0

Lymphocyte	0
commitment	0
and	0
differentiation	0
are	0
accompanied	0
by	0
programmed	0
gene	0
expression	0
or	0
repression	0
events	0
which	0
are	0
driven	0
by	0
lineage	9
and	10
stage	10
specific	10
transcription	10
factors	10
.	0

The	0
basic-helix-loop-helix	9
(	10
bHLH	10
)	10
transcription	10
factors	10
encoded	0
by	0
the	0
E2A	1
gene	2
are	0
involved	0
in	0
several	0
differentiation	0
events	0
during	0
B	0
and	0
T	0
cell	0
development	0
,	0
including	0
lineage	0
commitment	0
,	0
initiation	0
of	0
V	0
(	0
D	0
)	0
J	0
recombination	0
,	0
and	0
antigen	0
receptor	0
mediated	0
proliferation	0
and	0
differentiation	0
.	0

Several	0
recent	0
reviews	0
have	0
provided	0
a	0
comprehensive	0
discussion	0
of	0
biochemical	0
,	0
cellular	0
,	0
and	0
genetic	0
research	0
on	0
E2A	0
function	0
in	0
lymphocyte	0
development	0
(	0
1	0
,	0
2	0
)	0
.	0

Here	0
,	0
we	0
only	0
discuss	0
some	0
of	0
the	0
genetic	0
approaches	0
our	0
laboratory	0
(	0
except	0
where	0
it	0
is	0
noted	0
)	0
has	0
undertaken	0
to	0
investigate	0
the	0
molecular	0
pathways	0
mediated	0
by	0
E2A	9
transcription	10
factors	10
in	0
lymphocyte	0
development	0

D609	0
inhibits	0
ionizing	0
radiation-induced	0
oxidative	0
damage	0
by	0
acting	0
as	0
a	0
potent	0
antioxidant	0
.	0

Tricyclodecan-9-yl-xanthogenate	0
(	0
D609	0
)	0
has	0
been	0
extensively	0
studied	0
in	0
biological	0
systems	0
and	0
exhibits	0
a	0
variety	0
of	0
biological	0
functions	0
,	0
including	0
antiviral	0
,	0
antitumor	0
,	0
and	0
anti-inflammatory	0
activities	0
.	0

Most	0
of	0
these	0
activities	0
have	0
been	0
largely	0
attributed	0
to	0
the	0
inhibitory	0
effect	0
of	0
D609	0
on	0
phosphatidylcholine-specific	0
phospholipase	9
C	10
.	0

However	0
,	0
as	0
a	0
xanthate	0
derivative	0
,	0
D609	0
is	0
a	0
strong	0
electrolyte	0
and	0
readily	0
dissociates	0
to	0
xanthate	0
anions	0
and	0
cations	0
of	0
alkali	0
metals	0
in	0
solution	0
.	0

Xanthate	0
anions	0
and	0
protonated	0
xanthic	0
acid	0
contain	0
a	0
free	0
thiol	0
moiety	0
and	0
are	0
highly	0
reductive	0
.	0

This	0
implies	0
that	0
D609	0
and	0
other	0
xanthate	0
derivatives	0
may	0
function	0
as	0
potent	0
antioxidants	0
.	0

Indeed	0
,	0
we	0
found	0
that	0
D609	0
inhibited	0
the	0
Fenton	0
reaction-induced	0
oxidation	0
of	0
dihydrorhodamine	0
123	0
in	0
a	0
dose-dependent	0
manner	0
similar	0
to	0
that	0
of	0
pyrrolidinedithiocarbamate	0
,	0
a	0
well	0
known	0
antioxidant	0
.	0

In	0
addition	0
,	0
D609	0
inhibited	0
the	0
formation	0
of	0
the	0
alpha-phenyl-tert-butylnitrone-free	0
radical	0
spin	0
adducts	0
and	0
lipid	0
peroxidation	0
of	0
synaptosomal	0
membranes	0
by	0
the	0
Fenton	0
reagents	0
.	0

Furthermore	0
,	0
preincubation	0
of	0
lymphocytes	7
with	0
D609	0
resulted	0
in	0
a	0
significant	0
diminution	0
of	0
ionizing	0
radiation	0
(	0
IR	0
)	0
-induced	0
1	0
)	0
production	0
of	0
reactive	0
oxygen	0
species	0
;	0
2	0
)	0
decrease	0
in	0
intracellular	0
reduced	0
glutathione	0
;	0
3	0
)	0
oxidative	0
damage	0
to	0
proteins	0
and	0
lipids	0
;	0
and	0
4	0
)	0
activation	0
of	0
nuclear	9
factor-kappaB	10
.	0

Moreover	0
,	0
when	0
D609	0
(	0
50	0
mg/kg	0
i.v.	0
)	0
was	0
administered	0
to	0
mice	0
10	0
min	0
prior	0
to	0
total	0
body	0
IR	0
(	0
6.5	0
and	0
8.5	0
Gy	0
)	0
,	0
it	0
protected	0
the	0
mice	0
from	0
IR-induced	0
lethality	0
.	0

Thus	0
,	0
these	0
results	0
indicate	0
that	0
D609	0
is	0
a	0
potent	0
antioxidant	0
and	0
has	0
the	0
ability	0
to	0
inhibit	0
IR-induced	0
cellular	0
oxidative	0
stress	0
.	0

Inhibition	0
of	0
AP-1	9
by	0
the	0
glucocorticoid-inducible	0
protein	9
GILZ	10
.	0

The	0
immunosuppressive	0
effects	0
of	0
glucocorticoids	0
arise	0
largely	0
by	0
inhibition	0
of	0
cytokine	0
gene	0
expression	0
,	0
which	0
has	0
been	0
ascribed	0
to	0
interference	0
between	0
the	0
glucocorticoid	9
receptor	10
and	0
transcription	9
factors	10
such	0
as	0
AP-1	9
and	0
NF-kappa	9
B	10
as	0
well	0
as	0
by	0
competition	0
for	0
common	0
coactivators	0
.	0

Here	0
we	0
show	0
that	0
glucocorticoid-induced	0
inhibition	0
of	0
interleukin-2	0
mRNA	0
expression	0
in	0
activated	7
normal	8
T	8
cells	8
required	0
new	0
protein	0
synthesis	0
,	0
suggesting	0
that	0
this	0
phenomenon	0
is	0
secondary	0
to	0
expression	0
of	0
glucocorticoid-regulated	0
genes	1
.	0

One	0
of	0
the	0
most	0
prominent	0
glucocorticoid-induced	0
genes	1
is	0
glucocorticoid-induced	1
leucine	2
zipper	2
(	0
GILZ	1
)	0
,	0
which	0
has	0
been	0
reported	0
to	0
inhibit	0
activation-induced	0
up-regulation	0
of	0
Fas	3
ligand	4
(	4
FasL	4
)	4
mRNA	4
.	0

Indeed	0
,	0
transient	0
expression	0
of	0
GILZ	1
in	0
Jurkat	5
T	6
cells	6
blocked	0
induction	0
of	0
a	0
reporter	1
construct	2
driven	0
by	0
the	0
FasL	1
promoter	2
.	0

This	0
could	0
be	0
accounted	0
for	0
by	0
GILZ	9
-mediated	0
inhibition	0
of	0
Egr-2	9
and	0
Egr-3	9
,	0
NFAT/AP-1	9
-inducible	0
transcription	9
factors	10
that	0
bind	0
a	0
regulatory	1
element	2
in	0
the	0
FasL	1
promoter	2
and	0
up-regulate	0
FasL	0
expression	0
.	0

GILZ	9
also	0
potently	0
inhibited	0
AP-1-driven	1
and	2
IL-2	2
promoter-driven	2
reporter	2
constructs	2
,	0
and	0
recombinant	0
GILZ	9
specifically	0
interacted	0
with	0
c-Fos	9
and	0
c-Jun	9
in	0
vitro	0
and	0
inhibited	0
the	0
binding	0
of	0
active	9
AP-1	10
to	0
its	0
target	0
DNA	0
.	0

Whereas	0
homodimerization	0
of	0
GILZ	9
required	0
the	0
presence	0
of	0
its	0
leucine	9
zipper	10
,	0
the	0
interaction	0
with	0
c-Fos	9
and	0
c-Jun	9
occurred	0
through	0
the	0
N-terminal	9
60-amino	9
acid	10
region	10
of	0
GILZ	9
.	0

Thus	0
,	0
GILZ	9
represents	0
a	0
glucocorticoid-induced	0
gene	0
product	0
that	0
can	0
inhibit	0
a	0
variety	0
of	0
activation-induced	0
events	0
,	0
at	0
least	0
in	0
part	0
by	0
direct	0
interference	0
with	0
AP-1	9
,	0
and	0
is	0
therefore	0
a	0
candidate	0
for	0
a	0
mediator	0
of	0
glucocorticoid-induced	0
immunosuppression	0
.	0

Pharmacokinetic	0
differences	0
between	0
a	0
T	0
cell-tolerizing	0
and	0
a	0
T	0
cell-activating	0
peptide	0
.	0

Vaccination	0
with	0
a	0
peptide	0
representing	0
a	0
CTL	0
epitope	0
from	0
the	0
human	0
papillomavirus	0
(	0
HPV	0
)	0
16	0
E7	9
protein	10
induces	0
a	0
specific	0
CTL	0
response	0
that	0
prevents	0
the	0
outgrowth	0
of	0
HPV16	0
E7-expressing	0
tumors	0
.	0

In	0
contrast	0
,	0
vaccination	0
with	0
a	0
peptide	0
encoding	0
an	0
adenovirus	0
type	0
5	0
(	0
Ad5	0
)	0
E1A	0
CTL	0
epitope	0
results	0
in	0
CTL	0
tolerance	0
and	0
enhanced	0
growth	0
of	0
an	0
Ad5	0
E1A-expressing	0
tumor	0
.	0

It	0
is	0
unclear	0
why	0
these	0
peptides	0
induce	0
such	0
opposite	0
effects	0
.	0

To	0
determine	0
whether	0
a	0
difference	0
in	0
pharmacokinetics	0
can	0
explain	0
the	0
functional	0
contrasts	0
,	0
tritiated	0
Ad5	0
E1A	0
and	0
HPV16	0
E7	0
peptides	0
were	0
injected	0
into	0
mice	0
.	0

Results	0
show	0
that	0
the	0
tolerizing	0
peptide	0
spread	0
through	0
the	0
body	0
16	0
times	0
faster	0
than	0
the	0
activating	0
peptide	0
and	0
was	0
cleared	0
at	0
least	0
2	0
times	0
faster	0
.	0

The	0
HPV16	0
E7	0
peptide	0
kinetics	0
correlated	0
with	0
the	0
kinetics	0
of	0
HPV16	9
E7	10
-specific	0
CTL	0
induction	0
.	0

In	0
contrast	0
,	0
Ad5	0
E1A	0
peptide	0
injection	0
resulted	0
in	0
physical	0
deletion	0
of	0
preexisting	0
Ad5	9
E1A	10
-specific	0
CTLs	9
within	0
24	0
h	0
after	0
injection	0
.	0

This	0
tolerization	0
occurred	0
at	0
the	0
time	0
when	0
the	0
peptide	0
reached	0
its	0
maximum	0
peptide	0
concentration	0
in	0
the	0
organs	0
.	0

These	0
data	0
suggest	0
that	0
ubiquitous	0
expression	0
of	0
the	0
tolerizing	0
Ad5	0
E1A	0
peptide	0
within	0
a	0
short	0
period	0
of	0
time	0
causes	0
activation-induced	0
cell	0
death	0
of	0
Ad5	9
E1A	10
-specific	0
CTLs	9
.	0

Therefore	0
,	0
information	0
on	0
the	0
pharmacokinetics	0
of	0
peptides	0
is	0
vital	0
for	0
the	0
safety	0
and	0
efficacy	0
of	0
peptide-based	0
vaccines	0
.	0

Smad3	9
and	0
Smad4	9
mediate	0
transforming	9
growth	10
factor-beta1	10
-induced	0
IgA	0
expression	0
in	0
murine	7
B	8
lymphocytes	8
.	0

Transforming	9
growth	10
factor	10
(	10
TGF	10
)	10
-beta1	10
is	0
well	0
established	0
as	0
a	0
critical	0
IgA	9
isotype	10
switching	10
factor	10
and	0
Smad	9
molecules	10
have	0
been	0
reported	0
to	0
act	0
as	0
transducers	9
and	0
transcriptional	9
factors	10
in	0
the	0
expression	0
of	0
TGF-beta1	9
-targeted	0
genes	1
.	0

We	0
examined	0
the	0
involvement	0
of	0
Smad	9
proteins	10
in	0
TGF-beta1	9
-induced	0
IgA	0
expression	0
.	0

First	0
,	0
we	0
found	0
that	0
TGF-beta1	9
significantly	0
increases	0
endogenous	3
germ-line	4
(	4
GL	4
)	4
alpha	4
transcripts	4
by	0
LPS-stimulated	0
CH12.LX.4933	5
(	6
mu	6
(	6
+	6
)	6
)	6
B	6
lymphoma	6
cells	6
.	0

To	0
investigate	0
its	0
signaling	0
mechanisms	0
,	0
the	0
lymphoma	5
cell	6
line	6
was	0
transfected	0
with	0
pFL3	1
that	0
contains	0
the	0
TGF-beta-responsive	1
element	2
of	0
the	0
GLalpha	1
promoter	2
,	0
and	0
stimulated	0
with	0
TGF-beta1	9
.	0

Similar	0
to	0
endogenous	3
GLalpha	4
transcripts	4
,	0
TGF-beta1	9
induces	0
GLalpha	1
promoter	2
activity	0
and	0
overexpression	0
of	0
Smad3	9
markedly	0
enhances	0
the	0
promoter	0
activity	0
.	0

This	0
activity	0
is	0
further	0
augmented	0
by	0
cotransfected	9
Smad4	10
.	0

On	0
the	0
other	0
hand	0
,	0
Smad7	9
substantially	0
abrogates	0
the	0
synergistic	0
effect	0
of	0
Smad3/4	9
on	0
GLalpha	1
promoter	2
activity	0
.	0

In	0
addition	0
,	0
overexpression	0
of	0
Smad3/4	9
enhances	0
TGF-beta1	9
-induced	0
endogenous	3
GLalpha	4
transcripts	4
in	0
normal	7
spleen	8
B	8
cell	8
s	0
.	0

Finally	0
,	0
in	0
the	0
presence	0
of	0
TGF-beta1	9
,	0
overexpression	0
of	0
Smad3/4	9
selectively	0
increases	0
both	0
surface	0
IgA	0
expression	0
and	0
IgA	0
production	0
.	0

The	0
results	0
from	0
the	0
present	0
study	0
indicate	0
that	0
Smad3	9
,	0
Smad4	9
,	0
and	0
Smad7	9
,	0
at	0
least	0
in	0
part	0
,	0
serve	0
as	0
mediators	0
linking	0
TGF-beta1	9
to	0
transcriptional	0
regulation	0
of	0
IgA	1
switching	2
related	2
gene	2
and	0
regulation	0
of	0
IgA	0
class	0
switching	0
.	0

The	0
translesion	9
DNA	10
polymerase	10
zeta	10
plays	0
a	0
major	0
role	0
in	0
Ig	0
and	0
bcl-6	0
somatic	0
hypermutation	0
.	0

Ig	0
somatic	0
mutations	0
would	0
be	0
introduced	0
by	0
a	0
polymerase	9
(	0
pol	9
)	0
while	0
repairing	0
DNA	0
outside	0
main	0
DNA	0
replication	0
.	0

We	0
show	0
that	0
human	7
B	8
cells	8
constitutively	0
express	0
the	0
translesion	9
pol	10
zeta	10
,	0
which	0
effectively	0
extends	0
DNA	0
past	0
mismatched	0
bases	0
(	0
mispair	0
extender	0
)	0
,	0
and	0
pol	9
eta	10
,	0
which	0
bypasses	0
DNA	0
lesions	0
in	0
an	0
error-free	0
fashion	0
.	0

Upon	0
B	9
cell	10
receptor	10
(	0
BCR	9
)	0
engagement	0
and	0
coculture	0
with	0
activated	7
CD4+	8
T	8
cells	8
,	0
these	0
lymphocytes	7
upregulated	0
pol	9
zeta	10
,	0
downregulated	0
pol	9
eta	10
,	0
and	0
mutated	0
the	0
Ig	1
and	2
bcl-6	2
genes	2
.	0

Inhibition	0
of	0
the	0
pol	9
zeta	10
REV3	9
catalytic	10
subunit	10
by	0
specific	0
phosphorothioate-modified	0
oligonucleotides	0
impaired	0
Ig	0
and	0
bcl-6	0
hypermutation	0
and	0
UV	0
damage-induced	0
DNA	0
mutagenesis	0
,	0
without	0
affecting	0
cell	0
cycle	0
or	0
viability	0
.	0

Thus	0
,	0
pol	9
zeta	10
plays	0
a	0
critical	0
role	0
in	0
Ig	0
and	0
bcl-6	0
hypermutation	0
,	0
perhaps	0
facilitated	0
by	0
the	0
downregulation	0
of	0
pol	9
eta	10
.	0

Molecular	0
mechanism	0
of	0
cell	0
cycle	0
progression	0
induced	0
by	0
the	0
oncogene	9
product	10
Tax	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
.	0

The	0
trans-activator	9
protein	10
Tax	10
of	0
human	0
T-cell	0
leukemia	0
virus	0
type	0
I	0
(	0
HTLV-I	0
)	0
plays	0
an	0
important	0
role	0
in	0
the	0
development	0
of	0
adult	0
T-cell	0
leukemia	0
through	0
,	0
at	0
least	0
in	0
part	0
,	0
its	0
ability	0
to	0
stimulate	0
cell	0
growth	0
.	0

We	0
previously	0
reported	0
that	0
Tax	9
induced	0
cell	0
cycle	0
progression	0
from	0
G0/G1	0
phase	0
to	0
S	0
and	0
G2/M	0
phases	0
in	0
human	5
T-cell	6
line	6
Kit	6
225	6
cells	6
.	0

To	0
elucidate	0
molecular	0
mechanism	0
of	0
Tax	9
-induced	0
cell	0
cycle	0
progression	0
,	0
we	0
systematically	0
examined	0
the	0
effects	0
of	0
Tax	9
on	0
biochemical	0
events	0
associated	0
with	0
cell	0
cycle	0
progression	0
.	0

Introduction	0
of	0
Tax	9
into	0
resting	5
Kit	6
225	6
cells	6
induced	0
activation	0
of	0
the	0
G1/S	0
transition	0
regulation	0
cascade	0
consisting	0
of	0
activation	0
of	0
cyclin	9
dependent	10
kinase	10
2	10
(	0
CDK2	9
)	0
and	0
CDK4	9
,	0
phosphorylation	0
of	0
the	0
Rb	9
family	10
proteins	10
and	0
an	0
increase	0
in	0
free	0
E2F	9
.	0

The	0
kinase	0
activation	0
was	0
found	0
to	0
result	0
from	0
Tax	9
-induced	0
expression	0
of	0
genes	0
for	0
cell	9
cycle	10
regulatory	10
molecules	10
including	0
cyclin	9
D2	10
,	0
cyclin	9
E	10
,	0
E2F1	9
,	0
CDK2	9
,	0
CDK4	9
and	0
CDK6	9
,	0
and	0
Tax	9
-induced	0
reduction	0
of	0
CDK	9
inhibitors	10
p19	10
(	0
INK4d	9
)	0
and	0
p27	9
(	10
Kip1	10
)	10
.	0

These	0
modulations	0
by	0
Tax	9
always	0
paralleled	0
the	0
ability	0
of	0
Tax	9
to	0
activate	0
the	0
NF-kappaB	0
transcription	0
pathway	0
.	0

These	0
results	0
indicate	0
the	0
important	0
role	0
of	0
Tax	9
-mediated	0
trans-activation	0
of	0
the	0
genes	0
for	0
cell	9
cycle	10
regulatory	10
molecules	10
in	0
Tax	9
-induced	0
cell	0
cycle	0
progression	0
.	0

Cot	9
kinase	10
induces	0
cyclooxygenase-2	0
expression	0
in	0
T	7
cells	8
through	0
activation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
.	0

Cyclooxygenase-2	9
(	0
COX-2	9
)	0
is	0
induced	0
in	0
human	7
T	8
lymphocytes	8
upon	0
T	9
cell	10
receptor	10
triggering	0
.	0

Here	0
we	0
report	0
that	0
Cot	9
kinase	10
,	0
a	0
mitogen-activated	9
protein	10
kinase	10
kinase	10
kinase	10
involved	0
in	0
T	0
cell	0
activation	0
,	0
up-regulates	0
COX-2	1
gene	2
expression	0
in	0
Jurkat	5
T	6
cells	6
.	0

Induction	0
of	0
COX-2	0
promoter	0
activity	0
by	0
Cot	9
kinase	10
occurred	0
mainly	0
through	0
activation	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
.	0

Mutation	0
of	0
the	0
distal	1
(	2
-105/-97	2
)	2
and	0
proximal	1
(	2
-76/-61	2
)	2
NFAT	1
response	2
elements	2
in	0
the	0
COX-2	1
promoter	2
abolished	0
the	0
activation	0
induced	0
by	0
Cot	9
kinase	10
.	0

Even	0
more	0
,	0
coexpression	0
of	0
a	0
dominant	0
negative	0
version	0
of	0
NFAT	9
inhibited	0
Cot	9
kinase	10
-mediated	0
COX-2	1
promoter	2
activation	0
,	0
whereas	0
cotransfection	0
of	0
a	0
constitutively	0
active	0
version	0
of	0
the	0
calcium-dependent	9
phosphatase	10
calcineurin	10
synergizes	0
with	0
Cot	9
kinase	10
in	0
the	0
up-regulation	0
of	0
COX-2	1
promoter	2
-driven	0
transcription	0
.	0

Strikingly	0
,	0
Cot	9
kinase	10
increased	0
transactivation	0
mediated	0
by	0
a	0
GAL4-NFAT	9
fusion	10
protein	10
containing	0
the	0
N-terminal	9
transactivation	10
domain	10
of	0
NFATp	9
.	0

In	0
contrast	0
to	0
phorbol	0
ester	0
plus	0
calcium	0
ionophore	0
A23187	0
,	0
Cot	9
kinase	10
increases	0
both	0
COX-2	1
promoter	2
activity	0
and	0
NFAT	9
-mediated	0
transactivation	0
in	0
a	0
cyclosporin	0
A-independent	0
manner	0
.	0

These	0
data	0
indicate	0
that	0
Cot	9
kinase	10
up-regulates	0
COX-2	1
promoter	2
-driven	0
transcription	0
through	0
the	0
NFAT	1
response	2
elements	2
,	0
being	0
the	0
Cot	9
kinase	10
-induced	0
NFAT	9
-dependent	0
transactivation	0
presumably	0
implicated	0
in	0
this	0
up-regulation	0
.	0

Positive	0
and	0
negative	0
roles	0
of	0
the	0
trans-acting	9
T	10
cell	10
factor-1	10
for	0
the	0
acquisition	0
of	0
distinct	0
Ly-49	9
MHC	10
class	10
I	10
receptors	10
by	0
NK	7
cells	8
.	0

Members	0
of	0
the	0
Ly-49	1
gene	2
family	2
code	0
for	0
class	9
I	10
MHC-specific	10
receptors	10
that	0
regulate	0
NK	0
cell	0
function	0
.	0

Due	0
to	0
a	0
combinatorial	0
distribution	0
of	0
Ly-49	9
receptors	10
,	0
NK	7
cells	8
display	0
considerable	0
clonal	0
heterogeneity	0
.	0

The	0
acquisition	0
of	0
one	0
Ly-49	9
receptor	10
,	0
Ly-49A	9
is	0
strictly	0
dependent	0
on	0
the	0
transcriptional	9
trans-acting	10
factor	10
T	9
cell-specific	10
factor-1	10
(	0
TCF-1	9
)	0
.	0

Indeed	0
,	0
TCF-1	9
binds	0
to	0
two	0
sites	0
in	0
the	0
Ly-49a	1
promoter	2
and	0
regulates	0
its	0
activity	0
,	0
suggesting	0
that	0
the	0
Ly-49a	1
gene	2
is	0
a	0
direct	0
TCF-1	9
target	0
.	0

TCF-1	9
deficiency	0
resulted	0
in	0
the	0
altered	0
usage	0
of	0
additional	0
Ly-49	9
receptors	10
.	0

We	0
show	0
in	0
this	0
study	0
,	0
using	0
TCF-1	9
beta	10
(	10
2	10
)	10
-microglobulin	10
double-deficient	0
mice	0
,	0
that	0
these	0
repertoire	0
alterations	0
are	0
not	0
due	0
to	0
Ly-49/MHC	0
class	0
I	0
interactions	0
.	0

Our	0
findings	0
rather	0
suggest	0
a	0
TCF-1	9
-dependent	0
,	0
cell	0
autonomous	0
effect	0
on	0
the	0
acquisition	0
of	0
multiple	0
Ly-49	9
receptors	10
.	0

Besides	0
reduced	0
receptor	0
usage	0
(	0
Ly-49A	9
and	10
D	10
)	0
,	0
we	0
also	0
observed	0
no	0
effect	0
(	0
Ly-49C	9
)	0
and	0
significantly	0
expanded	0
(	0
Ly-49G	9
and	10
I	10
)	0
receptor	0
usage	0
in	0
the	0
absence	0
of	0
TCF-1	9
.	0

These	0
effects	0
did	0
not	0
in	0
all	0
cases	0
correlate	0
with	0
the	0
presence	0
of	0
TCF	1
binding	2
sites	2
in	0
the	0
respective	0
proximal	1
promoter	2
.	0

Therefore	0
,	0
besides	0
TCF-1	9
binding	0
to	0
the	0
proximal	1
promoter	2
,	0
Ly-49	0
acquisition	0
may	0
also	0
be	0
regulated	0
by	0
TCF-1	9
binding	0
to	0
more	0
distant	0
cis-acting	1
elements	2
and/or	0
by	0
regulating	0
the	0
expression	0
of	0
additional	0
trans-acting	1
factors	2
.	0

Consistent	0
with	0
the	0
observed	0
differential	0
,	0
positive	0
or	0
negative	0
role	0
of	0
TCF-1	9
for	0
Ly-49	9
receptor	10
acquisition	0
,	0
reporter	0
gene	0
assays	0
revealed	0
the	0
presence	0
of	0
an	0
inducing	0
as	0
well	0
as	0
a	0
repressing	0
TCF	1
site	2
in	0
certain	0
proximal	0
Ly-49	1
promoters	2
.	0

These	0
findings	0
reveal	0
an	0
important	0
role	0
of	0
TCF-1	9
for	0
the	0
formation	0
of	0
the	0
NK	9
cell	10
receptor	10
repertoire	0
.	0

Ligation	0
of	0
CD11b	9
and	0
CD11c	9
beta	10
(	10
2	10
)	10
integrins	9
by	0
antibodies	9
or	0
soluble	9
CD23	10
induces	0
macrophage	9
inflammatory	10
protein	10
1alpha	10
(	0
MIP-1alpha	9
)	0
and	0
MIP-1beta	9
production	0
in	0
primary	7
human	8
monocytes	8
through	0
a	0
pathway	0
dependent	0
on	0
nuclear	9
factor-kappaB	10
.	0

Chemokines	9
and	0
adhesion	9
molecules	10
such	0
as	0
integrins	9
play	0
a	0
major	0
part	0
in	0
the	0
trafficking	0
,	0
extravasation	0
,	0
and	0
recruitment	0
of	0
leukocytes	7
to	0
inflammatory	0
sites	0
.	0

This	0
study	0
investigated	0
the	0
effects	0
of	0
beta	0
(	0
2	0
)	0
integrin	0
engagement	0
on	0
chemokine	0
production	0
by	0
freshly	7
isolated	8
human	8
monocytes	8
.	0

We	0
found	0
that	0
ligation	0
of	0
CD11b	9
or	0
CD11c	9
but	0
not	0
CD11a	9
alpha	10
chains	10
of	0
beta	9
(	10
2	10
)	10
integrins	10
by	0
antibodies	9
or	0
soluble	9
CD23	10
(	10
sCD23	10
)	10
fusion	10
proteins	10
rapidly	0
induced	0
transcription	0
and	0
secretion	0
of	0
interleukin	9
8	10
,	0
macrophage	9
inflammatory	10
protein	10
(	10
MIP	10
)	10
1alpha	10
,	0
and	0
MIP-1beta	9
.	0

Because	0
the	0
promoters	1
of	0
these	0
chemokine	1
genes	2
contain	0
kappaB	1
binding	2
sites	2
,	0
we	0
assessed	0
the	0
possible	0
role	0
of	0
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
in	0
controlling	0
induction	0
of	0
the	0
genes	0
through	0
beta	0
(	0
2	0
)	0
integrin	0
engagement	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
showed	0
that	0
sCD23	9
or	0
antibodies	9
to	0
CD11b	9
or	0
to	0
CD11c	9
up-regulated	0
DNA-binding	0
activity	0
of	0
NF-kappaB	9
.	0

Activation	0
of	0
NF-kappaB	9
was	0
accompanied	0
by	0
degradation	0
of	0
its	0
cytosolic	9
inhibitor	10
IkappaB-alpha	10
.	0

Blockade	0
of	0
depletion	0
of	0
IkappaB-alpha	9
by	0
proteasome	0
inhibitors	0
(	0
proteasome	0
inhibitor	0
I	0
or	0
acetyl-leucinyl-leucinyl-norleucinal	0
)	0
led	0
to	0
concomitant	0
inhibition	0
of	0
NF-kappaB	0
DNA-binding	0
activity	0
and	0
expression	0
of	0
MIP-1alpha	3
and	4
MIP-1beta	4
messenger	4
RNA	4
induced	0
by	0
beta	0
(	0
2	0
)	0
integrin	0
ligation	0
.	0

These	0
results	0
suggest	0
that	0
triggering	0
of	0
CD11b	9
or	0
CD11c	9
beta	10
(	10
2	10
)	10
integrin	0
on	0
primary	7
human	8
monocytes	8
provides	0
activation	0
signals	0
leading	0
to	0
nuclear	0
translocation	0
of	0
NF-kappaB	9
and	0
subsequent	0
secretion	0
of	0
MIP-1alpha	9
and	0
MIP-1beta	9
that	0
may	0
have	0
an	0
important	0
role	0
in	0
recruitment	0
of	0
other	0
inflammatory	7
cells	8
during	0
initiation	0
of	0
an	0
inflammatory	0
response	0

Synergistic	0
transcriptional	0
activation	0
of	0
human	1
Acyl-coenzyme	2
A	2
:	2
cholesterol	2
acyltransterase-1	2
gene	2
by	0
interferon-gamma	9
and	0
all-trans-retinoic	0
acid	0
THP-1	7
cells	8
.	0

Acyl-coenzyme	9
A	10
:	10
cholesterol	10
acyltransferase	10
(	0
ACAT	9
)	0
is	0
an	0
intracellular	9
enzyme	10
involved	0
in	0
cellular	0
cholesterol	0
homeostasis	0
and	0
in	0
atherosclerotic	0
foam	0
cell	0
formation	0
.	0

Human	1
ACAT-1	2
gene	2
contains	0
two	0
promoters	1
(	0
P1	1
and	0
P7	1
)	0
,	0
each	0
located	0
in	0
a	0
different	0
chromosome	1
(	2
1	2
and	2
7	2
)	2
(	0
Li	0
,	0
B.	0
L.	0
,	0
Li	0
,	0
X.	0
L.	0
,	0
Duan	0
,	0
Z.	0
J.	0
,	0
Lee	0
,	0
O.	0
,	0
Lin	0
,	0
S.	0
,	0
Ma	0
,	0
Z.	0
M.	0
,	0
Chang	0
,	0
C.	0
C.	0
,	0
Yang	0
,	0
X.	0
Y.	0
,	0
Park	0
,	0
J.	0
P.	0
,	0
Mohandas	0
,	0
T.	0
K.	0
,	0
Noll	0
,	0
W.	0
,	0
Chan	0
,	0
L.	0
,	0
and	0
Chang	0
,	0
T.	0
Y.	0
(	0
1999	0
)	0
J.	0
Biol	0
Chem.	0
274	0
,	0
11060-11071	0
)	0
.	0

Interferon-gamma	9
(	0
IFN-gamma	9
)	0
,	0
a	0
cytokine	9
that	0
exerts	0
many	0
pro-atherosclerotic	0
effects	0
in	0
vivo	0
,	0
causes	0
up-regulation	0
of	0
ACAT-1	3
mRNA	4
in	0
human	7
blood	8
monocyte-derived	8
macrophages	8
and	0
macrophage-like	7
cells	8
but	0
not	0
in	0
other	0
cell	0
types	0
.	0

To	0
examine	0
the	0
molecular	0
nature	0
of	0
this	0
observation	0
,	0
we	0
identified	0
within	0
the	0
ACAT-1	1
P1	2
promoter	2
a	0
159-base	1
pair	2
core	2
region	2
.	0

This	0
region	0
contains	0
4	0
Sp1	1
elements	2
and	0
an	0
IFN-gamma	1
activated	2
sequence	2
(	0
GAS	1
)	0
that	0
overlaps	0
with	0
the	0
second	0
Sp1	1
element	2
.	0

In	0
the	0
monocytic	7
cell	8
line	8
THP-1	8
cell	8
,	0
the	0
combination	0
of	0
IFN-gamma	9
and	0
all-trans-retinoic	0
acid	0
(	0
a	0
known	0
differentiation	0
agent	0
)	0
enhances	0
the	0
ACAT-1	1
P1	2
promoter	2
but	0
not	0
the	0
P7	1
promoter	2
.	0

Additional	0
experiments	0
showed	0
that	0
all-trans-retinoic	0
acid	0
causes	0
large	0
induction	0
of	0
the	0
transcription	9
factor	10
STAT1	10
,	0
while	0
IFN-gamma	9
causes	0
activation	0
of	0
STAT1	9
such	0
that	0
it	0
binds	0
to	0
the	0
GAS/Sp1	1
site	2
in	0
the	0
ACAT-1	1
P1	2
promoter	2
.	0

Our	0
work	0
provides	0
a	0
molecular	0
mechanism	0
to	0
account	0
for	0
the	0
effect	0
of	0
IFN-gamma	9
in	0
causing	0
transcriptional	0
activation	0
of	0
ACAT-1	9
in	0
macrophage-like	7
cells	8
.	0

Inhaled	0
nitric	0
oxide	0
down-regulates	0
intrapulmonary	0
nitric	0
oxide	0
production	0
in	0
lipopolysaccharide-induced	0
acute	0
lung	0
injury	0
.	0

OBJECTIVE	0
:	0
To	0
examine	0
whether	0
inhaled	0
nitric	0
oxide	0
(	0
NO	0
)	0
affected	0
the	0
intrapulmonary	0
production	0
of	0
NO	0
,	0
reactive	0
oxygen	0
species	0
,	0
and	0
nuclear	9
factor-kappaB	10
in	0
a	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-induced	0
model	0
of	0
acute	0
lung	0
injury	0
.	0

DESIGN	0
:	0
Prospective	0
,	0
randomized	0
,	0
laboratory	0
study	0
.	0

SETTING	0
:	0
Experimental	0
laboratory	0
at	0
a	0
biomedical	0
institute	0
.	0

SUBJECTS	0
:	0
Twenty	0
male	0
rabbits	0
weighing	0
2.5-3.5	0
kg	0
.	0

INTERVENTIONS	0
:	0
Saline	0
or	0
LPS	0
(	0
5	0
mg/kg	0
of	0
body	0
weight	0
)	0
was	0
administered	0
intravenously	0
with	0
or	0
without	0
NO	0
inhalation	0
(	0
10	0
ppm	0
)	0
in	0
each	0
group	0
of	0
five	0
rabbits	0
.	0

MEASUREMENTS	0
AND	0
MAIN	0
RESULTS	0
:	0
LPS	0
increased	0
the	0
lung	0
leak	0
index	0
,	0
the	0
neutrophils	7
and	0
NO	0
levels	0
in	0
bronchoalveolar	0
lavage	0
fluid	0
,	0
and	0
NO	0
levels	0
produced	0
by	0
resting	0
and	0
stimulated	0
alveolar	7
macrophages	8
.	0

Inhaled	0
NO	0
decreased	0
the	0
lung	0
leak	0
index	0
,	0
the	0
neutrophils	7
and	0
NO	0
levels	0
as	0
measured	0
by	0
nitrite	0
levels	0
in	0
the	0
lavage	0
fluid	0
,	0
and	0
NO	0
produced	0
by	0
the	0
resting	0
and	0
stimulated	0
alveolar	7
macrophages	8
.	0

Inhaled	0
NO	0
also	0
blocked	0
the	0
activities	0
of	0
reactive	0
oxygen	0
species	0
and	0
nuclear	9
factor-kappaB	10
binding	0
to	0
DNA	0
in	0
lavage	7
cells	8
and	0
in	0
alveolar	7
macrophages	8
.	0

CONCLUSION	0
:	0
Inhaled	0
NO	0
attenuates	0
LPS-induced	0
acute	0
lung	0
injury	0
,	0
possibly	0
by	0
decreasing	0
NO	0
production	0
in	0
the	0
lungs	0
.	0

The	0
mechanism	0
of	0
reducing	0
NO	0
production	0
resulting	0
from	0
inhaled	0
NO	0
may	0
involve	0
,	0
in	0
part	0
,	0
the	0
activities	0
of	0
reactive	0
oxygen	0
species	0
and/or	0
nuclear	9
factor-kappaB	10
.	0

Treatment	0
of	0
allergic	0
airway	0
inflammation	0
and	0
hyperresponsiveness	0
by	0
antisense-induced	0
local	0
blockade	0
of	0
GATA-3	1
expression	0
.	0

Recent	0
studies	0
in	0
transgenic	0
mice	0
have	0
revealed	0
that	0
expression	0
of	0
a	0
dominant	0
negative	0
form	0
of	0
the	0
transcription	9
factor	10
GATA-3	10
in	0
T	7
cells	8
can	0
prevent	0
T	7
helper	8
cell	8
type	8
2	8
(	0
Th2	7
)	0
-mediated	0
allergic	0
airway	0
inflammation	0
in	0
mice	0
.	0

However	0
,	0
it	0
remains	0
unclear	0
whether	0
GATA-3	9
plays	0
a	0
role	0
in	0
the	0
effector	0
phase	0
of	0
allergic	0
airway	0
inflammation	0
and	0
whether	0
antagonizing	0
the	0
expression	0
and/or	0
function	0
of	0
GATA-3	1
can	0
be	0
used	0
for	0
the	0
therapy	0
of	0
allergic	0
airway	0
inflammation	0
and	0
hyperresponsiveness	0
.	0

Here	0
,	0
we	0
analyzed	0
the	0
effects	0
of	0
locally	0
antagonizing	0
GATA-3	9
function	0
in	0
a	0
murine	0
model	0
of	0
asthma	0
.	0

We	0
could	0
suppress	0
GATA-3	0
expression	0
in	0
interleukin	9
(	10
IL	10
)	10
-4	10
-producing	0
T	7
cells	8
in	0
vitro	0
and	0
in	0
vivo	0
by	0
an	0
antisense	0
phosphorothioate	0
oligonucleotide	0
overlapping	0
the	0
translation	1
start	2
site	2
of	0
GATA-3	1
,	0
whereas	0
nonsense	0
control	0
oligonucleotides	0
were	0
virtually	0
inactive	0
.	0

In	0
a	0
murine	0
model	0
of	0
asthma	0
associated	0
with	0
allergic	0
pulmonary	0
inflammation	0
and	0
hyperresponsiveness	0
in	0
ovalbumin	0
(	0
OVA	0
)	0
-sensitized	0
mice	0
,	0
local	0
intranasal	0
administration	0
of	0
fluorescein	0
isothiocyanate-labeled	0
GATA-3	0
antisense	0
oligonucleotides	0
led	0
to	0
DNA	0
uptake	0
in	0
lung	7
cells	8
associated	0
with	0
a	0
reduction	0
of	0
intracellular	0
GATA-3	0
expression	0
.	0

Such	0
intrapulmonary	0
blockade	0
of	0
GATA-3	0
expression	0
caused	0
an	0
abrogation	0
of	0
signs	0
of	0
lung	0
inflammation	0
including	0
infiltration	0
of	0
eosinophils	7
and	0
Th2	7
cytokine	0
production	0
.	0

Furthermore	0
,	0
treatment	0
with	0
antisense	0
but	0
not	0
nonsense	0
oligonucleotides	0
induced	0
a	0
significant	0
reduction	0
of	0
airway	0
hyperresponsiveness	0
in	0
OVA-sensitized	0
mice	0
to	0
levels	0
comparable	0
to	0
saline-treated	0
control	0
mice	0
,	0
as	0
assessed	0
by	0
both	0
enhanced	0
pause	0
(	0
PenH	0
)	0
responses	0
and	0
pulmonary	0
resistance	0
determined	0
by	0
body	0
plethysmography	0
.	0

These	0
data	0
indicate	0
a	0
critical	0
role	0
for	0
GATA-3	1
in	0
the	0
effector	0
phase	0
of	0
a	0
murine	0
asthma	0
model	0
and	0
suggest	0
that	0
local	0
delivery	0
of	0
GATA-3	0
antisense	0
oligonucleotides	0
may	0
be	0
a	0
novel	0
approach	0
for	0
the	0
treatment	0
of	0
airway	0
hyperresponsiveness	0
such	0
as	0
in	0
asthma	0
.	0

This	0
approach	0
has	0
the	0
potential	0
advantage	0
of	0
suppressing	0
the	0
expression	0
of	0
various	0
proinflammatory	9
Th2	10
cytokines	10
simultaneously	0
rather	0
than	0
suppressing	0
the	0
activity	0
of	0
a	0
single	0
cytokine	9
.	0

T	0
helper-cell	0
phenotype	0
regulates	0
atherosclerosis	0
in	0
mice	0
under	0
conditions	0
of	0
mild	0
hypercholesterolemia	0
.	0

BACKGROUND	0
:	0
T	7
cells	8
are	0
implicated	0
in	0
atherosclerosis	0
,	0
but	0
little	0
is	0
known	0
about	0
the	0
genetic	0
control	0
or	0
molecular	0
pathways	0
,	0
especially	0
under	0
conditions	0
of	0
mild	0
hypercholesterolemia	0
.	0

METHODS	0
AND	0
RESULTS	0
:	0
BALB/c	0
mice	0
,	0
making	0
a	0
CD4+	0
Th2	0
(	0
IL-4+	0
)	0
cell	0
response	0
,	0
express	0
both	0
MHC	9
class	10
II	10
antigens	10
(	0
IA	9
(	10
d	10
)	10
,	0
IE	9
(	10
d	10
)	10
)	0
and	0
are	0
atherosclerosis-resistant	0
.	0

C57Bl/6	0
mice	0
produce	0
a	0
CD4+	0
Th1	0
(	0
interferon	0
[	0
IFN	0
]	0
gamma+	0
)	0
response	0
,	0
express	0
IA	9
(	10
b	10
)	10
but	0
no	0
IE	9
,	0
and	0
are	0
atherosclerosis-prone	0
.	0

To	0
evaluate	0
T	0
helper-cell	0
phenotype	0
in	0
fatty	0
streak	0
formation	0
,	0
wild-type	0
C57Bl/6	0
mice	0
(	0
IA	0
(	0
b	0
)	0
+IE-	0
)	0
and	0
transgenic	0
mice	0
,	0
either	0
AB	0
(	0
o	0
)	0
,	0
IA	0
(	0
b	0
)	0
-IE-	0
;	0
ABEalpha	0
,	0
IA-IE	0
(	0
k	0
)	0
+	0
;	0
or	0
BL	0
:	0
TG	0
:	0
Ealpha	0
,	0
IA	0
(	0
b	0
)	0
+IE	0
(	0
k	0
)	0
+	0
,	0
were	0
fed	0
a	0
high-cholesterol	0
diet	0
for	0
16	0
weeks	0
and	0
evaluated	0
histomorphometrically	0
for	0
aortic	0
lesions	0
.	0

Lesion	0
size	0
in	0
AB	0
(	0
o	0
)	0
,	0
ABEalpha	0
,	0
and	0
BL	0
:	0
TG	0
:	0
Ealpha	0
strains	0
was	0
decreased	0
by	0
54	0
%	0
,	0
79	0
%	0
,	0
and	0
82	0
%	0
,	0
respectively	0
,	0
compared	0
with	0
wild-type	0
,	0
correlating	0
with	0
decreased	0
Th1	7
and	0
increased	0
Th2	7
expression	0
and	0
suggesting	0
that	0
T	0
helper-cell	0
phenotype	0
is	0
important	0
in	0
fatty	0
lesion	0
development	0
.	0

Decreasing	0
Th1	7
cells	8
by	0
antibodies	9
(	0
alpha-CD4	9
)	0
or	0
cytokines	9
(	0
IL-4	9
)	0
also	0
caused	0
>	0
/=80	0
%	0
reductions	0
in	0
lesion	0
size	0
.	0

Immunohistology	0
revealed	0
IFN-gamma	9
,	0
but	0
not	0
IL-4	9
,	0
colocalized	0
with	0
activated	0
macrophages	7
.	0

Confirming	0
these	0
findings	0
in	0
a	0
different	0
mouse	0
strain	0
,	0
BALB/c	0
Stat	0
6	0
knockout	0
mice	0
(	0
Th2	0
cell-deficient	0
)	0
developed	0
aortic	0
lesions	0
comparable	0
to	0
C57Bl/6	0
mice	0
on	0
the	0
same	0
diet	0
.	0

CONCLUSIONS	0
:	0
In	0
mildly	0
hypercholesterolemic	0
C57Bl/6	0
mice	0
,	0
presence	0
of	0
IA	9
(	10
b	10
)	10
and	0
absence	0
of	0
IE	9
regulated	0
CD4+	0
T	0
helper-cell	0
phenotype	0
;	0
fatty	0
lesions	0
were	0
proportional	0
to	0
IFNgamma+	7
Th1	8
cells	8
in	0
both	0
C57Bl/6	0
and	0
BALB/c	0
strains	0
.	0

IFN-gamma	9
may	0
participate	0
through	0
macrophage	0
activation	0
,	0
whereas	0
IL-4	9
may	0
act	0
to	0
limit	0
Th1-cell	0
response	0
.	0

Requirement	0
for	0
p38	9
and	0
p44/p42	9
mitogen-activated	9
protein	10
kinases	10
in	0
RAGE	9
-mediated	0
nuclear	9
factor-kappaB	10
transcriptional	0
activation	0
and	0
cytokine	0
secretion	0
.	0

Advanced	0
glycation	0
end	0
product	0
(	0
AGE	0
)	0
activation	0
of	0
the	0
signal-transducing	9
receptor	10
for	10
AGE	10
(	0
RAGE	9
)	0
has	0
been	0
linked	0
to	0
a	0
proinflammatory	0
phenotypic	0
change	0
within	0
cells	0
.	0

However	0
,	0
the	0
precise	0
intracellular	0
signaling	0
pathways	0
involved	0
have	0
not	0
been	0
elucidated	0
.	0

We	0
demonstrate	0
here	0
that	0
human	0
serum	0
albumin	0
modified	0
with	0
N	0
(	0
varepsilon	0
)	0
-	0
(	0
carboxymethyl	0
)	0
lysine	0
(	0
CML	0
)	0
,	0
a	0
major	0
AGE	0
adduct	0
that	0
progressively	0
accumulates	0
with	0
aging	0
,	0
diabetes	0
,	0
and	0
renal	0
failure	0
,	0
induced	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
-driven	0
reporter	0
gene	0
expression	0
in	0
human	7
monocytic	8
THP-1	8
cells	8
.	0

The	0
NF-kappaB	0
response	0
was	0
blocked	0
with	0
a	0
synthetic	0
peptide	0
corresponding	0
to	0
the	0
putative	9
ligand-binding	10
domain	10
of	0
RAGE	9
,	0
with	0
anti-	0
RAGE	9
antiserum	0
,	0
and	0
by	0
coexpression	0
of	0
truncated	9
receptors	10
lacking	0
the	0
intracellular	9
domain	10
.	0

Signal	0
transduction	0
from	0
RAGE	9
to	0
NF-kappaB	9
involved	0
the	0
generation	0
of	0
reactive	0
oxygen	0
species	0
,	0
since	0
reporter	0
gene	0
expression	0
was	0
blocked	0
with	0
the	0
antioxidant	0
N-acetyl-L-cysteine	0
.	0

CML-modified	9
albumin	10
produced	0
rapid	0
transient	0
activation	0
of	0
tyrosine	0
phosphorylation	0
,	0
extracellular	9
signal-regulated	10
kinase	10
1	10
and	10
2	10
,	0
and	0
p38	9
mitogen-activated	10
protein	10
kinase	10
(	0
MAPK	9
)	0
,	0
but	0
not	0
c-Jun	9
NH	10
(	10
2	10
)	10
-terminal	10
kinase	10
.	0

RAGE	9
-mediated	0
NF-kappaB	0
activation	0
was	0
suppressed	0
by	0
the	0
selective	0
p38	9
MAPK	10
inhibitor	0
SB203580	0
and	0
by	0
coexpression	0
of	0
a	0
kinase-dead	0
p38	0
dominant-negative	0
mutant	0
.	0

Activation	0
of	0
NF-kappaB	9
by	0
CML-modified	9
albumin	10
increased	0
secretion	0
of	0
proinflammatory	9
cytokines	10
(	0
tumor	9
necrosis	10
factor-alpha	10
,	0
interleukin-1beta	9
,	0
and	0
monocyte	9
chemoattractant	10
protein-1	10
)	0
severalfold	0
,	0
and	0
inhibition	0
of	0
p38	9
MAPK	10
blocked	0
these	0
increases	0
.	0

These	0
results	0
indicate	0
that	0
p38	9
MAPK	10
activation	0
mediates	0
RAGE	9
-induced	0
NF-kappaB	9
-dependent	0
secretion	0
of	0
proinflammatory	9
cytokines	10
and	0
suggest	0
that	0
accelerated	0
inflammation	0
may	0
be	0
a	0
consequence	0
of	0
cellular	0
activation	0
induced	0
by	0
this	0
receptor	0
.	0

Antigen-receptor	0
cross-linking	0
and	0
lipopolysaccharide	0
trigger	0
distinct	0
phosphoinositide	9
3-kinase	10
-dependent	0
pathways	0
to	0
NF-kappa	0
B	0
activation	0
in	0
primary	7
B	8
cells	8
.	0

The	0
NF-kappaB/Rel	9
transcription	10
factors	10
play	0
an	0
important	0
role	0
in	0
the	0
expression	0
of	0
genes	0
involved	0
in	0
B	0
cell	0
development	0
,	0
differentiation	0
and	0
function	0
.	0

Nuclear	9
NF-kappaB	10
is	0
induced	0
in	0
B	7
cells	8
by	0
engagement	0
of	0
either	0
the	0
BCR	9
or	0
CD40	9
or	0
by	0
stimulation	0
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
.	0

Despite	0
the	0
importance	0
of	0
NF-kappaB	9
to	0
B	0
cell	0
function	0
,	0
little	0
is	0
known	0
about	0
the	0
signaling	0
pathways	0
leading	0
to	0
NF-kappaB	0
activation	0
.	0

In	0
this	0
report	0
we	0
address	0
the	0
role	0
of	0
phosphoinositide	9
3'-kinase	10
(	0
PI	9
3-kinase	10
)	0
in	0
BCR	9
-	0
and	0
LPS-induced	0
NF-kappaB	0
activation	0
using	0
populations	0
of	0
primary	7
murine	8
resting	8
B	8
cells	8
.	0

Using	0
the	0
specific	0
pharmacological	0
inhibitors	0
of	0
PI	9
3-kinase	10
,	0
Wortmannin	0
and	0
LY294002	0
,	0
we	0
demonstrate	0
that	0
PI	9
3-kinase	10
activity	0
is	0
vital	0
for	0
BCR	9
-induced	0
NF-kappaB	9
DNA-binding	0
activity	0
.	0

Furthermore	0
,	0
we	0
show	0
that	0
this	0
is	0
achieved	0
via	0
protein	9
kinase	10
C	10
-dependent	0
degradation	0
of	0
IkappaBalpha	9
.	0

Similar	0
analyses	0
reveal	0
that	0
PI	9
3-kinase	10
is	0
also	0
critical	0
in	0
triggering	0
NF-kappaB	9
DNA-binding	0
activity	0
and	0
IkappaBalpha	9
degradation	0
following	0
LPS	0
stimulation	0
.	0

Interestingly	0
,	0
a	0
PKC	0
inhibitor	0
which	0
blocked	0
the	0
BCR	9
-induced	0
IkappaBalpha	9
degradation	0
had	0
no	0
effect	0
on	0
the	0
degradation	0
of	0
IkappaBalpha	9
after	0
LPS	0
stimulation	0
.	0

Taken	0
together	0
,	0
our	0
results	0
indicate	0
the	0
involvement	0
of	0
PI	9
3-kinase	10
in	0
at	0
least	0
two	0
distinct	0
signaling	0
pathways	0
leading	0
to	0
activation	0
of	0
NF-kappaB	9
in	0
B	7
cells	8
.	0

Tetramer-guided	0
epitope	0
mapping	0
:	0
rapid	0
identification	0
and	0
characterization	0
of	0
immunodominant	7
CD4+	8
T	8
cell	8
epitopes	8
from	0
complex	0
antigens	9
.	0

T	0
cell	0
responses	0
to	0
Ags	9
involve	0
recognition	0
of	0
selected	0
peptide	9
epitopes	10
contained	0
within	0
the	0
antigenic	9
protein	10
.	0

In	0
this	0
report	0
,	0
we	0
describe	0
a	0
new	0
approach	0
for	0
direct	0
identification	0
of	0
CD4+	7
T	8
cell	8
epitopes	8
of	0
complex	0
Ags	9
that	0
uses	0
human	9
class	10
II	10
tetramers	10
to	0
identify	0
reactive	0
cells	0
.	0

With	0
a	0
panel	0
of	0
60	0
overlapping	0
peptides	0
covering	0
the	0
entire	0
sequence	0
of	0
the	0
VP16	9
protein	10
,	0
a	0
major	0
Ag	9
for	0
HSV-2	0
,	0
we	0
generated	0
a	0
panel	0
of	0
class	9
II	10
MHC	10
tetramers	10
loaded	0
with	0
peptide	0
pools	0
that	0
were	0
used	0
to	0
stain	0
peripheral	7
lymphocytes	8
of	0
an	0
HSV-2	0
infected	0
individual	0
.	0

With	0
this	0
approach	0
,	0
we	0
identified	0
four	0
new	0
DRA1*0101/DRB1*0401-	0
and	0
two	0
DRA1*0101/DRB1*0404-restricted	0
,	0
VP16-specific	9
epitopes	10
.	0

By	0
using	0
tetramers	9
to	0
sort	0
individual	0
cells	0
,	0
we	0
easily	0
obtained	0
a	0
large	0
number	0
of	0
clones	0
specific	0
to	0
these	0
epitopes	9
.	0

Although	0
DRA1*0101/DRB1*0401	0
and	0
DRA1*0101/DRB1*0404	0
are	0
structurally	0
very	0
similar	0
,	0
nonoverlapping	0
VP16	9
epitopes	10
were	0
identified	0
,	0
illustrating	0
high	0
selectivity	0
of	0
individual	0
allele	0
polymorphisms	0
within	0
common	0
MHC	0
variants	0
.	0

This	0
rapid	0
approach	0
to	0
detecting	0
CD4+	7
T	8
cell	8
epitopes	8
from	0
complex	0
Ags	9
can	0
be	0
applied	0
to	0
any	0
known	0
Ag	9
that	0
gives	0
a	0
T	0
cell	0
response	0
.	0

Localized	0
pancreatic	0
NF-kappaB	0
activation	0
and	0
inflammatory	0
response	0
in	0
taurocholate-induced	0
pancreatitis	0
.	0

Transcription	9
factor	10
nuclear	10
factor-kappaB	10
(	0
NF-kappaB	9
)	0
is	0
activated	0
in	0
cerulein	0
pancreatitis	0
and	0
mediates	0
cytokine	0
expression	0
.	0

The	0
role	0
of	0
transcription	0
factor	0
activation	0
in	0
other	0
models	0
of	0
pancreatitis	0
has	0
not	0
been	0
established	0
.	0

Here	0
we	0
report	0
upregulation	0
of	0
NF-kappaB	9
and	0
inflammatory	9
molecules	10
,	0
and	0
their	0
correlation	0
with	0
local	0
pancreatic	0
injury	0
,	0
in	0
a	0
model	0
of	0
severe	0
pancreatitis	0
.	0

Rats	0
received	0
intraductal	0
infusion	0
of	0
taurocholate	0
or	0
saline	0
,	0
and	0
the	0
pancreatic	0
head	0
and	0
tail	0
were	0
analyzed	0
separately	0
.	0

NF-kappaB	9
and	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
activation	0
were	0
assessed	0
by	0
gel	0
shift	0
assay	0
,	0
and	0
mRNA	0
expression	0
of	0
interleukin-6	3
,	0
tumor	9
necrosis	10
factor-alpha	10
,	0
KC	0
,	0
monocyte	9
chemoattractant	10
protein-1	10
,	0
and	0
inducible	9
nitric	10
oxide	10
synthase	10
was	0
assessed	0
by	0
semiquantitative	0
RT-PCR	0
.	0

Morphological	0
damage	0
and	0
trypsin	0
activation	0
were	0
much	0
greater	0
in	0
the	0
pancreatic	0
head	0
than	0
tail	0
,	0
in	0
parallel	0
with	0
a	0
stronger	0
activation	0
of	0
NF-kappaB	3
and	4
cytokine	4
mRNA	4
.	0

Saline	0
infusion	0
mildly	0
affected	0
these	0
parameters	0
.	0

AP-1	9
was	0
strongly	0
activated	0
in	0
both	0
pancreatic	0
segments	0
after	0
either	0
taurocholate	0
or	0
saline	0
infusion	0
.	0

NF-kappaB	9
inhibition	0
with	0
N-acetylcysteine	0
ameliorated	0
the	0
local	0
inflammatory	0
response	0
.	0

Correlation	0
between	0
localized	0
NF-kappaB	9
activation	0
,	0
cytokine	0
upregulation	0
,	0
and	0
tissue	0
damage	0
suggests	0
a	0
key	0
role	0
for	0
NF-kappaB	9
in	0
the	0
development	0
of	0
the	0
inflammatory	0
response	0
of	0
acute	0
pancreatitis	0
.	0

CD45	9
tyrosine	10
phosphatase	10
controls	0
common	0
gamma-chain	9
cytokine	10
-mediated	0
STAT	9
and	0
extracellular	0
signal-related	0
kinase	0
phosphorylation	0
in	0
activated	7
human	8
lymphoblasts	8
:	0
inhibition	0
of	0
proliferation	0
without	0
induction	0
of	0
apoptosis	0
.	0

The	0
objective	0
of	0
this	0
study	0
was	0
to	0
test	0
whether	0
CD45	0
signals	0
can	0
influence	0
signaling	0
processes	0
in	0
activated	7
human	8
lymphoblasts	8
.	0

To	0
this	0
end	0
,	0
we	0
generated	0
lymphoblasts	7
which	0
proliferate	0
in	0
response	0
to	0
common	0
gamma-chain	9
cytokines	10
,	0
but	0
readily	0
undergo	0
apoptosis	0
after	0
cytokine	0
withdrawal	0
.	0

In	0
experiments	0
with	0
the	0
CD45R0	9
mAb	10
UCHL-1	10
,	0
but	0
not	0
control	9
CD45	10
mAbs	10
,	0
we	0
found	0
significant	0
inhibition	0
of	0
proliferation	0
.	0

Interestingly	0
,	0
the	0
pan-CD45	9
mAb	10
GAP8.3	10
,	0
which	0
is	0
most	0
effective	0
in	0
inhibition	0
of	0
OKT-3-mediated	0
proliferation	0
in	0
quiescent	7
lymphocytes	8
,	0
was	0
ineffective	0
in	0
lymphoblasts	7
.	0

Addition	0
of	0
CD3	9
mAb	10
OKT-3	10
had	0
no	0
influence	0
on	0
IL-2-mediated	0
proliferation	0
(	0
with	0
or	0
without	0
UCHL-1	9
)	0
.	0

In	0
contrast	0
,	0
after	0
addition	0
of	0
OKT-3	9
to	0
IL-4	9
-	0
and	0
IL-7	9
-stimulated	0
proliferation	0
assays	0
,	0
UCHL-1	9
signals	0
could	0
not	0
significantly	0
alter	0
cellular	0
proliferation	0
.	0

We	0
did	0
not	0
find	0
induction	0
of	0
apoptosis	0
following	0
CD45R0	0
signaling	0
.	0

In	0
Western	0
blots	0
using	0
mAbs	9
detecting	0
phosphorylated	9
STAT-3	10
,	10
STAT-5	10
,	10
STAT-6	10
,	0
or	0
extracellular	9
signal-related	10
kinase	10
1/2	10
,	0
we	0
found	0
that	0
CD45R0	0
signaling	0
could	0
effectively	0
diminish	0
phosphorylation	0
of	0
these	0
intracellular	0
signaling	0
components	0
.	0

Using	0
RT-PCR	0
,	0
we	0
found	0
that	0
CD45R0	0
signaling	0
inhibited	0
IL-2	0
mRNA	0
production	0
without	0
major	0
influence	0
on	0
IL-13	9
,	0
IL-5	9
,	0
or	0
IFN-gamma	3
mRNA	4
levels	0
.	0

Costimulation	0
with	0
OKT-3	9
and	0
IL-2	9
optimally	0
induced	0
secretion	0
of	0
IFN-gamma	9
,	0
TNF-alpha	9
,	0
and	0
IL-5	9
,	0
which	0
was	0
not	0
decreased	0
by	0
CD45	0
signals	0
.	0

In	0
conclusion	0
,	0
we	0
illustrate	0
that	0
CD45R0	0
signals	0
control	0
early	0
cytokine	0
receptor-associated	0
signaling	0
processes	0
and	0
mRNA	0
and	0
DNA	0
synthesis	0
in	0
activated	7
human	8
lymphoblasts	8
.	0

Furthermore	0
,	0
we	0
show	0
the	0
existence	0
of	0
CD45	9
epitopes	10
(	0
GAP8.3	9
)	0
,	0
which	0
are	0
active	0
and	0
critical	0
for	0
signaling	0
in	0
quiescent	7
lymphocytes	8
,	0
but	0
are	0
nonfunctional	0
in	0
activated	7
human	8
lymphoblasts	8
.	0

Pax5	1
determines	0
the	0
identity	0
of	0
B	7
cells	8
from	0
the	0
beginning	0
to	0
the	0
end	0
of	0
B-lymphopoiesis	0
.	0

Despite	0
being	0
one	0
of	0
the	0
most	0
intensively	0
studied	0
cell	0
types	0
,	0
the	0
molecular	0
basis	0
of	0
B	0
cell	0
specification	0
is	0
largely	0
unknown	0
.	0

The	0
Pax5	1
gene	2
encoding	0
the	0
transcription	9
factor	10
BSAP	10
is	0
required	0
for	0
progression	0
of	0
B-lymphopoiesis	0
beyond	0
the	0
pro-B	0
cell	0
stage	0
.	0

Pax5-deficient	7
pro-B	8
cells	8
are	0
,	0
however	0
,	0
not	0
yet	0
committed	0
to	0
the	0
B-lymphoid	7
lineage	8
,	0
but	0
instead	0
have	0
a	0
broad	0
lymphomyeloid	0
developmental	0
potential	0
.	0

Pax5	1
appears	0
to	0
mediate	0
B-lineage	0
commitment	0
by	0
repressing	0
the	0
transcription	0
of	0
non-B-lymphoid	1
genes	2
and	0
by	0
simultaneously	0
activating	0
the	0
expression	0
of	0
B-lineage-specific	1
genes	2
.	0

Pax5	1
thus	0
functions	0
both	0
as	0
a	0
transcriptional	0
repressor	0
and	0
activator	0
,	0
depending	0
on	0
its	0
interactions	0
with	0
corepressors	9
of	0
the	0
Groucho	9
protein	10
family	10
or	0
with	0
positive	0
regulators	0
such	0
as	0
the	0
TATA-binding	9
protein	10
.	0

Once	0
committed	0
to	0
the	0
B-lineage	7
,	0
B	7
cells	8
require	0
Pax5	1
function	0
to	0
maintain	0
their	0
B-lymphoid	0
identity	0
throughout	0
B	0
cell	0
development	0

Partners	0
in	0
transcription	0
:	0
NFAT	9
and	0
AP-1	9
.	0

Combinatorial	0
regulation	0
is	0
a	0
powerful	0
mechanism	0
that	0
enables	0
tight	0
control	0
of	0
gene	0
expression	0
,	0
via	0
integration	0
of	0
multiple	0
signaling	0
pathways	0
that	0
induce	0
different	0
transcription	9
factors	10
required	0
for	0
enhanceosome	0
assembly	0
.	0

The	0
four	0
calcium-regulated	0
transcription	9
factors	10
of	0
the	0
NFAT	9
family	10
act	0
synergistically	0
with	0
AP-1	9
(	10
Fos/Jun	10
)	10
proteins	10
on	0
composite	0
DNA	0
elements	0
which	0
contain	0
adjacent	0
NFAT	1
and	2
AP-1	2
binding	2
sites	2
,	0
where	0
they	0
form	0
highly	0
stable	0
ternary	0
complexes	0
to	0
regulate	0
the	0
expression	0
of	0
diverse	0
inducible	0
genes	0
.	0

Concomitant	0
induction	0
of	0
NFAT	9
and	0
AP-1	9
requires	0
concerted	0
activation	0
of	0
two	0
different	0
signaling	0
pathways	0
:	0
calcium/calcineurin	0
,	0
which	0
promotes	0
NFAT	0
dephosphorylation	0
,	0
nuclear	0
translocation	0
and	0
activation	0
;	0
and	0
protein	9
kinase	10
C	10
(	10
PKC	10
)	10
/Ras	10
,	0
which	0
promotes	0
the	0
synthesis	0
,	0
phosphorylation	0
and	0
activation	0
of	0
members	0
of	0
the	0
Fos	9
and	10
Jun	10
families	10
of	0
transcription	9
factors	10
.	0

A	0
fifth	0
member	0
of	0
the	0
NFAT	9
family	10
,	0
NFAT5	9
,	0
controls	0
the	0
cellular	0
response	0
to	0
osmotic	0
stress	0
,	0
by	0
a	0
mechanism	0
that	0
requires	0
dimer	0
formation	0
and	0
is	0
independent	0
of	0
calcineurin	9
or	0
of	0
interaction	0
with	0
AP-1	9
.	0

Pharmacological	0
interference	0
with	0
theNFAT	0
:	0
AP-1	0
interaction	0
may	0
be	0
useful	0
in	0
selective	0
manipulation	0
of	0
the	0
immune	0
response	0
.	0

Balanced	0
activation	0
of	0
NFAT	9
and	0
AP-1	9
is	0
known	0
to	0
be	0
required	0
for	0
productive	0
immune	0
responses	0
,	0
but	0
the	0
role	0
of	0
NFAT	0
:	0
AP-1	0
interactions	0
in	0
other	0
cell	0
types	0
and	0
biological	0
processes	0
remains	0
to	0
be	0
understood	0
.	0

Cytokine	0
production	0
by	0
Vgamma	7
(	8
+	8
)	8
-T-cell	8
subsets	8
is	0
an	0
important	0
factor	0
determining	0
CD4	0
(	0
+	0
)	0
-Th-cell	0
phenotype	0
and	0
susceptibility	0
of	0
BALB/c	0
mice	0
to	0
coxsackievirus	0
B3-induced	0
myocarditis	0
.	0

Two	0
coxsackievirus	0
B3	0
(	0
CVB3	0
)	0
variants	0
(	0
H3	0
and	0
H310A1	0
)	0
differ	0
by	0
a	0
single	0
amino	0
acid	0
mutation	0
in	0
the	0
VP2	9
capsid	10
protein	10
.	0

H3	0
induces	0
severe	0
myocarditis	0
in	0
BALB/c	0
mice	0
,	0
but	0
H310A1	0
is	0
amyocarditic	0
.	0

Infection	0
with	0
H3	0
,	0
but	0
not	0
H310A1	0
,	0
preferentially	0
activates	0
Vgamma4	7
Vdelta4	8
cells	8
,	0
which	0
are	0
strongly	0
positive	0
for	0
gamma	9
interferon	10
(	0
IFN-gamma	9
)	0
,	0
whereas	0
Vgamma1	7
Vdelta4	8
cells	8
are	0
increased	0
in	0
both	0
H3	0
and	0
H310A1	0
virus-infected	0
animals	0
.	0

Depletion	0
of	0
Vgamma1	7
(	8
+	8
)	8
cells	8
using	0
monoclonal	9
anti-Vgamma1	10
antibody	10
enhanced	0
myocarditis	0
and	0
CD4	0
(	0
+	0
)	0
-	0
,	0
IFN-gamma	9
(	0
+	0
)	0
-cell	0
responses	0
in	0
both	0
H3-	0
and	0
H310A1-infected	0
mice	0
yet	0
decreased	0
the	0
CD4	0
(	0
+	0
)	0
-	0
,	0
IL-4	0
(	0
+	0
)	0
-cell	0
response	0
.	0

Depleting	0
Vgamma4	7
(	8
+	8
)	8
cells	8
suppressed	0
myocarditis	0
and	0
reduced	0
CD4	7
(	8
+	8
)	8
IFN-gamma	8
(	8
+	8
)	8
cells	8
but	0
increased	0
CD4	7
(	8
+	8
)	8
IL-4	8
(	8
+	8
)	8
T	8
cells	8
.	0

The	0
role	0
of	0
cytokine	0
production	0
by	0
Vgamma1	7
(	8
+	8
)	8
and	8
Vgamma4	8
(	8
+	8
)	8
T	8
cells	8
was	0
investigated	0
by	0
adoptively	0
transferring	0
these	0
cells	0
isolated	0
from	0
H3-infected	0
BALB/c	0
Stat4	0
knockout	0
(	0
Stat4ko	0
)	0
(	0
defective	0
in	0
IFN-gamma	9
expression	0
)	0
or	0
BALB/c	0
Stat6ko	0
(	0
defective	0
in	0
IL-4	0
expression	0
)	0
mice	0
into	0
H3	0
virus-infected	0
wild-type	0
BALB/c	0
recipients	0
.	0

Vgamma4	7
and	8
Vgamma1	8
(	8
+	8
)	8
T	8
cells	8
from	0
Stat4ko	0
mice	0
expressed	0
IL-4	9
but	0
no	0
or	0
minimal	0
IFN-gamma	9
,	0
whereas	0
these	0
cell	0
populations	0
derived	0
from	0
Stat6ko	0
mice	0
expressed	0
IFN-gamma	9
but	0
no	0
IL-4	9
.	0

Stat4ko	7
Vgamma1	8
(	8
+	8
)	8
cells	8
(	8
IL-4	8
(	8
+	8
)	8
)	0
suppress	0
myocarditis	0
.	0

Stat6ko	7
Vgamma1	8
(	8
+	8
)	8
cells	8
(	8
IFN-gamma	8
(	8
+	8
)	8
)	8
were	0
not	0
inhibitory	0
.	0

Stat6ko	7
Vgamma4	8
(	8
+	8
)	8
cells	8
(	8
IFN-gamma	8
(	8
+	8
)	8
)	8
significantly	0
enhanced	0
myocarditis	0
.	0

Stat4ko	7
Vgamma4	8
(	8
+	8
)	8
cells	8
(	8
IL-4	8
(	8
+	8
)	8
)	8
neither	0
inhibited	0
nor	0
enhanced	0
disease	0
.	0

These	0
results	0
show	0
that	0
distinct	0
gammadelta-T-cell	7
subsets	8
control	0
myocarditis	0
susceptibility	0
and	0
bias	0
the	0
CD4	7
(	8
+	8
)	8
-Th-cell	8
response	0
.	0

The	0
cytokines	9
produced	0
by	0
the	0
Vgamma	7
subpopulation	8
have	0
a	0
significant	0
influence	0
on	0
the	0
CD4	9
(	0
+	0
)	0
-Th-cell	0
phenotype	0
.	0

Plasmin	9
-induced	0
expression	0
of	0
cytokines	9
and	0
tissue	9
factor	10
in	0
human	7
monocytes	8
involves	0
AP-1	9
and	0
IKKbeta	9
-mediated	0
NF-kappaB	0
activation	0
.	0

It	0
was	0
previously	0
shown	0
that	0
plasmin	9
activates	0
human	7
peripheral	8
monocytes	8
in	0
terms	0
of	0
lipid	0
mediator	0
release	0
and	0
chemotactic	0
migration	0
.	0

Here	0
it	0
is	0
demonstrated	0
that	0
plasmin	9
induces	0
proinflammatory	9
cytokine	10
release	0
and	0
tissue	9
factor	10
(	0
TF	9
)	0
expression	0
by	0
monocytes	7
.	0

Plasmin	9
0.043	0
to	0
1.43	0
CTA	0
U/mL	0
,	0
but	0
not	0
active	9
site-blocked	10
plasmin	10
,	0
triggered	0
concentration-dependent	0
expression	0
of	0
mRNA	0
for	0
interleukin-1alpha	9
(	0
IL-1alpha	9
)	0
,	0
IL-1beta	9
,	0
tumor	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
,	0
and	0
TF	9
with	0
maximum	0
responses	0
after	0
4	0
hours	0
.	0

Plasmin	9
-mediated	0
mRNA	0
expression	0
was	0
inhibited	0
in	0
a	0
concentration-dependent	0
manner	0
by	0
the	0
lysine	0
analogue	0
trans-4-	0
(	0
aminomethyl	0
)	0
cyclohexane-1-carboxylic	0
acid	0
(	0
t-AMCA	0
)	0
.	0

Increases	0
in	0
mRNA	0
levels	0
were	0
followed	0
by	0
concentration-	0
and	0
time-dependent	0
release	0
of	0
IL-1alpha	9
,	0
IL-1beta	9
and	0
TNF-alpha	9
and	0
by	0
TF	9
expression	0
on	0
monocyte	0
surfaces	0
.	0

Neither	0
cytokines	9
nor	0
TF	9
could	0
be	0
detected	0
when	0
monocytes	7
were	0
preincubated	0
with	0
actinomycin	0
D	0
or	0
cycloheximide	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
indicated	0
plasmin	9
-induced	0
activation	0
of	0
NF-kappaB	9
;	0
DNA-binding	9
complexes	10
were	0
composed	0
of	0
p50	9
,	0
p65	9
,	0
and	0
c-Rel	9
,	0
as	0
shown	0
by	0
supershift	0
experiments	0
.	0

Nuclear	0
translocation	0
of	0
NF-kappaB/Rel	9
proteins	10
coincided	0
with	0
IkappaBalpha	0
degradation	0
.	0

At	0
variance	0
with	0
endotoxic	0
lipopolysaccharide	0
,	0
plasmin	9
elicited	0
the	0
rapid	0
degradation	0
of	0
another	0
cytoplasmic	9
NF-kappaB	10
inhibitor	10
,	10
p105	10
.	0

Proteolysis	0
of	0
NF-kappaB	0
inhibitors	0
was	0
apparently	0
due	0
to	0
transient	0
activation	0
of	0
IkappaB	9
kinase	10
(	10
IKK	10
)	10
beta	10
that	0
reached	0
maximum	0
activity	0
at	0
1	0
hour	0
after	0
plasmin	9
stimulation	0
.	0

In	0
addition	0
,	0
AP-1	0
binding	0
was	0
increased	0
in	0
plasmin	9
-treated	0
monocytes	7
,	0
with	0
most	0
complexes	0
composed	0
of	0
JunD	9
,	0
c-Fos	9
,	0
and	0
FosB	9
.	0

These	0
findings	0
further	0
substantiate	0
the	0
role	0
of	0
plasmin	9
as	0
a	0
proinflammatory	0
activator	0
of	0
human	7
monocytes	8
and	0
reveal	0
an	0
important	0
new	0
link	0
between	0
the	0
plasminogen-plasmin	0
system	0
and	0
inflammation	0
.	0

(	0
Blood.	0
2001	0
;	0
97	0
:	0
3941-3950	0
)	0

STAT3	9
is	0
constitutively	0
active	0
in	0
some	0
patients	0
with	0
Polycythemia	0
rubra	0
vera	0
.	0

OBJECTIVE	0
:	0
Polycythemia	0
vera	0
is	0
a	0
clonal	0
stem	0
cell	0
disorder	0
characterized	0
by	0
hyperproliferation	0
of	0
the	0
erythroid	7
,	8
myeloid	8
,	8
and	8
megakaryocytic	8
lineages	8
.	0

While	0
it	0
has	0
been	0
shown	0
that	0
progenitor	7
cells	8
of	0
P.	0
vera	0
patients	0
are	0
hypersensitive	0
to	0
several	0
growth	0
factors	0
including	0
erythropoietin	9
,	0
insulin-like	9
growth	10
factor-1	10
,	0
thrombopoietin	9
,	0
interleukin-3	9
,	0
and	0
granulocyte/monocyte	9
colony-stimulating	10
factor	10
,	0
the	0
molecular	0
pathogenesis	0
of	0
this	0
disease	0
remains	0
unknown	0
.	0

Growth	0
factor	0
hypersensitivity	0
could	0
be	0
mediated	0
by	0
changes	0
in	0
signal	0
transduction	0
pathways	0
.	0

We	0
therefore	0
investigated	0
a	0
common	0
downstream	0
effector	0
of	0
cytokines	9
,	0
the	0
signal	9
transducers	10
and	10
activators	10
of	10
transcription	10
(	0
STATs	9
)	0
.	0

A	0
constitutive	0
activation	0
of	0
STAT	9
factors	10
could	0
explain	0
the	0
increased	0
proliferation	0
of	0
P.	7
vera	8
cells	8
even	0
in	0
the	0
absence	0
of	0
growth	0
factor	0
stimulation	0
.	0

METHODS	0
:	0
Peripheral	7
granulocytes	8
from	0
patients	0
with	0
P.	0
vera	0
and	0
from	0
healthy	0
volunteers	0
were	0
assayed	0
for	0
STAT1	9
,	10
3	10
,	10
and	10
5	10
DNA	0
binding	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

RESULTS	0
:	0
Four	0
of	0
14	0
P.	0
vera	0
patients	0
analyzed	0
showed	0
constitutive	0
STAT3	0
DNA	0
binding	0
in	0
unstimulated	7
peripheral	8
granulocytes	8
,	0
while	0
none	0
of	0
the	0
17	0
healthy	0
volunteers	0
tested	0
did	0
.	0

None	0
of	0
the	0
subjects	0
showed	0
constitutive	0
STAT1	9
or	0
STAT5	9
activity	0
.	0

Western	0
blotting	0
demonstrated	0
that	0
,	0
in	0
the	0
three	0
patients	0
,	0
STAT3	9
is	0
constitutively	0
phosphorylated	0
on	0
Tyr	0
705	0
,	0
whereas	0
it	0
is	0
unphosphorylated	0
in	0
the	0
other	0
patients	0
and	0
in	0
controls	0
.	0

Interestingly	0
,	0
constitutive	0
STAT3	9
activity	0
did	0
not	0
correlate	0
with	0
the	0
duration	0
of	0
disease	0
or	0
the	0
treatment	0
regimen	0
.	0

It	0
was	0
observed	0
in	0
a	0
recently	0
diagnosed	0
patient	0
and	0
in	0
two	0
patients	0
treated	0
only	0
with	0
phlebotomy	0
.	0

CONCLUSION	0
:	0
Our	0
data	0
suggest	0
that	0
constitutive	0
phosphorylation	0
and	0
activation	0
of	0
STAT3	9
is	0
not	0
a	0
secondary	0
event	0
induced	0
by	0
mutagenizing	0
agents	0
or	0
by	0
prolonged	0
hyperproliferation	0
of	0
hematopoietic	7
cells	8
,	0
but	0
rather	0
represents	0
a	0
primary	0
molecular	0
aberration	0
.	0

Constitutively	9
active	10
STAT3	10
may	0
contribute	0
to	0
the	0
growth	0
factor	0
hypersensitivity	0
of	0
P.	7
vera	8
cells	8
.	0

Identification	0
of	0
phosphorylation	9
sites	10
for	0
Bruton	9
's	10
tyrosine	10
kinase	10
within	0
the	0
transcriptional	9
regulator	10
BAP/TFII-I	10
.	0

Bruton	9
's	10
tyrosine	10
kinase	10
(	0
Btk	9
)	0
,	0
a	0
member	0
of	0
the	0
Tec	9
family	10
of	10
cytosolic	10
kinases	10
,	0
is	0
essential	0
for	0
B	7
cell	8
development	0
and	0
function	0
.	0

BAP/TFII-I	9
,	0
a	0
protein	0
implicated	0
in	0
transcriptional	0
regulation	0
,	0
is	0
associated	0
with	0
Btk	9
in	0
B	7
cells	8
and	0
is	0
transiently	0
phosphorylated	0
on	0
tyrosine	0
following	0
B	7
cell	8
receptor	0
engagement	0
.	0

BAP/TFII-I	9
is	0
a	0
substrate	0
for	0
Btk	9
in	0
vitro	0
and	0
is	0
hyperphosphorylated	0
on	0
tyrosine	0
upon	0
coexpression	0
with	0
Btk	9
in	0
mammalian	7
cells	8
.	0

In	0
an	0
effort	0
to	0
understand	0
the	0
physiologic	0
consequences	0
of	0
BAP/TFII-I	9
tyrosine	0
phosphorylation	0
following	0
B	0
cell	0
receptor	0
stimulation	0
,	0
site-directed	0
mutagenesis	0
and	0
phosphopeptide	0
mapping	0
were	0
used	0
to	0
locate	0
the	0
predominant	0
sites	0
of	0
BAP/TFII-I	9
phosphorylation	0
by	0
Btk	9
in	0
vitro	0
.	0

These	0
residues	0
,	0
Tyr248	0
,	0
Tyr357	0
,	0
and	0
Tyr462	0
,	0
were	0
also	0
found	0
to	0
be	0
the	0
major	0
sites	0
for	0
Btk	9
-dependent	0
phosphorylation	0
of	0
BAP/TFII-I	9
in	0
vivo	0
.	0

Residues	0
Tyr357	0
and	0
Tyr462	0
are	0
contained	0
within	0
the	0
loop	9
regions	10
of	0
adjacent	0
helix-loop-helix-like	9
repeats	10
within	0
BAP/TFII-I	9
.	0

Mutation	0
of	0
either	0
Tyr248	0
,	0
Tyr357	0
,	0
or	0
Tyr462	0
to	0
phenylalanine	0
reduced	0
transcription	0
from	0
a	0
c-fos	1
promoter	2
relative	0
to	0
wild-type	1
BAP/TFII-I	2
in	0
transfected	0
COS-7	5
cells	6
,	0
consistent	0
with	0
the	0
interpretation	0
that	0
phosphorylation	0
at	0
these	0
sites	0
contributes	0
to	0
transcriptional	0
activation	0
.	0

Phosphorylation	0
of	0
BAP/TFII-I	9
by	0
Btk	9
may	0
link	0
engagement	0
of	0
receptors	0
such	0
as	0
surface	0
immunoglobulin	9
to	0
modulation	0
of	0
gene	0
expression	0
.	0

Expression	0
of	0
interferon	9
consensus	10
sequence	10
binding	10
protein	10
induces	0
potent	0
immunity	0
against	0
BCR/ABL-induced	0
leukemia	0
.	0

Mice	0
deficient	0
in	0
the	0
interferon	9
consensus	10
sequence	10
binding	10
protein	10
(	0
ICSBP	9
)	0
develop	0
a	0
disease	0
resembling	0
chronic	0
myeloid	0
leukemia	0
(	0
CML	0
)	0
,	0
which	0
in	0
humans	0
is	0
caused	0
by	0
the	0
BCR/ABL	9
oncoprotein	10
.	0

Interferon-alpha	9
(	0
IFN-alpha	9
)	0
induces	0
ICSBP	9
expression	0
and	0
is	0
an	0
effective	0
therapy	0
for	0
CML	0
.	0

This	0
study	0
examined	0
whether	0
enforced	0
expression	0
of	0
ICSBP	9
might	0
antagonize	0
BCR/ABL-induced	0
leukemia	0
;	0
results	0
demonstrated	0
that	0
ICSBP-modified	7
cells	8
generated	0
a	0
protective	0
CD8	0
(	0
+	0
)	0
cytotoxic	0
T-cell	0
response	0
against	0
BCR/ABL-transformed	7
BaF3	8
cells	8
in	0
a	0
murine	0
leukemia	0
model	0
.	0

ICSBP	9
expression	0
represents	0
a	0
novel	0
means	0
of	0
stimulating	0
a	0
host	0
immune	0
response	0
to	0
BCR/ABL	7
(	8
+	8
)	8
leukemia	8
cells	8
and	0
a	0
potential	0
strategy	0
for	0
immunotherapy	0
of	0
CML	0
.	0

(	0
Blood.	0
2001	0
;	0
97	0
:	0
3491-3497	0
)	0

A	0
transcriptional	0
block	0
in	0
the	0
IL-2	1
promoter	2
at	0
the	0
-150	1
AP-1	2
site	2
in	0
effector	7
CD8+	8
T	8
cells	8
.	0

Both	0
CD4+	7
and	8
CD8+	8
T	8
cells	8
that	0
produce	0
IL-2	9
in	0
response	0
to	0
Ag	0
recognition	0
have	0
been	0
isolated	0
.	0

However	0
,	0
most	0
effector	7
CD8+	8
T	8
cells	8
recovered	0
after	0
exposure	0
to	0
Ag	9
do	0
not	0
produce	0
sufficient	0
IL-2	9
to	0
sustain	0
growth	0
,	0
and	0
depend	0
on	0
CD4+	7
T	8
helper	8
cells	8
for	0
this	0
obligate	0
growth	0
factor	0
.	0

IL-2	0
expression	0
in	0
CD4+	7
T	8
cells	8
is	0
primarily	0
controlled	0
at	0
the	0
level	0
of	0
transcription	0
,	0
but	0
mechanisms	0
restricting	0
IL-2	0
production	0
in	0
CD8+	7
T	8
cells	8
have	0
not	0
been	0
elucidated	0
.	0

To	0
evaluate	0
transcriptional	0
regulation	0
of	0
the	0
IL-2	1
gene	2
in	0
CD8+	7
T	8
cells	8
,	0
we	0
stably	0
transfected	0
reporter	1
genes	2
into	0
Ag	9
-specific	0
CD8+	5
T	6
cell	6
clones	6
.	0

CD28+	7
CD8	8
(	8
+	8
)	8
T	8
cells	8
unable	0
to	0
transcribe	0
the	0
IL-2	1
gene	2
in	0
response	0
to	0
antigenic	0
stimulation	0
had	0
a	0
block	0
in	0
transactivation	0
of	0
the	0
-150	1
CD28	2
response	2
element	2
(	2
CD28RE	2
)	2
/AP-1	2
site	2
of	0
the	0
IL-2	1
promoter	2
,	0
but	0
did	0
transactivate	0
the	0
composite	0
NFAT/AP-1	1
and	2
OCT/AP-1	2
sites	2
,	0
and	0
a	0
consensus	1
AP-1	2
motif	2
.	0

Mutation	0
of	0
the	0
nonconsensus	1
-150	2
AP-1	2
site	2
to	0
a	0
consensus	1
AP-1	2
site	2
,	0
or	0
insertion	0
of	0
a	0
CD28RE/AP-1	1
consensus	2
site	2
upstream	0
of	0
the	0
native	0
-150	1
CD28RE/AP-1	2
site	2
restored	0
transactivation	0
of	0
the	0
altered	0
promoter	1
.	0

These	0
results	0
suggest	0
that	0
the	0
defect	0
at	0
the	0
-150	1
site	2
may	0
reflect	0
the	0
absence	0
or	0
inactivity	0
of	0
a	0
required	0
factor	0
rather	0
than	0
repression	0
of	0
the	0
IL-2	1
promoter	2
.	0

Stem	9
cell	10
factor	10
and	0
interleukin-3	9
induce	0
stepwise	0
generation	0
of	0
erythroid	7
precursor	8
cells	8
from	0
a	0
basic	0
fibroblast	9
growth	10
factor	10
-dependent	0
hematopoietic	5
stem	6
cell	6
line	6
,	6
A-6	6
.	0

A	0
m	0
ultipotent	7
immature	8
myeloid	8
cell	8
population	8
was	0
produced	0
from	0
a	0
basic	9
fibroblast	10
growth	10
factor	10
(	0
bFGF	9
)	0
-dependent	0
hematopoietic	5
stem	6
cell	6
line	6
,	6
A-6	6
,	0
when	0
cultured	0
with	0
stem	9
cell	10
factor	10
(	0
SCF	9
)	0
replacing	0
bFGF	9
.	0

Those	0
cells	0
were	0
positive	0
for	0
stem	9
cell	10
markers	10
,	0
c-kit	9
and	0
CD34	9
,	0
and	0
a	0
myeloid	9
cell	10
marker	10
,	10
F4/80	10
.	0

Some	0
cell	0
fractions	0
were	0
also	0
positive	0
for	0
Mac-1	9
,	10
a	10
macrophage	10
marker	10
or	0
Gr-1	9
,	10
a	10
granulocytic	10
maker	10
,	0
but	0
negative	0
for	0
an	0
erythroid	9
marker	10
TER119	10
.	0

They	0
also	0
showed	0
the	0
expression	0
of	0
mRNA	0
for	0
the	0
myeloid-specific	9
PU.1	10
but	0
did	0
not	0
that	0
for	0
the	0
erythroid-specific	9
GATA-1	10
.	0

Among	0
various	0
cytokines	9
,	0
interleukin-3	9
(	0
IL-3	9
)	0
induced	0
erythroid	7
precursor	8
cells	8
that	0
expressed	0
the	0
erythroid-specific	9
GATA-1	10
and	0
beta-major	9
globin	10
.	0

The	0
quantitative	0
analysis	0
showed	0
that	0
erythroid	7
precursor	8
cells	8
were	0
newly	0
produced	0
from	0
the	0
immature	7
myeloid	8
cells	8
by	0
cultivation	0
with	0
IL-3	9
.	0

SCF	9
and	0
IL-3	9
induced	0
stepwise	0
generation	0
of	0
erythroid	7
precursor	8
cells	8
from	0
an	0
A-6	5
hematopoietic	6
stem	6
cell	6
line	6
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Distinct	0
BMI-1	9
and	0
EZH2	9
expression	0
patterns	0
in	0
thymocytes	7
and	0
mature	7
T	8
cells	8
suggest	0
a	0
role	0
for	0
Polycomb	1
genes	2
in	0
human	0
T	0
cell	0
differentiation	0
.	0

BMI-1	9
and	0
EZH2	9
Polycomb-group	9
(	10
PcG	10
)	10
proteins	10
belong	0
to	0
two	0
distinct	0
protein	0
complexes	0
involved	0
in	0
the	0
regulation	0
of	0
hematopoiesis	0
.	0

Using	0
unique	0
PcG-specific	0
antisera	0
and	0
triple	0
immunofluorescence	0
,	0
we	0
found	0
that	0
mature	7
resting	8
peripheral	8
T	8
cells	8
expressed	0
BMI-1	9
,	0
whereas	0
dividing	7
blasts	8
were	0
EZH2	0
(	0
+	0
)	0
.	0

By	0
contrast	0
,	0
subcapsular	7
immature	8
double-negative	8
(	8
DN	8
)	8
(	8
CD4	8
(	8
-	8
)	8
/CD8	8
(	8
-	8
)	8
)	8
T	8
cells	8
in	0
the	0
thymus	0
coexpressed	0
BMI-1	9
and	0
EZH2	9
or	0
were	0
BMI-1	0
single	0
positive	0
.	0

Their	0
descendants	0
,	0
double-positive	7
(	8
DP	8
;	8
CD4	8
(	8
+	8
)	8
/CD8	8
(	8
+	8
)	8
)	8
cortical	8
thymocytes	8
,	0
expressed	0
EZH2	9
without	0
BMI-1	9
.	0

Most	0
EZH2	7
(	8
+	8
)	8
DN	8
and	8
DP	8
thymocytes	8
were	0
dividing	0
,	0
while	0
DN	7
BMI-1	8
(	8
+	8
)	8
/EZH2	8
(	8
-	8
)	8
thymocytes	8
were	0
resting	0
and	0
proliferation	0
was	0
occasionally	0
noted	0
in	0
DN	7
BMI-1	8
(	8
+	8
)	8
/EZH2	8
(	8
+	8
)	8
cells	8
.	0

Maturation	0
of	0
DP	7
cortical	8
thymocytes	8
to	0
single-positive	7
(	8
CD4	8
(	8
+	8
)	8
/CD8	8
(	8
-	8
)	8
or	0
CD8	7
(	8
+	8
)	8
/CD4	8
(	8
-	8
)	8
)	8
medullar	8
thymocytes	8
correlated	0
with	0
decreased	0
detectability	0
of	0
EZH2	9
and	0
continued	0
relative	0
absence	0
of	0
BMI-1	9
.	0

Our	0
data	0
show	0
that	0
BMI-1	9
and	0
EZH2	9
expression	0
in	0
mature	7
peripheral	8
T	8
cells	8
is	0
mutually	0
exclusive	0
and	0
linked	0
to	0
proliferation	0
status	0
,	0
and	0
that	0
this	0
pattern	0
is	0
not	0
yet	0
established	0
in	0
thymocytes	7
of	0
the	0
cortex	0
and	0
medulla	0
.	0

T	7
cell	8
stage-specific	0
PcG	0
expression	0
profiles	0
suggest	0
that	0
PcG	1
genes	2
contribute	0
to	0
regulation	0
of	0
T	0
cell	0
differentiation	0
.	0

They	0
probably	0
reflect	0
stabilization	0
of	0
cell	0
type-specific	0
gene	0
expression	0
and	0
irreversibility	0
of	0
lineage	0
choice	0
.	0

The	0
difference	0
in	0
PcG	0
expression	0
between	0
medullar	7
thymocytes	8
and	0
mature	7
interfollicular	8
T	8
cells	8
indicates	0
that	0
additional	0
maturation	0
processes	0
occur	0
after	0
thymocyte	0
transportation	0
from	0
the	0
thymus	0
.	0

Stepwise	0
lineage	0
restriction	0
of	0
progenitors	7
in	0
lympho-myelopoiesis	0
.	0

It	0
has	0
long	0
been	0
controversial	0
whether	0
hematopoiesis	0
progresses	0
through	0
ordered	0
stages	0
of	0
determination	0
as	0
in	0
embryonic	0
development	0
.	0

This	0
is	0
due	0
to	0
the	0
absence	0
of	0
a	0
methodology	0
capable	0
of	0
exactly	0
determining	0
the	0
developmental	0
potential	0
of	0
hematopoietic	7
stem/progenitor	8
cells	8
.	0

The	0
multilineage	0
progenitor	0
(	0
MLP	0
)	0
assay	0
enabled	0
us	0
to	0
discriminate	0
among	0
seven	0
types	0
of	0
hematopoietic	0
progenitors	0
,	0
which	0
are	0
multipotent	0
progenitor	0
p-MTB	0
(	0
capable	0
of	0
generating	0
myeloid	7
,	8
T	8
and	8
B	8
cells	8
)	0
,	0
bipotent	0
progenitors	0
p-MT	0
,	0
p-MB	0
and	0
p-TB	0
,	0
and	0
unipotent	0
progenitors	0
p-M	0
,	0
p-T	0
and	0
p-B	0
.	0

Among	0
these	0
seven	0
types	0
,	0
the	0
p-TB	0
type	0
progenitor	0
was	0
found	0
to	0
be	0
absent	0
.	0

These	0
findings	0
indicate	0
that	0
the	0
process	0
of	0
lineage	0
commitment	0
proceeds	0
through	0
an	0
ordered	0
but	0
not	0
random	0
process	0
.	0

By	0
extending	0
the	0
area	0
of	0
investigation	0
to	0
include	0
the	0
erythroid	7
lineage	8
,	0
more	0
convincing	0
evidence	0
for	0
the	0
ordered	0
process	0
was	0
obtained	0
.	0

Detailed	0
and	0
exact	0
illustration	0
of	0
the	0
process	0
of	0
hematopoiesis	0
will	0
provide	0
an	0
opportunity	0
to	0
revive	0
hematopoiesis	0
as	0
one	0
of	0
the	0
most	0
fascinating	0
targets	0
of	0
research	0
in	0
developmental	0
biology	0

Epstein-Barr	0
Virus	0
and	0
its	0
glycoprotein-350	9
upregulate	0
IL-6	9
in	0
human	7
B-lymphocytes	8
via	0
CD21	9
,	0
involving	0
activation	0
of	0
NF-kappaB	9
and	0
different	0
signaling	0
pathways	0
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
is	0
a	0
ubiquitous	0
and	0
highly	0
immunotropic	0
gamma	0
herpesvirus	0
that	0
infects	0
more	0
than	0
90	0
%	0
of	0
humans	0
worldwide	0
.	0

Its	0
pathogenicity	0
leads	0
to	0
a	0
number	0
of	0
diseases	0
including	0
tumors	0
that	0
result	0
from	0
EBV	0
's	0
ability	0
to	0
readily	0
transform	0
B-lymphocytes	7
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
epithelial	7
cells	8
.	0

EBV	0
utilizes	0
CD21/CR2	9
as	0
its	0
receptor	0
on	0
B	7
cells	8
to	0
initiate	0
the	0
infection	0
process	0
.	0

EBV	0
binds	0
to	0
CR2	9
through	0
its	0
major	9
envelope	10
glycoprotein-350	10
(	0
gp350	9
)	0
and	0
is	0
also	0
a	0
remarkable	0
immunomodulating	0
agent	0
.	0

We	0
had	0
previously	0
shown	0
that	0
EBV	0
is	0
capable	0
of	0
modulating	0
the	0
synthesis	0
of	0
a	0
number	0
of	0
cytokines	9
.	0

We	0
now	0
show	0
that	0
while	0
both	0
purified	0
recombinant	9
gp350	10
(	0
rgp350	9
)	0
and	0
EBV	0
upregulate	0
IL-6	3
mRNA	4
synthesis	0
in	0
B	7
cells	8
,	0
EBV-induced	0
IL-6	0
gene	0
activation	0
occurs	0
for	0
a	0
significantly	0
longer	0
period	0
of	0
time	0
(	0
i.e.	0
12	0
hours	0
for	0
EBV	0
as	0
compared	0
to	0
6	0
hours	0
for	0
rgp350	9
)	0
.	0

Moreover	0
,	0
the	0
half-life	0
of	0
EBV-induced	0
IL-6	3
mRNA	4
was	0
also	0
significantly	0
longer	0
(	0
10	0
hours	0
)	0
than	0
that	0
of	0
mRNA	0
induced	0
by	0
rgp350	9
(	0
about	0
6	0
hours	0
)	0
.	0

Both	0
EBV	0
and	0
gp350	9
enhance	0
the	0
binding	0
of	0
the	0
NF-kappaB	9
transcription	10
factor	10
,	0
as	0
determined	0
by	0
band-shift	0
and	0
augment	0
NF-kappaB	9
-mediated	0
activation	0
of	0
a	0
CAT	1
reporter	2
plasmid	2
.	0

Furthermore	0
,	0
we	0
demonstrate	0
that	0
while	0
the	0
activation	0
of	0
IL-6	0
gene	0
expression	0
by	0
gp350	9
is	0
mediated	0
primarily	0
by	0
the	0
protein	0
kinase	0
C	0
pathway	0
,	0
EBV	0
can	0
mediate	0
its	0
effects	0
through	0
multiple	0
signaling	0
pathways	0
.	0

To	0
our	0
knowledge	0
this	0
is	0
the	0
first	0
report	0
showing	0
that	0
the	0
binding	0
of	0
a	0
herpesvirus	9
envelope	10
glycoprotein	10
to	0
CR2	9
on	0
human	7
B	8
cells	8
results	0
in	0
the	0
activation	0
of	0
the	0
NF-kappaB	9
transcription	10
factor	10
leading	0
to	0
the	0
upregulation	0
of	0
IL-6	0
gene	0
expression	0
in	0
these	0
lymphocytes	7
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Gene-	0
and	0
tissue-specificity	0
of	0
mutation	0
in	0
Big	0
Blue	0
rats	0
treated	0
with	0
the	0
hepatocarcinogen	0
N-hydroxy-2-acetylaminofluorene	0
.	0

In	0
a	0
previous	0
study	0
,	0
we	0
found	0
that	0
treating	0
transgenic	0
Big	0
Blue	0
rats	0
with	0
the	0
hepatocarcinogen	0
N-hydroxy-2-acetylaminofluorene	0
(	0
N-OH-AAF	0
)	0
produced	0
the	0
same	0
major	0
DNA	0
adduct	0
in	0
the	0
target	0
liver	0
and	0
the	0
nontarget	7
spleen	8
lymphocytes	8
and	0
bone	7
marrow	8
cells	8
,	0
induced	0
lacI	7
mutants	8
in	0
the	0
liver	0
,	0
and	0
induced	0
much	0
lower	0
frequencies	0
of	0
l	0
acI	7
and	8
hprt	8
mutants	8
in	0
spleen	7
lymphocytes	8
.	0

In	0
the	0
present	0
study	0
,	0
sequence	0
analysis	0
was	0
conducted	0
on	0
lacI	1
DNA	2
and	0
hprt	1
cDNA	2
from	0
the	0
mutants	0
,	0
to	0
determine	0
the	0
mutational	0
specificity	0
of	0
N-OH-AAF	0
in	0
the	0
rat	0
.	0

All	0
the	0
mutation	0
spectra	0
from	0
N-OH-AAF-treated	0
rats	0
differed	0
significantly	0
from	0
corresponding	0
mutation	0
profiles	0
from	0
untreated	0
animals	0
(	0
P	0
=	0
0.02	0
to	0
P	0
<	0
0.0001	0
)	0
.	0

Although	0
there	0
were	0
similarities	0
among	0
the	0
mutational	0
patterns	0
derived	0
from	0
N-OH-AAF-treated	0
rats	0
(	0
e.g.	0
,	0
G	0
:	0
C	0
--	0
>	0
T	0
:	0
A	0
transversion	0
was	0
the	0
most	0
common	0
mutation	0
in	0
all	0
mutation	0
sets	0
)	0
,	0
there	0
were	0
significant	0
differences	0
in	0
the	0
patterns	0
of	0
basepair	0
substitution	0
and	0
frameshift	0
mutation	0
between	0
the	0
liver	0
and	0
spleen	7
lymphocyte	8
lacI	8
mutants	8
(	0
P	0
=	0
0.02	0
)	0
and	0
between	0
the	0
spleen	7
lymphocyte	8
lacI	7
and	8
hprt	8
mutants	8
(	0
P	0
=	0
0.04	0
)	0
.	0

Also	0
,	0
multiplex	0
PCR	0
analysis	0
of	0
genomic	1
DNA	2
from	0
the	0
hprt	7
mutants	8
indicated	0
that	0
12	0
%	0
of	0
mutants	0
from	0
treated	0
rats	0
had	0
major	0
deletions	0
in	0
the	0
hprt	1
gene	2
;	0
no	0
corresponding	0
incidence	0
of	0
large	0
deletions	0
was	0
evident	0
among	0
lacI	0
mutations	0
.	0

All	0
the	0
mutation	0
profiles	0
reflect	0
the	0
general	0
mutational	0
specificity	0
of	0
the	0
major	0
DNA	0
adduct	0
formed	0
by	0
N-OH-AAF	0
.	0

The	0
differences	0
between	0
N-OH-AAF	0
mutation	0
in	0
the	0
endogenous	1
gene	2
and	0
transgene	1
can	0
be	0
partially	0
explained	0
by	0
the	0
structures	0
of	0
the	0
two	0
genes	0
.	0

The	0
tissue-specificity	0
of	0
the	0
mutation	0
spectra	0
may	0
contribute	0
to	0
targeting	0
tumor	0
formation	0
to	0
the	0
liver	0
.	0

Environ.	0
Mol.	0
Mutagen.	0
37	0
:	0
203-214	0
,	0
2001	0
.	0

Published	0
2001	0
Wiley-Liss	0
,	0
Inc	0
.	0

Caspase	9
-dependent	0
cleavage	0
of	0
the	0
hematopoietic	9
specific	10
adaptor	10
protein	10
Gads	10
alters	0
signalling	0
from	0
the	0
T	9
cell	10
receptor	10
.	0

Gads	9
is	0
a	0
SH2	9
and	10
SH3	10
domain	10
-containing	0
,	0
hematopoietic-specific	9
adaptor	10
protein	10
that	0
functions	0
in	0
signalling	0
from	0
the	0
T	9
cell	10
receptor	10
.	0

Gads	9
acts	0
by	0
linking	0
SLP-76	9
,	0
bound	0
by	0
the	0
carboxy-terminal	9
Gads	10
SH3	10
domain	10
,	0
to	0
tyrosine	9
phosphorylated	10
LAT	10
which	0
contains	0
binding	0
sites	0
for	0
the	0
Gads	9
SH2	10
domain	10
.	0

Gads	9
is	0
distinguished	0
from	0
Grb2	9
and	0
the	0
closely	0
related	0
Grap	9
protein	10
by	0
the	0
presence	0
of	0
a	0
120	9
amino	10
acid	10
unique	10
region	10
between	0
the	0
SH2	9
domain	10
and	0
the	0
carboxy	9
terminal	10
SH3	10
domain	10
.	0

Here	0
we	0
demonstrate	0
that	0
the	0
unique	0
region	0
of	0
Gads	9
contains	0
a	0
capase	9
cleavage	10
site	10
.	0

Induction	0
of	0
apoptosis	0
in	0
lymphocytes	7
results	0
in	0
detectable	0
Gads	9
cleavage	0
by	0
60	0
min	0
.	0

Gads	9
cleavage	0
is	0
blocked	0
in	0
vivo	0
by	0
treating	0
cells	0
with	0
a	0
caspase	0
3	0
inhibitor	0
.	0

A	0
putative	9
caspase	10
3	10
cleavage	10
site	10
was	0
identified	0
within	0
the	0
unique	0
region	0
and	0
mutation	0
of	0
this	0
site	0
prevented	0
Gads	9
cleavage	0
in	0
vitro	0
,	0
and	0
in	0
vivo	0
.	0

The	0
Gads	9
cleavage	0
products	0
retained	0
the	0
predicted	0
binding	0
specificity	0
for	0
SLP-76	9
and	0
LAT	9
.	0

Expression	0
of	0
the	0
Gads	9
cleavage	0
products	0
in	0
Jurkat	5
T	6
cells	6
inhibited	0
NFAT	0
activation	0
following	0
TCR	0
cross	0
linking	0
.	0

These	0
findings	0
indicate	0
that	0
cleavage	0
of	0
Gads	9
in	0
vivo	0
could	0
function	0
to	0
alter	0
signalling	0
downstream	0
of	0
the	0
T	9
cell	10
receptor	10
by	0
disrupting	0
cross	0
talk	0
between	0
SLP-76	9
and	0
LAT	9
.	0

Targeting	0
of	0
p300	9
to	0
the	0
interleukin-2	1
promoter	2
via	0
CREB-Rel	0
cross-talk	0
during	0
mitogen	9
and	0
oncogenic	0
molecular	0
signaling	0
in	0
activated	7
T-cells	8
.	0

In	0
this	0
report	0
,	0
we	0
explore	0
the	0
mechanisms	0
of	0
targeting	0
of	0
p300	9
to	0
the	0
interleukin-2	1
(	2
IL-2	2
)	2
promoter	2
in	0
response	0
to	0
mitogenic	0
and	0
oncogenic	0
molecular	0
signals	0
.	0

Recruitment	0
of	0
p300	9
by	0
cAMP-responsive	9
element-binding	10
protein-Rel	10
cross-talk	0
at	0
the	0
composite	9
CD28	10
response	10
element	10
(	0
CD28RE	9
)	0
-	0
TRE	1
element	2
of	0
the	0
IL-2	1
promoter	2
is	0
essential	0
for	0
promoter	0
inducibility	0
during	0
T-cell	0
activation	0
,	0
and	0
CD28RE-TRE	1
is	0
the	0
exclusive	0
target	0
of	0
the	0
human	7
T-cell	8
lymphotropic	0
virus	0
type	0
I	0
oncoprotein	9
Tax	10
.	0

The	0
intrinsic	0
histone	0
acetyltransferase	0
activity	0
of	0
p300	9
is	0
dispensable	0
for	0
activation	0
of	0
the	0
IL-2	1
promoter	2
,	0
and	0
the	0
N-terminal	9
743	10
residues	10
contain	0
the	0
minimal	0
structural	0
requirements	0
for	0
synergistic	0
transactivation	0
of	0
the	0
CD28RE-TRE	1
,	0
the	0
IL-2	1
promoter	2
,	0
and	0
endogenous	0
IL-2	1
gene	2
expression	0
.	0

Mutational	0
analysis	0
of	0
p300	9
reveals	0
differential	0
structural	0
requirements	0
for	0
the	0
N-terminal	0
p300	0
module	0
by	0
individual	0
cis-elements	1
within	0
the	0
IL-2	1
promoter	2
.	0

These	0
findings	0
provide	0
evidence	0
that	0
p300	9
assembles	0
at	0
the	0
IL-2	1
promoter	2
to	0
form	0
an	0
enhanceosome-like	0
signal	0
transduction	0
target	0
that	0
is	0
centrally	0
integrated	0
at	0
the	0
CD28RE-TRE	1
element	2
of	0
the	0
IL-2	1
promoter	2
through	0
specific	0
protein	0
module-targeted	0
associations	0
in	0
activated	7
T-cells	8
.	0

Regulation	0
of	0
cytokine	0
production	0
in	0
T-cell	7
responses	0
to	0
inhalant	0
allergen	0
:	0
GATA-3	9
expression	0
distinguishes	0
between	0
Th1-	0
and	0
Th2-polarized	0
immunity	0
.	0

BACKGROUND	0
:	0
The	0
precise	0
nature	0
of	0
allergen-specific	0
cytokine	0
responses	0
in	0
atopics	0
versus	0
non-atopics	0
,	0
in	0
particular	0
the	0
'Th1	0
polarity	0
'	0
of	0
responses	0
in	0
non-atopics	0
,	0
remains	0
controversial	0
.	0

This	0
is	0
due	0
in	0
part	0
to	0
the	0
relative	0
insensitivity	0
of	0
cytokine	0
detection	0
systems	0
,	0
and	0
associated	0
variations	0
in	0
kinetics	0
of	0
cytokine	0
production	0
and	0
catabolism	0
in	0
in	0
vitro	0
culture	0
systems	0
.	0

As	0
an	0
alternative	0
to	0
cytokine	0
measurement	0
,	0
this	0
study	0
focuses	0
on	0
expression	0
of	0
the	0
transcription	9
factor	10
GATA-3	10
for	0
analysis	0
of	0
allergen-specific	0
Th	0
cell	0
responses	0
.	0

METHODS	0
:	0
Cord	7
blood	8
mononuclear	8
cells	8
were	0
Th1-	0
or	0
Th2-polarized	0
by	0
culture	0
in	0
IL-12-	0
or	0
IL-4-employing	0
established	0
methods	0
;	0
PBMC	7
from	0
house	0
dust	0
mite	0
(	0
HDM	0
)	0
-sensitive	0
atopics	0
and	0
controls	0
were	0
stimulated	0
overnight	0
with	0
HDM	0
;	0
cytokine	0
production	0
was	0
measured	0
by	0
ELISA	0
and	0
GATA-3	3
mRNA	4
expression	0
by	0
PCR	0
.	0

RESULTS	0
:	0
Cytokine	9
-driven	0
Th2	0
polarization	0
of	0
naive	7
T	8
cells	8
is	0
associated	0
with	0
marked	0
upregulation	0
of	0
GATA-3	9
expression	0
,	0
whereas	0
a	0
reciprocal	0
expression	0
pattern	0
accompanies	0
differentiation	0
towards	0
the	0
Th1	0
cytokine	0
phenotype	0
.	0

In	0
T	7
cells	8
from	0
HDM	0
skin	0
prick	0
test-positive	0
(	0
HDM-SPT+/HDM-IgE+	0
)	0
volunteers	0
,	0
overnight	0
stimulation	0
results	0
in	0
marked	0
upregulation	0
of	0
GATA-3	9
expression	0
,	0
compared	0
to	0
an	0
equally	0
marked	0
downregulation	0
of	0
expression	0
in	0
T	7
cells	8
from	0
SPT-/IgE-	0
subjects	0
.	0

In	0
subjects	0
who	0
are	0
HDM-SPT+	0
but	0
IgE-	0
,	0
GATA-3	9
expression	0
levels	0
remained	0
relatively	0
stable	0
during	0
culture	0
with	0
HDM	0
.	0

CONCLUSIONS	0
:	0
Upregulation	0
of	0
GATA-3	9
expression	0
in	0
PBMC	7
is	0
a	0
hallmark	0
of	0
the	0
early	0
phase	0
of	0
Th2	0
recall	0
responses	0
to	0
specific	0
allergen	0
in	0
atopics	0
.	0

The	0
reciprocal	0
expression	0
pattern	0
observed	0
in	0
HDM-specific	0
recall	0
responses	0
of	0
non-atopics	0
provides	0
independent	0
confirmation	0
of	0
the	0
presence	0
of	0
underlying	0
Th1-like	0
immunity	0
in	0
these	0
subjects	0
.	0

The	0
parallel	0
findings	0
in	0
neonatal	7
T	8
cells	8
suggest	0
that	0
the	0
same	0
approach	0
may	0
be	0
utilized	0
for	0
monitoring	0
the	0
progress	0
of	0
allergen-specific	0
Th1/Th2	0
memory	0
development	0
during	0
early	0
childhood	0
,	0
and	0
hence	0
in	0
assessment	0
of	0
risk	0
for	0
future	0
allergic	0
disease	0
.	0

Copyright	0
2001	0
S.	0
Karger	0
AG	0
,	0
Basel	0

The	0
heat	0
shock	0
response	0
reduces	0
myelin	9
oligodendrocyte	10
glycoprotein	10
-induced	0
experimental	0
autoimmune	0
encephalomyelitis	0
in	0
mice	0
.	0

The	0
stress	0
response	0
(	0
SR	0
)	0
can	0
block	0
inflammatory	0
gene	0
expression	0
by	0
preventing	0
activation	0
of	0
transcription	9
factor	10
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappaB	9
)	0
.	0

As	0
inflammatory	0
gene	0
expression	0
contributes	0
to	0
the	0
pathogenesis	0
of	0
demyelinating	0
diseases	0
,	0
we	0
tested	0
the	0
effects	0
of	0
the	0
SR	0
on	0
the	0
progression	0
of	0
the	0
demyelinating	0
disease	0
experimental	0
autoimmune	0
encephalomyelitis	0
(	0
EAE	0
)	0
.	0

EAE	0
was	0
actively	0
induced	0
in	0
C57BL/6	0
mice	0
using	0
an	0
encephalitogenic	0
myelin	9
oligodendrocyte	10
glycoprotein	10
(	0
MOG	9
(	10
35-55	10
)	10
)	0
peptide	0
.	0

Whole	0
body	0
hyperthermia	0
was	0
used	0
to	0
induce	0
a	0
heat	0
shock	0
response	0
(	0
HSR	0
)	0
in	0
immunized	0
mice	0
2	0
days	0
after	0
the	0
booster	0
MOG	0
(	0
35-55	0
)	0
peptide	0
injection	0
.	0

The	0
HSR	0
reduced	0
the	0
incidence	0
of	0
EAE	0
by	0
70	0
%	0
,	0
delayed	0
disease	0
onset	0
by	0
6	0
days	0
,	0
and	0
attenuated	0
disease	0
severity	0
.	0

The	0
HSR	0
attenuated	0
leukocyte	7
infiltration	0
into	0
CNS	0
assessed	0
by	0
quantitation	0
of	0
perivascular	0
infiltrates	0
,	0
and	0
by	0
reduced	0
staining	0
for	0
CD4	9
and	0
CD25	9
immunopositive	0
T-cells	7
.	0

T-cell	0
activation	0
,	0
assessed	0
by	0
the	0
production	0
of	0
interferon	9
gamma	10
(	0
IFNgamma	9
)	0
in	0
response	0
to	0
MOG	9
(	10
35-55	10
)	10
,	0
was	0
also	0
decreased	0
by	0
the	0
HSR	0
.	0

The	0
HSR	0
reduced	0
inflammatory	0
gene	0
expression	0
in	0
the	0
brain	0
that	0
normally	0
occurs	0
during	0
EAE	0
,	0
including	0
the	0
early	0
increase	0
in	0
RANTES	9
(	0
regulated	9
on	10
activation	10
of	10
normal	10
T-cell	10
expressed	10
and	10
secreted	10
)	0
expression	0
,	0
and	0
the	0
later	0
expression	0
of	0
the	0
inducible	0
form	0
of	0
nitric	9
oxide	10
synthase	10
.	0

The	0
early	0
activation	0
of	0
transcription	9
factor	10
NF-kappaB	9
was	0
also	0
blocked	0
by	0
the	0
HSR	0
.	0

The	0
finding	0
that	0
the	0
SR	0
reduces	0
inflammation	0
in	0
the	0
brain	0
and	0
the	0
clinical	0
severity	0
of	0
EAE	0
opens	0
a	0
novel	0
therapeutic	0
approach	0
for	0
prevention	0
of	0
autoimmune	0
diseases	0
.	0

In	0
vivo	0
detection	0
of	0
intracellular	0
signaling	0
pathways	0
in	0
developing	0
thymocytes	7
.	0

Information	0
regarding	0
the	0
intracellular	0
signaling	0
processes	0
that	0
occur	0
during	0
the	0
development	0
of	0
T	7
cells	8
has	0
largely	0
been	0
obtained	0
with	0
the	0
use	0
of	0
transgenic	0
mouse	0
models	0
,	0
which	0
although	0
providing	0
invaluable	0
information	0
are	0
time	0
consuming	0
and	0
costly	0
.	0

To	0
this	0
end	0
,	0
we	0
have	0
developed	0
a	0
novel	0
system	0
that	0
facilitates	0
the	0
in	0
vivo	0
analysis	0
of	0
signal	0
transduction	0
pathways	0
during	0
T-lymphocyte	7
development	0
.	0

This	0
approach	0
uses	0
reporter-plasmids	1
for	0
the	0
detection	0
of	0
intracellular	0
signals	0
mediated	0
by	0
the	0
mitogen-activated	9
protein	10
kinase	10
or	0
cyclic	9
AMP-dependent	10
protein	10
kinase	10
.	0

Reporter-plasmids	1
are	0
transfected	0
into	0
thymocytes	7
in	0
fetal	0
thymic	0
organ	0
culture	0
by	0
accelerated	0
DNA/particle	0
bombardment	0
(	0
gene	0
gun	0
)	0
,	0
and	0
the	0
activation	0
of	0
a	0
signaling	0
pathway	0
is	0
determined	0
in	0
the	0
form	0
of	0
a	0
standard	0
luciferase	0
assay	0
.	0

Importantly	0
,	0
this	0
powerful	0
technique	0
preserves	0
the	0
structural	0
integrity	0
of	0
the	0
thymus	0
,	0
and	0
will	0
provide	0
an	0
invaluable	0
tool	0
to	0
study	0
how	0
thymocytes	7
respond	0
to	0
normal	0
environmental	0
stimuli	0
encountered	0
during	0
differentiation	0
within	0
the	0
thymic	0
milieu	0
.	0

Thus	0
,	0
this	0
method	0
allows	0
for	0
the	0
monitoring	0
of	0
signals	0
that	0
occur	0
in	0
a	0
biological	0
time	0
frame	0
,	0
such	0
as	0
during	0
differentiation	0
,	0
and	0
within	0
the	0
natural	0
environment	0
of	0
differentiating	7
cells	8
.	0

Core-binding	9
factor	10
beta	10
(	0
CBFbeta	9
)	0
,	0
but	0
not	0
CBFbeta-smooth	9
muscle	10
myosin	10
heavy	10
chain	10
,	0
rescues	0
definitive	0
hematopoiesis	0
in	0
CBFbeta	9
-deficient	0
embryonic	7
stem	8
cells	8
.	0

Core-binding	9
factor	10
beta	10
(	0
CBFbeta	9
)	0
is	0
the	0
non-DNA-binding	9
subunit	10
of	0
the	0
heterodimeric	9
CBFs	10
.	0

Genes	1
encoding	2
CBFbeta	2
(	0
CBFB	1
)	0
,	0
and	0
one	0
of	0
the	0
DNA-binding	9
CBFalpha	10
subunits	10
,	10
Runx1	10
(	0
also	0
known	0
as	0
CBFalpha2	9
,	0
AML1	9
,	0
and	0
PEBP2alphaB	9
)	0
,	0
are	0
required	0
for	0
normal	0
hematopoiesis	0
and	0
are	0
also	0
frequent	0
targets	0
of	0
chromosomal	0
translocations	0
in	0
acute	0
leukemias	0
in	0
humans	0
.	0

Homozygous	0
disruption	0
of	0
either	0
the	0
Runx1	1
or	2
Cbfb	2
gene	2
in	0
mice	0
results	0
in	0
embryonic	0
lethality	0
at	0
midgestation	0
due	0
to	0
hemorrhaging	0
in	0
the	0
central	0
nervous	0
system	0
,	0
and	0
severely	0
impairs	0
fetal	0
liver	0
hematopoiesis	0
.	0

Results	0
of	0
this	0
study	0
show	0
that	0
Cbfb-deficient	0
mouse	0
embryonic	7
stem	8
(	8
ES	8
)	8
cells	8
can	0
differentiate	0
into	0
primitive	7
erythroid	8
colonies	8
in	0
vitro	0
,	0
but	0
are	0
impaired	0
in	0
their	0
ability	0
to	0
produce	0
definitive	0
erythroid	7
and	8
myeloid	8
colonies	8
,	0
mimicking	0
the	0
in	0
vivo	0
defect	0
.	0

Definitive	0
hematopoiesis	0
is	0
restored	0
by	0
ectopic	0
expression	0
of	0
full-length	1
Cbfb	2
transgenes	2
,	0
as	0
well	0
as	0
by	0
a	0
transgene	0
encoding	0
only	0
the	0
heterodimerization	9
domain	10
of	0
CBFbeta	9
.	0

In	0
contrast	0
,	0
the	0
CBFbeta	9
-	0
smooth	9
muscle	10
myosin	10
heavy	10
chain	10
(	10
SMMHC	10
)	10
fusion	10
protein	10
generated	0
by	0
the	0
inv	9
(	10
16	10
)	10
associated	0
with	0
acute	5
myeloid	6
leukemias	6
(	0
M4Eo	5
)	0
can	0
not	0
rescue	0
definitive	0
hematopoiesis	0
by	0
Cbfb-deficient	7
ES	8
cells	8
.	0

Sequences	0
responsible	0
for	0
the	0
inability	0
of	0
CBFbeta	9
-SMMHC	0
to	0
rescue	0
definitive	0
hematopoiesis	0
reside	0
in	0
the	0
SMMHC	9
portion	10
of	0
the	0
fusion	9
protein	10
.	0

Results	0
also	0
show	0
that	0
the	0
CBFbeta-SMMHC	9
fusion	10
protein	10
transdominantly	0
inhibits	0
definitive	0
hematopoiesis	0
,	0
but	0
not	0
to	0
the	0
same	0
extent	0
as	0
homozygous	0
loss	0
of	0
Runx1	9
or	0
Cbfb	9
.	0

CBFbeta-SMMHC	9
preferentially	0
inhibits	0
the	0
differentiation	0
of	0
myeloid	7
lineage	8
cells	8
,	0
while	0
increasing	0
the	0
number	0
of	0
blastlike	7
cells	8
in	0
culture	0
.	0

The	0
latency	0
pattern	0
of	0
Epstein-Barr	0
virus	0
infection	0
and	0
viral	0
IL-10	9
expression	0
in	0
cutaneous	7
natural	8
killer/T-cell	8
lymphomas	8
.	0

The	0
nasal	7
type	8
,	8
extranodal	8
natural	8
killer	8
or	8
T	8
(	8
NK/T	8
)	8
-cell	8
lymphoma	8
is	0
usually	0
associated	0
with	0
latent	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
infection	0
.	0

In	0
order	0
to	0
elucidate	0
the	0
EBV	0
gene	0
expression	0
patterns	0
in	0
vivo	0
,	0
we	0
examined	0
eight	0
patients	0
with	0
cutaneous	0
EBV-related	0
NK/T-cell	0
lymphomas	0
,	0
including	0
six	0
patients	0
with	0
a	0
NK-cell	0
phenotype	0
and	0
two	0
patients	0
with	0
a	0
T-cell	0
phenotype	0
.	0

The	0
implication	0
of	0
EBV	0
in	0
the	0
skin	0
lesions	0
was	0
determined	0
by	0
the	0
presence	0
of	0
EBV-DNA	1
,	0
EBV-encoded	3
nuclear	4
RNA	4
(	0
EBER	3
)	0
and	0
a	0
clonality	0
of	0
EBV-DNA	1
fragments	2
containing	0
the	0
terminal	1
repeats	2
.	0

Transcripts	0
of	0
EBV-encoded	1
genes	2
were	0
screened	0
by	0
reverse	0
transcription-	0
polymerase	0
chain	0
reaction	0
(	0
RT-PCR	0
)	0
,	0
and	0
confirmed	0
by	0
Southern	0
blot	0
hybridization	0
.	0

The	0
expression	0
of	0
EBV-related	9
antigens	10
was	0
examined	0
by	0
immunostaining	0
using	0
paraffin-embedded	0
tissue	0
sections	0
and	0
cell	0
pellets	0
of	0
EBV-positive	5
cell	6
lines	6
.	0

Our	0
study	0
demonstrated	0
that	0
all	0
samples	0
from	0
the	0
patients	0
contained	0
EBV	3
nuclear	4
antigen	4
(	4
EBNA	4
)	4
-1	4
mRNA	4
which	0
was	0
transcribed	0
using	0
the	0
Q	1
promoter	2
,	0
whereas	0
both	0
the	0
Q	1
promoter	2
and	0
another	0
upstream	1
promoter	2
(	0
Cp/Wp	1
)	0
were	0
used	0
in	0
EBV-positive	5
cell	6
lines	6
,	0
B95.8	5
,	0
Raji	5
and	0
Jiyoye	5
.	0

Latent	3
membrane	4
protein-1	4
(	4
LMP-1	4
)	4
mRNA	4
was	0
detected	0
in	0
seven	0
of	0
eight	0
patients	0
and	0
all	0
cell	5
lines	6
,	0
whereas	0
EBNA-2	3
transcripts	4
were	0
found	0
only	0
in	0
the	0
cell	5
lines	6
.	0

Immunostaining	0
showed	0
no	0
LMP-1	9
,	10
EBNA-2	10
or	10
ZEBRA	10
antigens	10
in	0
the	0
paraffin-embedded	0
tissue	0
sections	0
,	0
although	0
they	0
were	0
positive	0
in	0
the	0
cell	5
line	6
cells	6
.	0

Latent	3
BHRF1	4
transcripts	4
encoding	0
bcl-2	3
homologue	4
and	0
BCRF1	3
transcripts	4
encoding	0
viral	9
interleukin	10
(	10
vIL	10
)	10
-10	10
were	0
detected	0
in	0
one	0
and	0
two	0
of	0
eight	0
patients	0
,	0
respectively	0
.	0

A	0
patient	0
with	0
NK-cell	0
lymphoma	0
expressing	0
both	0
transcripts	0
died	0
of	0
rapid	0
progression	0
of	0
the	0
illness	0
.	0

Our	0
results	0
indicate	0
that	0
the	0
restricted	0
expression	0
of	0
the	0
latency-associated	1
EBV	2
genes	2
and	0
the	0
production	0
of	0
vIL-10	3
and	4
bcl-2	4
homologue	4
may	0
favour	0
tumour	0
growth	0
,	0
evading	0
the	0
host	0
immune	0
surveillance	0
.	0

Copyright	0
2001	0
Cancer	0
Research	0
Campaign	0
.	0

Oxidized	0
alkyl	0
phospholipids	0
are	0
specific	0
,	0
high	0
affinity	0
peroxisome	0
proliferator-activated	0
receptor	0
gamma	0
ligands	0
and	0
agonists	0
.	0

Synthetic	0
high	0
affinity	0
peroxisome	0
proliferator-activated	0
receptor	0
(	0
PPAR	0
)	0
agonists	0
are	0
known	0
,	0
but	0
biologic	0
ligands	0
are	0
of	0
low	0
affinity	0
.	0

Oxidized	9
low	10
density	10
lipoprotein	10
(	0
oxLDL	9
)	0
is	0
inflammatory	0
and	0
signals	0
through	0
PPARs	9
.	0

We	0
showed	0
,	0
by	0
phospholipase	0
A	0
(	0
1	0
)	0
digestion	0
,	0
that	0
PPARgamma	0
agonists	0
in	0
oxLDL	9
arise	0
from	0
the	0
small	0
pool	0
of	0
alkyl	0
phosphatidylcholines	0
in	0
LDL	9
.	0

We	0
identified	0
an	0
abundant	0
oxidatively	0
fragmented	0
alkyl	0
phospholipid	0
in	0
oxLDL	9
,	0
hexadecyl	0
azelaoyl	0
phosphatidylcholine	0
(	0
azPC	0
)	0
,	0
as	0
a	0
high	0
affinity	0
ligand	0
and	0
agonist	0
for	0
PPARgamma	9
.	0

[	0
(	0
3	0
)	0
H	0
]	0
azPC	0
bound	0
recombinant	9
PPARgamma	10
with	0
an	0
affinity	0
(	0
K	0
(	0
d	0
)	0
(	0
(	0
app	0
)	0
)	0
approximately	0
40	0
nm	0
)	0
that	0
was	0
equivalent	0
to	0
rosiglitazone	0
(	0
BRL49653	0
)	0
,	0
and	0
competition	0
with	0
rosiglitazone	0
showed	0
that	0
binding	0
occurred	0
in	0
the	0
ligand-binding	9
pocket	10
.	0

azPC	0
induced	0
PPRE	0
reporter	0
gene	0
expression	0
,	0
as	0
did	0
rosiglitazone	0
,	0
with	0
a	0
half-maximal	0
effect	0
at	0
100	0
nm	0
.	0

Overexpression	0
of	0
PPARalpha	9
or	0
PPARgamma	9
revealed	0
that	0
azPC	0
was	0
a	0
specific	0
PPARgamma	0
agonist	0
.	0

The	0
scavenger	9
receptor	10
CD36	10
is	0
encoded	0
by	0
a	0
PPRE-responsive	1
gene	2
,	0
and	0
azPC	0
enhanced	0
expression	0
of	0
CD36	9
in	0
primary	7
human	8
monocytes	8
.	0

We	0
found	0
that	0
anti-CD36	9
inhibited	0
azPC	0
uptake	0
,	0
and	0
it	0
inhibited	0
PPRE	0
reporter	0
induction	0
.	0

Results	0
with	0
a	0
small	0
molecule	0
phospholipid	9
flippase	10
mimetic	10
suggest	0
azPC	0
acts	0
intracellularly	0
and	0
that	0
cellular	0
azPC	0
accumulation	0
was	0
efficient	0
.	0

Thus	0
,	0
certain	0
alkyl	0
phospholipid	0
oxidation	0
products	0
in	0
oxLDL	9
are	0
specific	0
,	0
high	0
affinity	0
extracellular	0
ligands	0
and	0
agonists	0
for	0
PPARgamma	9
that	0
induce	0
PPAR-responsive	1
genes	2

Regulation	0
of	0
the	0
human	1
MAT2B	2
gene	2
encoding	0
the	0
regulatory	9
beta	10
subunit	10
of	0
methionine	9
adenosyltransferase	10
,	0
MAT	9
II	10
.	0

Methionine	9
adenosyltransferase	10
(	0
MAT	9
)	0
catalyzes	0
the	0
biosynthesis	0
of	0
S-adenosylmethionine	9
(	0
AdoMet	9
)	0
,	0
a	0
key	0
molecule	0
in	0
transmethylation	0
reactions	0
and	0
polyamine	0
biosynthesis	0
.	0

The	0
MAT	9
II	10
isozyme	10
consists	0
of	0
a	0
catalytic	9
alpha2	10
and	10
a	10
regulatory	10
beta	10
subunit	10
.	0

Down-regulation	0
of	0
the	0
MAT	9
II	10
beta	10
subunit	10
expression	0
causes	0
a	0
6-10-fold	0
increase	0
in	0
intracellular	0
AdoMet	9
levels	0
.	0

To	0
understand	0
the	0
mechanism	0
by	0
which	0
the	0
beta	9
subunit	10
expression	0
is	0
regulated	0
,	0
we	0
cloned	0
the	0
MAT2B	1
gene	2
,	0
determined	0
its	0
organization	0
,	0
characterized	0
its	0
5'-flanking	1
sequences	2
,	0
and	0
elucidated	0
the	0
in	0
vitro	0
and	0
in	0
vivo	0
regulation	0
of	0
its	0
promoter	1
.	0

Transcription	0
of	0
the	0
MAT2B	1
gene	2
initiates	0
at	0
position	0
-203	0
relative	0
to	0
the	0
translation	1
start	2
site	2
.	0

Promoter	1
deletion	2
analysis	2
defined	0
a	0
minimal	1
promoter	2
between	0
positions	1
+52	2
and	2
+93	2
base	0
pairs	0
,	0
a	0
GC-rich	1
region	2
.	0

Inclusion	0
of	0
the	0
sequences	0
between	0
-4	0
and	0
+52	0
enhanced	0
promoter	0
activity	0
;	0
this	0
was	0
primarily	0
because	0
of	0
an	0
Sp1	1
recognition	2
site	2
at	0
+9/+15	0
.	0

The	0
inclusion	0
of	0
sequences	0
up	0
to	0
position	0
-115	0
provided	0
full	0
activity	0
;	0
this	0
was	0
attributed	0
to	0
a	0
TATA	1
at	0
-32	0
.	0

The	0
Sp1	1
site	2
at	0
position	0
+9	0
was	0
key	0
for	0
the	0
formation	0
of	0
protein.DNA	0
complexes	0
.	0

Mutation	0
of	0
both	0
the	0
Sp1	1
site	2
at	0
+9	0
and	0
the	0
TATA	1
at	0
-32	0
reduced	0
promoter	0
activity	0
to	0
its	0
minimal	0
level	0
.	0

Supershift	0
assays	0
showed	0
no	0
effect	0
of	0
the	0
anti-Sp1	9
antibody	10
on	0
complex	0
formation	0
,	0
whereas	0
the	0
anti-Sp3	9
antibody	10
had	0
a	0
strong	0
effect	0
on	0
protein.DNA	0
complex	0
formation	0
,	0
suggesting	0
that	0
Sp3	9
is	0
one	0
of	0
the	0
main	0
factors	0
binding	0
to	0
this	0
Sp1	1
site	2
.	0

Chromatin	0
immunoprecipitation	0
assays	0
supported	0
the	0
involvement	0
of	0
both	0
Sp1	9
and	0
Sp3	9
in	0
complexes	0
formed	0
on	0
the	0
MAT2B	1
promoter	2
.	0

The	0
data	0
show	0
that	0
the	0
5'-untranslated	1
sequences	2
play	0
an	0
important	0
role	0
in	0
regulating	0
the	0
MAT2B	1
gene	2
and	0
identifies	0
the	0
Sp1	1
site	2
at	0
+9	0
as	0
a	0
potential	0
target	0
for	0
modulating	0
MAT2B	0
expression	0
,	0
a	0
process	0
that	0
can	0
have	0
a	0
major	0
effect	0
on	0
intracellular	0
AdoMet	9
levels	0
.	0

Molecular	0
pathogenesis	0
of	0
influenza	0
A	0
virus	0
infection	0
and	0
virus-induced	0
regulation	0
of	0
cytokine	1
gene	2
expression	0
.	0

Despite	0
vaccines	0
and	0
antiviral	0
substances	0
influenza	0
still	0
causes	0
significant	0
morbidity	0
and	0
mortality	0
world	0
wide	0
.	0

Better	0
understanding	0
of	0
the	0
molecular	0
mechanisms	0
of	0
influenza	0
virus	0
replication	0
,	0
pathogenesis	0
and	0
host	0
immune	0
responses	0
is	0
required	0
for	0
the	0
development	0
of	0
more	0
efficient	0
means	0
of	0
prevention	0
and	0
treatment	0
of	0
influenza	0
.	0

Influenza	0
A	0
virus	0
,	0
which	0
replicates	0
in	0
epithelial	7
cells	8
and	0
leukocytes	7
,	0
regulates	0
host	0
cell	0
transcriptional	0
and	0
translational	0
systems	0
and	0
activates	0
,	0
as	0
well	0
as	0
downregulates	0
apoptotic	0
pathways	0
.	0

Influenza	0
A	0
virus	0
infection	0
results	0
in	0
the	0
production	0
of	0
chemotactic	0
(	0
RANTES	9
,	0
MIP-1	9
alpha	10
,	0
MCP-1	9
,	0
MCP-3	9
,	0
and	0
IP-10	9
)	0
,	0
pro-inflammatory	0
(	0
IL-1	9
beta	10
,	0
IL-6	9
,	0
IL-18	9
,	0
and	0
TNF-alpha	9
)	0
,	0
and	0
antiviral	9
(	10
IFN-alpha/beta	10
)	10
cytokines	10
.	0

Cytokine	0
gene	0
expression	0
is	0
associated	0
with	0
the	0
activation	0
of	0
NF-kappa	9
B	10
,	0
AP-1	9
,	0
STAT	9
and	0
IRF	9
signal	10
transducing	10
molecules	10
in	0
influenza	0
A	0
virus-infected	0
cells	0
.	0

In	0
addition	0
of	0
upregulating	0
cytokine	1
gene	2
expression	0
,	0
influenza	0
A	0
virus	0
infection	0
activates	0
caspase-1	9
enzyme	10
,	0
which	0
is	0
involved	0
in	0
the	0
proteolytic	0
processing	0
of	0
proIL-1	9
beta	10
and	0
proIL-18	9
into	0
their	0
biologically	0
active	0
forms	0
.	0

Influenza	0
A	0
virus-induced	0
IFN-alpha/beta	9
is	0
essential	0
in	0
host	0
's	0
antiviral	0
defence	0
by	0
activating	0
the	0
expression	0
of	0
antiviral	1
Mx	2
,	0
PKR	1
and	2
oligoadenylate	2
synthetase	2
genes	2
.	0

IFN-alpha/beta	9
also	0
prolongs	0
T	0
cell	0
survival	0
,	0
upregulates	0
IL-12	0
and	0
IL-18	0
receptor	0
gene	0
expression	0
and	0
together	0
with	0
IL-18	9
stimulates	0
NK	7
and	8
T	8
cell	8
IFN-gamma	0
production	0
and	0
the	0
development	0
of	0
Th1-type	0
immune	0
response	0
.	0

Comparison	0
of	0
hprt	0
and	0
lacI	0
mutant	0
frequency	0
with	0
DNA	0
adduct	0
formation	0
in	0
N-hydroxy-2-acetylaminofluorene-treated	0
Big	0
Blue	0
rats	0
.	0

N-Hydroxy-2-acetylaminofluorene	0
(	0
N-OH-AAF	0
)	0
is	0
the	0
proximate	0
carcinogenic	0
metabolite	0
of	0
the	0
powerful	0
rat	0
liver	0
carcinogen	0
2-acetylaminofluorene	0
.	0

In	0
this	0
study	0
,	0
transgenic	0
Big	0
Blue	0
(	0
R	0
)	0
rats	0
were	0
used	0
to	0
examine	0
the	0
relationship	0
between	0
in	0
vivo	0
mutagenicity	0
and	0
DNA	0
adduct	0
formation	0
by	0
N-OH-AAF	0
in	0
the	0
target	0
liver	0
compared	0
with	0
that	0
in	0
nontarget	0
tissues	0
.	0

Male	0
rats	0
were	0
given	0
one	0
,	0
two	0
,	0
or	0
four	0
doses	0
of	0
25	0
mg	0
N-OH-AAF/kg	0
body	0
weight	0
by	0
i.p.	0
injection	0
at	0
4-day	0
intervals	0
,	0
and	0
groups	0
of	0
treated	0
and	0
control	0
rats	0
were	0
euthanized	0
up	0
to	0
10	0
weeks	0
after	0
beginning	0
the	0
dosing	0
.	0

Mutant	0
frequencies	0
were	0
measured	0
in	0
the	0
spleen	1
lymphocyte	2
hprt	2
gene	2
,	0
and	0
lacI	0
mutant	0
frequencies	0
were	0
determined	0
in	0
the	0
liver	0
and	0
spleen	0
lymphocytes	7
.	0

At	0
6	0
weeks	0
after	0
beginning	0
the	0
dosing	0
,	0
the	0
hprt	0
mutant	0
frequency	0
in	0
spleen	7
lymphocytes	8
from	0
the	0
four-dose	0
group	0
was	0
16.5	0
x	0
10	0
(	0
-6	0
)	0
compared	0
with	0
3.2	0
x	0
10	0
(	0
-6	0
)	0
in	0
control	0
animals	0
.	0

Also	0
at	0
6	0
weeks	0
,	0
rats	0
given	0
one	0
,	0
two	0
,	0
or	0
four	0
doses	0
of	0
N-OH-AAF	0
had	0
lacI	0
mutant	0
frequencies	0
in	0
the	0
liver	0
of	0
97.6	0
,	0
155.6	0
,	0
and	0
406.8	0
x	0
10	0
(	0
-6	0
)	0
,	0
respectively	0
,	0
compared	0
with	0
a	0
control	0
frequency	0
of	0
25.7	0
x	0
10	0
(	0
-6	0
)	0
;	0
rats	0
given	0
four	0
doses	0
had	0
lacI	0
mutant	0
frequencies	0
in	0
spleen	7
lymphocytes	8
of	0
55.8	0
x	0
10	0
(	0
-6	0
)	0
compared	0
with	0
a	0
control	0
frequency	0
of	0
20.4	0
x	0
10	0
(	0
-6	0
)	0
.	0

Additional	0
rats	0
were	0
evaluated	0
for	0
DNA	0
adduct	0
formation	0
in	0
the	0
liver	0
,	0
spleen	7
lymphocytes	8
,	0
and	0
bone	0
marrow	0
by	0
(	0
32	0
)	0
P-postlabeling	0
.	0

Adduct	0
analysis	0
was	0
conducted	0
1	0
day	0
after	0
one	0
,	0
two	0
,	0
and	0
four	0
treatments	0
with	0
N-OH-AAF	0
,	0
5	0
days	0
after	0
one	0
treatment	0
,	0
and	0
9	0
days	0
after	0
two	0
treatments	0
.	0

N-	0
(	0
Deoxyguanosin-8-yl	0
)	0
-2-aminofluorene	0
was	0
the	0
major	0
DNA	0
adduct	0
identified	0
in	0
all	0
the	0
tissues	0
examined	0
.	0

Adduct	0
concentrations	0
increased	0
with	0
total	0
dose	0
to	0
maximum	0
values	0
in	0
samples	0
taken	0
1	0
day	0
after	0
two	0
doses	0
,	0
and	0
remained	0
essentially	0
the	0
same	0
after	0
four	0
doses	0
.	0

In	0
samples	0
taken	0
after	0
four	0
doses	0
,	0
adduct	0
levels	0
were	0
103	0
,	0
28	0
,	0
and	0
7	0
fmol/microg	0
of	0
DNA	0
in	0
liver	0
,	0
spleen	7
lymphocytes	8
,	0
and	0
bone	0
marrow	0
,	0
respectively	0
.	0

The	0
results	0
indicate	0
that	0
the	0
extent	0
of	0
both	0
DNA	0
adduct	0
formation	0
and	0
mutant	0
induction	0
correlates	0
with	0
the	0
organ	0
specificity	0
for	0
N-OH-AAF	0
carcinogenesis	0
in	0
the	0
rat	0
.	0

Environ.	0
Mol.	0
Mutagen.	0
37	0
:	0
195-202	0
,	0
2001	0
.	0

Published	0
2001	0
Wiley-Liss	0
,	0
Inc	0
.	0

Expression	0
of	0
Mad1	9
in	0
T	7
cells	8
leads	0
to	0
reduced	0
thymic	0
cellularity	0
and	0
impaired	0
mitogen-induced	0
proliferation	0
.	0

To	0
investigate	0
Mad1	9
function	0
in	0
vivo	0
,	0
transgenic	0
mice	0
were	0
generated	0
that	0
express	0
a	0
Mad1	1
transgene	2
in	0
T	7
lineage	8
cells	8
under	0
the	0
control	0
of	0
the	0
proximal	1
lck	2
promoter	2
.	0

Thymus	0
size	0
in	0
lck-Mad1	0
transgenic	0
mice	0
is	0
drastically	0
reduced	0
although	0
representation	0
of	0
the	0
various	0
thymocyte	7
sub	8
populations	8
appears	0
normal	0
.	0

To	0
investigate	0
more	0
closely	0
any	0
effects	0
of	0
Mad1	0
expression	0
on	0
thymocytes	7
,	0
we	0
examined	0
thymic	0
selection	0
using	0
MHC	0
class	0
I-restricted	0
H-Y-TCR	0
transgenic	0
mice	0
.	0

Mad1	0
expression	0
in	0
vivo	0
reduces	0
the	0
efficiency	0
of	0
positive	0
selection	0
.	0

Furthermore	0
,	0
thymocytes	7
and	0
splenic	7
T	8
cells	8
from	0
lck-Mad1	0
transgenic	0
mice	0
display	0
a	0
profound	0
proliferative	0
defect	0
in	0
response	0
to	0
activation	0
with	0
either	0
PMA/Ionomycin	0
or	0
immobilized	9
anti-CD3/CD28	10
antibody	10
.	0

This	0
proliferative	0
defect	0
is	0
not	0
reversed	0
by	0
addition	0
of	0
exogenous	9
IL-2	10
and	0
is	0
p53-independent	0
.	0

The	0
growth	0
inhibition	0
caused	0
by	0
Mad1	9
is	0
overcome	0
by	0
expression	0
of	0
active	9
c-Myc	10
.	0

Differential	0
requirement	0
for	0
the	0
transcription	9
factor	10
PU.1	10
in	0
the	0
generation	0
of	0
natural	7
killer	8
cells	8
versus	0
B	7
and	8
T	8
cells	8
.	0

PU.1	9
is	0
a	0
member	0
of	0
the	0
Ets	9
family	10
of	10
transcription	10
factors	10
required	0
for	0
the	0
development	0
of	0
various	0
lymphoid	5
and	6
myeloid	6
cell	6
lineages	6
,	0
but	0
its	0
role	0
in	0
natural	7
killer	8
(	8
NK	8
)	8
cell	8
development	0
is	0
not	0
known	0
.	0

The	0
study	0
shows	0
that	0
PU.1	9
is	0
expressed	0
in	0
NK	7
cells	8
and	0
that	0
,	0
on	0
cell	0
transfer	0
into	0
alymphoid	0
Rag2/gammac	0
(	0
-/-	0
)	0
mice	0
,	0
hematopoietic	7
progenitors	8
of	0
PU.1	7
(	8
-/-	8
)	8
fetal	8
liver	8
cells	8
could	0
generate	0
functional	0
NK	7
cells	8
but	0
not	0
B	7
or	8
T	8
cells	8
.	0

Nevertheless	0
,	0
the	0
numbers	0
of	0
bone	7
marrow	8
NK	8
cell	8
precursors	8
and	0
splenic	7
mature	8
NK	8
cells	8
were	0
reduced	0
compared	0
to	0
controls	0
.	0

Moreover	0
,	0
PU.1	7
(	8
-/-	8
)	8
NK	8
cells	8
displayed	0
reduced	0
expression	0
of	0
the	0
receptors	0
for	0
stem	9
cell	10
factor	10
and	0
interleukin	9
(	10
IL	10
)	10
-7	10
,	0
suggesting	0
a	0
nonredundant	0
role	0
for	0
PU.1	9
in	0
regulating	0
the	0
expression	0
of	0
these	0
cytokine	1
receptor	2
genes	2
during	0
NK	0
cell	0
development	0
.	0

PU.1	7
(	8
-/-	8
)	8
NK	8
cells	8
also	0
showed	0
defective	0
expression	0
of	0
inhibitory	0
and	0
activating	0
members	0
of	0
the	0
Ly49	9
family	10
and	0
failed	0
to	0
proliferate	0
in	0
response	0
to	0
IL-2	9
and	0
IL-12	9
.	0

Thus	0
,	0
despite	0
the	0
less	0
stringent	0
requirement	0
for	0
PU.1	9
in	0
NK	0
cell	0
development	0
compared	0
to	0
B	7
and	8
T	8
cells	8
,	0
PU.1	9
regulates	0
NK	0
cell	0
differentiation	0
and	0
homeostasis	0
.	0

Benzene-extracted	0
components	0
are	0
important	0
for	0
the	0
major	0
activity	0
of	0
diesel	0
exhaust	0
particles	0
:	0
effect	0
on	0
interleukin-8	1
gene	2
expression	0
in	0
human	7
bronchial	8
epithelial	8
cells	8
.	0

Epidemiologic	0
and	0
experimental	0
studies	0
suggest	0
that	0
diesel	0
exhaust	0
particles	0
(	0
DEPs	0
)	0
may	0
be	0
related	0
to	0
increasing	0
respiratory	0
mortality	0
and	0
morbidity	0
.	0

We	0
have	0
shown	0
that	0
DEPs	0
augmented	0
the	0
production	0
of	0
inflammatory	9
cytokines	10
by	0
human	7
airway	8
epithelial	8
cells	8
in	0
vitro	0
.	0

To	0
better	0
understand	0
the	0
mechanisms	0
of	0
their	0
proinflammatory	0
activities	0
,	0
we	0
studied	0
the	0
effects	0
of	0
several	0
components	0
extracted	0
from	0
DEPs	0
on	0
interleukin	0
(	0
IL	0
)	0
-8	0
expression	0
in	0
human	5
bronchial	6
epithelial	6
cell	6
line	6
BEAS-2B	6
and	0
normal	7
human	8
airway	8
epithelial	8
cells	8
obtained	0
from	0
very	0
peripheral	0
airways	0
by	0
an	0
ultrathin	0
bronchoscope	0
.	0

We	0
used	0
several	0
agents	0
active	0
on	0
signal	0
transduction	0
pathways	0
in	0
cytokine	0
expression	0
,	0
such	0
as	0
the	0
protein	0
kinase	0
C	0
inhibitor	0
staurosporin	0
,	0
antioxidant	0
agents	0
including	0
N-acetyl	0
cysteine	0
(	0
NAC	0
)	0
and	0
pyrrolidine	0
dithiocarbamate	0
(	0
PDTC	0
)	0
,	0
and	0
p38	9
mitogen-activated	10
protein	10
kinase	10
(	0
MAPK	9
)	0
inhibitor	0
SB203580	0
.	0

Benzene-extracted	0
components	0
showed	0
effects	0
mimicking	0
DEPs	0
on	0
IL-8	0
gene	0
expression	0
,	0
release	0
of	0
several	0
cytokines	9
(	0
IL-8	9
;	0
granulocyte	9
macrophage	10
colony-stimulating	10
factor	10
;	0
and	0
regulated	0
on	0
activation	0
,	0
normal	7
T	8
cells	8
expressed	0
and	0
secreted	0
)	0
and	0
nuclear	0
factor	0
(	0
NF	0
)	0
-kappa	0
B	0
activation	0
.	0

We	0
also	0
found	0
that	0
NAC	0
,	0
PDTC	0
,	0
and	0
SB203580	0
suppressed	0
the	0
activities	0
of	0
DEPs	0
and	0
their	0
benzene	0
extracts	0
,	0
suggesting	0
the	0
roles	0
of	0
oxidants-mediated	0
NF-kappa	0
B	0
activation	0
and	0
p38MAPK	9
pathways	0
.	0

Finally	0
,	0
benzo	0
[	0
a	0
]	0
pyrene	0
,	0
one	0
of	0
the	0
important	0
compounds	0
included	0
in	0
the	0
benzene	0
component	0
,	0
replicated	0
the	0
activities	0
shown	0
by	0
DEPs	0
.	0

The	0
nuclear	9
receptor	10
PPAR	10
gamma	10
is	0
expressed	0
by	0
mouse	7
T	8
lymphocytes	8
and	0
PPAR	0
gamma	0
agonists	0
induce	0
apoptosis	0
.	0

Peroxisome	9
proliferator-activated	10
receptor	10
(	10
PPAR	10
)	10
-gamma	10
is	0
a	0
nuclear	9
hormone	10
receptor	10
that	0
serves	0
as	0
a	0
trans	0
factor	0
to	0
regulate	0
lipid	0
metabolism	0
.	0

Intense	0
interest	0
is	0
focused	0
on	0
PPAR-gamma	9
and	0
its	0
ligands	0
owing	0
to	0
its	0
putative	0
role	0
in	0
adipocyte	0
differentiation	0
.	0

Little	0
is	0
known	0
,	0
however	0
,	0
about	0
the	0
functions	0
of	0
PPAR-gamma	9
in	0
the	0
immune	0
system	0
,	0
especially	0
in	0
T	7
lymphocytes	8
.	0

We	0
demonstrate	0
that	0
both	0
naive	7
and	8
activated	8
ovalbumin-specific	8
T	8
cells	8
from	0
DO11.10-transgenic	0
mice	0
express	0
PPAR-gamma	3
mRNA	0
and	0
protein	0
.	0

In	0
order	0
to	0
determine	0
the	0
function	0
of	0
PPAR-gamma	9
,	0
T	7
cells	8
were	0
stimulated	0
with	0
phorbol	0
12-myristate	0
13-acetate	0
and	0
ionomycin	0
or	0
antigen	0
and	0
antigen-presenting	7
cells	8
.	0

Simultaneous	0
exposure	0
to	0
PPAR-gamma	0
ligands	0
(	0
e.g.	0
15-deoxy-Delta	0
(	0
12	0
,	0
14	0
)	0
-prostaglandin	0
J	0
(	0
2	0
)	0
,	0
troglitazone	0
)	0
showed	0
drastic	0
inhibition	0
of	0
proliferation	0
and	0
significant	0
decreases	0
in	0
cell	0
viability	0
.	0

The	0
decrease	0
in	0
cell	0
viability	0
was	0
due	0
to	0
apoptosis	0
of	0
the	0
T	7
lymphocytes	8
,	0
and	0
occurred	0
only	0
when	0
cells	0
were	0
treated	0
with	0
PPAR-gamma	9
,	0
and	0
not	0
PPAR-alpha	0
agonists	0
,	0
revealing	0
specificity	0
of	0
this	0
response	0
for	0
PPAR-gamma	9
.	0

These	0
observations	0
suggest	0
that	0
PPAR-gamma	0
agonists	0
play	0
an	0
important	0
role	0
in	0
regulating	0
T	0
cell-mediated	0
immune	0
responses	0
by	0
inducing	0
apoptosis	0
.	0

T	0
cell	0
death	0
via	0
PPAR-gamma	0
ligation	0
may	0
act	0
as	0
a	0
potent	0
anti-inflammatory	0
signal	0
in	0
the	0
immune	0
system	0
,	0
and	0
ligands	0
could	0
possibly	0
be	0
used	0
to	0
control	0
disorders	0
in	0
which	0
excessive	0
inflammation	0
occurs	0
.	0

Suppression	0
of	0
lung	0
inflammation	0
in	0
rats	0
by	0
prevention	0
of	0
NF-kappaB	0
activation	0
in	0
the	0
liver	0
.	0

Activation	0
of	0
NF-kappaB	9
and	0
production	0
of	0
NF-kappaB	9
-dependent	0
chemokines	9
are	0
thought	0
to	0
be	0
involved	0
in	0
the	0
pathogenesis	0
of	0
neutrophilic	0
lung	0
inflammation	0
.	0

Calpain-1	0
inhibitor	0
(	0
CI-1	0
)	0
blocks	0
activation	0
of	0
NF-kappaB	9
by	0
preventing	0
proteolysis	0
of	0
the	0
inhibitory	0
protein	0
IkappaB-alpha	9
by	0
the	0
ubiquitin/proteasome	0
pathway	0
.	0

We	0
hypothesized	0
that	0
inhibition	0
of	0
proteasome	0
function	0
with	0
CI-1	0
would	0
block	0
NF-kappaB	0
activation	0
in	0
vivo	0
after	0
intraperitoneal	0
(	0
i.p.	0
)	0
treatment	0
with	0
bacterial	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
and	0
that	0
NF-kappaB	0
inhibition	0
would	0
be	0
associated	0
with	0
suppression	0
of	0
chemokine	0
gene	0
expression	0
and	0
attenuation	0
of	0
neutrophilic	0
alveolitis	0
.	0

We	0
treated	0
rats	0
with	0
a	0
single	0
i.p.	0
injection	0
of	0
CI-1	0
(	0
10	0
mg/kg	0
)	0
two	0
hours	0
prior	0
to	0
i.p.	0
LPS	0
(	0
7	0
mg/kg	0
)	0
.	0

Treatment	0
with	0
Cl-1	0
prevented	0
degradation	0
of	0
IkappaB-alpha	9
and	0
activation	0
of	0
NF-kappaB	9
in	0
the	0
liver	0
in	0
response	0
to	0
LPS	0
;	0
however	0
,	0
Cl-1	0
treatment	0
had	0
no	0
detected	0
effect	0
on	0
NF-kappaB	0
activation	0
in	0
lung	0
tissue	0
.	0

CI-1	0
treatment	0
prior	0
to	0
LPS	0
resulted	0
in	0
40	0
%	0
lower	0
MIP-2	0
concentration	0
in	0
lung	0
lavage	0
fluid	0
compared	0
to	0
rats	0
treated	0
with	0
vehicle	0
prior	0
to	0
LPS	0
(	0
502	0
+/-	0
112	0
pg/ml	0
vs.	0
859	0
+/-144	0
pg/ml	0
,	0
P	0
<	0
0.05	0
)	0
.	0

In	0
addition	0
,	0
CI-1	0
treatment	0
substantially	0
inhibited	0
LPS-induced	0
neutrophilic	0
alveolitis	0
(	0
2.7+	0
/-	0
1.2	0
x	0
10	0
(	0
5	0
)	0
vs.	0
43.7	0
+/-	0
12.2	0
x	0
10	0
(	0
5	0
)	0
lung	7
lavage	8
neutrophils	8
,	0
P	0
<	0
0.01	0
)	0
.	0

These	0
data	0
indicate	0
that	0
NF-kappaB	0
inhibition	0
in	0
the	0
liver	0
can	0
alter	0
lung	0
inflammation	0
induced	0
by	0
systemic	0
LPS	0
treatment	0
and	0
suggest	0
that	0
a	0
liver-lung	0
interaction	0
contributes	0
to	0
the	0
inflammatory	0
response	0
of	0
the	0
lung	0
.	0

Notch1	9
regulates	0
maturation	0
of	0
CD4+	7
and	8
CD8+	8
thymocytes	8
by	0
modulating	0
TCR	0
signal	0
strength	0
.	0

Notch	0
signaling	0
regulates	0
cell	0
fate	0
decisions	0
in	0
multiple	0
lineages	0
.	0

We	0
demonstrate	0
in	0
this	0
report	0
that	0
retroviral	0
expression	0
of	0
activated	0
Notch1	9
in	0
mouse	7
thymocytes	8
abrogates	0
differentiation	0
of	0
immature	7
CD4+CD8+	8
thymocytes	8
into	0
both	0
CD4	7
and	8
CD8	8
mature	8
single-positive	8
T	8
cells	8
.	0

The	0
ability	0
of	0
Notch1	9
to	0
inhibit	0
T	0
cell	0
development	0
was	0
observed	0
in	0
vitro	0
and	0
in	0
vivo	0
with	0
both	0
normal	7
and	8
TCR	8
transgenic	8
thymocytes	8
.	0

Notch1	9
-mediated	0
developmental	0
arrest	0
was	0
dose	0
dependent	0
and	0
was	0
associated	0
with	0
impaired	0
thymocyte	0
responses	0
to	0
TCR	0
stimulation	0
.	0

Notch1	9
also	0
inhibited	0
TCR-mediated	0
signaling	0
in	0
Jurkat	5
T	6
cells	6
.	0

These	0
data	0
indicate	0
that	0
constitutively	0
active	0
Notch1	9
abrogates	0
CD4+	0
and	0
CD8+	0
maturation	0
by	0
interfering	0
with	0
TCR	0
signal	0
strength	0
and	0
provide	0
an	0
explanation	0
for	0
the	0
physiological	0
regulation	0
of	0
Notch	0
expression	0
during	0
thymocyte	0
development	0
.	0

Expression	0
of	0
SART3	9
antigen	10
and	0
induction	0
of	0
CTLs	7
by	0
SART3-derived	0
peptides	0
in	0
breast	0
cancer	0
patients	0
.	0

We	0
recently	0
reported	0
the	0
SART3	9
tumour-rejection	10
antigen	10
as	0
possessing	0
tumour	0
epitopes	0
capable	0
of	0
inducing	0
HLA-class	7
I-restricted	8
cytotoxic	8
T	8
lymphocytes	8
(	0
CTLs	7
)	0
.	0

This	0
study	0
investigated	0
expression	0
of	0
the	0
SART3	9
antigen	10
in	0
breast	0
cancer	0
to	0
explore	0
an	0
appropriate	0
molecule	0
for	0
use	0
in	0
specific	0
immunotherapy	0
of	0
breast	0
cancer	0
patients	0
.	0

The	0
SART3	9
antigen	10
was	0
detected	0
in	0
all	0
of	0
the	0
breast	5
cancer	6
cell	6
lines	6
tested	0
,	0
30	0
of	0
40	0
(	0
75	0
%	0
)	0
breast	0
cancer	0
tissue	0
samples	0
,	0
and	0
0	0
of	0
3	0
non-tumourous	0
breast	0
tissue	0
samples	0
.	0

SART3	0
derived	0
peptides	0
at	0
positions	1
109-118	2
and	2
315-323	2
induced	0
HLA-A24	0
restricted	0
CTLs	7
that	0
reacted	0
to	0
breast	7
cancer	8
cells	8
from	0
the	0
peripheral	7
blood	8
mononuclear	8
cells	8
(	0
PBMCs	7
)	0
of	0
breast	0
cancer	0
patients	0
.	0

Therefore	0
,	0
the	0
SART3	9
antigen	10
and	0
its	0
peptides	0
could	0
be	0
an	0
appropriate	0
molecule	0
for	0
use	0
in	0
specific	0
immunotherapy	0
of	0
the	0
majority	0
of	0
HLA-A24-positive	0
breast	0
cancer	0
patients	0

Autostimulation	0
of	0
the	0
Epstein-Barr	0
virus	0
BRLF1	1
promoter	2
is	0
mediated	0
through	0
consensus	0
Sp1	1
and	2
Sp3	2
binding	2
sites	2
.	0

As	0
an	0
essential	0
step	0
in	0
the	0
lytic	0
cascade	0
,	0
the	0
Rta	0
homologues	0
of	0
gammaherpesviruses	0
all	0
activate	0
their	0
own	0
expression	0
.	0

Consistent	0
with	0
this	0
biologic	0
function	0
,	0
the	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
Rta	9
protein	10
powerfully	0
stimulates	0
the	0
promoter	1
of	0
its	0
own	0
gene	0
,	0
Rp	1
,	0
in	0
EBV-positive	7
B	8
cells	8
in	0
transient-transfection	0
reporter-based	0
assays	0
.	0

We	0
analyzed	0
the	0
activity	0
of	0
RpCAT	1
in	0
response	0
to	0
Rta	9
by	0
deletional	0
and	0
site-directed	0
mutagenesis	0
.	0

Two	0
cognate	1
Sp1	2
binding	2
sites	2
located	0
at	0
-279	0
and	0
-45	0
relative	0
to	0
the	0
transcriptional	1
start	2
site	2
proved	0
crucial	0
for	0
Rta-mediated	0
activation	0
.	0

Previously	0
described	0
binding	0
sites	0
for	0
the	0
cellular	0
transcription	9
factor	10
Zif268	10
and	0
the	0
viral	9
transactivator	10
ZEBRA	10
were	0
found	0
to	0
be	0
dispensable	0
for	0
activation	0
of	0
RpCAT	1
by	0
Rta	9
.	0

Gel	0
shift	0
analysis	0
,	0
using	0
extracts	0
of	0
B	7
cells	8
in	0
latency	0
or	0
induced	0
into	0
the	0
lytic	0
cycle	0
,	0
identified	0
Sp1	9
and	0
Sp3	9
as	0
the	0
predominant	0
cellular	9
proteins	10
bound	0
to	0
Rp	1
near	0
-45	0
.	0

During	0
the	0
lytic	0
cycle	0
,	0
ZEBRA	9
bound	0
Rp	1
near	0
the	0
Sp1/Sp3	1
site	2
.	0

The	0
binding	0
of	0
Sp1	9
and	0
Sp3	9
to	0
Rp	1
correlated	0
with	0
the	0
reporter	0
activities	0
in	0
the	0
mutagenesis	0
study	0
,	0
establishing	0
a	0
direct	0
link	0
between	0
transcriptional	0
activation	0
of	0
Rp	1
by	0
Rta	9
and	0
DNA	0
binding	0
by	0
Sp1	9
and/or	0
Sp3	9
.	0

The	0
relative	0
abundance	0
or	0
functional	0
state	0
of	0
the	0
cellular	0
Sp1	9
and	0
Sp3	9
transcription	9
factors	10
may	0
be	0
altered	0
in	0
response	0
to	0
stimuli	0
that	0
induce	0
the	0
BRLF1	1
promoter	2
and	0
thereby	0
contribute	0
to	0
the	0
activation	0
of	0
the	0
viral	0
lytic	0
cycle	0
.	0

Gene	0
transfer	0
of	0
antisense	0
hypoxia	9
inducible	10
factor-1	10
alpha	10
enhances	0
the	0
therapeutic	0
efficacy	0
of	0
cancer	0
immunotherapy	0
.	0

Solid	0
tumors	0
meet	0
their	0
demands	0
for	0
nascent	0
blood	0
vessels	0
and	0
increased	0
glycolysis	0
,	0
to	0
combat	0
hypoxia	0
,	0
by	0
activating	0
multiple	0
genes	0
involved	0
in	0
angiogenesis	0
and	0
glucose	0
metabolism	0
.	0

Hypoxia	9
inducible	10
factor-1	10
(	0
HIF-1	9
)	0
is	0
a	0
constitutively	0
expressed	0
basic	0
helix-loop-helix	9
transcription	10
factor	10
,	0
formed	0
by	0
the	0
assembly	0
of	0
HIF-1alpha	9
and	0
HIF-1beta	9
(	0
Arnt	9
)	0
,	0
that	0
is	0
stablized	0
in	0
response	0
to	0
hypoxia	0
,	0
and	0
rapidly	0
degraded	0
under	0
normoxic	0
conditions	0
.	0

It	0
activates	0
the	0
transcription	0
of	0
genes	0
important	0
for	0
maintaining	0
oxygen	0
homeostasis	0
.	0

Here	0
,	0
we	0
demonstrate	0
that	0
engineered	0
down-regulation	0
of	0
HIF-1alpha	9
by	0
intratumoral	0
gene	0
transfer	0
of	0
an	0
antisense	1
HIF-1alpha	2
plasmid	2
leads	0
to	0
the	0
down-regulation	0
of	0
VEGF	1
,	0
and	0
decreased	0
tumor	0
microvessel	0
density	0
.	0

Antisense	0
HIF-1alpha	0
monotherapy	0
resulted	0
in	0
the	0
complete	0
and	0
permanent	0
rejection	0
of	0
small	0
(	0
0.1	0
cm	0
in	0
diameter	0
)	0
EL-4	0
tumors	0
,	0
which	0
is	0
unusual	0
for	0
an	0
anti-angiogenic	0
agent	0
where	0
transient	0
suppression	0
of	0
tumor	0
growth	0
is	0
the	0
norm	0
.	0

It	0
induced	0
NK	7
cell	8
-dependent	0
rejection	0
of	0
tumors	0
,	0
but	0
failed	0
to	0
stimulate	0
systemic	0
T	7
cell	8
-mediated	0
anti-tumor	0
immunity	0
,	0
and	0
synergized	0
with	0
B7-1-mediated	0
immunotherapy	0
to	0
cause	0
the	0
NK	7
cell	8
and	0
CD8	7
T	8
cell	8
-dependent	0
rejection	0
of	0
larger	0
EL-4	0
tumors	0
(	0
0.4	0
cm	0
in	0
diameter	0
)	0
that	0
were	0
refractory	0
to	0
monotherapies	0
.	0

Mice	0
cured	0
of	0
their	0
tumors	0
by	0
combination	0
therapy	0
resisted	0
a	0
rechallenge	0
with	0
parental	7
tumor	8
cells	8
,	0
indicating	0
systemic	0
antitumor	0
immunity	0
had	0
been	0
achieved	0
.	0

In	0
summary	0
,	0
whilst	0
intensive	0
investigations	0
are	0
in	0
progress	0
to	0
target	0
the	0
many	0
HIF-1	9
effectors	0
,	0
the	0
results	0
herein	0
indicate	0
that	0
blocking	0
hypoxia-inducible	0
pathways	0
and	0
enhancing	0
NK-mediated	0
antitumor	0
immunity	0
by	0
targeting	0
HIF-1	9
itself	0
may	0
be	0
advantageous	0
,	0
especially	0
when	0
combined	0
with	0
cancer	0
immunotherapy	0
.	0

Runx2	1
:	0
a	0
novel	0
oncogenic	0
effector	0
revealed	0
by	0
in	0
vivo	0
complementation	0
and	0
retroviral	0
tagging	0
.	0

The	0
Runx2	1
(	0
Cbfa1	1
,	0
Pebp2alphaA	1
,	0
Aml3	1
)	0
gene	0
was	0
previously	0
identified	0
as	0
a	0
frequent	0
target	0
for	0
transcriptional	0
activation	0
by	0
proviral	0
insertion	0
in	0
T-cell	0
lymphomas	0
of	0
CD2-MYC	0
transgenic	0
mice	0
.	0

We	0
have	0
recently	0
shown	0
that	0
over-expression	0
of	0
the	0
full-length	0
,	0
most	0
highly	0
expressed	0
Runx2	1
isoform	0
in	0
the	0
thymus	0
perturbs	0
T-cell	0
development	0
,	0
leads	0
to	0
development	0
of	0
spontaneous	0
lymphomas	0
at	0
low	0
frequency	0
and	0
is	0
strongly	0
synergistic	0
with	0
Myc	9
.	0

To	0
gain	0
further	0
insight	0
into	0
the	0
relationship	0
of	0
Runx2	1
to	0
other	0
lymphomagenic	0
pathways	0
,	0
we	0
tested	0
the	0
effect	0
of	0
combining	0
the	0
CD2-Runx2	1
transgene	2
either	0
with	0
a	0
Pim1	1
transgene	2
(	0
E	1
(	2
mu	2
)	2
-Pim1	2
)	0
or	0
with	0
the	0
p53	1
null	0
genotype	0
,	0
as	0
each	0
of	0
these	0
displays	0
independent	0
synergy	0
with	0
Myc	9
.	0

In	0
both	0
cases	0
we	0
observed	0
synergistic	0
tumour	0
development	0
.	0

However	0
,	0
Runx2	9
appeared	0
to	0
have	0
a	0
dominant	0
effect	0
on	0
the	0
tumour	0
phenotype	0
in	0
each	0
case	0
,	0
with	0
most	0
tumours	0
conforming	0
to	0
the	0
CD3	0
(	0
+	0
)	0
,	0
CD8	0
(	0
+	0
)	0
,	0
CD4	0
(	0
+/-	0
)	0
phenotype	0
seen	0
in	0
CD2-Runx2	0
mice	0
.	0

Neonatal	0
infection	0
of	0
CD2-Runx2	0
mice	0
with	0
Moloney	0
murine	0
leukaemia	0
virus	0
(	0
Moloney	0
MLV	0
)	0
also	0
led	0
to	0
a	0
dramatic	0
acceleration	0
of	0
tumour	0
onset	0
.	0

Analysis	0
of	0
known	0
Moloney	1
MLV	2
target	2
genes	2
in	0
these	0
lymphomas	0
showed	0
a	0
high	0
frequency	0
of	0
rearrangement	0
at	0
c-Myc	1
or	0
N-Myc	1
(	0
82	0
%	0
)	0
,	0
and	0
a	0
significant	0
number	0
at	0
Pim1	1
or	0
Pim2	1
(	0
23	0
%	0
)	0
,	0
and	0
at	0
Pal1/Gfi1	1
(	0
18	0
%	0
)	0
.	0

These	0
results	0
indicate	0
that	0
Runx2	9
makes	0
a	0
distinct	0
contribution	0
to	0
T-cell	0
lymphoma	0
development	0
which	0
does	0
not	0
coincide	0
with	0
any	0
of	0
the	0
oncogene	0
complementation	0
groups	0
previously	0
identified	0
by	0
retroviral	0
tagging	0
.	0

The	0
involvement	0
of	0
TNF-alpha	9
-related	0
apoptosis-inducing	0
ligand	0
in	0
the	0
enhanced	0
cytotoxicity	0
of	0
IFN-beta	9
-stimulated	0
human	7
dendritic	8
cells	8
to	0
tumor	7
cells	8
.	0

TNF-alpha	9
-related	0
apoptosis-inducing	0
ligand	0
(	0
TRAIL	0
)	0
is	0
characterized	0
by	0
its	0
preferential	0
induction	0
of	0
apoptosis	0
of	0
tumor	7
cells	8
but	0
not	0
normal	7
cells	8
.	0

Dendritic	7
cells	8
(	0
DCs	7
)	0
,	0
besides	0
their	0
role	0
as	0
APCs	0
,	0
now	0
have	0
been	0
demonstrated	0
to	0
exert	0
cytotoxicity	0
or	0
cytostasis	0
on	0
some	0
tumor	7
cells	8
.	0

Here	0
,	0
we	0
report	0
that	0
both	0
human	7
CD34	8
(	8
+	8
)	8
stem	8
cell	8
-derived	0
DCs	7
(	0
CD34DCs	7
)	0
and	0
human	7
CD14	8
(	8
+	8
)	8
monocyte	8
-derived	0
DCs	7
(	0
MoDCs	7
)	0
express	0
TRAIL	0
and	0
exhibit	0
cytotoxicity	0
to	0
some	0
types	0
of	0
tumor	7
cells	8
partially	0
through	0
TRAIL	0
.	0

Moderate	0
expression	0
of	0
TRAIL	0
appeared	0
on	0
CD34DCs	7
from	0
the	0
8th	0
day	0
of	0
culture	0
and	0
was	0
also	0
seen	0
on	0
freshly	7
isolated	8
monocytes	8
.	0

The	0
level	0
of	0
TRAIL	0
expression	0
remained	0
constant	0
until	0
DC	0
maturation	0
.	0

TRAIL	0
expression	0
on	0
immature	7
CD34DCs	8
or	0
MoDCs	7
was	0
greatly	0
up-regulated	0
after	0
IFN-beta	9
stimulation	0
.	0

Moreover	0
,	0
IFN-beta	9
could	0
strikingly	0
enhance	0
the	0
ability	0
of	0
CD34DCs	7
or	0
MoDCs	7
to	0
kill	0
TRAIL-sensitive	0
tumor	7
cells	8
,	0
but	0
LPS	0
did	0
not	0
have	0
such	0
an	0
effect	0
.	0

The	0
up-regulation	0
of	0
TRAIL	0
on	0
IFN-beta	9
-stimulated	0
DCs	7
partially	0
contributed	0
to	0
the	0
increased	0
cytotoxicity	0
of	0
DCS	7
:	0
Pretreatment	0
of	0
TRAIL-sensitive	0
tumor	7
cells	8
with	0
caspase-3	0
inhibitor	0
could	0
significantly	0
increase	0
their	0
resistance	0
to	0
the	0
cytotoxicity	0
of	0
IFN-beta	9
-stimulated	0
DCS	7
:	0
In	0
contrast	0
,	0
NF-kappaB	0
inhibitor	0
could	0
significantly	0
increase	0
the	0
sensitivity	0
of	0
tumor	7
cells	8
to	0
the	0
killing	0
by	0
nonstimulated	0
or	0
LPS-stimulated	0
DCS	7
:	0
Our	0
studies	0
demonstrate	0
that	0
IFN-beta	9
-stimulated	0
DCs	7
are	0
functionally	0
cytotoxic	0
.	0

Thus	0
,	0
an	0
innate	0
mechanism	0
of	0
DC-mediated	0
antitumor	0
immunity	0
might	0
exist	0
in	0
vivo	0
in	0
which	0
DCs	7
act	0
as	0
effectors	0
to	0
directly	0
kill	0
tumor	7
cells	8
partially	0
via	0
TRAIL	0
.	0

Subsequently	0
,	0
DCs	7
act	0
as	0
APCs	0
involved	0
in	0
the	0
uptake	0
,	0
processing	0
,	0
and	0
presentation	0
of	0
apoptotic	9
tumor	10
Ags	10
to	0
cross-prime	0
CD8	7
(	8
+	8
)	8
CTL	8
cells	8
.	0

Tumor	7
cells	8
regulate	0
the	0
lytic	0
activity	0
of	0
tumor-specific	7
cytotoxic	8
t	8
lymphocytes	8
by	0
modulating	0
the	0
inhibitory	0
natural	0
killer	0
receptor	0
function	0
.	0

Tumor-infiltrating	7
p58+	8
T	8
cells	8
from	0
a	0
renal	0
tumor	0
were	0
specifically	0
expanded	0
in	0
response	0
to	0
tumor	0
cell	0
stimulation	0
and	0
cloned	0
.	0

These	0
p58+	7
T	8
cells	8
were	0
found	0
to	0
express	0
a	0
memory	7
phenotype	8
and	0
corresponded	0
to	0
clonal	0
TCRBV3	0
T-cell	0
expansion	0
.	0

Functionally	0
,	0
p58	7
(	8
+	8
)	8
CTLs	8
displayed	0
a	0
low	0
lytic	0
activity	0
for	0
HLA-A2	7
tumor	8
and	8
normal	8
cells	8
.	0

However	0
,	0
this	0
lytic	0
activity	0
was	0
significantly	0
increased	0
after	0
blockade	0
of	0
p58	9
with	0
specific	0
monoclonal	9
antibodies	10
.	0

Interestingly	0
,	0
we	0
demonstrated	0
that	0
stimulation	0
by	0
tumor	7
cells	8
was	0
required	0
to	0
trigger	0
the	0
inhibitory	0
effect	0
of	0
p58	9
on	0
the	0
lytic	0
activity	0
of	0
antigen-specific	7
CTLs	8
and	0
that	0
stimulation	0
of	0
the	0
inhibitory	0
function	0
of	0
p58	9
by	0
tumor	7
cells	8
correlated	0
with	0
an	0
inhibition	0
of	0
nuclear	0
factor-kappaB	0
activation	0
in	0
p58+	7
tumor-specific	8
CTLS	8
.	0

T-cell	9
factor-1	10
expression	0
during	0
human	7
natural	8
killer	8
cell	8
development	0
and	0
in	0
circulating	0
CD56	9
(	10
+	10
)	10
bright	0
natural	7
killer	8
cells	8
.	0

Transcription	9
factors	10
are	0
essential	0
to	0
govern	0
differentiation	0
along	0
the	0
lymphoid	7
lineage	8
from	0
uncommitted	7
hematopoietic	8
stem	8
cells	8
.	0

Although	0
many	0
of	0
these	0
transcription	9
factors	10
have	0
putative	0
roles	0
based	0
on	0
murine	0
knockout	0
experiments	0
,	0
their	0
function	0
in	0
human	0
lymphoid	0
development	0
is	0
less	0
known	0
and	0
was	0
studied	0
further	0
.	0

Transcription	0
factor	0
expression	0
in	0
fresh	0
and	0
cultured	0
adult	7
human	8
bone	8
marrow	8
and	8
umbilical	8
cord	8
blood	8
progenitors	8
was	0
evaluated	0
.	0

We	0
found	0
that	0
fresh	7
CD34	8
(	8
+	8
)	8
Lin	8
(	8
-	8
)	8
cells	8
that	0
are	0
human	0
leukocyte	0
antigen	0
(	0
HLA	0
)	0
-DR	0
(	0
-	0
)	0
or	0
CD38	0
(	0
-	0
)	0
constitutively	0
express	0
GATA-3	9
but	0
not	0
T-cell	9
factor-1	10
(	0
TCF-1	9
)	0
or	0
Id-3	9
.	0

Culture	0
with	0
the	0
murine	5
fetal	6
liver	6
cell	6
line	6
AFT024	6
and	0
defined	0
cytokines	9
was	0
capable	0
of	0
inducing	0
TCF-1	3
mRNA	4
.	0

However	0
,	0
no	0
T-cell	1
receptor	2
gene	2
rearrangement	0
was	0
identified	0
in	0
cultured	0
progeny	0
.	0

Id-3	9
,	0
a	0
basic	9
helix	10
loop	10
helix	10
factor	10
with	0
dominant	0
negative	0
function	0
for	0
T-cell	0
differentiation	0
transcription	9
factors	10
,	0
also	0
was	0
upregulated	0
and	0
may	0
explain	0
unsuccessful	0
T-cell	0
maturation	0
.	0

To	0
better	0
understand	0
the	0
developmental	0
link	0
between	0
natural	7
killer	8
(	8
NK	8
)	8
cells	8
derived	0
from	0
progenitors	7
,	0
we	0
studied	0
NK	7
cell	8
subsets	8
circulating	0
in	0
blood	0
.	0

CD56	7
(	8
+bright	8
)	8
,	0
but	0
not	0
CD56	7
(	8
+dim	8
)	8
,	0
NK	7
cells	8
constitutively	0
express	0
TCF-1	9
by	0
reverse	0
transcriptase	0
polymerase	0
chain	0
reaction	0
and	0
Western	0
blot	0
analysis	0
.	0

The	0
TCF-1	9
isoform	10
found	0
in	0
CD56	7
(	8
+bright	8
)	8
cells	8
,	0
which	0
express	0
lectin	9
but	0
not	0
immunoglobulin	9
class	10
I	10
recognizing	0
inhibitory	9
receptors	10
,	0
was	0
identical	0
to	0
that	0
induced	0
in	0
NK	0
cell	0
differentiation	0
culture	0
and	0
was	0
distinctly	0
different	0
from	0
isoforms	0
in	0
T	7
cells	8
.	0

These	0
results	0
suggest	0
that	0
TCF-1	9
does	0
not	0
target	0
human	1
killer	2
immunoglobulin	2
receptor	2
genes	2
,	0
TCF-1	9
is	0
uniquely	0
expressed	0
in	0
circulating	0
CD56	7
(	8
+bright	8
)	8
NK	8
cells	8
,	0
and	0
specific	0
TCF-1	9
isoforms	10
may	0
play	0
an	0
important	0
role	0
in	0
regulating	0
NK	0
differentiation	0
from	0
a	0
common	0
NK/T-cell	7
progenitor	8
.	0

Transcriptional	0
activation	0
by	0
a	0
matrix	9
associating	10
region-binding	10
protein	10
.	0

contextual	0
requirements	0
for	0
the	0
function	0
of	0
bright	9
.	0

Bright	9
(	0
B	9
cell	10
regulator	10
of	10
IgH	10
transcription	10
)	0
is	0
a	0
B	7
cell	8
-specific	0
,	0
matrix	9
associating	10
region-binding	10
protein	10
that	0
transactivates	0
gene	0
expression	0
from	0
the	0
IgH	1
intronic	2
enhancer	2
(	0
E	1
mu	2
)	0
.	0

We	0
show	0
here	0
that	0
Bright	9
has	0
multiple	0
contextual	0
requirements	0
to	0
function	0
as	0
a	0
transcriptional	9
activator	10
.	0

Bright	9
can	0
not	0
transactivate	0
via	0
out	0
of	0
context	0
,	0
concatenated	9
binding	10
sites	10
.	0

Transactivation	0
is	0
maximal	0
on	0
integrated	0
substrates	0
.	0

Two	0
of	0
the	0
three	0
previously	0
identified	0
binding	1
sites	2
in	0
E	1
mu	2
are	0
required	0
for	0
full	0
Bright	9
transactivation	0
.	0

The	0
Bright	9
DNA	10
binding	10
domain	10
defined	0
a	0
new	0
family	0
,	0
which	0
includes	0
SWI1	9
,	0
a	0
component	0
of	0
the	0
SWI.SNF	9
complex	10
shown	0
to	0
have	0
high	0
mobility	0
group-like	0
DNA	0
binding	0
characteristics	0
.	0

Similar	0
to	0
one	0
group	0
of	0
high	9
mobility	10
group	10
box	10
proteins	10
,	0
Bright	9
distorts	0
E	1
mu	2
binding	2
site	2
-containing	0
DNA	0
on	0
binding	0
,	0
supporting	0
the	0
concept	0
that	0
it	0
mediates	0
E	1
mu	2
remodeling	0
.	0

Transfection	0
studies	0
further	0
implicate	0
Bright	9
in	0
facilitating	0
spatially	0
separated	0
promoter-enhancer	0
interactions	0
in	0
both	0
transient	0
and	0
stable	0
assays	0
.	0

Finally	0
,	0
we	0
show	0
that	0
overexpression	0
of	0
Bright	9
leads	0
to	0
enhanced	0
DNase	0
I	0
sensitivity	0
of	0
the	0
endogenous	0
E	1
mu	2
matrix	0
associating	0
regions	0
.	0

These	0
data	0
further	0
suggest	0
that	0
Bright	9
may	0
contribute	0
to	0
increased	0
gene	0
expression	0
by	0
remodeling	0
the	0
immunoglobulin	1
locus	2
during	0
B	7
cell	8
development	0
.	0

Analysis	0
of	0
BCL-6	0
mutations	0
in	0
classic	0
Hodgkin	0
disease	0
of	0
the	0
B-	7
and	8
T-cell	8
type	8
.	0

BCL-6	1
is	0
essential	0
for	0
germinal	0
center	0
formation	0
and	0
thus	0
for	0
affinity	0
maturation	0
of	0
immunoglobulin	1
(	2
Ig	2
)	2
genes	2
by	0
somatic	0
mutations	0
.	0

The	0
5'-noncoding	1
region	2
of	0
the	0
BCL-6	1
gene	2
is	0
even	0
a	0
target	0
for	0
the	0
mutation	0
machinery	0
.	0

Translocations	0
of	0
the	0
BCL-6	1
gene	2
to	0
heterologous	1
promoters	2
and	0
mutations	0
of	0
its	0
5'-noncoding	1
regulatory	2
region	2
were	0
reported	0
to	0
be	0
potential	0
mechanisms	0
for	0
deregulating	0
BCL-6	1
expression	0
and	0
for	0
playing	0
a	0
role	0
in	0
the	0
genesis	0
of	0
non-Hodgkin	0
lymphoma	0
.	0

In	0
line	0
with	0
this	0
hypothesis	0
is	0
the	0
observation	0
that	0
B-cell	0
lymphoma	0
with	0
somatic	0
mutations	0
,	0
such	0
as	0
diffuse	0
large	0
B-cell	0
lymphoma	0
and	0
follicular	0
lymphoma	0
,	0
also	0
carry	0
BCL-6	0
mutations	0
,	0
some	0
of	0
which	0
are	0
recurrently	0
detectable	0
.	0

Classic	0
Hodgkin	0
disease	0
(	0
cHD	0
)	0
is	0
also	0
derived	0
from	0
B	7
cells	8
with	0
high	0
loads	0
of	0
somatic	0
mutations	0
and	0
thus	0
a	0
further	0
candidate	0
for	0
BCL-6	0
mutations	0
.	0

To	0
determine	0
the	0
presence	0
and	0
potential	0
role	0
of	0
BCL-6	0
mutations	0
in	0
cHD	0
,	0
the	0
5'-noncoding	1
BCL-6	2
proportion	0
of	0
single	7
Hodgkin	8
and	8
Reed-Sternberg	8
(	8
HRS	8
)	8
cells	8
from	0
6	0
cases	0
of	0
cHD	0
and	0
6	0
cases	0
of	0
HD-derived	5
cell	6
lines	6
was	0
analyzed	0
.	0

All	0
B-cell-derived	0
HD	0
cases	0
and	0
cell	0
lines	0
harbored	0
BCL-6	0
mutations	0
.	0

In	0
contrast	0
,	0
both	0
T-cell-derived	0
HD	0
cases	0
and	0
cell	0
lines	0
were	0
devoid	0
of	0
BCL-6	0
mutations	0
.	0

With	0
only	0
one	0
exception	0
,	0
there	0
were	0
no	0
lymphoma-specific	0
recurrent	0
BCL-6	0
mutations	0
detected	0
,	0
and	0
BCL-6	9
protein	10
was	0
absent	0
from	0
the	0
HRS	7
cells	8
of	0
most	0
cases	0
.	0

In	0
conclusion	0
,	0
(	0
1	0
)	0
somatic	0
BCL-6	0
mutations	0
are	0
restricted	0
to	0
cHD	0
cases	0
of	0
B-cell	7
origin	0
,	0
and	0
(	0
2	0
)	0
the	0
BCL-6	0
mutations	0
represent	0
mostly	0
irrelevant	0
somatic	0
base	0
substitutions	0
without	0
consequences	0
for	0
BCL-6	9
protein	10
expression	0
and	0
the	0
pathogenesis	0
of	0
cHD	0
.	0

Gadd45gamma	1
is	0
dispensable	0
for	0
normal	0
mouse	0
development	0
and	0
T-cell	0
proliferation	0
.	0

Gadd45gamma	1
,	0
a	0
family	0
member	0
of	0
the	0
growth	1
arrest	2
and	2
DNA	2
damage-inducible	2
gene	2
family	2
45	2
(	0
Gadd45	1
)	0
,	0
is	0
strongly	0
induced	0
by	0
interleukin-2	9
(	0
IL-2	9
)	0
in	0
peripheral	7
T	8
cells	8
.	0

While	0
in	0
most	0
tissues	0
all	0
Gadd45	1
family	2
members	2
are	0
expressed	0
,	0
Gadd45gamma	1
is	0
the	0
only	0
member	0
that	0
is	0
induced	0
by	0
IL-2	9
.	0

Here	0
we	0
show	0
that	0
the	0
IL-2	9
-induced	0
expression	0
of	0
Gadd45gamma	1
is	0
dependent	0
on	0
a	0
signaling	0
pathway	0
mediated	0
by	0
the	0
tyrosine	9
kinase	10
Jak3	10
and	0
the	0
transcription	9
factors	10
Stat5a	9
and	0
Stat5b	9
(	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
)	0
.	0

Previous	0
studies	0
with	0
ectopically	0
overexpressed	0
Gadd45gamma	1
in	0
various	0
cell	0
lines	0
implicated	0
its	0
function	0
in	0
negative	0
growth	0
control	0
.	0

To	0
analyze	0
the	0
physiological	0
role	0
of	0
Gadd45gamma	1
we	0
used	0
homologous	0
recombination	0
to	0
generate	0
mice	0
lacking	0
Gadd45gamma	1
.	0

Gadd45gamma	1
-deficient	0
mice	0
develop	0
normally	0
,	0
are	0
indistinguishable	0
from	0
their	0
littermates	0
,	0
and	0
are	0
fertile	0
.	0

Furthermore	0
,	0
hematopoiesis	0
in	0
mice	0
lacking	0
Gadd45gamma	1
is	0
not	0
impaired	0
and	0
Gadd45gamma	1
-deficient	0
T	7
lymphocytes	8
show	0
normal	0
responses	0
to	0
IL-2	9
.	0

These	0
data	0
demonstrate	0
that	0
Gadd45gamma	1
is	0
not	0
essential	0
for	0
normal	0
mouse	0
development	0
and	0
hematopoiesis	0
,	0
possibly	0
due	0
to	0
functional	0
redundancy	0
among	0
the	0
Gadd45	1
family	2
members	2
.	0

Gadd45gamma	1
is	0
also	0
dispensable	0
for	0
IL-2	9
-induced	0
T-cell	0
proliferation	0
.	0

Decreased	0
expression	0
of	0
c-myc	1
family	2
genes	2
in	0
thymuses	0
from	0
myasthenia	0
gravis	0
patients	0
.	0

The	0
thymus	0
is	0
a	0
critical	0
organ	0
for	0
the	0
elimination	0
of	0
autoreactive	7
T	8
cells	8
by	0
apoptosis	0
.	0

We	0
studied	0
the	0
expression	0
of	0
apoptosis-associated	0
genes	0
,	0
bcl-xL	1
,	0
bad	1
,	0
caspase-3	1
,	0
and	0
c-myc	1
family	2
genes	2
in	0
myasthenia	0
gravis	0
(	0
MG	0
)	0
thymuses	0
.	0

We	0
observed	0
that	0
the	0
mRNA	0
levels	0
of	0
myc	1
family	2
genes	2
,	0
c-myc	1
and	0
max	1
,	0
were	0
markedly	0
reduced	0
in	0
MG	0
thymuses	0
.	0

These	0
results	0
indicate	0
that	0
c-myc	1
-mediated	0
signaling	0
is	0
abnormal	0
in	0
MG	0
thymuses	0
.	0

The	0
levels	0
of	0
molecules	0
whose	0
expressions	0
are	0
associated	0
with	0
myc	1
,	0
such	0
as	0
STAM	9
,	0
prothymosin-alpha	9
,	0
and	0
NFkappaB	9

Immunohistochemical	0
detection	0
of	0
interferon-gamma-producing	7
cells	8
in	0
dermatophytosis	0
.	0

Skin	0
lesions	0
of	0
dermatophytosis	0
are	0
thought	0
to	0
be	0
a	0
result	0
of	0
a	0
T	7
cell	8
-dependent	0
inflammatory	0
response	0
that	0
is	0
mediated	0
by	0
various	0
cytokines	9
.	0

We	0
examined	0
whether	0
IFN-gamma-positive	7
cells	8
(	0
as	0
expression	0
of	0
Th1	7
response	0
)	0
were	0
present	0
in	0
the	0
skin	0
lesions	0
of	0
dermatophytosis	0
in	0
situ	0
by	0
immunohistochemical	0
techniques	0
.	0

Mixtures	0
of	0
CD4-positive	7
T	8
cells	8
and	0
CD8-positive	7
T	8
cells	8
were	0
found	0
to	0
be	0
present	0
in	0
the	0
dermal	0
infiltrates	0
of	0
the	0
lesions	0
.	0

Considerable	0
numbers	0
of	0
CD1a-positive	7
cells	8
were	0
detected	0
in	0
the	0
upper	0
dermis	0
and	0
epidermis	0
.	0

A	0
marked	0
accumulation	0
of	0
CD68-positive	7
cells	8
was	0
found	0
in	0
the	0
upper	0
dermis	0
.	0

IFN-gamma-positive	7
cells	8
were	0
present	0
in	0
the	0
upper	0
dermis	0
of	0
the	0
lesions	0
.	0

The	0
pattern	0
of	0
IFN-gamma	9
staining	0
appeared	0
to	0
be	0
intracellular	0
in	0
mononuclear	7
lymphoid	8
cells	8
.	0

The	0
staining	0
was	0
considered	0
to	0
be	0
highly	0
specific	0
because	0
it	0
could	0
be	0
completely	0
blocked	0
by	0
preabsorption	0
with	0
recombinant	9
IFN-gamma	10
.	0

Our	0
data	0
support	0
the	0
hypothesis	0
that	0
the	0
skin	0
lesions	0
of	0
dermatophytosis	0
may	0
be	0
associated	0
with	0
a	0
Th1	7
response	0
.	0

Th1	7
response	0
,	0
which	0
is	0
characterized	0
by	0
IFN-gamma	9
release	0
,	0
is	0
thought	0
to	0
be	0
involved	0
in	0
the	0
host	0
defense	0
against	0
dermatophytes	0
and	0
to	0
reflect	0
cutaneous	0
reaction	0
in	0
dermatophytosis	0
.	0

Regulation	0
of	0
the	0
helix-loop-helix	9
proteins	10
,	0
E2A	9
and	0
Id3	9
,	0
by	0
the	0
Ras	9
-	0
ERK	9
MAPK	9
cascade	0
.	0

Activation	0
of	0
mitogen-activated	9
protein	10
kinase	10
(	0
MAPK	9
)	0
pathways	0
leads	0
to	0
cellular	0
differentiation	0
and/or	0
proliferation	0
in	0
a	0
wide	0
variety	0
of	0
cell	0
types	0
,	0
including	0
developing	7
thymocytes	8
.	0

The	0
basic	9
helix-loop-helix	10
(	10
bHLH	10
)	10
proteins	10
E12	9
and	0
E47	9
and	0
an	0
inhibitor	9
HLH	10
protein	10
,	0
Id3	9
,	0
play	0
key	0
roles	0
in	0
thymocyte	0
differentiation	0
.	0

We	0
show	0
here	0
that	0
E2A	9
DNA	0
binding	0
is	0
lowered	0
in	0
primary	7
immature	8
thymocytes	8
consequent	0
to	0
T	0
cell	0
receptor	0
(	0
TCR	0
)	0
-mediated	0
ligation	0
.	0

Whereas	0
expression	0
of	0
E2A	0
mRNA	0
and	0
protein	0
are	0
unaltered	0
,	0
Id3	3
transcripts	4
are	0
rapidly	0
induced	0
upon	0
signaling	0
from	0
the	0
TCR	9
.	0

Activation	0
of	0
Id3	0
transcription	0
is	0
regulated	0
in	0
a	0
dose-dependent	0
manner	0
by	0
the	0
extracellular	0
signal-regulated	0
kinase	0
(	0
ERK	9
)	0
MAPK	9
module	0
.	0

These	0
observations	0
directly	0
connect	0
the	0
ERK	9
MAPK	9
cascade	0
and	0
HLH	9
proteins	10
in	0
a	0
linear	0
pathway	0
.	0

Retinoic	0
acid	0
up-regulates	0
myeloid	0
ICAM-3	0
expression	0
and	0
function	0
in	0
a	0
cell-specific	0
fashion	0
--	0
evidence	0
for	0
retinoid	0
signaling	0
pathways	0
in	0
the	0
mast	7
cell	8
lineage	8
.	0

Investigation	0
of	0
mast	0
cell	0
responsiveness	0
toward	0
retinoic	0
acid	0
(	0
RA	0
)	0
revealed	0
selective	0
promotion	0
of	0
ICAM-3	9
expression	0
in	0
the	0
human	5
mast	6
cell	6
line	6
HMC-1	6
.	0

This	0
process	0
was	0
dose-	0
and	0
time-dependent	0
and	0
detectable	0
by	0
flow	0
cytometry	0
,	0
Western	0
blot	0
analysis	0
,	0
ELISA	0
,	0
and	0
Northern	0
blot	0
analysis	0
.	0

ICAM-3	9
modulation	0
was	0
found	0
to	0
be	0
cell-type	0
dependent	0
,	0
detectable	0
also	0
for	0
HL-60	5
cells	6
and	0
monocytes	7
but	0
not	0
U-937	5
and	0
only	0
weakly	0
for	0
KU812	5
cells	6
.	0

Terminally	7
differentiated	8
skin	8
mast	8
cells	8
also	0
failed	0
to	0
up-modulate	0
their	0
ICAM-3	9
,	0
suggesting	0
the	0
requirement	0
for	0
some	0
degree	0
of	0
immaturity	0
for	0
the	0
process	0
.	0

RA-mediated	0
effects	0
on	0
ICAM-1	9
expression	0
,	0
studied	0
in	0
parallel	0
,	0
were	0
clearly	0
distinct	0
from	0
those	0
on	0
ICAM-3	9
.	0

Investigation	0
of	0
retinoid	9
receptor	10
expression	0
,	0
known	0
to	0
mediate	0
intracellular	0
RA	0
signaling	0
,	0
revealed	0
presence	0
of	0
RAR	3
alpha	4
,	4
RAR	4
gamma	4
,	4
RXR	4
beta	4
,	4
and	4
RXR	4
gamma	4
transcripts	4
in	0
all	0
cell	0
lines	0
studied	0
,	0
and	0
HMC-1	5
cells	6
were	0
the	0
only	0
line	0
lacking	0
RXR	9
alpha	10
.	0

RAR	9
beta	10
,	0
not	0
expressed	0
at	0
baseline	0
,	0
was	0
induced	0
by	0
RA	0
in	0
a	0
fashion	0
obviously	0
correlating	0
with	0
ICAM-3	9
up-regulation	0
.	0

Increased	0
ICAM-3	9
expression	0
was	0
of	0
functional	0
significance	0
,	0
such	0
that	0
processes	0
stimulated	0
or	0
co-stimulated	0
via	0
ICAM-3	9
(	0
homotypic	0
aggregation	0
,	0
IL-8	0
secretion	0
)	0
were	0
clearly	0
enhanced	0
upon	0
RA	0
pretreatment	0
,	0
suggesting	0
that	0
RA	0
may	0
contribute	0
via	0
hitherto	0
unrecognized	0
pathways	0
to	0
immune	0
function	0
and	0
host	0
defense	0
.	0

CD28	9
and	0
T	7
cell	8
co-stimulation	0
.	0

Over	0
the	0
last	0
decade	0
the	0
concept	0
of	0
T	7
cell	8
co-stimulation	0
has	0
emerged	0
to	0
take	0
a	0
central	0
role	0
in	0
the	0
process	0
of	0
T	0
cell	0
activation	0
.	0

However	0
,	0
the	0
exact	0
definition	0
of	0
co-stimulation	0
is	0
still	0
unclear	0
.	0

In	0
this	0
review	0
,	0
we	0
re-examine	0
the	0
concept	0
of	0
co-stimulation	0
.	0

We	0
suggest	0
that	0
while	0
co-stimulation	0
is	0
important	0
,	0
there	0
is	0
little	0
evidence	0
to	0
link	0
co-stimulation	0
with	0
T	7
cell	8
anergy	0
.	0

We	0
then	0
suggest	0
a	0
framework	0
for	0
studying	0
co-stimulation	0
.	0

Focusing	0
on	0
recent	0
advances	0
in	0
our	0
understanding	0
of	0
CD28	9
,	0
we	0
discuss	0
four	0
areas	0
of	0
T	7
cell	8
activation	0
where	0
co-stimulation	0
may	0
play	0
a	0
role	0
.	0

Regulation	0
of	0
activator	9
protein-1	10
and	0
NF-kappa	9
B	10
in	0
CD8+	7
T	8
cells	8
exposed	0
to	0
peripheral	9
self-antigens	10
.	0

The	0
transcriptional	0
events	0
that	0
control	0
T	7
cell	8
tolerance	0
to	0
peripheral	9
self	10
Ags	10
are	0
still	0
unknown	0
.	0

In	0
this	0
study	0
,	0
we	0
analyzed	0
the	0
regulation	0
of	0
AP-1	9
-	0
and	0
NF-kappa	9
B	10
-mediated	0
transcription	0
during	0
in	0
vivo	0
induction	0
of	0
tolerance	0
to	0
a	0
self	9
Ag	10
expressed	0
exclusively	0
on	0
hepatocytes	7
.	0

Naive	7
CD8	8
(	8
+	8
)	8
Desire	8
(	8
Des	8
)	8
(	8
+	8
)	8
T	8
cells	8
isolated	0
from	0
the	0
Des	0
TCR-transgenic	0
mice	0
that	0
are	0
specific	0
for	0
the	0
H-2K	9
(	10
b	10
)	10
class	10
I	10
Ag	10
were	0
transferred	0
into	0
Alb-K	0
(	0
b	0
)	0
-transgenic	0
mice	0
that	0
express	0
the	0
H-2K	9
(	10
b	10
)	10
Ag	10
on	0
hepatocytes	7
only	0
.	0

Tolerance	0
develops	0
in	0
these	0
mice	0
.	0

We	0
found	0
that	0
the	0
self-reactive	7
CD8	8
(	8
+	8
)	8
Des	8
(	8
+	8
)	8
T	8
cells	8
were	0
transiently	0
activated	0
,	0
then	0
became	0
unresponsive	0
and	0
were	0
further	0
deleted	0
.	0

In	0
contrast	0
to	0
CD8	7
(	8
+	8
)	8
Des	8
(	8
+	8
)	8
T	8
cells	8
activated	0
in	0
vivo	0
with	0
APCs	0
,	0
which	0
express	0
high	0
AP-1	9
and	0
high	0
NF-kappa	9
B	10
transcriptional	0
activity	0
,	0
the	0
unresponsive	0
CD8	7
(	8
+	8
)	8
Des	8
(	8
+	8
)	8
T	8
cells	8
expressed	0
no	0
AP-1	9
and	0
only	0
weak	0
NF-kappa	9
B	10
transcriptional	0
activity	0
.	0

The	0
differences	0
in	0
NF-kappa	9
B	10
transcriptional	0
activity	0
correlated	0
with	0
the	0
generation	0
of	0
distinct	0
NF-kappa	9
B	10
complexes	10
.	0

Indeed	0
,	0
in	0
vivo	0
primed	7
T	8
cells	8
predominantly	0
express	0
p50/p50	9
and	10
p65/p50	10
dimers	10
,	0
whereas	0
these	0
p50-containing	9
complexes	10
are	0
barely	0
detectable	0
in	0
tolerant	7
T	8
cells	8
that	0
express	0
p65-	9
and	10
c-Rel-containing	10
complexes	10
.	0

These	0
observations	0
suggest	0
that	0
fine	0
regulation	0
of	0
NF-kappa	9
B	10
complex	10
formation	0
may	0
determine	0
T	7
cell	8
fate	0
.	0

Transcriptional	0
regulation	0
in	0
lymphocytes	7
.	0

Lymphocytes	7
have	0
been	0
used	0
to	0
investigate	0
many	0
cellular	0
processes	0
,	0
including	0
lineage	0
commitment	0
,	0
differentiation	0
,	0
proliferation	0
and	0
apoptosis	0
.	0

The	0
transcription	9
factors	10
that	0
mediate	0
these	0
processes	0
are	0
often	0
expressed	0
broadly	0
in	0
many	0
cell	0
types	0
.	0

The	0
emerging	0
theme	0
is	0
one	0
of	0
cell-type-specific	0
regulation	0
,	0
affecting	0
not	0
only	0
the	0
functional	0
activation	0
of	0
transcription	9
factors	10
but	0
also	0
their	0
access	0
to	0
appropriate	0
regions	0
of	0
DNA	0
.	0

Existence	0
of	0
retinoic	9
acid-receptor	10
-independent	0
retinoid	9
X-receptor	10
-dependent	0
pathway	0
in	0
myeloid	7
cell	8
function	0
.	0

We	0
previously	0
reported	0
that	0
ER-27191	0
(	0
4-	0
[	0
4	0
,	0
5	0
,	0
7	0
,	0
8	0
,	0
9	0
,	0
10-hexahydro-7	0
,	0
7	0
,	0
10	0
,	0
10-tetramethyl-1-	0
(	0
3-pyridylmethyl	0
)	0
anthra	0
[	0
1	0
,	0
2-b	0
]	0
pyrrol-3-yl	0
]	0
benzoic	0
acid	0
)	0
is	0
a	0
potent	0
antagonist	0
of	0
retinoic	9
acid	10
receptor	10
(	0
RAR	9
)	0
,	0
and	0
ER-35795	0
(	0
(	0
2E	0
,	0
4E	0
,	0
6E	0
)	0
-7-	0
[	0
1-	0
(	0
1-methylethyl	0
)	0
-8-chloro-1	0
,	0
2	0
,	0
3	0
,	0
4-tetrahydroquinolin-6-yl	0
]	0
-6-fluoro-3-methyl-2	0
,	0
4	0
,	0
6-nonatrienoic	0
acid	0
)	0
is	0
a	0
novel	0
retinoid	9
X	10
receptor	10
(	0
RXR	9
)	0
-specific	0
agonist	0
.	0

By	0
using	0
these	0
compounds	0
,	0
we	0
investigated	0
whether	0
distinct	0
RAR	9
-dependent	0
and	0
RXR	9
-dependent	0
pathways	0
operate	0
to	0
mediate	0
the	0
diverse	0
activities	0
of	0
retinoids	0
,	0
particularly	0
,	0
the	0
effects	0
of	0
the	0
RXR	9
pathway	0
on	0
cellular	0
function	0
.	0

ER-27191	0
completely	0
antagonized	0
HL60	5
cell	6
differentiation	0
induced	0
by	0
all-trans-retinoic	0
acid	0
(	0
atRA	0
)	0
.	0

However	0
,	0
the	0
differentiation	0
induced	0
by	0
the	0
ER-35795	0
was	0
not	0
antagonized	0
at	0
all	0
by	0
the	0
RAR	9
antagonist	0
,	0
but	0
was	0
inhibited	0
by	0
an	0
RXR	9
homodimer	10
antagonist	0
(	0
LGD100754	0
,	0
(	0
2E	0
,	0
4E	0
,	0
6Z	0
)	0
-7-	0
(	0
3-n-propoxy-5	0
,	0
6	0
,	0
7	0
,	0
8-tetrahydro-5	0
,	0
5	0
,	0
8	0
,	0
8-tetramethylnaphthalen-2-yl	0
)	0
-3-methylocta-2	0
,	0
4	0
,	0
6-trienoic	0
acid	0
)	0
.	0

Its	0
agonistic	0
action	0
on	0
RXR/RAR	9
heterodimer	10
,	0
on	0
the	0
other	0
hand	0
,	0
was	0
neutralized	0
by	0
the	0
RAR	9
antagonist	0
.	0

During	0
HL60	5
cell	6
differentiation	0
,	0
atRA	0
induced	0
RARbeta	3
mRNA	4
,	0
while	0
the	0
RXR	9
had	0
no	0
effect	0
.	0

Interestingly	0
,	0
a	0
functional	0
RXR	9
-pathway	0
was	0
also	0
seen	0
in	0
lipopolysaccharide-induced	0
inhibition	0
of	0
mouse	7
splenocyte	8
proliferation	0
.	0

These	0
results	0
strongly	0
suggest	0
the	0
existence	0
of	0
a	0
pharmacological	0
RXR	9
-dependent	0
pathway	0
that	0
is	0
activated	0
by	0
a	0
ligand	0
that	0
can	0
bind	0
to	0
RXR	9
.	0

Targeting	0
Src	9
homology	10
2	10
domain-containing	10
tyrosine	10
phosphatase	10
(	0
SHP-1	9
)	0
into	0
lipid	0
rafts	0
inhibits	0
CD3	9
-induced	0
T	7
cell	8
activation	0
.	0

To	0
study	0
the	0
mechanism	0
by	0
which	0
protein	9
tyrosine	10
phosphatases	10
(	0
PTPs	9
)	0
regulate	0
CD3	9
-induced	0
tyrosine	0
phosphorylation	0
,	0
we	0
investigated	0
the	0
distribution	0
of	0
PTPs	9
in	0
subdomains	0
of	0
plasma	0
membrane	0
.	0

We	0
report	0
here	0
that	0
the	0
bulk	0
PTP	9
activity	0
associated	0
with	0
T	7
cell	8
membrane	0
is	0
present	0
outside	0
the	0
lipid	0
rafts	0
,	0
as	0
determined	0
by	0
sucrose	0
density	0
gradient	0
sedimentation	0
.	0

In	0
Jurkat	5
T	6
cells	6
,	0
approximately	0
5	0
--	0
10	0
%	0
of	0
Src	9
homology	10
2	10
domain-containing	10
tyrosine	10
phosphatase	10
(	0
SHP-1	9
)	0
is	0
constitutively	0
associated	0
with	0
plasma	0
membrane	0
,	0
and	0
nearly	0
50	0
%	0
of	0
SHP-2	9
is	0
translocated	0
to	0
plasma	0
membrane	0
after	0
vanadate	0
treatment	0
.	0

Similar	0
to	0
transmembrane	9
PTP	10
,	0
CD45	9
,	0
the	0
membrane-associated	0
populations	0
of	0
SHP-1	9
and	0
SHP-2	9
are	0
essentially	0
excluded	0
from	0
lipid	0
rafts	0
,	0
where	0
other	0
signaling	9
molecules	10
such	0
as	0
Lck	9
,	10
linker	10
for	10
activation	10
of	10
T	10
cells	10
,	0
and	0
CD3	9
zeta	10
are	0
enriched	0
.	0

We	0
further	0
demonstrated	0
that	0
CD3	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
these	0
substrates	0
is	0
largely	0
restricted	0
to	0
lipid	0
rafts	0
,	0
unless	0
PTPs	9
are	0
inhibited	0
.	0

It	0
suggests	0
that	0
a	0
restricted	0
partition	0
of	0
PTPs	9
among	0
membrane	0
subdomains	0
may	0
regulate	0
protein	0
tyrosine	0
phosphorylation	0
in	0
T	7
cell	8
membrane	0
.	0

To	0
test	0
this	0
hypothesis	0
,	0
we	0
targeted	0
SHP-1	9
into	0
lipid	0
rafts	0
by	0
using	0
the	0
N-terminal	9
region	10
of	10
Lck	10
(	0
residues	9
1	10
--	10
14	10
)	0
.	0

The	0
results	0
indicate	0
that	0
the	0
expression	0
of	0
Lck/SHP-1	9
chimera	10
inside	0
lipid	0
rafts	0
profoundly	0
inhibits	0
CD3	9
-induced	0
tyrosine	0
phosphorylation	0
of	0
CD3	9
zeta/epsilon	10
,	0
IL-2	0
generation	0
,	0
and	0
nuclear	0
mobilization	0
of	0
NF-AT	9
.	0

Collectively	0
,	0
these	0
results	0
suggest	0
that	0
the	0
exclusion	0
of	0
PTPs	9
from	0
lipid	0
rafts	0
may	0
be	0
a	0
mechanism	0
that	0
potentiates	0
TCR	9
/	0
CD3	9
activation	0

An	0
instructive	0
component	0
in	0
T	7
helper	8
cell	8
type	8
2	8
(	0
Th2	7
)	0
development	0
mediated	0
by	0
GATA-3	9
.	0

Although	0
interleukin	9
(	10
IL	10
)	10
-12	10
and	0
IL-4	9
polarize	0
naive	7
CD4	8
(	8
+	8
)	8
T	8
cells	8
toward	0
T	0
helper	0
cell	0
type	0
1	0
(	0
Th1	0
)	0
or	0
Th2	0
phenotypes	0
,	0
it	0
is	0
not	0
known	0
whether	0
cytokines	9
instruct	0
the	0
developmental	0
fate	0
in	0
uncommitted	7
progenitors	8
or	0
select	0
for	0
outgrowth	0
of	0
cells	0
that	0
have	0
stochastically	0
committed	0
to	0
a	0
particular	0
fate	0
.	0

To	0
distinguish	0
these	0
instructive	0
and	0
selective	0
models	0
,	0
we	0
used	0
surface	0
affinity	0
matrix	0
technology	0
to	0
isolate	0
committed	7
progenitors	8
based	0
on	0
cytokine	0
secretion	0
phenotype	0
and	0
developed	0
retroviral-based	0
tagging	0
approaches	0
to	0
directly	0
monitor	0
individual	0
progenitor	0
fate	0
decisions	0
at	0
the	0
clonal	0
and	0
population	0
levels	0
.	0

We	0
observe	0
IL-4	9
-dependent	0
redirection	0
of	0
phenotype	0
in	0
cells	0
that	0
have	0
already	0
committed	0
to	0
a	0
non-IL-4-producing	0
fate	0
,	0
inconsistent	0
with	0
predictions	0
of	0
the	0
selective	0
model	0
.	0

Further	0
,	0
retroviral	0
tagging	0
of	0
naive	7
progenitors	8
with	0
the	0
Th2-specific	9
transcription	10
factor	10
GATA-3	10
provided	0
direct	0
evidence	0
for	0
instructive	0
differentiation	0
,	0
and	0
no	0
evidence	0
for	0
the	0
selective	0
outgrowth	0
of	0
cells	0
committed	0
to	0
either	0
the	0
Th1	0
or	0
Th2	0
fate	0
.	0

These	0
data	0
would	0
seem	0
to	0
exclude	0
selection	0
as	0
an	0
exclusive	0
mechanism	0
in	0
Th1	7
/	0
Th2	7
differentiation	0
,	0
and	0
support	0
an	0
instructive	0
model	0
of	0
cytokine-driven	0
transcriptional	0
programming	0
of	0
cell	0
fate	0
decisions	0
.	0

In	0
vitro-activated	0
human	7
lupus	8
T	8
cells	8
express	0
normal	0
estrogen	9
receptor	10
proteins	10
which	0
bind	0
to	0
the	0
estrogen	9
response	10
element	10
.	0

We	0
have	0
shown	0
that	0
estrogen	9
receptor	10
(	0
ERalpha	9
,	0
ERbeta	9
)	0
transcripts	0
are	0
expressed	0
in	0
SLE	7
and	8
normal	8
T	8
cells	8
.	0

In	0
this	0
study	0
,	0
T	0
cell	0
nuclear	0
extracts	0
from	0
female	0
lupus	0
patients	0
and	0
normal	0
donors	0
were	0
tested	0
for	0
biologically	0
active	0
ER	9
proteins	10
capable	0
of	0
binding	0
to	0
the	0
human	1
estrogen	2
response	2
element	2
(	0
hERE	1
)	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

When	0
peripheral	7
blood	8
T	8
cells	8
were	0
stimulated	0
with	0
17beta-estradiol	0
(	0
E2	0
)	0
,	0
PMA	0
and	0
ionomycin	0
,	0
two	0
major	0
retarded	0
bands	0
in	0
T	0
cell	0
nuclear	0
extracts	0
exhibited	0
a	0
migration	0
pattern	0
similar	0
to	0
slow	0
migrating	0
protein-ERE	9
complexes	10
in	0
human	0
breast	0
cancer	0
cell	0
extracts	0
.	0

T	7
cells	8
cultured	0
only	0
with	0
E2	0
did	0
not	0
have	0
these	0
complexes	0
.	0

The	0
formation	0
of	0
the	0
complexes	0
was	0
inhibited	0
by	0
competition	0
with	0
the	0
hERE	0
cold	0
oligonucleotide	0
and	0
partially	0
with	0
anti-ERalpha	9
antibodies	10
.	0

There	0
was	0
no	0
notable	0
difference	0
in	0
the	0
migration	0
pattern	0
of	0
ERE-binding	9
proteins	10
between	0
the	0
SLE	0
and	0
normal	0
T	0
cell	0
extracts	0
.	0

Together	0
,	0
these	0
results	0
suggest	0
that	0
activated	7
human	8
T	8
cells	8
,	0
whether	0
lupus-derived	0
or	0
normal-derived	0
,	0
contain	0
biologically	0
active	0
ERalpha	9
proteins	10
.	0

Other	0
factors	0
may	0
be	0
responsible	0
for	0
differential	0
sensitivity	0
of	0
lupus	7
T	8
cells	8
to	0
estrogen	0
.	0

Mechanism	0
of	0
the	0
inhibitory	0
effect	0
of	0
protease	0
inhibitor	0
on	0
tumor	9
necrosis	10
factor	10
alpha	10
production	0
of	0
monocytes	7
.	0

If	0
the	0
inflammatory	0
response	0
becomes	0
excessive	0
or	0
uncontrolled	0
by	0
some	0
stimuli	0
,	0
inappropriate	0
inflammatory	0
responses	0
occur	0
.	0

Monocytes	7
are	0
extremely	0
important	0
cells	0
for	0
regulating	0
the	0
cytokine	0
network	0
and	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNFalpha	9
)	0
and	0
interleukin-	9
(	10
IL	10
)	10
10	10
,	0
which	0
are	0
mainly	0
synthesized	0
by	0
monocytes	7
,	0
are	0
representative	0
cytokines	9
that	0
play	0
a	0
central	0
role	0
in	0
the	0
cytokine	0
network	0
.	0

Protease	0
inhibitors	0
such	0
as	0
gabexate	0
mesilate	0
(	0
GM	0
)	0
and	0
ulinastatin	0
(	0
UTI	0
)	0
have	0
been	0
shown	0
to	0
have	0
various	0
beneficial	0
effects	0
by	0
inhibiting	0
the	0
activation	0
of	0
leukocytes	7
,	0
but	0
the	0
mechanism	0
for	0
this	0
has	0
yet	0
to	0
be	0
fully	0
elucidated	0
.	0

In	0
this	0
study	0
we	0
investigated	0
the	0
mechanism	0
of	0
the	0
inhibitory	0
effect	0
of	0
protease	0
inhibitors	0
on	0
the	0
proinflammatory	0
cytokine	0
production	0
of	0
lipopolysaccharide-	0
(	0
LPS	0
)	0
stimulated	0
monocytes	7
.	0

LPS-stimulated	0
monocytes	7
were	0
treated	0
with	0
GM	0
or	0
UTI	0
.	0

The	0
value	0
of	0
TNFalpha	9
and	0
IL-10	9
in	0
the	0
culture	0
medium	0
of	0
monocytes	7
was	0
measured	0
and	0
each	0
mRNA	0
expression	0
was	0
assayed	0
.	0

The	0
inhibitory	0
effect	0
of	0
protease	0
inhibitors	0
on	0
the	0
activity	0
of	0
intracellular	0
signal	0
transduction	0
pathways	0
such	0
as	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
and	0
nuclear	9
factor	10
kappa	10
B	10
(	0
NFkappaB	9
)	0
were	0
also	0
evaluated	0
.	0

GM	0
decreased	0
the	0
TNFalpha	9
production	0
of	0
LPS-stimulated	0
monocytes	7
as	0
shown	0
by	0
the	0
inhibition	0
of	0
mRNA	0
expression	0
and	0
increased	0
the	0
IL-10	9
production	0
of	0
LPS-stimulated	0
monocytes	7
.	0

GM	0
also	0
suppressed	0
the	0
NFkappaB	9
activity	0
of	0
LPS-stimulated	0
monocytes	7
.	0

UTI	0
decreased	0
the	0
TNFalpha	9
production	0
of	0
LPS-stimulated	0
monocytes	7
,	0
but	0
did	0
not	0
inhibit	0
the	0
TNFalpha	3
mRNA	4
expression	0
.	0

The	0
present	0
study	0
shows	0
that	0
the	0
inhibitory	0
effect	0
of	0
GM	0
on	0
the	0
TNFalpha	9
production	0
of	0
activated	0
human	7
monocytes	8
is	0
mediated	0
by	0
the	0
suppression	0
of	0
NFkappaB	9
activation	0
,	0
while	0
the	0
mechanism	0
of	0
UTI	0
inhibiting	0
TNFalpha	9
production	0
of	0
human	7
monocytes	8
may	0
be	0
due	0
to	0
the	0
inhibition	0
of	0
either	0
the	0
translation	0
or	0
secretion	0
of	0
TNFalpha	9
.	0

Homocysteine	0
stimulates	0
the	0
expression	0
of	0
monocyte	9
chemoattractant	10
protein-1	10
in	0
endothelial	7
cells	8
leading	0
to	0
enhanced	0
monocyte	0
chemotaxis	0
.	0

Hyperhomocysteinemia	0
has	0
been	0
identified	0
as	0
an	0
independent	0
risk	0
factor	0
for	0
atherosclerosis	0
.	0

The	0
infiltration	0
of	0
monocytes	7
into	0
the	0
arterial	0
wall	0
is	0
one	0
of	0
the	0
key	0
events	0
during	0
atherogenesis	0
.	0

Monocyte	9
chemoattractant	10
protein-1	10
(	0
MCP-1	9
)	0
is	0
a	0
potent	0
chemokine	9
that	0
stimulates	0
the	0
migration	0
of	0
monocytes	7
into	0
the	0
intima	0
of	0
the	0
arterial	0
wall	0
.	0

The	0
mechanism	0
by	0
which	0
increased	0
monocyte	0
infiltration	0
occurs	0
in	0
atherosclerotic	0
lesions	0
in	0
patients	0
with	0
hyperhomocysteinemia	0
has	0
not	0
been	0
delineated	0
.	0

The	0
objective	0
of	0
the	0
present	0
study	0
was	0
to	0
investigate	0
the	0
effect	0
of	0
homocysteine	0
on	0
MCP-1	9
production	0
in	0
endothelial	7
cells	8
.	0

Cells	0
were	0
incubated	0
with	0
homocysteine	0
.	0

The	0
secretion	0
of	0
MCP-1	9
protein	10
was	0
significantly	0
increased	0
(	0
195	0
%	0
as	0
compared	0
to	0
the	0
control	0
)	0
in	0
cells	0
treated	0
with	0
pathological	0
concentrations	0
of	0
homocysteine	0
.	0

Such	0
effect	0
was	0
accompanied	0
by	0
an	0
increased	0
expression	0
of	0
MCP-1	3
mRNA	4
(	0
176	0
%	0
as	0
compared	0
to	0
the	0
control	0
)	0
in	0
endothelial	7
cells	8
which	0
resulted	0
in	0
enhanced	0
monocyte	0
chemotaxis	0
.	0

The	0
p38	9
MAP	10
kinase	10
as	0
well	0
as	0
other	0
members	0
of	0
the	0
p38	0
MAP	0
kinase	0
pathway	0
,	0
including	0
MKK3	9
,	0
MKK6	9
,	0
ATF-2	9
and	0
Elk-1	9
,	0
were	0
activated	0
in	0
homocysteine-treated	7
cells	8
.	0

Homocysteine-induced	0
MCP-1	9
expression	0
and	0
subsequent	0
monocyte	0
chemotaxis	0
were	0
blocked	0
by	0
a	0
p38	9
MAP	10
kinase	10
inhibitor	0
(	0
SB203580	0
)	0
suggesting	0
that	0
the	0
p38	9
MAP	10
kinase	10
pathway	0
might	0
be	0
involved	0
in	0
homocysteine-induced	0
MCP-1	9
expression	0
in	0
endothelial	7
cells	8
.	0

In	0
contrast	0
,	0
staurosporine	0
,	0
a	0
protein	9
kinase	10
C	10
inhibitor	0
,	0
had	0
no	0
effect	0
on	0
homocysteine-induced	0
MCP-1	9
expression	0
.	0

In	0
conclusion	0
,	0
our	0
results	0
indicate	0
that	0
homocysteine	0
stimulates	0
MCP-1	9
expression	0
in	0
endothelial	7
cells	8
leading	0
to	0
enhanced	0
monocyte	0
chemotaxis	0
.	0

Inducible	0
resistance	0
to	0
Fas-mediated	0
apoptosis	0
in	0
B	7
cells	8
.	0

Apoptosis	0
produced	0
in	0
B	7
cells	8
through	0
Fas	9
(	0
APO-1	9
,	0
CD95	9
)	0
triggering	0
is	0
regulated	0
by	0
signals	0
derived	0
from	0
other	0
surface	0
receptors	0
:	0
CD40	0
engagement	0
produces	0
upregulation	0
of	0
Fas	9
expression	0
and	0
marked	0
susceptibility	0
to	0
Fas	9
-induced	0
cell	0
death	0
,	0
whereas	0
antigen	0
receptor	0
engagement	0
,	0
or	0
IL-4R	0
engagement	0
,	0
inhibits	0
Fas	9
killing	0
and	0
in	0
so	0
doing	0
induces	0
a	0
state	0
of	0
Fas	9
-resistance	0
,	0
even	0
in	0
otherwise	0
sensitive	0
,	0
CD40	9
-stimulated	0
targets	0
.	0

Surface	9
immunoglobulin	10
and	0
IL-4R	9
utilize	0
at	0
least	0
partially	0
distinct	0
pathways	0
to	0
produce	0
Fas	9
-resistance	0
that	0
differentially	0
depend	0
on	0
PKC	9
and	0
STAT6	9
,	0
respectively	0
.	0

Further	0
,	0
surface	0
immunoglobulin	0
signaling	0
for	0
inducible	0
Fas	9
-resistance	0
bypasses	0
Btk	9
,	0
requires	0
NF-kappaB	9
,	0
and	0
entails	0
new	0
macromolecular	0
synthesis	0
.	0

Terminal	0
effectors	0
of	0
B	7
cell	8
Fas	9
-resistance	0
include	0
the	0
known	0
anti-apoptotic	9
gene	10
products	10
,	0
Bcl-xL	9
and	0
FLIP	9
,	0
and	0
a	0
novel	0
anti-apoptotic	1
gene	2
that	0
encodes	0
FAIM	9
(	0
Fas	9
Apoptosis	10
Inhibitory	10
Molecule	10
)	0
.	0

faim	9
was	0
identified	0
by	0
differential	0
display	0
and	0
exists	0
in	0
two	0
alternatively	0
spliced	0
forms	0
;	0
faim-S	9
is	0
broadly	0
expressed	0
,	0
but	0
faim-L	0
expression	0
is	0
tissue-specific	0
.	0

The	0
FAIM	1
sequence	2
is	0
highly	0
evolu-	0
tionarily	0
conserved	0
,	0
suggesting	0
an	0
important	0
role	0
for	0
this	0
molecule	0
throughout	0
phylogeny	0
.	0

Inducible	0
resistance	0
to	0
Fas	9
killing	0
is	0
hypothesized	0
to	0
protect	0
foreign	0
antigen-specific	0
B	7
cells	8
during	0
potentially	0
hazardous	0
interactions	0
with	0
FasL-bearing	7
T	8
cells	8
,	0
whereas	0
autoreactive	7
B	8
cells	8
fail	0
to	0
become	0
Fas	9
-resistant	0
and	0
are	0
deleted	0
via	0
Fas	9
-dependent	0
cytotoxicity	0
.	0

Inadvertent	0
or	0
aberrant	0
acquisition	0
of	0
Fas	9
-resistance	0
may	0
permit	0
autoreactive	7
B	8
cells	8
to	0
escape	0
Fas	9
deletion	0
,	0
and	0
malignant	7
lymphocytes	8
to	0
impede	0
anti-tumor	0
immunity	0
.	0

Stromal	9
cell-derived	10
factor	10
1	10
alpha	10
-induced	0
chemotaxis	0
in	0
T	7
cells	8
is	0
mediated	0
by	0
nitric	0
oxide	0
signaling	0
pathways	0
.	0

Stromal	9
cell-derived	10
factor	10
1	10
alpha	10
(	0
SDF1	9
alpha	10
)	0
and	0
its	0
cognate	0
chemokine	9
receptor	10
CXCR4	10
act	0
as	0
potent	0
chemoattractants	0
and	0
regulate	0
trafficking	0
and	0
homing	0
of	0
hematopoietic	7
progenitor	8
cells	8
and	0
lymphocytes	7
.	0

However	0
,	0
the	0
molecular	0
mechanisms	0
regulating	0
SDF1	9
alpha	10
-driven	0
cell	0
migration	0
are	0
not	0
well	0
defined	0
.	0

In	0
this	0
study	0
,	0
we	0
have	0
explored	0
the	0
roles	0
of	0
the	0
second	0
messenger	0
NO	0
and	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
in	0
SDF1	9
alpha	10
-induced	0
T	0
cell	0
migration	0
.	0

SDF1	9
alpha	10
treatment	0
of	0
Jurkat	5
T	6
cells	6
increased	0
the	0
activity	0
of	0
NO	9
synthase	10
,	0
which	0
catalyzes	0
the	0
generation	0
of	0
NO	0
.	0

We	0
observed	0
that	0
pretreatment	0
of	0
Jurkat	5
cells	6
or	0
activated	0
PBLs	7
with	0
several	0
NO	0
donors	0
significantly	0
enhanced	0
the	0
SDF1	9
alpha	10
-induced	0
migration	0
,	0
whereas	0
various	0
inhibitors	0
of	0
NO	9
synthase	10
markedly	0
abrogated	0
the	0
chemotactic	0
response	0
in	0
a	0
concentration-dependent	0
manner	0
.	0

Furthermore	0
,	0
we	0
observed	0
that	0
inhibitors	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
,	0
which	0
is	0
linked	0
to	0
NO	0
signaling	0
pathways	0
,	0
also	0
significantly	0
blocked	0
the	0
SDF1	9
alpha	10
-induced	0
chemotactic	0
response	0
.	0

However	0
,	0
these	0
compounds	0
did	0
not	0
have	0
a	0
significant	0
effect	0
on	0
SDF1	9
alpha	10
-induced	0
mitogen-activated	0
protein	0
kinase	0
activity	0
.	0

In	0
addition	0
,	0
the	0
MAP/Erk	0
kinase	0
kinase	0
inhibitor	0
PD98059	0
did	0
not	0
abrogate	0
SDF1	9
alpha	10
-induced	0
chemotaxis	0
.	0

AKT	9
,	0
which	0
has	0
been	0
shown	0
to	0
mediate	0
NO	0
production	0
,	0
was	0
also	0
phosphorylated	0
upon	0
SDF1	9
alpha	10
stimulation	0
.	0

These	0
studies	0
suggest	0
that	0
NO-related	0
signaling	0
pathways	0
may	0
mediate	0
SDF1	9
alpha	10
-induced	0
chemotaxis	0
,	0
but	0
not	0
mitogen-activated	9
protein	10
kinase	10
activation	0
.	0

The	0
lack	0
of	0
NF-kappa	0
B	0
transactivation	0
and	0
PKC	0
epsilon	0
expression	0
in	0
CD4	7
(	8
+	8
)	8
CD8	8
(	8
+	8
)	8
thymocytes	8
correlates	0
with	0
negative	0
selection	0
.	0

Deletion	0
of	0
autoreactive	7
thymocytes	8
at	0
the	0
DP	0
stage	0
is	0
the	0
basis	0
for	0
tolerance	0
to	0
thymus-expressed	9
self	10
antigens	10
.	0

In	0
this	0
study	0
we	0
investigated	0
whether	0
distinct	0
signalling	0
pathways	0
are	0
induced	0
in	0
DP	7
thymocytes	8
as	0
compared	0
to	0
mature	7
T	8
cells	8
upon	0
stimulation	0
with	0
antigen	0
.	0

Using	0
triple	0
transgenic	0
mice	0
expressing	0
a	0
TCR	1
transgene	2
,	0
dominant	9
negative	10
ras/Mek	10
proteins	10
and	0
a	0
reporter	1
gene	2
construct	2
with	0
AP-1	1
or	2
NF-kappa	2
B	2
binding	2
sites	2
,	0
we	0
showed	0
a	0
complete	0
lack	0
of	0
transcriptional	0
activity	0
of	0
NF-kappa	9
B	10
but	0
not	0
AP-1	9
in	0
DP	7
thymocytes	8
,	0
whereas	0
both	0
were	0
transcriptionally	0
active	0
in	0
mature	7
T	8
cells	8
after	0
antigenic	0
stimulation	0
.	0

Lack	0
of	0
NF-kappa	9
B	10
induction	0
correlated	0
with	0
increased	0
death	0
in	0
response	0
to	0
antigen	9
.	0

AP-1	9
induction	0
was	0
dependent	0
on	0
the	0
integrity	0
of	0
the	0
ras/Mek	0
pathway	0
indicating	0
that	0
this	0
pathway	0
was	0
activated	0
in	0
the	0
DP	7
thymocytes	8
.	0

In	0
contrast	0
,	0
we	0
found	0
a	0
complete	0
lack	0
of	0
constitutive	0
expression	0
of	0
the	0
epsilon	9
isoform	10
of	10
Protein	10
Kinase	10
C	10
(	0
PKC	9
)	0
in	0
DP	7
thymocytes	8
,	0
although	0
it	0
was	0
present	0
in	0
mature	7
thymocytes	8
and	0
peripheral	7
T	8
cells	8
.	0

Taken	0
together	0
the	0
results	0
suggest	0
that	0
the	0
lack	0
of	0
PKC	9
epsilon	10
in	0
DP	7
thymocytes	8
could	0
lead	0
to	0
the	0
absence	0
of	0
NF-kappa	9
B	10
activity	0
after	0
antigenic	0
stimulation	0
contributing	0
to	0
negative	0
selection	0
.	0

Cell	0
Death	0
and	0
Differentiation	0
(	0
2000	0
)	0
7	0
,	0
1253	0
-	0
1262	0
.	0

CD2	0
stimulation	0
leads	0
to	0
the	0
delayed	0
and	0
prolonged	0
activation	0
of	0
STAT1	9
in	0
T	7
cells	8
but	0
not	0
NK	7
cells	8
.	0

OBJECTIVE	0
:	0
T	7
lymphocytes	8
can	0
be	0
activated	0
by	0
soluble	0
factors	0
such	0
as	0
cytokines	9
or	0
through	0
direct	0
cell-cell	0
interactions	0
.	0

Although	0
cytokine	9
receptors	10
are	0
known	0
to	0
signal	0
through	0
STAT	9
family	10
transcription	10
factors	10
,	0
the	0
mechanisms	0
by	0
which	0
other	0
cell-surface	9
molecules	10
,	0
such	0
as	0
CD2	9
,	0
transduce	0
signals	0
is	0
unclear	0
.	0

The	0
goal	0
of	0
this	0
study	0
was	0
to	0
determine	0
whether	0
stimulation	0
of	0
T	7
cells	8
through	0
CD2	9
recapitulates	0
aspects	0
of	0
cytokine	9
-induced	0
T-cell	0
activation	0
by	0
use	0
of	0
STAT	9
transcription	10
factors	10
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
T	7
cells	8
were	0
treated	0
with	0
anti-CD2	9
antibodies	10
or	0
cells	0
bearing	0
the	0
natural	0
CD2	9
ligand	10
CD58	10
,	0
after	0
which	0
signaling	0
through	0
STAT	9
transcription	10
factors	10
was	0
assessed	0
.	0

RESULTS	0
:	0
Stimulation	0
of	0
CD2	9
on	0
primary	7
T	8
lymphocytes	8
leads	0
to	0
the	0
tyrosine	0
phosphorylation	0
,	0
nuclear	0
translocation	0
,	0
and	0
DNA	0
binding	0
of	0
STAT1	9
.	0

In	0
contrast	0
to	0
stimulation	0
by	0
cytokines	9
,	0
the	0
activation	0
of	0
STAT1	9
in	0
response	0
to	0
CD2	0
ligation	0
is	0
delayed	0
and	0
does	0
not	0
involve	0
Jak	9
kinases	10
.	0

Furthermore	0
,	0
while	0
STAT	0
phosphorylation	0
induced	0
by	0
cytokines	9
is	0
generally	0
transient	0
,	0
STAT1	0
phosphorylation	0
following	0
CD2	0
stimulation	0
persists	0
for	0
a	0
period	0
of	0
days	0
.	0

Transcription	0
of	0
key	0
target	0
genes	0
such	0
as	0
IRF1	1
and	0
c-fos	1
proceeds	0
with	0
delayed	0
kinetics	0
following	0
CD2	0
stimulation	0
,	0
suggesting	0
that	0
this	0
unique	0
pattern	0
of	0
STAT	0
activation	0
may	0
lead	0
to	0
a	0
distinct	0
cellular	0
response	0
following	0
CD2	0
ligation	0
.	0

This	0
pathway	0
appears	0
to	0
be	0
restricted	0
to	0
T	7
cells	8
,	0
as	0
stimulation	0
of	0
CD2	9
on	0
NK	7
cells	8
does	0
not	0
lead	0
to	0
STAT1	0
activation	0
.	0

CONCLUSION	0
:	0
Stimulation	0
of	0
T	7
cells	8
through	0
cell-surface	9
molecules	10
such	0
as	0
CD2	9
involves	0
activation	0
of	0
STAT	9
transcription	10
factors	10
,	0
thus	0
recapitulating	0
elements	0
of	0
cytokine	0
signaling	0
.	0

NFATc1	9
and	0
NFATc2	9
together	0
control	0
both	0
T	0
and	0
B	0
cell	0
activation	0
and	0
differentiation	0
.	0

NFAT	9
transcription	10
factors	10
play	0
critical	0
roles	0
in	0
gene	0
transcription	0
during	0
immune	0
responses	0
.	0

To	0
investigate	0
further	0
the	0
two	0
most	0
prominent	0
NFAT	9
family	10
members	10
,	0
NFATc1	9
and	0
NFATc2	9
,	0
we	0
generated	0
mice	0
bearing	0
lymphoid	0
systems	0
devoid	0
of	0
both	0
.	0

Doubly	0
deficient	0
T	7
cells	8
displayed	0
cell	0
surface	0
markers	0
of	0
activation	0
yet	0
were	0
significantly	0
deficient	0
in	0
the	0
development	0
of	0
multiple	0
effector	0
functions	0
,	0
including	0
Th	9
cytokine	10
production	0
,	0
surface	9
effector	10
molecule	10
expression	0
,	0
and	0
cytolytic	0
activity	0
.	0

Nevertheless	0
,	0
doubly	7
deficient	8
B	8
cells	8
were	0
hyperactivated	0
,	0
as	0
evidenced	0
by	0
extremely	0
elevated	0
serum	0
IgG1	9
and	0
IgE	9
,	0
as	0
well	0
as	0
plasma	7
cell	8
expansion	0
and	0
infiltration	0
of	0
end	0
organs	0
.	0

Thus	0
,	0
in	0
T	7
cells	8
,	0
NFATc1	9
and	0
NFATc2	9
are	0
dispensable	0
for	0
inflammatory	0
reactivity	0
but	0
are	0
required	0
for	0
effector	0
differentiation	0
,	0
while	0
in	0
B	7
cells	8
,	0
NFATs	9
regulate	0
both	0
normal	0
homeostasis	0
and	0
differentiation	0
.	0

Epstein-barr	0
virus	0
immediate-early	9
protein	10
BZLF1	10
is	0
SUMO-1	0
modified	0
and	0
disrupts	0
promyelocytic	0
leukemia	0
bodies	0
.	0

Although	0
the	0
immediate-early	9
proteins	10
of	0
both	0
herpes	0
simplex	0
virus	0
(	0
HSV	0
)	0
and	0
cytomegalovirus	0
(	0
CMV	0
)	0
are	0
known	0
to	0
modify	0
promyelocytic	0
leukemia	0
(	0
PML	0
)	0
(	0
ND10	0
)	0
bodies	0
in	0
the	0
nucleus	0
of	0
the	0
host	0
cell	0
,	0
it	0
has	0
been	0
unclear	0
whether	0
lytic	0
infection	0
with	0
gamma	0
herpesviruses	0
induces	0
a	0
similar	0
effect	0
.	0

The	0
PML	9
protein	10
is	0
induced	0
by	0
interferon	9
,	0
involved	0
in	0
major	9
histocompatibility	10
complex	10
class	10
I	10
presentation	0
,	0
and	0
necessary	0
for	0
certain	0
types	0
of	0
apoptosis	0
.	0

Therefore	0
,	0
it	0
is	0
likely	0
that	0
PML	0
bodies	0
function	0
in	0
an	0
antiviral	0
capacity	0
.	0

SUMO-1	0
modification	0
of	0
PML	9
is	0
known	0
to	0
be	0
required	0
for	0
the	0
formation	0
of	0
PML	0
bodies	0
.	0

To	0
examine	0
whether	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
lytic	0
replication	0
interferes	0
with	0
PML	0
bodies	0
,	0
we	0
expressed	0
the	0
EBV	1
immediate-early	2
genes	2
BZLF1	1
(	2
Z	2
)	2
and	0
BRLF1	1
(	2
R	2
)	2
in	0
EBV-positive	5
cell	6
lines	6
and	0
examined	0
PML	9
localization	0
.	0

Both	0
Z	0
and	0
R	0
expression	0
resulted	0
in	0
PML	9
dispersion	0
in	0
EBV-positive	7
cells	8
.	0

Z	0
but	0
not	0
R	0
expression	0
is	0
sufficient	0
to	0
disrupt	0
PML	0
bodies	0
in	0
EBV-negative	5
cell	6
lines	6
.	0

We	0
show	0
that	0
dispersion	0
of	0
PML	0
bodies	0
by	0
Z	1
requires	0
a	0
portion	0
of	0
the	0
transcriptional	1
activation	2
domain	2
of	0
Z	1
but	0
not	0
the	0
DNA-binding	0
function	0
.	0

As	0
was	0
previously	0
reported	0
for	0
the	0
HSV-1	9
ICP0	10
and	10
CMV	10
IE1	10
proteins	10
,	0
Z	1
reduces	0
the	0
amount	0
of	0
SUMO-1-modified	9
PML	10
.	0

We	0
also	0
found	0
that	0
Z	1
itself	0
is	0
SUMO-1	0
modified	0
(	0
through	0
amino	0
acid	0
12	0
)	0
and	0
that	0
Z	1
competes	0
with	0
PML	9
for	0
limiting	0
amounts	0
of	0
SUMO-1	9
.	0

These	0
results	0
suggest	0
that	0
disruption	0
of	0
PML	0
bodies	0
is	0
important	0
for	0
efficient	0
lytic	0
replication	0
of	0
EBV	0
.	0

Furthermore	0
,	0
Z	1
may	0
potentially	0
alter	0
the	0
function	0
of	0
a	0
variety	0
of	0
cellular	0
proteins	0
by	0
inhibiting	0
SUMO-1	0
modification	0

Suppression	0
of	0
nuclear	9
factor-kappaB	10
and	0
stimulation	0
of	0
inhibitor	9
kappaB	10
by	0
troglitazone	0
:	0
evidence	0
for	0
an	0
anti-inflammatory	0
effect	0
and	0
a	0
potential	0
antiatherosclerotic	0
effect	0
in	0
the	0
obese	0
.	0

To	0
elucidate	0
whether	0
troglitazone	0
exerts	0
an	0
antiinflammatory	0
effect	0
in	0
humans	0
,	0
in	0
vivo	0
,	0
we	0
investigated	0
the	0
suppression	0
of	0
nuclear	9
factor	10
kappaB	10
(	0
NFkappaB	9
)	0
in	0
mononuclear	7
cells	8
(	8
MNC	8
)	8
by	0
this	0
drug	0
.	0

We	0
measured	0
intranuclear	9
NFkappaB	10
,	0
total	0
cellular	9
NFkappaB	10
,	0
inhibitor	9
kappaB	10
(	10
IkappaB	10
)	10
alpha	10
,	0
reactive	0
oxygen	0
species	0
(	0
ROS	0
)	0
generation	0
,	0
and	0
p47	9
(	10
phox	10
)	10
subunit	10
(	0
a	0
key	0
component	0
protein	0
of	0
nicotinamide	9
adenine	10
dinucleotide	10
phosphate	10
oxidase	10
)	0
in	0
MNC	7
.	0

Plasma	9
tumor	10
necrosis	10
factor	10
(	10
TNF	10
)	10
-alpha	10
,	0
soluble	9
intercellular	10
adhesion	10
molecule-1	10
(	0
sICAM-1	9
)	0
,	0
monocyte	9
chemoattractant	10
protein-1	10
(	10
MCP-1	10
)	10
,	0
plasminogen	9
activator	10
inhibitor	10
type	10
1	10
(	0
PAI-1	9
)	0
,	0
C-reactive	9
protein	10
(	10
CRP	10
)	10
,	0
and	0
interleukin	9
(	10
IL	10
)	10
-10	10
(	0
antiinflammatory	9
cytokine	10
)	0
concentrations	0
were	0
also	0
measured	0
as	0
mediators	0
of	0
inflammatory	0
activity	0
that	0
are	0
regulated	0
by	0
the	0
proinflammatory	9
transcription	10
factor	10
NFkappaB	10
.	0

Seven	0
nondiabetic	0
obese	0
patients	0
were	0
given	0
400	0
mg	0
troglitazone	0
daily	0
for	0
4	0
weeks	0
.	0

Blood	0
samples	0
were	0
collected	0
before	0
and	0
at	0
weekly	0
intervals	0
thereafter	0
.	0

MNC	7
were	0
separated	0
;	0
and	0
the	0
levels	0
of	0
intranuclear	9
NFkappaB	10
,	0
total	0
cellular	9
NFkappaB	10
,	0
IkappaBalpha	9
,	0
and	0
p47	9
(	10
phox	10
)	10
subunit	10
and	0
ROS	0
generation	0
were	0
determined	0
.	0

Plasma	0
was	0
used	0
to	0
measure	0
insulin	0
glucose	0
,	0
TNFalpha	9
,	0
sICAM	9
,	0
MCP-1	9
,	0
PAI-1	9
,	0
CRP	9
,	0
and	0
IL-10	9
.	0

Plasma	0
insulin	0
concentrations	0
fell	0
significantly	0
at	0
week	0
1	0
,	0
from	0
31.2	0
+/-	0
29.1	0
to	0
14.2	0
+/-	0
11.4	0
mU/L	0
(	0
P	0
<	0
0.01	0
)	0
and	0
remained	0
low	0
throughout	0
4	0
weeks	0
.	0

Plasma	0
glucose	0
concentrations	0
did	0
not	0
alter	0
significantly	0
.	0

There	0
was	0
a	0
fall	0
in	0
intranuclear	9
NFkappaB	10
,	0
total	0
cellular	9
NFkappaB	10
,	0
and	0
p47	9
(	10
phox	10
)	10
subunit	10
,	0
with	0
an	0
increase	0
in	0
cellular	0
IkappaBalpha	9
at	0
week	0
2	0
,	0
which	0
persisted	0
until	0
week	0
4	0
.	0

There	0
was	0
a	0
parallel	0
fall	0
in	0
ROS	0
generation	0
by	0
MNC	7
at	0
week	0
1	0
;	0
this	0
progressed	0
and	0
persisted	0
until	0
week	0
4	0
(	0
P	0
<	0
0.001	0
)	0
.	0

Plasma	0
TNF-alpha	9
,	0
sICAM-1	9
,	0
MCP-1	9
,	0
and	0
PAI-1	9
concentrations	0
fell	0
significantly	0
at	0
week	0
4	0
.	0

Plasma	0
IL-10	9
concentration	0
increased	0
significantly	0
,	0
whereas	0
plasma	9
CRP	10
concentrations	0
decreased	0
.	0

We	0
conclude	0
that	0
troglitazone	0
has	0
an	0
antiinflammatory	0
action	0
that	0
may	0
contribute	0
to	0
its	0
putative	0
antiatherosclerotic	0
effects	0
.	0

Tyrosine	0
phosphorylation-dependent	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Requirement	0
for	0
p56	9
LCK	10
and	10
ZAP-70	10
protein	10
tyrosine	10
kinases	10
.	0

Phosphorylation	0
of	0
the	0
N-terminal	9
domain	10
of	0
I	9
kappa	10
B	10
inhibitory	10
subunits	10
induces	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappa	10
B	10
.	0

Although	0
serine	0
phosphorylation	0
has	0
been	0
shown	0
to	0
induce	0
ubiquitination	0
and	0
subsequent	0
proteasome-mediated	0
degradation	0
of	0
I	9
kappa	10
B-alpha	10
,	0
little	0
is	0
known	0
about	0
the	0
mechanisms	0
that	0
lead	0
to	0
release	0
of	0
active	0
NF-kappa	9
B	10
in	0
T	7
cells	8
as	0
a	0
consequence	0
of	0
tyrosine	0
phosphorylation	0
of	0
I	9
kappa	10
B-alpha	10
[	0
Imbert	0
,	0
V.	0
,	0
Rupec	0
,	0
R.A.	0
,	0
Livolsi	0
,	0
A.	0
,	0
Pahl	0
,	0
H.L.	0
,	0
Traenckner	0
,	0
B.M.	0
,	0
Mueller-Dieckmann	0
,	0
C.	0
,	0
Farahifar	0
,	0
D.	0
,	0
Rossi	0
,	0
B.	0
,	0
Auberger	0
,	0
P.	0
,	0
Baeuerle	0
,	0
P.	0
&	0
Peyron	0
,	0
J.F.	0
(	0
1996	0
)	0
Cell	0
86	0
,	0
787	0
--	0
798	0
]	0
.	0

The	0
involvement	0
of	0
the	0
tyrosine	9
kinases	10
p56	9
(	10
lck	10
)	10
and	0
ZAP-70	9
in	0
this	0
reaction	0
is	0
demonstrated	0
here	0
using	0
specific	0
pharmacological	0
inhibitors	0
and	0
Jurkat	5
mutants	6
unable	0
to	0
express	0
these	0
kinases	9
.	0

Although	0
the	0
inhibitors	0
prevented	0
both	0
pervanadate-induced	0
phosphorylation	0
of	0
I	9
kappa	10
B-alpha	10
on	0
Tyr42	0
and	0
NF-kappa	9
B	10
activation	0
,	0
we	0
observed	0
that	0
,	0
in	0
p56	5
(	6
lck	6
)	6
-deficient	6
Jurkat	6
mutants	6
,	0
NF-kappa	9
B	10
could	0
still	0
associate	0
with	0
I	9
kappa	10
B-alpha	10
despite	0
phosphorylation	0
on	0
Tyr42	0
.	0

Furthermore	0
,	0
the	0
SH2	9
domain	10
of	0
p56	9
(	10
lck	10
)	10
appeared	0
to	0
be	0
required	0
for	0
pervanadate-induced	0
NF-kappa	9
B	10
activation	0
but	0
not	0
for	0
Tyr42	0
phosphorylation	0
.	0

These	0
results	0
show	0
that	0
p56	9
(	10
lck	10
)	10
and	0
ZAP-70	9
are	0
key	0
components	0
of	0
the	0
signaling	0
pathway	0
that	0
leads	0
to	0
phosphotyrosine-dependent	0
NF-kappa	9
B	10
activation	0
in	0
T	7
cells	8
and	0
confirm	0
that	0
tyrosine	9
kinases	10
must	0
control	0
at	0
least	0
two	0
different	0
steps	0
to	0
induce	0
activation	0
of	0
NF-kappa	9
B	10
.	0

Finally	0
,	0
we	0
show	0
that	0
H	0
(	0
2	0
)	0
O	0
(	0
2	0
)	0
,	0
which	0
stimulates	0
p56	9
(	10
lck	10
)	10
and	0
ZAP-70	9
in	0
T	7
cells	8
,	0
is	0
an	0
activator	0
of	0
NF-kappa	9
B	10
through	0
tyrosine	0
phosphorylation	0
of	0
I	9
kappa	10
B-alpha	10
.	0

Specific	0
missense	0
mutations	0
in	0
NEMO	1
result	0
in	0
hyper-IgM	0
syndrome	0
with	0
hypohydrotic	0
ectodermal	0
dysplasia	0
.	0

The	0
gene	0
that	0
encodes	0
nuclear	1
factor	2
kappaB	2
(	2
NF-kappaB	2
)	2
essential	2
modulator	2
(	0
or	0
NEMO	1
,	0
also	0
known	0
as	0
IKKgamma	1
)	0
is	0
required	0
for	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	10
.	0

We	0
describe	0
mutations	0
in	0
the	0
putative	9
zinc-finger	10
domain	10
of	0
NEMO	9
that	0
result	0
in	0
an	0
X-linked	0
primary	0
immunodeficiency	0
characterized	0
by	0
hyper-IgM	0
syndrome	0
and	0
hypohydrotic	0
ectodermal	0
dysplasia	0
(	0
XHM-ED	0
)	0
.	0

These	0
mutations	0
prevent	0
CD40	9
ligand	10
(	0
CD40L	9
)	0
-mediated	0
degradation	0
of	0
inhibitor	0
of	0
NF-kappaB	9
alpha	10
(	0
IkappaB-alpha	9
)	0
and	0
account	0
for	0
the	0
following	0
observations	0
:	0
B	7
cells	8
from	0
XHM-ED	0
patients	0
are	0
unable	0
to	0
undergo	0
immunoglobulin	0
class-switch	0
recombination	0
and	0
antigen-presenting	7
cells	8
(	0
APCs	7
)	0
are	0
unable	0
to	0
synthesize	0
the	0
NF-kappaB-regulated	9
cytokines	10
interleukin	9
12	10
(	0
IL-12	9
)	0
or	0
tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
when	0
stimulated	0
with	0
CD40L	9
.	0

Nevertheless	0
,	0
innate	0
immunity	0
is	0
preserved	0
in	0
XHM-ED	0
patients	0
because	0
APCs	7
retain	0
the	0
capacity	0
to	0
respond	0
to	0
stimulation	0
by	0
lipopolysaccharide	0
or	0
Staphylococcus	9
aureus	10
Cowan	10
's	10
antigen	10
(	0
SAC	9
)	0
.	0

Overall	0
,	0
the	0
phenotype	0
observed	0
in	0
XHM-ED	0
patients	0
shows	0
that	0
the	0
putative	9
zinc-finger	10
domain	10
of	0
NEMO	9
has	0
a	0
regulatory	0
function	0
and	0
demonstrates	0
the	0
definite	0
requirement	0
of	0
CD40	9
-mediated	0
NF-kappaB	0
activation	0
for	0
B	7
cell	8
immunoglobulin	0
class-switching	0
.	0

Granulocytic	0
differentiation	0
of	0
human	7
NB4	8
promyelocytic	8
leukemia	8
cells	8
induced	0
by	0
all-trans	0
retinoic	0
acid	0
metabolites	0
.	0

The	0
metabolism	0
of	0
all-trans	0
retinoic	0
acid	0
(	0
ATRA	0
)	0
has	0
been	0
reported	0
to	0
be	0
partly	0
responsible	0
for	0
the	0
in	0
vivo	0
resistance	0
to	0
ATRA	0
seen	0
in	0
the	0
treatment	0
of	0
human	0
acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
.	0

However	0
,	0
ATRA	0
metabolism	0
appears	0
to	0
be	0
involved	0
in	0
the	0
growth	0
inhibition	0
of	0
several	0
cancer	5
cell	6
lines	6
in	0
vitro	0
.	0

The	0
purpose	0
of	0
this	0
study	0
was	0
to	0
evaluate	0
the	0
in	0
vitro	0
activity	0
of	0
the	0
principal	0
metabolites	0
of	0
ATRA	0
[	0
4-hydroxy-retinoic	0
acid	0
(	0
4-OH-RA	0
)	0
,	0
18-hydroxy-retinoic	0
acid	0
(	0
18-OH-RA	0
)	0
,	0
4-oxo-retinoic	0
acid	0
(	0
4-oxo-RA	0
)	0
,	0
and	0
5	0
,	0
6-epoxy-retinoic	0
acid	0
(	0
5	0
,	0
6-epoxy-RA	0
)	0
]	0
in	0
NB4	5
,	6
a	6
human	6
promyelocytic	6
leukemia	6
cell	6
line	6
that	0
exhibits	0
the	0
APL	0
diagnostic	0
t	0
(	0
15	0
;	0
17	0
)	0
chromosomal	0
translocation	0
and	0
expresses	0
the	0
PML-RAR	9
alpha	10
fusion	10
protein	10
.	0

We	0
established	0
that	0
the	0
four	0
ATRA	0
metabolites	0
were	0
indeed	0
formed	0
by	0
the	0
NB4	5
cells	6
in	0
vitro	0
.	0

NB4	0
cell	0
growth	0
was	0
inhibited	0
(	0
69-78	0
%	0
at	0
120	0
h	0
)	0
and	0
cell	0
cycle	0
progression	0
in	0
the	0
G1	0
phase	0
(	0
82-85	0
%	0
at	0
120	0
h	0
)	0
was	0
blocked	0
by	0
ATRA	0
and	0
all	0
of	0
the	0
metabolites	0
at	0
1	0
microM	0
concentration	0
.	0

ATRA	0
and	0
its	0
metabolites	0
could	0
induce	0
NB4	5
cells	6
differentiation	0
with	0
similar	0
activity	0
,	0
as	0
evaluated	0
by	0
cell	0
morphology	0
,	0
by	0
the	0
nitroblue	0
tetrazolium	0
reduction	0
test	0
(	0
82-88	0
%	0
at	0
120	0
h	0
)	0
or	0
by	0
the	0
expression	0
of	0
the	0
maturation	9
specific	10
cell	10
surface	10
marker	10
CD11c	10
.	0

In	0
addition	0
,	0
nuclear	0
body	0
reorganization	0
to	0
macropunctated	0
structures	0
,	0
as	0
well	0
as	0
the	0
degradation	0
of	0
PML-RAR	9
alpha	10
,	0
was	0
found	0
to	0
be	0
similar	0
for	0
ATRA	0
and	0
all	0
of	0
its	0
metabolites	0
.	0

Comparison	0
of	0
the	0
relative	0
potency	0
of	0
the	0
retinoids	0
using	0
the	0
nitroblue	0
tetrazolium	0
reduction	0
test	0
showed	0
effective	0
concentrations	0
required	0
to	0
differentiate	0
50	0
%	0
of	0
cells	0
in	0
72	0
h	0
as	0
follows	0
:	0
ATRA	0
,	0
15.8	0
+/-	0
1.7	0
nM	0
;	0
4-oxo-RA	0
,	0
38.3	0
+/-	0
1.3	0
nM	0
;	0
18-OH-RA	0
,	0
55.5	0
+/-	0
1.8	0
nM	0
;	0
4-OH-RA	0
,	0
79.8	0
+/-	0
1.8	0
nM	0
;	0
and	0
5	0
,	0
6-epoxy-RA	0
,	0
99.5	0
+/-	0
1.5	0
nM	0
.	0

The	0
ATRA	0
metabolites	0
were	0
found	0
to	0
exert	0
their	0
differentiation	0
effects	0
via	0
the	0
RAR	9
alpha	10
nuclear	10
receptors	10
,	0
because	0
the	0
RAR	0
alpha-specific	0
antagonist	0
BMS614	0
blocked	0
metabolite-induced	0
CD11c	0
expression	0
in	0
NB4	5
cells	6
.	0

These	0
data	0
demonstrate	0
that	0
the	0
principal	0
ATRA	0
Phase	0
1	0
metabolites	0
can	0
elicit	0
leukemia	7
cell	8
growth	0
inhibition	0
and	0
differentiation	0
in	0
vitro	0
through	0
the	0
RAR	0
alpha	0
signaling	0
pathway	0
,	0
and	0
they	0
suggest	0
that	0
these	0
metabolites	0
may	0
play	0
a	0
role	0
in	0
ATRA	0
antileukemic	0
activity	0
in	0
vivo	0
.	0

Expression	0
of	0
oestrogen	9
and	10
progesterone	10
receptors	10
by	0
mast	7
cells	8
alone	0
,	0
but	0
not	0
lymphocytes	7
,	0
macrophages	7
or	0
other	0
immune	7
cells	8
in	0
human	0
upper	0
airways	0
.	0

BACKGROUND	0
:	0
Nasal	0
polyposis	0
often	0
coexists	0
with	0
asthma	0
in	0
airway	0
inflammatory	0
conditions	0
characterised	0
by	0
the	0
infiltration	0
of	0
a	0
range	0
of	0
immune	7
cells	8
.	0

A	0
potentially	0
important	0
role	0
for	0
ovarian	0
hormones	0
has	0
been	0
implicated	0
in	0
airway	0
inflammation	0
but	0
the	0
cellular	0
target	0
for	0
such	0
action	0
is	0
not	0
known	0
.	0

METHODS	0
:	0
Expression	0
of	0
oestrogen	9
receptors	10
(	0
ER	9
)	0
and	0
progesterone	9
receptors	10
(	0
PR	9
)	0
was	0
examined	0
using	0
immunohistochemistry	0
in	0
formalin	0
fixed	0
nasal	0
polyp	0
tissues	0
from	0
47	0
subjects	0
.	0

The	0
cells	0
positive	0
for	0
ER	9
or	0
PR	9
were	0
confirmed	0
by	0
spatial	0
location	0
,	0
dual	0
immunolabelling	0
,	0
and	0
histochemical	0
staining	0
.	0

RESULTS	0
:	0
Consistent	0
with	0
the	0
known	0
features	0
of	0
nasal	0
polyps	0
,	0
CD4+	7
(	8
T	8
helper/inducer	8
)	8
,	0
CD8+	7
(	8
cytotoxic/suppressor	8
)	8
,	0
CD68+	7
(	0
macrophages	7
)	0
,	0
mast	7
cells	8
,	0
eosinophils	7
and	0
neutrophils	7
were	0
all	0
clearly	0
detected	0
by	0
their	0
relevant	0
monoclonal	9
antibodies	10
or	0
appropriate	0
histochemical	0
staining	0
,	0
but	0
only	0
mast	7
cells	8
tested	0
positive	0
for	0
ER	9
/PR	0
labelling	0
with	0
their	0
polyclonal	9
and	10
monoclonal	10
antibodies	10
.	0

The	0
frequencies	0
for	0
expression	0
were	0
61.7	0
%	0
for	0
ER	7
positive	8
and	0
59.6	0
%	0
for	0
PR	7
positive	8
cells	8
.	0

The	0
expression	0
of	0
ER	9
/	0
PR	9
was	0
independent	0
of	0
patient	0
sex	0
and	0
age	0
but	0
was	0
highly	0
correlated	0
with	0
the	0
numbers	0
of	0
mast	7
cells	8
(	0
r	0
=	0
0.973	0
,	0
p	0
<	0
0.001	0
for	0
ER	9
;	0
r	0
=	0
0.955	0
,	0
p	0
<	0
0.001	0
for	0
PR	9
)	0
.	0

Fewer	0
than	0
5	0
%	0
of	0
mast	7
cells	8
were	0
found	0
to	0
be	0
negative	0
for	0
ER	9
/	0
PR	9
expression	0
.	0

CONCLUSIONS	0
:	0
Mast	7
cells	8
alone	0
,	0
but	0
not	0
lymphocytes	7
,	0
macrophages	7
,	0
or	0
other	0
immune	7
cells	8
,	0
express	0
ER	9
/	0
PR	9
in	0
human	0
upper	0
airways	0
.	0

Numerous	0
ER/PR	7
positive	8
mast	8
cells	8
exist	0
in	0
nasal	0
polyps	0
,	0
indicating	0
that	0
this	0
may	0
be	0
a	0
major	0
route	0
for	0
the	0
involvement	0
of	0
sex	0
hormones	0
in	0
airway	0
inflammation	0
when	0
exposed	0
to	0
the	0
higher	0
and	0
varying	0
concentration	0
of	0
oestrogen	0
and	0
progesterone	0
characteristic	0
of	0
females	0
.	0

NF	0
kappa	0
b	0
signaling	0
in	0
posthypoxic	7
endothelial	8
cells	8
:	0
relevance	0
to	0
E-selectin	0
expression	0
and	0
neutrophil	0
adhesion	0
.	0

Our	0
previous	0
studies	0
have	0
implicated	0
the	0
nuclear	0
transcription	0
factor	0
kappa	0
B	0
(	0
NF	9
kappa	10
B	10
)	0
in	0
the	0
regulation	0
of	0
adhesion	9
molecule	10
expression	0
in	0
endothelial	7
cells	8
exposed	0
to	0
anoxia-reoxygenation	0
(	0
A/R	0
)	0
or	0
a	0
redox	0
imbalance	0
.	0

The	0
objectives	0
of	0
this	0
study	0
were	0
(	0
1	0
)	0
to	0
define	0
the	0
kinetics	0
of	0
NF	9
kappa	10
B	10
activation	0
by	0
examining	0
I	0
kappa	0
B	0
alpha	0
degradation	0
and	0
the	0
nuclear	0
translocation	0
of	0
p65	9
in	0
response	0
to	0
A/R	0
or	0
redox	0
imbalance	0
(	0
induced	0
by	0
treatment	0
of	0
cells	0
with	0
diamide	0
and	0
buthionine	0
sulfoximine	0
)	0
and	0
(	0
2	0
)	0
to	0
determine	0
whether	0
the	0
signal	0
for	0
I	0
kappa	0
B	0
alpha	0
degradation	0
,	0
nuclear	0
translocation	0
of	0
p65	9
,	0
and	0
E-selectin	9
-mediated	0
neutrophil	0
adhesion	0
is	0
related	0
to	0
the	0
activity	0
of	0
protein	9
tyrosine	10
kinase	10
(	0
PTK	9
)	0
,	0
protein	9
tyrosine	10
phosphatase	10
(	0
PTPase	9
)	0
and/or	0
protein	9
kinase	10
C	10
(	0
PKC	9
)	0
.	0

The	0
results	0
demonstrate	0
that	0
both	0
A/R	0
and	0
redox	0
imbalance	0
led	0
to	0
I	0
kappa	0
B	0
alpha	0
degradation	0
within	0
30	0
min	0
and	0
the	0
concomitant	0
appearance	0
of	0
p65	9
in	0
the	0
nucleus	0
,	0
consistent	0
with	0
rapid	0
cytosolic	0
activation	0
of	0
NF	9
kappa	10
B	10
and	0
subsequent	0
nuclear	0
translocation	0
of	0
the	0
activated	9
p65	10
subunit	10
.	0

Inhibition	0
of	0
PKC	9
blocked	0
I	9
kappa	10
B	10
alpha	10
degradation	0
and	0
p65	9
translocation	0
in	0
A/R-challenged	0
,	0
but	0
not	0
redox-altered	0
,	0
endothelial	7
cells	8
.	0

However	0
,	0
both	0
A/R-	0
and	0
redox-induced	0
NF	0
kappa	0
B	0
activation	0
was	0
blocked	0
by	0
inhibition	0
of	0
PTK	9
.	0

Similarly	0
,	0
A/R-induced	0
E-selectin	0
expression	0
and	0
neutrophil-endothelial	0
cell	0
adhesion	0
were	0
blocked	0
by	0
inhibition	0
of	0
PKC	9
or	0
PTK	9
,	0
while	0
only	0
PTK	9
inhibited	0
the	0
redox-induced	0
adhesion	0
response	0
.	0

Pretreatment	0
of	0
cells	0
with	0
N-acetyl	0
cysteine	0
effectively	0
blocked	0
A/R-	0
or	0
redox-induced	0
I	0
kappa	0
B	0
degradation	0
and	0
significantly	0
attenuated	0
the	0
respective	0
neutrophil	0
adhesion	0
responses	0
.	0

Collectively	0
,	0
these	0
findings	0
indicate	0
that	0
A/R-induced	0
E-selectin	0
expression	0
and	0
neutrophil-endothelial	0
cell	0
adhesion	0
are	0
mediated	0
by	0
both	0
PKC	9
and	0
PTK	9
,	0
which	0
signal	0
rapid	0
activation	0
of	0
NF	9
kappa	10
B	10
.	0

This	0
A/R-induced	0
NF	9
kappa	10
B	10
signaling	0
response	0
appears	0
to	0
be	0
mediated	0
,	0
at	0
least	0
in	0
part	0
,	0
by	0
intracellular	0
redox	0
imbalance	0
.	0

Copyright	0
2001	0
S.	0
Karger	0
AG	0
,	0
Basel	0

Induction	0
of	0
apoptosis	0
in	0
human	7
lymphocytes	8
by	0
the	0
herbicide	0
2	0
,	0
4-dichlorophenoxyacetic	0
acid	0
.	0

Dimethylammonium	0
salt	0
of	0
2	0
,	0
4-dichlorophenoxyacetic	0
acid	0
(	0
DMA-2	0
,	0
4-D	0
)	0
is	0
a	0
widely	0
used	0
herbicide	0
that	0
is	0
considered	0
moderately	0
toxic	0
.	0

In	0
the	0
present	0
study	0
we	0
found	0
that	0
DMA-2	0
,	0
4-D	0
is	0
able	0
to	0
cause	0
apoptosis	0
in	0
peripheral	7
blood	8
lymphocytes	8
of	0
healthy	0
individuals	0
and	0
Jurkat	5
T	6
cells	6
.	0

Apoptosis	0
induced	0
by	0
DMA-2	0
,	0
4-D	0
was	0
dose	0
and	0
time	0
dependent	0
,	0
independent	0
of	0
Fas	9
,	0
TNF	9
receptor	10
1	10
or	0
the	0
aromatic	9
hydrocarbon	10
receptor	10
,	0
and	0
involved	0
disruption	0
of	0
the	0
mitochondrial	0
transmembrane	0
potential	0
and	0
activation	0
of	0
caspase-9	9
.	0

ZVAD-FMK	0
,	0
a	0
broad-spectrum	0
inhibitor	0
of	0
caspases	9
,	0
blocked	0
DMA-2	0
,	0
4-D-induced	0
apoptosis	0
completely	0
.	0

While	0
an	0
inhibitor	0
of	0
caspase-9	9
,	0
as	0
well	0
as	0
caspase-9	9
and	0
caspase-3	0
inhibitors	0
in	0
combination	0
,	0
strongly	0
blocked	0
DMA-2	0
,	0
4-D-induced	0
apoptosis	0
,	0
an	0
inhibitor	0
of	0
caspase-3	9
had	0
a	0
moderate	0
inhibitory	0
effect	0
.	0

Unlike	0
Fas	9
-mediated	0
apoptosis	0
,	0
the	0
initiator	9
caspase	10
,	0
caspase-8	9
,	0
was	0
not	0
involved	0
in	0
DMA-2	0
,	0
4-D-induced	0
apoptosis	0
.	0

Transfection	0
of	0
Jurkat	5
cells	6
with	0
Bcl-2	9
prevented	0
DMA-2	0
,	0
4-D-induced	0
disruption	0
of	0
the	0
mitochondrial	0
transmembrane	0
potential	0
and	0
led	0
to	0
a	0
complete	0
blockage	0
of	0
apoptosis	0
.	0

Our	0
data	0
indicate	0
that	0
DMA-2	0
,	0
4-D	0
kills	0
human	7
lymphocytes	8
by	0
initiating	0
apoptosis	0
via	0
a	0
direct	0
effect	0
on	0
mitochondria	0
.	0

The	0
activation	0
of	0
caspases	9
occurs	0
downstream	0
of	0
mitochondrial	0
damage	0
,	0
and	0
the	0
dysfunction	0
of	0
mitochondria	0
appears	0
to	0
be	0
sufficient	0
for	0
triggering	0
all	0
downstream	0
events	0
leading	0
to	0
apoptosis	0
.	0

Inhibition	0
of	0
Th1	0
differentiation	0
by	0
IL-6	9
is	0
mediated	0
by	0
SOCS1	9
.	0

Interleukin	9
6	10
(	0
IL-6	9
)	0
is	0
a	0
cytokine	9
produced	0
by	0
immune	7
and	8
nonimmune	8
cells	8
and	0
exhibits	0
functional	0
pleiotropy	0
and	0
redundancy	0
.	0

IL-6	9
plays	0
an	0
important	0
role	0
in	0
the	0
differentiation	0
of	0
several	0
cell	0
types	0
.	0

Here	0
,	0
we	0
describe	0
a	0
novel	0
function	0
of	0
IL-6	9
:	0
the	0
negative	0
regulation	0
of	0
CD4	9
+	0
Th1	0
cell	0
differentiation	0
.	0

While	0
IL-6	9
-directed	0
CD4	9
+	0
Th2	0
differentiation	0
is	0
mediated	0
by	0
IL-4	9
,	0
inhibition	0
of	0
Th1	0
differentiation	0
by	0
IL-6	9
is	0
independent	0
of	0
IL-4	9
.	0

IL-6	9
upregulates	0
suppressor	9
of	10
cytokine	10
signaling	10
1	10
(	0
SOCS1	9
)	0
expression	0
in	0
activated	7
CD4+	8
T	8
cells	8
,	0
thereby	0
interfering	0
with	0
signal	9
transducer	10
and	10
activator	10
of	10
transcription	10
1	10
(	0
STAT1	9
)	0
phosphorylation	0
induced	0
by	0
interferon	9
gamma	10
(	0
IFNgamma	9
)	0
.	0

Inhibition	0
of	0
IFNgamma	9
receptor-mediated	0
signals	0
by	0
IL-6	9
prevents	0
autoregulation	0
of	0
IFNgamma	1
gene	2
expression	0
by	0
IFNgamma	9
during	0
CD4+	7
T	8
cell	8
activation	0
,	0
thereby	0
preventing	0
Th1	0
differentiation	0
.	0

Thus	0
,	0
IL-6	9
promotes	0
CD4	9
+	0
Th2	0
differentiation	0
and	0
inhibits	0
Th1	0
differentiation	0
by	0
two	0
independent	0
molecular	0
mechanisms	0
.	0

Interaction	0
between	0
CCAAT/enhancer	9
binding	10
protein	10
and	0
cyclic	9
AMP	10
response	10
element	10
binding	10
protein	10
1	10
regulates	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
transcription	0
in	0
cells	0
of	0
the	0
monocyte/macrophage	7
lineage	8
.	0

Recent	0
observations	0
have	0
shown	0
two	0
CCAAT/enhancer	1
binding	2
protein	2
(	2
C/EBP	2
)	2
binding	2
sites	2
to	0
be	0
critically	0
important	0
for	0
efficient	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
replication	0
within	0
cells	0
of	0
the	0
monocyte/macrophage	7
lineage	8
,	0
a	0
cell	0
type	0
likely	0
involved	0
in	0
transport	0
of	0
the	0
virus	0
to	0
the	0
brain	0
.	0

Additionally	0
,	0
sequence	0
variation	0
at	0
C/EBP	1
site	2
I	2
,	0
which	0
lies	0
immediately	0
upstream	0
of	0
the	0
distal	1
nuclear	2
factor	2
kappa	2
B	2
site	2
and	0
immediately	0
downstream	0
of	0
a	0
binding	0
site	0
for	0
activating	9
transcription	10
factor	10
(	0
ATF	9
)	0
/	0
cyclic	9
AMP	10
response	10
element	10
binding	10
protein	10
(	0
CREB	9
)	0
,	0
has	0
been	0
shown	0
to	0
affect	0
HIV-1	1
long	2
terminal	2
repeat	2
(	0
LTR	1
)	0
activity	0
.	0

Given	0
that	0
C/EBP	9
proteins	10
have	0
been	0
shown	0
to	0
interact	0
with	0
many	0
other	0
transcription	9
factors	10
including	0
members	0
of	0
the	0
ATF/CREB	9
family	10
,	0
we	0
proceeded	0
to	0
determine	0
whether	0
an	0
adjacent	0
ATF/CREB	1
binding	2
site	2
could	0
affect	0
C/EBP	9
protein	10
binding	0
to	0
C/EBP	1
site	2
I	2
.	0

Electrophoretic	0
mobility	0
shift	0
analyses	0
indicated	0
that	0
selected	0
ATF/CREB	1
site	2
variants	2
assisted	0
in	0
the	0
recruitment	0
of	0
C/EBP	9
proteins	10
to	0
an	0
adjacent	0
,	0
naturally	0
occurring	0
,	0
low-affinity	0
C/EBP	1
site	2
.	0

This	0
biophysical	0
interaction	0
appears	0
to	0
occur	0
via	0
at	0
least	0
two	0
mechanisms	0
.	0

First	0
,	0
low	0
amounts	0
of	0
CREB-1	9
and	0
C/EBP	9
appear	0
to	0
heterodimerize	0
and	0
bind	0
to	0
a	0
site	0
consisting	0
of	0
a	0
half	0
site	0
from	0
both	0
the	0
ATF/CREB	1
and	2
C/EBP	2
binding	2
sites	2
.	0

In	0
addition	0
,	0
CREB-1	9
homodimers	10
bind	0
to	0
the	0
ATF/CREB	1
site	2
and	0
recruit	0
C/EBP	9
dimers	10
to	0
their	0
cognate	0
weak	1
binding	2
sites	2
.	0

This	0
interaction	0
is	0
reciprocal	0
,	0
since	0
C/EBP	9
dimer	10
binding	0
to	0
a	0
strong	0
C/EBP	1
site	2
leads	0
to	0
enhanced	0
CREB-1	9
recruitment	0
to	0
ATF/CREB	1
sites	2
that	0
are	0
weakly	0
bound	0
by	0
CREB	9
.	0

Sequence	0
variation	0
at	0
both	0
C/EBP	1
and	2
ATF/CREB	2
sites	2
affects	0
the	0
molecular	0
interactions	0
involved	0
in	0
mediating	0
both	0
of	0
these	0
mechanisms	0
.	0

Most	0
importantly	0
,	0
sequence	0
variation	0
at	0
the	0
ATF/CREB	1
binding	2
site	2
affected	0
basal	0
LTR	1
activity	0
as	0
well	0
as	0
LTR	1
function	0
following	0
interleukin-6	9
stimulation	0
,	0
a	0
treatment	0
that	0
leads	0
to	0
increases	0
in	0
C/EBP	0
activation	0
.	0

Thus	0
,	0
HIV-1	1
LTR	2
ATF/CREB	1
binding	2
site	2
sequence	0
variation	0
may	0
modulate	0
cellular	0
signaling	0
at	0
the	0
viral	1
promoter	2
through	0
the	0
C/EBP	0
pathway	0

Selective	0
inhibition	0
of	0
interleukin-4	0
gene	0
expression	0
in	0
human	7
T	8
cells	8
by	0
aspirin	0
.	0

Previous	0
studies	0
indicated	0
that	0
aspirin	0
(	0
acetylsalicylic	0
acid	0
[	0
ASA	0
]	0
)	0
can	0
have	0
profound	0
immunomodulatory	0
effects	0
by	0
regulating	0
cytokine	0
gene	0
expression	0
in	0
several	0
types	0
of	0
cells	0
.	0

This	0
study	0
is	0
the	0
first	0
in	0
which	0
concentrations	0
of	0
ASA	0
in	0
the	0
therapeutic	0
range	0
were	0
found	0
to	0
significantly	0
reduce	0
interleukin	9
(	10
IL	10
)	10
-4	10
secretion	0
and	0
RNA	0
expression	0
in	0
freshly	7
isolated	8
and	8
mitogen-primed	8
human	8
CD4+	8
T	8
cells	8
.	0

In	0
contrast	0
,	0
ASA	0
did	0
not	0
affect	0
IL-13	9
,	0
interferon-gamma	9
,	0
and	0
IL-2	9
expression	0
.	0

ASA	0
inhibited	0
IL-4	9
,	0
but	0
not	0
IL-2	9
,	0
promoter-driven	0
chloramphenicol	0
acetyltransferase	0
expression	0
in	0
transiently	0
transfected	0
Jurkat	5
T	6
cells	6
.	0

The	0
structurally	0
unrelated	0
nonsteroidal	0
anti-inflammatory	0
drugs	0
indomethacin	0
and	0
flurbiprofen	0
did	0
not	0
affect	0
cytokine	0
gene	0
expression	0
in	0
T	7
cells	8
,	0
whereas	0
the	0
weak	0
cyclo-oxygenase	0
inhibitor	0
salicylic	0
acid	0
was	0
at	0
least	0
as	0
effective	0
as	0
ASA	0
in	0
inhibiting	0
IL-4	9
expression	0
and	0
promoter	0
activity	0
.	0

The	0
inhibitory	0
effect	0
of	0
ASA	0
on	0
IL-4	0
transcription	0
was	0
not	0
mediated	0
by	0
decreased	0
nuclear	0
expression	0
of	0
the	0
known	0
salicylate	9
target	10
nuclear	10
factor	10
(	10
NF	10
)	10
-kappaB	10
and	0
was	0
accompanied	0
by	0
reduced	0
binding	0
of	0
an	0
inducible	0
factor	0
to	0
an	0
IL-4	1
promoter	2
region	2
upstream	0
of	0
,	0
but	0
not	0
overlapping	0
,	0
the	0
NF	1
of	2
activated	2
T	2
cells-	2
and	2
NF-kappaB-binding	2
P1	2
element	2
.	0

It	0
is	0
concluded	0
that	0
anti-inflammatory	0
salicylates	0
,	0
by	0
means	0
of	0
a	0
previously	0
unrecognized	0
mechanism	0
of	0
action	0
,	0
can	0
influence	0
the	0
nature	0
of	0
adaptive	0
immune	0
responses	0
by	0
selectively	0
inhibiting	0
the	0
expression	0
of	0
IL-4	9
,	0
a	0
critical	0
effector	0
of	0
these	0
responses	0
,	0
in	0
CD4+	7
T	8
cells	8
.	0

Molecular	0
and	0
cellular	0
mediators	0
of	0
interleukin-1	9
-dependent	0
acute	0
inflammatory	0
arthritis	0
.	0

OBJECTIVE	0
:	0
To	0
examine	0
the	0
molecular	0
and	0
cellular	0
mechanisms	0
in	0
a	0
model	0
of	0
acute	0
inflammatory	0
monarticular	0
arthritis	0
induced	0
by	0
methylated	9
bovine	10
serum	10
albumin	10
(	0
mBSA	9
)	0
and	0
interleukin-1	9
(	0
IL-1	9
)	0
.	0

METHODS	0
:	0
Mice	0
were	0
injected	0
intraarticularly	0
with	0
mBSA	9
on	0
day	0
0	0
and	0
subcutaneously	0
with	0
recombinant	9
human	10
IL-1beta	10
on	0
days	0
0-2	0
.	0

At	0
day	0
7	0
,	0
knee	0
joints	0
were	0
removed	0
and	0
assessed	0
histologically	0
.	0

Flow	0
cytometry	0
and	0
RNase	0
protection	0
were	0
used	0
to	0
analyze	0
IL-1	9
-dependent	0
events	0
.	0

RESULTS	0
:	0
C57BL/6	0
(	0
B6	0
)	0
,	0
129/Sv	0
,	0
and	0
(	0
B6	0
x	0
129/	0
Sv	0
)	0
F1	0
hybrid	0
mice	0
,	0
all	0
H-2b	0
strains	0
,	0
were	0
susceptible	0
to	0
mBSA	9
/IL-1-induced	0
arthritis	0
,	0
whereas	0
C3H/HeJ	0
(	0
H-2k	0
)	0
mice	0
were	0
not	0
.	0

B6	0
mice	0
lacking	0
T	7
and	8
B	8
cells	8
(	0
RAG1-/-	0
)	0
or	0
major	9
histocompatibility	10
complex	10
(	10
MHC	10
)	10
class	10
II	10
antigens	10
(	0
MHCII-/-	0
)	0
,	0
and	0
B6	0
mice	0
treated	0
with	0
a	0
CD4+	9
T	10
cell-depleting	10
monoclonal	10
antibody	10
,	0
were	0
resistant	0
to	0
disease	0
.	0

In	0
contrast	0
,	0
B	0
cell-deficient	0
(	0
muMT/	0
muMT	0
)	0
mice	0
developed	0
arthritis	0
at	0
an	0
incidence	0
and	0
severity	0
similar	0
to	0
that	0
of	0
controls	0
.	0

RelB-deficient	0
(	0
RelB-/-	0
)	0
bone	0
marrow	0
chimeric	0
mice	0
had	0
arthritis	0
that	0
was	0
significantly	0
reduced	0
in	0
incidence	0
and	0
severity	0
.	0

In	0
B6	0
mice	0
,	0
flow	0
cytometry	0
demonstrated	0
an	0
IL-1-dependent	7
leukocyte	8
infiltration	0
into	0
the	0
synovial	0
compartment	0
and	0
RNase	0
protection	0
assays	0
revealed	0
induction	0
of	0
messenger	3
RNA	4
(	0
mRNA	3
)	0
for	0
the	0
chemokines	9
monocyte	9
chemoattractant	10
protein	10
1	10
,	0
macrophage	9
inhibitory	10
protein	10
2	10
(	0
MIP-2	9
)	0
,	0
RANTES	9
,	0
MIP-1alpha	9
,	0
and	0
MIP-1beta	9
,	0
in	0
vivo	0
and	0
in	0
vitro	0
.	0

CONCLUSION	0
:	0
Arthritis	0
induced	0
by	0
mBSA	9
/	0
IL-1	9
is	0
strain	0
specific	0
and	0
dependent	0
on	0
CD4+	7
T	8
lymphocytes	8
and	0
at	0
least	0
partially	0
on	0
RelB	9
,	0
but	0
not	0
on	0
B	7
lymphocytes	8
or	0
antibody	9
.	0

IL-1	9
contributes	0
to	0
leukocyte	0
recruitment	0
to	0
the	0
synovium	0
and	0
directly	0
induces	0
chemokine	0
mRNA	0
production	0
by	0
synovial	7
cells	8
.	0

This	0
model	0
of	0
acute	0
monarticular	0
arthritis	0
is	0
particularly	0
suitable	0
for	0
further	0
investigations	0
into	0
cell-mediated	0
immunity	0
in	0
arthritis	0
and	0
the	0
role	0
of	0
IL-1	9
.	0

Positive	0
and	0
negative	0
regulation	0
of	0
granulopoiesis	0
by	0
endogenous	9
RARalpha	10
.	0

Acute	0
promyelocytic	0
leukemia	0
(	0
APL	0
)	0
is	0
always	0
associated	0
with	0
chromosomal	0
translocations	0
that	0
disrupt	0
the	0
retinoic	1
acid	2
receptor	2
alpha	2
(	2
RARalpha	2
)	2
gene	2
.	0

Whether	0
these	0
translocations	0
relate	0
to	0
a	0
role	0
for	0
endogenous	9
RARalpha	10
in	0
normal	0
granulopoiesis	0
remains	0
uncertain	0
because	0
most	0
studies	0
addressing	0
this	0
question	0
have	0
used	0
non-physiological	0
overexpression	0
systems	0
.	0

Granulocyte	0
differentiation	0
in	0
cells	0
derived	0
from	0
RARalpha-deficient	0
(	0
RARalpha	0
(	0
-/-	0
)	0
)	0
mice	0
was	0
studied	0
and	0
evaluated	0
in	0
the	0
context	0
of	0
agonist-bound	9
and	10
ligand-free	10
RARalpha	10
.	0

Our	0
results	0
demonstrate	0
that	0
RARalpha	9
is	0
dispensable	0
for	0
granulopoiesis	0
,	0
as	0
RARalpha	0
(	0
-/-	0
)	0
mice	0
have	0
a	0
normal	7
granulocyte	8
population	8
despite	0
an	0
impaired	0
ability	0
to	0
respond	0
to	0
retinoids	0
.	0

However	0
,	0
although	0
it	0
is	0
not	0
absolutely	0
required	0
,	0
RARalpha	9
can	0
bidirectionally	0
modulate	0
granulopoiesis	0
.	0

RARalpha	9
stimulates	0
differentiation	0
in	0
response	0
to	0
exogenous	0
retinoic	0
acid	0
.	0

Furthermore	0
,	0
endogenous	0
retinoids	0
control	0
granulopoiesis	0
in	0
vivo	0
,	0
as	0
either	0
vitamin	0
A-deficient	0
mice	0
or	0
animals	0
treated	0
with	0
an	0
RAR	0
antagonist	0
accumulate	0
more	0
immature	7
granulocytes	8
in	0
their	0
bone	0
marrow	0
.	0

Conversely	0
,	0
RARalpha	9
acts	0
to	0
limit	0
differentiation	0
in	0
the	0
absence	0
of	0
ligand	9
because	0
granulocyte	7
precursors	8
from	0
RARalpha	0
(	0
-/-	0
)	0
mice	0
differentiate	0
earlier	0
in	0
culture	0
.	0

Thus	0
,	0
the	0
block	0
in	0
granulopoiesis	0
exerted	0
by	0
RARalpha	9
fusion	9
proteins	10
expressed	0
in	0
APL	7
cells	8
may	0
correspond	0
to	0
an	0
amplification	0
of	0
a	0
normal	0
function	0
of	0
unliganded	9
RARalpha	10
.	0

Expression	0
and	0
function	0
of	0
a	0
stem	1
cell	2
promoter	2
for	0
the	0
murine	1
CBFalpha2	2
gene	2
:	0
distinct	0
roles	0
and	0
regulation	0
in	0
natural	7
killer	8
and	8
T	8
cell	8
development	0
.	0

The	0
Runt	9
family	10
transcription	10
factor	10
CBFalpha2	9
(	0
AML1	9
,	0
PEBP2alphaB	9
,	0
or	0
Runx1	9
)	0
is	0
required	0
by	0
hematopoietic	7
stem	8
cells	8
and	0
expressed	0
at	0
high	0
levels	0
in	0
T-lineage	7
cells	8
.	0

In	0
human	7
T	8
cells	8
CBFalpha2	9
is	0
usually	0
transcribed	0
from	0
a	0
different	1
promoter	2
(	0
distal	1
promoter	2
)	0
than	0
in	0
myeloid	7
cells	8
(	0
proximal	1
promoter	2
)	0
,	0
but	0
the	0
developmental	0
and	0
functional	0
significance	0
of	0
this	0
promoter	0
switch	0
has	0
not	0
been	0
known	0
.	0

Here	0
,	0
we	0
report	0
that	0
both	0
coding	1
and	2
noncoding	2
sequences	2
of	0
the	0
distal	1
5	2
'	2
end	2
are	0
highly	0
conserved	0
between	0
the	0
human	1
and	2
the	2
murine	2
genes	2
,	0
and	0
the	0
distal	1
promoter	2
is	0
responsible	0
for	0
the	0
overwhelming	0
majority	0
of	0
CBFalpha2	0
expression	0
in	0
murine	0
hematopoietic	7
stem	8
cells	8
as	0
well	0
as	0
in	0
T	7
cells	8
.	0

Distal	0
promoter	0
activity	0
is	0
maintained	0
throughout	0
T	0
cell	0
development	0
and	0
at	0
lower	0
levels	0
in	0
B	0
cell	0
development	0
,	0
but	0
downregulated	0
in	0
natural	0
killer	0
cell	0
development	0
.	0

The	0
distal	1
N-terminal	2
isoform	2
binds	0
to	0
functionally	0
important	0
regulatory	1
sites	2
from	0
known	0
target	1
genes	2
with	0
two-	0
to	0
threefold	0
higher	0
affinity	0
than	0
the	0
proximal	1
N-terminal	2
isoform	2
.	0

Neither	0
full-length	1
isoform	2
alters	0
growth	0
of	0
a	0
myeloid	5
cell	6
line	6
under	0
nondifferentiating	0
conditions	0
,	0
but	0
the	0
proximal	1
isoform	2
selectively	0
delays	0
mitotic	0
arrest	0
of	0
the	0
cell	0
line	0
under	0
differentiating	0
conditions	0
,	0
resulting	0
in	0
the	0
generation	0
of	0
greater	0
numbers	0
of	0
neutrophils	7
.	0

Constitutive	0
PI3-K	0
activity	0
is	0
essential	0
for	0
proliferation	0
,	0
but	0
not	0
survival	0
,	0
of	0
Theileria	7
parva-transformed	8
B	8
cells	8
.	0

Theileria	0
is	0
an	0
intracellular	0
parasite	0
that	0
causes	0
lymphoproliferative	0
disorders	0
in	0
cattle	0
,	0
and	0
infection	0
of	0
leucocytes	7
induces	0
a	0
transformed	0
phenotype	0
similar	0
to	0
tumour	7
cells	8
,	0
but	0
the	0
mechanisms	0
by	0
which	0
the	0
parasite	0
induces	0
this	0
phenotype	0
are	0
not	0
understood	0
.	0

Here	0
,	0
we	0
show	0
that	0
infected	7
B	8
lymphocytes	8
display	0
constitutive	0
phosphoinositide	0
3-kinase	0
(	0
PI3-K	0
)	0
activity	0
,	0
which	0
appears	0
to	0
be	0
necessary	0
for	0
proliferation	0
,	0
but	0
not	0
survival	0
.	0

Importantly	0
,	0
we	0
demonstrate	0
that	0
one	0
mechanism	0
by	0
which	0
PI3-K	9
mediates	0
the	0
proliferation	0
of	0
infected	7
B	8
lymphocytes	8
is	0
through	0
the	0
induction	0
of	0
a	0
granulocyte-monocyte	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
-dependent	0
autocrine	0
loop	0
.	0

PI3-K	9
induction	0
of	0
GM-CSF	9
appears	0
to	0
be	0
at	0
the	0
transcriptional	0
level	0
and	0
,	0
consistently	0
,	0
we	0
demonstrate	0
that	0
PI3-K	9
is	0
also	0
involved	0
in	0
the	0
constitutive	0
induction	0
of	0
AP-1	9
and	0
NF-kappaB	9
,	0
which	0
characterizes	0
Theileria-infected	0
leucocytes	7
.	0

Taken	0
together	0
,	0
our	0
results	0
highlight	0
a	0
novel	0
strategy	0
exploited	0
by	0
the	0
intracellular	0
parasite	0
Theileria	0
to	0
induce	0
continued	0
proliferation	0
of	0
its	0
host	7
leucocyte	8
.	0

Lymphokine	9
dependence	0
of	0
STAT3	0
activation	0
produced	0
by	0
surface	0
immunoglobulin	0
cross-linking	0
and	0
by	0
phorbol	0
ester	0
plus	0
calcium	0
ionophore	0
treatment	0
in	0
B	7
cells	8
.	0

Stimulation	0
of	0
B	7
cells	8
by	0
surface	9
immunoglobulin	10
(	0
sIg	9
)	0
triggering	0
,	0
or	0
through	0
the	0
mitogenic	0
combination	0
of	0
phorbol	0
ester	0
and	0
calcium	0
ionophore	0
,	0
is	0
accompanied	0
by	0
activation	0
of	0
STAT	9
transcription	10
factors	10
.	0

The	0
mechanism	0
responsible	0
for	0
the	0
delayed	0
nuclear	0
accumulation	0
of	0
phosphorylated	9
STAT3	10
was	0
examined	0
in	0
detail	0
,	0
focusing	0
on	0
the	0
role	0
of	0
B	9
cell-derived	10
lymphokines	10
.	0

sIg	9
-induced	0
activation	0
of	0
STAT3	9
was	0
partially	0
inhibited	0
in	0
B	7
cells	8
obtained	0
from	0
IL-6-	0
or	0
IL-10-deficient	0
mice	0
,	0
and	0
was	0
partially	0
blocked	0
by	0
neutralizing	9
antibodies	10
directed	0
against	0
either	0
of	0
these	0
lymphokines	9
.	0

sIg	9
-induced	0
STAT3	0
activation	0
was	0
completely	0
inhibited	0
by	0
combining	0
IL-6-	9
and	10
IL-10-specific	10
neutralizing	10
antibodies	10
,	0
or	0
by	0
adding	0
individual	0
neutralizing	9
antibodies	10
to	0
B	7
cells	8
obtained	0
from	0
lymphokine-deficient	0
animals	0
.	0

In	0
contrast	0
,	0
IL-10	9
alone	0
appeared	0
to	0
account	0
for	0
STAT3	0
activation	0
resulting	0
from	0
B	0
cell	0
stimulation	0
with	0
phorbol	0
ester	0
and	0
calcium	0
ionophore	0
.	0

In	0
keeping	0
with	0
these	0
results	0
,	0
soluble	0
IL-6	9
and	0
IL-10	9
were	0
found	0
in	0
supernatant	0
fluid	0
obtained	0
from	0
stimulated	7
B	8
cells	8
.	0

This	0
work	0
indicates	0
that	0
a	0
lymphokine	0
pathway	0
is	0
responsible	0
for	0
STAT3	0
activation	0
that	0
occurs	0
late	0
after	0
B	0
cell	0
stimulation	0
,	0
and	0
points	0
out	0
differences	0
in	0
B	0
cell	0
activation	0
that	0
result	0
from	0
stimulation	0
through	0
the	0
antigen	9
receptor	10
and	0
through	0
pharmacological	0
mimicry	0
of	0
signaling	9
mediators	10
.	0

Transcription	9
factor	10
AP-4	10
is	0
a	0
ligand	9
for	0
immunoglobulin-kappa	1
promoter	2
E-box	2
elements	2
.	0

Immunoglobulin	1
(	2
Ig	2
)	2
-kappa	2
promoters	2
from	0
humans	0
and	0
mice	0
share	0
conserved	1
sequences	2
.	0

The	0
octamer	1
element	2
is	0
common	0
to	0
all	0
Ig	1
promoters	2
and	0
pivotal	0
for	0
their	0
function	0
.	0

However	0
,	0
other	0
conserved	1
sequence	2
motifs	2
,	0
that	0
differ	0
between	0
Ig	1
variable	2
gene	2
families	2
,	0
are	0
required	0
for	0
normal	0
promoter	0
function	0
.	0

These	0
conserved	0
motifs	0
do	0
not	0
stimulate	0
transcription	0
in	0
the	0
absence	0
of	0
an	0
octamer	1
.	0

One	0
example	0
is	0
an	0
E-box	1
of	0
the	0
E47/E12	1
type	2
(	2
5'-CAGCTG-3	2
'	2
)	2
,	0
which	0
is	0
found	0
in	0
all	0
promoters	0
of	0
the	0
human	1
and	2
murine	2
Ig-kappa	2
gene	2
subgroups/families	2
,	0
with	0
the	0
exception	0
of	0
subgroups	0
II	0
and	0
VI	0
and	0
their	0
related	0
murine	1
families	2
.	0

In	0
the	0
present	0
study	0
we	0
show	0
that	0
the	0
ubiquitously	0
expressed	0
transcription	9
factor	10
AP-4	10
,	0
and	0
not	0
E47	9
,	0
interacts	0
specifically	0
with	0
the	0
kappa	1
promoter	2
E-boxes	2
when	0
tested	0
in	0
electrophoretic	0
mobility-shift	0
assays	0
using	0
nuclear	0
extracts	0
derived	0
from	0
human	5
and	6
murine	6
B-cell	6
lines	6
.	0

Furthermore	0
,	0
AP-4	9
,	0
unlike	0
E47	9
,	0
did	0
not	0
act	0
as	0
a	0
transactivator	9
,	0
which	0
is	0
in	0
agreement	0
with	0
previous	0
studies	0
on	0
intact	0
kappa	1
promoters	2
,	0
showing	0
that	0
transcription	0
is	0
absent	0
when	0
the	0
octamer	1
element	2
has	0
been	0
mutated	0
.	0

Based	0
on	0
these	0
data	0
,	0
and	0
the	0
conservation	0
of	0
the	0
5'-CAGCTG-3	1
'	2
motif	2
among	0
human	1
and	2
murine	2
kappa	2
promoters	2
,	0
we	0
propose	0
that	0
AP-4	9
is	0
the	0
major	9
ligand	10
for	0
Ig-kappa	1
promoter	2
E-boxes	2
.	0

A	0
16-mer	0
peptide	0
(	0
RQIKIWFQNRRMKWKK	0
)	0
from	0
antennapedia	0
preferentially	0
targets	0
the	0
Class	0
I	0
pathway	0
.	0

Translocation	0
of	0
antigenic	0
peptides	0
into	0
the	0
cytosol	0
of	0
antigen	7
presenting	8
cells	8
facilitates	0
proteosomal	0
processing	0
and	0
loading	0
into	0
Class	9
I	10
molecules	10
for	0
MHC	0
presentation	0
on	0
the	0
cell	0
surface	0
.	0

The	0
DNA	9
binding	10
domain	10
of	0
the	0
Drosophila	9
transcription	10
factor	10
(	0
Antennapedia	9
)	0
,	0
a	0
60	9
amino	10
acid	10
protein	10
,	0
is	0
rapidly	0
taken	0
up	0
by	0
cells	0
and	0
has	0
been	0
fused	0
to	0
selected	0
antigens	9
to	0
enhance	0
their	0
immunogenicity	0
.	0

We	0
now	0
demonstrate	0
that	0
a	0
16	0
amino	0
acid	0
peptide	0
from	0
antennapedia	0
can	0
facilitate	0
the	0
cytoplasmic	0
uptake	0
of	0
CTL	0
epitope	0
9-mer	0
peptides	0
.	0

Synthetic	0
peptides	0
were	0
made	0
containing	0
the	0
16-mer	0
antennapedia	0
peptide	0
linked	0
in	0
tandem	0
to	0
the	0
ovalbumin	0
SIINFEKL	0
CTL	0
peptide	0
.	0

The	0
peptide	0
complex	0
was	0
shown	0
to	0
rapidly	0
internalise	0
into	0
APCs	7
by	0
confocal	0
microscopy	0
.	0

This	0
peptide	0
induced	0
CTL	7
in	0
C57BL/6	0
mice	0
and	0
protected	0
them	0
against	0
growth	0
of	0
an	0
ovalbumin	5
expressing	6
tumour	6
cell	6
line	6
(	0
E.G7-OVA	5
)	0
.	0

The	0
ability	0
of	0
the	0
hybrid	0
peptide	0
to	0
be	0
processed	0
and	0
presented	0
by	0
APCs	7
was	0
similar	0
,	0
whether	0
the	0
SIINFEKL	0
sequence	0
was	0
appended	0
at	0
the	0
C-terminus	9
or	0
N-terminus	9
of	0
the	0
Antennapedia	0
peptide	0
.	0

The	0
production	0
of	0
synthetic	0
peptides	0
containing	0
other	0
CTL	0
peptide	0
epitopes	0
may	0
be	0
useful	0
for	0
priming	0
CTLs	7
in	0
vitro	0
and	0
in	0
vivo	0

Bone	7
marrow	8
cells	8
promote	0
TH2	0
polarization	0
and	0
inhibit	0
virus-specific	0
CTL	0
generation	0
.	0

This	0
laboratory	0
recently	0
reported	0
that	0
human	7
bone	8
marrow	8
cells	8
(	0
BMC	7
)	0
inhibit	0
the	0
generation	0
of	0
virus-specific	7
CTL	8
in	0
culture	0
.	0

The	0
culture	0
supernatants	0
contained	0
increased	0
levels	0
of	0
prostaglandin	9
E	10
(	10
2	10
)	10
(	10
PGE	10
(	10
2	10
)	10
)	10
(	0
shown	0
to	0
favor	0
TH2	0
cell	0
development	0
)	0
and	0
also	0
inhibited	0
EBV-CTL	0
effector	0
cell	0
development	0
.	0

In	0
this	0
study	0
,	0
we	0
obtained	0
PBL	7
from	0
Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
IgG	9
antibody	10
positive	0
kidney	0
transplant	0
recipients	0
(	0
R	0
)	0
and	0
their	0
living-related	0
donors	0
(	0
LRD	0
)	0
one	0
year	0
after	0
renal	0
transplantation	0
.	0

EBV-specific	7
CTL	8
were	0
then	0
generated	0
in	0
vitro	0
by	0
stimulating	0
PBL	7
with	0
autologous	0
EBV-transformed	7
B	8
cells	8
(	0
EBV-B	7
)	0
in	0
the	0
presence	0
or	0
absence	0
of	0
autologous	7
BMC	8
.	0

The	0
addition	0
of	0
BMC	7
to	0
the	0
EBV-CTL	7
generation	8
cultures	8
increased	0
the	0
intracellular	0
expression	0
in	0
CD3+	7
cells	8
of	0
IL-4	9
,	10
-5	10
,	10
-6	10
,	10
-10	10
,	10
and	10
-13	10
.	0

These	0
CD3+	7
cells	8
also	0
expressed	0
increased	0
levels	0
of	0
the	0
TH2	9
associated	10
receptor	10
CCR3	10
.	0

Inhibition	0
was	0
even	0
observed	0
by	0
preparing	0
EBV-CTL	7
generating	8
cultures	8
in	0
trans-wells	0
that	0
separated	0
the	0
autologous	7
BMC	8
from	0
the	0
PBL	7
+	0
EBV-B	7
.	0

It	0
was	0
then	0
observed	0
that	0
CD3+	7
cells	8
obtained	0
after	0
7	0
days	0
of	0
culture	0
in	0
the	0
presence	0
of	0
autologous	7
BMC	8
could	0
be	0
used	0
as	0
inhibitors	0
of	0
EBV-CTL	0
generation	0
.	0

Protein	9
Kinase	10
A	10
(	0
PKA	9
)	0
,	0
a	0
cAMP	9
kinase	10
that	0
is	0
involved	0
in	0
the	0
upregulation	0
of	0
TH2	9
cytokine	10
activity	0
,	0
was	0
increased	0
in	0
EBV-CTL	7
cultures	8
by	0
the	0
presence	0
of	0
BMC	7
.	0

Additionally	0
,	0
IL-4-mediated	0
signal	0
transduction	0
and	0
activation	0
of	0
transcription	0
(	0
STAT-6	9
)	0
phosphorylation	0
was	0
slightly	0
increased	0
.	0

These	0
results	0
show	0
that	0
the	0
BMC	7
inhibition	0
is	0
mediated	0
by	0
soluble	9
factors	10
(	0
cytokines	9
)	0
and	0
that	0
cell-cell	0
contact	0
in	0
this	0
autologous	0
system	0
is	0
not	0
required	0
,	0
so	0
that	0
BMC	7
(	0
at	0
least	0
partially	0
,	0
via	0
cytokine	0
production	0
)	0
promote	0
TH2	0
polarization	0
in	0
culture	0
.	0

Moreover	0
,	0
TH2	7
cells	8
induced	0
by	0
culturing	0
with	0
autologous	7
BMC	8
directly	0
inhibit	0
EBV-CTL	0
generation	0
,	0
and	0
TH2	9
associated	0
PKA	9
,	0
CCR3	9
,	0
and	0
STAT-6	9
phosphorylation	0
are	0
enhanced	0
by	0
BMC	7
.	0

Reduction	0
in	0
DNA	0
binding	0
activity	0
of	0
the	0
transcription	9
factor	10
Pax-5a	9
in	0
B	7
lymphocytes	8
of	0
aged	0
mice	0
.	0

Aging	0
has	0
been	0
associated	0
with	0
intrinsic	0
changes	0
of	0
the	0
humoral	0
immune	0
response	0
,	0
which	0
may	0
lead	0
to	0
an	0
increased	0
occurrence	0
of	0
autoimmune	0
disorders	0
and	0
pathogenic	0
susceptibility	0
.	0

The	0
transcription	9
factor	10
Pax-5	9
is	0
a	0
key	0
regulator	0
of	0
B	0
cell	0
development	0
.	0

Pax-5a/B	9
cell-specific	10
activator	10
protein	10
and	0
an	0
alternatively	9
spliced	10
isoform	10
,	10
Pax-5d	10
,	0
may	0
have	0
opposing	0
functions	0
in	0
transcriptional	0
regulation	0
due	0
to	0
the	0
lack	0
of	0
a	0
transactivation	9
domain	10
in	0
Pax-5d	9
.	0

To	0
study	0
B	7
cell	8
-specific	0
changes	0
that	0
occur	0
during	0
the	0
aging	0
process	0
,	0
we	0
investigated	0
expression	0
patterns	0
of	0
Pax-5a	9
and	10
5d	10
in	0
mature	7
B	8
cells	8
of	0
young	0
and	0
aged	0
mice	0
.	0

RNase	0
protection	0
assays	0
showed	0
a	0
similar	0
transcriptional	0
pattern	0
for	0
both	0
age	0
groups	0
that	0
indicates	0
that	0
aging	0
has	0
no	0
affect	0
on	0
transcription	0
initiation	0
or	0
alternative	0
splicing	0
for	0
either	0
isoform	9
.	0

In	0
contrast	0
,	0
a	0
significant	0
reduction	0
in	0
the	0
DNA	0
binding	0
activity	0
of	0
Pax-5a	9
but	0
not	0
Pax-5d	9
protein	0
was	0
observed	0
in	0
aged	7
B	8
cells	8
in	0
vitro	0
,	0
while	0
Western	0
blot	0
analyses	0
showed	0
that	0
similar	0
levels	0
of	0
Pax-5a	9
and	10
5d	10
proteins	0
were	0
present	0
in	0
both	0
age	0
groups	0
.	0

The	0
observed	0
decrease	0
in	0
Pax-5a	9
binding	0
activity	0
correlated	0
with	0
changes	0
in	0
expression	0
of	0
two	0
Pax-5	1
target	2
genes	2
in	0
aged	7
B	8
cells	8
.	0

Expression	0
of	0
the	0
Ig	9
J	10
chain	10
and	0
the	0
secreted	0
form	0
of	0
Ig	9
mu	10
,	0
which	0
are	0
both	0
known	0
to	0
be	0
suppressed	0
by	0
Pax-5a	9
in	0
mature	7
B	8
cells	8
,	0
were	0
increased	0
in	0
B	7
cells	8
of	0
aged	0
mice	0
.	0

Together	0
,	0
our	0
studies	0
suggest	0
that	0
changes	0
associated	0
with	0
the	0
aging	0
phenotype	0
cause	0
posttranslational	0
modification	0
(	0
s	0
)	0
of	0
Pax-5a	9
but	0
not	0
Pax-5d	9
,	0
which	0
may	0
lead	0
to	0
an	0
abnormal	0
B	0
cell	0
phenotype	0
in	0
aged	0
mice	0
,	0
associated	0
with	0
elevated	0
levels	0
of	0
J	9
chain	10
,	0
and	0
secretion	0
of	0
IgM	9

NF-kappa	9
B/Rel	10
participation	0
in	0
the	0
lymphokine-dependent	0
proliferation	0
of	0
T	7
lymphoid	8
cells	8
.	0

Proliferative	0
responses	0
of	0
lymphoid	7
cells	8
to	0
IL-2	9
and	0
IL-4	9
depend	0
on	0
activation	0
of	0
the	0
cells	0
,	0
but	0
the	0
mechanism	0
(	0
s	0
)	0
by	0
which	0
activation	0
enhances	0
cellular	0
competence	0
to	0
respond	0
to	0
cytokines	9
is	0
not	0
fully	0
understood	0
.	0

The	0
NF-kappaB/Rel	9
family	10
represents	0
one	0
signal	0
transduction	0
pathway	0
induced	0
during	0
such	0
activation	0
.	0

We	0
show	0
in	0
this	0
study	0
that	0
inhibition	0
of	0
NF-kappaB	9
through	0
the	0
expression	0
of	0
an	0
IkappaBalpha	9
(	0
inhibitory	9
protein	10
that	0
dissociates	0
from	0
NF-kappaB	9
)	0
mutant	0
refractory	0
to	0
signal-induced	0
degradation	0
(	0
IkappaBalpha	9
(	10
DeltaN	10
)	10
)	0
interfered	0
with	0
the	0
acquisition	0
of	0
competence	0
to	0
proliferate	0
in	0
response	0
to	0
IL-4	9
as	0
well	0
as	0
IL-2	9
.	0

Thymocytes	7
and	0
T	7
cells	8
from	0
IkappaBalpha	9
(	10
DeltaN	10
)	10
transgenic	0
mice	0
expressed	0
normal	0
levels	0
of	0
IL-2R	9
subunits	10
.	0

However	0
,	0
transgenic	7
cells	8
exhibited	0
a	0
dramatic	0
defect	0
in	0
Stat5A	0
activation	0
treatment	0
with	0
IL-2	9
,	0
and	0
a	0
similar	0
defect	0
was	0
observed	0
for	0
IL-4	9
-induced	0
Stat5	9
.	0

In	0
contrast	0
,	0
T	7
lymphoid	8
cells	8
with	0
inhibition	0
of	0
NF-kappaB	9
showed	0
normal	0
insulin	0
receptor	0
substrate-2	0
phosphorylation	0
and	0
only	0
a	0
modest	0
decrease	0
in	0
Stat6	0
activation	0
and	0
insulin	0
receptor	0
substrate-1	0
phosphorylation	0
after	0
IL-4	0
stimulation	0
.	0

These	0
results	0
indicate	0
that	0
the	0
NF-kappaB/Rel/IkappaBalpha	0
system	0
can	0
regulate	0
cytokine	9
receptor	10
capacitation	0
through	0
effects	0
on	0
the	0
induction	0
of	0
downstream	0
signaling	0
by	0
the	0
Stat	9
transcription	10
factor	10
family	10
.	0

BMS-189453	0
,	0
a	0
novel	0
retinoid	0
receptor	0
antagonist	0
,	0
is	0
a	0
potent	0
testicular	0
toxin	0
.	0

BMS-189453	0
is	0
a	0
synthetic	0
retinoid	0
that	0
acts	0
as	0
an	0
antagonist	0
at	0
retinoic	9
acid	10
receptors	10
alpha	10
,	10
beta	10
,	10
and	10
gamma	10
.	0

In	0
Sprague	0
Dawley	0
rats	0
at	0
daily	0
oral	0
doses	0
of	0
15	0
,	0
60	0
,	0
or	0
240	0
mg/kg	0
for	0
1	0
month	0
,	0
BMS-189453	0
produced	0
increases	0
in	0
leukocyte	7
counts	0
,	0
alkaline	9
phosphatase	10
and	0
alanine	9
aminotransferase	10
levels	0
,	0
and	0
marked	0
testicular	0
degeneration	0
and	0
atrophy	0
at	0
all	0
doses	0
.	0

Significant	0
overt	0
signs	0
of	0
toxicity	0
and	0
deaths	0
occurred	0
at	0
240	0
mg/kg	0
,	0
whereas	0
body-weight	0
and	0
food-consumption	0
decreases	0
occurred	0
at	0
60	0
and	0
240	0
mg/kg	0
.	0

When	0
BMS-189453	0
was	0
administered	0
to	0
male	0
rats	0
at	0
daily	0
doses	0
ranging	0
from	0
12.5	0
to	0
100	0
mg/kg	0
for	0
1	0
week	0
,	0
only	0
minimal	0
testicular	0
changes	0
occurred	0
at	0
all	0
doses	0
,	0
shortly	0
after	0
the	0
dosing	0
period	0
.	0

However	0
,	0
after	0
a	0
1-month	0
drug-free	0
observation	0
period	0
,	0
marked	0
testicular	0
atrophy	0
was	0
evident	0
at	0
all	0
doses	0
.	0

BMS-189453	0
was	0
then	0
administered	0
at	0
doses	0
of	0
2	0
,	0
10	0
,	0
or	0
50	0
mg/kg	0
to	0
male	0
rats	0
for	0
1	0
,	0
3	0
,	0
or	0
7	0
consecutive	0
days	0
.	0

Dose-	0
and	0
duration-dependent	0
testicular	0
toxicity	0
that	0
occurred	0
after	0
a	0
1-month	0
observation	0
period	0
did	0
not	0
recover	0
,	0
and	0
,	0
in	0
some	0
cases	0
,	0
was	0
more	0
severe	0
4	0
months	0
after	0
the	0
last	0
dose	0
.	0

In	0
rabbits	0
administered	0
BMS-189453	0
at	0
oral	0
doses	0
of	0
2	0
,	0
10	0
,	0
or	0
50	0
mg/kg	0
for	0
1	0
week	0
,	0
testicular	0
degeneration	0
and	0
atrophy	0
were	0
evident	0
in	0
the	0
high-dose	0
group	0
at	0
1	0
month	0
following	0
treatment	0
.	0

These	0
studies	0
indicate	0
that	0
retinoid	0
antagonists	0
can	0
selectively	0
produce	0
progressive	0
and	0
prolonged	0
testicular	0
toxicity	0
after	0
single	0
or	0
repeated	0
oral	0
doses	0
that	0
are	0
otherwise	0
well	0
tolerated	0
.	0

Sequential	0
involvement	0
of	0
NFAT	9
and	0
Egr	9
transcription	9
factors	10
in	0
FasL	0
regulation	0
.	0

The	0
critical	0
function	0
of	0
NFAT	9
proteins	10
in	0
maintaining	0
lymphoid	0
homeostasis	0
was	0
revealed	0
in	0
mice	0
lacking	0
both	0
NFATp	9
and	0
NFAT4	9
(	0
DKO	0
)	0
.	0

DKO	0
mice	0
exhibit	0
increased	0
lymphoproliferation	0
,	0
decreased	0
activation-induced	0
cell	0
death	0
,	0
and	0
impaired	0
induction	0
of	0
FasL	9
.	0

The	0
transcription	9
factors	10
Egr2	9
and	0
Egr3	9
are	0
potent	0
activators	0
of	0
FasL	0
expression	0
.	0

Here	0
we	0
find	0
that	0
Egr2	1
and	0
Egr3	1
are	0
NFAT	1
target	2
genes	2
.	0

Activation	0
of	0
FasL	9
occurs	0
via	0
the	0
NFAT	9
-dependent	0
induction	0
of	0
Egr3	1
,	0
as	0
demonstrated	0
by	0
the	0
ability	0
of	0
exogenously	0
provided	0
NFATp	9
to	0
restore	0
Egr	9
-dependent	0
FasL	0
promoter	0
activity	0
in	0
DKO	7
lymph	8
node	8
cells	8
.	0

Further	0
,	0
Egr3	1
expression	0
is	0
enriched	0
in	0
Th1	7
cells	8
,	0
suggesting	0
a	0
molecular	0
basis	0
for	0
the	0
known	0
preferential	0
expression	0
of	0
FasL	9
in	0
the	0
Th1	0
versus	0
Th2	0
subset	0
.	0

Mechanisms	0
and	0
clinical	0
relevance	0
of	0
nongenomic	0
glucocorticoid	0
actions	0
.	0

Glucocorticoids	0
have	0
profound	0
anti-inflammatory	0
and	0
immunosuppressive	0
actions	0
when	0
used	0
therapeutically	0
.	0

The	0
therapeutic	0
dose	0
is	0
quite	0
variable	0
and	0
depends	0
on	0
the	0
disease	0
,	0
but	0
ranges	0
from	0
very	0
low	0
to	0
extremely	0
high	0
.	0

The	0
rationale	0
for	0
the	0
use	0
of	0
various	0
dosage	0
regimens	0
for	0
specific	0
clinical	0
indications	0
is	0
the	0
existence	0
of	0
three	0
distinct	0
,	0
therapeutically	0
relevant	0
effects	0
:	0
genomic	0
,	0
specific	0
nongenomic	0
and	0
unspecific	0
nongenomic	0
.	0

Genomic	0
effects	0
are	0
mediated	0
by	0
cytosolic	9
receptors	10
that	0
alter	0
expression	0
of	0
specific	0
genes	0
.	0

Specific	0
nongenomic	0
effects	0
occur	0
within	0
a	0
few	0
minutes	0
and	0
are	0
mediated	0
by	0
steroid-selective	9
membrane	10
receptors	10
.	0

Unspecific	0
nongenomic	0
effects	0
occur	0
within	0
seconds	0
,	0
but	0
only	0
at	0
high	0
glucocorticoid	0
dosages	0
,	0
and	0
seem	0
to	0
result	0
from	0
direct	0
interactions	0
with	0
biological	0
membranes	0
.	0

For	0
unspecific	0
nongenomic	0
effects	0
,	0
methylprednisolone	0
and	0
other	0
glucocorticoids	0
have	0
been	0
shown	0
to	0
inhibit	0
cation	0
cycling	0
across	0
the	0
plasma	0
membrane	0
,	0
but	0
to	0
have	0
little	0
effect	0
on	0
protein	0
synthesis	0
.	0

Thus	0
,	0
glucocorticoids	0
could	0
diminish	0
or	0
prevent	0
the	0
acute	0
immune	0
response	0
by	0
interfering	0
with	0
processes	0
such	0
as	0
the	0
rise	0
in	0
intracellular	0
Ca2+	0
concentration	0
.	0

It	0
is	0
proposed	0
that	0
the	0
additional	0
therapeutic	0
benefit	0
of	0
higher	0
doses	0
is	0
obtained	0
via	0
these	0
nongenomic	0
effects	0
.	0

High	0
glucose-induced	0
intercellular	9
adhesion	10
molecule-1	10
(	0
ICAM-1	9
)	0
expression	0
through	0
an	0
osmotic	0
effect	0
in	0
rat	7
mesangial	8
cells	8
is	0
PKC-NF-kappa	0
B-dependent	0
.	0

AIMS/HYPOTHESIS	0
:	0
Infiltration	0
of	0
mononuclear	7
cells	8
and	0
glomerular	0
enlargement	0
accompanied	0
by	0
glomerular	7
cell	8
proliferation	0
are	0
very	0
early	0
characteristics	0
of	0
the	0
pathophysiology	0
of	0
diabetes	0
.	0

To	0
clarify	0
the	0
mechanism	0
of	0
early	0
diabetic	0
nephropathy	0
,	0
we	0
measured	0
[	0
3H	0
]	0
-thymidine	0
incorporation	0
and	0
cell	0
numbers	0
to	0
show	0
the	0
influence	0
of	0
a	0
high	0
ambient	0
glucose	0
concentration	0
and	0
the	0
osmotic	0
effect	0
on	0
rat	7
mesangial	8
cell	8
proliferation	0
.	0

We	0
also	0
measured	0
the	0
effect	0
of	0
high	0
glucose	0
on	0
the	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
and	0
vascular	9
adhesion	10
molecule-1	10
by	0
flow	0
cytometry	0
and	0
semiquantitative	0
RT-PCR	0
in	0
mesangial	7
cells	8
and	0
the	0
adhesion	0
of	0
leukocytes	7
to	0
mesangial	7
cells	8
.	0

METHODS/RESULTS	0
:	0
Cells	0
exposed	0
to	0
high	0
D-glucose	0
(	0
30	0
mmol/l	0
)	0
caused	0
an	0
increase	0
in	0
[	0
3H	0
]	0
-thymidine	0
incorporation	0
and	0
cell	0
numbers	0
at	0
24	0
and	0
48	0
h	0
and	0
normalized	0
at	0
72	0
h	0
(	0
p	0
<	0
0.05	0
)	0
,	0
whereas	0
these	0
changes	0
were	0
not	0
found	0
in	0
high	0
mannitol	0
(	0
30	0
mmol/l	0
)	0
,	0
IL-1	9
beta	10
,	0
or	0
TNF	9
alpha	10
-stimulated	0
mesangial	7
cells	8
.	0

Cells	0
exposed	0
to	0
high-glucose	0
(	0
15	0
,	0
30	0
,	0
or	0
60	0
mmol/l	0
)	0
or	0
osmotic	0
agents	0
(	0
L-glucose	0
,	0
raffinose	0
and	0
mannitol	0
)	0
showed	0
that	0
intercellular	9
adhesion	10
molecule-1	10
expression	0
began	0
to	0
increase	0
after	0
24	0
h	0
,	0
reached	0
its	0
maximum	0
at	0
24	0
and	0
48	0
h	0
and	0
gradually	0
decreased	0
afterwards	0
.	0

The	0
stimulatory	0
effects	0
of	0
high	0
glucose	0
and	0
high	0
mannitol	0
on	0
mRNA	0
expression	0
were	0
observed	0
as	0
early	0
as	0
6	0
h	0
and	0
reached	0
its	0
maximum	0
at	0
12	0
h	0
.	0

Up-regulation	0
of	0
ICAM-1	9
protein	0
and	0
mRNA	0
was	0
also	0
found	0
in	0
IL-1-beta	9
and	0
TNF-alpha	9
-stimulated	0
mesangial	7
cells	8
.	0

Neither	0
vascular	9
adhesion	10
molecule-1	10
protein	0
nor	0
mRNA	0
expression	0
was	0
,	0
however	0
,	0
affected	0
by	0
high	0
glucose	0
and	0
high	0
mannitol	0
.	0

Notably	0
,	0
the	0
protein	0
kinase	0
C	0
inhibitors	0
calphostin	0
C	0
and	0
staurosporine	0
reduced	0
high	0
glucose-	0
or	0
high	0
mannitol-induced	0
intercellular	3
adhesion	4
molecule-1	4
mRNA	0
expression	0
and	0
high	0
glucose-induced	0
proliferation	0
.	0

Furthermore	0
,	0
the	0
NF-kappa	0
B	0
inhibitor	0
N-tosyl-L-phenylalanine	0
chloromethyl	0
ketone	0
reduced	0
high	0
glucose-	0
or	0
high	0
mannitol-induced	0
intercellular	3
adhesion	4
molecule-1	4
mRNA	0
expression	0
and	0
high	0
glucose-induced	0
proliferation	0
.	0

Results	0
showed	0
that	0
high	0
glucose	0
(	0
15	0
,	0
30	0
mmol/l	0
)	0
or	0
high	0
concentrations	0
of	0
osmotic	0
agents	0
remarkably	0
increased	0
the	0
number	0
of	0
adherent	0
leukocytes	7
to	0
mesangial	7
cells	8
(	0
p	0
<	0
0.01	0
)	0
compared	0
with	0
control	7
cells	8
(	0
5	0
mmol/l	0
D-glucose	0
)	0
.	0

Functional	0
blocking	0
of	0
intercellular	9
adhesion	10
molecule-1	10
on	0
mesangial	7
cells	8
with	0
rat	9
intercellular	10
adhesion	10
molecule-1	10
monoclonal	10
antibody	10
,	0
calphostin	0
C	0
,	0
staurosporine	0
,	0
or	0
N-tosyl-L-phenylalanine	0
chloromethyl	0
ketone	0
significantly	0
inhibited	0
high	0
glucose-	0
or	0
high	0
mannitol-induced	0
increase	0
in	0
leukocyte	0
adhesion	0
(	0
p	0
<	0
<	0
0.05	0
)	0
.	0

CONCLUSION/INTERPRETATION	0
:	0
These	0
results	0
suggest	0
that	0
high	0
glucose	0
can	0
upregulate	0
intercellular	9
adhesion	10
molecule-1	10
protein	0
and	0
mRNA	0
expression	0
but	0
not	0
vascular	0
adhesion	0
molecule-1	0
expression	0
in	0
mesangial	7
cells	8
and	0
promote	0
leukocyte	0
adhesion	0
through	0
up-regulation	0
of	0
intercellular	9
adhesion	10
molecule-1	10
through	0
osmotic	0
effect	0
,	0
possibly	0
depending	0
on	0
the	0
protein	9
kinase	10
C	10
nuclear	9
factor-kappa	10
B	10
(	0
PKC	9
-	0
NF-kappa	9
B	10
)	0
pathway	0
.	0

High	0
glucose	0
itself	0
can	0
also	0
promote	0
mesangial	0
cell	0
proliferation	0
through	0
the	0
PKC-NF-kappa	0
B	0
pathways	0
.	0

We	0
conclude	0
that	0
hyperglycaemia	0
in	0
itself	0
seems	0
to	0
be	0
an	0
important	0
factor	0
in	0
the	0
development	0
of	0
early	0
diabetic	0
nephropathy	0
.	0

Combined	0
corticosteroid/	0
granulocyte	9
colony-stimulating	10
factor	10
(	0
G-CSF	9
)	0
therapy	0
in	0
the	0
treatment	0
of	0
severe	0
congenital	0
neutropenia	0
unresponsive	0
to	0
G-CSF	9
:	0
Activated	0
glucocorticoid	9
receptors	10
synergize	0
with	0
G-CSF	9
signals	0
.	0

More	0
than	0
90	0
%	0
of	0
patients	0
with	0
severe	0
congenital	0
neutropenia	0
(	0
SCN	0
)	0
respond	0
to	0
granulocyte	9
colony-stimulating	10
factor	10
(	0
G-CSF	9
)	0
therapy	0
.	0

The	0
basis	0
for	0
the	0
refractory	0
state	0
in	0
the	0
remaining	0
patients	0
is	0
unknown	0
.	0

To	0
address	0
this	0
issue	0
,	0
we	0
studied	0
a	0
child	0
with	0
SCN	0
who	0
was	0
totally	0
unresponsive	0
to	0
G-CSF	9
and	0
had	0
a	0
novel	0
point	0
mutation	0
in	0
the	0
extracellular	9
domain	10
of	0
the	0
G-CSF	9
receptor	10
(	0
GCSF-R	9
)	0
.	0

Marrow	0
stromal	0
support	0
of	0
granulopoiesis	0
was	0
evaluated	0
by	0
plating	0
CD34	7
(	8
+	8
)	8
cells	8
on	0
preformed	0
stromal	0
layers	0
.	0

Nonadherent	7
cells	8
were	0
harvested	0
and	0
assayed	0
in	0
clonogenic	0
assays	0
for	0
granulocytic	0
colony	0
production	0
.	0

The	0
in	0
vitro	0
effect	0
of	0
G-CSF	9
and	0
corticosteroids	0
on	0
granulopoiesis	0
was	0
evaluated	0
in	0
clonogenic	0
assays	0
of	0
marrow	7
mononuclear	8
cells	8
,	0
by	0
proliferation	0
studies	0
of	0
the	0
murine	5
myeloid	6
cell	6
line	6
32D	6
expressing	0
the	0
patient	0
's	0
mutated	9
G-CSFR	10
,	0
and	0
by	0
measuring	0
STAT5	0
activation	0
in	0
nuclear	0
extracts	0
from	0
stimulated	7
cells	8
.	0

Patient	0
's	0
stroma	0
supported	0
granulopoiesis	0
derived	0
from	0
control	0
marrow	7
CD34	8
(	8
+	8
)	8
cells	8
in	0
a	0
normal	0
manner	0
.	0

Normal	0
stroma	0
,	0
however	0
,	0
failed	0
to	0
induce	0
granulopoiesis	0
from	0
patient	0
's	0
CD34	7
(	8
+	8
)	8
cells	8
.	0

Clonogenic	0
assays	0
of	0
the	0
patient	0
's	0
marrow	7
mononuclear	8
cells	8
incorporating	0
either	0
G-CSF	9
or	0
hydrocortisone	0
produced	0
little	0
neutrophil	0
growth	0
.	0

In	0
contrast	0
,	0
inclusion	0
of	0
both	0
G-CSF	9
and	0
hydrocortisone	0
in	0
the	0
cytokine	9
``	10
cocktail	10
''	10
markedly	0
increased	0
the	0
neutrophil	0
numbers	0
.	0

Proliferation	0
of	0
32D	5
cells	6
expressing	0
the	0
mutated	9
receptor	10
and	0
STAT5	0
activation	0
were	0
improved	0
by	0
a	0
combination	0
of	0
G-CSF	9
and	0
dexamethasone	0
.	0

When	0
small	0
daily	0
doses	0
of	0
oral	0
prednisone	0
were	0
then	0
administered	0
to	0
the	0
patient	0
with	0
conventional	0
doses	0
of	0
subcutaneous	9
G-CSF	10
,	0
the	0
patient	0
responded	0
with	0
increased	0
neutrophil	0
numbers	0
and	0
with	0
a	0
complete	0
reversal	0
of	0
the	0
infectious	0
problems	0
.	0

These	0
data	0
provide	0
insight	0
into	0
SCN	0
unresponsive	0
to	0
standard	0
G-CSF	9
treatment	0
and	0
to	0
the	0
potential	0
corrective	0
action	0
of	0
combined	0
treatment	0
with	0
G-CSF	9
and	0
corticosteroids	0
through	0
synergistic	0
activation	0
of	0
STAT5	9
.	0

Human	7
renal	8
mesangial	8
cells	8
are	0
a	0
target	0
for	0
the	0
anti-inflammatory	0
action	0
of	0
9-cis	0
retinoic	0
acid	0
.	0

Mesangial	7
cells	8
play	0
an	0
active	0
role	0
in	0
the	0
inflammatory	0
response	0
to	0
glomerular	0
injury	0
.	0

We	0
have	0
studied	0
in	0
cultured	5
human	6
mesangial	6
cells	6
(	0
CHMC	5
)	0
several	0
effects	0
of	0
9-cis	0
retinoic	0
acid	0
(	0
9-cRA	0
)	0
,	0
an	0
activator	0
of	0
both	0
retinoic	9
acid	10
receptors	10
(	0
RARs	9
)	0
and	0
retinoid	9
X	10
receptors	10
(	0
RXRs	9
)	0
.	0

9-cRA	0
inhibited	0
foetal	0
calf	0
serum-induced	0
CHMC	5
proliferation	0
.	0

It	0
also	0
prevented	0
CHMC	5
death	0
induced	0
by	0
the	0
inflammatory	0
mediator	0
H	0
(	0
2	0
)	0
O	0
(	0
2	0
)	0
.	0

This	0
preventive	0
effect	0
was	0
not	0
due	0
to	0
any	0
increase	0
in	0
H	0
(	0
2	0
)	0
O	0
(	0
2	0
)	0
catabolism	0
and	0
it	0
persisted	0
even	0
when	0
both	0
catalase	0
and	0
glutathione	0
synthesis	0
were	0
inhibited	0
.	0

Finally	0
,	0
9-cRA	0
diminished	0
monocyte	0
adhesion	0
to	0
FCS-stimulated	5
CHMC	6
.	0

Interestingly	0
,	0
the	0
retinoid	0
also	0
inhibited	0
in	0
FCS-stimulated	7
cells	8
the	0
protein	0
expression	0
of	0
two	0
mesangial	9
adhesion	10
molecules	10
,	0
fibronectin	9
and	0
osteopontin	9
,	0
but	0
it	0
did	0
not	0
modify	0
the	0
protein	0
expression	0
of	0
intercellular	9
adhesion	10
molecule-1	10
and	0
vascular	9
adhesion	10
molecule-1	10
.	0

All	0
major	0
RARs	9
and	10
RXRs	10
isotypes	10
were	0
expressed	0
in	0
CHMC	5
regardless	0
of	0
the	0
presence	0
or	0
absence	0
of	0
9-cRA	0
.	0

Transcripts	0
to	0
RAR-alpha	3
,	0
RAR-beta	3
and	0
RXR-alpha	3
increased	0
after	0
incubation	0
with	0
9-cRA	0
whereas	0
RXR-gamma	3
was	0
inhibited	0
,	0
suggesting	0
a	0
major	0
role	0
for	0
RARs	9
and	0
RXRs	9
in	0
9-cRA-anti-inflammatory	0
effects	0
.	0

9-cRA	0
was	0
toxic	0
only	0
at	0
50	0
microM	0
(	0
a	0
concentration	0
50	0
-	0
5000	0
times	0
higher	0
than	0
required	0
for	0
the	0
effects	0
above	0
)	0
.	0

Cell	0
death	0
occurred	0
by	0
apoptosis	0
,	0
whose	0
onset	0
was	0
associated	0
with	0
a	0
pronounced	0
increase	0
in	0
catalase	0
activity	0
and	0
reduced	0
glutathione	0
content	0
,	0
being	0
more	0
effectively	0
induced	0
by	0
all-trans	0
retinoic	0
acid	0
.	0

Modulation	0
of	0
the	0
oxidant/antioxidant	0
balance	0
failed	0
to	0
inhibit	0
apoptosis	0
.	0

We	0
conclude	0
that	0
mesangial	7
cells	8
might	0
be	0
a	0
target	0
for	0
the	0
treatment	0
of	0
inflammatory	0
glomerulopathies	0
with	0
9-cRA	0
.	0

Expression	0
of	0
mammalian	1
defensin	2
genes	2
.	0

Antimicrobial	0
peptides	0
are	0
a	0
prevalent	0
mechanism	0
of	0
host	0
defense	0
found	0
throughout	0
nature	0
.	0

In	0
mammals	0
,	0
defensins	9
are	0
among	0
the	0
most	0
abundant	0
of	0
these	0
broad-spectrum	0
antibiotics	0
,	0
and	0
are	0
expressed	0
in	0
epithelial	7
and	8
hematopoietic	8
cells	8
.	0

The	0
defensin	0
peptides	0
are	0
especially	0
abundant	0
in	0
neutrophils	7
;	0
however	0
,	0
gene	0
expression	0
is	0
limited	0
to	0
the	0
promyelocyte	0
stage	0
.	0

In	0
epithelial	7
cells	8
,	0
defensin	1
genes	2
are	0
found	0
as	0
both	0
constitutively	0
expressed	0
and	0
inducible	0
.	0

Induction	0
has	0
been	0
observed	0
in	0
vitro	0
by	0
stimulation	0
with	0
bacterial	0
lipopolysaccharide	0
as	0
well	0
as	0
inflammatory	0
mediators	0
.	0

In	0
vivo	0
,	0
up-regulation	0
of	0
several	0
defensin	1
genes	2
occurs	0
in	0
both	0
infectious	0
and	0
inflammatory	0
states	0
.	0

Gene	0
regulation	0
occurs	0
via	0
signal	0
transduction	0
pathways	0
common	0
to	0
other	0
innate	0
immune	0
responses	0
,	0
utilizing	0
transcription	9
factors	10
such	0
as	0
nuclear	9
factor	10
(	10
NF	10
)	10
-kappaB	10
and	0
NF	9
interleukin-6	10
.	0

Together	0
,	0
the	0
data	0
suggest	0
a	0
broad-based	0
innate	0
host	0
defense	0
whereby	0
potent	0
antimicrobial	0
peptides	0
are	0
present	0
to	0
prevent	0
initial	0
colonization	0
by	0
pathogenic	0
microorganisms	0
.	0

In	0
addition	0
,	0
the	0
recognition	0
of	0
bacteria	0
coupled	0
with	0
a	0
nascent	0
inflammatory	0
response	0
can	0
bolster	0
this	0
defense	0
by	0
a	0
coordinated	0
up-regulation	0
of	0
the	0
peptides	0
.	0

Multiple	0
signals	0
required	0
for	0
cyclic	9
AMP-responsive	10
element	10
binding	10
protein	10
(	0
CREB	9
)	0
binding	0
protein	0
interaction	0
induced	0
by	0
CD3/CD28	0
costimulation	0
.	0

The	0
optimal	0
activation	0
of	0
cAMP-responsive	9
element	10
binding	10
protein	10
(	0
CREB	9
)	0
,	0
similar	0
to	0
the	0
full	0
activation	0
of	0
T	7
lymphocytes	8
,	0
requires	0
the	0
stimulation	0
of	0
both	0
CD3	9
and	0
CD28	9
.	0

Using	0
a	0
reporter	0
system	0
to	0
detect	0
interaction	0
of	0
CREB	9
and	0
CREB-binding	9
protein	10
(	0
CBP	9
)	0
,	0
in	0
this	0
study	0
we	0
found	0
that	0
CREB	9
binds	0
to	0
CBP	9
only	0
by	0
engagement	0
of	0
both	0
CD3	9
and	0
CD28	9
.	0

CD3/CD28	9
-promoted	0
CREB	9
-	0
CBP	9
interaction	0
was	0
dependent	0
on	0
p38	9
mitogen-activated	10
protein	10
kinase	10
(	0
MAPK	9
)	0
and	0
calcium/calmodulin-dependent	9
protein	10
kinase	10
(	10
CaMK	10
)	10
IV	10
in	0
addition	0
to	0
the	0
previously	0
identified	0
extracellular	0
signal-regulated	0
kinase	0
pathway	0
.	0

Extracellular	9
signal-regulated	10
kinase	10
,	10
CaMKIV	10
,	0
and	0
p38	9
MAPK	10
were	0
also	0
the	0
kinases	0
involved	0
in	0
CREB	9
Ser	0
(	0
133	0
)	0
phosphorylation	0
induced	0
by	0
CD3/CD28	9
.	0

A	0
reconstitution	0
experiment	0
illustrated	0
that	0
optimum	0
CREB	9
-	0
CBP	9
interaction	0
and	0
CREB	9
trans-activation	0
were	0
attained	0
when	0
these	0
three	0
kinase	0
pathways	0
were	0
simultaneously	0
activated	0
in	0
T	7
cells	8
.	0

Our	0
results	0
demonstrate	0
that	0
coordinated	0
activation	0
of	0
different	0
kinases	9
leads	0
to	0
full	0
activation	0
of	0
CREB	9
.	0

Notably	0
,	0
CD28	0
ligation	0
activated	0
p38	9
MAPK	10
and	0
CaMKIV	9
,	0
the	0
kinases	9
stimulated	0
by	0
CD3	0
engagement	0
,	0
suggesting	0
that	0
CD28	9
acts	0
by	0
increasing	0
the	0
activation	0
extent	0
of	0
p38	9
MAPK	10
and	0
CaMKIV	9
.	0

These	0
results	0
support	0
the	0
model	0
of	0
a	0
minimum	0
activation	0
threshold	0
for	0
CREB	9
-	0
CBP	9
interaction	0
that	0
can	0
be	0
reached	0
only	0
when	0
both	0
CD3	9
and	0
CD28	9
are	0
stimulated	0
.	0

The	0
murine	1
IL-2	2
promoter	2
contains	0
distal	1
regulatory	2
elements	2
responsive	0
to	0
the	0
Ah	9
receptor	10
,	0
a	0
member	0
of	0
the	0
evolutionarily	0
conserved	0
bHLH-PAS	9
transcription	10
factor	10
family	10
.	0

Signaling	0
through	0
the	0
TCR	9
and	0
costimulatory	0
signals	0
primarily	0
control	0
transcription	0
of	0
the	0
IL-2	1
gene	2
in	0
naive	7
T	8
cells	8
.	0

The	0
minimal	1
promoter	2
necessary	0
for	0
this	0
expression	0
lies	0
proximal	0
,	0
between	0
-300	0
and	0
the	0
transcription	1
start	2
site	2
.	0

We	0
had	0
previously	0
shown	0
that	0
activation	0
of	0
the	0
arylhydrocarbon	9
receptor	10
(	0
AHR	9
)	0
,	0
a	0
member	0
of	0
the	0
bHLH-PAS	9
family	10
of	10
transcription	10
factors	10
,	0
leads	0
to	0
increased	0
mRNA	0
expression	0
of	0
IL-2	3
in	0
murine	7
fetal	8
thymocytes	8
.	0

The	0
AHR	9
is	0
abundant	0
in	0
the	0
thymus	0
and	0
may	0
play	0
a	0
role	0
for	0
the	0
development	0
of	0
the	0
immune	0
system	0
.	0

Moreover	0
,	0
its	0
overactivation	0
by	0
chemicals	0
such	0
as	0
dioxins	0
leads	0
to	0
immunosuppression	0
and	0
thymic	0
involution	0
.	0

Binding	0
motifs	0
for	0
the	0
liganded	9
AHR	10
can	0
be	0
identified	0
in	0
the	0
distal	1
region	2
-1300	2
to	2
-800	2
of	0
the	0
mouse	1
IL-2	2
promoter	2
.	0

We	0
show	0
here	0
that	0
these	0
DNA	1
motifs	2
,	0
the	0
so-called	0
dioxin	1
response	2
elements	2
,	0
after	0
binding	0
to	0
the	0
liganded	9
AHR	10
are	0
sufficient	0
to	0
transactivate	0
luciferase	0
expression	0
in	0
a	0
reporter	0
gene	0
system	0
.	0

The	0
IL-2	1
gene	2
can	0
be	0
induced	0
by	0
the	0
AHR	9
also	0
in	0
thymocytes	7
in	0
vivo	0
after	0
injection	0
of	0
2	0
,	0
3	0
,	0
7	0
,	0
8-tetrachlorodibenzo-p-dioxin	0
,	0
a	0
potent	0
ligand	0
of	0
the	0
AHR	9
.	0

The	0
AHR	9
mediates	0
the	0
IL-2	0
induction	0
as	0
shown	0
with	0
AHR	9
-deficient	0
mice	0
.	0

However	0
,	0
in	0
spleen	7
cells	8
in	0
vitro	0
costimulation	0
via	0
the	0
TCR	9
is	0
necessary	0
for	0
optimal	0
IL-2	1
gene	2
induction	0
.	0

Thus	0
,	0
the	0
IL-2	1
promoter	2
region	2
contains	0
novel	0
distal	1
regulatory	2
elements	2
that	0
can	0
be	0
addressed	0
by	0
the	0
AHR	9
to	0
induce	0
IL-2	1
and	0
can	0
cooperate	0
with	0
the	0
proximal	1
promoter	2

Visualization	0
of	0
Syk-antigen	9
receptor	10
interactions	0
using	0
green	9
fluorescent	10
protein	10
:	0
differential	0
roles	0
for	0
Syk	9
and	0
Lyn	9
in	0
the	0
regulation	0
of	0
receptor	0
capping	0
and	0
internalization	0
.	0

The	0
cross-linking	0
of	0
the	0
B	9
cell	10
Ag	10
receptor	10
(	0
BCR	9
)	0
is	0
coupled	0
to	0
the	0
stimulation	0
of	0
multiple	0
intracellular	0
signal	0
transduction	0
cascades	0
via	0
receptor-associated	0
,	0
protein	9
tyrosine	10
kinases	10
of	0
both	0
the	0
Src	9
and	10
Syk	10
families	10
.	0

To	0
monitor	0
changes	0
in	0
the	0
subcellular	0
distribution	0
of	0
Syk	9
in	0
B	7
cells	8
responding	0
to	0
BCR	9
cross-linking	0
,	0
we	0
expressed	0
in	0
Syk	9
-deficient	0
DT40	5
B	6
cells	6
a	0
fusion	9
protein	10
consisting	0
of	0
Syk	9
coupled	0
to	0
green	9
fluorescent	10
protein	10
.	0

Treatment	0
of	0
these	0
cells	0
with	0
anti-IgM	9
Abs	10
leads	0
to	0
the	0
recruitment	0
of	0
the	0
kinase	9
from	0
cytoplasmic	0
and	0
nuclear	0
compartments	0
to	0
the	0
site	0
of	0
the	0
cross-linked	9
receptor	10
at	0
the	0
plasma	0
membrane	0
.	0

The	0
Syk-receptor	9
complexes	10
aggregate	0
into	0
membrane	0
patches	0
that	0
redistribute	0
to	0
form	0
a	0
cap	0
at	0
one	0
pole	0
of	0
the	0
cell	0
.	0

Syk	9
is	0
not	0
demonstrably	0
associated	0
with	0
the	0
internalized	9
receptor	10
.	0

Catalytically	0
active	0
Syk	9
promotes	0
and	0
stabilizes	0
the	0
formation	0
of	0
tightly	9
capped	10
BCR	10
complexes	10
at	0
the	0
plasma	0
membrane	0
.	0

Lyn	9
is	0
not	0
required	0
for	0
the	0
recruitment	0
of	0
Syk	9
to	0
the	0
cross-linked	9
receptor	10
,	0
but	0
is	0
required	0
for	0
the	0
internalization	0
of	0
the	0
clustered	0
BCR	9
complexes	10
.	0

In	0
the	0
absence	0
of	0
Lyn	9
,	0
receptor-Syk	9
complexes	10
at	0
the	0
plasma	0
membrane	0
are	0
long	0
lived	0
,	0
and	0
the	0
receptor-mediated	0
activation	0
of	0
the	0
NF-AT	9
transcription	10
factor	10
is	0
enhanced	0
.	0

Thus	0
,	0
Lyn	9
appears	0
to	0
function	0
to	0
negatively	0
regulate	0
aspects	0
of	0
BCR	9
-dependent	0
signaling	0
by	0
stimulating	0
receptor	0
internalization	0
and	0
down-regulation	0
.	0

Renal	0
interstitial	0
fibrosis	0
is	0
reduced	0
in	0
angiotensin	9
II	10
type	10
1a	10
receptor	10
-deficient	0
mice	0
.	0

Unilateral	0
ureteral	0
obstruction	0
(	0
UUO	0
)	0
results	0
in	0
tubulointerstitial	0
fibrosis	0
of	0
the	0
affected	0
kidney	0
by	0
stimulating	0
the	0
renin-angiotensin	0
system	0
.	0

This	0
study	0
established	0
a	0
UUO	0
model	0
in	0
angiotensin	9
type	10
1a	10
receptor	10
(	0
AT1a	9
)	0
deficient	0
(	0
mutant	0
)	0
mice	0
to	0
elucidate	0
the	0
role	0
of	0
angiotensin	9
II	10
through	0
AT1a	9
on	0
the	0
fibrosis	0
of	0
the	0
obstructed	0
kidney	0
(	0
OBK	0
)	0
.	0

The	0
relative	0
volume	0
of	0
the	0
tubulointerstitium	0
was	0
measured	0
by	0
an	0
image	0
analyzer	0
;	0
deposition	0
of	0
collagen	9
types	10
III	10
and	10
IV	10
and	0
monocyte	7
/	0
macrophage	7
infiltration	0
were	0
histologically	0
examined	0
using	0
specific	9
antibodies	10
.	0

Also	0
determined	0
were	0
the	0
mRNA	0
levels	0
of	0
transforming	9
growth	10
factor-beta	10
by	0
Northern	0
blot	0
analysis	0
.	0

Nuclear	9
factor-kappaB	10
activity	0
was	0
assessed	0
by	0
gel	0
shift	0
assay	0
.	0

UUO	0
in	0
wild	0
mice	0
resulted	0
in	0
a	0
marked	0
expansion	0
of	0
relative	0
volume	0
of	0
the	0
tubulointerstitium	0
,	0
together	0
with	0
increased	0
deposition	0
of	0
collagen	9
types	10
III	10
and	10
IV	10
and	0
number	0
of	0
infiltrated	0
monocytes	7
/	0
macrophages	7
in	0
the	0
interstitium	0
,	0
relative	0
to	0
sham-operated	0
mice	0
.	0

In	0
comparison	0
,	0
these	0
changes	0
were	0
significantly	0
lower	0
in	0
mutant	0
mice	0
with	0
UUO	0
.	0

The	0
mRNA	0
level	0
of	0
transforming	9
growth	10
factor-beta	10
was	0
significantly	0
higher	0
in	0
the	0
OBK	0
of	0
wild	0
mice	0
with	0
UUO	0
compared	0
with	0
sham-operated	0
mice	0
.	0

In	0
contrast	0
,	0
the	0
increase	0
in	0
mRNA	0
level	0
in	0
the	0
OBK	0
of	0
mutant	0
mice	0
was	0
significantly	0
less	0
than	0
in	0
wild	0
mice	0
.	0

Finally	0
,	0
UUO	0
resulted	0
in	0
activation	0
of	0
nuclear	9
factor-kappaB	10
in	0
wild	0
mice	0
but	0
was	0
inhibited	0
in	0
the	0
OBK	0
of	0
mutant	0
mice	0
.	0

The	0
results	0
provide	0
direct	0
evidence	0
that	0
angiotensin	9
II	10
acting	0
via	0
the	0
AT1a	9
plays	0
a	0
pivotal	0
role	0
in	0
the	0
development	0
of	0
tubulointerstitial	0
fibrosis	0
in	0
UUO	0
.	0

HLA-DQ	9
tetramers	10
identify	0
epitope-specific	7
T	8
cells	8
in	0
peripheral	0
blood	0
of	0
herpes	0
simplex	0
virus	0
type	0
2-infected	0
individuals	0
:	0
direct	0
detection	0
of	0
immunodominant	7
antigen-responsive	8
cells	8
.	0

Ag-specific	7
CD4+	8
T	8
cells	8
are	0
present	0
in	0
peripheral	0
blood	0
in	0
low	0
frequency	0
,	0
where	0
they	0
undergo	0
recruitment	0
and	0
expansion	0
during	0
immune	0
responses	0
and	0
in	0
the	0
pathogenesis	0
of	0
numerous	0
autoimmune	0
diseases	0
.	0

MHC	9
tetramers	10
,	0
which	0
constitute	0
a	0
labeled	9
MHC-peptide	10
ligand	10
suitable	0
for	0
binding	0
to	0
the	0
Ag-specific	9
receptor	10
on	0
T	7
cells	8
,	0
provide	0
a	0
novel	0
approach	0
for	0
the	0
detection	0
and	0
characterization	0
of	0
such	0
rare	7
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
utilized	0
this	0
technology	0
to	0
identify	0
HLA	9
DQ	10
-restricted	0
Ag-specific	7
T	8
cells	8
in	0
the	0
peripheral	0
blood	0
of	0
human	0
subjects	0
and	0
to	0
identify	0
immunodominant	0
epitopes	0
associated	0
with	0
viral	0
infection	0
.	0

Peptides	0
representing	0
potential	0
epitope	9
regions	10
of	0
the	0
VP16	9
protein	10
from	0
HSV-2	0
were	0
loaded	0
onto	0
recombinant	9
DQ0602	10
molecules	10
to	0
generate	0
a	0
panel	0
of	0
Ag-specific	9
DQ0602	10
tetramers	10
.	0

VP16	9
Ag	10
-specific	0
DQ-restricted	7
T	8
cells	8
were	0
identified	0
and	0
expanded	0
from	0
the	0
peripheral	0
blood	0
of	0
HSV-2-infected	0
individuals	0
,	0
representing	0
two	0
predominant	0
epitope	0
specificities	0
.	0

Although	0
the	0
VP16	0
369-380	0
peptide	0
has	0
a	0
lower	0
binding	0
affinity	0
for	0
DQ0602	9
molecules	10
than	0
the	0
VP16	0
33-52	0
peptide	0
,	0
T	7
cells	8
that	0
recognized	0
the	0
VP16	0
369-380	0
peptide	0
occurred	0
at	0
a	0
much	0
higher	0
frequency	0
than	0
those	0
that	0
were	0
specific	0
for	0
the	0
VP16	0
33-52	0
peptide	0
.	0

Down-regulation	0
of	0
BOB.1/OBF.1	9
and	0
Oct2	9
in	0
classical	0
Hodgkin	0
disease	0
but	0
not	0
in	0
lymphocyte	0
predominant	0
Hodgkin	0
disease	0
correlates	0
with	0
immunoglobulin	0
transcription	0
.	0

In	0
contrast	0
to	0
the	0
tumor	7
cells	8
(	0
L	7
&	8
H	8
cells	8
)	0
of	0
lymphocyte	0
predominant	0
Hodgkin	0
disease	0
(	0
LPHD	0
)	0
,	0
Hodgkin	7
and	8
Reed-Sternberg	8
(	8
HRS	8
)	8
cells	8
of	0
classical	0
Hodgkin	0
disease	0
(	0
cHD	0
)	0
are	0
unable	0
to	0
transcribe	0
immunoglobulin	9
,	0
despite	0
the	0
presence	0
of	0
rearranged	1
immunoglobulin	2
genes	2
.	0

Although	0
initial	0
studies	0
have	0
suggested	0
crippling	0
immunoglobulin	0
gene	0
mutations	0
to	0
be	0
the	0
cause	0
of	0
absent	0
immunoglobulin	0
expression	0
in	0
cHD	0
,	0
recent	0
work	0
of	0
our	0
group	0
has	0
demonstrated	0
an	0
impaired	0
activation	0
of	0
the	0
immunoglobulin	1
promoter	2
as	0
a	0
superior	0
mechanism	0
.	0

As	0
immunoglobulin	0
transcription	0
is	0
mainly	0
regulated	0
by	0
the	0
B-cell	9
transcription	10
factors	10
Oct2	9
and	0
BOB.1/OBF.1	9
,	0
we	0
analyzed	0
35	0
cases	0
of	0
LPHD	0
,	0
32	0
cases	0
of	0
cHD	0
,	0
and	0
2	0
Hodgkin	5
disease	6
cell	6
lines	6
for	0
the	0
expression	0
of	0
these	0
transcription	9
factors	10
and	0
also	0
in	0
parallel	0
for	0
immunoglobulin	0
expression	0
.	0

Our	0
results	0
demonstrate	0
an	0
absence	0
of	0
Oct2	9
and/or	0
BOB.1/OBF.1	9
in	0
cHD	0
and	0
a	0
striking	0
overexpression	0
of	0
Oct2	9
in	0
LPHD	0
.	0

Immunoglobulin	0
expression	0
was	0
lacking	0
in	0
cHD	0
but	0
present	0
in	0
LPHD	0
.	0

Furthermore	0
,	0
the	0
reintroduction	0
of	0
BOB.1/OBF.1	9
and	0
Oct2	9
into	0
cultured	0
HRS	7
cells	8
restored	0
the	0
activity	0
of	0
cotransduced	0
immunoglobulin	1
promoter	2
constructs	2
.	0

Our	0
findings	0
dismiss	0
the	0
concept	0
that	0
the	0
different	0
immunoglobulin	0
expression	0
in	0
cHD	0
and	0
LPHD	0
is	0
due	0
to	0
disrupting	0
mutations	0
of	0
immunoglobulin	1
V	2
genes	2
in	0
cHD	0
but	0
is	0
most	0
likely	0
due	0
to	0
a	0
down-regulation	0
of	0
Oct2	9
and/or	0
BOB.1/OBF.1	9
.	0

This	0
study	0
further	0
revealed	0
Oct2	9
as	0
a	0
new	0
and	0
valuable	0
marker	0
for	0
the	0
identification	0
of	0
L	7
&	8
H	8
cells	8
and	0
their	0
distinction	0
from	0
HRS	7
cells	8
.	0

The	0
impairment	0
of	0
immunoglobulin	0
transcription	0
with	0
a	0
down-regulated	0
synthesis	0
of	0
Oct2	9
and	0
BOB.1/OBF.1	9
is	0
the	0
first	0
established	0
general	0
recurrent	0
defect	0
found	0
in	0
HRS	7
cells	8
.	0

Constitutive	0
expression	0
of	0
NF-kappa	9
B	10
is	0
a	0
characteristic	0
feature	0
of	0
mycosis	0
fungoides	0
:	0
implications	0
for	0
apoptosis	0
resistance	0
and	0
pathogenesis	0
.	0

The	0
NF-kappa	9
B	10
family	10
of	10
transcription	10
factors	10
is	0
an	0
important	0
regulator	0
of	0
genes	0
expressed	0
during	0
inflammatory	0
responses	0
,	0
immunoglobulin	0
(	0
Ig	0
)	0
class	0
switching	0
,	0
cellular	0
differentiation	0
,	0
and	0
apoptosis	0
.	0

Recently	0
,	0
members	0
of	0
the	0
NF-kappaB	9
family	10
,	0
including	0
p65	9
(	10
Rel	10
A	10
)	10
,	0
have	0
been	0
implicated	0
in	0
promoting	0
survival	0
of	0
various	0
hematopoeitic	0
neoplasms	0
,	0
including	0
T	0
cell	0
malignancies	0
such	0
as	0
adult	0
T	0
cell	0
leukemia-lymphoma	0
.	0

We	0
investigated	0
the	0
expression	0
of	0
active	9
NF-kappa	10
B	10
p65	10
(	10
Rel	10
A	10
)	10
in	0
cases	0
of	0
mycosis	0
fungoides	0
(	0
MF	0
)	0
and	0
the	0
effect	0
of	0
chemical	0
inhibitors	0
of	0
NF-kappa	9
B	10
on	0
apoptosis	0
in	0
cutaneous	5
T	6
cell	6
lymphoma	6
(	6
CTCL	6
)	6
cell	6
lines	6
.	0

Paraffin-embedded	0
tissues	0
from	0
23	0
cutaneous	0
lesions	0
and	0
a	0
single	0
lymph	0
node	0
biopsy	0
from	0
patients	0
diagnosed	0
with	0
MF	0
were	0
evaluated	0
for	0
p65	0
(	0
Rel	0
A	0
)	0
expression	0
by	0
using	0
a	0
monoclonal	9
mouse	10
antibody	10
that	0
detects	0
the	0
activated	0
form	0
of	0
p65	9
(	10
Rel	10
A	10
)	10
.	0

Apoptosis	0
after	0
treatment	0
with	0
the	0
NF-kappa	0
B	0
inhibitors	0
gliotoxin	0
,	0
MG132	0
,	0
BAY	0
11-7082	0
,	0
and	0
BAY	0
11-7085	0
was	0
quantitatively	0
measured	0
in	0
the	0
CTCL	5
cell	6
lines	6
HuT-78	6
and	6
HH	6
by	0
propidium	0
iodide	0
(	0
PI	0
)	0
/cell	0
cycle	0
analysis	0
for	0
detection	0
of	0
a	0
hypodiploid	0
(	0
sub-G	0
(	0
0	0
)	0
)	0
population	0
and	0
by	0
determination	0
of	0
increased	0
Annexin	0
V/7-amino-actinomycin	0
D	0
(	0
7-AAD	0
)	0
expression	0
.	0

Nuclear	0
extracts	0
from	0
CTCL	7
cells	8
before	0
and	0
after	0
chemical	0
inhibition	0
were	0
analyzed	0
for	0
NF-kappa	0
B	0
nuclear	0
DNA-binding	0
activity	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
(	0
EMSA	0
)	0
with	0
quantitative	0
densitometry	0
.	0

Nuclear	0
expression	0
of	0
p65	9
(	10
Rel	10
A	10
)	10
before	0
and	0
after	0
treatment	0
with	0
the	0
various	0
inhibitory	0
compounds	0
was	0
measured	0
by	0
immunofluorescence	0
staining	0
in	0
each	0
CTCL	5
cell	6
line	6
.	0

Neoplastic	7
T	8
lymphocytes	8
from	0
22	0
of	0
24	0
cases	0
of	0
MF	0
showed	0
strong	0
nuclear	0
and	0
cytoplasmic	0
expression	0
of	0
active	9
p65	10
(	10
Rel	10
A	10
)	10
.	0

Compared	0
with	0
untreated	0
control	7
cells	8
,	0
a	0
marked	0
increase	0
in	0
apoptosis	0
,	0
a	0
significant	0
decrease	0
in	0
NF-kappa	0
B	0
DNA-binding	0
activity	0
,	0
and	0
a	0
marked	0
decrease	0
in	0
nuclear	0
p65	0
(	0
Rel	0
A	0
)	0
expression	0
were	0
seen	0
in	0
cells	0
from	0
both	0
CTCL	5
cell	6
lines	6
after	0
chemical	0
NF-kappa	0
B	0
inhibition	0
.	0

These	0
data	0
show	0
that	0
the	0
active	0
form	0
of	0
NF-kappa	9
B	10
p65	10
(	10
Rel	10
A	10
)	10
is	0
commonly	0
expressed	0
in	0
neoplastic	7
T	8
lymphocytes	8
in	0
patients	0
with	0
MF	0
.	0

In	0
CTCL	5
cell	6
lines	6
,	0
the	0
significant	0
decrease	0
in	0
nuclear	0
NF-kappa	0
B	0
expression	0
and	0
the	0
marked	0
increase	0
in	0
spontaneous	0
apoptosis	0
caused	0
by	0
chemical	0
NF-kappa	0
B	0
inhibition	0
suggest	0
a	0
critical	0
role	0
for	0
NF-kappa	9
B	10
in	0
the	0
pathogenesis	0
and	0
tumor	0
cell	0
maintenance	0
of	0
CTCLs	0
.	0

HUM	0
PATHOL	0
31	0
:	0
1482-1490	0
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
tax	9
protein	10
activates	0
transcription	0
through	0
AP-1	1
site	2
by	0
inducing	0
DNA	0
binding	0
activity	0
in	0
T	7
cells	8
.	0

Human	0
T-cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
Tax	9
protein	10
induces	0
the	0
expression	0
of	0
various	0
family	0
members	0
of	0
the	0
transcription	9
factor	10
AP-1	10
,	0
such	0
as	0
c-Jun	9
,	0
JunD	9
,	0
c-Fos	9
,	0
and	0
Fra-1	9
,	0
at	0
the	0
level	0
of	0
RNA	0
expression	0
in	0
T	7
cells	8
.	0

We	0
examined	0
the	0
activity	0
of	0
Tax	9
in	0
transcription	0
through	0
AP-1-binding	1
sites	2
(	0
AP-1	1
site	2
)	0
in	0
T	7
cells	8
.	0

Transient	0
transfection	0
studies	0
showed	0
that	0
Tax	9
activated	0
the	0
expression	0
of	0
a	0
luciferase	1
gene	2
regulated	0
by	0
two	0
copies	0
of	0
an	0
AP-1	1
site	2
in	0
the	0
human	5
Jurkat	6
T-cell	6
line	6
.	0

Tax	9
activates	0
the	0
expression	0
of	0
viral	1
and	2
cellular	2
genes	2
through	0
two	0
different	0
enhancers	0
:	0
a	0
cAMP-responsive	1
(	2
CRE	2
)	2
-like	2
element	2
and	0
a	0
kappaB	1
element	2
.	0

Two	0
Tax	9
mutants	10
differentially	0
activated	0
expression	0
of	0
these	0
two	0
elements	0
.	0

Tax703	9
preferentially	0
activated	0
the	0
kappaB	1
element	2
but	0
not	0
the	0
CRE-like	0
one	0
,	0
whereas	0
TaxM22	9
showed	0
the	0
reverse	0
.	0

In	0
addition	0
,	0
Tax703	9
and	0
Tax	9
,	0
but	0
not	0
TaxM22	9
,	0
converted	0
cell	0
growth	0
of	0
a	0
mouse	5
T-cell	6
line	6
from	0
being	0
interleukin	0
(	0
IL	0
)	0
-2-dependent	0
to	0
being	0
IL-2-independent	0
.	0

Unlike	0
the	0
wild-type	9
Tax	10
,	0
Tax703	9
and	0
TaxM22	9
only	0
weakly	0
activated	0
the	0
AP-1	1
site	2
in	0
the	0
T-cell	5
line	6
.	0

Thus	0
,	0
Tax	9
seems	0
to	0
activate	0
the	0
AP-1	1
site	2
via	0
mechanisms	0
distinct	0
from	0
those	0
of	0
kappaB	1
or	2
CRE-like	2
elements	2
,	0
and	0
the	0
activation	0
of	0
the	0
AP-1	1
site	2
is	0
dispensable	0
for	0
IL-2-independent	0
growth	0
of	0
CTLL-2	0
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
showed	0
that	0
Tax	9
induced	0
strong	0
binding	0
activity	0
to	0
an	0
AP-1	1
site	2
in	0
CTLL-2	0
,	0
whereas	0
Tax703	9
did	0
not	0
,	0
indicating	0
that	0
the	0
induction	0
of	0
binding	0
activity	0
to	0
the	0
AP-1	1
site	2
is	0
essential	0
for	0
the	0
transcriptional	0
activation	0
by	0
Tax	9
.	0

The	0
binding	9
complex	10
induced	0
by	0
Tax	9
in	0
CTLL-2	0
contained	0
JunD	9
and	0
Fra-2	9
.	0

Other	0
AP-1	9
proteins	10
were	0
undetectable	0
.	0

Activation	0
of	0
transcription	0
through	0
the	0
AP-1	1
site	2
in	0
Jurkat	5
cells	6
by	0
JunD	9
and/or	0
Fra-2	9
was	0
weak	0
.	0

c-Jun	9
,	0
JunB	9
,	0
and	0
c-Fos	9
activation	0
was	0
greater	0
,	0
although	0
the	0
level	0
was	0
still	0
less	0
than	0
that	0
with	0
Tax	9
.	0

Thus	0
,	0
the	0
induction	0
of	0
AP-1	3
mRNA	4
by	0
Tax	9
may	0
not	0
be	0
sufficient	0
for	0
a	0
complete	0
activation	0
of	0
AP-1	1
site	2
by	0
Tax	9
.	0

Our	0
results	0
suggest	0
that	0
Tax	9
activates	0
the	0
transcription	0
of	0
cellular	1
genes	2
with	0
AP-1	1
sites	2
by	0
inducing	0
the	0
DNA-binding	0
activity	0
of	0
AP-1	9
proteins	10
in	0
T	7
cells	8
,	0
a	0
mechanism	0
distinct	0
from	0
those	0
of	0
CRE-like	1
and	2
kappaB	2
elements	2
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Strict	0
control	0
of	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
replication	0
by	0
a	0
genetic	0
switch	0
:	0
Tet	0
for	0
Tat	0
.	0

Live-attenuated	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
variants	0
have	0
shown	0
great	0
promise	0
as	0
AIDS	0
vaccines	0
,	0
but	0
continued	0
replication	0
can	0
lead	0
to	0
the	0
selection	0
of	0
faster-replicating	0
variants	0
that	0
are	0
pathogenic	0
.	0

We	0
therefore	0
designed	0
HIV-1	1
genomes	2
that	0
replicate	0
exclusively	0
upon	0
addition	0
of	0
the	0
nontoxic	0
effector	0
doxycycline	0
(	0
dox	0
)	0
.	0

This	0
was	0
achieved	0
by	0
replacement	0
of	0
the	0
viral	0
TAR-Tat	0
system	0
for	0
transcriptional	0
activation	0
by	0
the	0
Escherichia	0
coli-derived	0
Tet	0
system	0
for	0
inducible	0
gene	0
expression	0
.	0

These	0
designer	0
``	0
HIV-rtTA	0
''	0
viruses	0
replicate	0
in	0
a	0
strictly	0
dox-dependent	0
manner	0
both	0
in	0
a	0
T-cell	5
line	6
and	0
in	0
primary	7
blood	8
cells	8
,	0
and	0
the	0
rate	0
of	0
replication	0
can	0
be	0
fine-tuned	0
by	0
simple	0
variation	0
of	0
the	0
dox	0
concentration	0
.	0

These	0
HIV-rtTA	0
viruses	0
provide	0
a	0
tool	0
to	0
perform	0
genetics	0
,	0
e.g.	0
,	0
selection	0
and	0
optimization	0
experiments	0
,	0
with	0
the	0
E.	0
coli-derived	0
Tet	0
reagents	0
in	0
a	0
eukaryotic	0
background	0
.	0

Furthermore	0
,	0
such	0
viruses	0
may	0
represent	0
improved	0
vaccine	0
candidates	0
because	0
their	0
replication	0
can	0
be	0
turned	0
on	0
and	0
off	0
at	0
will	0
.	0

Synovial	0
fluid	0
induced	0
nuclear	9
factor-kappaB	10
DNA	0
binding	0
in	0
a	0
monocytic	5
cell	6
line	6
.	0

OBJECTIVE	0
:	0
To	0
determine	0
the	0
effects	0
of	0
synovial	0
fluids	0
(	0
SF	0
)	0
on	0
DNA	0
binding	0
activity	0
of	0
transcription	9
factor	10
nuclear	9
factor-kappaB	10
(	0
NF-kappaB	9
)	0
in	0
the	0
Mono	5
Mac	6
6	6
monocytic/macrophage	6
cell	6
line	6
as	0
a	0
model	0
for	0
the	0
interaction	0
between	0
SF	0
and	0
synovial	7
tissue	8
macrophages	8
in	0
arthritis	0
.	0

METHODS	0
:	0
Mono	5
Mac	6
6	6
cells	6
were	0
incubated	0
with	0
SF	0
from	0
the	0
knee	0
joints	0
of	0
human	0
subjects	0
with	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
,	0
undifferentiated	0
seronegative	0
oligoarthritis	0
,	0
and	0
osteoarthritis	0
(	0
OA	0
)	0
.	0

Nuclear	0
extracts	0
prepared	0
from	0
the	0
Mono	5
Mac	6
6	6
cells	6
and	0
RA	0
synovial	0
tissue	0
were	0
analyzed	0
by	0
electrophoretic	0
mobility	0
shift	0
analysis	0
(	0
EMSA	0
)	0
for	0
NF-kappaB	9
DNA	10
binding	10
proteins	10
.	0

RESULTS	0
:	0
Induction	0
of	0
NF-kappaB	9
DNA	0
binding	0
by	0
the	0
p65	9
(	10
RelA	10
)	10
/p50	10
heterodimer	10
was	0
observed	0
in	0
response	0
to	0
incubation	0
of	0
Mono	5
Mac	6
6	6
cells	6
with	0
SF	0
(	0
20	0
%	0
in	0
culture	0
medium	0
)	0
from	0
5	0
of	0
8	0
subjects	0
with	0
RA	0
,	0
4	0
of	0
5	0
with	0
OA	0
,	0
and	0
none	0
of	0
3	0
with	0
undifferentiated	0
seronegative	0
oligoarthritis	0
.	0

Incubation	0
of	0
SF	0
with	0
neutralizing	9
antibodies	10
against	0
tumor	9
necrosis	10
factor-alpha	10
(	10
TNF-alpha	10
)	10
,	0
but	0
not	0
antibodies	9
against	0
interleukin	9
6	10
(	10
IL-6	10
)	10
,	0
significantly	0
reduced	0
the	0
induction	0
of	0
p65/p50	0
binding	0
activity	0
in	0
SF	0
from	0
subjects	0
with	0
RA	0
and	0
OA	0
.	0

Unexpectedly	0
,	0
a	0
slowly	0
migrating	0
SF	0
inducible	0
NF-kappaB	9
-binding	0
complex	0
was	0
observed	0
in	0
EMSA	0
of	0
Mono	5
Mac	6
6	6
cells	6
after	0
incubation	0
with	0
SF	0
from	0
5	0
of	0
8	0
RA	0
and	0
2	0
of	0
5	0
OA	0
subjects	0
.	0

The	0
induction	0
of	0
this	0
complex	0
by	0
SF	0
was	0
not	0
affected	0
by	0
neutralization	0
of	0
TNF-alpha	9
or	0
IL-6	9
in	0
SF	0
,	0
and	0
the	0
complex	0
was	0
not	0
inducible	0
by	0
TNF-alpha	9
,	0
IL-1beta	0
,	0
TNF-alpha	9
/	0
IL-1beta	9
,	0
IL-6	9
,	0
platelet	9
derived	10
growth	10
factor	10
,	0
lipopolysaccharide	0
,	0
or	0
tetradecanoyl	0
phorbol	0
acetate	0
.	0

The	0
slowly	0
migrating	9
complex	10
could	0
not	0
be	0
supershifted	0
with	0
antibodies	9
against	0
NF-kappaB	9
,	0
Jun	9
,	0
or	0
the	0
transcriptional	0
coactivators	0
p300	9
or	0
CBP	9
.	0

A	0
NF-kappaB-binding	9
complex	10
with	0
similar	0
slow	0
mobility	0
was	0
observed	0
in	0
nuclear	0
extracts	0
prepared	0
from	0
fresh	0
human	0
RA	0
synovial	0
tissue	0
.	0

CONCLUSION	0
:	0
Biological	0
activity	0
of	0
TNF-alpha	9
in	0
SF	0
from	0
RA	0
and	0
OA	0
subjects	0
is	0
capable	0
of	0
inducing	0
p65/p50	9
NF-kappaB	10
DNA	0
binding	0
activity	0
in	0
macrophages	7
.	0

A	0
property	0
of	0
SF	0
that	0
is	0
independent	0
of	0
TNF-alpha	9
and	0
other	0
cytokines	9
is	0
responsible	0
for	0
the	0
induction	0
of	0
a	0
novel	0
slowly	0
migrating	0
NF-kappaB-binding	9
complex	10
.	0

Soluble	0
mediators	0
in	0
SF	0
of	0
subjects	0
with	0
RA	0
and	0
OA	0
can	0
therefore	0
modulate	0
binding	0
of	0
nuclear	9
proteins	10
to	0
the	0
NF-kappaB	9
binding	10
site	10
in	0
macrophages	7
and	0
may	0
play	0
a	0
role	0
in	0
inflammatory	0
gene	0
expression	0
in	0
arthritis	0
.	0

Peroxisome	9
proliferator	10
activator	10
receptor-gamma	10
agonists	0
and	0
15-deoxy-Delta	0
(	0
12	0
,	0
14	0
)	0
(	0
12	0
,	0
14	0
)	0
-PGJ	0
(	0
2	0
)	0
induce	0
apoptosis	0
in	0
normal	0
and	0
malignant	0
B-lineage	7
cells	8
.	0

The	0
research	0
described	0
herein	0
evaluates	0
the	0
expression	0
and	0
functional	0
significance	0
of	0
peroxisome	9
proliferator	10
activator	10
receptor-gamma	10
(	10
PPAR-gamma	10
)	10
on	0
B-lineage	7
cells	8
.	0

Normal	7
mouse	8
B	8
cells	8
and	0
a	0
variety	0
of	0
B	7
lymphoma	8
cells	8
reflective	0
of	0
stages	0
of	0
B	0
cell	0
differentiation	0
(	0
e.g.	0
,	0
70Z/3	0
,	0
CH31	0
,	0
WEHI-231	0
,	0
CH12	0
,	0
and	0
J558	0
)	0
express	0
PPAR-gamma	3
mRNA	4
and	0
,	0
by	0
Western	0
blot	0
analysis	0
,	0
the	0
67-kDa	9
PPAR-gamma	10
protein	10
.	0

15-Deoxy-Delta	0
(	0
12	0
,	0
14	0
)	0
-PGJ	0
(	0
2	0
)	0
(	0
15d-PGJ	0
(	0
2	0
)	0
)	0
,	0
a	0
PPAR-gamma	0
agonist	0
,	0
has	0
a	0
dose-dependent	0
antiproliferative	0
and	0
cytotoxic	0
effect	0
on	0
normal	7
and	8
malignant	8
B	8
cells	8
as	0
shown	0
by	0
[	0
(	0
3	0
)	0
H	0
]	0
thymidine	0
and	0
3-	0
[	0
4	0
,	0
5-dimethylthiazol-2-yl	0
]	0
-2	0
,	0
5-diphenyltetrazolium	0
bromide	0
assays	0
.	0

Only	0
PPAR-gamma	0
agonists	0
(	0
thiazolidinediones	0
)	0
,	0
and	0
not	0
PPAR-alpha	0
agonists	0
,	0
mimicked	0
the	0
effect	0
of	0
15d-PGJ	0
(	0
2	0
)	0
on	0
B-lineage	7
cells	8
,	0
indicating	0
that	0
the	0
mechanism	0
by	0
which	0
15d-PGJ	0
(	0
2	0
)	0
negatively	0
affects	0
B-lineage	7
cells	8
involves	0
in	0
part	0
PPAR-gamma	9
.	0

The	0
mechanism	0
by	0
which	0
PPAR-gamma	0
agonists	0
induce	0
cytotoxicity	0
is	0
via	0
apoptosis	0
,	0
as	0
shown	0
by	0
annexin	0
V	0
staining	0
and	0
as	0
confirmed	0
by	0
DNA	0
fragmentation	0
detected	0
using	0
the	0
TUNEL	0
assay	0
.	0

Interestingly	0
,	0
addition	0
of	0
PGF	0
(	0
2alpha	0
)	0
,	0
which	0
was	0
not	0
known	0
to	0
affect	0
lymphocytes	7
,	0
dramatically	0
attenuated	0
the	0
deleterious	0
effects	0
of	0
PPAR-gamma	0
agonists	0
on	0
B	7
lymphomas	8
.	0

Surprisingly	0
,	0
15d-PGJ	0
(	0
2	0
)	0
induced	0
a	0
massive	0
increase	0
in	0
nuclear	0
mitogen-activated	0
protein	0
kinase	0
activation	0
,	0
and	0
pretreatment	0
with	0
PGF	0
(	0
2alpha	0
)	0
blunted	0
the	0
mitogen-activated	0
protein	0
kinase	0
activation	0
.	0

This	0
is	0
the	0
first	0
study	0
evaluating	0
PPAR-gamma	0
expression	0
and	0
its	0
significance	0
on	0
B	7
lymphocytes	8
.	0

PPAR-gamma	0
agonists	0
may	0
serve	0
as	0
a	0
counterbalance	0
to	0
the	0
stimulating	0
effects	0
of	0
other	0
PGs	0
,	0
namely	0
PGE	0
(	0
2	0
)	0
,	0
which	0
promotes	0
B	0
cell	0
differentiation	0
.	0

Finally	0
,	0
the	0
use	0
of	0
PGs	0
,	0
such	0
as	0
15d-PGJ	0
(	0
2	0
)	0
,	0
and	0
synthetic	0
PPAR-gamma	0
agonists	0
to	0
induce	0
apoptosis	0
in	0
B-lineage	7
cells	8
may	0
lead	0
to	0
the	0
development	0
of	0
novel	0
therapies	0
for	0
fatal	7
B	8
lymphomas	8

Inhibition	0
of	0
STAT3	0
signaling	0
leads	0
to	0
apoptosis	0
of	0
leukemic	7
large	8
granular	8
lymphocytes	8
and	0
decreased	0
Mcl-1	0
expression	0
.	0

Large	0
granular	0
lymphocyte	0
(	0
LGL	0
)	0
leukemia	0
is	0
characterized	0
by	0
the	0
expansion	0
of	0
antigen-activated	7
cytotoxic	8
T	8
lymphocytes	8
.	0

These	0
leukemic	7
cells	8
are	0
resistant	0
to	0
Fas-mediated	0
apoptosis	0
despite	0
expressing	0
high	0
levels	0
of	0
Fas	9
.	0

We	0
found	0
that	0
leukemic	7
LGL	8
from	0
19	0
patients	0
displayed	0
high	0
levels	0
of	0
activated	9
STAT3	10
.	0

Treatment	0
of	0
leukemic	7
LGL	8
with	0
the	0
JAK-selective	0
tyrosine	0
kinase	0
inhibitor	0
AG-490	0
induced	0
apoptosis	0
with	0
a	0
corresponding	0
decrease	0
in	0
STAT	9
-DNA	0
binding	0
activity	0
.	0

Moreover	0
,	0
using	0
an	0
antisense	0
oligonucleotide	0
approach	0
to	0
diminish	0
STAT3	0
expression	0
,	0
we	0
found	0
that	0
Fas	0
sensitivity	0
was	0
restored	0
in	0
leukemic	7
LGL	8
.	0

AG-490-induced	0
apoptosis	0
in	0
leukemic	7
LGL	8
was	0
independent	0
of	0
Bcl-xL	0
or	0
Bcl-2	0
expression	0
.	0

However	0
,	0
we	0
found	0
that	0
the	0
Bcl-2-family	9
protein	10
Mcl-1	10
was	0
significantly	0
reduced	0
by	0
AG-490	0
treatment	0
.	0

Activated	9
STAT3	10
was	0
shown	0
to	0
bind	0
an	0
SIE-related	1
element	2
in	0
the	0
murine	1
mcl-1	2
promoter	2
.	0

Using	0
a	0
luciferase	0
reporter	0
assay	0
,	0
we	0
demonstrated	0
that	0
v-src	0
overexpression	0
in	0
NIH3T3	0
induced	0
STAT3	9
-dependent	0
transcriptional	0
activity	0
from	0
the	0
mcl-1	1
promoter	2
and	0
increased	0
endogenous	0
Mcl-1	0
protein	0
levels	0
.	0

We	0
conclude	0
that	0
STAT3	9
activation	0
contributed	0
to	0
accumulation	0
of	0
the	0
leukemic	7
LGL	8
clones	8
.	0

These	0
findings	0
suggest	0
that	0
investigation	0
should	0
focus	0
on	0
novel	0
strategies	0
targeting	0
STAT3	9
in	0
the	0
treatment	0
of	0
LGL	0
leukemia	0
.	0

Decreased	0
immediate	0
inflammatory	1
gene	2
induction	0
in	0
activating	9
transcription	10
factor-2	10
mutant	0
mice	0
.	0

Transcription	9
factor	10
activating	10
transcription	10
factor	10
(	10
ATF	10
)	10
-2	10
is	0
activated	0
by	0
inflammatory	0
signals	0
transduced	0
by	0
the	0
JNK	0
and	0
p38	0
MAP	0
kinase	0
pathways	0
.	0

To	0
better	0
define	0
the	0
role	0
of	0
ATF-2	9
in	0
inflammation	0
,	0
adult	0
mice	0
expressing	0
small	0
amounts	0
of	0
a	0
mutant	9
ATF-2	10
protein	10
were	0
challenged	0
with	0
lipopolysaccharide	0
(	0
LPS	0
)	0
,	0
anti-CD3	9
antibody	10
or	0
virus	0
.	0

Within	0
3	0
h	0
of	0
challenge	0
by	0
LPS	0
,	0
ATF-2	0
mutant	0
mice	0
had	0
decreased	0
induction	0
of	0
the	0
adhesion	9
molecules	10
E-selectin	9
,	0
P-selectin	9
and	0
VCAM-1	9
as	0
well	0
as	0
the	0
cytokines	9
tumor	9
necrosis	10
factor-alpha	10
,	0
IL-1beta	9
and	0
IL-6	9
compared	0
with	0
control	0
mice	0
.	0

Stimulation	0
of	0
T	7
lymphocytes	8
by	0
anti-CD3	9
antibody	10
also	0
showed	0
less	0
induction	0
of	0
IL-1	9
and	0
IL-6	9
in	0
ATF-2	0
mutant	0
tissues	0
.	0

ATF-2	7
mutant	8
thymocytes	8
treated	0
with	0
anti-CD3	9
antibody	10
in	0
vitro	0
demonstrated	0
reduced	0
induction	0
of	0
c-Jun	9
,	0
JunB	9
,	0
JunD	9
and	0
Fra-2	9
.	0

However	0
,	0
similar	0
to	0
what	0
was	0
observed	0
after	0
p38	0
kinase	0
inhibition	0
in	0
normal	0
mice	0
,	0
relative	0
ATF-2	0
deficiency	0
did	0
not	0
prevent	0
the	0
development	0
of	0
a	0
mononuclear	7
cell	8
infiltrate	0
in	0
the	0
week	0
following	0
an	0
inflammatory	0
stimulus	0
.	0

ATF-2	0
mutant	0
mice	0
proved	0
more	0
susceptible	0
to	0
death	0
than	0
control	0
mice	0
from	0
LPS	0
plus	0
D-galactosamine	0
injection	0
or	0
Coxsackievirus	0
B3	0
infection	0
and	0
had	0
a	0
higher	0
incidence	0
of	0
mononuclear	0
pulmonary	0
infiltrates	0
after	0
exposure	0
to	0
Herpes	0
simplex	0
virus-1	0
.	0

ATF-2	9
is	0
essential	0
for	0
maximal	0
immediate	0
induction	0
of	0
adhesion	9
molecules	10
and	0
cytokine	1
genes	2
,	0
but	0
at	0
later	0
time	0
points	0
may	0
even	0
protect	0
against	0
overactive	0
immune	0
responses	0
.	0

LIGHT	9
,	0
a	0
TNF-like	9
molecule	10
,	0
costimulates	0
T	0
cell	0
proliferation	0
and	0
is	0
required	0
for	0
dendritic	7
cell	8
-mediated	0
allogeneic	0
T	0
cell	0
response	0
.	0

LIGHT	9
is	0
a	0
recently	0
identified	0
member	0
of	0
the	0
TNF	9
superfamily	10
and	0
its	0
receptors	0
,	0
herpesvirus	9
entry	10
mediator	10
and	0
lymphotoxin	9
beta	10
receptor	10
,	0
are	0
found	0
in	0
T	7
cells	8
and	0
stromal	7
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
demonstrate	0
that	0
LIGHT	9
is	0
selectively	0
expressed	0
on	0
immature	7
dendritic	8
cells	8
(	0
DCs	7
)	0
generated	0
from	0
human	7
PBMCs	8
.	0

In	0
contrast	0
,	0
LIGHT	9
is	0
not	0
detectable	0
in	0
DCs	7
either	0
freshly	0
isolated	0
from	0
PBMCs	7
or	0
rendered	0
mature	0
in	0
vitro	0
by	0
LPS	0
treatment	0
.	0

Blockade	0
of	0
LIGHT	9
by	0
its	0
soluble	9
receptors	10
,	0
lymphotoxin	9
beta	10
receptor-Ig	10
or	0
HVEM-Ig	9
,	0
inhibits	0
the	0
induction	0
of	0
DC	7
-mediated	0
primary	0
allogeneic	0
T	0
cell	0
response	0
.	0

Furthermore	0
,	0
engagement	0
of	0
LIGHT	9
costimulates	0
human	0
T	0
cell	0
proliferation	0
,	0
amplifies	0
the	0
NF-kappaB	0
signaling	0
pathway	0
,	0
and	0
preferentially	0
induces	0
the	0
production	0
of	0
IFN-gamma	9
,	0
but	0
not	0
IL-4	9
,	0
in	0
the	0
presence	0
of	0
an	0
antigenic	0
signal	0
.	0

Our	0
results	0
suggest	0
that	0
LIGHT	9
is	0
a	0
costimulatory	9
molecule	10
involved	0
in	0
DC	7
-mediated	0
cellular	0
immune	0
responses	0
.	0

Suppression	0
of	0
HIV	0
type	0
1	0
replication	0
by	0
a	0
dominant-negative	9
Ets-1	10
mutant	10
.	0

Activity	0
of	0
the	0
distal	1
region	2
of	0
the	0
human	0
immunodeficiency	0
virus	0
(	0
HIV-1	0
)	0
long	1
terminal	2
repeat	2
(	0
LTR	1
)	0
,	0
which	0
contains	0
binding	1
sites	2
for	0
the	0
Ets-1	9
and	10
USF-1	10
proteins	10
,	0
is	0
integral	0
for	0
HIV-1	0
replication	0
.	0

The	0
Ets-1	9
and	10
USF-1	10
proteins	10
play	0
a	0
critical	0
role	0
in	0
the	0
activity	0
of	0
the	0
HIV-1	1
LTR	2
distal	2
enhancer	2
region	2
,	0
as	0
indicated	0
by	0
the	0
potent	0
dominant	0
negative	0
effect	0
of	0
a	0
mutant	1
Ets-1	2
lacking	2
trans-activation	2
domains	2
on	0
the	0
transcriptional	0
activity	0
of	0
the	0
LTR	1
.	0

To	0
determine	0
the	0
biological	0
relevance	0
of	0
the	0
Ets-1	9
and	10
USF-1	10
proteins	10
in	0
HIV-1	0
replication	0
,	0
we	0
examined	0
the	0
effect	0
of	0
expression	0
of	0
the	0
dominant-negative	0
mutant	0
of	0
Ets-1	1
(	0
dnEts-1	1
)	0
on	0
HIV-1	0
infection	0
of	0
T	7
cells	8
.	0

We	0
demonstrated	0
that	0
expression	0
of	0
dnEts	1
markedly	0
suppressed	0
HIV-1	0
infection	0
of	0
a	0
T	5
cell	6
line	6
.	0

This	0
finding	0
indicates	0
that	0
formation	0
of	0
a	0
transcriptionaly	9
active	10
USF-1/Ets-1	10
complex	10
is	0
important	0
in	0
the	0
productive	0
infection	0
of	0
cells	0
by	0
HIV-1	0
,	0
and	0
suggests	0
that	0
inhibition	0
of	0
the	0
interaction	0
between	0
USF-1	9
and	0
Ets-1	9
with	0
the	0
HIV-1	1
LTR	2
may	0
provide	0
a	0
new	0
target	0
for	0
anti-HIV-1	0
gene	0
therapy	0
.	0

Human	7
eosinophils	8
constitutively	0
express	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
p	10
and	10
c	10
.	0

BACKGROUND	0
:	0
Eosinophils	7
are	0
now	0
known	0
to	0
produce	0
a	0
variety	0
of	0
proinflammatory	9
cytokines	10
,	0
although	0
the	0
molecular	0
factors	0
that	0
regulate	0
their	0
production	0
are	0
poorly	0
understood	0
.	0

The	0
expression	0
of	0
almost	0
all	0
of	0
the	0
cytokines	9
produced	0
by	0
eosinophils	7
,	0
including	0
the	0
proallergic	9
cytokine	10
IL-4	10
,	0
is	0
now	0
known	0
to	0
be	0
regulated	0
at	0
the	0
level	0
of	0
transcription	0
by	0
members	0
of	0
the	0
nuclear	9
factor	10
of	10
activated	10
T	10
cells	10
(	0
NFAT	9
)	0
family	0
of	0
transcription	0
factors	0
.	0

OBJECTIVE	0
:	0
We	0
sought	0
to	0
characterize	0
the	0
expression	0
of	0
different	0
NFAT	9
proteins	10
in	0
resting	7
and	8
activated	8
eosinophils	8
.	0

METHODS	0
:	0
Nuclear	0
and	0
whole	0
cell	0
extracts	0
were	0
obtained	0
from	0
both	0
peripheral	7
blood	8
eosinophils	8
and	0
those	0
obtained	0
from	0
bronchoalveolar	0
lavage	0
fluid	0
of	0
asthmatic	0
subjects	0
after	0
endobronchial	0
allergen	0
challenge	0
.	0

NFAT	9
expression	0
was	0
determined	0
by	0
using	0
immunoprecipitation	0
and	0
Western	0
blot	0
analysis	0
,	0
DNA-binding	0
assays	0
,	0
and	0
RT-PCR	0
analysis	0
of	0
eosinophil	3
mRNA	4
.	0

RESULTS	0
:	0
Both	0
peripheral	7
blood	8
and	8
bronchoalveolar	8
lavage	8
fluid	8
eosinophils	8
expressed	0
NFATp	9
and	10
NFATc	10
protein	10
.	0

Unlike	0
activated	7
T	8
cells	8
,	0
which	0
express	0
multiple	0
NFATc	0
isoforms	0
,	0
eosinophils	7
preferentially	0
express	0
the	0
approximately	0
85-kd	0
isoform	0
.	0

In	0
addition	0
,	0
eosinophils	7
were	0
found	0
to	0
constitutively	0
express	0
NFATc	3
mRNA	4
.	0

A	0
brief	0
incubation	0
with	0
the	0
T	9
(	10
H	10
)	10
2	10
cytokines	10
IL-4	9
and	0
IL-5	9
was	0
sufficient	0
to	0
induce	0
the	0
nuclear	0
translocation	0
of	0
NFATc	9
.	0

Eosinophil	0
nuclear	0
extracts	0
contain	0
multiple	0
factors	0
that	0
can	0
specifically	0
recognize	0
the	0
IL-4	1
promoter	2
P1	2
NFAT	2
site	2
in	0
DNA-binding	0
assays	0
,	0
including	0
NFATp	9
.	0

CONCLUSION	0
:	0
NFATp	9
and	0
NFATc	9
can	0
regulate	0
the	0
expression	0
of	0
cytokines	9
and	0
other	0
genes	0
in	0
eosinophils	7
but	0
appear	0
to	0
be	0
regulated	0
by	0
a	0
novel	0
signal	0
transduction	0
mechanism	0
in	0
these	0
cells	0
.	0

BLyS	9
BINDS	0
TO	0
B	7
CELLS	8
WITH	0
HIGH	0
AFFINITY	0
AND	0
INDUCES	0
ACTIVATION	0
OF	0
THE	0
TRANSCRIPTION	9
FACTORS	10
NF-kappaB	9
AND	0
ELF-1	9
.	0

B	9
lymphocyte	10
stimulator	10
(	0
BLyS	9
)	0
is	0
a	0
novel	0
member	0
of	0
the	0
TNF	9
family	10
of	10
proteins	10
expressed	0
by	0
myeloid	7
cells	8
as	0
membrane-bound	0
and	0
soluble	0
forms	0
.	0

BLyS	9
was	0
shown	0
to	0
act	0
specifically	0
on	0
B	7
cells	8
,	0
inducing	0
proliferation	0
and	0
immunoglobulin	0
production	0
both	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

The	0
present	0
study	0
was	0
undertaken	0
to	0
characterize	0
binding	0
of	0
radiolabeled	9
BLyS	10
to	0
its	0
cognate	9
receptor	10
on	0
human	7
B	8
lymphocytes	8
and	0
examine	0
intracellular	0
events	0
initiated	0
by	0
BLyS	9
binding	0
.	0

Similar	0
to	0
other	0
TNF	9
family	10
members	10
,	0
BLyS	9
is	0
present	0
in	0
solution	0
as	0
a	0
homotrimer	9
as	0
determined	0
by	0
gel	0
filtration	0
chromatography	0
and	0
light	0
scattering	0
analysis	0
.	0

BLyS	9
binding	0
to	0
B	7
cells	8
is	0
specific	0
as	0
other	0
TNF	9
family	10
members	10
tested	0
did	0
not	0
compete	0
for	0
(	0
125	0
)	0
I-	0
BLyS	9
binding	0
.	0

Analysis	0
of	0
equilibrium	0
binding	0
of	0
(	9
125	10
)	10
I-labeled	10
BLyS	10
to	0
purified	0
human	7
tonsillar	8
B	8
cells	8
demonstrated	0
saturable	0
binding	0
.	0

Scatchard	0
analysis	0
of	0
the	0
binding	0
data	0
revealed	0
a	0
single	0
class	0
of	0
high-affinity	0
binding	0
on	0
human	7
B	8
cells	8
with	0
approximately	0
2600	0
binding	0
sites	0
per	0
cell	0
and	0
an	0
apparent	0
dissociation	0
constant	0
(	0
K	0
(	0
D	0
)	0
)	0
of	0
about	0
0.1	0
nM	0
.	0

In	0
addition	0
we	0
report	0
that	0
BLyS	9
binding	0
to	0
B	7
cells	8
results	0
in	0
the	0
activation	0
of	0
NF-kappaB	9
and	0
the	0
Ets	9
family	10
transcription	10
factor	10
,	0
ELF-1	9
,	0
and	0
in	0
the	0
induction	0
of	0
mRNA	0
for	0
Polo-like	9
kinase	10
(	0
PLK	9
)	0
.	0

Copyright	0
2001	0
Academic	0
Press	0
.	0

Design	0
and	0
use	0
of	0
an	0
inducibly	0
activated	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
Nef	9
to	0
study	0
immune	0
modulation	0
.	0

The	0
Nef	9
protein	10
of	0
the	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
has	0
been	0
shown	0
to	0
enhance	0
the	0
infectivity	0
of	0
virus	0
particles	0
,	0
downmodulate	0
cell	9
surface	10
proteins	10
,	0
and	0
associate	0
with	0
many	0
intracellular	9
proteins	10
that	0
are	0
thought	0
to	0
facilitate	0
HIV	0
infection	0
.	0

One	0
of	0
the	0
challenges	0
in	0
defining	0
the	0
molecular	0
events	0
regulated	0
by	0
Nef	9
has	0
been	0
obtaining	0
good	0
expression	0
of	0
Nef	9
protein	10
in	0
T	7
cells	8
.	0

This	0
has	0
been	0
attributed	0
to	0
effects	0
of	0
Nef	9
on	0
cell	0
proliferation	0
and	0
apoptosis	0
.	0

We	0
have	0
designed	0
a	0
Nef	9
protein	10
that	0
is	0
readily	0
expressed	0
in	0
T-cell	5
lines	6
and	0
whose	0
function	0
is	0
inducibly	0
activated	0
.	0

It	0
is	0
composed	0
of	0
a	0
fusion	0
between	0
full-length	9
Nef	10
and	0
the	0
estrogen	9
receptor	10
hormone-binding	10
domain	10
(	0
Nef-ER	9
)	0
.	0

The	0
Nef-ER	9
is	0
kept	0
in	0
an	0
inactive	0
state	0
due	0
to	0
steric	0
hindrance	0
,	0
and	0
addition	0
of	0
the	0
membrane-permeable	0
drug	0
4-hydroxytamoxifen	0
(	0
4-HT	0
)	0
,	0
which	0
binds	0
to	0
the	0
ER	9
domain	10
,	0
leads	0
to	0
inducible	0
activation	0
of	0
Nef-ER	9
within	0
cells	0
.	0

We	0
demonstrate	0
that	0
Nef-ER	9
inducibly	0
associates	0
with	0
the	0
62-kDa	9
Ser/Thr	10
kinase	10
and	0
is	0
localized	0
to	0
specific	0
membrane	0
microdomains	0
(	0
lipid	0
rafts	0
)	0
only	0
after	0
activation	0
.	0

Using	0
this	0
inducible	0
Nef	9
,	0
we	0
also	0
compared	0
the	0
specific	0
requirements	0
for	0
CD4	9
and	0
HLA-A2	9
downmodulation	0
in	0
a	0
SupT1	5
T-cell	6
line	6
.	0

Half-maximal	0
downmodulation	0
of	0
cell	9
surface	10
CD4	10
required	0
very	0
little	0
active	0
Nef-ER	9
and	0
occurred	0
as	0
early	0
as	0
4	0
h	0
after	0
addition	0
of	0
4-HT	0
.	0

In	0
contrast	0
,	0
50	0
%	0
downmodulation	0
of	0
HLA-A2	9
by	0
Nef	9
required	0
16	0
to	0
24	0
h	0
and	0
about	0
50-	0
to	0
100-fold-greater	0
concentrations	0
of	0
4-HT	0
.	0

These	0
data	0
suggest	0
that	0
HLA-A2	9
downmodulation	0
may	0
require	0
certain	0
threshold	0
levels	0
of	0
active	0
Nef	9
.	0

The	0
differential	0
timing	0
of	0
CD4	9
and	0
HLA-A2	9
downmodulation	0
may	0
have	0
implications	0
for	0
HIV	0
pathogenesis	0
and	0
immune	0
evasion	0
.	0

Regulation	0
of	0
chemokine	0
mRNA	0
expression	0
in	0
a	0
rat	0
model	0
of	0
vanadium-induced	0
pulmonary	0
inflammation	0
.	0

Environmental	0
and	0
occupational	0
exposure	0
to	0
vanadium	0
dusts	0
results	0
in	0
toxic	0
effects	0
mainly	0
confined	0
to	0
the	0
respiratory	0
system	0
.	0

Using	0
a	0
rat	0
model	0
of	0
acute	0
lung	0
inflammation	0
induced	0
by	0
intratracheal	0
instillation	0
of	0
sodium	0
metavanadate	0
(	0
NaVO3	0
)	0
at	0
the	0
dose	0
of	0
200	0
microg	0
V/kg	0
,	0
we	0
investigated	0
the	0
relationship	0
between	0
the	0
cytologic	0
characterization	0
of	0
pulmonary	0
inflammation	0
and	0
the	0
expression	0
of	0
chemokine	3
mRNA	4
.	0

Significant	0
polymorphonuclear	7
leukocyte	8
(	0
PMN	7
)	0
influx	0
(	0
P	0
<	0
0.01	0
)	0
into	0
the	0
lung	0
was	0
noted	0
4	0
h	0
after	0
NaVO3	0
instillation	0
,	0
whereas	0
alveolar	7
macrophages	8
(	0
AMs	7
)	0
in	0
bronchoalveolar	7
lavage	8
(	8
BAL	8
)	8
cells	8
appeared	0
to	0
decrease	0
significantly	0
.	0

In	0
contrast	0
,	0
neither	0
PMNs	7
nor	0
AMs	7
changed	0
substantially	0
1	0
h	0
after	0
NaVO3	0
instillation	0
.	0

By	0
Northern	0
analysis	0
,	0
macrophage	3
inflammatory	4
protein	4
(	4
MIP	4
)	4
-2	4
mRNA	4
in	0
BAL	7
cells	8
increased	0
markedly	0
1	0
h	0
after	0
NaVO3	0
instillation	0
and	0
reduced	0
a	0
little	0
bit	0
at	0
4	0
h	0
,	0
whereas	0
MIP-1alpha	3
mRNA	4
in	0
BAL	7
cells	8
was	0
expressed	0
relatively	0
high	0
1	0
h	0
after	0
NaVO3	0
instillation	0
,	0
although	0
a	0
basal	0
expression	0
was	0
detected	0
in	0
control	0
group	0
,	0
and	0
returned	0
rapidly	0
nearly	0
to	0
control	0
level	0
at	0
4	0
h	0
.	0

Since	0
MIP-2	9
is	0
a	0
potent	0
PMN	7
chemoattractant	0
and	0
MIP-1alpha	9
is	0
a	0
potent	0
macrophage/monocyte	0
chemoattractant	0
has	0
been	0
well	0
known	0
.	0

The	0
facts	0
that	0
PMN	7
influx	0
was	0
preceded	0
by	0
increased	0
MIP-2	0
mRNA	0
expression	0
,	0
suggesting	0
that	0
MIP-2	9
is	0
involved	0
in	0
the	0
development	0
of	0
NaVO3-induced	0
pulmonary	0
inflammation	0
,	0
whereas	0
increased	0
MIP-1alpha	3
mRNA	4
expression	0
was	0
followed	0
by	0
decreased	0
AMs	7
in	0
BAL	7
cells	8
,	0
suggesting	0
AMs	7
might	0
be	0
activated	0
by	0
MIP-1alpha	9
,	0
adherent	0
to	0
the	0
lining	0
surface	0
of	0
the	0
airways	0
and	0
then	0
resistant	0
to	0
be	0
washed	0
out	0
.	0

To	0
delineate	0
the	0
mechanisms	0
of	0
transcriptional	0
activation	0
,	0
we	0
recently	0
cloned	0
the	0
5'-flanking	1
region	2
of	0
the	0
MIP-2	1
gene	2
.	0

The	0
promotor	1
region	2
contains	0
consensus	1
binding	2
sites	2
for	0
transcription	9
factor	10
nuclear	10
factor	10
kappaB	10
(	0
NF-kappaB	9
)	0
and	0
activator	9
protein-1	10
(	0
AP-1	9
)	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assay	0
,	0
increased	0
nuclear	0
NF-kappaB	9
,	0
not	0
AP-1	9
,	0
binding	0
activity	0
was	0
detected	0
1	0
h	0
after	0
NaVO3	0
instillation	0
,	0
which	0
correlated	0
with	0
the	0
induction	0
of	0
MIP-2	3
mRNA	4
.	0

p65	9
(	10
Rel	10
A	10
)	10
and	0
p50	9
protein	10
appears	0
to	0
be	0
involved	0
in	0
MIP-2	0
NF-kappaB	9
binding	0
.	0

Taken	0
together	0
,	0
our	0
studies	0
suggest	0
that	0
MIP-2	9
is	0
an	0
important	0
mediator	0
of	0
NaVO3-induced	0
pulmonary	0
inflammation	0
in	0
the	0
rat	0
model	0
.	0

In	0
addition	0
,	0
elevated	0
MIP-2	3
mRNA	4
levels	0
are	0
accompanied	0
by	0
increased	0
NF-kappaB	9
binding	0
activity	0
in	0
BAL	7
cells	8
,	0
suggesting	0
possible	0
MIP-2	9
transcriptional	0
regulation	0
through	0
NF-kappaB	9
.	0

Activation	0
of	0
signal	0
transduction	0
and	0
apoptosis	0
in	0
healthy	7
lymphomonocytes	8
exposed	0
to	0
bystander	0
HIV-1-infected	7
cells	8
.	0

Persistent	0
activation	0
of	0
the	0
immune	0
system	0
is	0
one	0
of	0
the	0
hallmarks	0
of	0
HIV-1	0
infection	0
.	0

In	0
this	0
study	0
we	0
analysed	0
the	0
induction	0
of	0
factors	0
involved	0
in	0
cytokine	0
signal	0
transduction	0
,	0
such	0
as	0
STAT	9
1	10
proteins	10
and	0
IRF-1	3
mRNA	4
,	0
in	0
normal	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
exposed	0
to	0
HIV-infected	7
cells	8
,	0
and	0
the	0
induction	0
of	0
apoptosis	0
.	0

Western	0
blot	0
analyses	0
and	0
reverse	0
transcriptase-polymerase	0
chain	0
reaction	0
results	0
indicate	0
that	0
both	0
cells	0
infected	0
with	0
a	0
X4	0
strain	0
and	0
cells	0
infected	0
with	0
a	0
R5	0
strain	0
are	0
able	0
to	0
increase	0
intracellular	0
levels	0
of	0
STAT	9
1alpha	10
and	10
beta	10
proteins	0
as	0
well	0
as	0
IRF-1	3
mRNA	4
.	0

This	0
effect	0
was	0
prevented	0
by	0
neutralizing	0
antibodies	0
against	0
interferon-alpha	9
(	0
IFN-alpha	9
)	0
.	0

HIV-1-infected	7
cells	8
dose-dependently	0
induced	0
apoptotic	0
commitment	0
in	0
normal	7
PBMC	8
,	0
as	0
revealed	0
by	0
DNA	0
fragmentation	0
analysis	0
,	0
but	0
this	0
was	0
not	0
accompanied	0
by	0
an	0
increase	0
of	0
caspase-3	0
activity	0
,	0
even	0
if	0
a	0
slight	0
up-regulation	0
of	0
IL-1beta-converting	3
enzyme	4
mRNA	4
was	0
detected	0
.	0

Apoptosis	0
induction	0
could	0
be	0
abrogated	0
mainly	0
by	0
antibodies	9
against	0
tumour	9
necrosis	10
factor-alpha	10
(	0
TNF-alpha	9
)	0
and	0
,	0
to	0
a	0
lesser	0
extent	0
,	0
by	0
antibodies	9
against	0
IFN-gamma	9
.	0

All	0
these	0
findings	0
suggest	0
that	0
uninfected	7
PBMC	8
can	0
undergo	0
activation	0
of	0
signal	0
transduction	0
and	0
apoptosis	0
after	0
exposure	0
to	0
bystander	0
HIV-infected	7
cells	8
,	0
subsequent	0
to	0
the	0
induction	0
of	0
cytokines	9
such	0
as	0
IFNs	9
and	0
TNF-alpha	9
.	0

The	0
physical	0
association	0
of	0
protein	9
kinase	10
C	10
theta	10
with	0
a	0
lipid	0
raft-associated	0
inhibitor	0
of	0
kappa	9
B	10
factor	10
kinase	10
(	10
IKK	10
)	10
complex	10
plays	0
a	0
role	0
in	0
the	0
activation	0
of	0
the	0
NF-kappa	0
B	0
cascade	0
by	0
TCR	9
and	0
CD28	9
.	0

We	0
investigated	0
the	0
role	0
of	0
protein	9
kinase	10
C	10
theta	10
(	0
PKCtheta	9
)	0
in	0
the	0
activation	0
of	0
the	0
NF-kappaB	9
cascade	0
in	0
primary	7
human	8
CD4	8
(	8
+	8
)	8
lymphocytes	8
.	0

Among	0
six	0
or	0
so	0
PKC	9
isoforms	10
expressed	0
in	0
T	7
cells	8
,	0
only	0
PKCtheta	9
participates	0
in	0
the	0
assembly	0
of	0
the	0
supramolecular	0
activation	0
clusters	0
at	0
the	0
contact	0
site	0
of	0
the	0
TCR	9
with	0
Ag	9
.	0

Signaling	0
via	0
both	0
the	0
TCR	9
and	0
CD28	9
is	0
required	0
for	0
optimal	0
activation	0
of	0
the	0
multisubunit	9
IkappaB	10
kinase	10
(	10
IKK	10
)	10
complex	10
in	0
primary	7
human	8
T	8
lymphocytes	8
;	0
this	0
activation	0
could	0
be	0
inhibited	0
by	0
a	0
Ca	0
(	0
2+	0
)	0
-independent	0
PKC	0
isoform	0
inhibitor	0
,	0
rottlerin	0
.	0

Moreover	0
,	0
endogenous	0
PKCtheta	9
physically	0
associates	0
with	0
activated	0
IKK	9
complexes	10
in	0
CD3/CD28-costimulated	7
primary	8
CD4	8
(	8
+	8
)	8
T	8
cells	8
.	0

The	0
same	0
set	0
of	0
stimuli	0
also	0
induced	0
relocation	0
of	0
endogenous	0
PKCtheta	9
and	0
IKKs	9
to	0
a	0
GM1	0
ganglioside-enriched	0
,	0
detergent-insoluble	0
membrane	0
compartment	0
in	0
primary	7
T	8
cells	8
.	0

IKKs	9
recruited	0
to	0
these	0
lipid	0
rafts	0
were	0
capable	0
of	0
phosphorylating	0
a	0
recombinant	0
IkappaBalpha	0
sustrate	0
.	0

Confocal	0
microscopy	0
further	0
demonstrated	0
that	0
exogenously	0
expressed	0
PKCtheta	9
and	0
IKKss	9
colocalize	0
in	0
the	0
membrane	0
of	0
CD3/CD28-costimulated	5
Jurkat	6
T	6
cells	6
.	0

Constitutively	0
active	0
but	0
not	0
kinase-inactive	9
PKCtheta	10
activated	0
IKKbeta	9
in	0
Jurkat	5
T	6
cells	6
.	0

Expression	0
of	0
dominant-active	9
PKCtheta	10
also	0
had	0
stimulatory	0
effects	0
on	0
the	0
CD28	1
response	2
element	2
of	0
the	0
IL-2	1
promoter	2
.	0

Taken	0
together	0
,	0
these	0
data	0
show	0
that	0
the	0
activation	0
of	0
PKCtheta	9
by	0
the	0
TCR	9
and	0
CD28	9
plays	0
an	0
important	0
role	0
in	0
the	0
assembly	0
and	0
activation	0
of	0
IKK	9
complexes	10
in	0
the	0
T	0
cell	0
membrane	0

T-cell	7
-mediated	0
regulation	0
of	0
osteoclastogenesis	0
by	0
signalling	0
cross-talk	0
between	0
RANKL	9
and	0
IFN-gamma	9
.	0

Bone	0
resorption	0
is	0
regulated	0
by	0
the	0
immune	0
system	0
,	0
where	0
T-cell	7
expression	0
of	0
RANKL	9
(	0
receptor	9
activator	10
of	10
nuclear	10
factor	10
(	10
NF	10
)	10
-kappaB	10
ligand	10
)	0
,	0
a	0
member	0
of	0
the	0
tumour-necrosis	9
factor	10
family	10
that	0
is	0
essential	0
for	0
osteoclastogenesis	0
,	0
may	0
contribute	0
to	0
pathological	0
conditions	0
,	0
such	0
as	0
autoimmune	0
arthritis	0
.	0

However	0
,	0
whether	0
activated	7
T	8
cells	8
maintain	0
bone	0
homeostasis	0
by	0
counterbalancing	0
the	0
action	0
of	0
RANKL	9
remains	0
unknown	0
.	0

Here	0
we	0
show	0
that	0
T-cell	7
production	0
of	0
interferon	9
(	10
IFN	10
)	10
-gamma	10
strongly	0
suppresses	0
osteoclastogenesis	0
by	0
interfering	0
with	0
the	0
RANKL	9
-RANK	0
signalling	0
pathway	0
.	0

IFN-gamma	9
induces	0
rapid	0
degradation	0
of	0
the	0
RANK	9
adapter	10
protein	10
,	0
TRAF6	9
(	0
tumour	9
necrosis	10
factor	10
receptor-associated	10
factor	10
6	10
)	0
,	0
which	0
results	0
in	0
strong	0
inhibition	0
of	0
the	0
RANKL	9
-induced	0
activation	0
of	0
the	0
transcription	9
factor	10
NF-kappaB	9
and	0
JNK	9
.	0

This	0
inhibition	0
of	0
osteoclastogenesis	0
is	0
rescued	0
by	0
overexpressing	0
TRAF6	9
in	0
precursor	7
cells	8
,	0
which	0
indicates	0
that	0
TRAF6	9
is	0
the	0
target	0
critical	0
for	0
the	0
IFN-gamma	9
action	0
.	0

Furthermore	0
,	0
we	0
provide	0
evidence	0
that	0
the	0
accelerated	0
degradation	0
of	0
TRAF6	9
requires	0
both	0
its	0
ubiquitination	0
,	0
which	0
is	0
initiated	0
by	0
RANKL	9
,	0
and	0
IFN-gamma	9
-induced	0
activation	0
of	0
the	0
ubiquitin-proteasome	0
system	0
.	0

Our	0
study	0
shows	0
that	0
there	0
is	0
cross-talk	0
between	0
the	0
tumour	9
necrosis	10
factor	10
and	0
IFN	9
families	10
of	0
cytokines	9
,	0
through	0
which	0
IFN-gamma	9
provides	0
a	0
negative	0
link	0
between	0
T-cell	7
activation	0
and	0
bone	0
resorption	0
.	0

Our	0
results	0
may	0
offer	0
a	0
therapeutic	0
approach	0
to	0
treat	0
the	0
inflammation-induced	0
tissue	0
breakdown	0
.	0

Stromal-derived	9
factor	10
1	10
and	0
thrombopoietin	9
regulate	0
distinct	0
aspects	0
of	0
human	0
megakaryopoiesis	0
.	0

The	0
role	0
of	0
the	0
chemokine	9
binding	0
stromal-derived	9
factor	10
1	10
(	0
SDF-1	9
)	0
in	0
normal	0
human	0
megakaryopoiesis	0
at	0
the	0
cellular	0
and	0
molecular	0
levels	0
and	0
its	0
comparison	0
with	0
that	0
of	0
thrombopoietin	9
(	0
TPO	9
)	0
have	0
not	0
been	0
determined	0
.	0

In	0
this	0
study	0
it	0
was	0
found	0
that	0
SDF-1	9
,	0
unlike	0
TPO	9
,	0
does	0
not	0
stimulate	0
alpha	0
(	0
IIb	0
)	0
beta	0
(	0
3	0
)	0
(	0
+	0
)	0
cell	0
proliferation	0
or	0
differentiation	0
or	0
have	0
an	0
antiapoptotic	0
effect	0
.	0

However	0
,	0
it	0
does	0
induce	0
chemotaxis	0
,	0
trans-Matrigel	0
migration	0
,	0
and	0
secretion	0
of	0
matrix	0
metalloproteinase	9
9	10
(	0
MMP-9	9
)	0
and	0
vascular	9
endothelial	10
growth	10
factor	10
(	0
VEGF	9
)	0
by	0
these	0
cells	0
,	0
and	0
both	0
SDF-1	9
and	0
TPO	9
increase	0
the	0
adhesion	0
of	0
alpha	7
(	8
IIb	8
)	8
beta	8
(	8
3	8
)	8
(	8
+	8
)	8
cells	8
to	0
fibrinogen	9
and	0
vitronectin	9
.	0

Investigating	0
the	0
intracellular	0
signaling	0
pathways	0
induced	0
by	0
SDF-1	9
and	0
TPO	9
revealed	0
some	0
overlapping	0
patterns	0
of	0
protein	0
phosphorylation/activation	0
(	0
mitogen-activated	9
protein	10
kinase	10
[	10
MAPK	10
]	10
p42/44	10
,	0
MAPK	9
p38	10
,	0
and	0
AKT	9
[	10
protein	10
kinase	10
B	10
]	10
)	0
and	0
some	0
that	0
were	0
distinct	0
for	0
TPO	9
(	0
eg	0
,	0
JAK-STAT	9
)	0
and	0
for	0
SDF-1	9
(	0
eg	0
,	0
NF-kappa	9
B	10
)	0
.	0

It	0
was	0
also	0
found	0
that	0
though	0
inhibition	0
of	0
phosphatidyl-inositol	9
3-kinase	10
(	0
PI-3K	9
)	0
by	0
LY294002	0
in	0
alpha	7
(	8
IIb	8
)	8
beta	8
(	8
3	8
)	8
(	8
+	8
)	8
cells	8
induced	0
apoptosis	0
and	0
inhibited	0
chemotaxis	0
adhesion	0
and	0
the	0
secretion	0
of	0
MMP-9	9
and	0
VEGF	9
,	0
the	0
inhibition	0
of	0
MAPK	9
p42/44	10
(	0
by	0
the	0
MEK	0
inhibitor	0
U0126	0
)	0
had	0
no	0
effect	0
on	0
the	0
survival	0
,	0
proliferation	0
,	0
and	0
migration	0
of	0
these	0
cells	0
.	0

Hence	0
,	0
it	0
is	0
suggested	0
that	0
the	0
proliferative	0
effect	0
of	0
TPO	9
is	0
more	0
related	0
to	0
activation	0
of	0
the	0
JAK-STAT	0
pathway	0
(	0
unique	0
to	0
TPO	9
)	0
,	0
and	0
the	0
PI-3K-AKT	0
axis	0
is	0
differentially	0
involved	0
in	0
TPO-	0
and	0
SDF-1-dependent	0
signaling	0
.	0

Accordingly	0
,	0
PI-3K	9
is	0
involved	0
in	0
TPO	9
-mediated	0
inhibition	0
of	0
apoptosis	0
,	0
TPO-	0
and	0
SDF-1-regulated	0
adhesion	0
to	0
fibrinogen	9
and	0
vitronectin	9
,	0
and	0
SDF-1	9
-mediated	0
migration	0
.	0

This	0
study	0
expands	0
the	0
understanding	0
of	0
the	0
role	0
of	0
SDF-1	9
and	0
TPO	9
in	0
normal	0
human	0
megakaryopoiesis	0
and	0
indicates	0
the	0
molecular	0
basis	0
of	0
the	0
observed	0
differences	0
in	0
cellular	0
responses	0
.	0

(	0
Blood.	0
2000	0
;	0
96	0
:	0
4142-4151	0
)	0

Adhesion	0
of	0
immature	7
and	8
mature	8
T	8
cells	8
induces	0
in	0
human	7
thymic	8
epithelial	8
cells	8
(	0
TEC	7
)	0
activation	0
of	0
IL-6	9
gene	10
trascription	10
factors	10
(	0
NF-kappaB	9
and	0
NF-IL6	9
)	0
and	0
IL-6	0
gene	0
expression	0
:	0
role	0
of	0
alpha3beta1	9
and	10
alpha6beta4	10
integrins	10
.	0

T	7
cell	8
precursors	8
homed	0
to	0
thymus	0
develop	0
in	0
close	0
contact	0
with	0
stromal	7
cells	8
.	0

Among	0
them	0
,	0
thymic	7
epithelial	8
cells	8
(	0
TEC	7
)	0
are	0
known	0
to	0
exert	0
dominant	0
roles	0
in	0
their	0
survival	0
and	0
functional	0
shaping	0
.	0

Key	0
molecules	0
mediating	0
TEC	7
/	0
thymocytes	7
interactions	0
include	0
cytokines	9
and	0
growth	9
factors	10
secreted	0
by	0
the	0
two	0
cell	0
types	0
and	0
adhesion	9
receptors	10
mediating	0
cell	0
contact	0
.	0

Signaling	0
events	0
triggered	0
in	0
thymocytes	7
by	0
adhesion	0
to	0
epithelial	7
cells	8
have	0
been	0
extensively	0
investigated	0
,	0
whereas	0
little	0
is	0
known	0
on	0
the	0
opposite	0
phenomenon	0
.	0

We	0
have	0
previously	0
investigated	0
this	0
issue	0
in	0
a	0
co-culture	0
system	0
composed	0
of	0
TEC	7
cultures	8
derived	0
from	0
human	0
normal	0
thymus	0
and	0
heterologous	7
thymocytes	8
.	0

We	0
demonstrated	0
that	0
thymocytes	7
adhere	0
to	0
TEC	7
involving	0
beta1	9
and	10
beta4	10
integrins	10
and	0
induce	0
the	0
clustering	0
of	0
alpha3beta1	9
and	10
alpha6beta4	10
heterodimers	10
at	0
the	0
TEC	0
surface	0
.	0

In	0
addition	0
thymocyte	0
adhesion	0
was	0
followed	0
by	0
activation	0
of	0
NF-kappaB	9
and	0
NF-IL6	9
gene	9
transcription	10
factors	10
and	0
enhanced	0
IL-6	0
production	0
.	0

The	0
two	0
latter	0
phenomena	0
were	0
reproduced	0
by	0
the	0
cross-linking	0
of	0
the	0
alpha3	9
,	0
alpha6	9
,	0
beta1	9
and	10
beta4	10
integrins	10
,	0
thus	0
implying	0
that	0
the	0
alpha3beta1	9
and	10
alpha6beta4	10
heterodimers	10
can	0
signal	0
during	0
thymocyte	0
adhesion	0
.	0

We	0
have	0
extended	0
our	0
previous	0
work	0
investigating	0
in	0
the	0
same	0
experimental	0
setting	0
the	0
inducing	0
activity	0
of	0
non	0
stimulated	0
or	0
activated	0
policlonal	7
or	8
clonal	8
mature	8
T	8
cells	8
as	0
representative	0
of	0
the	0
more	0
mature	7
thymocyte	8
subset	8
.	0

We	0
found	0
that	0
adhesion	0
of	0
unstimulated	7
T	8
cell	8
i	0
)	0
involved	0
beta1	0
,	0
but	0
not	0
beta4	0
integrin	0
functions	0
at	0
the	0
surface	0
ii	0
)	0
induced	0
the	0
clustering	0
of	0
alpha3beta1	9
,	0
but	0
not	0
alpha2beta1	9
heterodimers	10
at	0
the	0
TEC	0
surface	0
and	0
iii	0
)	0
up-regulated	0
the	0
nuclear	0
binding	0
activity	0
of	0
NF-kappaB	9
transcription	10
factor	10
and	0
the	0
IL-6	0
secretion	0
.	0

We	0
propose	0
that	0
alpha3beta1	9
and	10
alpha6beta4	10
heterodimers	10
are	0
induced	0
to	0
cluster	0
at	0
the	0
TEC	0
surface	0
recognizing	0
yet	0
unknown	0
cellular	9
ligands	10
differentially	0
expressed	0
during	0
T	0
cell	0
development	0
.	0

Identification	0
and	0
characterization	0
of	0
SKAT-2	1
,	0
a	0
novel	0
Th2-specific	1
zinc	2
finger	2
gene	2
.	0

We	0
have	0
identified	0
a	0
novel	0
Kruppel-type	1
zinc	2
finger	2
(	2
ZF	2
)	2
gene	2
,	0
SKAT-2	1
,	0
which	0
is	0
selectively	0
expressed	0
by	0
murine	7
Th2	8
cells	8
.	0

The	0
protein	0
encoded	0
by	0
this	0
gene	0
has	0
14	0
C2H2-type	0
ZF	0
tandemly	0
arrayed	0
at	0
its	0
C	1
terminus	2
and	0
N-terminal	1
SCAN	1
box	2
and	0
KRAB	1
domains	2
.	0

SKAT-2	1
is	0
tissue	0
restricted	0
in	0
expression	0
at	0
the	0
RNA	0
level	0
,	0
detectable	0
only	0
in	0
brain	0
and	0
at	0
low	0
levels	0
in	0
kidney	0
and	0
spleen	0
and	0
few	0
hematopoietic	5
cell	6
lines	6
.	0

By	0
in	0
situ	0
hybridization	0
,	0
SKAT-2	1
expression	0
was	0
found	0
to	0
peak	0
in	0
antigen-stimulated	0
CD4	7
(	8
+	8
)	8
T	8
cells	8
after	0
2-3	0
days	0
of	0
culture	0
under	0
Th2	0
but	0
not	0
Th1	0
biasing	0
conditions	0
.	0

This	0
pattern	0
of	0
expression	0
closely	0
mirrored	0
that	0
of	0
GATA-3	9
in	0
the	0
same	0
cells	0
.	0

In	0
transient	0
transfection	0
experiments	0
in	0
phorbol	0
12-myristate	0
13-acetate/ionomycin-stimulated	0
EL4	5
cells	6
,	0
SKAT-2	1
was	0
found	0
to	0
up-regulate	0
the	0
activity	0
of	0
the	0
IL-4	1
but	2
not	2
the	2
IL-5	2
promoter	2
,	0
contrasting	0
with	0
the	0
ability	0
of	0
GATA-3	9
to	0
activate	0
both	0
promoters	1
.	0

This	0
result	0
was	0
confirmed	0
using	0
clones	0
of	0
EL4	5
cells	6
stably	0
expressing	0
an	0
inducible	0
form	0
of	0
SKAT-2	1
,	0
thus	0
SKAT-2	1
is	0
a	0
novel	0
Th2-specific	1
gene	2
that	0
may	0
play	0
a	0
role	0
in	0
selective	0
regulation	0
of	0
cytokine	1
genes	2
in	0
T	7
cells	8
.	0

hsp70	9
interacting	10
protein	10
Hip	10
does	0
not	0
affect	0
glucocorticoid	9
receptor	10
folding	0
by	0
the	0
hsp90-based	0
chaperone	0
machinery	0
except	0
to	0
oppose	0
the	0
effect	0
of	0
BAG-1	9
.	0

Reticulocyte	0
lysate	0
contains	0
a	0
chaperone	0
system	0
that	0
assembles	0
glucocorticoid	9
receptor	10
(	10
GR	10
)	10
.hsp90	10
heterocomplexes	10
.	0

Using	0
purified	9
proteins	10
,	0
we	0
have	0
prepared	0
a	0
five-protein	0
heterocomplex	0
assembly	0
system	0
consisting	0
of	0
two	0
proteins	0
essential	0
for	0
heterocomplex	0
assembly-	0
hsp90	9
and	0
hsp70	9
-and	0
three	0
proteins	0
that	0
act	0
as	0
co-chaperones	0
to	0
enhance	0
assembly-	0
Hop	9
,	0
hsp40	9
,	0
p23	9
[	0
Morishima	0
,	0
Y.	0
,	0
Kanelakis	0
,	0
K.	0
C.	0
,	0
Silverstein	0
,	0
A.	0
M.	0
,	0
Dittmar	0
,	0
K.	0
D.	0
,	0
Estrada	0
,	0
L.	0
,	0
and	0
Pratt	0
,	0
W.	0
B.	0
(	0
2000	0
)	0
J.	0
Biol.	0
Chem.	0
275	0
,	0
6894-6900	0
]	0
.	0

The	0
hsp70	9
co-chaperone	10
Hip	10
has	0
been	0
recovered	0
in	0
receptor.hsp90	9
heterocomplexes	10
at	0
an	0
intermediate	0
stage	0
of	0
assembly	0
in	0
reticulocyte	0
lysate	0
,	0
and	0
Hip	9
is	0
also	0
thought	0
to	0
be	0
an	0
intrinsic	0
component	0
of	0
the	0
assembly	0
machinery	0
.	0

Here	0
we	0
show	0
that	0
immunodepletion	0
of	0
Hip	9
from	0
reticulocyte	0
lysate	0
or	0
addition	0
of	0
high	0
levels	0
of	0
Hip	9
to	0
the	0
purified	0
five-protein	0
system	0
does	0
not	0
affect	0
GR.hsp90	0
heterocomplex	0
assembly	0
or	0
the	0
activation	0
of	0
steroid	0
binding	0
activity	0
that	0
occurs	0
with	0
assembly	0
.	0

Despite	0
the	0
fact	0
that	0
Hip	9
does	0
not	0
affect	0
assembly	0
,	0
it	0
is	0
recovered	0
in	0
GR.hsp90	9
heterocomplexes	10
assembled	0
by	0
both	0
systems	0
.	0

In	0
the	0
five-protein	0
system	0
,	0
Hip	9
prevents	0
inhibition	0
of	0
assembly	0
by	0
the	0
hsp70	9
co-chaperone	10
BAG-1	10
,	0
and	0
cotransfection	0
of	0
Hip	9
with	0
BAG-1	9
opposes	0
BAG-1	9
reduction	0
of	0
steroid	0
binding	0
activity	0
in	0
COS	5
cells	6
.	0

We	0
conclude	0
that	0
Hip	9
is	0
not	0
a	0
component	0
of	0
the	0
assembly	0
machinery	0
but	0
that	0
it	0
could	0
play	0
a	0
regulatory	0
role	0
in	0
opposition	0
to	0
BAG-1	9
.	0

Cutting	0
edge	0
:	0
STAT6-deficient	0
mice	0
have	0
enhanced	0
tumor	0
immunity	0
to	0
primary	0
and	0
metastatic	0
mammary	0
carcinoma	0
.	0

STAT4	9
and	0
STAT6	9
are	0
essential	0
for	0
the	0
development	0
of	0
CD4	0
(	0
+	0
)	0
Th1	0
and	0
Th2	0
development	0
,	0
respectively	0
.	0

Tumor	0
immunologists	0
have	0
hypothesized	0
that	0
Th1	7
cells	8
are	0
critical	0
in	0
tumor	0
immunity	0
because	0
they	0
facilitate	0
differentiation	0
of	0
CD8	7
(	8
+	8
)	8
T	8
cells	8
,	0
which	0
are	0
potent	0
anti-tumor	7
effectors	8
.	0

We	0
have	0
used	0
STAT4	0
(	0
-/-	0
)	0
and	0
STAT6	0
(	0
-/-	0
)	0
mice	0
to	0
test	0
this	0
hypothesis	0
.	0

BALB/c	0
and	0
knockout	0
mice	0
were	0
challenged	0
in	0
the	0
mammary	0
gland	0
with	0
the	0
highly	0
malignant	0
and	0
spontaneously	0
metastatic	0
BALB/c-derived	0
4T1	0
mammary	0
carcinoma	0
.	0

Primary	0
tumor	0
growth	0
and	0
metastatic	0
disease	0
are	0
reduced	0
in	0
STAT6	0
(	0
-/-	0
)	0
mice	0
relative	0
to	0
BALB/c	0
and	0
STAT4	0
(	0
-/-	0
)	0
mice	0
.	0

Ab	0
depletions	0
demonstrate	0
that	0
the	0
effect	0
is	0
mediated	0
by	0
CD8	7
(	8
+	8
)	8
T	8
cells	8
,	0
and	0
immunized	0
STAT6	0
(	0
-/-	0
)	0
mice	0
have	0
higher	0
levels	0
of	0
4T1-specific	7
CTL	8
than	0
BALB/c	0
or	0
STAT4	0
(	0
-/-	0
)	0
mice	0
.	0

Surprisingly	0
,	0
Th1	7
or	8
Th2	8
cells	8
are	0
not	0
involved	0
,	0
because	0
CD4	0
depletion	0
does	0
not	0
diminish	0
the	0
anti-tumor	0
effect	0
.	0

Therefore	0
,	0
deletion	0
of	0
the	0
STAT6	1
gene	2
facilitates	0
development	0
of	0
potent	0
anti-tumor	0
immunity	0
via	0
a	0
CD4	0
(	0
+	0
)	0
-independent	0
pathway	0
.	0

Activation	0
of	0
oncogenic	9
transcription	10
factor	10
AP-1	10
in	0
T	7
cells	8
infected	0
with	0
human	0
T	0
cell	0
leukemia	0
virus	0
type	0
1	0
.	0

Human	0
T	0
cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
Tax	9
protein	10
transforms	0
primary	7
human	8
T	8
cells	8
in	0
vitro	0
.	0

We	0
previously	0
showed	0
that	0
Tax	9
induces	0
the	0
expression	0
of	0
various	0
family	0
members	0
of	0
the	0
transcription	9
factor	10
AP-1	10
such	0
as	0
c-Jun	9
,	0
JunD	9
,	0
c-Fos	9
,	0
and	0
Fra-1	9
at	0
the	0
mRNA	0
level	0
in	0
T	7
cells	8
.	0

In	0
this	0
study	0
,	0
we	0
have	0
examined	0
the	0
ability	0
of	0
Tax	9
to	0
activate	0
transcription	0
through	0
the	0
AP-1-binding	1
site	2
(	0
AP-1	1
site	2
)	0
.	0

A	0
transient	0
transfection	0
study	0
showed	0
that	0
Tax	9
can	0
activate	0
transcription	0
through	0
the	0
AP-1-binding	1
site	2
in	0
a	0
human	5
T	6
cell	6
line	6
,	0
whereas	0
any	0
combination	0
of	0
AP-1	9
proteins	10
did	0
so	0
much	0
less	0
than	0
Tax	9
,	0
indicating	0
that	0
the	0
activation	0
of	0
the	0
AP-1	1
site	2
by	0
Tax	9
may	0
require	0
a	0
mechanism	0
other	0
than	0
the	0
induction	0
of	0
AP-1	3
mRNA	4
.	0

Fresh	7
peripheral	8
blood	8
leukemia	8
cells	8
of	0
all	0
surveyed	0
ATL	0
patients	0
displayed	0
constitutive	0
AP-1	0
DNA-binding	0
activity	0
,	0
whereas	0
no	0
normal	0
individuals	0
did	0
.	0

However	0
,	0
the	0
HTLV-1	1
genes	2
,	0
including	0
tax	1
,	0
are	0
not	0
significantly	0
expressed	0
in	0
fresh	0
leukemia	7
cells	8
from	0
ATL	0
patients	0
.	0

Our	0
present	0
results	0
suggest	0
that	0
activation	0
of	0
AP-1	9
occurs	0
through	0
Tax-dependent	0
and	0
-independent	0
mechanisms	0
in	0
HTLV-1-infected	0
T	7
cells	8
,	0
which	0
may	0
play	0
some	0
roles	0
in	0
dysregulated	0
phenotypes	0
of	0
HTLV-1-infected	7
cells	8
.	0

2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-pentachlorobiphenyl	0
induces	0
apoptosis	0
in	0
human	7
monocytic	8
cells	8
.	0

Polychlorinatedbiphenyls	0
(	0
PCBs	0
)	0
are	0
a	0
group	0
of	0
persistent	0
and	0
widely	0
dispersed	0
environmental	0
pollutants	0
,	0
some	0
of	0
which	0
may	0
be	0
immunotoxic	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
investigated	0
the	0
effect	0
of	0
PCBs	0
on	0
immune	0
system	0
by	0
assessing	0
apoptotic	0
cell	0
death	0
in	0
human	5
monocytic	6
U937	6
cells	6
.	0

Among	0
the	0
various	0
congeners	0
tested	0
,	0
2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-pentachlorobiphenyl	0
(	0
PeCB	0
)	0
,	0
a	0
highly	0
ortho-substituted	0
congener	0
,	0
specifically	0
induced	0
DNA	0
fragmentation	0
,	0
a	0
hallmark	0
of	0
apoptosis	0
,	0
while	0
the	0
other	0
examined	0
di-	0
,	0
tri-	0
,	0
tetra-	0
,	0
and	0
pentachlorobiphenyls	0
did	0
not	0
.	0

To	0
further	0
study	0
the	0
2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-PeCB-induced	0
cell	0
death	0
,	0
various	0
features	0
of	0
apoptosis	0
were	0
examined	0
.	0

2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-PeCB	0
caused	0
a	0
decrease	0
in	0
cell	0
viability	0
and	0
induced	0
cellular	0
morphologic	0
features	0
characteristic	0
of	0
apoptosis	0
such	0
as	0
chromatin	0
aggregation	0
and	0
apoptotic	0
bodies	0
.	0

In	0
addition	0
,	0
caspase-3	9
,	0
an	0
executioner	0
of	0
apoptosis	0
,	0
was	0
activated	0
and	0
its	0
substrate	0
,	0
poly	9
(	10
ADP-ribose	10
)	10
polymerase	10
(	0
PARP	9
)	0
,	0
was	0
cleaved	0
during	0
2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-PeCB-induced	0
apoptosis	0
.	0

In	0
contrast	0
,	0
3	0
,	0
3	0
'	0
,	0
4	0
,	0
4	0
'	0
,	0
5-PeCB	0
,	0
a	0
congener	0
of	0
coplanar	0
structure	0
,	0
as	0
well	0
as	0
2	0
,	0
3	0
,	0
7	0
,	0
8-TCDD	0
did	0
not	0
induce	0
apoptosis	0
in	0
these	0
human	7
monocytic	8
cells	8
,	0
although	0
they	0
potently	0
induced	0
CYP	9
1A1	10
in	0
human	5
hepatoma	6
Hep	6
G2	6
cells	6
.	0

Taken	0
together	0
,	0
the	0
data	0
indicate	0
that	0
2	0
,	0
2	0
'	0
,	0
4	0
,	0
6	0
,	0
6'-PeCB	0
induces	0
apoptosis	0
in	0
human	7
monocytic	8
cells	8
through	0
a	0
mechanism	0
that	0
is	0
independent	0
of	0
the	0
arylhydrocarbon	9
receptor	10
.	0

This	0
suggests	0
a	0
possibly	0
separate	0
mechanism	0
by	0
which	0
PCBs	0
cause	0
immunosuppression	0
.	0

Effects	0
of	0
deregulated	0
Raf	0
activation	0
on	0
integrin	9
,	0
cytokine-receptor	0
expression	0
and	0
the	0
induction	0
of	0
apoptosis	0
in	0
hematopoietic	7
cells	8
.	0

The	0
effects	0
of	0
deregulated	0
Raf	0
activation	0
on	0
the	0
growth	0
and	0
differentiation	0
of	0
hematopoietic	7
cells	8
were	0
investigated	0
.	0

The	0
cytokine-dependent	5
murine	6
myeloid	6
FDC-P1	6
and	0
human	5
erythroleukemic	6
TF-1	6
cell	6
lines	6
were	0
transformed	0
to	0
grow	0
in	0
response	0
to	0
deregulated	0
Raf	0
expression	0
in	0
the	0
absence	0
of	0
exogenous	9
cytokines	10
.	0

The	0
conditionally	0
active	0
Raf	9
proteins	10
were	0
regulated	0
by	0
beta-estradiol	0
as	0
cDNAs	1
containing	0
the	0
Raf	9
catalytic	10
,	0
but	0
lacking	0
negative-regulatory	9
domains	10
,	0
were	0
ligated	0
to	0
the	0
hormone	9
binding	10
domain	10
of	0
the	0
estrogen	9
receptor	10
(	0
deltaRaf	9
:	10
ER	10
)	0
.	0

Continuous	0
deltaRaf	9
expression	0
prevented	0
apoptosis	0
in	0
the	0
absence	0
of	0
exogenous	9
cytokines	10
and	0
altered	0
the	0
morphology	0
of	0
the	0
FD/deltaRaf	7
:	8
ER	8
cells	8
as	0
they	0
grew	0
in	0
large	0
aggregated	0
masses	0
(	0
>	0
100	0
cells	0
)	0
whereas	0
the	0
parental	5
cytokine-dependent	6
FDC-P1	6
cells	6
grew	0
in	0
smaller	0
grape-like	0
clusters	0
(	0
<	0
10	0
cells	0
)	0
.	0

FD/deltaRaf-1	5
:	6
ER	6
cells	6
growing	0
in	0
response	0
to	0
Raf	0
activation	0
displayed	0
decreased	0
levels	0
of	0
the	0
Mac-2	9
and	10
Mac-3	10
molecules	10
on	0
their	0
cell	7
surface	8
.	0

In	0
contrast	0
,	0
when	0
these	0
cells	0
were	0
cultured	0
in	0
IL-3	9
,	0
higher	0
levels	0
of	0
these	0
adhesion	9
molecules	10
were	0
detected	0
.	0

Expression	0
of	0
activated	0
Raf	9
oncoproteins	10
also	0
abrogated	0
cytokine	0
dependency	0
and	0
prevented	0
apoptosis	0
of	0
TF-1	5
cells	6
.	0

Moreover	0
,	0
the	0
differentiation	0
status	0
of	0
these	0
Raf-responsive	7
cells	8
was	0
more	0
immature	0
upon	0
Raf	0
activation	0
as	0
culture	0
with	0
the	0
differentiation-inducing	0
agent	0
phorbol	0
12	0
myristate	0
13-acetate	0
(	0
PMA	0
)	0
and	0
beta-estradiol	0
resulted	0
in	0
decreased	0
levels	0
of	0
the	0
CD11b	9
and	10
CD18	10
integrin	10
molecules	10
on	0
the	0
cell	7
surface	8
.	0

In	0
contrast	0
when	0
the	0
Raf-responsive	7
cells	8
were	0
induced	0
to	0
differentiate	0
with	0
PMA	0
and	0
GM-CSF	9
,	0
in	0
the	0
absence	0
of	0
deltaRaf	9
:	10
ER	10
activation	0
,	0
increased	0
levels	0
of	0
the	0
CD11b	9
and	10
CD18	10
molecules	10
were	0
detected	0
.	0

Retinoic	0
acid	0
(	0
RA	0
)	0
inhibited	0
3H-thymidine	0
incorporation	0
in	0
response	0
to	0
GM-CSF	9
.	0

Interestingly	0
,	0
Raf	0
activation	0
counterbalanced	0
the	0
inhibition	0
of	0
DNA	0
synthesis	0
caused	0
by	0
RA	0
but	0
not	0
PMA	0
.	0

Thus	0
deregulated	0
Raf	0
expression	0
can	0
alter	0
cytokine	0
dependency	0
,	0
integrin	0
expression	0
and	0
the	0
stage	0
of	0
differentiation	0
.	0

These	0
Raf-responsive	5
cell	6
lines	6
will	0
be	0
useful	0
in	0
elucidating	0
the	0
roles	0
of	0
the	0
MAP	0
kinase	0
cascade	0
on	0
hematopoietic	7
cell	8
differentiation	0
and	0
malignant	0
transformation	0

Cyclic	0
AMP	0
activates	0
p38	9
mitogen-activated	10
protein	10
kinase	10
in	0
Th2	7
cells	8
:	0
phosphorylation	0
of	0
GATA-3	9
and	0
stimulation	0
of	0
Th2	7
cytokine	0
gene	0
expression	0
.	0

cAMP	0
is	0
an	0
important	0
second	0
messenger	0
with	0
immunomodulatory	0
properties	0
.	0

Elevation	0
of	0
intracellular	0
cAMP	0
in	0
T	7
cells	8
,	0
induced	0
by	0
agents	0
such	0
as	0
IL-1alpha	9
or	0
PGs	9
,	0
inhibits	0
T	0
cell	0
activation	0
.	0

In	0
effector	0
T	7
cells	8
,	0
an	0
increase	0
in	0
the	0
level	0
of	0
intracellular	0
cAMP	0
inhibits	0
cytokine	9
production	0
in	0
Th1	7
cells	8
but	0
stimulates	0
cytokine	9
production	0
in	0
Th2	7
cells	8
.	0

Here	0
we	0
report	0
that	0
cAMP-induced	0
effects	0
in	0
Th2	7
cells	8
occur	0
independently	0
of	0
the	0
protein	9
kinase	10
A	10
pathway	0
,	0
which	0
is	0
the	0
major	0
mediator	0
of	0
cAMP-induced	0
signaling	0
events	0
in	0
most	0
cell	0
types	0
.	0

Instead	0
,	0
cAMP	0
stimulates	0
activation	0
of	0
p38	9
mitogen-activated	10
protein	10
kinase	10
in	0
Th2	7
cells	8
.	0

This	0
appears	0
to	0
be	0
a	0
Th2	7
-selective	0
event	0
because	0
cAMP	0
barely	0
increased	0
p38	9
phosphorylation	0
in	0
Th1	7
cells	8
.	0

We	0
show	0
that	0
in	0
Th2	7
cells	8
,	0
cAMP	0
promotes	0
the	0
production	0
of	0
both	0
IL-5	9
and	0
IL-13	9
,	0
which	0
play	0
distinct	0
but	0
critical	0
roles	0
in	0
asthma	0
pathogenesis	0
.	0

Our	0
data	0
also	0
show	0
that	0
cAMP	0
causes	0
increased	0
phosphorylation	0
of	0
the	0
transcription	9
factor	10
GATA-3	10
,	0
which	0
we	0
have	0
shown	0
is	0
a	0
critical	0
regulator	0
of	0
Th2	7
cytokine	0
gene	0
expression	0
and	0
,	0
in	0
turn	0
,	0
of	0
airway	0
inflammation	0
in	0
mice	0
.	0

Thus	0
,	0
Th2	7
-specific	0
GATA-3	9
expression	0
and	0
p38	9
mitogen-activated	10
protein	10
kinase	10
activation	0
together	0
provide	0
a	0
molecular	0
basis	0
for	0
the	0
differential	0
effects	0
of	0
cAMP	0
in	0
the	0
two	0
T	7
helper	8
cell	8
subsets	8
.	0

Characterization	0
of	0
IL-4	9
and	0
IL-13	9
signals	0
dependent	0
on	0
the	0
human	9
IL-13	10
receptor	10
alpha	10
chain	10
1	10
:	0
redundancy	0
of	0
requirement	0
of	0
tyrosine	0
residue	0
for	0
STAT3	0
activation	0
.	0

IL-4	9
and	0
IL-13	9
are	0
pleiotropic	9
cytokines	10
whose	0
biological	0
activities	0
overlap	0
with	0
each	0
other	0
.	0

IL-13	9
receptor	10
alpha	10
chain	10
1	10
(	0
IL-13R	9
alpha	10
1	10
)	0
is	0
necessary	0
for	0
binding	0
to	0
IL-13	9
,	0
and	0
the	0
heterodimer	0
composed	0
of	0
IL-13R	9
alpha	10
1	10
and	0
IL-4R	9
alpha	10
chain	10
transduces	0
IL-13	9
and	0
IL-4	9
signals	0
;	0
however	0
,	0
the	0
functional	0
mapping	0
of	0
the	0
intracellular	9
domain	10
of	0
IL-13R	9
alpha	10
1	10
is	0
not	0
fully	0
understood	0
.	0

In	0
this	0
study	0
,	0
we	0
constructed	0
wild	0
and	0
mutated	0
types	0
of	0
human	9
IL-13R	10
alpha	10
1	10
,	0
and	0
analyzed	0
IL-4	9
and	0
IL-13	9
signals	0
using	0
an	0
IL-13R	9
alpha	10
1	10
-transfected	0
human	5
B	6
cell	6
line	6
.	0

Expression	0
of	0
IL-13R	9
alpha	10
1	10
evoked	0
STAT3	9
activation	0
by	0
IL-4	9
and	0
IL-13	9
,	0
and	0
in	0
stimulated	0
human	7
B	8
cells	8
,	0
on	0
which	0
IL-13R	9
alpha	10
1	10
was	0
highly	0
expressed	0
,	0
IL-4	9
and	0
IL-13	9
induced	0
STAT3	9
activation	0
.	0

Replacement	0
of	0
the	0
two	0
tyrosine	0
residues	0
completely	0
abolished	0
STAT3	9
activation	0
,	0
although	0
replacing	0
either	0
tyrosine	0
residue	0
alone	0
retained	0
it	0
.	0

Furthermore	0
,	0
we	0
found	0
that	0
the	0
Box1	9
region	10
and	0
the	0
C-terminal	9
tail	10
of	0
IL-13R	9
alpha	10
1	10
were	0
critical	0
for	0
binding	0
to	0
Tyk2	9
,	0
and	0
activation	0
of	0
Jak1	9
,	0
Tyk2	9
,	0
the	0
insulin	9
receptor	10
substrate-1	10
and	0
STAT6	9
respectively	0
.	0

These	0
results	0
suggest	0
that	0
STAT3	9
activation	0
is	0
involved	0
with	0
IL-4	9
and	0
IL-13	9
signals	0
in	0
human	7
B	8
cells	8
along	0
with	0
the	0
activation	0
of	0
STAT6	9
,	0
and	0
that	0
there	0
is	0
a	0
unique	0
sequence	0
in	0
IL-13R	9
alpha	10
1	10
to	0
activate	0
STAT3	9
.	0

Functional	0
uncoupling	0
of	0
the	0
Janus	0
kinase	0
3-Stat5	0
pathway	0
in	0
malignant	0
growth	0
of	0
human	0
T	0
cell	0
leukemia	0
virus	0
type	0
1-transformed	0
human	7
T	8
cells	8
.	0

Human	0
T	0
cell	0
leukemia	0
virus	0
type	0
1	0
(	0
HTLV-1	0
)	0
transforms	0
cytokine	9
-dependent	0
T	7
lymphocytes	8
and	0
causes	0
adult	0
T	0
cell	0
leukemia	0
.	0

Janus	9
tyrosine	10
kinase	10
(	10
Jak	10
)	10
3	10
and	0
transcription	9
factors	10
Stat5a	9
and	0
Stat5b	9
are	0
essential	0
for	0
the	0
proliferation	0
of	0
normal	7
T	8
cells	8
and	0
are	0
constitutively	0
hyperactivated	0
in	0
both	0
HTLV-1-transformed	5
human	6
T	6
cell	6
lines	6
and	0
lymphocytes	7
isolated	0
from	0
HTLV-1-infected	0
patients	0
;	0
therefore	0
,	0
a	0
critical	0
role	0
for	0
the	0
Jak3-Stat5	0
pathway	0
in	0
the	0
progression	0
of	0
this	0
disease	0
has	0
been	0
postulated	0
.	0

We	0
recently	0
reported	0
that	0
tyrphostin	0
AG-490	0
selectively	0
blocked	0
IL-2	0
activation	0
of	0
Jak3/Stat5	9
and	0
growth	0
of	0
murine	5
T	6
cell	6
lines	6
.	0

Here	0
we	0
demonstrate	0
that	0
disruption	0
of	0
Jak3/Stat5a/b	0
signaling	0
with	0
AG-490	0
(	0
50	0
&	0
mgr	0
;	0
M	0
)	0
blocked	0
the	0
proliferation	0
of	0
primary	7
human	8
T	8
lymphocytes	8
,	0
but	0
paradoxically	0
failed	0
to	0
inhibit	0
the	0
proliferation	0
of	0
HTLV-1-transformed	5
human	6
T	6
cell	6
lines	6
,	0
HuT-102	5
and	0
MT-2	5
.	0

Structural	0
homologues	0
of	0
AG-490	0
also	0
inhibited	0
the	0
proliferation	0
of	0
primary	7
human	8
T	8
cells	8
,	0
but	0
not	0
HTLV-1-infected	7
cells	8
.	0

Disruption	0
of	0
constitutive	0
Jak3/Stat5	0
activation	0
by	0
AG-490	0
was	0
demonstrated	0
by	0
inhibition	0
of	0
1	0
)	0
tyrosine	0
phosphorylation	0
of	0
Jak3	9
,	0
Stat5a	9
(	0
Tyr	0
(	0
694	0
)	0
)	0
,	0
and	0
Stat5b	9
(	0
Tyr	0
(	0
699	0
)	0
)	0
;	0
2	0
)	0
serine	0
phosphorylation	0
of	0
Stat5a	9
(	0
Ser	0
(	0
726	0
)	0
)	0
as	0
determined	0
by	0
a	0
novel	0
phosphospecific	9
Ab	10
;	0
and	0
3	0
)	0
Stat5a/b	0
DNA	0
binding	0
to	0
the	0
Stat5-responsive	1
beta-casein	2
promoter	2
.	0

In	0
contrast	0
,	0
AG-490	0
had	0
no	0
effect	0
on	0
DNA	0
binding	0
by	0
p50/p65	9
components	10
of	0
NF-kappaB	9
,	0
a	0
transcription	9
factor	10
activated	0
by	0
the	0
HTLV-1-encoded	9
phosphoprotein	10
,	10
Tax	10
.	0

Collectively	0
,	0
these	0
data	0
suggest	0
that	0
the	0
Jak3-Stat5	0
pathway	0
in	0
HTLV-1-transformed	7
T	8
cells	8
has	0
become	0
functionally	0
redundant	0
for	0
proliferation	0
.	0

Reversal	0
of	0
this	0
functional	0
uncoupling	0
may	0
be	0
required	0
before	0
Jak3/Stat5	0
inhibitors	0
will	0
be	0
useful	0
in	0
the	0
treatment	0
of	0
this	0
malignancy	0
.	0

The	0
Epstein-Barr	1
virus	2
promoter	2
initiating	0
B-cell	0
transformation	0
is	0
activated	0
by	0
RFX	9
proteins	10
and	0
the	0
B-cell-specific	9
activator	10
protein	10
BSAP/Pax5	10
.	0

Epstein-Barr	0
virus	0
(	0
EBV	0
)	0
-induced	0
B-cell	7
growth	0
transformation	0
,	0
a	0
central	0
feature	0
of	0
the	0
virus	0
'	0
strategy	0
for	0
colonizing	0
the	0
human	0
B-cell	0
system	0
,	0
requires	0
full	0
virus	0
latent	0
gene	0
expression	0
and	0
is	0
initiated	0
by	0
transcription	0
from	0
the	0
viral	1
promoter	2
Wp	2
.	0

Interestingly	0
,	0
when	0
EBV	0
accesses	0
other	0
cell	0
types	0
,	0
this	0
growth-transforming	0
program	0
is	0
not	0
activated	0
.	0

The	0
present	0
work	0
focuses	0
on	0
a	0
region	0
of	0
Wp	1
which	0
in	0
reporter	0
assays	0
confers	0
B-cell	7
-specific	0
activity	0
.	0

Bandshift	0
studies	0
indicate	0
that	0
this	0
region	0
contains	0
three	0
factor	0
binding	0
sites	0
,	0
termed	0
sites	1
B	2
,	2
C	2
,	2
and	2
D	2
,	0
in	0
addition	0
to	0
a	0
previously	0
characterized	0
CREB	1
site	2
.	0

Here	0
we	0
show	0
that	0
site	1
C	2
binds	0
members	0
of	0
the	0
ubiquitously	0
expressed	0
RFX	9
family	10
of	10
proteins	10
,	0
notably	0
RFX1	9
,	0
RFX3	9
,	0
and	0
the	0
associated	0
factor	0
MIBP1	9
,	0
whereas	0
sites	1
B	2
and	2
D	2
both	0
bind	0
the	0
B-cell-specific	9
activator	10
protein	10
BSAP/Pax5	10
.	0

In	0
reporter	0
assays	0
with	0
mutant	1
Wp	2
constructs	2
,	0
the	0
loss	0
of	0
factor	0
binding	0
to	0
any	0
one	0
of	0
these	0
sites	0
severely	0
impaired	0
promoter	0
activity	0
in	0
B	7
cells	8
,	0
while	0
the	0
wild-type	1
promoter	2
could	0
be	0
activated	0
in	0
non-B	7
cells	8
by	0
ectopic	0
BSAP	0
expression	0
.	0

We	0
suggest	0
that	0
Wp	1
regulation	0
by	0
BSAP	9
helps	0
to	0
ensure	0
the	0
B-cell	7
specificity	0
of	0
EBV	0
's	0
growth-transforming	0
function	0
.	0

Activation	0
of	0
the	0
Lck	9
tyrosine	10
protein	10
kinase	10
by	0
the	0
Herpesvirus	0
saimiri	0
tip	9
protein	10
involves	0
two	0
binding	0
interactions	0
.	0

The	0
Tip	9
protein	10
of	0
Herpesvirus	0
saimiri	0
strain	0
484C	0
binds	0
to	0
and	0
activates	0
the	0
Lck	9
tyrosine	10
protein	10
kinase	10
.	0

Two	0
sequences	0
in	0
the	0
Tip	9
protein	10
were	0
previously	0
shown	0
to	0
be	0
involved	0
in	0
binding	0
to	0
Lck	9
.	0

A	0
proline-rich	9
region	10
,	0
residues	0
132-141	0
,	0
binds	0
to	0
the	0
SH3	9
domain	10
of	0
the	0
Lck	9
protein	10
.	0

We	0
show	0
here	0
that	0
the	0
other	0
Lck-binding	9
domain	10
,	0
residues	0
104-113	0
,	0
binds	0
to	0
the	0
carboxyl-terminal	9
half	10
of	0
Lck	9
and	0
that	0
this	0
binding	0
does	0
not	0
require	0
the	0
Lck	9
SH3	10
domain	10
.	0

Mutated	0
Tip	9
containing	0
only	0
one	0
functional	0
Lck-binding	9
domain	10
can	0
bind	0
stably	0
to	0
Lck	9
,	0
although	0
not	0
as	0
strongly	0
as	0
wild-type	9
Tip	10
.	0

Interaction	0
of	0
Tip	9
with	0
Lck	9
through	0
either	0
Lck-binding	9
domain	10
increases	0
the	0
activity	0
of	0
Lck	9
in	0
vivo	0
.	0

Simultaneous	0
binding	0
of	0
both	0
domains	0
is	0
required	0
for	0
maximal	0
activation	0
of	0
Lck	9
.	0

The	0
transient	0
expression	0
of	0
Tip	9
in	0
T	7
cells	8
was	0
found	0
to	0
stimulate	0
both	0
Stat3	9
-dependent	0
and	0
NF-AT	9
-dependent	0
transcription	0
.	0

Mutant	0
forms	0
of	0
Tip	9
lacking	0
one	0
or	0
the	0
other	0
of	0
the	0
two	0
Lck-binding	9
domains	10
retained	0
the	0
ability	0
to	0
stimulate	0
Stat3	9
-dependent	0
transcription	0
.	0

Tip	9
lacking	0
the	0
proline-rich	0
Lck-binding	9
domain	10
exhibited	0
almost	0
wild-type	0
activity	0
in	0
this	0
assay	0
.	0

In	0
contrast	0
,	0
ablation	0
of	0
either	0
Lck-binding	9
domain	10
abolished	0
the	0
ability	0
of	0
Tip	9
to	0
stimulate	0
NF-AT	9
-dependent	0
transcription	0
.	0

Full	0
biological	0
activity	0
of	0
Tip	9
,	0
therefore	0
,	0
appears	0
to	0
require	0
both	0
Lck-binding	9
domains	10
.	0

Accumulation	0
of	0
RXR	9
alpha	10
during	0
activation	0
of	0
cycling	0
human	7
T	8
lymphocytes	8
:	0
modulation	0
of	0
RXRE	0
transactivation	0
function	0
by	0
mitogen-activated	0
protein	0
kinase	0
pathways	0
.	0

We	0
have	0
previously	0
reported	0
that	0
the	0
activation	0
of	0
resting	0
human	7
immature	8
peripheral	8
blood	8
T	8
(	8
PBT	8
)	8
lymphocytes	8
is	0
associated	0
with	0
the	0
loss	0
of	0
retinoid	9
X	10
receptor	10
alpha	10
(	0
RXRalpha	9
)	0
expression	0
.	0

In	0
the	0
present	0
study	0
,	0
we	0
have	0
demonstrated	0
that	0
,	0
unlike	0
resting	0
cells	0
,	0
activation	0
of	0
cycling	7
human	8
mature	8
PBT	8
lymphocytes	8
,	0
and	0
T	5
lymphocyte	6
leukemia	6
cell	6
lines	6
is	0
accompanied	0
by	0
the	0
accumulation	0
of	0
RXRalpha	9
mRNA	0
and	0
protein	0
.	0

Interestingly	0
,	0
cyclosporin	0
A	0
further	0
augmented	0
RXRalpha	9
expression	0
,	0
indicating	0
the	0
involvement	0
of	0
calcineurin	0
pathways	0
in	0
the	0
process	0
.	0

9-cis	0
retinoic	0
acid	0
inhibited	0
the	0
accumulation	0
,	0
suggesting	0
that	0
retinoids	0
can	0
regulate	0
the	0
synthesis	0
of	0
their	0
own	0
receptors	0
during	0
T	0
cell	0
activation	0
.	0

Transfection	0
analysis	0
in	0
Jurkat	5
cells	6
,	0
using	0
RXRE-dependent	0
reporter	0
assays	0
,	0
showed	0
that	0
RXRalpha	9
accumulated	0
during	0
T	0
cell	0
activation	0
was	0
transcriptionally	0
inactive	0
.	0

To	0
investigate	0
the	0
mechanism	0
of	0
such	0
inhibition	0
,	0
the	0
role	0
of	0
two	0
mitogen-activated	0
protein	0
kinase	0
pathways	0
,	0
c-Jun	9
N-terminal	10
kinase	10
(	0
JNK	9
)	0
and	0
extracellular	9
signal-regulated	10
kinase	10
(	0
ERK	9
)	0
,	0
in	0
modulating	0
RXRE-dependent	0
transcription	0
,	0
was	0
explored	0
.	0

The	0
expression	0
of	0
constitutively	0
active	0
MAP/ERK	9
kinase	10
kinase	10
1	10
(	0
MEKK1	9
)	0
inhibited	0
RXRE-dependent	0
transcription	0
,	0
whereas	0
dominant	9
negative	10
MEKK1	10
increased	0
the	0
transcription	0
,	0
indicating	0
the	0
involvement	0
of	0
JNK	9
signaling	0
pathways	0
in	0
the	0
process	0
.	0

In	0
contrast	0
,	0
expression	0
of	0
constitutively	9
active	10
MEK1	10
,	0
which	0
activates	0
ERK	9
pathway	0
,	0
enhanced	0
RXRE-dependent	0
activation	0
.	0

When	0
both	0
were	0
activated	0
simultaneously	0
,	0
JNK	9
pathway	0
was	0
dominant	0
over	0
ERK	9
pathway	0
and	0
resulted	0
in	0
inhibition	0
of	0
RXRE-mediated	0
transcription	0
.	0

These	0
data	0
demonstrate	0
a	0
dual	0
regulatory	0
control	0
of	0
RXRalpha	9
expression	0
during	0
the	0
activation	0
of	0
resting	7
and	8
cycling	8
T	8
lymphocytes	8
and	0
indicate	0
a	0
dynamic	0
balance	0
between	0
JNK	0
and	0
ERK	0
pathways	0
in	0
modulating	0
RXRE-mediated	0
transactivation	0
.	0

The	0
proteasome	9
regulates	0
receptor-mediated	0
endocytosis	0
of	0
interleukin-2	9
.	0

Recent	0
studies	0
have	0
increasingly	0
implicated	0
the	0
proteasome	9
in	0
the	0
regulation	0
of	0
cell	9
surface	10
receptors	10
.	0

In	0
the	0
present	0
study	0
,	0
we	0
investigated	0
the	0
role	0
of	0
the	0
proteasome	9
for	0
ligand-dependent	0
endocytosis	0
and	0
degradation	0
of	0
the	0
interleukin-2	9
(	10
IL-2	10
)	10
-interleukin-2	10
receptor	10
(	10
IL-2R	10
)	10
complex	10
.	0

Proteasome	0
inhibitors	0
impaired	0
internalization	0
of	0
IL-2.IL-2R	9
and	0
prevented	0
the	0
lysosomal	0
degradation	0
of	0
this	0
cytokine	9
.	0

Based	0
on	0
time-course	0
studies	0
,	0
proteasome	9
activity	0
is	0
primarily	0
required	0
after	0
initial	0
endocytosis	0
of	0
the	0
IL-2.IL-2R	9
.	0

Proteasome	0
function	0
was	0
also	0
necessary	0
for	0
the	0
lysosomal	0
degradation	0
of	0
IL-2	9
internalized	0
by	0
IL-2R	9
that	0
were	0
comprised	0
of	0
cytoplasmic	9
tailless	10
beta-	9
or	10
gamma	10
c-subunits	10
,	0
suggesting	0
that	0
the	0
target	0
protein	0
for	0
the	0
proteasome	9
is	0
independent	0
of	0
either	0
the	0
cytoplasmic	9
tail	10
of	0
the	0
IL-2R	9
beta-	9
or	10
gamma	10
c-subunits	10
and	0
their	0
associated	0
signaling	0
components	0
.	0

Therefore	0
,	0
a	0
functional	0
proteasome	9
is	0
required	0
for	0
optimal	0
endocytosis	0
of	0
the	0
IL-2R/ligand	9
complex	10
and	0
is	0
essential	0
for	0
the	0
subsequent	0
lysosomal	0
degradation	0
of	0
IL-2	9
,	0
possibly	0
by	0
regulating	0
trafficking	0
to	0
the	0
lysosome	0
.	0

Functional	0
characterization	0
of	0
the	0
two	0
alternative	0
promoters	0
of	0
human	1
p45	2
NF-E2	2
gene	2
.	0

OBJECTIVE	0
:	0
The	0
transcription	9
factor	10
NF-E2	10
,	0
a	0
heterodimeric	9
protein	10
complex	10
composed	0
of	0
p45	9
and	0
small	0
Maf	9
family	10
proteins	10
,	0
is	0
considered	0
crucial	0
for	0
the	0
proper	0
differentiation	0
of	0
erythrocytes	7
and	0
megakaryocytes	7
in	0
vivo	0
.	0

We	0
report	0
the	0
results	0
of	0
studies	0
aimed	0
at	0
understanding	0
the	0
regulatory	0
mechanisms	0
controlling	0
p45	1
gene	2
expression	0
in	0
erythroid	7
cells	8
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
Human	3
p45	4
mRNAs	4
have	0
two	0
alternative	0
isoforms	0
,	0
aNF-E2	3
and	0
fNF-E2	3
,	0
and	0
these	0
isoforms	0
are	0
transcribed	0
from	0
the	0
alternative	1
promoters	2
.	0

We	0
investigated	0
lineage-specific	0
expression	0
of	0
both	0
isomers	0
in	0
human	0
erythroid	7
and	8
megakaryocytic	8
cells	8
by	0
reverse	0
transcriptase	0
polymerase	0
chain	0
reaction	0
or	0
Northern	0
blot	0
analysis	0
.	0

For	0
functional	0
characterization	0
of	0
both	0
promoters	0
,	0
plasmids	0
in	0
which	0
reporter	1
genes	2
were	0
placed	0
under	0
the	0
control	0
of	0
a	0
series	0
of	0
truncated	0
or	0
mutated	0
promoter	1
fragments	2
were	0
transfected	0
to	0
human	5
hematopoietic	6
cell	6
lines	6
.	0

RESULTS	0
:	0
When	0
CD34	7
(	8
+	8
)	8
cells	8
isolated	0
from	0
human	0
cord	0
blood	0
were	0
induced	0
to	0
unilineage	0
erythroid	0
or	0
megakaryocytic	0
differentiation	0
in	0
liquid	0
suspension	0
culture	0
,	0
both	0
transcripts	0
,	0
although	0
barely	0
detected	0
at	0
day	0
0	0
,	0
were	0
induced	0
in	0
both	0
erythroid	0
and	0
megakaryocytic	0
cultures	0
.	0

fNF-E2	3
mRNA	4
was	0
found	0
to	0
be	0
more	0
abundant	0
in	0
erythroid	7
cells	8
than	0
megakaryocytic	7
cells	8
at	0
day	0
7	0
of	0
culture	0
.	0

Although	0
both	0
isomers	0
were	0
expressed	0
in	0
human	5
erythroid-megakaryocytic	6
cell	6
lines	6
,	0
megakaryocytic	0
maturation	0
with	0
loss	0
of	0
erythroid	0
phenotype	0
induced	0
by	0
phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
resulted	0
in	0
exclusive	0
downregulation	0
of	0
fNF-E2	3
,	0
suggesting	0
that	0
fNF-E2	1
promoter	2
is	0
more	0
erythroid	0
specific	0
.	0

Functional	0
analysis	0
of	0
fNF-E2	1
promoter	2
showed	0
that	0
the	0
promoter	0
is	0
active	0
only	0
in	0
erythroid-megakaryocytic	7
cells	8
and	0
that	0
the	0
double	1
GATA	2
sit	2
e	0
in	0
the	0
proximal	0
region	0
is	0
necessary	0
for	0
its	0
efficient	0
activity	0
.	0

CONCLUSION	0
:	0
These	0
results	0
suggest	0
that	0
GATA	9
proteins	10
,	0
which	0
govern	0
the	0
differentiation	0
of	0
erythroid	7
lineage	8
cells	8
,	0
are	0
required	0
for	0
full	0
promoter	0
activity	0
of	0
the	0
p45	1
gene	2
.	0

Transcriptional	0
activation	0
of	0
heme	1
oxygenase-1	2
and	0
its	0
functional	0
significance	0
in	0
acetaminophen-induced	0
hepatitis	0
and	0
hepatocellular	0
injury	0
in	0
the	0
rat	0
.	0

BACKGROUND/AIM	0
:	0
Glutathione	0
depletion	0
contributes	0
to	0
acetaminophen	0
hepatotoxicity	0
and	0
is	0
known	0
to	0
induce	0
the	0
oxidative	0
stress	0
reactant	0
heme	9
oxygenase-1	10
.	0

The	0
metabolites	0
of	0
the	0
heme	0
oxygenase	0
pathway	0
,	0
biliverdin	0
,	0
carbon	0
monoxide	0
,	0
and	0
iron	0
may	0
modulate	0
acetaminophen	0
toxicity	0
.	0

The	0
aim	0
of	0
this	0
study	0
was	0
to	0
assess	0
cell-type	0
specific	0
expression	0
of	0
heme	1
oxygenase-1	2
and	0
its	0
impact	0
on	0
liver	0
injury	0
and	0
microcirculatory	0
disturbances	0
in	0
a	0
model	0
of	0
acetaminophen-induced	0
hepatitis	0
.	0

METHODS	0
:	0
Gene	0
expression	0
of	0
heme	1
oxygenase-1	2
was	0
studied	0
by	0
Northern-	0
and	0
Western	0
analysis	0
as	0
well	0
as	0
immunohistochemistry	0
.	0

The	0
time	0
course	0
of	0
heme	9
oxygenase-1	10
and	10
-2	10
,	0
cytokine-induced	9
neutrophil	10
chemoattractant-1	10
,	0
and	0
intercellular	9
adhesion	10
molecule-1	10
was	0
studied	0
by	0
Northern	0
analysis	0
.	0

DNA-binding	0
activity	0
of	0
nuclear	9
factor-kappaB	10
was	0
determined	0
by	0
electrophoretic	0
mobility	0
shift	0
assay	0
.	0

Sinusoidal	0
perfusion	0
and	0
leukocyte-endothelial	0
interactions	0
were	0
assessed	0
by	0
intravital	0
microscopy	0
.	0

RESULTS	0
:	0
Acetaminophen	0
caused	0
a	0
moderate	0
sinusoidal	0
perfusion	0
failure	0
(	0
-15	0
%	0
)	0
and	0
infiltration	0
of	0
neutrophils	7
along	0
with	0
activation	0
of	0
nuclear	9
factor-kappaB	10
and	0
intercellular	9
adhesion	10
molecule-1	10
and	0
cytokine-induced	9
neutrophil	10
chemoattractant-1	10
mRNAs	0
.	0

Induction	0
of	0
heme	9
oxygenase-1	10
mRNA	0
and	0
protein	0
(	0
approximately	0
30-fold	0
)	0
in	0
hepatocytes	7
and	0
non-parenchymal	7
cells	8
paralleled	0
the	0
inflammatory	0
response	0
.	0

Blockade	0
of	0
heme	0
oxygenase	0
activity	0
with	0
tin-protoporphyrin-IX	0
abrogated	0
acetaminophen-induced	0
hepatic	7
neutrophil	8
accumulation	0
and	0
nuclear	9
factor-kappaB	10
activation	0
,	0
but	0
failed	0
to	0
affect	0
sinusoidal	0
perfusion	0
and	0
liver	0
injury	0
.	0

CONCLUSIONS	0
:	0
The	0
inflammatory	0
response	0
associated	0
with	0
acetaminophen	0
hepatotoxicity	0
is	0
modulated	0
by	0
the	0
parallel	0
induction	0
of	0
the	0
heme	1
oxygenase-1	2
gene	2
.	0

However	0
,	0
heme	1
oxygenase-1	2
has	0
no	0
permissive	0
effect	0
on	0
sinusoidal	0
perfusion	0
and	0
does	0
not	0
affect	0
liver	0
injury	0
in	0
this	0
model	0
.	0

These	0
data	0
argue	0
against	0
a	0
central	0
role	0
of	0
nuclear	9
factor-kappaB	10
activation	0
and	0
neutrophil	0
infiltration	0
as	0
perpetuating	0
factors	0
of	0
liver	0
injury	0
in	0
acetaminophen	0
toxicity	0
.	0

Tumor	9
necrosis	10
factor-alpha	10
-induced	0
proliferation	0
requires	0
synthesis	0
of	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
.	0

OBJECTIVE	0
:	0
Tumor	9
necrosis	10
factor-	10
alpha	10
(	0
TNF-alpha	9
)	0
induces	0
a	0
variety	0
of	0
cellular	0
responses	0
,	0
some	0
of	0
them	0
being	0
at	0
least	0
seemingly	0
contradictory	0
.	0

Thus	0
,	0
we	0
set	0
out	0
to	0
find	0
differences	0
in	0
the	0
modes	0
of	0
proliferative	0
and	0
apoptotic	0
responses	0
to	0
TNF-	9
alpha	10
.	0

MATERIALS	0
AND	0
METHODS	0
:	0
We	0
screened	0
a	0
panel	0
of	0
acute	5
myeloid	6
leukemia-derived	6
cell	6
lines	6
for	0
TNF-	9
alpha	10
-responsiveness	0
.	0

In	0
two	0
lines	0
(	0
OCI-AML-1	5
,	0
OCI-AML-11	5
)	0
,	0
TNF-	9
alpha	10
acted	0
as	0
an	0
apoptotic	0
agent	0
;	0
in	0
others	0
(	0
HU-3	5
,	0
M-07e	5
,	0
TF-1	5
)	0
,	0
it	0
had	0
the	0
opposite	0
effect	0
,	0
preventing	0
apoptosis	0
and	0
inducing	0
proliferation	0
.	0

Direct	0
and	0
indirect	0
signaling	0
mechanisms	0
,	0
including	0
NF-kappaB	9
activation	0
and	0
cytokine	0
synthesis	0
,	0
were	0
analyzed	0
.	0

RESULTS	0
:	0
All	0
cell	0
lines	0
tested	0
expressed	0
TNF-	9
alpha	10
receptors	10
I	10
and	10
II	10
and	0
responded	0
to	0
TNF-	9
alpha	10
by	0
upregulation	0
of	0
intercellular	9
adhesion	10
molecule-1	10
.	0

In	0
contrast	0
to	0
granulocyte-macrophage	9
colony-stimulating	10
factor	10
(	0
GM-CSF	9
)	0
,	0
TNF-	9
alpha	10
did	0
not	0
activate	0
the	0
MAP	9
kinase	10
and	0
p70S6	0
kinase	0
pathways	0
.	0

Nevertheless	0
,	0
inhibitors	0
of	0
these	0
pathways	0
clearly	0
reduced	0
the	0
TNF-alpha	9
-induced	0
cell	0
growth	0
,	0
indicating	0
that	0
TNF-	7
alpha-proliferative	8
cells	8
produced	0
a	0
growth	0
factor	0
that	0
induced	0
proliferation	0
upon	0
stimulation	0
of	0
the	0
above	0
pathways	0
.	0

Anti-GM-CSF	9
antibodies	10
inhibited	0
the	0
TNF-alpha	9
-induced	0
growth	0
,	0
suggesting	0
the	0
presence	0
of	0
an	0
autocrine	0
loop	0
for	0
cell	0
proliferation	0
mediated	0
by	0
GM-CSF	9
.	0

Supporting	0
this	0
notion	0
,	0
TNF-alpha	9
-induced	0
upregulation	0
of	0
GM-CSF	3
mRNA	4
levels	0
and	0
protein	0
secretion	0
in	0
the	0
TNF-alpha	9
-proliferative	0
,	0
but	0
not	0
in	0
the	0
TNF-alpha-apoptotic	5
cell	6
lines	6
.	0

CONCLUSION	0
:	0
These	0
data	0
identify	0
GM-CSF	9
synthesis	0
as	0
an	0
early	0
and	0
essential	0
step	0
in	0
TNF-	0
alpha-induced	0
proliferation	0
.	0

We	0
show	0
for	0
the	0
first	0
time	0
that	0
TNF-alpha-treated	5
cell	6
lines	6
producing	0
no	0
or	0
only	0
minimal	0
amounts	0
of	0
GM-CSF	9
demonstrate	0
an	0
apoptotic	0
phenotype	0
,	0
while	0
cell	0
lines	0
with	0
high	0
GM-CSF	9
expression	0
rates	0
can	0
escape	0
from	0
growth	0
arrest	0
or	0
even	0
apoptosis	0
.	0

In	0
this	0
context	0
,	0
we	0
discuss	0
arguments	0
pointing	0
at	0
NF-kappaB	9
as	0
regulator	0
of	0
GM-CSF	9
synthesis	0
and	0
thus	0
indirectly	0
as	0
regulator	0
for	0
the	0
escape	0
of	0
TNF-alpha	9
-induced	0
apoptosis	0

Glucocorticoid	9
receptor	10
content	0
of	0
T	7
lymphocytes	8
:	0
evidence	0
for	0
heterogeneity	0
.	0

Glucocorticoid	9
receptors	10
were	0
measured	0
in	0
T	7
lymphocytes	8
that	0
were	0
isolated	0
from	0
peripheral	0
blood	0
by	0
either	0
nylon	0
wool	0
filtration	0
or	0
E-rosette	0
sedimentation	0
.	0

T	7
cells	8
isolated	0
by	0
nylon	0
wool	0
filtration	0
specifically	0
bind	0
6.7	0
+/-	0
0.2	0
fmol	0
of	0
dexamethasone	0
per	0
million	0
cells	0
(	0
equivalent	0
to	0
4000	0
+/-	0
200	0
receptors	0
per	0
cell	0
)	0
,	0
whereas	0
T	7
cells	8
isolated	0
by	0
E-rosette	0
sedimentation	0
bind	0
12.0	0
+/-	0
0.7	0
fmol	0
of	0
dexamethasone	0
per	0
million	0
cells	0
(	0
equivalent	0
to	0
7200	0
+/-	0
400	0
receptors	0
per	0
cell	0
)	0
.	0

This	0
difference	0
in	0
the	0
amount	0
of	0
dexamethasone	0
bound	0
by	0
the	0
two	0
T	0
cell	0
preparations	0
was	0
significant	0
(	0
p	0
less	0
than	0
.001	0
)	0
and	0
was	0
present	0
immediately	0
after	0
cell	0
isolation	0
.	0

The	0
binding	0
affinities	0
of	0
the	0
different	0
T	5
cell	6
preparations	6
for	0
dexamethasone	0
were	0
similar	0
.	0

T	0
cells	0
that	0
are	0
isolated	0
by	0
a	0
combination	0
of	0
nylon	0
wool	0
filtration	0
followed	0
by	0
E-rosette	0
sedimentation	0
bind	0
the	0
same	0
amount	0
of	0
dexamethasone	0
as	0
T	7
cells	8
isolated	0
by	0
nylon	0
wool	0
filtration	0
alone	0
.	0

T	7
cells	8
isolated	0
by	0
a	0
combination	0
of	0
E-rosette	0
sedimentation	0
following	0
by	0
nylon	0
wool	0
filtration	0
bind	0
less	0
dexamethasone	0
than	0
do	0
T	7
cells	8
isolated	0
by	0
E-rosette	0
sedimentation	0
alone	0
.	0

These	0
findings	0
suggest	0
that	0
T	7
cells	8
are	0
heterogeneous	0
with	0
respect	0
to	0
their	0
quantity	0
of	0
glucocorticoid	9
receptors	10
.	0

Isolation	0
of	0
T	7
cells	8
by	0
E-rosette	0
sedimentation	0
enriches	0
for	0
T	7
cells	8
that	0
have	0
a	0
greater	0
number	0
of	0
glucocorticoid	9
receptors	10
,	0
and	0
isolation	0
of	0
T	7
cells	8
by	0
nylon	0
wool	0
filtration	0
enriches	0
for	0
T	7
cells	8
that	0
have	0
a	0
lesser	0
number	0
of	0
glucocorticoid	9
receptors	10
.	0

Glucocorticoid	9
receptors	10
and	0
glucocorticoid	0
sensitivity	0
of	0
human	7
leukemic	8
cells	8
.	0

We	0
have	0
established	0
optimal	0
conditions	0
for	0
the	0
measurement	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
in	0
human	7
white	8
cells	8
using	0
a	0
whole-cell	0
binding	0
assay	0
with	0
[	0
3H	0
]	0
dexamethasone	0
as	0
the	0
ligand	0
,	0
and	0
the	0
subsequent	0
determination	0
of	0
the	0
GR	9
content	0
in	0
normal	7
human	8
lymphocytes	8
and	0
in	0
leukemic	7
cells	8
of	0
patients	0
with	0
various	0
forms	0
of	0
acute	0
and	0
chronic	0
leukemia	0
.	0

A	0
number	0
of	0
leukemia	5
cell	6
lines	6
in	0
continuous	0
culture	0
were	0
also	0
subjected	0
to	0
the	0
GR	9
assay	0
,	0
and	0
the	0
results	0
were	0
correlated	0
with	0
the	0
sensitivity	0
of	0
these	0
cell	5
lines	6
to	0
glucocorticoid	0
steroids	0
in	0
vitro	0
.	0

The	0
GR	9
content	0
of	0
normal	7
human	8
lymphocytes	8
amounted	0
to	0
4	0
,	0
850	0
+/-	0
1	0
,	0
340	0
(	0
mean	0
+/-	0
SD	0
)	0
receptors/cell	0
.	0

The	0
mean	0
equilibrium	0
dissociation	0
constant	0
(	0
KD	0
)	0
of	0
the	0
interaction	0
of	0
[	0
3H	0
]	0
dexamethasone	0
with	0
the	0
GR	9
was	0
1.2	0
x	0
10	0
(	0
-8	0
)	0
M	0
.	0

Steroidal	0
compounds	0
with	0
a	0
known	0
glucocorticoid	0
potency	0
effectively	0
competed	0
for	0
the	0
binding	0
,	0
whereas	0
steroids	0
devoid	0
of	0
glucocorticoid	0
activity	0
(	0
e.g.	0
estradiol-17	0
beta	0
and	0
testosterone	0
)	0
were	0
ineffective	0
.	0

The	0
GR	9
content	0
of	0
the	0
blast	7
cells	8
obtained	0
from	0
eight	0
patients	0
suffering	0
from	0
acute	0
leukemia	0
and	0
four	0
patients	0
with	0
a	0
blast	0
crisis	0
of	0
chronic	0
myelocytic	0
leukemia	0
was	0
found	0
to	0
be	0
highly	0
variable	0
(	0
3	0
,	0
230-29	0
,	0
900	0
receptors/cell	0
)	0
,	0
while	0
the	0
lymphocytes	7
of	0
six	0
patients	0
with	0
chronic	0
lymphatic	0
leukemia	0
contained	0
a	0
rather	0
stable	0
GR	9
content	0
(	0
2	0
,	0
930-5	0
,	0
120	0
receptors/cell	0
)	0
,	0
which	0
was	0
comparable	0
with	0
that	0
of	0
normal	7
lymphocytes	8
.	0

GR	9
was	0
identified	0
in	0
all	0
the	0
12	0
malignant	5
continuous	6
white	6
cell	6
lines	6
studied	0
.	0

Large	0
cells	0
contained	0
more	0
GR	9
than	0
the	0
smaller	0
ones	0
.	0

There	0
was	0
no	0
apparent	0
correlation	0
between	0
the	0
GR	9
concentration	0
and	0
the	0
sensitivity	0
of	0
the	0
cells	0
in	0
vitro	0
to	0
glucocorticoids	0
as	0
judged	0
by	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
studies	0
.	0

Distribution	0
of	0
the	0
surface	0
markers	0
in	0
the	0
leukemic	5
cell	6
lines	6
did	0
not	0
relate	0
to	0
the	0
GR	9
concentration	0
.	0

We	0
conclude	0
that	0
the	0
presence	0
of	0
GR	9
is	0
probably	0
a	0
universal	0
feature	0
of	0
the	0
leukemic	7
cells	8
,	0
and	0
,	0
from	0
a	0
clinical	0
standpoint	0
,	0
probably	0
does	0
not	0
alone	0
imply	0
steroid	0
responsiveness	0
.	0

Evidence	0
for	0
a	0
steroid	9
receptor	10
in	0
rheumatoid	7
synovial	8
tissue	8
cells	8
.	0

One	0
mechanism	0
by	0
which	0
glucocorticoids	0
could	0
exert	0
their	0
anti-inflammatory	0
action	0
is	0
via	0
rapidly	0
saturable	0
,	0
stereo-specific	9
cytoplasmic	10
protein	10
receptors	10
.	0

This	0
report	0
is	0
of	0
an	0
investigation	0
into	0
such	0
a	0
possibility	0
in	0
synovial	7
cells	8
.	0

Synovium	0
,	0
obtained	0
from	0
knee	0
joints	0
of	0
rheumatoid	0
patients	0
undergoing	0
surgery	0
,	0
was	0
incubated	0
with	0
clostridiopeptidase	9
A	10
and	0
trypsin-EDTA	9
to	0
obtain	0
cell	0
suspensions	0
.	0

These	0
,	0
together	0
with	0
cells	0
obtained	0
from	0
synovial	0
fluid	0
aspirated	0
from	0
patients	0
with	0
rheumatoid	0
arthritis	0
,	0
were	0
identified	0
by	0
electron	0
microscopy	0
.	0

Duplicate	0
samples	0
of	0
these	0
cell	0
suspensions	0
were	0
incubated	0
with	0
increasing	0
concentrations	0
of	0
H3Dexamethasone	0
(	0
1	0
x	0
10	0
(	0
-10	0
)	0
M-1	0
x	0
10	0
(	0
-9	0
)	0
M	0
)	0
for	0
30	0
minutes	0
at	0
37	0
degrees	0
C	0
.	0

Analysis	0
of	0
the	0
proportion	0
of	0
steroid	0
bound	0
to	0
whole	7
cells	8
showed	0
evidence	0
for	0
specific	0
,	0
rapidly	0
saturable	0
,	0
receptors	0
in	0
the	0
cells	0
obtained	0
from	0
synovial	0
tissue	0
,	0
but	0
this	0
was	0
not	0
found	0
in	0
synovial	7
fluid	8
cells	8
.	0

Electron	0
micrographs	0
showed	0
that	0
cells	0
obtained	0
from	0
synovial	0
tissue	0
consisted	0
of	0
synovial	7
fibroblast	8
-	0
and	0
macrophage-types	7
,	0
lymphocytes	7
,	0
monocytes	7
and	0
macrophages	7
.	0

Polymorphonuclear	7
leucocytes	8
appeared	0
to	0
be	0
absent	0
.	0

However	0
,	0
in	0
synovial	7
fluid	8
cell	8
type	8
polymorphonuclear	8
leucocytes	8
were	0
the	0
predominant	0
cell	0
type	0
.	0

We	0
concluded	0
from	0
this	0
,	0
that	0
one	0
or	0
more	0
of	0
the	0
cell	0
types	0
present	0
in	0
synovial	0
tissue	0
contain	0
a	0
specific	9
steroid	10
receptor	10
,	0
but	0
that	0
this	0
is	0
lacking	0
in	0
synovial	7
fluid	8
polymorphonuclear	8
leucocytes	8
.	0

Clinical	0
implications	0
of	0
glucocorticoid	9
receptors	10
in	0
human	0
leukemia	0
.	0

Glucorticoid	9
receptors	10
were	0
studied	0
in	0
various	0
populations	0
of	0
normal	0
human	7
peripheral	8
blood	8
lymphocytes	8
and	0
leukemic	7
lymphoblasts	8
.	0

Normal	7
lymphocytes	8
contain	0
low	0
levels	0
of	0
glucocorticoid	9
receptor	10
(	0
approximately	0
2	0
,	0
500	0
sites/cell	0
)	0
which	0
are	0
identical	0
in	0
T-	0
and	0
non-T-fractions	0
.	0

Phytohemagglutinin	9
treatment	0
increases	0
levels	0
about	0
3-fold	0
.	0

Leukemic	7
lymphoblasts	8
contain	0
larger	0
numbers	0
of	0
receptor	0
sites	0
.	0

Presence	0
of	0
receptor	0
is	0
correlated	0
with	0
in	0
vitro	0
sensitivitiy	0
to	0
glucocorticoids	0
and	0
in	0
vivo	0
response	0
to	0
therapy	0
.	0

Quantity	0
of	0
receptor	0
is	0
also	0
correlated	0
with	0
complete	0
remission	0
duration	0
independently	0
of	0
leukemic	7
cell	8
type	8
(	0
T	0
or	0
null	0
)	0
,	0
initial	0
WBC	7
,	0
or	0
age	0
of	0
patient	0
.	0

Quantitative	0
determination	0
of	0
glucocorticoid	9
receptor	10
levels	0
in	0
acute	0
lymphoblastic	0
leukemia	0
may	0
be	0
of	0
value	0
both	0
as	0
an	0
independent	0
prognostic	0
variable	0
and	0
in	0
suggesting	0
which	0
patients	0
should	0
receive	0
glucocorticoid	0
therapy	0
.	0

Functional	0
and	0
physical	0
interaction	0
of	0
protein-tyrosine	9
kinases	10
Fyn	10
and	10
Csk	10
in	0
the	0
T-cell	0
signaling	0
system	0
.	0

The	0
Src-like	9
protein-tyrosine	10
kinase	10
Fyn	9
is	0
associated	0
with	0
T-cell	9
antigen	10
receptor	10
.	0

Transient	0
expression	0
of	0
actively	0
mutated	0
Fyn	9
,	0
having	0
Phe-528	0
instead	0
of	0
Tyr-528	0
or	0
Thr-338	0
instead	0
of	0
Ile-338	0
,	0
in	0
Jurkat	7
T-cells	8
stimulated	1
the	2
serum	2
response	2
element	2
(	0
SRE	1
)	0
,	0
12-O-tetradecanoyl-phorbol-13-acetate	1
response	2
element	2
,	0
cyclic	1
AMP	2
response	2
element	2
,	0
and	0
c-fos	1
promoter	2
.	0

The	0
stimulation	0
of	0
SRE	1
was	0
particularly	0
prominent	0
not	0
only	0
with	0
active	0
Fyn	9
but	0
also	0
with	0
normal	9
(	10
wild-type	10
)	10
Fyn	10
.	0

SRE	1
was	0
also	0
stimulated	0
by	0
both	0
normal	9
and	10
active	10
Lck	10
.	0

Furthermore	0
,	0
normal	9
and	10
active	10
Fyn	10
stimulated	0
transcription	0
from	0
the	0
IL-2	1
gene	2
promoter	2
when	0
transfected	0
cells	0
were	0
stimulated	0
by	0
concanavalin	9
A	10
plus	0
12-O-tetradecanoylphorbol-13-acetate	0
.	0

Under	0
the	0
same	0
conditions	0
,	0
Lck	9
did	0
not	0
stimulate	0
IL-2	1
promoter	2
unless	0
it	0
was	0
activated	0
by	0
mutation	0
.	0

Interestingly	0
,	0
a	0
mutant	9
Fyn	10
,	0
which	0
has	0
deletions	0
within	0
the	0
SH2	9
region	10
and	0
so	0
is	0
able	0
to	0
transform	0
chicken	7
embryo	8
fibroblasts	8
,	0
did	0
not	0
stimulate	0
either	0
the	0
c-fos	1
or	2
IL-2	2
promoter	2
,	0
suggesting	0
the	0
importance	0
of	0
this	0
region	0
in	0
T-cell	7
signaling	0
.	0

Csk	9
,	0
which	0
phosphorylates	0
tyrosine	0
residues	0
in	0
the	0
negative	0
regulatory	0
sites	0
of	0
Src	9
family	10
kinases	10
,	0
down-regulated	0
Fyn-	0
and	0
Lck-mediated	0
stimulation	0
of	0
the	0
serum	1
response	2
element	2
and	0
Fyn-mediated	0
enhancement	0
of	0
IL-2	1
promoter	2
activity	0
.	0

These	0
data	0
suggest	0
that	0
Fyn	9
and	0
Lck	9
,	0
whose	0
activities	0
are	0
regulated	0
by	0
Csk	9
,	0
are	0
involved	0
in	0
different	0
phases	0
of	0
T-cell	7
activation	0
.	0

A	0
novel	0
NF-kappa	9
B	10
complex	10
containing	0
p65	9
homodimers	10
:	0
implications	0
for	0
transcriptional	0
control	0
at	0
the	0
level	0
of	0
subunit	0
dimerization	0
.	0

The	0
predominant	0
inducible	0
form	0
of	0
the	0
NF-kappa	9
B	10
transcription	10
factor	10
is	0
a	0
heteromeric	9
complex	10
containing	0
two	0
Rel-related	9
DNA-binding	10
subunits	10
,	0
termed	9
p65	10
and	0
p50	9
.	0

Prior	0
transfection	0
studies	0
have	0
shown	0
that	0
when	0
these	0
p65	9
and	10
p50	10
subunits	10
are	0
expressed	0
independently	0
as	0
stable	9
homodimers	10
,	0
p65	9
stimulates	0
kappa	0
B-directed	0
transcription	0
,	0
whereas	0
p50	9
functions	0
as	0
a	0
kappa	0
B-specific	0
repressor	0
.	0

While	0
authentic	0
p50	9
homodimers	10
(	0
previously	0
termed	0
KBF1	9
)	0
have	0
been	0
detected	0
in	0
nuclear	0
extracts	0
from	0
nontransfected	0
cells	0
,	0
experimental	0
evidence	0
supporting	0
the	0
existence	0
of	0
p65	9
homodimers	10
in	0
vivo	0
was	0
lacking	0
.	0

We	0
now	0
provide	0
direct	0
biochemical	0
evidence	0
for	0
the	0
presence	0
of	0
an	0
endogenous	0
pool	0
of	0
inducible	0
p65	9
homodimers	10
in	0
intact	0
human	7
T	8
cells	8
.	0

As	0
with	0
the	0
prototypical	0
NF-kappa	9
B	10
p50-p65	10
heterodimer	10
,	0
this	0
novel	0
p65	9
homodimeric	10
form	10
of	0
NF-kappa	9
B	10
is	0
functionally	0
sequestered	0
in	0
the	0
cytoplasm	0
but	0
rapidly	0
appears	0
in	0
the	0
nuclear	0
compartment	0
following	0
cellular	0
stimulation	0
.	0

Site-directed	0
mutagenesis	0
studies	0
indicate	0
that	0
the	0
homodimerization	0
function	0
of	0
p65	9
is	0
dependent	0
upon	0
the	0
presence	0
of	0
cysteine	0
216	0
and	0
a	0
conserved	0
recognition	0
motif	0
for	0
protein	9
kinase	10
A	10
(	0
RRPS	9
;	0
amino	0
acids	0
273	0
to	0
276	0
)	0
,	0
both	0
of	0
which	0
reside	0
within	0
a	0
91-amino-acid	0
segment	0
of	0
the	0
Rel	9
homology	10
domain	10
that	0
mediates	0
self-association	0
.	0

In	0
contrast	0
,	0
mutations	0
at	0
these	0
two	0
sites	0
do	0
not	0
affect	0
heterodimerization	0
of	0
p65	9
with	0
p50	9
or	0
its	0
functional	0
interaction	0
with	0
I	0
kappa	0
B	0
alpha	0
.	0

These	0
later	0
findings	0
indicate	0
that	0
neither	0
homo-	0
nor	0
heterodimer	0
formation	0
is	0
an	0
absolute	0
prerequisite	0
for	0
I	9
kappa	10
B	10
alpha	10
recognition	0
of	0
p65	9
.	0

Taken	0
together	0
with	0
prior	0
in	0
vivo	0
transcription	0
studies	0
,	0
these	0
results	0
suggest	0
that	0
the	0
biological	0
activities	0
of	0
p65	9
and	10
p50	10
homodimers	10
are	0
independently	0
regulated	0
,	0
thereby	0
providing	0
an	0
integrated	0
and	0
flexible	0
control	0
mechanism	0
for	0
the	0
rapid	0
activation	0
and	0
repression	0
of	0
NF-kappa	9
B	10
/	0
Rel	9
-directed	0
gene	0
expression	0
.	0

Carrier	0
determination	0
for	0
X-linked	0
agammaglobulinemia	0
using	0
X	0
inactivation	0
analysis	0
of	0
purified	7
B	8
cells	8
.	0

We	0
report	0
the	0
development	0
of	0
a	0
relatively	0
quick	0
and	0
simple	0
method	0
for	0
the	0
assessment	0
of	0
X	0
inactivation	0
status	0
for	0
carrier	0
determination	0
in	0
families	0
affected	0
by	0
X-linked	0
agammaglobulinemia	0
(	0
XLA	0
)	0
.	0

This	0
method	0
utilises	0
an	0
immunomagnetic	0
separation	0
technique	0
for	0
B	7
cell	8
purification	0
and	0
a	0
polymerase	0
chain	0
reaction	0
(	0
PCR	0
)	0
based	0
assay	0
for	0
the	0
determination	0
of	0
methylation	0
status	0
at	0
the	0
androgen	1
receptor	2
(	2
AR	2
)	2
gene	2
locus	2
to	0
assess	0
whether	0
X	0
inactivation	0
is	0
random	0
or	0
non-random	0
at	0
this	0
locus	0
.	0

We	0
report	0
the	0
results	0
we	0
have	0
obtained	0
using	0
this	0
assay	0
to	0
investigate	0
females	0
known	0
to	0
be	0
carriers	0
of	0
various	0
X-linked	0
immunodeficiency	0
disorders	0
.	0

In	0
addition	0
,	0
we	0
investigated	0
four	0
females	0
from	0
different	0
families	0
affected	0
by	0
XLA	0
,	0
two	0
of	0
whom	0
were	0
of	0
unknown	0
carrier	0
status	0
,	0
and	0
we	0
discuss	0
the	0
results	0
obtained	0
with	0
this	0
and	0
other	0
X-inactivation	0
assays	0
.	0

A	0
similar	0
assay	0
has	0
recently	0
been	0
described	0
by	0
Allen	0
et	0
al.	0
(	0
1992	0
)	0
and	0
applied	0
to	0
members	0
of	0
one	0
family	0
affected	0
by	0
XLA	0
.	0

Effects	0
of	0
IL-4	9
and	0
Fc	9
gamma	10
receptor	10
II	10
engagement	0
on	0
Egr-1	9
expression	0
during	0
stimulation	0
of	0
B	7
lymphocytes	8
by	0
membrane	0
immunoglobulin	0
crosslinking	0
.	0

Egr-1	1
is	0
an	0
immediate	1
early	2
gene	2
that	0
is	0
rapidly	0
upregulated	0
in	0
response	0
to	0
mitogenic	0
signals	0
induced	0
by	0
antigen	0
receptor	0
crosslinking	0
on	0
murine	7
B	8
lymphocytes	8
.	0

It	0
has	0
been	0
shown	0
that	0
levels	0
of	0
Egr-1	1
expression	0
are	0
closely	0
correlated	0
with	0
B	7
cell	8
proliferation	0
in	0
several	0
models	0
of	0
B	0
cell	0
activation	0
and	0
tolerance	0
.	0

We	0
compared	0
the	0
expression	0
of	0
Egr-1	1
during	0
B	0
cell	0
stimulation	0
with	0
Fab'2	9
and	0
IgG	9
anti-immunoglobulin	10
(	0
anti-Ig	9
)	0
,	0
since	0
it	0
is	0
known	0
that	0
Fab'2	9
anti-Ig	10
is	0
mitogenic	0
while	0
IgG	9
anti-Ig	10
is	0
not	0
,	0
owing	0
to	0
a	0
dominant	0
inhibitory	0
effect	0
of	0
crosslinking	0
the	0
B	9
cell	10
Fc	10
gamma	10
RII	10
to	0
membrane	9
Ig	10
.	0

While	0
mitogenic	0
doses	0
of	0
Fab'2	9
anti-Ig	10
induce	0
large	0
and	0
rapid	0
increases	0
in	0
Egr-1	0
expression	0
,	0
IgG	9
anti-Ig	10
results	0
in	0
smaller	0
increases	0
in	0
Egr-1	3
mRNA	4
,	0
comparable	0
to	0
that	0
seen	0
with	0
submitogenic	0
concentrations	0
of	0
Fab'2	9
anti-Ig	10
.	0

However	0
,	0
the	0
correlation	0
between	0
Egr-1	0
expression	0
and	0
B	0
cell	0
proliferation	0
breaks	0
down	0
when	0
IL-4	9
is	0
added	0
as	0
a	0
co-mitogen	0
to	0
induce	0
B	0
cell	0
proliferation	0
with	0
IgG	9
anti-Ig	10
or	0
submitogenic	0
concentrations	0
of	0
Fab'2	9
anti-Ig	10
.	0

No	0
corresponding	0
increases	0
in	0
Egr-1	3
mRNA	4
levels	0
are	0
observed	0
when	0
IL-4	9
is	0
added	0
.	0

Therefore	0
,	0
IL-4	9
overcomes	0
Fc	0
receptor-mediated	0
inhibition	0
of	0
B	7
cell	8
proliferation	0
without	0
affecting	0
inhibition	0
of	0
Egr-1	3
mRNA	4
induction	0
,	0
as	0
demonstrated	0
earlier	0
for	0
c-myc	3
mRNA	4
in	0
this	0
system	0
.	0

Identification	0
of	0
a	0
novel	0
cyclosporin-sensitive	1
element	2
in	0
the	0
human	1
tumor	2
necrosis	2
factor	2
alpha	2
gene	2
promoter	2
.	0

Tumor	9
necrosis	10
factor	10
alpha	10
(	0
TNF-alpha	9
)	0
,	0
a	0
cytokine	9
with	0
pleiotropic	0
biological	0
effects	0
,	0
is	0
produced	0
by	0
a	0
variety	0
of	0
cell	0
types	0
in	0
response	0
to	0
induction	0
by	0
diverse	0
stimuli	0
.	0

In	0
this	0
paper	0
,	0
TNF-alpha	3
mRNA	4
is	0
shown	0
to	0
be	0
highly	0
induced	0
in	0
a	0
murine	5
T	6
cell	6
clone	6
by	0
stimulation	0
with	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
ligands	0
or	0
by	0
calcium	0
ionophores	0
alone	0
.	0

Induction	0
is	0
rapid	0
,	0
does	0
not	0
require	0
de	0
novo	0
protein	0
synthesis	0
,	0
and	0
is	0
completely	0
blocked	0
by	0
the	0
immunosuppressant	0
cyclosporin	0
A	0
(	0
CsA	0
)	0
.	0

We	0
have	0
identified	0
a	0
human	1
TNF-alpha	2
promoter	2
element	2
,	0
kappa	1
3	2
,	0
which	0
plays	0
a	0
key	0
role	0
in	0
the	0
calcium-mediated	0
inducibility	0
and	0
CsA	0
sensitivity	0
of	0
the	0
gene	0
.	0

In	0
electrophoretic	0
mobility	0
shift	0
assays	0
,	0
an	0
oligonucleotide	0
containing	0
kappa	1
3	2
forms	0
two	0
DNA	0
protein	0
complexes	0
with	0
proteins	0
that	0
are	0
present	0
in	0
extracts	0
from	0
unstimulated	7
T	8
cells	8
.	0

These	0
complexes	0
appear	0
in	0
nuclear	0
extracts	0
only	0
after	0
T	0
cell	0
stimulation	0
.	0

Induction	0
of	0
the	0
inducible	0
nuclear	9
complexes	10
is	0
rapid	0
,	0
independent	0
of	0
protein	0
synthesis	0
,	0
and	0
blocked	0
by	0
CsA	0
,	0
and	0
thus	0
,	0
exactly	0
parallels	0
the	0
induction	0
of	0
TNF-alpha	3
mRNA	4
by	0
TCR	0
ligands	0
or	0
by	0
calcium	0
ionophore	0
.	0

Our	0
studies	0
indicate	0
that	0
the	0
kappa	9
3	10
binding	10
factor	10
resembles	0
the	0
preexisting	0
component	0
of	0
nuclear	9
factor	10
of	0
activated	7
T	8
cells	8
.	0

Thus	0
,	0
the	0
TNF-alpha	1
gene	2
is	0
an	0
immediate	0
early	0
gene	0
in	0
activated	0
T	7
cells	8
and	0
provides	0
a	0
new	0
model	0
system	0
in	0
which	0
to	0
study	0
CsA-sensitive	1
gene	2
induction	0
in	0
activated	7
T	8
cells	8
.	0

Differences	0
in	0
expression	0
of	0
transcription	9
factor	10
AP-1	10
in	0
human	5
promyelocytic	6
HL-60	6
cells	6
during	0
differentiation	0
towards	0
macrophages	7
versus	0
granulocytes	7
.	0

Commitment	0
of	0
HL-60	5
cells	6
to	0
macrophage	0
or	0
granulocytic	0
differentiation	0
was	0
achieved	0
by	0
incubation	0
with	0
4	0
beta-phorbol	0
12-myristate	0
13-acetate	0
(	0
PMA	0
)	0
for	0
30-60	0
min	0
or	0
with	0
dimethyl	0
sulphoxide	0
(	0
DMSO	0
)	0
for	0
24	0
h	0
respectively	0
.	0

The	0
commitment	0
stage	0
towards	0
PMA-induced	0
macrophage	0
differentiation	0
was	0
associated	0
with	0
increases	0
in	0
jun	0
B	0
and	0
c-fos	0
mRNA	0
levels	0
,	0
as	0
well	0
as	0
with	0
an	0
increase	0
in	0
the	0
binding	0
activity	0
of	0
transcription	9
factor	10
AP-1	10
.	0

Nevertheless	0
,	0
gel	0
retardation	0
analysis	0
indicated	0
that	0
the	0
AP-1	9
activity	0
detected	0
in	0
untreated	0
cells	0
was	0
drastically	0
reduced	0
during	0
the	0
commitment	0
stage	0
of	0
DMSO-induced	0
HL-60	0
differentiation	0
towards	0
granulocytes	7
.	0

When	0
HL-60	5
cells	6
were	0
treated	0
with	0
sodium	0
butyrate	0
,	0
which	0
induced	0
monocytic	0
differentiation	0
,	0
a	0
remarkable	0
increase	0
in	0
AP-1	0
binding	0
activity	0
was	0
detected	0
.	0

Treatment	0
of	0
HL-60	5
cells	6
with	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
,	0
another	0
monocytic	0
differentiation	0
agent	0
,	0
induced	0
a	0
weak	0
,	0
but	0
appreciable	0
,	0
increase	0
in	0
AP-1	9
activity	0
.	0

Furthermore	0
,	0
addition	0
of	0
sodium	0
butyrate	0
or	0
1	0
alpha	0
,	0
25-dihydroxyvitamin	0
D3	0
to	0
HL-60	5
cells	6
induced	0
the	0
expression	0
of	0
c-fos	1
,	2
c-jun	2
,	2
jun	2
B	2
and	2
jun	2
D	2
proto-oncogenes	2
.	0

In	0
contrast	0
,	0
when	0
HL-60	5
cells	6
were	0
treated	0
with	0
retinoic	0
acid	0
,	0
a	0
granulocytic	0
differentiation	0
inducer	0
,	0
no	0
enhanced	0
AP-1	0
binding	0
activity	0
was	0
observed	0
,	0
and	0
only	0
a	0
weak	0
increase	0
in	0
jun	3
D	4
mRNA	4
level	0
was	0
detected	0
.	0

These	0
data	0
indicate	0
that	0
formation	0
of	0
AP-1	9
is	0
not	0
required	0
for	0
the	0
induction	0
of	0
HL-60	5
differentiation	0
towards	0
granulocytes	7
,	0
whereas	0
induction	0
of	0
monocytic	0
differentiation	0
is	0
correlated	0
with	0
an	0
increase	0
in	0
AP-1	9
activity	0
.	0

The	0
differential	0
expression	0
of	0
AP-1	9
activity	0
may	0
be	0
critical	0
in	0
the	0
differentiation	0
of	0
HL-60	5
cells	6
towards	0
monocytic	7
or	8
granulocytic	8
lineages	8

Glucocorticoid	9
receptors	10
and	0
sensitivity	0
in	0
leukemias	0
.	0

In	0
an	0
attempt	0
to	0
investigate	0
the	0
utility	0
of	0
glucocorticoid	9
receptor	10
determination	0
to	0
predict	0
clinical	0
responsiveness	0
in	0
human	0
leukemias	0
we	0
have	0
studied	0
glucocorticoid	9
receptors	10
in	0
the	0
leukemic	7
cells	8
from	0
46	0
patients	0
and	0
in	0
the	0
lymphocytes	7
from	0
18	0
normal	0
donors	0
.	0

In	0
the	0
normal	7
lymphocytes	8
there	0
were	0
3	0
,	0
875	0
(	0
Median	0
)	0
specific	0
binding	0
sites	0
per	0
cell	0
.	0

The	0
blasts	7
from	0
17	0
patients	0
with	0
ANLL	0
had	0
on	0
average	0
higher	0
levels	0
of	0
binding	9
sites	10
per	0
cell	0
(	0
Median	0
=	0
7	0
,	0
250	0
,	0
range	0
:	0
0	0
to	0
15	0
,	0
295	0
)	0
than	0
the	0
other	0
leukemias	0
.	0

Of	0
the	0
15	0
patients	0
with	0
CLL	0
,	0
six	0
had	0
received	0
glucocorticoid	0
treatment	0
for	0
3	0
to	0
5	0
years	0
.	0

Their	0
lymphocytes	7
had	0
lower	0
number	0
of	0
receptors	0
(	0
Median	0
=	0
2	0
,	0
000	0
)	0
than	0
the	0
other	0
cases	0
which	0
were	0
newly	0
diagnosed	0
(	0
Median	0
=	0
4	0
,	0
500	0
)	0
.	0

Four	0
patients	0
had	0
ALL/AUL	0
,	0
three	0
patients	0
had	0
blast	0
crisis	0
as	0
terminal	0
phase	0
of	0
CML	0
,	0
and	0
seven	0
had	0
leukemic	0
Non-Hodgkin	0
lymphomas	0
(	0
Median	0
=	0
3	0
,	0
500	0
sites/cell	0
)	0
.	0

In	0
24	0
patients	0
we	0
have	0
also	0
studied	0
the	0
in	0
vitro	0
sensitivity	0
of	0
the	0
leukemic	7
cells	8
to	0
dexamethasone	0
.	0

There	0
was	0
no	0
marked	0
correlation	0
between	0
glucocorticoid	9
receptor	10
levels	0
and	0
in	0
vitro	0
sensitivity	0
.	0

An	0
attempt	0
to	0
correlate	0
receptor	0
levels	0
with	0
clinical	0
responsiveness	0
demonstrated	0
that	0
glucocorticoid	9
receptor	10
determination	0
might	0
be	0
of	0
value	0
in	0
patients	0
with	0
lymphoid	0
malignancies	0
but	0
probably	0
not	0
in	0
patients	0
with	0
other	0
leukemias	0
.	0

'Activation-labile	9
'	10
glucocorticoid-receptor	10
complexes	10
of	0
a	0
steroid-resistant	0
variant	0
of	0
CEM-C7	5
human	6
lymphoid	6
cells	6
.	0

For	0
cytoplasmic	9
glucocorticoid-receptor	10
complexes	10
to	0
enter	0
and	0
accumulate	0
in	0
the	0
nucleus	0
a	0
temperature-dependent	0
event	0
,	0
'activation	0
'	0
is	0
required	0
.	0

Activation	0
can	0
be	0
achieved	0
in	0
vitro	0
by	0
increased	0
ionic	0
strength	0
,	0
dilution	0
or	0
gel	0
filtration	0
and	0
is	0
manifested	0
by	0
an	0
increased	0
affinity	0
of	0
steroid-receptor	9
complex	10
for	0
DNA	1
and	0
an	0
altered	0
elution	0
profile	0
from	0
ion-exchange	0
resins	0
.	0

Munck	0
and	0
Foley	0
have	0
shown	0
that	0
activated	9
complexes	10
isolated	0
from	0
thymocytes	0
elute	0
from	0
DEAE-cellulose	0
in	0
a	0
manner	0
identical	0
to	0
complexes	0
activated	0
in	0
vitro	0
.	0

We	0
report	0
here	0
that	0
DEAE-cellulose	0
chromatography	0
of	0
steroid-receptor	9
complexes	10
from	0
CEM-C7	5
,	0
a	0
cloned	5
human	6
leukaemic	6
T-cell	6
line	6
sensitive	0
to	0
the	0
cytolytic	0
action	0
of	0
glucocorticoids	0
,	0
and	0
its	0
steroid-resistant	5
subclone	6
4R4	6
demonstrated	0
that	0
steroid	9
receptors	10
of	0
clone	5
4R4	6
can	0
not	0
form	0
stable	0
activated	0
complexes	0
.	0

This	0
defines	0
a	0
new	0
defect	0
in	0
receptor	0
action	0
,	0
activation	0
lability	0
(	0
r+act1	0
)	0
,	0
which	0
is	0
unlike	0
either	0
the	0
r-	5
,	6
r+nt-	6
,	6
or	6
r+nti	6
phenotypes	6
previously	0
described	0
for	0
mouse	5
lymphoid	6
variants	6
.	0

Granulocytes	7
in	0
the	0
endometrium	0
of	0
post-partum	0
women	0
.	0

Endometrial	0
samples	0
of	0
women	0
at	0
various	0
stages	0
of	0
gonadal	0
activity	0
after	0
parturition	0
were	0
examined	0
for	0
the	0
presence	0
and	0
numbers	0
of	0
endometrial	7
granulocytes	8
.	0

Although	0
samples	0
at	0
all	0
the	0
stages	0
contained	0
significant	0
numbers	0
of	0
the	0
granulocytes	7
(	0
i.e.	0
greater	0
than	0
7/high-power	0
field	0
)	0
,	0
the	0
100	0
%	0
values	0
for	0
late-proliferative	0
and	0
adaptation	0
hyperplasia	0
were	0
significantly	0
higher	0
than	0
the	0
values	0
for	0
the	0
resting	0
(	0
81.8	0
%	0
)	0
,	0
early	0
(	0
82.4	0
%	0
)	0
and	0
mid-	0
(	0
87.9	0
%	0
)	0
proliferative	0
and	0
secretory	0
(	0
83.3	0
%	0
)	0
phases	0
.	0

We	0
suggest	0
that	0
this	0
correlates	0
with	0
the	0
suggestion	0
that	0
the	0
granulocytes	7
constitute	0
a	0
receptor	0
system	0
for	0
oestrogens	0
.	0

Interaction	0
of	0
glucocorticoids	0
with	0
macrophages	7
.	0

Identification	0
of	0
glucocorticoid	9
receptors	10
in	0
monocytes	7
and	0
macrophages	7
.	0

Glucocorticoid	0
binding	0
was	0
measured	0
in	0
resident	0
and	0
thioglycollate-elicited	7
mouse	8
peritoneal	8
macrophages	8
,	0
rabbit	7
alveolar	8
macrophages	8
,	0
and	0
human	7
monocytes	8
.	0

Two	0
assays	0
of	0
binding	0
were	0
used	0
--	0
an	0
assay	0
with	0
intact	7
cells	8
in	0
suspension	0
or	0
monolayers	0
,	0
and	0
an	0
assay	0
of	0
cytosol	0
and	0
nuclear	0
forms	0
of	0
glucocorticoid	9
receptors	10
.	0

The	0
mononuclear	7
phagocytes	8
contained	0
approximately	0
equal	0
to	0
4	0
--	0
10	0
X	0
10	0
(	0
3	0
)	0
high	9
affinity	10
receptor	10
sites	10
per	0
cell	0
,	0
with	0
dissociation	0
constants	0
of	0
approximately	0
equal	0
to	0
2	0
--	0
8	0
nM	0
dexamethasone	0
.	0

The	0
binding	0
to	0
the	0
saturable	9
sites	10
was	0
specific	0
for	0
steroids	0
with	0
glucocorticoid	0
or	0
antiglucocorticoid	0
activity	0
.	0

Cortisol	0
,	0
corticosterone	0
,	0
and	0
progesterone	0
competed	0
with	0
dexamethasone	0
for	0
binding	0
,	0
whereas	0
estradiol	0
,	0
dihydrotestosterone	0
,	0
and	0
11-epicortisol	0
competed	0
very	0
little	0
.	0

Binding	0
of	0
dexamethasone	0
to	0
cytosol	0
and	0
nuclear	0
forms	0
of	0
the	0
receptor	9
complex	10
and	0
temperature-sensitive	0
translocation	0
of	0
cytosol	0
forms	0
to	0
nuclear	0
forms	0
were	0
shown	0
.	0

At	0
37	0
degrees	0
C	0
the	0
predominant	0
form	0
of	0
the	0
hormone-receptor	9
complex	10
was	0
nuclear	0
.	0

These	0
results	0
demonstrate	0
that	0
corticosteroids	0
interact	0
with	0
macrophages	7
at	0
physiological	0
concentrations	0
.	0

Nitric	0
oxide	0
signaling	0
:	0
a	0
possible	0
role	0
for	0
G	9
proteins	10
.	0

We	0
have	0
previously	0
reported	0
various	0
inductive	0
effects	0
of	0
nitric	0
oxide	0
on	0
human	7
PBMC	8
.	0

We	0
describe	0
a	0
novel	0
and	0
potentially	0
important	0
mechanism	0
of	0
nitric	0
oxide	0
signaling-through	0
direct	0
activation	0
of	0
guanine	9
nucleotide-binding	10
proteins	10
(	0
G	9
proteins	10
)	0
.	0

We	0
have	0
found	0
that	0
nitric	0
oxide	0
treatment	0
of	0
membranes	0
isolated	0
from	0
fresh	7
human	8
PBMC	8
enhances	0
the	0
ability	0
of	0
these	0
membranes	0
to	0
hydrolyze	0
[	0
gamma-32P	0
]	0
GTP	0
and	0
bind	0
[	0
gamma-35S	0
]	0
GTP	0
.	0

In	0
addition	0
,	0
treatment	0
of	0
whole	0
cells	0
with	0
nitric	0
oxide	0
yielded	0
membranes	0
with	0
enhanced	0
GTPase	0
activity	0
.	0

Furthermore	0
,	0
the	0
GTPase	0
activity	0
of	0
pure	0
,	0
recombinant	0
Gs	9
alpha	10
,	0
Gi	9
alpha	10
1	10
,	0
and	0
p21ras	9
was	0
greatly	0
enhanced	0
by	0
nitric	0
oxide	0
.	0

In	0
support	0
of	0
the	0
existence	0
of	0
this	0
pathway	0
in	0
whole	0
cells	0
,	0
we	0
found	0
that	0
the	0
G	0
protein	0
inhibitor	0
,	0
GDP-beta-S	0
,	0
blocked	0
NF-kappa	9
B	10
translocation	0
induced	0
by	0
nitric	0
oxide	0
or	0
LPS	0
in	0
permeabilized	7
cells	8
.	0

In	0
addition	0
,	0
nitric	0
oxide	0
greatly	0
reduced	0
the	0
pertussis	0
toxin-mediated	0
ADP-ribosylation	0
of	0
45-	9
and	10
41-kDa	10
proteins	10
in	0
membranes	0
of	0
these	0
cells	0
.	0

Because	0
G	9
proteins	10
play	0
a	0
central	0
role	0
in	0
many	0
diverse	0
signaling	0
systems	0
,	0
activation	0
by	0
an	0
endogenous	0
and	0
inducible	0
oxidant	0
may	0
represent	0
a	0
novel	0
signaling	0
pathway	0
.	0

The	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
promoter	2
cis-acting	2
element	2
CLE0	1
mediates	0
induction	0
signals	0
in	0
T	7
cells	8
and	0
is	0
recognized	0
by	0
factors	0
related	0
to	0
AP1	9
and	0
NFAT	9
.	0

Expression	0
of	0
the	0
granulocyte-macrophage	1
colony-stimulating	2
factor	2
(	2
GM-CSF	2
)	2
gene	2
in	0
T	0
cells	0
is	0
activated	0
by	0
the	0
combination	0
of	0
phorbol	0
ester	0
(	0
phorbol	0
myristate	0
acetate	0
)	0
and	0
calcium	0
ionophore	0
(	0
A23187	0
)	0
,	0
which	0
mimic	0
antigen	0
stimulation	0
through	0
the	0
T-cell	9
receptor	10
.	0

We	0
have	0
previously	0
shown	0
that	0
a	0
fragment	0
containing	0
bp	1
-95	2
to	2
+27	2
of	0
the	0
mouse	1
GM-CSF	2
promoter	2
can	0
confer	0
inducibility	0
to	0
reporter	1
genes	2
in	0
the	0
human	5
Jurkat	6
T-cell	6
line	6
.	0

Here	0
we	0
use	0
an	0
in	0
vitro	0
transcription	0
system	0
to	0
demonstrate	0
that	0
a	0
cis-acting	1
element	2
(	0
positions	1
-54	2
to	2
-40	2
)	0
,	0
referred	0
to	0
as	0
CLE0	1
,	0
is	0
a	0
target	0
for	0
the	0
induction	0
signals	0
.	0

We	0
observed	0
induction	0
with	0
templates	0
containing	0
intact	0
CLE0	1
but	0
not	0
with	0
templates	0
with	0
deleted	1
or	2
mutated	2
CLE0	2
.	0

We	0
also	0
observed	0
that	0
two	0
distinct	0
signals	0
were	0
required	0
for	0
the	0
stimulation	0
through	0
CLE0	1
,	0
since	0
only	0
extracts	0
from	0
cells	0
treated	0
with	0
both	0
phorbol	0
myristate	0
acetate	0
and	0
A23187	0
supported	0
optimal	0
induction	0
.	0

Stimulation	0
probably	0
was	0
mediated	0
by	0
CLE0-binding	9
proteins	10
because	0
depletion	0
of	0
these	0
proteins	0
specifically	0
reduced	0
GM-CSF	9
transcription	0
.	0

One	0
of	0
the	0
binding	9
factors	10
possessed	0
biochemical	0
and	0
immunological	0
features	0
identical	0
to	0
those	0
of	0
the	0
transcription	9
factor	10
AP1	10
.	0

Another	0
factor	0
resembled	0
the	0
T-cell-specific	9
factor	10
NFAT	10
.	0

The	0
characteristics	0
of	0
these	0
two	0
factors	0
are	0
consistent	0
with	0
their	0
involvement	0
in	0
GM-CSF	0
induction	0
.	0

The	0
presence	0
of	0
CLE0-like	1
elements	2
in	0
the	0
promoters	1
of	0
interleukin-3	1
(	2
IL-3	2
)	2
,	2
IL-4	2
,	2
IL-5	2
,	2
GM-CSF	2
,	2
and	2
NFAT	2
sites	2
in	0
the	0
IL-2	1
promoter	2
suggests	0
that	0
the	0
factors	0
we	0
detected	0
,	0
or	0
related	0
factors	0
that	0
recognize	0
these	0
sites	0
,	0
may	0
account	0
for	0
the	0
coordinate	0
induction	0
of	0
these	0
genes	0
during	0
T-cell	7
activation	0
.	0

Identification	0
and	0
characterization	0
of	0
an	0
Alu-containing	1
,	2
T-cell-specific	2
enhancer	2
located	0
in	0
the	0
last	0
intron	1
of	0
the	0
human	1
CD8	2
alpha	2
gene	2
.	0

Expression	0
of	0
the	0
human	1
CD8	2
alpha	2
gene	2
is	0
restricted	0
to	0
cells	0
of	0
the	0
lymphoid	7
lineage	8
and	0
developmentally	0
regulated	0
during	0
thymopoiesis	0
.	0

As	0
an	0
initial	0
step	0
towards	0
understanding	0
the	0
molecular	0
basis	0
for	0
tissue-specific	0
expression	0
of	0
this	0
gene	0
,	0
we	0
surveyed	0
the	0
surrounding	0
chromatin	0
structure	0
for	0
potential	0
cis-acting	1
regulatory	2
regions	2
by	0
DNase	9
I	10
hypersensitivity	0
mapping	0
and	0
found	0
four	0
hypersensitive	0
sites	0
,	0
three	0
of	0
which	0
were	0
T	0
cell	0
restricted	0
.	0

By	0
using	0
a	0
reporter-based	0
expression	0
approach	0
,	0
a	0
T-cell-specific	1
enhancer	2
was	0
identified	0
by	0
its	0
close	0
association	0
with	0
a	0
prominent	0
T-cell-restricted	1
hypersensitive	2
sites	2
in	0
the	0
last	0
intron	0
of	0
the	0
CD8	1
alpha	2
gene	2
.	0

Deletion	0
studies	0
demonstrated	0
that	0
the	0
minimal	0
enhancer	0
is	0
adjacent	0
to	0
a	0
negative	0
regulatory	0
element	0
.	0

DNA	0
sequence	0
analysis	0
of	0
the	0
minimal	1
enhancer	2
revealed	0
a	0
striking	0
cluster	0
of	0
consensus	1
binding	2
sites	2
for	0
Ets-1	9
,	10
TCF-1	10
,	10
CRE	10
,	10
GATA-3	10
,	10
LyF-1	10
,	10
and	10
bHLH	10
proteins	10
which	0
were	0
verified	0
by	0
electrophoretic	0
mobility	0
shift	0
assays	0
.	0

In	0
addition	0
,	0
the	0
5	1
'	2
end	2
of	0
the	0
enhancer	1
was	0
composed	0
of	0
an	0
Alu	0
repeat	0
which	0
contained	0
the	0
GATA-3	1
,	2
bHLH	2
,	2
and	2
LyF-1	2
binding	2
sites	2
.	0

Site-directed	0
mutation	0
of	0
the	0
Ets-1	1
and	2
GATA-3	2
sites	2
dramatically	0
reduced	0
enhancer	0
activity	0
.	0

The	0
functional	0
importance	0
of	0
the	0
other	0
binding	0
sites	0
only	0
became	0
apparent	0
when	0
combinations	0
of	0
mutations	0
were	0
analyzed	0
.	0

Taken	0
together	0
,	0
these	0
results	0
suggest	0
that	0
the	0
human	1
CD8	2
alpha	2
gene	2
is	0
regulated	0
by	0
the	0
interaction	0
of	0
multiple	0
T-cell	9
nuclear	10
proteins	10
with	0
a	0
transcriptional	0
enhancer	0
located	0
in	0
the	0
last	0
intron	1
of	0
the	0
gene	0
.	0

Comparison	0
of	0
the	0
CD8	1
alpha	2
enhancer	2
with	0
other	0
recently	0
identified	0
T-cell-specific	1
regulatory	2
elements	2
suggests	0
that	0
a	0
common	0
set	0
of	0
transcription	9
factors	10
regulates	0
several	0
T-cell	1
genes	2
.	0

Molecular	0
regulation	0
of	0
the	0
human	1
IL-3	2
gene	2
:	0
inducible	0
T	0
cell-restricted	0
expression	0
requires	0
intact	0
AP-1	1
and	2
Elf-1	2
nuclear	2
protein	2
binding	2
sites	2
.	0

Interleukin	9
3	10
(	0
IL-3	9
)	0
is	0
a	0
hematopoietic	9
stem-cell	10
growth	10
and	10
differentiation	10
factor	10
that	0
is	0
expressed	0
solely	0
in	0
activated	0
T	7
and	8
NK	8
cells	8
.	0

Studies	0
to	0
date	0
have	0
identified	0
elements	0
5	0
'	0
to	0
the	0
IL-3	1
coding	2
sequences	2
that	0
regulate	0
its	0
transcription	0
,	0
but	0
the	0
sequences	0
that	0
confer	0
T	0
cell-specific	0
expression	0
remain	0
to	0
be	0
clearly	0
defined	0
.	0

We	0
have	0
now	0
identified	0
DNA	1
sequences	2
that	0
are	0
required	0
for	0
T	0
cell-restricted	0
IL-3	1
gene	2
transcription	0
.	0

A	0
series	0
of	0
transient	0
transfections	0
performed	0
with	0
human	1
IL-3-chloramphenicol	2
acetyltransferase	2
(	2
CAT	2
)	2
reporter	2
plasmids	2
in	0
T	7
and	8
non-T	8
cells	8
revealed	0
that	0
a	0
plasmid	1
containing	0
319	0
bp	0
of	0
5	1
'	2
flanking	2
sequences	2
was	0
active	0
exclusively	0
in	0
T	7
cells	8
.	0

Deletion	0
analysis	0
revealed	0
that	0
T	7
cell	8
specificity	0
was	0
conferred	0
by	0
a	0
49-bp	1
fragment	2
(	0
bp	1
-319	2
to	2
-270	2
)	0
that	0
included	0
a	0
potential	1
binding	2
site	2
for	0
AP-1	9
transcription	10
factors	10
6	0
bp	0
upstream	0
of	0
a	0
binding	1
site	2
for	2
Elf-1	2
,	0
a	0
member	0
of	0
the	0
Ets	9
family	10
of	0
transcription	9
factors	10
.	0

DNaseI	9
footprint	0
and	0
electrophoretic	0
mobility	0
shift	0
assay	0
analyses	0
performed	0
with	0
MLA-144	5
T	6
cell	6
nuclear	0
extracts	0
demonstrated	0
that	0
this	0
49-bp	1
region	2
contains	0
a	0
nuclear	1
protein	2
binding	2
region	2
that	0
includes	0
consensus	1
AP-1	2
and	2
Elf-1	2
binding	2
sites	2
.	0

In	0
addition	0
,	0
extracts	0
prepared	0
from	0
purified	7
human	8
T	8
cells	8
contained	0
proteins	0
that	0
bound	0
to	0
synthetic	0
oligonucleotides	0
corresponding	0
to	0
the	0
AP-1	1
and	2
Elf-1	2
binding	2
sites	2
.	0

In	0
vitro-transcribed	0
and	0
-translated	0
Elf-1	9
protein	10
bound	0
specifically	0
to	0
the	0
Elf-1	1
site	2
,	0
and	0
Elf-1	0
antisera	0
competed	0
and	0
super	0
shifted	0
nuclear	0
protein	0
complexes	0
present	0
in	0
MLA-144	5
nuclear	0
extracts	0
.	0

Moreover	0
,	0
addition	0
of	0
anti-Jun	0
family	0
antiserum	0
in	0
electrophoretic	0
mobility	0
shift	0
assay	0
reactions	0
completely	0
blocked	0
formation	0
of	0
the	0
AP-1-related	9
complexes	10
.	0

Transient	0
transfection	0
studies	0
in	0
MLA-144	5
T	6
cells	6
revealed	0
that	0
constructs	0
containing	0
mutations	0
in	0
the	0
AP-1	1
site	2
almost	0
completely	0
abolished	0
CAT	0
activity	0
while	0
mutation	0
of	0
the	0
Elf-1	1
site	2
or	0
the	0
NF-IL-3	1
site	2
,	0
a	0
previously	0
described	0
nuclear	1
protein	2
binding	2
site	2
(	0
bp.	1
-155	2
to	2
-148	2
)	0
in	0
the	0
IL-3	1
promoter	2
,	0
reduced	0
CAT	0
activity	0
to	0
<	0
25	0
%	0
of	0
the	0
activity	0
given	0
by	0
wild-type	0
constructs	0
.	0

We	0
conclude	0
that	0
expression	0
of	0
the	0
human	1
IL-3	2
gene	2
requires	0
the	0
AP-1	1
and	2
Elf-1	2
binding	2
sites	2
;	0
however	0
,	0
unlike	0
other	0
previously	0
characterized	0
cytokine	1
genes	2
such	0
as	0
IL-2	9
,	0
the	0
AP-1	9
and	10
Elf-1	10
factors	10
can	0
bind	0
independently	0
in	0
the	0
IL-3	1
gene	2
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
400	0
WORDS	0
)	0

Combination	0
IL-2	9
and	0
IL-4	9
reduces	0
glucocorticoid	0
receptor-binding	0
affinity	0
and	0
T	7
cell	8
response	0
to	0
glucocorticoids	0
.	0

The	0
mechanisms	0
contributing	0
to	0
persistent	0
T	7
cell	8
activation	0
and	0
poor	0
response	0
to	0
glucocorticoids	0
in	0
chronic	0
inflammatory	0
illnesses	0
such	0
as	0
steroid	0
resistant	0
(	0
SR	0
)	0
asthma	0
are	0
poorly	0
defined	0
.	0

We	0
examined	0
the	0
possibility	0
that	0
certain	0
cytokines	0
,	0
specifically	0
IL-2	9
and	0
IL-4	9
,	0
could	0
affect	0
T	0
cell	0
response	0
to	0
glucocorticoids	0
.	0

A	0
[	0
3H	0
]	0
dexamethasone	0
radioligand-binding	0
assay	0
was	0
used	0
to	0
measure	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
(	0
GR	9
)	0
and	0
dissociation	0
constant	0
(	0
Kd	0
)	0
in	0
PBMC	7
from	0
normal	0
donors	0
and	0
patients	0
with	0
SR	0
asthma	0
,	0
cultured	0
in	0
the	0
absence	0
and	0
presence	0
of	0
these	0
cytokines	9
.	0

PBMC	0
from	0
normal	0
donors	0
incubated	0
for	0
48	0
h	0
in	0
the	0
presence	0
of	0
combination	0
IL-2	9
+	0
IL-4	9
had	0
nuclear	0
GR	0
with	0
significantly	0
reduced	0
binding	0
affinity	0
(	0
GR	0
Kd	0
=	0
36.1	0
+/-	0
1.63	0
nM	0
,	0
mean	0
+/-	0
SEM	0
;	0
p	0
=	0
0.0001	0
)	0
as	0
compared	0
with	0
PBMC	7
incubated	0
with	0
medium	0
alone	0
(	0
GR	0
Kd	0
=	0
6.74	0
+/-	0
0.46	0
nM	0
)	0
.	0

The	0
cytosolic	0
GR	0
Kd	0
remained	0
unchanged	0
.	0

However	0
,	0
when	0
PBMC	7
were	0
incubated	0
with	0
IL-2	9
alone	0
or	0
IL-4	9
alone	0
,	0
no	0
change	0
in	0
GR-binding	0
affinity	0
was	0
observed	0
.	0

Furthermore	0
,	0
when	0
T	7
cells	8
and	0
non-T	7
cells	8
were	0
individually	0
stimulated	0
with	0
combination	0
IL-2	0
+	0
IL-4	0
,	0
a	0
significant	0
reduction	0
in	0
GR-binding	0
affinity	0
was	0
observed	0
only	0
in	0
the	0
T	7
cell	8
population	8
(	0
p	0
=	0
0.0001	0
)	0
.	0

The	0
IL-2	0
+	0
IL-4-induced	0
alteration	0
in	0
PBMC	0
GR	0
Kd	0
was	0
associated	0
with	0
an	0
increase	0
in	0
GR	0
number	0
(	0
8348	0
+/-	0
964	0
vs	0
1710	0
+/-	0
228	0
sites/cell	0
;	0
p	0
=	0
0.0003	0
)	0
.	0

More	0
importantly	0
,	0
the	0
alteration	0
in	0
PBMC	0
GR-binding	0
affinity	0
with	0
IL-2	9
+	0
IL-4	9
was	0
associated	0
with	0
a	0
functional	0
change	0
in	0
T	0
cell	0
response	0
to	0
methylprednisolone	0
MPN	0
,	0
i.e.	0
,	0
a	0
reduced	0
inhibitory	0
effect	0
of	0
MPN	0
on	0
PMA/ionomycin-induced	0
T	7
cell	8
proliferation	0
.	0

These	0
effects	0
of	0
IL-2	9
+	0
IL-4	9
on	0
PBMC	7
GR	9
affinity	0
and	0
response	0
to	0
MPN	0
were	0
blocked	0
by	0
co-incubation	0
with	0
IFN-gamma	9
.	0

Freshly	0
isolated	0
PBMC	7
from	0
four	0
patients	0
with	0
SR	0
asthma	0
had	0
a	0
significantly	0
reduced	0
GR-binding	0
affinity	0
(	0
Kd	0
=	0
40.0	0
+/-	0
2.68	0
nM	0
;	0
p	0
=	0
0.0001	0
)	0
when	0
compared	0
with	0
seven	0
normal	0
subjects	0
(	0
7.15	0
+/-	0
0.41	0
nM	0
)	0
.	0

The	0
altered	0
PBMC	0
GR	0
binding	0
from	0
patients	0
with	0
SR	0
asthma	0
reversed	0
to	0
normal	0
when	0
incubated	0
with	0
medium	0
alone	0
,	0
but	0
was	0
sustained	0
with	0
IL-2	9
+	0
IL-4	9
.	0

These	0
observations	0
suggest	0
that	0
with	0
persistent	0
inflammation	0
certain	0
cytokines	9
may	0
contribute	0
to	0
an	0
impaired	0
response	0
to	0
glucocorticoids	0
.	0

Furthermore	0
,	0
the	0
effects	0
of	0
IL-2	9
and	0
IL-4	9
were	0
blocked	0
by	0
IFN-gamma	9
.	0

Characterization	0
of	0
the	0
human	1
CD4	2
gene	2
promoter	2
:	0
transcription	0
from	0
the	0
CD4	1
gene	2
core	2
promoter	2
is	0
tissue-specific	0
and	0
is	0
activated	0
by	0
Ets	9
proteins	10
.	0

We	0
analyzed	0
the	0
5	1
'	2
transcription	2
control	2
sequences	2
of	0
the	0
human	1
CD4	2
gene	2
.	0

We	0
located	0
the	0
transcription	1
initiation	2
site	2
and	0
showed	0
that	0
the	0
CD4	1
core	2
promoter	2
(	0
positions	1
-40	2
to	2
+16	2
)	0
lacks	0
a	0
classical	0
``	0
TATA	0
''	0
or	0
initiator	1
positioning	2
consensus	2
sequence	2
but	0
directs	0
precise	0
and	0
efficient	0
transcription	0
when	0
coupled	0
to	0
the	0
ubiquitously	0
active	0
simian	1
virus	2
40	2
enhancer	2
.	0

The	0
transcriptional	0
activity	0
of	0
the	0
CD4	1
gene	2
promoter	2
correlated	0
with	0
CD4	0
expression	0
in	0
various	0
cell	0
types	0
.	0

Interestingly	0
,	0
the	0
CD4	1
core	2
promoter	2
also	0
displayed	0
a	0
tissue-specific	0
transcriptional	0
activity	0
.	0

Within	0
this	0
fragment	0
,	0
three	0
nucleic	0
acid	0
sequences	0
are	0
completely	0
conserved	0
in	0
the	0
murine	1
CD4	2
gene	2
.	0

One	0
of	0
these	0
sequences	0
contains	0
a	0
perfect	1
ETS	2
consensus	2
sequence	2
.	0

Another	0
ETS	1
consensus	2
sequence	2
is	0
located	0
1060	0
nt	0
upstream	0
.	0

Electrophoretic-mobility-shift	0
assays	0
showed	0
that	0
the	0
core	0
promoter	0
ETS	0
motif	0
binds	0
an	0
Ets-related	9
protein	10
specifically	0
expressed	0
at	0
high	0
levels	0
in	0
CD4+	7
cells	8
.	0

Moreover	0
,	0
in	0
CD4-	7
cells	8
,	0
overexpression	0
of	0
Ets-1	9
or	0
Ets-2	9
efficiently	0
and	0
specifically	0
activated	0
transcription	0
from	0
the	0
CD4	1
promoter	2
and	0
core	1
promoter	2
.	0

These	0
data	0
indicate	0
that	0
Ets	9
transcription	10
factors	10
play	0
a	0
central	0
role	0
in	0
controlling	0
CD4	0
gene	0
expression	0
,	0
by	0
binding	0
to	0
both	0
a	0
classical	1
remote	2
site	2
and	0
an	0
unusual	0
proximal	1
activator	2
sequence	2

Glucocorticoid	0
receptor	0
activation	0
and	0
inactivation	0
in	0
c	0
ultured	5
human	6
lymphocytes	6
.	0

Although	0
glucocorticoids	0
are	0
not	0
cytolytic	0
for	0
and	0
do	0
not	0
inhibit	0
the	0
growth	0
of	0
the	0
IM-9	5
line	6
of	0
cultured	5
human	6
lymphoblasts	6
,	0
these	0
cells	0
have	0
a	0
high	0
steroid-binding	0
capacity	0
.	0

We	0
have	0
used	0
IM-9	7
cells	8
in	0
order	0
to	0
examine	0
whether	0
unoccupied	9
glucocorticoid	10
receptors	10
are	0
inactivated	0
and	0
activated	0
in	0
intact	7
cells	8
.	0

when	0
IM-9	7
cells	8
are	0
incubated	0
in	0
glucose-free	0
medium	0
in	0
a	0
nitrogen	0
atmosphere	0
,	0
both	0
their	0
ability	0
to	0
bind	0
triamcinolone	0
acetonide	0
and	0
their	0
ATP	0
levels	0
decline	0
and	0
,	0
when	0
glucose	0
and	0
oxygen	0
are	0
reintroduced	0
,	0
ATP	0
levels	0
and	0
receptor	0
activity	0
return	0
.	0

The	0
specific	0
glucocorticoid-binding	0
activity	0
of	0
cytosol	0
prepared	0
from	0
cells	0
exposed	0
to	0
various	0
degrees	0
of	0
energy	0
limitation	0
is	0
directly	0
correlated	0
with	0
the	0
ATP	0
content	0
.	0

Receptor	0
activation	0
in	0
intact	7
cells	8
is	0
rapid	0
and	0
independent	0
of	0
protein	0
synthesis	0
.	0

Cytosol	0
prepared	0
from	0
inactivated	0
cells	0
can	0
not	0
be	0
activated	0
by	0
addition	0
of	0
ATP	0
.	0

The	0
inactivation	0
of	0
glucocorticoid	9
receptors	10
that	0
occurs	0
when	0
cytosol	0
from	0
normal	0
IM-9	5
cells	6
is	0
incubated	0
at	0
25	0
degrees	0
C	0
is	0
inhibited	0
by	0
molybdate	0
,	0
vanadate	0
,	0
fluoride	0
,	0
ATP	0
,	0
and	0
several	0
other	0
nucleotides	0
.	0

The	0
experiments	0
with	0
intact	7
human	8
lymphoblasts	8
suggest	0
that	0
assays	0
of	0
specific	0
glucocorticoid-binding	0
capacity	0
do	0
not	0
necessarily	0
reflect	0
the	0
cellular	0
content	0
of	0
receptor	9
protein	10
.	0

Glucocorticoids	0
and	0
lymphocytes	7
.	0

II	0
.	0

Cell	0
cycle-dependent	0
changes	0
in	0
glucocorticoid	9
receptor	10
content	0
.	0

To	0
study	0
variations	0
in	0
glucocorticoid	9
receptor	10
levels	0
during	0
the	0
cell	0
cycle	0
,	0
we	0
have	0
separated	0
mitogen-stimulated	5
human	6
peripheral	6
lymphocytes	6
and	0
rat	7
lymph	8
node	8
cells	8
by	0
unit	0
gravity	0
sedimentation	0
and	0
measured	0
glucocorticoid	0
binding	0
in	0
the	0
resultant	0
fractions	0
.	0

By	0
morphologic	0
criteria	0
and	0
thymidine	0
incorporation	0
,	0
the	0
fractions	0
were	0
separated	0
into	0
populations	0
of	0
G0	7
and	8
G1	8
phase	8
and	8
S	8
and	8
post-S	8
phase	8
cells	8
.	0

A	0
2-	0
to	0
3-fold	0
increase	0
in	0
glucocorticoid	0
receptor	0
sites	0
per	0
cell	0
,	0
for	0
cells	0
in	0
the	0
S	0
and	0
post-S	0
phase	0
over	0
those	0
in	0
G0	0
and	0
G1	0
,	0
was	0
observed	0
with	0
both	0
nonstimulated	7
rat	8
lymph	8
node	8
cell	8
suspensions	8
and	0
concanavalin	5
A-stimulated	6
human	6
peripheral	6
lymphocytes	6
.	0

These	0
observations	0
together	0
with	0
those	0
from	0
other	0
studies	0
indicate	0
that	0
formation	0
of	0
new	0
glucocorticoid	9
receptors	10
near	0
the	0
S	0
phase	0
may	0
be	0
a	0
general	0
phenomenon	0
in	0
proliferating	7
cells	8
.	0

We	0
propose	0
that	0
this	0
increase	0
in	0
glucocorticoid	9
receptors	10
during	0
the	0
cell	0
cycle	0
may	0
explain	0
the	0
increase	0
in	0
glucocorticoid	9
receptors	10
in	0
mitogen-stimulated	7
lymphocytes	8
.	0

The	0
leukocyte	7
migration	0
inhibition	0
response	0
to	0
certain	0
breast	9
cancer-related	10
antigens	10
(	0
MCF-7	9
and	0
MuMTV	9
)	0
:	0
their	0
potential	0
as	0
discriminants	0
.	0

Certain	0
oncogenic	0
viruses	0
have	0
been	0
implicated	0
in	0
human	0
breast	0
cancer	0
,	0
including	0
the	0
murine	0
mammary	0
tumor	0
virus	0
(	0
MuMTV	0
)	0
and	0
the	0
Mason-Pfizer	0
monkey	0
virus	0
(	0
MPMV	0
)	0
.	0

We	0
have	0
used	0
the	0
leukocyte	0
migration	0
inhibition	0
(	0
LMI	0
)	0
response	0
to	0
assay	0
the	0
response	0
to	0
several	0
potential	0
breast	0
cancer-related	0
antigens	0
,	0
including	0
MuMTV	9
,	0
MPMV	9
,	0
and	0
a	0
breast	5
cancer	6
cultured	6
cell	6
line	6
,	0
MCF-7	5
,	0
in	0
96	0
breast	0
cancer	0
patients	0
,	0
in	0
32	0
women	0
with	0
benign	0
breast	0
disease	0
,	0
and	0
in	0
67	0
normal	0
women	0
.	0

The	0
lowest	0
tenth	0
percentile	0
of	0
control	0
(	0
LMI	0
)	0
responses	0
was	0
used	0
as	0
the	0
cutoff	0
point	0
to	0
designate	0
responders	0
.	0

Breast	0
cancer	0
patients	0
showed	0
significant	0
responses	0
to	0
MuMTV	9
(	0
49	0
%	0
and	0
to	0
MCF-7	0
(	0
50	0
%	0
)	0
,	0
but	0
not	0
to	0
MPMV	9
(	0
29	0
%	0
)	0
.	0

In	0
a	0
paired-antigen	0
study	0
using	0
MuMTV	9
and	0
MCF-7	9
,	0
75	0
%	0
of	0
the	0
breast	0
cancer	0
patients	0
responded	0
,	0
versus	0
18	0
%	0
of	0
the	0
normal	0
women	0
(	0
P	0
less	0
than	0
0.0050	0
)	0
.	0

The	0
potential	0
for	0
this	0
assay	0
to	0
distinguish	0
``	0
normal	0
''	0
from	0
``	0
breast	0
cancer	0
''	0
was	0
analyzed	0
using	0
a	0
migration	0
index	0
derived	0
from	0
discriminant	0
analysis	0
.	0

The	0
ability	0
of	0
the	0
assay	0
to	0
discriminate	0
``	0
normal	0
''	0
from	0
``	0
cancer	0
''	0
was	0
significant	0
(	0
P	0
less	0
than	0
0.001	0
)	0
and	0
showed	0
a	0
sensitivity	0
of	0
detecting	0
``	0
cancer	0
''	0
of	0
75	0
%	0
.	0

The	0
overall	0
responses	0
to	0
MuMTV	9
and	0
MCF-7	9
were	0
analyzed	0
with	0
reference	0
to	0
certain	0
prognostic	0
factors	0
,	0
but	0
showed	0
no	0
relation	0
to	0
age	0
,	0
menstrual	0
status	0
,	0
estrogen	0
receptor	0
status	0
,	0
or	0
stage	0
of	0
disease	0
.	0

The	0
above	0
reactions	0
suggest	0
that	0
a	0
large	0
proportion	0
of	0
breast	0
cancer	0
patients	0
exhibit	0
presensitization	0
to	0
antigenfs	0
found	0
in	0
MuMTV	9
and	0
MCF-7	9
,	0
which	0
may	0
be	0
cross-reactive	0
with	0
antigens	0
in	0
the	0
primary	0
cancer	0
.	0

These	0
responses	0
appear	0
to	0
be	0
independent	0
of	0
major	0
prognostic	0
variables	0
.	0

Further	0
refinement	0
of	0
this	0
assay	0
may	0
yield	0
one	0
which	0
is	0
more	0
highly	0
discriminating	0
for	0
breast	0
cancer	0
.	0

Chronic	0
lymphatic	0
leukaemia	0
:	0
cellular	0
effects	0
of	0
glucocorticoids	0
in	0
vitro	0
.	0

Glucocorticoid	9
receptor	10
levels	0
and	0
steroid	0
induced	0
inhibition	0
of	0
nucleic	0
acid	0
precursors	0
have	0
been	0
examined	0
in	0
lymphocytes	7
from	0
27	0
patients	0
at	0
different	0
stages	0
of	0
chronic	0
lymphatic	0
leukaemia	0
.	0

No	0
correlation	0
can	0
be	0
found	0
between	0
the	0
level	0
of	0
glucocorticoid	9
receptors	10
and	0
the	0
stage	0
of	0
the	0
disease	0
.	0

On	0
the	0
other	0
hand	0
,	0
a	0
significant	0
difference	0
(	0
P	0
less	0
than	0
0.02	0
)	0
was	0
found	0
between	0
stage	0
O	0
and	0
stage	0
III/IV	0
patients	0
,	0
in	0
terms	0
of	0
the	0
in	0
vitro	0
effect	0
of	0
dexamethasone	0
on	0
[	0
3H	0
]	0
uridine	0
incorporation	0
.	0

Pyrrolidine	0
dithiocarbamate	0
inhibits	0
NF-kappa	9
B	10
mobilization	0
and	0
TNF	0
production	0
in	0
human	7
monocytes	8
.	0

The	0
human	1
TNF	2
promoter	2
contains	0
four	0
potential	0
nuclear	1
factor-kappa	2
B	2
(	2
NF-kappa	2
B	2
)	2
-binding	2
sites	2
,	0
with	0
the	0
strongest	0
binding	0
seen	0
for	0
the	0
-605	0
motif	0
.	0

Nuclear	0
extracts	0
from	0
unstimulated	5
cells	6
of	0
the	0
human	5
monocytic	6
cell	6
line	6
,	0
Mono	5
Mac	6
6	6
,	0
contain	0
one	0
specific	9
binding	10
protein	10
(	0
complex	9
II	10
)	0
,	0
consistent	0
with	0
a	0
constitutive	9
p50	10
homodimer	10
.	0

Stimulation	0
of	0
Mono	5
Mac	6
6	6
cells	6
with	0
LPS	0
will	0
increase	0
complex	9
II	10
and	0
will	0
strongly	0
induce	0
a	0
second	0
specific	0
complex	0
(	0
complex	9
I	10
)	0
,	0
which	0
represents	0
the	0
p50/65	9
heterodimer	10
.	0

Treatment	0
of	0
Mono	7
Mac	8
6	8
cells	8
with	0
pyrrolidine-dithiocarbamate	0
(	0
PDTC	0
)	0
at	0
300	0
microM	0
will	0
block	0
the	0
LPS-induced	9
complex	10
I	10
almost	0
completely	0
and	0
will	0
reduce	0
complex	9
II	10
to	0
the	0
constitutive	0
level	0
.	0

Binding	0
activity	0
of	0
other	0
nuclear	9
factors	10
that	0
recognize	0
the	0
SP-1	0
and	0
c/EBP	0
motifs	0
of	0
the	0
human	1
TNF	2
promoter	2
is	0
not	0
affected	0
by	0
such	0
treatment	0
.	0

Northern	0
blot	0
analysis	0
demonstrates	0
that	0
PDTC	0
treatment	0
will	0
strongly	0
reduce	0
LPS-induced	9
TNF	10
transcripts	10
.	0

Secreted	0
TNF	9
protein	10
as	0
detected	0
in	0
the	0
Wehi	0
164S/ActD	0
bioassay	0
and	0
in	0
a	0
sandwich	0
immunoassay	0
was	0
similarly	0
reduced	0
by	0
PDTC	0
.	0

Kinetic	0
analyses	0
show	0
that	0
after	0
LPS	0
stimulation	0
,	0
NF-kappa	9
B	10
will	0
peak	0
at	0
1	0
h	0
,	0
TNF	0
transcript	0
prevalence	0
at	0
2	0
h	0
,	0
and	0
TNF	9
protein	10
at	0
4	0
h	0
.	0

PDTC	0
did	0
not	0
shift	0
this	0
response	0
to	0
LPS	0
to	0
a	0
later	0
time	0
,	0
but	0
suppressed	0
NF-kappa	0
B	0
mobilization	0
,	0
TNF	9
transcripts	10
,	0
and	0
TNF	9
protein	10
over	0
the	0
entire	0
8-h	0
observation	0
period	0
.	0

Analysis	0
of	0
freshly	0
isolated	0
,	0
LPS-stimulated	7
blood	8
monocytes	8
showed	0
a	0
similar	0
blockade	0
of	0
NF-kappa	9
B	10
.	0

Furthermore	0
,	0
in	0
these	0
primary	0
cells	0
,	0
induction	0
of	0
TNF	9
transcripts	10
,	0
as	0
determined	0
by	0
Northern	0
blot	0
analysis	0
and	0
by	0
quantitative	0
polymerase	0
chain	0
reaction	0
,	0
was	0
prevented	0
by	0
PDTC	0
as	0
was	0
TNF	9
protein	10
production	0
.	0

These	0
data	0
show	0
that	0
dithiocarbamates	0
can	0
profoundly	0
affect	0
cytokine	0
expression	0
and	0
suggest	0
that	0
NF-kappa	9
B	10
is	0
involved	0
in	0
LPS-induced	0
TNF	0
gene	0
expression	0
in	0
human	7
monocytes	8
.	0

Comparing	0
regions	0
of	0
the	0
Epstein-Barr	9
virus	10
ZEBRA	10
protein	10
which	0
function	0
as	0
transcriptional	1
activating	2
sequences	2
in	0
Saccharomyces	0
cerevisiae	0
and	0
in	0
B	7
cells	8
.	0

The	0
ZEBRA	9
protein	10
activates	0
expression	0
of	0
Epstein-Barr	0
virus	0
early-lytic-cycle	1
genes	2
in	0
human	7
B	8
lymphocytes	8
.	0

Here	0
it	0
is	0
shown	0
that	0
ZEBRA	9
also	0
behaves	0
as	0
a	0
sequence-specific	9
transcriptional	10
activator	10
in	0
Saccharomyces	0
cerevisiae	0
.	0

Deletional	0
mutagenesis	0
defined	0
three	0
regions	0
of	0
ZEBRA	9
that	0
participate	0
in	0
activation	0
in	0
S.	0
cerevisiae	0
.	0

These	0
regions	0
are	0
designated	0
YI	9
(	0
amino	9
acids	10
[	10
aa	10
]	10
1	10
to	10
25	10
)	0
,	0
YII	9
(	0
aa	9
51	10
to	10
102	10
)	0
,	0
and	0
YIII	9
(	0
aa	9
228	10
to	10
245	10
)	0
.	0

Two	0
of	0
the	0
three	0
regions	0
of	0
the	0
native	0
ZEBRA	9
protein	10
act	0
together	0
to	0
mediate	0
activation	0
when	0
assayed	0
on	0
ZEBRA	9
binding	10
sites	10
.	0

However	0
,	0
when	0
fused	0
to	0
the	0
DNA	9
binding	10
domain	10
of	0
GAL	9
4	0
and	0
assayed	0
on	0
GAL4	9
binding	10
sites	10
,	0
regions	9
YII	10
and	10
YIII	10
were	0
each	0
sufficient	0
to	0
confer	0
activation	0
in	0
S.	0
cerevisiae	0
.	0

Regions	0
of	0
ZEBRA	9
which	0
affected	0
activation	0
in	0
S.	0
cerevisiae	0
were	0
also	0
required	0
in	0
human	7
B	8
lymphocytes	8
.	0

The	0
amino-terminal	9
region	10
of	0
ZEBRA	9
(	0
aa	9
1	10
to	10
98	10
)	0
was	0
required	0
for	0
activation	0
both	0
in	0
S.	0
cerevisiae	0
and	0
in	0
human	7
B	8
cells	8
;	0
deletion	0
of	0
the	0
carboxy-terminal	9
18	10
aa	10
also	0
significantly	0
reduced	0
activation	0
in	0
both	0
cell	0
types	0
.	0

Thus	0
,	0
the	0
behavior	0
of	0
ZEBRA	9
in	0
human	7
B	8
cells	8
and	0
S.	0
cerevisiae	0
suggests	0
that	0
the	0
protein	0
contains	0
universal	9
activation	10
motifs	10
that	0
interact	0
with	0
conserved	0
components	0
of	0
the	0
transcription	0
machinery	0
.	0

However	0
,	0
certain	0
deletion	9
mutants	10
of	0
ZEBRA	9
containing	0
mutations	0
in	0
the	0
N-terminal	9
region	10
exhibited	0
discordant	0
behaviors	0
in	0
S.	0
cerevisiae	0
and	0
in	0
B	0
cells	0
.	0

For	0
example	0
,	0
deletion	0
of	0
ZEBRA	9
aa	10
26	10
to	10
51	10
impaired	0
activation	0
to	0
a	0
great	0
extent	0
in	0
B	7
cells	8
but	0
had	0
little	0
or	0
no	0
effect	0
in	0
S.	0
cerevisiae	0
.	0

The	0
discordant	0
mutants	0
may	0
reflect	0
interactions	0
with	0
a	0
variable	9
domain	10
of	0
a	0
conserved	0
component	0
or	0
unique	0
interactions	0
with	0
specialized	0
components	0
of	0
the	0
basal	0
transcription	0
apparatus	0
in	0
different	0
cells	0
.	0

Functional	0
interaction	0
of	0
the	0
v-Rel	9
and	10
c-Rel	10
oncoproteins	10
with	0
the	0
TATA-binding	9
protein	10
and	0
association	0
with	0
transcription	9
factor	10
IIB	10
.	0

Rel	9
family	10
proteins	10
regulate	0
the	0
expression	0
of	0
genes	0
linked	0
to	0
kappa	0
B-binding	0
motifs	0
.	0

Little	0
is	0
known	0
,	0
however	0
,	0
of	0
the	0
mechanism	0
by	0
which	0
they	0
enhance	0
transcription	0
.	0

We	0
have	0
investigated	0
the	0
ability	0
of	0
the	0
v-Rel	9
and	10
c-Rel	10
oncoproteins	10
to	0
interact	0
with	0
components	0
of	0
the	0
basal	0
transcription	0
machinery	0
.	0

Here	0
we	0
report	0
that	0
both	0
the	0
acidic	0
transcription	0
activation	0
domain	0
mapping	0
to	0
the	0
unique	0
C	9
terminus	10
of	0
chicken	9
c-Rel	10
and	0
the	0
F9	9
cell-specific	10
activation	10
region	10
common	0
to	0
both	0
v-Rel	9
and	0
c-Rel	9
interact	0
with	0
the	0
TATA-binding	9
protein	10
(	0
TBP	9
)	0
and	0
transcription	9
factor	10
IIB	10
(	0
TFIIB	9
)	0
in	0
vitro	0
and	0
in	0
vivo	0
.	0

We	0
also	0
demonstrate	0
that	0
TPB	9
interaction	0
with	0
Rel	9
activation	10
regions	10
leads	0
to	0
synergistic	0
activation	0
of	0
transcription	0
of	0
a	0
kappa	1
B-linked	2
reporter	2
gene	2
.	0

Combined	0
with	0
the	0
observation	0
that	0
the	0
mouse	9
c-Rel	10
and	10
human	10
RelA	10
proteins	10
also	0
interact	0
with	0
TBP	9
and	0
TFIIB	9
in	0
vitro	0
,	0
these	0
results	0
suggest	0
that	0
association	0
with	0
basal	9
transcription	10
factors	10
is	0
important	0
for	0
the	0
transcriptional	0
activities	0
of	0
Rel	9
family	10
proteins	10
.	0

p21ras	9
and	0
calcineurin	0
synergize	0
to	0
regulate	0
the	0
nuclear	9
factor	10
of	0
activated	0
T	7
cells	8
.	0

In	0
T	7
lymphocytes	8
,	0
triggering	0
of	0
the	0
T	9
cell	10
receptor	10
(	0
TCR	9
)	0
induces	0
several	0
signaling	0
cascades	0
which	0
ultimately	0
synergize	0
to	0
induce	0
the	0
activity	0
of	0
the	0
nuclear	9
factor	10
of	0
activated	0
T	7
cells	8
(	0
NFAT	5
)	0
,	0
a	0
DNA	9
binding	10
complex	10
critical	0
to	0
the	0
inducibility	0
and	0
T	0
cell	0
specificity	0
of	0
the	0
T	9
cell	10
growth	10
factor	10
interleukin	9
2	10
.	0

One	0
immediate	0
consequence	0
of	0
T	0
cell	0
activation	0
via	0
the	0
TCR	9
is	0
an	0
increase	0
in	0
cytosolic	0
calcium	0
.	0

Calcium	0
signals	0
are	0
important	0
for	0
NFAT	5
induction	0
,	0
and	0
recent	0
studies	0
have	0
identified	0
calcineurin	9
,	0
a	0
calcium-calmodulin	9
dependent	10
serine-threonine	10
phosphatase	10
,	0
as	0
a	0
prominent	0
component	0
of	0
the	0
calcium	0
signaling	0
pathway	0
in	0
T	7
cells	8
.	0

A	0
second	0
important	0
molecule	0
in	0
TCR	0
signal	0
transduction	0
is	0
the	0
guanine	9
nucleotide	10
binding	10
protein	10
,	0
p21ras	9
,	0
which	0
is	0
coupled	0
to	0
the	0
TCR	9
by	0
a	0
protein	9
tyrosine	10
kinase	10
dependent	0
mechanism	0
.	0

The	0
experiments	0
presented	0
here	0
show	0
that	0
expression	0
by	0
transfection	0
of	0
mutationally	0
activated	0
calcineurin	9
or	0
activated	0
p21ras	9
alone	0
is	0
insufficient	0
for	0
NFAT	7
transactivation	0
.	0

However	0
,	0
coexpression	0
of	0
the	0
activated	0
calcineurin	0
with	0
activated	0
p21ras	0
could	0
mimic	0
TCR	0
signals	0
in	0
NFAT	7
induction	0
.	0

These	0
data	0
identify	0
calcineurin	9
and	0
p21ras	9
as	0
cooperative	0
partners	0
in	0
T	7
cell	8
activation	0
.	0

Expression	0
of	0
the	0
chicken	9
GATA	10
factor	10
family	10
during	0
early	0
erythroid	0
development	0
and	0
differentiation	0
.	0

The	0
DNA	0
motif	0
WGATAR	0
has	0
been	0
identified	0
within	0
transcriptional	1
regulatory	2
domains	2
of	0
globin	1
and	0
other	0
erythroid-specific	1
genes	2
and	0
the	0
activator	9
proteins	10
that	0
bind	0
to	0
this	0
regulatory	1
element	2
,	0
the	0
GATA	9
factors	10
,	0
belong	0
to	0
a	0
multi-gene	9
family	10
that	0
is	0
expressed	0
in	0
chicken	7
erythroid	8
cells	8
.	0

Here	0
we	0
show	0
that	0
,	0
as	0
in	0
chickens	0
,	0
multiple	0
members	0
of	0
the	0
GATA	9
factor	10
family	10
are	0
expressed	0
in	0
human	7
and	8
murine	8
erythroid	8
cells	8
.	0

During	0
the	0
early	0
stages	0
of	0
chicken	0
embryogenesis	0
(	0
well	0
before	0
blood	0
island	0
formation	0
)	0
,	0
each	0
of	0
the	0
GATA	9
family	10
members	10
is	0
transcribed	0
with	0
a	0
unique	0
temporal	0
and	0
spatial	0
pattern	0
.	0

In	0
the	0
primitive	7
erythroid	8
lineage	8
,	0
transcription	0
of	0
the	0
embryonic	1
epsilon-globin	2
gene	2
parallels	0
GATA-1	0
expression	0
while	0
the	0
switch	0
to	0
beta-globin	0
transcription	0
in	0
definitive	7
erythroid	8
cells	8
is	0
directly	0
preceded	0
by	0
a	0
pronounced	0
increase	0
in	0
GATA-3	9
accumulation	0
.	0

The	0
timing	0
and	0
pattern	0
of	0
expression	0
of	0
these	0
different	0
mRNAs	3
during	0
avian	0
erythroid	0
development	0
and	0
differentiation	0
suggests	0
that	0
temporally	0
regulated	0
changes	0
in	0
GATA	9
factor	10
expression	0
are	0
required	0
for	0
vertebrate	0
hematopoiesis	0
.	0

Molecular	0
regulation	0
of	0
human	9
interleukin	10
2	10
and	0
T-cell	7
function	0
by	0
interleukin	9
4	10
.	0

Distinct	0
functional	0
T-cell	7
subsets	8
,	0
differing	0
in	0
the	0
patterns	0
of	0
lymphokines	9
produced	0
,	0
regulate	0
cell-mediated	0
and	0
humoral	0
immune	0
responses	0
.	0

The	0
two	0
major	0
types	0
and	0
their	0
principal	0
products	0
,	0
interleukin	9
4	10
and	0
interferon	9
gamma	10
(	0
IL-4	9
and	0
IFN-gamma	9
)	0
,	0
are	0
reciprocally	0
negatively	0
interactive	0
.	0

To	0
analyze	0
the	0
molecular	0
mechanism	0
of	0
IL-4-mediated	0
suppression	0
of	0
cell-mediated	0
immunity	0
we	0
studied	0
its	0
effects	0
on	0
expression	0
of	0
interleukin	9
2	10
(	0
IL-2	9
)	0
and	0
IFN-gamma	9
.	0

IL-4	9
pretreatment	0
of	0
Jurkat	7
cells	8
prior	0
to	0
stimulation	0
resulted	0
in	0
a	0
decrease	0
in	0
transcription	0
of	0
the	0
IL2	1
gene	2
.	0

IL-4	9
suppressed	0
IL-2	0
and	0
IFN-gamma	0
mRNA	0
levels	0
in	0
primary	7
human	8
T	8
cells	8
,	0
and	0
addition	0
of	0
anti-CD28	9
antibodies	10
relieved	0
this	0
suppression	0
.	0

Using	0
enhancer-reporter	1
constructs	2
,	0
IL-4	9
specifically	0
down-regulated	0
the	0
NFIL-2B	1
element	2
.	0

Electrophoretic	0
mobility	0
shift	0
assays	0
using	0
a	0
DNA	0
oligomer	0
containing	0
the	0
NFIL-2B	1
binding	2
site	2
indicated	0
that	0
IL-4	9
inhibited	0
the	0
NFIL-2B	9
complex	10
and	0
that	0
the	0
NFIL-2B	9
DNA	10
binding	10
factor	10
is	0
distinct	0
from	0
AP-	9
1	0
.	0

These	0
results	0
suggest	0
that	0
IL-4	9
may	0
regulate	0
development	0
and	0
function	0
of	0
T-cell	7
subsets	8
involved	0
in	0
cell-mediated	0
immunity	0
in	0
part	0
by	0
inhibiting	9
factors	10
required	0
for	0
transcription	0
of	0
the	0
IL2	1
gene	2

Immunochemical	0
differences	0
between	0
glucocorticoid	9
receptors	10
from	0
corticoid-sensitive	7
and	8
-resistant	8
malignant	8
lymphocytes	8
.	0

We	0
have	0
explored	0
the	0
possibility	0
of	0
using	0
antibodies	9
against	0
purified	0
rat	0
liver	0
glucocorticoid	9
receptors	10
to	0
study	0
the	0
immunochemical	0
properties	0
of	0
glucocorticoid	9
receptors	10
from	0
murine	7
and	8
human	8
malignant	8
lymphocytes	8
.	0

For	0
this	0
purpose	0
,	0
purified	9
immune	10
immunoglobulin	10
G	10
was	0
covalently	0
linked	0
to	0
Sepharose	9
CL-4B	10
.	0

We	0
then	0
examined	0
the	0
ability	0
of	0
the	0
affinity	0
gel	0
to	0
recognize	0
cytosolic	9
[	10
3H	10
]	10
triamcinolone	10
acetonide-receptor	10
complexes	10
from	0
the	0
corticoid-sensitive	5
(	6
CS	6
)	6
and	6
-resistant	6
strains	6
of	6
mouse	6
lymphoma	6
P1798	6
,	0
from	0
CS	7
lymphocytes	8
of	0
patients	0
with	0
chronic	0
lymphatic	0
leukemia	0
,	0
and	0
from	0
a	0
CS	5
clone	6
of	0
human	7
leukemic	8
lymphoblasts	8
in	0
tissue	0
culture	0
(	0
CH6	5
)	0
.	0

Mouse	0
thymus	0
was	0
used	0
as	0
a	0
source	0
of	0
glucocorticoid	9
receptor	10
from	0
normal	7
CS	8
lymphocytes	8
.	0

Whereas	0
the	0
immunoaffinity	0
column	0
retained	0
70	0
to	0
84	0
%	0
of	0
the	0
58-	0
to	0
62-A	0
(	0
Stokes	0
radius	0
)	0
[	9
3H	10
]	10
triamcinolone	10
acetonide-receptor	10
complexes	10
characteristic	0
of	0
the	0
CS	5
mouse	6
and	6
human	6
lymphocytes	6
,	0
it	0
failed	0
to	0
recognize	0
the	0
27-	0
to	0
28-A	0
(	0
Stokes	0
radius	0
)	0
glucocorticoid	9
receptor	10
present	0
in	0
corticoid-resistant	0
mouse	5
lymphoma	6
P1798	6
cells	6
.	0

Therefore	0
,	0
under	0
appropriate	0
experimental	0
conditions	0
,	0
it	0
was	0
possible	0
to	0
demonstrate	0
cross-reactivity	0
between	0
the	0
antiserum	0
against	0
rat	9
liver	10
glucocorticoid	10
receptor	10
and	0
the	0
58-	0
to	0
62-A	0
(	0
Stokes	0
radius	0
)	0
glucocorticoid	9
receptor	10
from	0
species	0
as	0
diverse	0
as	0
mouse	0
and	0
humans	0
.	0

Heterogeneity	0
of	0
the	0
in	0
vitro	0
responses	0
to	0
glucocorticoids	0
in	0
acute	0
leukemia	0
.	0

In	0
leukocyte	7
population	8
freshly	0
isolated	0
from	0
the	0
blood	0
of	0
26	0
patients	0
with	0
acute	0
leukemia	0
,	0
we	0
have	0
measured	0
several	0
parameters	0
including	0
glucocorticoid	9
receptors	10
,	0
nucleoside	0
incorporation	0
,	0
percentage	0
of	0
cells	0
in	0
S	0
phase	0
,	0
and	0
steroid-induced	0
cell	0
lysis	0
.	0

In	0
addition	0
,	0
in	0
some	0
cases	0
,	0
the	0
short-term	0
response	0
to	0
steroid	0
therapy	0
was	0
determined	0
.	0

Although	0
,	0
in	0
all	0
the	0
patients	0
studied	0
,	0
leukocytes	7
were	0
found	0
to	0
contain	0
glucocorticoid	9
receptors	10
,	0
we	0
failed	0
to	0
demonstrate	0
any	0
correlation	0
between	0
the	0
level	0
of	0
binding	0
sites	0
and	0
the	0
in	0
vitro	0
or	0
in	0
vivo	0
response	0
to	0
glucocorticoids	0
.	0

This	0
absence	0
of	0
correlation	0
could	0
be	0
in	0
part	0
explained	0
by	0
the	0
marked	0
heterogeneity	0
of	0
the	0
steroid	0
response	0
demonstrated	0
in	0
leukocyte	0
subpopulations	0
.	0

It	0
appears	0
,	0
however	0
,	0
that	0
the	0
degree	0
of	0
steroid	0
action	0
in	0
vitro	0
as	0
well	0
as	0
the	0
extent	0
of	0
spontaneous	0
and	0
dexamethasone-induced	0
cell	0
death	0
may	0
be	0
related	0
to	0
the	0
number	0
of	0
cells	0
in	0
the	0
S	0
phase	0
of	0
the	0
cell	0
cycle	0
.	0

Glucocorticoid	9
receptors	10
in	0
cytosol	0
and	0
nuclear	0
extract	0
of	0
human	7
leukocytes	8
.	0

Cortisol	0
binding	0
by	0
cytosol	0
and	0
0.4	0
M	0
KCl	0
extract	0
of	0
the	0
nuclear	0
fraction	0
of	0
human	7
leukocytes	8
were	0
studied	0
by	0
gel	0
chromatography	0
and	0
ion	0
exchange	0
filtration	0
on	0
DEAE	0
cellulose	0
.	0

The	0
cytoplasmic	9
cortisol	10
binding	10
protein	10
has	0
a	0
molecular	0
weight	0
95	0
000	0
and	0
the	0
soluble	9
nuclear	10
binding	10
protein	10
50	0
000	0
.	0

The	0
absence	0
of	0
the	0
uptake	0
of	0
radioactive	0
cortisol	0
by	0
isolated	0
nuclei	0
and	0
the	0
apparent	0
requirement	0
of	0
the	0
cytosol	0
for	0
glucocorticoid	0
specific	0
binding	0
in	0
nuclear	0
receptor	0
sites	0
was	0
observed	0
.	0

The	0
association	0
constant	0
characterising	0
the	0
binding	0
of	0
cortisol	0
to	0
cytosol	0
was	0
KA	0
=	0
3.5	0
.	0
10	0
(	0
9	0
)	0
l/mol	0
.	0

Corticosteroid-induced	0
lymphopenia	0
,	0
immunosuppression	0
,	0
and	0
body	0
defense	0
.	0

The	0
apparent	0
paradox	0
of	0
heightened	0
adrenal	0
corticosteroid	0
levels	0
associated	0
with	0
reduction	0
in	0
the	0
competence	0
of	0
the	0
body	0
's	0
defensive	0
apparatus	0
to	0
cope	0
with	0
exposure	0
to	0
new	0
microbial	9
antigens	10
is	0
considered	0
.	0

The	0
question	0
is	0
asked	0
how	0
this	0
lowered	0
defensive	0
capability	0
,	0
which	0
occurs	0
in	0
the	0
face	0
of	0
a	0
threat	0
to	0
body	0
integrity	0
,	0
is	0
consistent	0
with	0
Cannon	0
's	0
principals	0
of	0
the	0
``	0
wisdom	0
of	0
the	0
body.	0
''	0

The	0
suggestion	0
is	0
offered	0
that	0
the	0
immunologic	0
response	0
to	0
self-antigens	9
exposed	0
by	0
disease	0
or	0
trauma	0
may	0
be	0
suppressed	0
by	0
corticosteroid	0
to	0
offset	0
the	0
likelihood	0
of	0
autoimmune	0
attack	0
.	0

Protein	9
tyrosine	10
kinase	10
activation	0
is	0
required	0
for	0
lipopolysaccharide	0
induction	0
of	0
cytokines	9
in	0
human	7
blood	8
monocytes	8
.	0

Bacterial	0
LPS	0
induce	0
production	0
of	0
cytokines	9
such	0
as	0
IL-1	9
,	0
IL-6	9
,	0
and	0
TNF	9
in	0
mononuclear	7
phagocytes	8
,	0
and	0
this	0
represents	0
a	0
central	0
component	0
in	0
the	0
pathogenesis	0
of	0
septic	0
shock	0
syndrome	0
.	0

However	0
,	0
the	0
mechanisms	0
by	0
which	0
LPS	0
activates	0
these	0
cells	0
to	0
express	0
cytokines	9
are	0
not	0
completely	0
characterized	0
.	0

The	0
present	0
study	0
addressed	0
the	0
role	0
of	0
different	0
protein	9
kinases	10
in	0
the	0
LPS	0
induction	0
of	0
cytokines	9
.	0

It	0
is	0
shown	0
that	0
LPS	0
induced	0
a	0
12-	0
to	0
16-fold	0
increase	0
in	0
IL-1	0
beta	0
,	0
IL-6	0
,	0
and	0
TNF-alpha	0
mRNA	0
levels	0
,	0
and	0
this	0
was	0
completely	0
or	0
more	0
than	0
80	0
%	0
blocked	0
by	0
the	0
protein	0
tyrosine	0
kinase	0
specific	0
inhibitors	0
herbimycin	0
A	0
and	0
genistein	0
at	0
the	0
concentrations	0
of	0
1.7	0
and	0
37	0
microM	0
,	0
respectively	0
.	0

Protein	9
kinase	10
C	10
inhibition	0
by	0
staurosporine	0
reduced	0
LPS	0
induction	0
of	0
TNF-alpha	9
,	0
whereas	0
it	0
had	0
no	0
effects	0
on	0
IL-6	9
and	0
IL-1	0
beta	0
.	0

Inhibition	0
of	0
protein	9
kinase	10
A	10
by	0
H89	0
reduced	0
IL-6	3
mRNA	4
levels	0
but	0
did	0
not	0
detectably	0
change	0
IL-1	0
beta	0
or	0
TNF-alpha	0
mRNA	0
levels	0
.	0

In	0
contrast	0
,	0
LPS	0
did	0
not	0
increase	0
leukemia	3
inhibitory	4
factor	4
mRNA	4
,	0
which	0
was	0
constitutively	0
expressed	0
and	0
not	0
significantly	0
reduced	0
by	0
these	0
inhibitors	0
.	0

In	0
addition	0
to	0
cytokine	3
mRNA	4
levels	0
,	0
LPS-induced	0
IL-6	0
protein	0
synthesis	0
and	0
IL-6	0
bioactivity	0
were	0
also	0
reduced	0
to	0
baseline	0
levels	0
by	0
the	0
PTK	0
inhibitors	0
herbimycin	0
A	0
and	0
genistein	0
.	0

Both	0
PTK	0
inhibitors	0
also	0
reduced	0
the	0
LPS	0
activation	0
of	0
nuclear	9
factor-kappa	10
B	10
(	0
NF-kappa	9
B	10
)	0
,	0
which	0
is	0
a	0
transcription	9
factor	10
involved	0
in	0
the	0
expression	0
of	0
cytokine	3
genes	4
such	0
as	0
IL-6	1
and	0
TNF-alpha	1
.	0

The	0
activation	0
of	0
NF-kappa	9
B	10
was	0
also	0
reduced	0
by	0
H89	0
,	0
whereas	0
staurosporine	0
had	0
no	0
effect	0
on	0
this	0
response	0
.	0

In	0
summary	0
,	0
these	0
findings	0
suggest	0
that	0
protein	9
kinase	10
C	10
and	0
protein	9
kinase	10
A	10
appear	0
to	0
have	0
selective	0
effects	0
in	0
the	0
LPS	0
induction	0
of	0
cytokines	9
,	0
whereas	0
PTK	9
is	0
required	0
for	0
LPS	0
induction	0
of	0
a	0
broad	0
spectrum	0
of	0
cytokines	9
and	0
NF-kappa	9
B	10
activation	0
in	0
monocytes	7
.	0

In	0
vivo	0
control	0
of	0
NF-kappa	9
B	10
activation	0
by	0
I	9
kappa	10
B	10
alpha	10
.	0

The	0
transcription	9
factor	10
NF-kappa	9
B	10
is	0
stored	0
in	0
the	0
cytoplasm	0
in	0
complexes	0
with	0
the	0
inhibitor	9
protein	10
I	10
kappa	10
B	10
alpha	10
.	0

It	0
has	0
been	0
shown	0
in	0
vitro	0
that	0
dissociation	0
of	0
I	9
kappa	10
B	10
alpha	10
from	0
these	0
complexes	0
results	0
in	0
active	9
NF-kappa	10
B	10
.	0

In	0
this	0
report	0
we	0
show	0
that	0
lipopolysaccharide	0
(	0
LPS	0
)	0
-induced	0
activation	0
of	0
B	7
or	8
pre-B	8
cells	8
results	0
in	0
loss	0
of	0
I	9
kappa	10
B	10
alpha	10
from	0
NF-kappa	9
B	10
complexes	10
in	0
vivo	0
.	0

Many	0
liberated	0
NF-kappa	9
B	10
dimers	10
reached	0
the	0
nucleus	0
,	0
where	0
increased	0
c-rel	9
,	0
p65	0
and	0
p50	0
were	0
detected	0
by	0
immunoblotting	0
and	0
by	0
DNA	0
binding	0
assays	0
.	0

Some	0
liberated	9
dimers	10
were	0
retained	0
in	0
the	0
cytoplasm	0
,	0
however	0
,	0
through	0
binding	0
to	0
newly	0
synthesized	0
I	9
kappa	10
B	10
alpha	10
,	0
a	0
finding	0
which	0
strongly	0
suggests	0
(	0
i	0
)	0
that	0
the	0
LPS-induced	0
signal	0
causes	0
dissociation	0
of	0
complexes	0
rather	0
than	0
preventing	0
their	0
association	0
and	0
(	0
ii	0
)	0
that	0
dissociation	0
results	0
from	0
modification	0
of	0
I	9
kappa	10
B	10
alpha	10
and	0
not	0
of	0
c-rel	9
or	0
p65	9
.	0

No	0
effect	0
of	0
LPS	0
treatment	0
was	0
detected	0
on	0
p105	9
or	0
p100	9
,	0
which	0
also	0
retain	0
rel	9
family	10
members	10
in	0
the	0
cytoplasm	0
.	0

Quite	0
unexpectedly	0
,	0
we	0
also	0
found	0
that	0
in	0
unstimulated	7
cells	8
there	0
is	0
a	0
constant	0
ongoing	0
process	0
of	0
degradation	0
and	0
replacement	0
of	0
complexed	9
I	10
kappa	10
B	10
alpha	10
.	0

We	0
propose	0
that	0
this	0
turnover	0
results	0
in	0
the	0
low	0
level	0
of	0
active	9
NF-kappa	10
B	10
presumably	0
necessary	0
even	0
in	0
the	0
unstimulated	0
cell	0
,	0
and	0
that	0
the	0
high	0
rate	0
of	0
synthesis	0
of	0
I	9
kappa	10
B	10
alpha	10
provides	0
the	0
ability	0
to	0
turn	0
off	0
NF-kappa	9
B	10
activity	0
rapidly	0
as	0
soon	0
as	0
the	0
activating	0
signal	0
ceases	0
.	0

Identification	0
of	0
a	0
killer	1
cell-specific	2
regulatory	2
element	2
of	0
the	0
mouse	1
perforin	2
gene	2
:	0
an	0
Ets-binding	0
site-homologous	0
motif	0
that	0
interacts	0
with	0
Ets-related	9
proteins	10
.	0

The	0
gene	0
encoding	0
the	0
cytolytic	9
protein	10
perforin	9
is	0
selectively	0
expressed	0
by	0
activated	7
killer	8
lymphocytes	8
.	0

To	0
understand	0
the	0
mechanisms	0
underlying	0
the	0
cell-type-specific	0
expression	0
of	0
this	0
gene	0
,	0
we	0
have	0
characterized	0
the	0
regulatory	0
functions	0
and	0
the	0
DNA-protein	0
interactions	0
of	0
the	0
5'-flanking	1
region	2
of	0
the	0
mouse	1
perforin	2
gene	2
(	0
Pfp	1
)	0
.	0

A	0
region	0
extending	0
from	0
residues	1
+62	2
through	2
-141	2
,	0
which	0
possesses	0
the	0
essential	0
promoter	0
activity	0
,	0
and	0
regions	0
further	0
upstream	0
,	0
which	0
are	0
able	0
to	0
either	0
enhance	0
or	0
suppress	0
gene	0
expression	0
,	0
were	0
identified	0
.	0

The	0
region	0
between	0
residues	1
-411	2
and	2
-566	2
was	0
chosen	0
for	0
further	0
characterization	0
,	0
since	0
it	0
contains	0
an	0
enhancer-like	0
activity	0
.	0

We	0
have	0
identified	0
a	0
32-mer	0
sequence	0
(	0
residues	1
-491	2
to	2
-522	2
)	0
which	0
appeared	0
to	0
be	0
capable	0
of	0
enhancing	0
gene	0
expression	0
in	0
a	0
killer	0
cell-specific	0
manner	0
.	0

Within	0
this	0
segment	0
,	0
a	0
9-mer	0
motif	0
(	0
5'-ACAGGAAGT-3	0
'	0
,	0
residues	1
-505	2
to	2
-497	2
;	0
designated	0
NF-P	0
motif	0
)	0
,	0
which	0
is	0
highly	0
homologous	0
to	0
the	0
Ets	1
proto-oncoprotein-binding	2
site	2
,	0
was	0
found	0
to	0
interact	0
with	0
two	0
proteins	0
,	0
NF-P1	9
and	0
NF-P2	9
.	0

NF-P2	9
appears	0
to	0
be	0
induced	0
by	0
reagents	0
known	0
to	0
up-regulate	0
the	0
perforin	0
message	0
level	0
and	0
is	0
present	0
exclusively	0
in	0
killer	7
cells	8
.	0

Electrophoretic	0
mobility	0
shift	0
assay	0
and	0
UV	0
cross-linking	0
experiments	0
revealed	0
that	0
NF-P1	9
and	0
NF-P2	9
may	0
possess	0
common	0
DNA-binding	9
subunits	10
.	0

However	0
,	0
the	0
larger	0
native	0
molecular	0
mass	0
of	0
NF-P1	9
suggests	0
that	0
NF-P1	9
contains	0
an	0
additional	0
non-DNA-binding	9
subunit	10
(	0
s	0
)	0
.	0

In	0
view	0
of	0
the	0
homology	0
between	0
the	0
NF-P	9
motif	10
and	0
other	0
Ets	9
proto-oncoprotein-binding	10
sites	10
,	0
it	0
is	0
postulated	0
that	0
NF-P1	9
and	0
NF-P2	9
belong	0
to	0
the	0
Ets	9
protein	10
family	10
.	0

Results	0
obtained	0
from	0
the	0
binding	0
competition	0
assay	0
,	0
nevertheless	0
,	0
suggest	0
that	0
NF-P1	9
and	0
NF-P2	9
are	0
related	0
to	0
but	0
distinct	0
from	0
Ets	9
proteins	10
,	0
e.g.	0
,	0
Ets-1	9
,	0
Ets-2	9
,	0
and	0
NF-AT/Elf-1	9
,	0
known	0
to	0
be	0
expressed	0
in	0
T	7
cells	8
.	0

The	0
role	0
of	0
NF-kappa	1
B1	2
(	2
p50/p105	2
)	2
gene	2
expression	0
in	0
activation	0
of	0
human	7
blood	8
T-lymphocytes	8
via	0
CD2	9
and	10
CD28	10
adhesion	10
molecules	10
.	0

Stimulation	0
of	0
primary	7
human	8
T-lymphocytes	8
via	0
CD2	9
and	10
CD28	10
adhesion	10
molecules	10
induces	0
a	0
long-lasting	0
proliferation	0
(	0
>	0
3	0
weeks	0
)	0
.	0

This	0
potent	0
activation	0
does	0
not	0
require	0
accessory	0
cells	0
,	0
such	0
as	0
monocytes	7
,	0
but	0
depends	0
on	0
persistent	0
interleukin	9
2	10
(	0
IL-2	9
)	0
secretion	0
and	0
receptivity	0
,	0
which	0
is	0
associated	0
with	0
high	0
and	0
prolonged	0
expression	0
of	0
the	0
inducible	0
CD25/IL-2	1
receptor	2
alpha	2
(	2
IL-2R	2
alpha	2
)	2
chain	2
gene	2
.	0

The	0
transcription	9
factor	10
NF-kappa	10
B	10
participates	0
in	0
the	0
regulation	0
of	0
both	0
IL-2	1
and	2
IL-2R	2
alpha	2
genes	2
,	0
as	0
well	0
as	0
multiple	1
cellular	2
genes	2
involved	0
in	0
T-cell	0
proliferation	0
.	0

To	0
evaluate	0
the	0
role	0
of	0
NF-kappa	9
B	10
in	0
human	7
peripheral	8
blood	8
T-lymphocytes	8
,	0
we	0
previously	0
analyzed	0
the	0
activation	0
of	0
NF-kappa	9
B-related	10
complexes	10
in	0
response	0
to	0
CD2+CD28	0
costimulation	0
.	0

We	0
demonstrated	0
a	0
long-term	0
induction	0
of	0
p50/p65	9
heterodimer	10
,	0
a	0
putative	9
p65/c-Rel	10
heterodimer	10
,	0
and	0
a	0
constitutive	0
nuclear	0
expression	0
of	0
KBF1/p50	9
homodimers	10
.	10

As	0
the	0
role	0
of	0
p50	9
remains	0
unclear	0
,	0
we	0
focused	0
our	0
present	0
study	0
on	0
NF-kappa	9
B1	10
(	0
p50/p105	9
)	0
gene	0
regulation	0
.	0

Using	0
electrophoretic	0
mobility	0
shift	0
assays	0
and	0
Western	0
and	0
Northern	0
blot	0
analyses	0
,	0
we	0
studied	0
NF-kappa	1
B1	2
gene	2
expression	0
during	0
T-cell	0
stimulation	0
via	0
CD2+CD28	9
.	0

We	0
observed	0
a	0
transient	0
4-	0
to	0
5-fold	0
increase	0
of	0
NF-kappa	0
B1	0
gene	0
expression	0
at	0
both	0
the	0
mRNA	0
and	0
protein	0
levels	0
,	0
lasting	0
for	0
at	0
least	0
24	0
h	0
.	0

p50	0
DNA-binding	0
activity	0
apparently	0
stays	0
highly	0
controlled	0
when	0
p105	0
expression	0
is	0
enhanced	0
by	0
a	0
physiological	0
stimulus	0
of	0
peripheral	7
blood	8
T-cells	8
.	0

Partial	0
inhibition	0
of	0
p50	0
and	0
p105	0
expression	0
by	0
NF-kappa	9
B1	10
antisense	0
oligonucleotides	0
significantly	0
reduced	0
T-cell	0
proliferation	0
and	0
CD25/IL-2R	9
alpha	10
cell	0
surface	0
expression	0
.	0

(	0
ABSTRACT	0
TRUNCATED	0
AT	0
250	0
WORDS	0
)	0

Vitamin	9
D	10
receptor	10
quantitation	0
in	0
human	7
blood	8
mononuclear	8
cells	8
in	0
health	0
and	0
disease	0
.	0

Vitamin	9
D	10
receptor	10
(	0
VDR	0
)	0
concentration	0
was	0
quantitated	0
in	0
human	7
peripheral	8
blood	8
mononuclear	8
cells	8
(	0
PBMC	7
)	0
from	0
patients	0
with	0
absorptive	0
hypercalciuria	0
(	0
AH	0
)	0
and	0
patients	0
with	0
high	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
due	0
to	0
acquired	0
or	0
transient	0
disease	0
states	0
and	0
the	0
results	0
compared	0
to	0
those	0
in	0
normal	0
subjects	0
.	0

VDR	0
concentration	0
in	0
resting	7
cells	8
was	0
not	0
different	0
between	0
the	0
three	0
groups	0
and	0
represented	0
constitutive	0
receptor	0
expression	0
of	0
monocytes	7
.	0

Following	0
activation	0
with	0
phytohemagglutinin	9
,	0
patients	7
with	0
hypercalcitriolemia	0
demonstrated	0
significantly	0
greater	0
VDR	0
concentrations	0
.	0

Patients	0
with	0
AH	0
demonstrated	0
a	0
normal	0
value	0
for	0
the	0
group	0
,	0
but	0
6	0
patients	0
had	0
significantly	0
greater	0
concentrations	0
of	0
VDR	9
despite	0
normal	0
plasma	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
in	0
four	0
of	0
the	0
patients	0
.	0

Proliferation	0
,	0
as	0
assessed	0
from	0
[	0
3H	0
]	0
thymidine	0
incorporation	0
was	0
inversely	0
correlated	0
with	0
serum	0
1	0
,	0
25	0
(	0
OH	0
)	0
2D3	0
and	0
was	0
significant	0
(	0
R	0
=	0
-0.299	0
,	0
p	0
=	0
0.048	0
)	0
.	0

Taken	0
together	0
,	0
the	0
results	0
suggest	0
that	0
PBMC	7
provide	0
a	0
useful	0
system	0
for	0
studying	0
VDR	9
status	0
in	0
transient	0
or	0
acquired	0
states	0
of	0
hypercalcitriolemia	0
.	0

Furthermore	0
,	0
the	0
studies	0
in	0
patients	0
with	0
absorptive	0
hypercalciuria	0
disclosed	0
it	0
to	0
be	0
a	0
heterogeneous	0
disorder	0
,	0
characterized	0
by	0
both	0
vitamin	0
D-dependent	0
and	0
D-independent	0
forms	0
of	0
receptor	0
up-regulation	0
.	0

Reactive	0
oxygen	0
intermediates	0
activate	0
NF-kappa	9
B	10
in	0
a	0
tyrosine	0
kinase-dependent	0
mechanism	0
and	0
in	0
combination	0
with	0
vanadate	0
activate	0
the	0
p56lck	9
and	10
p59fyn	10
tyrosine	10
kinases	10
in	0
human	7
lymphocytes	8
.	0

We	0
have	0
previously	0
observed	0
that	0
ionizing	0
radiation	0
induces	0
tyrosine	0
phosphorylation	0
in	0
human	7
B-lymphocyte	8
precursors	8
by	0
stimulation	0
of	0
unidentified	0
tyrosine	9
kinases	10
and	0
this	0
phosphorylation	0
is	0
substantially	0
augmented	0
by	0
vanadate	0
.	0

Ionizing	0
radiation	0
generates	0
reactive	0
oxygen	0
intermediates	0
(	0
ROI	0
)	0
.	0

Because	0
H2O2	0
is	0
a	0
potent	0
ROI	0
generator	0
that	0
readily	0
crosses	0
the	0
plasma	0
membrane	0
,	0
we	0
used	0
H2O2	0
to	0
examine	0
the	0
effects	0
of	0
ROI	0
on	0
signal	0
transduction	0
.	0

We	0
now	0
provide	0
evidence	0
that	0
the	0
tyrosine	0
kinase	0
inhibitor	0
herbimycin	0
A	0
and	0
the	0
free	0
radical	0
scavenger	0
N-acetyl-cysteine	0
inhibit	0
both	0
radiation-induced	0
and	0
H2O2-induced	0
activation	0
of	0
NF-kappa	9
B	10
,	0
indicating	0
that	0
activation	0
triggered	0
by	0
ROI	0
is	0
dependent	0
on	0
tyrosine	0
kinase	0
activity	0
.	0

H2O2	0
was	0
found	0
to	0
stimulate	0
Ins-1	9
,	10
4	10
,	10
5-P3	10
production	0
in	0
a	0
tyrosine	0
kinase-dependent	0
manner	0
and	0
to	0
induce	0
calcium	0
signals	0
that	0
were	0
greatly	0
augmented	0
by	0
vanadate	0
.	0

The	0
synergistic	0
induction	0
of	0
tyrosine	0
phosphorylation	0
by	0
H2O2	0
plus	0
vanadate	0
included	0
physiologically	0
relevant	0
proteins	0
such	0
as	0
PLC	9
gamma	10
1	10
.	0

Although	0
treatment	0
of	0
cells	0
with	0
H2O2	0
alone	0
did	0
not	0
affect	0
the	0
activity	0
of	0
src	9
family	10
kinases	10
,	0
treatment	0
with	0
H2O2	0
plus	0
vanadate	0
led	0
to	0
activation	0
of	0
the	0
p56lck	9
and	10
p59fyn	10
tyrosine	10
kinases	10
.	0

The	0
combined	0
inhibition	0
of	0
phosphatases	9
and	0
activation	0
of	0
kinases	9
provides	0
a	0
potent	0
mechanism	0
for	0
the	0
synergistic	0
effects	0
of	0
H2O2	0
plus	0
vanadate	0
.	0

Induction	0
of	0
tyrosine	0
phosphorylation	0
by	0
ROI	0
may	0
thus	0
lead	0
to	0
many	0
of	0
the	0
pleiotropic	0
effects	0
of	0
ROI	0
in	0
lymphoid	7
cells	8
,	0
including	0
downstream	0
activation	0
of	0
PLC	9
gamma	10
1	10
and	0
NF-kappa	9
B	10

Influence	0
of	0
sex	9
hormone	10
binding	10
globulin	10
and	0
serum	9
albumin	10
on	0
the	0
conversion	0
of	0
androstenedione	0
to	0
testosterone	0
by	0
human	7
erythrocytes	8
.	0

The	0
influence	0
of	0
human	9
serum	10
albumin	10
and	0
sex	9
hormone	10
binding	10
globulin	10
(	0
SHBG	9
)	0
on	0
the	0
enzymic	0
conversion	0
of	0
androstenedione	0
to	0
testosterone	0
in	0
human	7
erythrocytes	8
was	0
investigated	0
in	0
vitro	0
.	0

Total	0
plasma	0
and	0
albumin	9
delayed	0
the	0
conversion	0
rate	0
of	0
androstenedione	0
,	0
while	0
SHBG	9
increased	0
it	0
markedly	0
.	0

The	0
effect	0
of	0
SHBG	9
was	0
largely	0
abolished	0
by	0
heating	0
to	0
60	0
degrees	0
C	0
for	0
1	0
h	0
and	0
by	0
saturating	0
its	0
binding	0
sites	0
by	0
DHT	0
.	0

The	0
effect	0
of	0
both	0
proteins	0
was	0
found	0
to	0
be	0
related	0
to	0
their	0
concentration	0
.	0

It	0
appears	0
that	0
the	0
binding	0
sites	0
of	0
albumin	9
provide	0
a	0
mechanism	0
for	0
retarding	0
androstenedione	0
uptake	0
by	0
the	0
erythrocytes	7
and	0
that	0
the	0
high	0
binding	0
affinity	0
of	0
SHBG	9
for	0
testosterone	0
facilitates	0
the	0
diffusion	0
of	0
this	0
steroid	0
out	0
of	0
the	0
cell	0
and	0
thus	0
,	0
displaces	0
the	0
chemical	0
equilibrium	0
within	0
the	0
cell	0
.	0

Glucocorticoids	0
and	0
lymphocytes	7
.	0

I	0
.	0

Increased	0
glucocorticoid	9
receptor	10
levels	0
in	0
antigen-stimulated	5
lymphocytes	6
.	0

Recently	0
a	0
2-	0
to	0
3-fold	0
increase	0
in	0
the	0
number	0
of	0
glucocorticoid	9
receptors	10
in	0
human	7
peripheral	8
lymphocytes	8
has	0
been	0
noted	0
after	0
in	0
vitro	0
mitogen	0
stimulation	0
.	0

Here	0
,	0
we	0
extend	0
these	0
observations	0
to	0
in	0
vivo	0
immunization	0
.	0

After	0
unilateral	0
immunization	0
of	0
adrenalectomized	0
male	0
rats	0
,	0
a	0
50	0
%	0
increase	0
in	0
glucocorticoid	0
receptor	0
sites	0
per	0
cell	0
,	0
determined	0
by	0
binding	0
of	0
dexamethasone	0
,	0
was	0
observed	0
in	0
cell	0
suspensions	0
of	0
homolateral	0
lymph	0
nodes	0
over	0
those	0
from	0
the	0
contralateral	0
nonimmunized	0
side	0
of	0
the	0
same	0
animal	0
.	0

The	0
association	0
constant	0
for	0
dexamethasone	0
was	0
similar	0
in	0
both	0
groups	0
,	0
as	0
was	0
the	0
stereospecificity	0
for	0
various	0
steroids	0
,	0
the	0
time	0
course	0
of	0
cytoplasmic	0
and	0
nuclear	0
association	0
,	0
and	0
cytoplasmic-to-nuclear	0
translocation	0
.	0

Despite	0
a	0
50	0
%	0
increase	0
in	0
the	0
number	0
of	0
glucocorticoid	0
receptor	0
sites	0
per	0
cell	0
,	0
the	0
cells	0
from	0
the	0
homolateral	0
and	0
controlateral	0
lymph	0
nodes	0
were	0
equally	0
sensitive	0
to	0
the	0
inhibitory	0
effects	0
of	0
dexamethasone	0
,	0
as	0
determined	0
by	0
measurements	0
of	0
the	0
incorporation	0
of	0
radiolabeled	0
precursors	0
of	0
protein	0
,	0
RNA	0
,	0
and	0
DNA	0
,	0
or	0
measurements	0
of	0
in	0
vitro	0
cell	0
survival	0
.	0

Glucocorticoid	0
receptors	0
and	0
actions	0
in	0
rat	7
thymocytes	8
and	0
immunologically	0
stimulated	0
human	7
peripheral	8
lymphocytes	8
.	0

After	0
reviewing	0
briefly	0
our	0
earlier	0
studies	0
on	0
glucocorticoid	0
receptors	0
and	0
mechanisms	0
in	0
thymus	7
cells	8
,	0
we	0
have	0
outlined	0
results	0
from	0
the	0
following	0
two	0
areas	0
of	0
current	0
interest	0
in	0
our	0
laboratories	0
:	0
the	0
``	0
life-cycle	0
''	0
of	0
glucocorticoid	0
receptors	0
and	0
complexes	0
in	0
thymus	7
cells	8
,	0
and	0
the	0
levels	0
of	0
glucocorticoid	0
receptors	0
and	0
sensitivity	0
in	0
immunologically	7
stimulated	8
human	8
peripheral	8
lymphocytes	8
.	0

Several	0
of	0
our	0
results	0
on	0
energetics	0
and	0
kinetics	0
of	0
hormone	0
binding	0
to	0
glucocorticoid	9
receptors	10
in	0
rat	7
thymus	8
cells	8
seem	0
to	0
require	0
extension	0
of	0
the	0
simplest	0
model	0
of	0
hormone-receptor	0
transformations	0
in	0
intact	7
cells	8
.	0

ATP-depletion	0
experiments	0
suggest	0
the	0
existence	0
of	0
a	0
nonbinding	0
form	0
of	0
the	0
receptor	0
;	0
``	0
chase	0
''	0
experiments	0
suggest	0
reaction	0
of	0
hormone	0
directly	0
with	0
nuclear-bound	0
receptor	0
;	0
experiments	0
on	0
depletion	0
and	0
replenishment	0
of	0
cytoplasmic	9
receptor	10
using	0
cortisol	0
and	0
dexamethasone	0
suggest	0
the	0
existence	0
of	0
at	0
least	0
two	0
subpopulations	0
of	0
nuclear-bound	9
hormone-receptor	10
complex	10
.	0

We	0
have	0
found	0
that	0
mitogen	0
or	0
immunologic	0
stimulation	0
of	0
human	7
peripheral	8
lymphocytes	8
in	0
culture	0
leads	0
within	0
24	0
h	0
or	0
so	0
to	0
a	0
striking	0
increase	0
in	0
the	0
number	0
of	0
glucocorticoid	9
receptor	10
sites	0
per	0
cell	0
.	0

We	0
believe	0
this	0
increase	0
may	0
be	0
due	0
to	0
partial	0
synchronization	0
of	0
the	0
cell	0
population	0
in	0
a	0
phase	0
of	0
the	0
cell	0
cycle	0
in	0
which	0
receptor	0
content	0
is	0
high	0
.	0

Contrary	0
to	0
the	0
widely	0
held	0
view	0
that	0
mitogen-stimulated	7
cells	8
become	0
insensitive	0
to	0
glucocorticoids	0
,	0
our	0
experiments	0
show	0
that	0
with	0
respect	0
to	0
inhibition	0
of	0
thymidine	0
and	0
uridine	0
incorporation	0
and	0
glucose	0
uptake	0
,	0
the	0
cells	0
are	0
highly	0
sensitive	0
to	0
dexamethasone	0
at	0
24	0
,	0
48	0
,	0
and	0
72	0
h	0
after	0
stimulation	0
with	0
concanavalin	9
A	10
.	0

Nuclear	0
glucocorticoid	0
binding	0
in	0
chronic	7
lymphatic	8
leukemia	8
lymphocytes	8
.	0

A	0
reliable	0
procedure	0
is	0
described	0
for	0
isolating	0
3H-triamcinolone	9
acetonide	10
(	10
3H-TA	10
)	10
receptor	10
complexes	10
from	0
purified	0
chronic	0
lymphatic	7
leukemia	8
(	8
CLL	8
)	8
lymphocyte	8
nuclei	0
,	0
based	0
on	0
the	0
use	0
of	0
carbobenzoxy-L-phenylalanine	0
(	0
CBZ-L-phe	0
)	0
to	0
prevent	0
breakdown	0
of	0
hormone-receptor	9
complexes	10
during	0
extraction	0
of	0
nuclei	0
with	0
0.6M	0
KCl	0
.	0

Using	0
this	0
method	0
,	0
specific	0
nuclear	0
glucocorticoid	0
binding	0
was	0
demonstrated	0
in	0
14/14	0
patients	0
with	0
untreated	0
CLL	0
.	0

No	0
correlation	0
was	0
found	0
between	0
levels	0
of	0
nuclear-associated	0
3H-TA	0
and	0
peripheral	0
white	0
blood	0
cell	0
count	0
or	0
rosetting	0
ability	0
of	0
circulating	7
lymphocytes	8
.	0

Multiple	0
closely-linked	0
NFAT/octamer	1
and	0
HMG	1
I	2
(	2
Y	2
)	2
binding	2
sites	2
are	0
part	0
of	0
the	0
interleukin-4	0
promoter	0
.	0

We	0
show	0
here	0
that	0
the	0
immediate	1
upstream	2
region	2
(	0
from	0
position	0
-12	0
to	0
-270	0
)	0
of	0
the	0
murine	1
interleukin	2
4	2
(	2
Il-4	2
)	2
gene	2
harbors	0
a	0
strong	0
cell-type	0
specific	0
transcriptional	1
enhancer	2
.	0

In	0
T	7
lymphoma	8
cells	8
,	0
the	0
activity	0
of	0
the	0
Il-4	1
promoter/enhancer	2
is	0
stimulated	0
by	0
phorbol	0
esters	0
,	0
Ca++	0
ionophores	0
and	0
agonists	0
of	0
protein	9
kinase	10
A	10
and	0
inhibited	0
by	0
low	0
doses	0
of	0
the	0
immunosuppressant	0
cyclosporin	0
A	0
.	0

The	0
Il-4	1
promoter/enhancer	2
is	0
transcriptionally	0
inactive	0
in	0
B	7
lymphoma	8
cells	8
and	0
HeLa	7
cells	8
.	0

DNase	0
I	0
footprint	0
protection	0
experiments	0
revealed	0
six	0
sites	0
of	0
the	0
Il-4	1
promoter/enhancer	2
to	0
be	0
bound	0
by	0
nuclear	9
proteins	10
from	0
lymphoid	7
and	8
myeloid	8
cells	8
.	0

Among	0
them	0
are	0
four	0
purine	0
boxes	0
which	0
have	0
been	0
described	0
to	0
be	0
important	0
sequence	0
motifs	0
of	0
the	0
Il-2	1
promoter	2
.	0

They	0
contain	0
the	0
motif	0
GGAAA	0
and	0
are	0
recognized	0
by	0
the	0
inducible	9
and	10
cyclosporin	10
A-sensitive	10
transcription	10
factor	10
NFAT-1	10
.	0

Three	0
of	0
the	0
Il-4	1
NFAT-1	2
sites	2
are	0
closely	0
linked	0
to	0
weak	0
binding	0
sites	0
of	0
Octamer	9
factors	10
.	0

Several	0
purine	0
boxes	0
and	0
an	0
AT-rich	1
protein-binding	2
site	2
of	0
the	0
Il-4	0
promoter	0
are	0
also	0
recognized	0
by	0
the	0
high	9
mobility	10
group	10
protein	10
HMG	9
I	10
(	10
Y	10
)	0
.	0

Whereas	0
the	0
binding	0
of	0
NFAT-1	9
and	0
Octamer	9
factors	10
enhance	0
the	0
activity	0
of	0
the	0
Il-4	1
promoter	2
,	0
the	0
binding	0
of	0
HMG	0
I	0
(	0
Y	0
)	0
suppresses	0
its	0
activity	0
and	0
,	0
therefore	0
,	0
appears	0
to	0
be	0
involved	0
in	0
the	0
suppression	0
of	0
Il-4	9
transcription	0
in	0
resting	7
T	8
lymphocytes	8
.	0

Reversibility	0
of	0
the	0
differentiated	0
state	0
in	0
somatic	7
cells	8
.	0

Analysis	0
of	0
de	0
novo	0
gene	0
activation	0
in	0
multinucleated	7
heterokaryons	8
has	0
shown	0
that	0
the	0
differentiated	0
state	0
,	0
although	0
stable	0
,	0
is	0
not	0
irreversible	0
,	0
and	0
can	0
be	0
reprogrammed	0
in	0
the	0
presence	0
of	0
appropriate	0
combinations	0
of	0
trans-acting	9
regulatory	10
molecules	10
.	0

These	0
properties	0
have	0
been	0
exploited	0
to	0
design	0
strategies	0
for	0
identifying	0
novel	0
regulators	0
of	0
cellular	0
differentiation	0
.	0

Phosphatidylcholine	0
hydrolysis	0
activates	0
NF-kappa	9
B	10
and	0
increases	0
human	0
immunodeficiency	0
virus	0
replication	0
in	0
human	7
monocytes	8
and	0
T	7
lymphocytes	8
.	0

We	0
have	0
tested	0
whether	0
breakdown	0
of	0
phosphatidylcholine	0
(	0
PC	0
)	0
initiated	0
by	0
exogenous	0
addition	0
of	0
a	0
PC-specific	9
phospholipase	10
C	10
(	0
PC-PLC	9
)	0
from	0
Bacillus	0
cereus	0
or	0
by	0
endogenous	0
overexpression	0
of	0
PC-PLC	9
induces	0
functional	0
activation	0
of	0
NF-kappa	9
B	10
and	0
increases	0
human	1
immunodeficiency	2
virus	2
(	2
HIV	2
)	2
enhancer	2
activity	0
.	0

PC-PLC-activated	0
hydrolysis	0
of	0
PC	0
was	0
found	0
to	0
induce	0
bona	0
fide	0
p50/p65	9
NF-kappa	10
B	10
binding	0
activity	0
in	0
three	0
different	0
cell	5
lines	6
of	0
human	0
or	0
murine	0
origin	0
.	0

No	0
significant	0
changes	0
in	0
the	0
turnover	0
of	0
other	0
cellular	0
phospholipids	0
were	0
detected	0
in	0
PC-PLC-treated	5
cells	6
.	0

Induction	0
of	0
NF-kappa	9
B	10
by	0
PC-PLC	9
did	0
not	0
depend	0
on	0
de	0
novo	0
synthesis	0
of	0
proteins	0
or	0
autocrine	0
secretion	0
of	0
either	0
tumor	9
necrosis	10
factor	10
or	0
interleukin	9
1	10
.	0

In	0
human	5
monocytic	6
and	6
lymphoblastoid	6
T-cell	6
lines	6
,	0
induction	0
of	0
NF-kappa	9
B	10
by	0
PC-PLC	9
resulted	0
in	0
clear	0
induction	0
of	0
luciferase	9
expression	0
vectors	0
placed	0
under	0
the	0
control	0
of	0
synthetic	1
kappa	2
B	2
enhancers	2
or	0
wild	0
type	0
,	0
but	0
not	0
kappa	0
B-mutated	0
,	0
HIV	1
long	2
terminal	2
repeat	2
constructs	2
.	0

HIV	0
replication	0
was	0
increased	0
by	0
PC-PLC	9
in	0
chronically	0
infected	0
monocytes	7
and	0
T	0
lymphocytes	7
.	0

NF-kappa	0
B	0
activation	0
promoted	0
by	0
addition	0
of	0
exogenous	9
PC-PLC	10
correlated	0
with	0
an	0
intense	0
production	0
of	0
diacylglycerol	0
.	0

However	0
,	0
addition	0
of	0
a	0
phosphatidylinositol-specific	9
PLC	10
from	0
B.cereus	0
also	0
induced	0
diacylglycerol	0
but	0
did	0
not	0
activate	0
kappa	9
B	10
enhancer-directed	10
vectors	10
.	0

PC-PLC-induced	0
NF-kappa	0
B	0
activation	0
could	0
not	0
be	0
blocked	0
by	0
a	0
specific	0
inhibitor	0
of	0
phorbol	9
ester-inducible	10
protein	10
kinases	10
C	10
.	0

These	0
results	0
indicate	0
that	0
a	0
cellular	0
transduction	0
pathway	0
,	0
dependent	0
on	0
specific	0
PC	0
breakdown	0
,	0
is	0
functional	0
in	0
T	7
lymphocytes	8
and	0
monocytes	7
and	0
may	0
be	0
used	0
by	0
various	0
transmembrane	0
receptors	0
to	0
activate	0
HIV	0
transcription	0
through	0
NF-kappa	0
B-dependent	0
induction	0
of	0
the	0
HIV	1
enhancer	2
.	0

Novel	0
mechanism	0
for	0
inhibition	0
of	0
human	7
T	8
cells	8
by	0
glucocorticoids	0
.	0

Glucocorticoids	0
inhibit	0
signal	0
transduction	0
through	0
IL-2	9
receptor	10
.	0

Interaction	0
of	0
IL-2	9
with	0
its	0
high	9
affinity	10
membrane	10
receptor	10
complex	10
(	0
IL-2R	9
)	0
present	0
on	0
activated	0
T	7
lymphocytes	8
induces	0
cell	0
proliferation	0
and	0
mediates	0
effector	0
functions	0
.	0

Glucocorticoids	0
inhibit	0
IL-2	9
production	0
by	0
inhibiting	0
TCR-mediated	0
signal	0
transduction	0
.	0

We	0
asked	0
whether	0
they	0
also	0
inhibit	0
the	0
action	0
of	0
IL-2	9
by	0
inhibiting	0
signal	0
transduction	0
through	0
IL-2R	9
.	0

Human	7
peripheral	8
blood	8
T	8
cells	8
,	0
stimulated	0
with	0
PMA	0
for	0
48	0
h	0
(	0
PMA	5
blasts	6
)	0
,	0
were	0
incubated	0
with	0
IL-2	9
in	0
the	0
presence	0
of	0
incremental	0
dosages	0
of	0
dexamethasone	0
(	0
Dex	0
;	0
10	0
(	0
-5	0
)	0
-10	0
(	0
-9	0
)	0
M	0
)	0
.	0

Dex	0
inhibited	0
the	0
IL-2-dependent	0
proliferation	0
of	0
PMA	5
blasts	6
in	0
a	0
dose-dependent	0
fashion	0
(	0
IC50	0
,	0
5	0
x	0
10	0
(	0
-8	0
)	0
M	0
)	0
.	0

Cell	0
surface	0
expression	0
of	0
IL-2R	9
alpha-	10
and	10
beta-chains	10
as	0
determined	0
by	0
immunofluorescence	0
analysis	0
was	0
not	0
affected	0
by	0
Dex	0
.	0

In	0
addition	0
,	0
Scatchard	0
plot	0
analysis	0
of	0
125I-labeled	9
IL-2	10
showed	0
that	0
Dex	0
did	0
not	0
affect	0
the	0
binding	0
of	0
IL-2	9
,	0
thus	0
suggesting	0
that	0
inhibition	0
is	0
due	0
to	0
a	0
postreceptor	0
effect	0
.	0

Inhibition	0
of	0
T	0
cell	0
proliferation	0
by	0
Dex	0
was	0
associated	0
with	0
decreased	0
IL-2-dependent	0
tyrosine	0
phosphorylation	0
of	0
several	0
intracellular	9
proteins	10
and	0
decreased	0
phosphorylation	0
of	0
the	0
retinoblastoma	9
gene	10
product	10
Rb	10
,	0
a	0
protein	0
essential	0
for	0
controlling	0
the	0
progression	0
of	0
cells	0
through	0
the	0
cell	0
cycle	0
.	0

IL-2-dependent	0
IL-2R	0
alpha	0
expression	0
in	0
PMA	5
blasts	6
and	0
NF-kB	9
induction	0
in	0
resting	7
human	8
T	8
cells	8
were	0
also	0
inhibited	0
by	0
Dex	0
.	0

These	0
results	0
demonstrate	0
that	0
glucocorticoids	0
inhibit	0
preactivated	5
T	6
cells	6
by	0
down-regulating	0
signal	0
transduction	0
through	0
IL-2R	9
.	0

Chronic	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
infection	0
stimulates	0
distinct	0
NF-kappa	0
B/rel	0
DNA	0
binding	0
activities	0
in	0
myelomonoblastic	7
cells	8
.	0

The	0
relationship	0
between	0
human	0
immunodeficiency	0
virus	0
type	0
1	0
(	0
HIV-1	0
)	0
infection	0
and	0
the	0
induction	0
of	0
NF-kappa	0
B	0
binding	0
activity	0
was	0
examined	0
in	0
a	0
myeloid	5
cell	6
model	6
of	0
HIV-1	0
infection	0
derived	0
from	0
the	0
PLB-985	5
cell	6
line	6
.	0

Chronic	0
infection	0
of	0
PLB-985	5
cells	6
led	0
to	0
increased	0
monocyte-specific	0
surface	0
marker	0
expression	0
,	0
increased	0
c-fms	0
gene	0
transcription	0
,	0
and	0
morphological	0
alterations	0
consistent	0
with	0
differentiation	0
along	0
the	0
monocytic	0
pathway	0
.	0

PLB-IIIB	5
cells	6
displayed	0
a	0
constitutive	0
NF-kappa	0
B-like	0
binding	0
activity	0
that	0
was	0
distinct	0
from	0
that	0
induced	0
by	0
tumor	9
necrosis	10
factor	10
alpha	10
or	0
phorbol	0
12-myristate	0
13-acetate	0
treatment	0
of	0
the	0
parental	5
PLB-985	6
cell	6
line	6
.	0

This	0
unique	0
DNA	0
binding	0
activity	0
consisted	0
of	0
proteins	0
of	0
70	9
,	10
90	10
,	10
and	10
100	10
kDa	10
with	0
a	0
high	0
degree	0
of	0
binding	0
specificity	0
for	0
the	0
NF-kappa	9
B	10
site	10
within	0
the	0
PRDII	9
domain	10
of	0
beta	9
interferon	10
.	0

In	0
this	0
report	0
,	0
we	0
characterize	0
the	0
nature	0
of	0
these	0
proteins	0
and	0
demonstrate	0
that	0
binding	0
of	0
these	0
proteins	0
is	0
also	0
induced	0
following	0
Sendai	0
paramyxovirus	0
infection	0
.	0

The	0
70-kDa	9
protein	10
corresponds	0
to	0
the	0
NF-kappa	9
B	10
RelA	10
(	10
p65	10
)	10
subunit	10
,	0
which	0
is	0
activated	0
in	0
response	0
to	0
an	0
acute	0
paramyxovirus	0
infection	0
or	0
a	0
chronic	0
HIV-1	0
infection	0
.	0

Virus	0
infection	0
does	0
not	0
appear	0
to	0
alter	0
the	0
amount	0
of	0
RelA	9
(	0
p65	9
)	0
or	0
NFKB1	9
(	0
p50	9
)	0
but	0
rather	0
affects	0
the	0
capacity	0
of	0
I	9
kappa	10
B	10
alpha	10
to	0
sequester	0
RelA	9
(	10
p65	10
)	10
,	0
therefore	0
leading	0
to	0
constitutive	0
levels	0
of	0
RelA	0
DNA	0
binding	0
activity	0
and	0
to	0
increased	0
levels	0
of	0
NF-kappa	0
B-dependent	0
gene	0
activity	0
.	0

The	0
virally	0
induced	0
90-	9
to	10
100-kDa	10
proteins	10
have	0
a	0
distinct	0
binding	0
specificity	0
for	0
the	0
PRDII	1
domain	2
and	0
an	0
AT-rich	1
sequence	2
but	0
do	0
not	0
cross-react	0
with	0
NF-kappa	0
B	0
subunit-specific	0
antisera	0
directed	0
against	0
NFKB1	9
(	0
p105	9
or	0
p50	9
)	0
,	0
NFKB2	9
(	0
p100	9
or	0
p52	9
)	0
,	0
RelA	9
(	0
p65	9
)	0
,	0
or	0
c-rel	9
.	0

DNA	0
binding	0
of	0
the	0
90-	9
to	10
100-kDa	10
proteins	10
was	0
not	0
inhibited	0
by	0
recombinant	9
I	10
kappa	10
B	10
alpha/MAD-3	10
and	0
was	0
resistant	0
to	0
tryptic	0
digestion	0
,	0
suggesting	0
that	0
these	0
proteins	0
may	0
not	0
be	0
NF-kappa	9
B	10
related	10
.	0

Transient	0
cotransfection	0
experiments	0
demonstrated	0
that	0
RelA	0
and	0
NFKB1	0
expression	0
maximally	0
stimulated	0
HIV-1	1
LTR-	2
and	2
NF-kappa	2
B-dependent	2
reporter	2
genes	2
;	0
differences	0
in	0
NF-kappa	0
B-like	0
binding	0
activity	0
were	0
also	0
reflected	0
in	0
higher	0
constitutive	0
levels	0
of	0
NF-kappa	0
B-regulated	0
gene	0
expression	0
in	0
HIV-1-infected	5
myeloid	6
cells	6
.	0

Presence	0
of	0
estrogen-binding	0
sites	0
on	0
macrophage-like	7
synoviocytes	8
and	0
CD8+	5
,	6
CD29+	6
,	6
CD45RO+	6
T	6
lymphocytes	6
in	0
normal	0
and	0
rheumatoid	0
synovium	0
.	0

OBJECTIVE	0
.	0

To	0
study	0
the	0
presence	0
of	0
estrogen-binding	0
sites	0
(	0
EBS	0
)	0
in	0
the	0
synovial	0
tissues	0
of	0
male	0
and	0
female	0
patients	0
with	0
rheumatoid	0
arthritis	0
(	0
RA	0
)	0
and	0
in	0
age-	0
and	0
sex-matched	0
healthy	0
controls	0
.	0

METHODS	0
.	0

Both	0
type	0
1	0
(	0
high	0
affinity	0
,	0
low	0
binding	0
capacity	0
)	0
and	0
type	0
2	0
(	0
reduced	0
affinity	0
,	0
higher	0
binding	0
capacity	0
)	0
EBS	0
were	0
investigated	0
in	0
both	0
soluble	0
and	0
nuclear	0
fractions	0
of	0
homogenized	0
synovial	0
tissue	0
samples	0
by	0
a	0
dextran-coated	0
charcoal	0
method	0
.	0

To	0
determine	0
what	0
type	0
of	0
synovial	7
cell	8
was	0
positive	0
for	0
EBS	0
,	0
cryosections	0
of	0
synovial	0
tissues	0
were	0
immunostained	0
with	0
a	0
specific	0
monoclonal	9
anti-estrogen	10
receptor	10
antibody	10
(	0
anti-ER	9
MAb	10
)	0
using	0
both	0
immunofluorescence	0
and	0
immunoperoxidase	0
techniques	0
.	0

Double	0
immunostaining	0
with	0
the	0
anti-ER	9
MAb	10
and	0
with	0
specific	9
MAb	10
to	0
detect	0
different	0
macrophage	9
antigens	10
(	0
Ber-MAC3	9
,	0
MAC387	9
,	0
CD68	9
)	0
and	0
CD8+	5
T	6
cell	6
subsets	6
(	0
CD29+	5
,	0
CD45RO+	5
and	0
CD29-	5
,	0
CD45RO-	5
)	0
was	0
performed	0
.	0

RESULTS	0
.	0

Higher	0
affinity	0
EBS	0
were	0
found	0
mostly	0
in	0
nuclear	0
cell	0
fractions	0
of	0
either	0
RA	0
or	0
control	0
synovial	0
tissues	0
(	0
28	0
of	0
the	0
33	0
)	0
.	0

These	0
EBS	0
were	0
present	0
to	0
a	0
lesser	0
extent	0
in	0
soluble	0
cell	0
fractions	0
(	0
11	0
of	0
the	0
33	0
)	0
.	0

Immunostaining	0
showed	0
the	0
estrogen	7
receptor-positive	8
cells	8
to	0
be	0
the	0
macrophage-like	7
synoviocytes	8
and	0
the	0
CD8+	5
,	0
CD29+	5
T	6
cells	6
both	0
in	0
RA	0
and	0
in	0
control	0
synovial	0
tissues	0
.	0

Higher	0
nuclear	0
content	0
of	0
EBS	0
was	0
consistent	0
with	0
more	0
intense	0
nuclear	0
staining	0
of	0
synoviocytes	7
and	0
T	7
cells	8
.	0

CONCLUSION	0
.	0

It	0
is	0
conceivable	0
that	0
the	0
immunomodulatory	0
activity	0
exerted	0
by	0
estrogens	0
is	0
at	0
least	0
partly	0
mediated	0
through	0
their	0
interaction	0
with	0
EBS	0
that	0
are	0
present	0
on	0
macrophage-like	7
synoviocytes	8
,	0
functioning	0
as	0
antigen-processing	7
and	8
antigen-presenting	8
cells	8
,	0
and	0
on	0
antigen-experienced	5
(	6
memory	6
)	6
CD8+	6
T	6
lymphocytes	6
(	0
CD29+	5
,	0
CD45RO+	5

